[{"decision_number":"EMA/PE/0000232894","pip_number":"EMA/PE/0000232894","active_substance":"adeno-associated viral vector serotype 9 containing the human MECP2 gene (TSHA-102)","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of Rett syndrome","routes_of_administration":"Intrathecal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/04/2025","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Taysha Gene Therapies Inc E-mail: medinfo@tayshagtx.comTel: +1 8334898742","first_published_date":"18/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000232894"},{"decision_number":"EMA/PE/0000232896","pip_number":"EMA/PE/0000232896","active_substance":"antisense oligonucleotide against patatin like phospholipase domain containing protein 3 gene (PNPLA3), conjugated to N-acetylgalactosamine (AZD2693), sodium salt","invented_name":"","therapeutic_area":"Hepatobiliary disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of metabolic dysfunction-associated steatohepatitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"21/02/2025","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB Email: paediatrics@astrazeneca.com Tel. +46 855324400","first_published_date":"18/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000232896"},{"decision_number":"EMA/PE/0000182345","pip_number":"EMA/PE/0000182345","active_substance":"inbakicept, nogapendekin alfa","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of bladder cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Serum Life Science Europe GmbHEmail: info@sls-eu.comTel: +49 5111699080&nbsp","first_published_date":"17/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000182345"},{"decision_number":"EMA/PE/0000182333","pip_number":"EMA/PE/0000182333","active_substance":"precemtabart tocentecan","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Healthcare KGaAEmail: service@merckgroup.comTel.: +49 6151725200","first_published_date":"17/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000182333"},{"decision_number":"EMA/PE/0000182297","pip_number":"EMA/PE/0000182297","active_substance":"oxybutynin","invented_name":"","therapeutic_area":"Renal and urinary disorders","pharmaceutical_forms":"Vaginal delivery system","condition_indication":"Treatment of myoneurogenic bladder disorders","routes_of_administration":"Vaginal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LiGalli B.V.Email: info@ligalli.healthTel: +31 850806821&nbsp","first_published_date":"17/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000182297"},{"decision_number":"EMA/PE/0000182239","pip_number":"EMA/PE/0000182239","active_substance":"setmelanotide","invented_name":"Imcivree","therapeutic_area":"Metabolism and nutrition disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of appetite and general nutrition disorders","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Rhythm Pharmaceuticals, Inc; Tel. +1 8572544457; E-mail: RhythmRegulatory@rhythmtx.com","first_published_date":"27/11/2018","last_updated_date":"17/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000182239"},{"decision_number":"EMA/PE/0000182217","pip_number":"EMA/PE/0000182217","active_substance":"cedazuridine;decitabine","invented_name":"Inaqovi","therapeutic_area":"Blood and lymphatic system disorders","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of acute myeloid leukaemia","routes_of_administration":"Gastric use;Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Otsuka Pharmaceutical Netherlands B.V.Email: paediatrics-info@otsuka-europe.com Tel.:  +49 691700860","first_published_date":"21/06/2023","last_updated_date":"17/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000182217"},{"decision_number":"EMA/PE/0000182170","pip_number":"EMA/PE/0000182170","active_substance":"regorafenib","invented_name":"Stivarga","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Film-coated tablet;Granules","condition_indication":"Treatment of all conditions contained in the category of malignant neoplasms (except haematopoietic and lymphoid tissue)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer AGEmail: pediatrics-medical-affairs-europe@bayer.comTel: +49 3046815333&nbsp","first_published_date":"27/11/2012","last_updated_date":"17/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000182170"},{"decision_number":"EMA/PE/0000181778","pip_number":"EMA/PE/0000181778","active_substance":"rilvegostomig","invented_name":"","therapeutic_area":"Gastrointestinal disorders","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of gastric and gastroesophageal junction adenocarcinoma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel. +46 8553 27591","first_published_date":"17/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000181778"},{"decision_number":"EMA/PE/0000181518","pip_number":"EMA/PE/0000181518","active_substance":"Lerodalcibep","invented_name":"","therapeutic_area":"Metabolism and nutrition disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of hypercholesterolaemia","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LIB Therapeutics Inc.Email: LIBadmin@libtherapeutics.comTel: +1 7347301170","first_published_date":"30/06/2021","last_updated_date":"17/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000181518"},{"decision_number":"EMA/PE/0000181441","pip_number":"EMA/PE/0000181441","active_substance":"telisotuzumab conjugated to (2S)-2-(2-bromoacetamido)-N-[(2S)-1-({3-[(7S)-7-ethyl-7-hydroxy- 8,11-dioxo-7,8,11,13-tetrahydro-2H,10H-[1,3]dioxolo[4,5-g]pyrano[3',4':6,7]indolizino[1,2- b]quinolin-14-yl]bicyclo[1.1.1]pentan-1-yl}amino)-1-oxopropan-2-yl]-3-methylbutanamide","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of gastric and gastroesophageal junction adenocarcinoma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Abbvie LimitedEmail: paediatricteam@abbvie.comTel: +44(0) 1628925033","first_published_date":"17/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000181441"},{"decision_number":"EMA/PE/0000221101","pip_number":"EMA/PE/0000221101","active_substance":"esepapogene zalarnarepvec","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of human papillomavirus (HPV) 16 positive oropharyngeal squamous cell carcinoma","routes_of_administration":"Intravenous use","decision_type":"","decision_date":"","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Hookipa Biotech GmbHE-mail : mark.winderlich@hookipapharma.comTel :  +43 676846674237&nbsp","first_published_date":"17/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000221101"},{"decision_number":"EMA/PE/0000181335","pip_number":"EMA/PE/0000181335","active_substance":"Budesonide;Formoterol (fumarate);glycopyrronium bromide","invented_name":"Trixeo Aerosphere","therapeutic_area":"Respiratory, thoracic and mediastinal disorders","pharmaceutical_forms":"Pressurised inhalation;Suspension","condition_indication":"Treatment of asthma","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca ABEmail: paediatrics@astrazeneca.comTel. +46 855324400","first_published_date":"05/03/2018","last_updated_date":"17/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000181335"},{"decision_number":"EMA/PE/0000220986","pip_number":"EMA/PE/0000220986","active_substance":"tenapanor","invented_name":"","therapeutic_area":"Metabolism and nutrition disorders","pharmaceutical_forms":"Coated tablet","condition_indication":"Treatment of hyperphosphataemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pharma Gateway ABE-mail : info@ardelyx.com&nbsp","first_published_date":"17/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000220986"},{"decision_number":"EMA/PE/0000221175","pip_number":"EMA/PE/0000221175","active_substance":"vibegron","invented_name":"Obgemsa","therapeutic_area":"Renal and urinary disorders","pharmaceutical_forms":"Film-coated tablet;Granules","condition_indication":"Treatment of myoneurogenic bladder disorders","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"16/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pierre Fabre Médicament; E-mail: info@urovant.com; Tel: +1 8338768268","first_published_date":"24/08/2023","last_updated_date":"17/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000221175"},{"decision_number":"P/0360/2021","pip_number":"EMA/PE/0000181300","active_substance":"avalglucosidase alfa","invented_name":"Nexviadyme","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of Pompe disease","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi B.V.E-mail: eumedinfo.gz@sanofi.comTel: +31 (0) 20 245 3917","first_published_date":"21/04/2017","last_updated_date":"17/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000181300"},{"decision_number":"P/0019/2024","pip_number":"EMA/PE/0000181294","active_substance":"Tolebrutinib","invented_name":"","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of multiple sclerosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi Winthrop Industrie Email: eumedinfo.gz@sanofi.com Tel. +31 (0)202453917","first_published_date":"24/06/2021","last_updated_date":"17/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000181294"},{"decision_number":"EMA/PE/0000181238","pip_number":"EMA/PE/0000181238","active_substance":"resiquimod","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of melanoma","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eikon Therapeutics Inc.Email: vangalas@eikontx.comTel: +1 3417770566&nbsp","first_published_date":"17/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000181238"},{"decision_number":"EMA/PE/0000181236","pip_number":"EMA/PE/0000181236","active_substance":"telisotuzumab conjugated to (2S)-2-(2-bromoacetamido)-N-[(2S)-1-({3-[(7S)-7-ethyl-7-hydroxy- 8,11-dioxo-7,8,11,13-tetrahydro-2H,10H-[1,3]dioxolo[4,5-g]pyrano[3',4':6,7]indolizino[1,2- b]quinolin-14-yl]bicyclo[1.1.1]pentan-1-yl}amino)-1-oxopropan-2-yl]-3-methylbutanamide","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer (small cell and non-small cell lung cancer)","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"05/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Abbvie LimitedEmail: paediatricteam@abbvie.comTel: +44(0) 1628925033","first_published_date":"17/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000181236"},{"decision_number":"EMA/PE/0000221419","pip_number":"EMA/PE/0000221419","active_substance":"pneumococcal polysaccharide serotype 3 - diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 8 – diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 15C – diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 6A – diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 15A – diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 16F – diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 19A – diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 23A – diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 24F – diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 17F – diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 33F – diphtheria CRM197 conjugate (15-valent pneumococcal polysaccharide conjugate vaccine [V114]);pneumococcal polysaccharide serotype 10A – diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 12F – diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 20A – diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 31 – diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 35B – diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 7F – diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 22F – diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 9N – diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 11A – diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 23B – diphtheria CRM197 conjugate (V116)","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Solution for injection in pre-filled syringe","condition_indication":"Prevention of disease caused by Streptococcus pneumoniae","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"13/11/2023","last_updated_date":"17/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000221419-0"},{"decision_number":"P/0470/2022","pip_number":"EMA/PE/0000181219","active_substance":"bedaquiline fumarate","invented_name":"Sirturo; Sirturo","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Tablet;Granules","condition_indication":"Treatment of multi-drug-resistant tuberculosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen Cilag International Email: contact@Janssen-emea.com Tel. +32 14602111","first_published_date":"08/04/2011","last_updated_date":"17/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000181219"},{"decision_number":"EMA/PE/0000221199","pip_number":"EMA/PE/0000221199","active_substance":"bemcentinib","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of non-small cell lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bergenbio ASAEmail : post@bergenbio.comTel:  + 47 559 611 59&nbsp","first_published_date":"16/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000221199"},{"decision_number":"EMA/PE/0000221424","pip_number":"EMA/PE/0000221424","active_substance":"dermatophagoides pteronyssinus extract","invented_name":"","therapeutic_area":"Immune system disorders","pharmaceutical_forms":"Solution for skin-prick test","condition_indication":"Diagnosis of house dust mite allergy","routes_of_administration":"Intraepidermal use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medicina España S.A.E-mail: info@roxall.es Tel.:  +34 944438000","first_published_date":"16/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000221424"},{"decision_number":"EMA/PE/0000221500","pip_number":"EMA/PE/0000221500","active_substance":"phleum pratense pollen extract","invented_name":"","therapeutic_area":"Immune system disorders","pharmaceutical_forms":"Solution for skin-prick test","condition_indication":"Diagnosis of grass pollen allergy","routes_of_administration":"Intraepidermal use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"05/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medicina España S.A.E-mail: info@roxall.es Tel.:  +34 944438000","first_published_date":"16/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000221500"},{"decision_number":"EMA/PE/0000221511","pip_number":"EMA/PE/0000221511","active_substance":"recombinant human apolipoprotein A-I","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of lecithin-cholesterol acyltransferase deficiency","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Abionyx PharmaE-mail: info@abionyx.comTel.:   +33(0) 562 249 706&nbsp","first_published_date":"16/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000221511"},{"decision_number":"EMA/PE/0000221664","pip_number":"EMA/PE/0000221664","active_substance":"parietaria judaica pollen extract","invented_name":"","therapeutic_area":"Immune system disorders","pharmaceutical_forms":"Solution for skin-prick test","condition_indication":"Diagnosis of weed pollen allergy","routes_of_administration":"Intraepidermal use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medicina España S.A.E-mail: info@roxall.es Tel.:  +34 944438000","first_published_date":"16/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000221664"},{"decision_number":"EMA/PE/0000221674","pip_number":"EMA/PE/0000221674","active_substance":"xaluritamig","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of prostate cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V.; Tel. +44 (0)1223 420305; E-mail: pipenquiry@amgen.com","first_published_date":"16/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000221674"},{"decision_number":"EMA/PE/0000221695","pip_number":"EMA/PE/0000221695","active_substance":"cupressus arizonica pollen extract","invented_name":"","therapeutic_area":"Immune system disorders","pharmaceutical_forms":"Solution for skin-prick test","condition_indication":"Diagnosis of cypress pollen allergy","routes_of_administration":"Intraepidermal use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"05/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medicina España S.A.E-mail: info@roxall.es Tel.:  +34 944438000","first_published_date":"16/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000221695"},{"decision_number":"EMA/PE/0000221772","pip_number":"EMA/PE/0000221772","active_substance":"olea europaea pollen extract","invented_name":"","therapeutic_area":"Immune system disorders","pharmaceutical_forms":"Solution for skin-prick test","condition_indication":"Diagnosis of olive pollen allergy","routes_of_administration":"Intraepidermal use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medicina España S.A.E-mail: info@roxall.es Tel.:  +34 944438000","first_published_date":"16/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000221772"},{"decision_number":"EMA/PE/0000183758","pip_number":"EMA/PE/0000183758","active_substance":"zimislecel","invented_name":"","therapeutic_area":"Endocrine disorders","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of type 1 diabetes in individuals with impaired awareness of hypoglycaemia resulting in recurrent severe hypoglycaemia","routes_of_administration":"Intraportal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vertex Pharmaceuticals (Ireland) Limited; E-mail: vertexmedicalinfo@vrtx.com; Tel: +353 17617299","first_published_date":"10/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000183758"},{"decision_number":"P/0012/2024","pip_number":"EMA/PE/0000183430","active_substance":"tralokinumab","invented_name":"Adtralza","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of atopic dermatitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LEO Pharma A/S E-mail: raleodk@leo-pharma.com Tel. +45 44945888","first_published_date":"19/06/2018","last_updated_date":"10/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000183430"},{"decision_number":"EMA/PE/0000183866","pip_number":"EMA/PE/0000183866","active_substance":"brexpiprazole","invented_name":"Rxulti","therapeutic_area":"Psychiatric disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of schizophrenia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Otsuka Pharmaceutical Development and Commercialisation Europe GmbH; E-mail: paediatric-info@otsuka-europe.com; Tel. +49 69 955 044 328","first_published_date":"22/08/2012","last_updated_date":"10/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000183866"},{"decision_number":"EMA/PE/0000184400","pip_number":"EMA/PE/0000184400","active_substance":"dapagliflozin;eplerenone","invented_name":"","therapeutic_area":"Cardiac disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of heart failure","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"05/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ELPEN Pharmaceutical Co. Inc; E-mail: regulatoryaffairs@elpen.gr; Tel. +30 2106039326; &nbsp","first_published_date":"10/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000184400"},{"decision_number":"EMA/PE/0000183220","pip_number":"EMA/PE/0000183220","active_substance":"iclepertin","invented_name":"","therapeutic_area":"Psychiatric disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of schizophrenia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"22/11/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"22/09/2021","last_updated_date":"10/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000183220"},{"decision_number":"P/0452/2021","pip_number":"EMEA-002944-PIP01-20","active_substance":"2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid tris(hydroxymethyl)aminomethane salt (1:1) (PF-06882961)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Age appropriate oral formulation;Tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/10/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG  E-mail: medical.information@pfizer.com Tel: +44 (0)1304 616161","first_published_date":"20/02/2023","last_updated_date":"10/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002944-pip01-20"},{"decision_number":"P/0153/2023","pip_number":"EMEA-003104-PIP02-22","active_substance":"Favezelimab;pembrolizumab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Hodgkin lymphoma","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"30/05/2024","last_updated_date":"10/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003104-pip02-22"},{"decision_number":"P/0143/2022","pip_number":"EMEA-002979-PIP01-21","active_substance":"pamrevlumab","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of Duchenne muscular dystrophy","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"FibroGen, Inc.;  +1 4159781200; ecarrier@fibrogen.com;  ","first_published_date":"17/04/2023","last_updated_date":"10/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002979-pip01-21"},{"decision_number":"P/0355/2022","pip_number":"EMEA-001613-PIP04-21","active_substance":"tezepelumab","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic spontaneous urticaria","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"12/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V. ; E-mail: medinfointernational@amgen.com; Tel. +44 (0)1223 420305","first_published_date":"24/08/2023","last_updated_date":"10/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001613-pip04-21"},{"decision_number":"P/0362/2017","pip_number":"EMEA-001758-PIP01-15-M02","active_substance":"Lumicitabine","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for oral suspension","condition_indication":"Treatment of lower respiratory tract disease caused by human respiratory syncytial virus (RSV)","routes_of_administration":"Oral use;Gastric use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; Tel. + 32 1460 2111; E-mail: contact@janssen-emea.com","first_published_date":"25/04/2016","last_updated_date":"10/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001758-pip01-15-m02"},{"decision_number":"EMA/PE/0000182447","pip_number":"EMA/PE/0000182447","active_substance":"amlitelimab","invented_name":"","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Solution for injection in pre-filled syringe","condition_indication":"Treatment of atopic dermatitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi Winthrop Industrie; Email: contact-us@sanofi.com; Tel: +31 202 453 703","first_published_date":"13/02/2025","last_updated_date":"09/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000182447"},{"decision_number":"EMA/PE/0000183373","pip_number":"EMA/PE/0000183373","active_substance":"tadalafil;tamsulosin","invented_name":"","therapeutic_area":"Renal and urinary disorders","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of benign prostatic hyperplasia","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Midas Pharma GmbH; E-mail: info@midas-pharma.com; Tel. +49 6132 9900","first_published_date":"09/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000183373"},{"decision_number":"EMA/PE/0000183329","pip_number":"EMA/PE/0000183329","active_substance":"interleukin-23 receptor antagonist peptide","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Age appropriate dosage form;Film-coated tablet","condition_indication":"Treatment of psoriasis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; Tel. +32 1460 2111; E-mail: contact@janssen-emea.com","first_published_date":"02/10/2024","last_updated_date":"09/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000183329"},{"decision_number":"EMA/PE/0000183137","pip_number":"EMA/PE/0000183137","active_substance":"encaleret","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Age appropriate oral dosage formulation;Film-coated tablet","condition_indication":"Treatment of hypoparathyroidism","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BridgeBio Europe B.V.; E-mail: medinfo@bridgebio.com Tel:  +1 (650)6003610","first_published_date":"13/09/2024","last_updated_date":"09/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000183137"},{"decision_number":"P/0381/2022","pip_number":"EMA/PE/0000182808","active_substance":"zoliflodacin","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Granules for oral suspension","condition_indication":"Treatment of gonococcal infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Entasis Therapeutic Inc.; E-mail: Enquiries@entasistx.com; Tel.: +1 7818108940","first_published_date":"29/07/2020","last_updated_date":"09/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000182808"},{"decision_number":"EMA/PE/0000183083","pip_number":"EMA/PE/0000183083","active_substance":"(S)-(4-amino-1,3-dihydrofuro[3,4-c][1,7]naphthyridin-8-yl)(3-(4-(trifluoromethyl)phenyl)morpholino)methanone","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of non-small cell lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe BV; E-mail: medinfointernational@amgen.com; Tel. +44 (0)1223 420305","first_published_date":"09/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000183083"},{"decision_number":"EMA/PE/0000182525","pip_number":"EMA/PE/0000182525","active_substance":"modified messenger ribonucleic acid encoding individual patient-specific tumour neoantigens (V940/ mRNA-4157)","invented_name":"","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Dispersion for injection","condition_indication":"Treatment of melanoma","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme B.V.E-mail: pip.information@msd.com Tel.:  +33 180464738","first_published_date":"09/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000182525"},{"decision_number":"EMA/PE/0000182462","pip_number":"EMA/PE/0000182462","active_substance":"bizalimogene ralaplasmid;mavilimogene ralaplasmid;rocakinogene sifuplasmid","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"human papilloma virus (HPV) type 16 and/or type 18 positive malignancies","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Inovio Pharmaceuticals Inc.; E-mail: ino@inovio.com Tel:  +1 2674404200","first_published_date":"09/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000182462"},{"decision_number":"EMA/PE/0000182440","pip_number":"EMA/PE/0000182440","active_substance":"resiniferatoxin","invented_name":"","therapeutic_area":"Musculoskeletal and connective tissue disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic musculoskeletal pain","routes_of_administration":"Intra-articular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Grünenthal GmbH; Tel. +49 2415690E-mail: pediatrics@grunenthal.com","first_published_date":"09/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000182440"},{"decision_number":"P/0389/2024","pip_number":"EMEA-003580-PIP01-24","active_substance":"6'-([(1S,3S)-3-([5-(difluoromethoxy)-2- pyrimidinyl]amino)cyclopentyl]amino)-2H- [1,3'-bipyridin]-2-one (AZD0780)","invented_name":"","therapeutic_area":"Metabolism and nutrition disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of elevated cholesterol;Treatment of mixed dyslipidaemia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"05/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com","first_published_date":"09/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003580-pip01-24"},{"decision_number":"P/0398/2024","pip_number":"EMEA-003564-PIP01-23","active_substance":"olorofim","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of invasive aspergillosis;Treatment of non-Aspergillus invasive mould infections","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"17/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Shionogi B.V.; E-mail: shionogiclintrials-admin@shionogi.co.jp; Tel: +44 203534200","first_published_date":"09/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003564-pip01-23"},{"decision_number":"P/0392/2024","pip_number":"EMEA-003558-PIP01-23","active_substance":"linaprazan glurate","invented_name":"","therapeutic_area":"Gastrointestinal disorders","pharmaceutical_forms":"Tablet;Granules","condition_indication":"Treatment of gastro-oesophageal reflux disease","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cinclus Pharma Holding ABE-mail: info@cincluspharma.com Tel.:  +46 (0)8133310","first_published_date":"09/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003558-pip01-23"},{"decision_number":"P/0394/2024","pip_number":"EMEA-003588-PIP01-24","active_substance":"7-ethyl-10-hydroxy-camptothecin","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Implant","condition_indication":"Treatment of soft tissue sarcoma","routes_of_administration":"Implant use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cebiotex S.L.E-mail: jbertran@cebiotex.com Tel.:  +34 934344412","first_published_date":"09/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003588-pip01-24"},{"decision_number":"P/0396/2024","pip_number":"EMEA-003592-PIP01-24","active_substance":"gorilla adenovirus vector expressing HPV6 and HPV11 antigens (PRGN-2012)","invented_name":"","therapeutic_area":"Respiratory, thoracic and mediastinal disorders","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of respiratory papillomatosis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Precigen Inc.E-mail: contact@precigen.com Tel.:  +1 3015569900","first_published_date":"09/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003592-pip01-24"},{"decision_number":"P/0402/2024","pip_number":"EMEA-003614-PIP01-24","active_substance":"diazoxide choline","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Prolonged-release tablet;Age-appropriate oral dosage form","condition_indication":"Treatment of Prader-Willi syndrome","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"18/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Soleno Therapeutics Europe LimitedE-mail: info@soleno.life Tel.: +353 16111505","first_published_date":"09/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003614-pip01-24"},{"decision_number":"P/0393/2024","pip_number":"EMEA-003556-PIP02-24","active_substance":"tulisokibart","invented_name":"","therapeutic_area":"Gastrointestinal disorders","pharmaceutical_forms":"Concentrate for solution for infusion;Solution for injection;Age appropriate dosage form for parenteral use","condition_indication":"Treatment of Crohn's disease","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme B.V.pip.information@msd.com+33 180464738","first_published_date":"08/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003556-pip02-24"},{"decision_number":"P/0390/2024","pip_number":"EMEA-003556-PIP01-23","active_substance":"tulisokibart","invented_name":"","therapeutic_area":"Gastrointestinal disorders","pharmaceutical_forms":"Concentrate for solution for infusion;Solution for injection;Age appropriate dosage form for parenteral use","condition_indication":"Treatment of ulcerative colitis","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme B.V.pip.information@msd.com+33 180464738","first_published_date":"08/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003556-pip01-23"},{"decision_number":"P/0391/2024","pip_number":"EMEA-003506-PIP01-23","active_substance":"doruxapapogenum ralaplasmidum","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of recurrent respiratory papillomatosis","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Inovio Pharmaceuticals IncE-mail: cheryl.elder@inovio.com Tel.: +1 2674298777","first_published_date":"08/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003506-pip01-23"},{"decision_number":"P/0397/2024","pip_number":"EMEA-002978-PIP02-24","active_substance":"trastuzumab deruxtecan","invented_name":"Enhertu","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of all conditions in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"05/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Daiichi Sankyo Europe GmbH; E-mail: service@daiichi-sankyo.eu; Tel.: +49 8978080","first_published_date":"08/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002978-pip02-24"},{"decision_number":"EMA/PE/0000225184","pip_number":"EMA/PE/0000225184","active_substance":"nirmatrelvir;ritonavir","invented_name":"Paxlovid","therapeutic_area":"Surgical and medical procedures","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral dosage formulation","condition_indication":"Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG  E-mail: medical.information@pfizer.com Tel: +44 (0)1304 616161","first_published_date":"07/01/2021","last_updated_date":"08/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000225184"},{"decision_number":"EMA/PE/0000224486","pip_number":"EMA/PE/0000224486","active_substance":"amlodipine;ramipril;rosuvastatin","invented_name":"","therapeutic_area":"Vascular disorders","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of coronary artery disease;Treatment of essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"05/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Adamed Pharma S.A.E-mail: agnieszka.leszczynska@adamed.comTel:  + 48 532512603","first_published_date":"08/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000224486"},{"decision_number":"EMA/PE/0000224202","pip_number":"EMA/PE/0000224202","active_substance":"Dengue tetravalent vaccine (live, attenuated)","invented_name":"Qdenga","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Prevention of dengue fever","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Vaccines, Inc. E-mail: amy.atwood@takeda.com Tel. +1 6174 442147","first_published_date":"24/07/2017","last_updated_date":"08/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000224202"},{"decision_number":"EMA/PE/0000221803","pip_number":"EMA/PE/0000221803","active_substance":"betula pendula pollen extract","invented_name":"","therapeutic_area":"Immune system disorders","pharmaceutical_forms":"Solution for skin-prick test","condition_indication":"Diagnosis of birch pollen allergy","routes_of_administration":"Intraepidermal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medicina España S.A.E-mail: info@roxall.es Tel.:  +34 944438000","first_published_date":"08/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000221803"},{"decision_number":"EMA/PE/0000183059","pip_number":"EMA/PE/0000183059","active_substance":"abrocitinib","invented_name":"Cibinqo","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of atopic dermatitis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/11/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG; Tel. +44 (0)1304 646 607; E-mail: pip_enquiries@pfizer.com","first_published_date":"14/02/2019","last_updated_date":"05/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000183059"},{"decision_number":"EMA/PE/0000221076","pip_number":"EMA/PE/0000221076","active_substance":"adrenaline (epinephrine)","invented_name":"Eurneffy","therapeutic_area":"Surgical and medical procedures","pharmaceutical_forms":"Nasal spray (solution)","condition_indication":"Treatment of allergic reactions","routes_of_administration":"Nasal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/11/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ARS Pharmaceuticals IRL LimitedE-mail: Medicalinformation.eu@ars-pharma.com Tel: +353 15241639","first_published_date":"09/09/2021","last_updated_date":"05/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000221076"},{"decision_number":"EMA/PE/0000221589","pip_number":"EMA/PE/0000221589","active_substance":"split influenza virus, inactivated containing antigens equivalent to the A/H1N1-like strain;split influenza virus, inactivated containing antigens equivalent to the A/H3N2-like strain;split influenza virus, inactivated containing antigens equivalent to the B-like strain (Victoria lineage);split influenza virus, inactivated containing antigens equivalent to the B-like strain (Yamagata lineage)","invented_name":"Efluelda Tetra","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of influenza infection","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"25/11/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi PasteurE-mail: contact-us@sanofi.comTel. +33 1 6974 5695","first_published_date":"24/04/2019","last_updated_date":"05/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000221589"},{"decision_number":"EMA/PE/0000238005","pip_number":"EMA/PE/0000238005","active_substance":"inebilizumab","invented_name":"Uplizna","therapeutic_area":"Surgical and medical procedures","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of immunoglobulin G4-related disease","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/11/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Horizon Therapeutics Ireland Designated Activity Company Tel. +44 (0)1223420305 E-mail: medinfointernational@amgen.com&nbsp","first_published_date":"13/02/2025","last_updated_date":"05/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000238005"},{"decision_number":"EMA/PE/0000238074","pip_number":"EMA/PE/0000238074","active_substance":"Mitapivat","invented_name":"Pyrukynd","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Age appropriate oral solid dosage form;Film-coated tablet","condition_indication":"Treatment of thalassaemia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/11/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Agios Pharmaceuticals, Inc.Tel.  +1 8332288474E-mail: medinfo@agios.com","first_published_date":"10/05/2023","last_updated_date":"05/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000238074"},{"decision_number":"EMA/PE/0000182362","pip_number":"EMA/PE/0000182362","active_substance":"tildrakizumab","invented_name":"Ilumetri","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of psoriasis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/11/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Almirall, S.AE-mail: global.regulatory@almirall.com Tel: +34 932913506","first_published_date":"16/04/2014","last_updated_date":"05/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000182362"},{"decision_number":"EMA/PE/0000221709","pip_number":"EMA/PE/0000221709","active_substance":"apitegromab","invented_name":"","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of spinal muscular atrophy","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/11/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Scholar Rock Inc. Email: info@scholarrock.com  Tel. +1 8572593860","first_published_date":"17/03/2025","last_updated_date":"05/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000221709"},{"decision_number":"P/0391/2023","pip_number":"EMA/PE/0000254020","active_substance":"risankizumab","invented_name":"Skyrizi","therapeutic_area":"Gastrointestinal disorders","pharmaceutical_forms":"Concentrate for solution for infusion;Concentrate for solution for injection;Age appropriate dosage form for parenteral use","condition_indication":"Treatment of ulcerative colitis","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/06/2025","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"28/01/2019","last_updated_date":"05/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000254020"},{"decision_number":"P/0492/2023","pip_number":"EMA/PE/0000274326","active_substance":"risankizumab","invented_name":"Skyrizi","therapeutic_area":"Musculoskeletal and connective tissue disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondylarthritis and juvenile idiopathic arthritis)","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/10/2025","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"12/02/2018","last_updated_date":"05/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000274326"},{"decision_number":"P/0388/2024","pip_number":"EMEA-001451-PIP02-24","active_substance":"tildrakizumab","invented_name":"Ilumetri","therapeutic_area":"Musculoskeletal and connective tissue disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis and juvenile idiopathic arthritis)","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/11/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Almirall, S.A.E-mail: global.regulatory@almirall.comTel.:  +34 933128699","first_published_date":"02/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001451-pip02-24"},{"decision_number":"P/0387/2024","pip_number":"EMEA-001943-PIP07-24","active_substance":"ravulizumab","invented_name":"Ultomiris","therapeutic_area":"Renal and urinary disorders","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of primary immunoglobulin A nephropathy","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/11/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alexion Europe SAS; E-mail: pip.enquiries.eu@alexion.com; Tel: +33 147100615","first_published_date":"02/12/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001943-pip07-24"},{"decision_number":"EMA/PE/0000232315","pip_number":"EMA/PE/0000232315","active_substance":"spesolimab","invented_name":"Spevigo","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Solution for infusion;Solution for injection","condition_indication":"Treatment of Netherton syndrome","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/03/2025","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"15/07/2024","last_updated_date":"02/12/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000232315"},{"decision_number":"P/0268/2022","pip_number":"EMEA-003116-PIP01-21","active_substance":"Gliadin protease","invented_name":"","therapeutic_area":"Gastroentology-Hepatology;Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Age appropriate oral solid pharmaceutical form","condition_indication":"Treatment of coeliac disease","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"28/08/2023","last_updated_date":"27/11/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003116-pip01-21"},{"decision_number":"P/0263/2023","pip_number":"EMEA-002819-PIP01-20-M01","active_substance":"Magrolimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion;Age appropriate dosage form for parenteral use","condition_indication":"Treatment of acute myeloid leukaemia;Treatment of myelodysplastic syndromes, including juvenile myelomonocytic leukemia","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd.; Tel. +44 (0)1223 897 300; E-mail: regulatory.pip@gilead.com","first_published_date":"10/03/2023","last_updated_date":"27/11/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002819-pip01-20-m01"},{"decision_number":"P/0116/2024","pip_number":"EMEA-003448-PIP01-23","active_substance":"Losmapimod","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Film-coated tablet;Dispersible mini-tablet formulation","condition_indication":"Treatment of facioscapulohumeral muscular dystrophy","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Fulcrum Therapeutics Inc.info@fulcrumtx.com+1 6176518851","first_published_date":"11/06/2025","last_updated_date":"27/11/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003448-pip01-23"},{"decision_number":"P/0183/2024","pip_number":"EMEA-002341-PIP02-23","active_substance":"ganaxolone","invented_name":"Ztalmy","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Oral suspension","condition_indication":"Treatment of tuberous sclerosis complex","routes_of_administration":"Oral use;Gastric use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"17/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Marinus Pharmaceuticals Inc.; E-mail: regulatory@marinuspharma.com; Tel.  +1 4848014670","first_published_date":"06/06/2025","last_updated_date":"27/11/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002341-pip02-23"},{"decision_number":"P/0432/2022","pip_number":"EMEA-003156-PIP01-21","active_substance":"Efavaleukin alfa","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Systemic Lupus Erythematosus (SLE)","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V. ; E-mail: medinfointernational@amgen.com; Tel. +44 (0)1223 420305","first_published_date":"04/10/2023","last_updated_date":"27/11/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003156-pip01-21"},{"decision_number":"P/0393/2018","pip_number":"EMEA-002284-PIP01-17","active_substance":"Evobrutinib","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of multiple sclerosis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/12/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck KGaA; Tel. +49 6151 725200; E-mail: service@merckgroup.com","first_published_date":"14/02/2019","last_updated_date":"27/11/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002284-pip01-17"},{"decision_number":"P/0524/2022","pip_number":"EMEA-003153-PIP01-21","active_substance":"HIV-1 Maturation Inhibitor (GSK3640254)","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral formulation","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"30/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ViiV Healthcare UK LimitedE-mail: eu.paediatric-plans@gsk.com Tel: +1 4388998201","first_published_date":"13/11/2023","last_updated_date":"20/11/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003153-pip01-21"},{"decision_number":"P/0196/2020","pip_number":"EMEA-001489-PIP02-19","active_substance":"Idasanutlin","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet;Film-coated dispersible tablet","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/05/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"04/03/2021","last_updated_date":"17/11/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001489-pip02-19"},{"decision_number":"P/0081/2020","pip_number":"EMEA-001489-PIP01-13-M02","active_substance":"Idasanutlin","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet;Film-coated dispersible tablet","condition_indication":"Treatment of acute lymphoblastic leukaemia;Treatment of acute myeloid leukaemia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"04/12/2014","last_updated_date":"17/11/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001489-pip01-13-m02"},{"decision_number":"P/0098/2021","pip_number":"EMEA-002821-PIP01-20","active_substance":"Respiratory Syncytial Virus PreF3 recombinant fusion protein (RSVPreF3)","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Prevention of RSV-associated lower respiratory tract illness through maternal immunisation","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"19/03/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Biologicals SA; E-mail: eu.paediatric-plans@gsk.com; Tel:  +1 4388998201","first_published_date":"19/11/2021","last_updated_date":"17/11/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002821-pip01-20"},{"decision_number":"P/0157/2024","pip_number":"EMEA-002475-PIP04-23","active_substance":"spesolimab","invented_name":"Spevigo","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Solution for infusion;Solution for injection","condition_indication":"Treatment of hidradenitis suppurativa","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"06/06/2025","last_updated_date":"17/11/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002475-pip04-23"},{"decision_number":"P/0294/2020","pip_number":"EMEA-002554-PIP02-19","active_substance":"cilofexor","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral dosage formulation","condition_indication":"Treatment of primary sclerosing cholangitis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"12/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd; E-mail: regulatory.pip@gilead.com; Tel. +44 (0)1223 897300","first_published_date":"24/06/2021","last_updated_date":"14/11/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002554-pip02-19"},{"decision_number":"P/0309/2024","pip_number":"EMEA-003521-PIP01-23","active_substance":"single-stranded 5' capped mRNA encoding the HAs of the influenza virus strains A/H1N1, A/H3N2, and B/Victoria and the N-terminal domain (NTD) and receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein (mRNA-1083)","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Dispersion for injection","condition_indication":"Prevention of Coronavirus disease 2019 (COVID-19);Prevention of influenza","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Moderna Biotech Spain S.L.E-mail: EMEAMedInfo@modernatx.comTel: +34 900031015","first_published_date":"09/07/2025","last_updated_date":"14/11/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003521-pip01-23"},{"decision_number":"P/0100/2021","pip_number":"EMEA-002815-PIP01-20","active_substance":"rozibafusp alfa","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Systemic Lupus Erythematosus (SLE)","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"17/03/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V. ; E-mail: medinfointernational@amgen.com; Tel. +44 (0)1223 420305","first_published_date":"19/11/2021","last_updated_date":"13/11/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002815-pip01-20"},{"decision_number":"P/0469/2022","pip_number":"EMEA-003156-PIP02-22","active_substance":"Efavaleukin alfa","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of ulcerative colitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/11/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V. ; E-mail: medinfointernational@amgen.com; Tel. +44 (0)1223 420305","first_published_date":"12/10/2023","last_updated_date":"13/11/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003156-pip02-22"},{"decision_number":"P/0321/2024","pip_number":"EMEA-002713-PIP02-21-M02","active_substance":"etrasimod","invented_name":"Velsipity","therapeutic_area":"Gastrointestinal disorders","pharmaceutical_forms":"Age appropriate oral solid dosage form;Film-coated tablet","condition_indication":"Treatment of Crohn's disease","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG  E-mail: medical.information@pfizer.com Tel: +44 (0)1304 616161","first_published_date":"28/08/2023","last_updated_date":"10/11/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002713-pip02-21-m02"},{"decision_number":"P/0523/2022","pip_number":"EMEA-003152-PIP01-21","active_substance":"dolutegravir;HIV-1 Maturation Inhibitor (GSK3640254)","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Age appropriate oral dosage formulation;Film-coated tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"30/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ViiV Healthcare UK LimitedE-mail: eu.paediatric-plans@gsk.com Tel: +1 4388998201","first_published_date":"13/11/2023","last_updated_date":"10/11/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003152-pip01-21"},{"decision_number":"EMA/PE/0000246904","pip_number":"EMA/PE/0000246904","active_substance":"cobolimab","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms including lymphoma","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/09/2025","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Tel. +1 4388998201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"21/05/2024","last_updated_date":"10/11/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000246904"},{"decision_number":"EMA/PE/0000232853","pip_number":"EMA/PE/0000232853","active_substance":"nitrosomonas eutropha, strain D23, live","invented_name":"","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Cutaneous spray","condition_indication":"Treatment of atopic dermatitis","routes_of_administration":"Cutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/09/2025","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aobiome Therapeutics Corp.E-mail: hkim@aobiome.com Tel:  +1 7814397159","first_published_date":"06/11/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000232853"},{"decision_number":"P/0395/2024","pip_number":"EMEA-003288-PIP01-22","active_substance":"bexicaserin","invented_name":"","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of seizures and seizure disorders","routes_of_administration":"Oral use;Gastroenteral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Longboard Pharmaceuticals Inc.E-mail: info@longboardpharma.com Tel:  +1 8587899283","first_published_date":"06/11/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003288-pip01-22"},{"decision_number":"EMA/PE/0000231113","pip_number":"EMA/PE/0000231113","active_substance":"nemvaleukin alfa","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except central nervous system, haematopoietic and lymphoid tissue);Treatment of malignant neoplasms of the lymphoid tissue","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"21/03/2025","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mural Oncology, Inc. E-mail: info@muraloncology.com Tel: +1 781 614 0100","first_published_date":"13/11/2024","last_updated_date":"06/11/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000231113"},{"decision_number":"EMA/PE/0000257243","pip_number":"EMA/PE/0000257243","active_substance":"pozelimab","invented_name":"","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of myasthenia gravis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/08/2025","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Regeneron Ireland DAC; E-mail: clinicaltrials@regeneron.com","first_published_date":"05/04/2024","last_updated_date":"06/11/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000257243"},{"decision_number":"P/0118/2024","pip_number":"EMEA-001260-PIP01-11-M03","active_substance":"outer membrane vesicles (OMV) from n. meningitidis strain NZ 98/254;recombinant neisseria meningitis group B Protein 936-741;meningococcal group W-135 oligosaccharides conjugated to corynebacterium diphtheriae CRM197 protein;meningococcal group A oligosaccharides conjugated to corynebacterium diphtheriae CRM197 protein;meningococcal group C oligosaccharides conjugated to corynebacterium diphtheriae CRM197 protein;recombinant neisseria meningitis group B Protein 287-953;recombinant Neisseria meningitis group B Protein 961c;meningococcal group Y oligosaccharides conjugated to corynebacterium diphtheriae CRM197 protein (MenABCWY)","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Powder and suspension for suspension for injection","condition_indication":"Prevention of meningococcal meningitis","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Biologicalse-mail: eu.paediatric-plans@gsk.com tel. +1 4388998201","first_published_date":"11/02/2013","last_updated_date":"28/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001260-pip01-11-m03"},{"decision_number":"P/0026/2022","pip_number":"EMEA-002996-PIP01-21","active_substance":"ExPEC9V","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of infections caused by extraintestinal pathogenic Escherichia coli (ExPEC)","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/02/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; Tel. +32 1460 2111; E-mail: contact@janssen-emea.com","first_published_date":"12/04/2023","last_updated_date":"28/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002996-pip01-21"},{"decision_number":"P/0271/2021","pip_number":"EMEA-002575-PIP02-20","active_substance":"pralsetinib","invented_name":"Gavreto","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of thyroid cancer","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/07/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"22/07/2022","last_updated_date":"28/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002575-pip02-20"},{"decision_number":"P/0273/2021","pip_number":"EMEA-002712-PIP01-19-M01","active_substance":"cotadutide","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of non-alcoholic steatohepatitis (NASH)","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/07/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel. +46 8553 27591","first_published_date":"22/09/2021","last_updated_date":"27/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002712-pip01-19-m01"},{"decision_number":"P/0506/2021","pip_number":"EMEA-002287-PIP01-17-M03","active_substance":"cotadutide","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel. +46 8553 27591","first_published_date":"17/01/2019","last_updated_date":"27/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002287-pip01-17-m03"},{"decision_number":"P/0384/2024","pip_number":"EMEA-000434-PIP01-08-M10","active_substance":"ambrisentan","invented_name":"Volibris","therapeutic_area":"Respiratory, thoracic and mediastinal disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of pulmonary arterial hypertension","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services LimitedE-mail: eu.paediatric-plans@gsk.com&nbsp","first_published_date":"23/12/2009","last_updated_date":"23/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000434-pip01-08-m10"},{"decision_number":"EMA/PE/0000221282","pip_number":"EMA/PE/0000221282","active_substance":"teplizumab","invented_name":"","therapeutic_area":"Metabolism and nutrition disorders","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of type I diabetes mellitus","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi Winthrop IndustrieE-mail: contact-us@sanofi.comTel: +33155712472","first_published_date":"25/02/2010","last_updated_date":"23/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000221282"},{"decision_number":"EMA/PE/0000181891","pip_number":"EMA/PE/0000181891","active_substance":"sildenafil citrate;testosterone","invented_name":"","therapeutic_area":"Psychiatric disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypoactive sexual desire disorder","routes_of_administration":"Sublingual use;Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Freya Pharma Solutions Holding B.V.E-mail: info@freyapharmasolutions.comTel:  +31 646237282","first_published_date":"23/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000181891"},{"decision_number":"EMA/PE/0000225106","pip_number":"EMA/PE/0000225106","active_substance":"Ibrexafungerp","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Tablet","condition_indication":"Prevention of recurrent vulvovaginal candidiasis;Treatment of vulvovaginal candidiasis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Glaxosmithkline Trading Services LimitedE-mail: info@scynexis.comTel: +1(201)8845485","first_published_date":"04/03/2021","last_updated_date":"23/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000225106"},{"decision_number":"P/0371/2024","pip_number":"EMEA-003440-PIP01-23","active_substance":"cyclic GMP-AMP synthase inhibitor (BI 3000202)","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type 1 Interferonopathies","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"22/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003440-pip01-23"},{"decision_number":"P/0385/2024","pip_number":"EMEA-001716-PIP08-23","active_substance":"venglustat","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of Fabry disease","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi B.V.E-mail: eumedinfo.gz@sanofi.comTel: +31 (0) 20 245 3917","first_published_date":"22/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001716-pip08-23"},{"decision_number":"P/0356/2024","pip_number":"EMEA-001858-PIP02-16-M04","active_substance":"daunorubicin;cytarabine","invented_name":"Vyxeos liposomal (previously Vyxeos)","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Powder for concentrate for infusion","condition_indication":"Treatment of acute myeloid leukaemia","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Jazz Pharmaceuticals Ireland LimitedE-mail: ukregulatory@jazzpharma.com Tel:  +1 6504963777","first_published_date":"28/09/2017","last_updated_date":"22/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001858-pip02-16-m04"},{"decision_number":"P/0363/2024","pip_number":"EMEA-002358-PIP02-18-M04","active_substance":"avapritinib","invented_name":"Ayvakyt","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Blueprint Medicines (Netherlands) B.VE-mail: MedinfoEurope@blueprintmedicines.com Tel.: +31 850644001","first_published_date":"24/04/2019","last_updated_date":"22/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002358-pip02-18-m04"},{"decision_number":"P/0362/2024","pip_number":"EMEA-002482-PIP01-24","active_substance":"zirconium (89Zr) girentuximab senvedoxam","invented_name":"","therapeutic_area":"Renal and urinary disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Diagnosis of indeterminate renal masses for diagnostic purposes","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Telix InnovationsE-mail: info@telixpharma.com","first_published_date":"22/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002482-pip01-24"},{"decision_number":"P/0386/2024","pip_number":"EMEA-000524-PIP02-24","active_substance":"teplizumab","invented_name":"","therapeutic_area":"Metabolism and nutrition disorders","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Prevention of of stage 3 type 1 diabetes mellitus","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi Winthrop IndustrieE-mail: contact-us@sanofi.comTel: +33155712472","first_published_date":"22/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000524-pip02-24"},{"decision_number":"P/0357/2024","pip_number":"EMEA-003531-PIP01-23","active_substance":"(R)-3-(1-cyclopropyl-3-(2-fluoro-4-(trifluoromethoxy)benzyl)ureido)piperidine-1-carboxamide (JNT-517)","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Oral powder;Tablet;Granules for oral suspension","condition_indication":"Treatment of hyperphenylalaninemia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Otsuka Pharmaceutical Netherlands B.V.E-mail: asati@otsuka-europe.com Tel.: ‭+49 (0)1746798505","first_published_date":"22/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003531-pip01-23"},{"decision_number":"P/0369/2024","pip_number":"EMEA-003565-PIP01-23","active_substance":"idroxioleic acid","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Powder for oral suspension","condition_indication":"Treatment of glioma","routes_of_administration":"Oral use;Gastric use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Laminar Pharmaceuticals S.A.E-mail: info@laminarpharma.comTel.: +34 971439886","first_published_date":"22/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003565-pip01-23"},{"decision_number":"P/0366/2024","pip_number":"EMEA-003642-PIP01-24","active_substance":"dexfadrostat phosphate","invented_name":"","therapeutic_area":"Endocrine disorders","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of primary aldosteronism","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Damian Pharma AGE-mail: info@damianpharma.com Tel.:  +41 616010978","first_published_date":"22/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003642-pip01-24"},{"decision_number":"P/0361/2024","pip_number":"EMEA-003643-PIP01-24","active_substance":"recombinant human progranulin fused to an Fc fragment engineered to contain a human transferrin receptor 1 binding domain (DNL593)","invented_name":"","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of frontotemporal dementia","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Denali Therapeutics Inc.E-mail: DNL310Inquiries-team@dnli.comTel.  +1 6508668548 ext 1033","first_published_date":"22/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003643-pip01-24"},{"decision_number":"P/0368/2024","pip_number":"EMEA-003646-PIP01-24","active_substance":"plinabulin","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung carcinoma (small cell and non-small cell carcinoma)","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Beyondspring Pharmaceuticals Inc.E-mail: claire.li@beyondspringpharma.com Tel.: +1 4016880172","first_published_date":"22/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003646-pip01-24"},{"decision_number":"P/0378/2024","pip_number":"EMEA-003648-PIP01-24","active_substance":"ALK inhibitor (NVL-655)","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer (small cell and non-small cell lung cancer)","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Nuvalent Inc.E-mail: info@nuvalent.com Tel.:  +1 8573577000","first_published_date":"22/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003648-pip01-24"},{"decision_number":"P/0358/2024","pip_number":"EMEA-003649-PIP01-24","active_substance":"zidesamtinib","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung malignant neoplasms","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Nuvalent Inc.E-mail: info@nuvalent.com Tel.:  +1 8573577000","first_published_date":"22/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003649-pip01-24"},{"decision_number":"P/0380/2024","pip_number":"EMEA-003656-PIP01-24","active_substance":"zipalertinib","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of non-small cell lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Taiho Pharma Europe Ltd.; Tel. +1 609 250 7336; E-mail: clinicaltrialinfo@taihooncology.com","first_published_date":"22/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003656-pip01-24"},{"decision_number":"P/0387/2023","pip_number":"EMEA-003002-PIP03-22","active_substance":"derivative of 6-[2-(pyridin-2-yl)phenoxy]methyl}-1,2,3,4-tetrahydroisoquinoline","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral formulation","condition_indication":"Treatment of portal hypertension","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"07/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"04/10/2024","last_updated_date":"22/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003002-pip03-22"},{"decision_number":"P/0352/2024","pip_number":"EMEA-000439-PIP03-23","active_substance":"bitopertin","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Film-coated tablet;Age appropriate dosage form","condition_indication":"Treatment of erythropoietic protoporphyria;Treatment of X-linked protoporphyria","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Disc Medicine B.V.E-mail: alin@discmedicine.comTel.: +31 641649363","first_published_date":"22/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000439-pip03-23"},{"decision_number":"P/0379/2024","pip_number":"EMEA-003526-PIP01-23","active_substance":"recombinant varicella zoster virus glycoprotein E adjuvanted (CRV-101)","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Powder and suspension for suspension for injection","condition_indication":"Prevention of varicella zoster virus (VZV) reactivation","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Curevo Inc.E-mail: office@curevovaccine.comTel.: +1 2064925722&nbsp","first_published_date":"21/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003526-pip01-23"},{"decision_number":"P/0377/2024","pip_number":"EMEA-003089-PIP02-23","active_substance":"dazukibart","invented_name":"","therapeutic_area":"Musculoskeletal and connective tissue disorders","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of idiopathic inflammatory myopathies","routes_of_administration":"Parenteral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"24/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG  E-mail: medical.information@pfizer.com Tel: +44 (0)1304 616161","first_published_date":"21/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003089-pip02-23"},{"decision_number":"P/0373/2024","pip_number":"EMEA-003495-PIP02-24","active_substance":"3,3-Dimethyl-N-(6-methyl-5-{[2-(1-methyl-1H-pyrazol-4-yl)pyridine-4-yl]oxy}pyridine-2-yl)-2-oxopyrrolidine-1-carboxamide hydrochloride hydrate","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of tenosynovial giant cell tumours","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Europe B.V.; Tel.: +49 6151725200; E-mail: service@merckgroup.com","first_published_date":"21/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003495-pip02-24"},{"decision_number":"P/0355/2024","pip_number":"EMEA-001794-PIP02-16-M09","active_substance":"vamorolone","invented_name":"Agamree","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Oral suspension","condition_indication":"Treatment of Duchenne muscular dystrophy","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Santhera Pharmaceuticals (Deutschland) GmbHE-mail: office@santhera.comTel.:  +49 76211690200","first_published_date":"19/06/2018","last_updated_date":"21/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001794-pip02-16-m09"},{"decision_number":"P/0353/2024","pip_number":"EMEA-001501-PIP07-20-M02","active_substance":"dupilumab","invented_name":"Dupixent","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Solution for injection in pre-filled syringe","condition_indication":"Treatment of chronic spontaneous urticaria","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi Winthrop IndustrieE-mail: catherine.anselmino@sanofi.com Tel.: 0640438252","first_published_date":"12/01/2022","last_updated_date":"21/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001501-pip07-20-m02"},{"decision_number":"P/0383/2024","pip_number":"EMEA-001160-PIP01-11-M05","active_substance":"recombinant human A disintegrin and metalloprotease with thrombospind type-1 motifs 13","invented_name":"Adzynma","therapeutic_area":"Blood and lymphatic system disorders","pharmaceutical_forms":"Powder and solvent for solution for infusion","condition_indication":"Treatment of thrombotic thrombocytopenic purpura (TTP)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Pharmaceuticals International AG Ireland Branch; E-mail: medinfoemea@takeda.com; Tel: +44 (0) 3333 000181","first_published_date":"26/03/2012","last_updated_date":"21/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001160-pip01-11-m05"},{"decision_number":"P/0381/2024","pip_number":"EMEA-001142-PIP02-16-M02","active_substance":"ceftolozane;tazobactam","invented_name":"Zerbaxa","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of pneumonia","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"24/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme B.V.E-mail: pip.information@msd.com Tel.:  +33 180464738","first_published_date":"12/02/2018","last_updated_date":"21/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001142-pip02-16-m02"},{"decision_number":"P/0374/2024","pip_number":"EMEA-001124-PIP01-10-M06","active_substance":"Lomitapide","invented_name":"Lojuxta","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of (heterozygous or homozygous) familial hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"24/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Chiesi Farmaceutici S.p.A.E-mail: s.alizert@chiesi.com  Tel.: +33 673780082","first_published_date":"19/01/2012","last_updated_date":"21/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001124-pip01-10-m06"},{"decision_number":"P/0375/2024","pip_number":"EMEA-001075-PIP04-15-M07","active_substance":"romosozumab","invented_name":"Evenity","therapeutic_area":"Musculoskeletal and connective tissue disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of osteoporosis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"24/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"UCB Pharma S.A.; E-mail: UCBCares.UK@ucb.comTel: +44 (0)1753777100","first_published_date":"22/04/2016","last_updated_date":"21/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001075-pip04-15-m07"},{"decision_number":"P/0376/2024","pip_number":"EMEA-000468-PIP02-12-M09","active_substance":"posaconazole","invented_name":"Noxafil","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Oral suspension;Gastro-resistant tablet;Gastro-resistant powder for oral suspension;Concentrate for solution for infusion","condition_indication":"Prevention of invasive fungal infections;Treatment of invasive fungal infections","routes_of_administration":"Oral use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"08/02/2013","last_updated_date":"21/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000468-pip02-12-m09"},{"decision_number":"P/0370/2024","pip_number":"EMEA-000311-PIP03-11-M07","active_substance":"ustekinumab","invented_name":"Stelara","therapeutic_area":"Musculoskeletal and connective tissue disorders","pharmaceutical_forms":"Solution for injection;Concentrate for solution for infusion","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis)","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; E-mail: contact@janssen-emea.com; Tel.: +32 14602111","first_published_date":"19/04/2012","last_updated_date":"21/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000311-pip03-11-m07"},{"decision_number":"P/0382/2024","pip_number":"EMEA-002536-PIP01-18-M04","active_substance":"Lebrikizumab","invented_name":"Ebglyss","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of atopic dermatitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"04/03/2021","last_updated_date":"21/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002536-pip01-18-m04"},{"decision_number":"P/0359/2024","pip_number":"EMEA-002905-PIP01-20-M01","active_substance":"brensocatib","invented_name":"","therapeutic_area":"Respiratory, thoracic and mediastinal disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of non-cystic fibrosis bronchiectasis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Insmed Netherlands B.V.E-mail: medicalinformation@insmed.comTel.: +1 9089474303","first_published_date":"22/03/2022","last_updated_date":"21/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002905-pip01-20-m01"},{"decision_number":"P/0360/2024","pip_number":"EMEA-003133-PIP01-21-M01","active_substance":"fidrisertib","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of fibrodysplasia ossificans progressiva","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ipsen PharmaE-mail: GlobalMedInfo@ipsen.comTel.: +33 158335427","first_published_date":"29/08/2023","last_updated_date":"21/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003133-pip01-21-m01"},{"decision_number":"P/0364/2024","pip_number":"EMEA-003174-PIP01-21-M02","active_substance":"pridopidine hydrochloride","invented_name":"","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of Huntington's disease","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Prilenia Therapeutics B.V.E-mail: info@prilenia.comTel. +31 358080509","first_published_date":"26/10/2023","last_updated_date":"21/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003174-pip01-21-m02"},{"decision_number":"P/0365/2024","pip_number":"EMEA-003426-PIP01-23-M02","active_substance":"mRNA encoding for the linked NTD and RBD domains of the spike glycoprotein of SARS-CoV-2 (mRNA-1283)","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Dispersion for injection","condition_indication":"Prevention of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Moderna Biotech Spain, S.L.E-mail: EMEAMedInfo@modernatx.comTel.  +34 900031015","first_published_date":"18/03/2025","last_updated_date":"21/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003426-pip01-23-m02"},{"decision_number":"P/0367/2024","pip_number":"EMEA-000069-PIP01-07-M09","active_substance":"Mepolizumab","invented_name":"Nucala","therapeutic_area":"Immune system disorders","pharmaceutical_forms":"Powder for solution for infusion;Solution for injection in pre-filled syringe","condition_indication":"Treatment of hypereosinophilic syndrome","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Glaxosmithkline Trading Services LimitedE-mail: eu.paediatric-plans@gsk.comTel.:  +44 2089903650","first_published_date":"07/10/2010","last_updated_date":"21/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000069-pip01-07-m09"},{"decision_number":"P/0327/2024","pip_number":"EMEA-002972-PIP02-23","active_substance":"seralutinib","invented_name":"","therapeutic_area":"Respiratory, thoracic and mediastinal disorders","pharmaceutical_forms":"Inhalation powder;Capsule, hard","condition_indication":"Treatment of pulmonary arterial hypertension","routes_of_administration":"Inhalation use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gossamer Bio 002 Limited; E-mail: regaffairs@gossamerbio.com; Tel: +1 8586841300","first_published_date":"20/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002972-pip02-23"},{"decision_number":"P/0324/2024","pip_number":"EMEA-002705-PIP06-23","active_substance":"iptacopan","invented_name":"Fabhalta","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Capsule, hard;Age-appropriate oral dosage form","condition_indication":"Treatment of myasthenia gravis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"20/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002705-pip06-23"},{"decision_number":"P/0335/2024","pip_number":"EMEA-003009-PIP01-21-M01","active_substance":"zamtocabtagene autoleucel","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of mature B cell neoplasms","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Miltenyi Biomedicine GmbH; E-mail: biomedicine_global_RA@miltenyi.com","first_published_date":"19/04/2023","last_updated_date":"20/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003009-pip01-21-m01"},{"decision_number":"P/0334/2024","pip_number":"EMEA-002899-PIP01-20-M03","active_substance":"sotrovimab","invented_name":"Xevudy","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Tel. +1 4388998201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"19/08/2021","last_updated_date":"20/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002899-pip01-20-m03"},{"decision_number":"P/0323/2024","pip_number":"EMEA-002818-PIP01-20-M01","active_substance":"Human plasma derived C1-inhibitor (OCTA-C1-INH)","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of hereditary angioedema","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Octapharma Pharmazeutika Produktionsgesellschaft mbH; E-mail: wolfgang.frenzel@octapharma.com; Tel: +43 1610321315","first_published_date":"28/04/2022","last_updated_date":"20/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002818-pip01-20-m01"},{"decision_number":"P/0320/2024","pip_number":"EMEA-002812-PIP02-20-M03","active_substance":"rimegepant","invented_name":"Vydura","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Oral lyophilisate","condition_indication":"Treatment of migraine headaches","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG  E-mail: medical.information@pfizer.com Tel: +44 (0)1304 616161","first_published_date":"08/10/2021","last_updated_date":"20/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002812-pip02-20-m03"},{"decision_number":"P/0322/2024","pip_number":"EMEA-002705-PIP03-20-M01","active_substance":"iptacopan","invented_name":"Fabhalta","therapeutic_area":"Renal and urinary disorders","pharmaceutical_forms":"Age appropriate formulation;Capsule, hard","condition_indication":"Treatment of paroxysmal nocturnal haemoglobinuria","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"08/09/2022","last_updated_date":"20/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002705-pip03-20-m01"},{"decision_number":"P/0348/2024","pip_number":"EMEA-002600-PIP03-21-M03","active_substance":"pegcetacoplan","invented_name":"Aspaveli","therapeutic_area":"Renal and urinary disorders","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of glomerulonephritis and nephrotic syndrome","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"24/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Swedish Orphan Biovitrum AB (publ); medical.info@sobi.com; +46 86972000","first_published_date":"28/08/2023","last_updated_date":"20/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002600-pip03-21-m03"},{"decision_number":"P/0347/2024","pip_number":"EMEA-002535-PIP04-21-M02","active_substance":"Ibrexafungerp citrate","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Tablet;Powder for oral solution;Powder for solution for injection or infusion","condition_indication":"Treatment of invasive candidiasis","routes_of_administration":"Oral use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Glaxosmithkline Trading Services LimitedE-mail: info@scynexis.comTel: +1(201)8845485","first_published_date":"28/09/2023","last_updated_date":"20/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002535-pip04-21-m02"},{"decision_number":"P/0344/2024","pip_number":"EMEA-002499-PIP03-24","active_substance":"tafasitamab","invented_name":"Minjuvi","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of mature B-cell neoplasms excluding diffuse large B-cell lymphoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Incyte Biosciences Distribution B.V. E-mail: RA@incyte.comTel. +1 3024252734","first_published_date":"17/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002499-pip03-24"},{"decision_number":"P/0319/2024","pip_number":"EMEA-002350-PIP02-20-M01","active_substance":"deucravacitinib","invented_name":"Sotyktu","therapeutic_area":"Musculoskeletal and connective tissue disorders","pharmaceutical_forms":"Age appropriate oral solid dosage form;Film-coated tablet","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb International Corporation; E-mail: medical.information@bms.com; Tel. +44 1423 533 610","first_published_date":"11/05/2023","last_updated_date":"17/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002350-pip02-20-m01"},{"decision_number":"P/0350/2024","pip_number":"EMEA-002341-PIP01-18-M03","active_substance":"ganaxolone","invented_name":"Ztalmy","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Oral suspension;Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of cyclin-dependent kinase-like 5 deficiency disorder","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Immedica Pharma AB; E-mail: info@immedica.comTel. +46 (0)853339500","first_published_date":"27/03/2020","last_updated_date":"17/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002341-pip01-18-m03"},{"decision_number":"P/0343/2024","pip_number":"EMEA-002319-PIP01-17-M03","active_substance":"rezafungin acetate","invented_name":"Rezzayo","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Powder for concentrate for solution for infusion;Age appropriate dosage form for parenteral use","condition_indication":"Treatment of invasive candidiasis","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mundipharma Corporation (Ireland) Limited; E-mail: regaffairs-enquiries@mundipharma-rd.eu; Tel: +44 (0)1223424211 ","first_published_date":"24/04/2019","last_updated_date":"17/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002319-pip01-17-m03"},{"decision_number":"P/0342/2024","pip_number":"EMEA-002166-PIP01-17-M08","active_substance":"lasmiditan","invented_name":"Reyvow","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Tablet;Orodispersible tablet","condition_indication":"Treatment of migraine","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"27/11/2018","last_updated_date":"17/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002166-pip01-17-m08"},{"decision_number":"P/0339/2024","pip_number":"EMEA-002152-PIP01-17-M04","active_substance":"daratumumab","invented_name":"Darzalex; Darzalex","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Solution for injection;Concentrate for solution for infusion","condition_indication":"Treatment of lymphoid malignancies (except mature B-cell neoplasms)","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International N.V.; E-mail: nbuhl@its.jnj.com; Tel. +353 8574 46696","first_published_date":"27/11/2018","last_updated_date":"17/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002152-pip01-17-m04"},{"decision_number":"P/0337/2024","pip_number":"EMEA-002133-PIP01-17-M04","active_substance":"cefiderocol","invented_name":"Fetcroja","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of infections due to aerobic Gram-negative bacteria","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Shionogi Limited; E-mail: shionogiclintrials-admin@shionogi.co.jp; Tel. +44 (0)20 3534 200","first_published_date":"28/01/2019","last_updated_date":"17/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002133-pip01-17-m04"},{"decision_number":"P/0330/2024","pip_number":"EMEA-002106-PIP01-16-M03","active_substance":"leriglitazone","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Oral suspension","condition_indication":"Treatment of adrenoleukodystrophy","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Minoryx Therapeutics S.L.; Tel. ++34 935441466; E-mail: umeya@minoryx.com","first_published_date":"03/03/2021","last_updated_date":"17/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002106-pip01-16-m03"},{"decision_number":"P/0331/2024","pip_number":"EMEA-001988-PIP01-16-M02","active_substance":"macimorelin","invented_name":"Ghryvelin (previously Macimorelin Aeterna Zentaris)","therapeutic_area":"Endocrine disorders","pharmaceutical_forms":"Granules for oral solution","condition_indication":"Diagnosis of growth hormone deficiency","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Atnahs Pharma Netherlands B.V.; E-mail: nammer@aezsinc.comTel.:+49 69426023228","first_published_date":"29/05/2017","last_updated_date":"17/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001988-pip01-16-m02"},{"decision_number":"P/0338/2024","pip_number":"EMEA-003638-PIP01-24","active_substance":"rememulgene arelactibac","invented_name":"","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Concentrate for cutaneous solution","condition_indication":"Treatment of diabetic foot ulcer;Treatment of venous leg ulcer","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aurealis Oy E-mail: clinical@aurealistherapeutics.comTel: +358 503279385","first_published_date":"16/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003638-pip01-24"},{"decision_number":"P/0326/2024","pip_number":"EMEA-003632-PIP01-24","active_substance":"Empagliflozin / Derivative of 3‐phenyl‐3H,4H,6H,7H‐pyrano[3,4‐d]imidazol‐4‐one (BI 690517)","invented_name":"","therapeutic_area":"Cardiac disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of heart failure","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"16/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003632-pip01-24"},{"decision_number":"P/0318/2024","pip_number":"EMEA-003629-PIP01-24","active_substance":"montelukast sodium;rupatadine fumarate","invented_name":"","therapeutic_area":"Respiratory, thoracic and mediastinal disorders","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of allergic rhinitis","routes_of_administration":"Oral use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Noucor Health S.A. E-mail: regulatory@noucor.comTel: +34 937376690","first_published_date":"16/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003629-pip01-24"},{"decision_number":"P/0317/2024","pip_number":"EMEA-003571-PIP01-23","active_substance":"rilonacept","invented_name":"","therapeutic_area":"Cardiac disorders","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of idiopathic pericarditis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kiniksa Pharmaceuticals (UK) Limited E-mail: medinfo@kiniksa.comTel: +17814319100","first_published_date":"16/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003571-pip01-23"},{"decision_number":"P/0340/2024","pip_number":"EMEA-003524-PIP01-23","active_substance":"adeno‐associated viral vector serotype 8 containing the 3' human otoferlin coding sequence / adeno‐associated viral vector serotype 8 containing the 5' human otoferlin coding sequence","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of otoferlin gene-mediated hearing loss","routes_of_administration":"Auricular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sensorion SA; E-mail: contact@sensorion-pharma.com; Tel.  +33  4672 07730","first_published_date":"16/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003524-pip01-23"},{"decision_number":"P/0316/2024","pip_number":"EMEA-003510-PIP01-23","active_substance":"recombinant humanized IgG1, kappa light chain, long-acting monoclonal antibody (STAR-0215)","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of hereditary angioedema attacks","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Astria Therapeutics Inc E-mail: info@astriatx.comTel: +1 6173491971","first_published_date":"16/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003510-pip01-23"},{"decision_number":"P/0332/2024","pip_number":"EMEA-003460-PIP01-23","active_substance":"mannose-1-phosphate (GLM101)","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of phosphomannomutase 2-congenital disorder of glycosylation","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Glycomine Inc E-mail: opopescu@glycomine.comTel: +1 (650)2647560","first_published_date":"16/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003460-pip01-23"},{"decision_number":"P/0346/2024","pip_number":"EMEA-003425-PIP02-23","active_substance":"belumosudil","invented_name":"","therapeutic_area":"Immune system disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of chronic lung allograft dysfunction","routes_of_administration":"Oral use;Naso-gastric use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi Winthrop IndustrieE-mail: contact-us@sanofi.comTel: +33 1 55713302","first_published_date":"16/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003425-pip02-23"},{"decision_number":"P/0345/2024","pip_number":"EMEA-003388-PIP01-23","active_substance":"hydroxycarbamide","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Dispersible tablet","condition_indication":"Treatment of sickle cell disease","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Theravia E-mail: regulatory@theravia.comTel: +33 172690186","first_published_date":"16/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003388-pip01-23"},{"decision_number":"P/0336/2024","pip_number":"EMEA-003258-PIP02-23","active_substance":"retatrutide","invented_name":"","therapeutic_area":"Metabolism and nutrition disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of obesity","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly And Company Limitedemail: EU_PAEDIATRIC@lilly.comphone: +44 1256315000","first_published_date":"16/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003258-pip02-23"},{"decision_number":"P/0313/2024","pip_number":"EMEA-001720-PIP01-14-M04","active_substance":"patiromer sorbitex calcium","invented_name":"Veltassa","therapeutic_area":"Metabolism and nutrition disorders","pharmaceutical_forms":"Powder for oral suspension","condition_indication":"Treatment of hyperkalaemia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vifor Francepatiromer_ra@viforpharma.com+41 588518000","first_published_date":"21/12/2015","last_updated_date":"15/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001720-pip01-14-m04"},{"decision_number":"P/0314/2024","pip_number":"EMEA-001733-PIP02-15-M03","active_substance":"gemtuzumab ozogamicin","invented_name":"Mylotarg","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of acute myeloid leukaemia","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG  E-mail: medical.information@pfizer.com Tel: +44 (0)1304 616161","first_published_date":"25/04/2016","last_updated_date":"15/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001733-pip02-15-m03"},{"decision_number":"P/0315/2024","pip_number":"EMEA-001786-PIP01-15-M04","active_substance":"Ebola Zaire Vaccine (rVSV∆G-ZEBOV-GP, live)","invented_name":"Ervebo","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of ebola disease","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme B.V.pip.information@msd.com+33 180464738","first_published_date":"29/05/2017","last_updated_date":"15/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001786-pip01-15-m04"},{"decision_number":"P/0349/2024","pip_number":"EMEA-001930-PIP01-16-M06","active_substance":"Neisseria meningitidis serogroup A polysaccharide conjugated to tetanus toxoid;N. meningitidis serogroup C polysaccharide conjugated to tetanus toxoid;N. meningitidis serogroup Y polysaccharide conjugated to tetanus toxoid;N. meningitidis serogroup W polysaccharide conjugated to tetanus toxoid (MenACYW)","invented_name":"MenQuadfi","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of invasive meningococcal disease","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"24/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi Pasteur Europecontact-us@sanofi.com+33 (0)169745695","first_published_date":"05/03/2018","last_updated_date":"15/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001930-pip01-16-m06"},{"decision_number":"P/0329/2024","pip_number":"EMEA-001531-PIP01-13-M06","active_substance":"tasimelteon","invented_name":"Hetlioz; Hetlioz","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Capsule, hard;Age-appropriate liquid form","condition_indication":"Treatment of disorders of the sleep-wake schedule","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vanda Pharmaceuticals Netherlands B.V.christos.polymeropoulos@vandapharma.com+1 2025312922","first_published_date":"25/06/2014","last_updated_date":"15/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001531-pip01-13-m06"},{"decision_number":"P/0328/2024","pip_number":"EMEA-001426-PIP01-13-M03","active_substance":"recombinant varicella zoster virus glycoprotein E","invented_name":"Shingrix","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Powder and suspension for suspension for injection;Suspension for injection","condition_indication":"Prevention of varicella zoster virus (VZV) reactivation","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Biologicalseu.paediatric-plans@gsk.com +1 4388998021","first_published_date":"03/09/2013","last_updated_date":"15/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001426-pip01-13-m03"},{"decision_number":"P/0041/2019","pip_number":"EMEA-002338-PIP01-18","active_substance":"lanalumab","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Concentrate for solution for injection","condition_indication":"Treatment of autoimmune hepatitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/01/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"24/04/2019","last_updated_date":"14/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002338-pip01-18"},{"decision_number":"P/0325/2024","pip_number":"EMEA-000315-PIP02-15-M04","active_substance":"osilodrostat","invented_name":"Isturisa","therapeutic_area":"Endocrine disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of adrenal cortical hyperfunction","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Recordati Rare Diseasesroquelaure.c@recordati.com+33 170824420","first_published_date":"29/03/2016","last_updated_date":"14/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000315-pip02-15-m04"},{"decision_number":"P/0351/2024","pip_number":"EMEA-000157-PIP01-07-M06","active_substance":"belatacept","invented_name":"Nulojix","therapeutic_area":"Renal and urinary disorders","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Prevention of rejection of transplanted kidney","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG; Email: medical.information@bms.com; Tel. +44 1895523740","first_published_date":"07/01/2009","last_updated_date":"14/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000157-pip01-07-m06"},{"decision_number":"EMA/PE/0000227301","pip_number":"EMA/PE/0000227301","active_substance":"mRNA encoding Influenza A, H1N1 strain, hemagglutinin glycoprotein, mRNA encoding Influenza A, H3N2 strain, hemagglutinin glycoprotein, mRNA encoding Influenza B/Victoria, hemagglutinin glycoprotein, mRNA-1283","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Dispersion for injection","condition_indication":"Prevention of influenza and coronavirus 2019 (COVID-19)","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"20/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Moderna Biotech Spain S.L.E-mail: EMEAMedInfo@modernatx.comTel: +34 900031015","first_published_date":"14/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000227301"},{"decision_number":"P/0333/2024","pip_number":"EMEA-001556-PIP02-24","active_substance":"aldesleukin","invented_name":"","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of amyotrophic lateral sclerosis","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/09/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Iltoo Pharma; d.leroux@iltoopharma.fr+33 972553302","first_published_date":"14/10/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001556-pip02-24"},{"decision_number":"P/0522/2023","pip_number":"EMEA-002640-PIP01-19-M01","active_substance":"cendakimab","invented_name":"","therapeutic_area":"Immune system disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of eosinophilic esophagitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"10/06/2022","last_updated_date":"09/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002640-pip01-19-m01"},{"decision_number":"P/0085/2023","pip_number":"EMEA-002944-PIP02-22","active_substance":"danuglipron","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Age appropriate oral dosage formulation;Tablet","condition_indication":"Treatment of obesity","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/03/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG  E-mail: medical.information@pfizer.com Tel: +44 (0)1304 616161","first_published_date":"25/09/2025","last_updated_date":"09/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002944-pip02-22"},{"decision_number":"P/0215/2024","pip_number":"EMEA-003463-PIP01-23","active_substance":"human alpha-1 proteinase inhibitor, modified (SerpinPC)","invented_name":"","therapeutic_area":"Blood and lymphatic system disorders","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of Haemophilia B","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Apcintex LimitedE-mail: presentstudies@centessa.comTel: +1 6178700986","first_published_date":"26/06/2025","last_updated_date":"08/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003463-pip01-23"},{"decision_number":"P/0043/2017","pip_number":"EMEA-001073-PIP02-14","active_substance":"varicella-zoster virus (inactivated)","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Powder and solvent for suspension for injection","condition_indication":"Prevention of Varicella Zoster virus disease","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe), Inc; Belgium; Tel. +31 41663179 ; Fax +31 412662571; E-mail: pip.information@merck.com;  ","first_published_date":"17/03/2017","last_updated_date":"07/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001073-pip02-14"},{"decision_number":"P/0502/2022","pip_number":"EMEA-001207-PIP06-22","active_substance":"obinutuzumab","invented_name":"Gazyvaro","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate and solvent for concentrate for solution for infusion","condition_indication":"Prevention of cytokine release syndrome induced by anti CD20/CD3 antibodies","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"10/11/2023","last_updated_date":"07/10/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001207-pip06-22"},{"decision_number":"P/0372/2024","pip_number":"EMEA-002740-PIP03-24","active_substance":"lenacapavir sodium","invented_name":"Sunlenca","therapeutic_area":"","pharmaceutical_forms":"Concentrate for solution for injection;Film-coated tablet;Age-appropriate oral and/or subcutaneous dosage form","condition_indication":"Prevention of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Subcutaneous use;Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Limited; Tel. +44 (0)1223 897300; E-mail: regulatory.pip@gilead.com","first_published_date":"25/09/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002740-pip03-24"},{"decision_number":"P/0311/2024","pip_number":"EMEA-003549-PIP01-23","active_substance":"efinopegdutide","invented_name":"","therapeutic_area":"Metabolism and nutrition disorders","pharmaceutical_forms":"Solution for injection in pre-filled syringe","condition_indication":"Treatment of metabolic dysfunction-associated steatohepatitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme B.V.; E-mail: pip.information@merck.com; Tel:  +31 412663179","first_published_date":"09/07/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003549-pip01-23"},{"decision_number":"P/0310/2024","pip_number":"EMEA-003616-PIP01-24","active_substance":"tarumase","invented_name":"","therapeutic_area":"Injury, poisoning and procedural complications","pharmaceutical_forms":"Gel","condition_indication":"Treatment of chronic wounds","routes_of_administration":"Cutaneous use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Solascure Limited; E-mail: info@solascure.com; Tel:  +44 1223827959; &nbsp","first_published_date":"09/07/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003616-pip01-24"},{"decision_number":"P/0308/2024","pip_number":"EMEA-003513-PIP01-23","active_substance":"transglutaminase 2 inhibitor","invented_name":"","therapeutic_area":"Gastrointestinal disorders","pharmaceutical_forms":"Capsule, hard Age-appropriate oral formulation","condition_indication":"Treatment of coeliac disease","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dr. Falk Pharma GmbH; Email: zentrale@drfalkpharma.de; Tel.: +49 76115140","first_published_date":"09/07/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003513-pip01-23"},{"decision_number":"P/0301/2024","pip_number":"EMEA-003610-PIP01-24","active_substance":"Copper (64Cu) oxodotreotide","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Solution for injection","condition_indication":"Diagnosis of neuroendocrine tumours (excluding neuroblastoma)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Curium Pet France; E-mail: regulatory.cpf@curiumpharma.com; Tel: +33 685451333","first_published_date":"09/07/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003610-pip01-24"},{"decision_number":"P/0300/2024","pip_number":"EMEA-003628-PIP01-24","active_substance":"anitocabtagene autoleucel","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of Multiple Myeloma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kite Pharma EU B.V.; Tel. +1 4242091332; E-mail: regulatory@kitepharma.com","first_published_date":"09/07/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003628-pip01-24"},{"decision_number":"P/0292/2024","pip_number":"EMEA-003502-PIP01-23","active_substance":"mezagitamab","invented_name":"","therapeutic_area":"Blood and lymphatic system disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of immune thrombocytopenia","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Pharmaceuticals International AG Ireland Branch; E-mail: medinfoemea@takeda.com; Tel: +44 (0) 3333 000181","first_published_date":"09/07/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003502-pip01-23"},{"decision_number":"P/0287/2024","pip_number":"EMEA-003622-PIP01-24","active_substance":"inobrodib","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of Multiple Myeloma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cellcentric Limited; E-mail: info@cellcentric.com; Tel: +44(0)1799531130","first_published_date":"09/07/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003622-pip01-24"},{"decision_number":"P/0306/2024","pip_number":"EMEA-003344-PIP01-22-M01","active_substance":"fosigotifator sodium tromethamine","invented_name":"","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Age appropriate dosage form, other;Granules","condition_indication":"Treatment of vanishing white matter disease","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Abbvie Deutschland GmbH & Co. KG; E-mail: paediatricteam@abbvie.com; Tel: +44 1628925033","first_published_date":"04/10/2024","last_updated_date":"09/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003344-pip01-22-m01"},{"decision_number":"P/0304/2024","pip_number":"EMEA-003253-PIP01-22-M01","active_substance":"Humanised monoclonal antibody derivative against fibroblast growth factor receptor 3 (SAR442501)","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Concentrate for solution for injection","condition_indication":"Treatment of achondroplasia","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi B.V.E-mail: eumedinfo.GZ@sanofi.com Tel. +31 2024 54000&nbsp","first_published_date":"09/07/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003253-pip01-22-m01"},{"decision_number":"P/0274/2024","pip_number":"EMEA-003607-PIP01-24","active_substance":"buparlisib","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of head and neck epithelial malignant neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Adlai Nortye USA Inc.; E-mal: buranh0301@adlainortye.com; Tel: +1 8482307430","first_published_date":"09/07/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003607-pip01-24"},{"decision_number":"P/0302/2024","pip_number":"EMEA-003241-PIP01-22-M01","active_substance":"osivelotor","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Age appropriate oral solid dosage form;Tablet","condition_indication":"Treatment of sickle cell disease","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG  E-mail: medical.information@pfizer.com Tel: +44 (0)1304 616161","first_published_date":"05/04/2024","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003241-pip01-22-m01"},{"decision_number":"P/0288/2024","pip_number":"EMEA-002780-PIP02-20-M02","active_substance":"multivalent pneumococcal polysaccharide conjugate to carrier protein (PCV21)","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of disease caused by Streptococcus pneumoniae","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi Winthrop IndustrieE-mail: contact-us@sanofi.comTel: +33 1 69 74 56 95","first_published_date":"10/01/2023","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002780-pip02-20-m02"},{"decision_number":"P/0277/2024","pip_number":"EMEA-002703-PIP01-19-M01","active_substance":"vonoprazan","invented_name":"","therapeutic_area":"Gastrointestinal disorders","pharmaceutical_forms":"Tablet;Age appropriate dosage form","condition_indication":"Treatment of gastroesophageal reflux disease;Treatment of Helicobacter pylori infection","routes_of_administration":"Oral use;Gastric use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Phathom Pharmaceuticals, Inc. E-mail: Medicalinformation@phathompharma.com Tel. +1 8887757428","first_published_date":"22/09/2021","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002703-pip01-19-m01"},{"decision_number":"P/0275/2024","pip_number":"EMEA-002689-PIP02-23-M01","active_substance":"navepegritide","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of achondroplasia","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ascendis Pharma Growth Disorders A/S E-mail: medinfo@ascendispharma.com Tel: +45 70 22 22 44","first_published_date":"13/05/2025","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002689-pip02-23-m01"},{"decision_number":"P/0291/2024","pip_number":"EMEA-001957-PIP02-19-M01","active_substance":"Dexamethasone sodium phosphate encapsulated in human autologous erythrocytes","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of ataxia telangiectasia","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Quince Therapeutics S.p.A.E-mail: info@quincetx.com Tel.:  +39 0236504470","first_published_date":"05/03/2021","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001957-pip02-19-m01"},{"decision_number":"P/0298/2024","pip_number":"EMEA-002597-PIP01-19-M02","active_substance":"Efgartigimod alfa","invented_name":"Vyvgart","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of myasthenia gravis","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Argenx  E-mail: regulatory@argenx.com  Tel.  +32 93103400","first_published_date":"29/07/2020","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002597-pip01-19-m02"},{"decision_number":"P/0294/2024","pip_number":"EMEA-001949-PIP01-16-M07","active_substance":"Gadopiclenol","invented_name":"Elucirem","therapeutic_area":"Vascular disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Detection and visualisation of areas with disruption of the blood brain barrier and/or abnormal vascularity for diagnostic purposes","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GuerbetE-mail: philippe.bourrinet@guerbet.com Tel.:  +33 0145915076","first_published_date":"21/04/2017","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001949-pip01-16-m07"},{"decision_number":"P/0293/2024","pip_number":"EMEA-001949-PIP02-18-M05","active_substance":"Gadopiclenol","invented_name":"","therapeutic_area":"Vascular disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Detection and visualization of disorders or lesions with suspected abnormal vascularity in various body regions for diagnostic purposes","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GuerbetE-mail: philippe.bourrinet@guerbet.com Tel.:  +33 0145915076","first_published_date":"24/06/2019","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001949-pip02-18-m05"},{"decision_number":"P/0279/2024","pip_number":"EMEA-002563-PIP02-19-M03","active_substance":"cenobamate","invented_name":"Ontozry","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Tablet;Film-coated tablet;Age appropriate oral liquid dosage formulation;Age appropriate dosage form for parenteral use","condition_indication":"Treatment of epilepsy","routes_of_administration":"Oral use;Parenteral use;Gastric use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. E-mail: patrizia.ciavatta@angelinipharma.com  Tel.  +39 3429277049","first_published_date":"29/07/2020","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002563-pip02-19-m03"},{"decision_number":"P/0289/2024","pip_number":"EMEA-002064-PIP01-16-M06","active_substance":"Gilteritinib (as fumarate)","invented_name":"Xospata","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral dosage formulation","condition_indication":"Treatment of acute myeloid leukaemia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Astellas Pharma Europe B.V.E-mail: regulatory.eu@astellas.comTel: +31 715454006","first_published_date":"17/04/2018","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002064-pip01-16-m06"},{"decision_number":"P/0297/2024","pip_number":"EMEA-002479-PIP01-18-M02","active_substance":"narsoplimab","invented_name":"","therapeutic_area":"Blood and lymphatic system disorders","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment in haematopoietic stem cell transplantation","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Omeros Ireland Limited; E-mail: regulatory@omeros.com; Tel: +1 206-676-5000","first_published_date":"03/04/2020","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002479-pip01-18-m02"},{"decision_number":"P/0259/2024","pip_number":"EMEA-002942-PIP02-20-M02","active_substance":"survodutide","invented_name":"","therapeutic_area":"Metabolism and nutrition disorders","pharmaceutical_forms":"Solution for injection in pre-filled syringe","condition_indication":"Treatment of obesity","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"10/05/2023","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002942-pip02-20-m02"},{"decision_number":"P/0276/2024","pip_number":"EMEA-002706-PIP01-19-M03","active_substance":"allogeneic bone marrow derived mesenchymal stromal cells, ex-vivo expanded (MC0518)","invented_name":"","therapeutic_area":"Immune system disorders","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of acute graft-versus-host disease (aGvHD)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"medac Gesellschaft für klinische Spezialpräparate mbH Tel.  +49 410380060E-mail: contact@medac.de","first_published_date":"22/09/2021","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002706-pip01-19-m03"},{"decision_number":"P/0290/2024","pip_number":"EMEA-001944-PIP01-16-M05","active_substance":"vadadustat","invented_name":"Vafseo","therapeutic_area":"Blood and lymphatic system disorders","pharmaceutical_forms":"Tablet;Age appropriate oral formulation","condition_indication":"Treatment of anaemia due to chronic disorders","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Akebia Europe LimitedE-mail: info@akebia.comTel. +1 6178712098&nbsp","first_published_date":"17/03/2017","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001944-pip01-16-m05"},{"decision_number":"P/0296/2024","pip_number":"EMEA-002246-PIP01-17-M05","active_substance":"bupivacaine;meloxicam","invented_name":"","therapeutic_area":"Musculoskeletal and connective tissue disorders","pharmaceutical_forms":"Prolonged-release wound solution","condition_indication":"Treatment of acute postoperative pain","routes_of_administration":"Intralesional use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Heron Therapeutics B.V.; E-mail: HTX011-ct@herontx.com; Tel: +1 8582514420","first_published_date":"12/04/2019","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002246-pip01-17-m05"},{"decision_number":"P/0285/2024","pip_number":"EMEA-001855-PIP01-15-M06","active_substance":"fitusiran","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Subcutaneous use","condition_indication":"Treatment of congenital haemophilia A;Treatment of congenital haemophilia B","routes_of_administration":"Solution for injection","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi B.V.E-mail: eumedinfo.gz@sanofi.comTel: +31 (0) 20 245 3917","first_published_date":"29/10/2019","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001855-pip01-15-m06"},{"decision_number":"P/0295/2024","pip_number":"EMEA-002115-PIP01-17-M06","active_substance":"pretomanid","invented_name":"Dovprela (previously Pretomanid FGK)","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Dispersible tablet;Tablet","condition_indication":"Treatment of multi-drug-resistant tuberculosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"20/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Global Alliance for TB Drug Development; Tel. +1 2122277450; E-mail: info@tballiance.org","first_published_date":"12/04/2019","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002115-pip01-17-m06"},{"decision_number":"P/0312/2024","pip_number":"EMEA-001849-PIP02-15-M05","active_substance":"avelumab","invented_name":"Bavencio","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms);Treatment of malignant neoplasms of lymphoid tissue;Treatment of malignant neoplasms of the central nervous system","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"22/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Healthcare KGaAEmail: service@merckgroup.comTel.: +49 6151725200","first_published_date":"21/04/2017","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001849-pip02-15-m05"},{"decision_number":"P/0278/2024","pip_number":"EMEA-002700-PIP01-19-M02","active_substance":"crinecerfont","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Capsule, hard;Oral solution","condition_indication":"Treatment of congenital adrenal hyperplasia","routes_of_administration":"Oral use;Gastric use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Neurocrine Therapeutics Ltd; E-mail: medinfo@neurocrine.com; Tel. +01 8776 413461","first_published_date":"20/07/2021","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002700-pip01-19-m02"},{"decision_number":"P/0284/2024","pip_number":"EMEA-001825-PIP01-15-M05","active_substance":"darunavir;cobicistat;emtricitabine;tenofovir alafenamide","invented_name":"Symtuza","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of human immunodeficiency virus type-1 (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; Tel. + 32 1460 2111; E-mail: contact@janssen-emea.com","first_published_date":"18/07/2016","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001825-pip01-15-m05"},{"decision_number":"P/0286/2024","pip_number":"EMEA-002033-PIP02-23","active_substance":"vosoritide","invented_name":"Voxzogo","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of ataxia telangiectasia","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BioMarin International Limited; Tel. +44 (0)20 7420 0800; E-mail: biomarin-europe@bmrn.com","first_published_date":"07/07/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002033-pip02-23"},{"decision_number":"P/0283/2024","pip_number":"EMEA-001750-PIP01-15-M07","active_substance":"rilpivirine;dolutegravir","invented_name":"Juluca","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ViiV Healthcare UK LimitedE-mail: eu.paediatric-plans@gsk.com Tel: +1 4388998201","first_published_date":"29/03/2016","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001750-pip01-15-m07"},{"decision_number":"P/0282/2024","pip_number":"EMEA-001739-PIP02-16-M02","active_substance":"sufentanil citrate;ketamine (hydrochloride)","invented_name":"","therapeutic_area":"General disorders and administration site conditions","pharmaceutical_forms":"Nasal spray (solution)","condition_indication":"Treatment of acute pain","routes_of_administration":"Intranasal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cessatech A/S; E-mail: info@cessatech.com; Tel: +45 93872309  ","first_published_date":"30/03/2020","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001739-pip02-16-m02"},{"decision_number":"P/0281/2024","pip_number":"EMEA-001613-PIP03-21-M01","active_substance":"tezepelumab","invented_name":"Tezspire","therapeutic_area":"Gastrointestinal disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of eosinophilic esophagitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca ABEmail: paediatrics@astrazeneca.comTel.  +46 855326000","first_published_date":"14/11/2024","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001613-pip03-21-m01"},{"decision_number":"P/0280/2024","pip_number":"EMEA-001373-PIP01-12-M06","active_substance":"bupropion hydrochloride;naltrexone hydrochloride","invented_name":"Mysimba","therapeutic_area":"Metabolism and nutrition disorders","pharmaceutical_forms":"Prolonged-release tablet","condition_indication":"Treatment of obesity","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Orexigen Therapeutics Ireland LimitedE-mail: eu-regulatory@orexigen.comTel: +353 87 318 5448","first_published_date":"09/09/2013","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001373-pip01-12-m06"},{"decision_number":"P/0303/2024","pip_number":"EMEA-001290-PIP01-12-M01","active_substance":"human normal immunoglobulin (SCNG20%)","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of Primary Immunodeficiency (PID)","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LFB BiotechnologiesE-mail: LFB-enregistrement@lfb.fr Tel.: +33 666242239","first_published_date":"11/02/2013","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001290-pip01-12-m01"},{"decision_number":"P/0307/2024","pip_number":"EMEA-001214-PIP04-19-M01","active_substance":"Benralizumab","invented_name":"Fasenra","therapeutic_area":"Blood and lymphatic system disorders","pharmaceutical_forms":"Solution for injection;Solution for injection/infusion","condition_indication":"Treatment of hypereosinophilic syndrome","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca ABEmail: paediatrics@astrazeneca.comTel.  +46 855326000","first_published_date":"13/03/2024","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001214-pip04-19-m01"},{"decision_number":"P/0305/2024","pip_number":"EMEA-000780-PIP01-09-M08","active_substance":"Midostaurin","invented_name":"Rydapt","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Oral solution;Capsule, soft","condition_indication":"Treatment of acute myeloid leukaemia;Treatment of malignant mastocytosis;Treatment of mast cell leukaemia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"07/02/2011","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000780-pip01-09-m08"},{"decision_number":"P/0299/2024","pip_number":"EMEA-000205-PIP02-11-M07","active_substance":"ceftobiprole medocaril (sodium)","invented_name":"Zevtera and associated names","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of pneumonia","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Basilea Pharmaceutica Deutschland GmbH Email: medical.information@basilea.com Tel. +41 6160611 11","first_published_date":"17/10/2012","last_updated_date":"07/07/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000205-pip02-11-m07"},{"decision_number":"P/0219/2024","pip_number":"EMEA-003641-PIP01-24","active_substance":"purified antigen fractions of inactivated split virion influenza virus type A, H1N1;influenza virus type A, H3N2;influenza virus type B, Victoria lineage","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of influenza infection","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Biologicalse-mail: eu.paediatric-plans@gsk.com tel. +1 4388998201","first_published_date":"26/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003641-pip01-24"},{"decision_number":"P/0220/2024","pip_number":"EMEA-003640-PIP01-24","active_substance":"recombinant Influenza Hemagglutinin-strain A (H1N1 subtype);recombinant Influenza Hemagglutinin-strain A (H3N2 subtype);recombinant influenza hemagglutinin-strain B (RIV3)","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Solution for injection in pre-filled syringe","condition_indication":"Prevention of influenza","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi Winthrop Industrie; E-mail: contact-us@sanofi.com; Tel: +33 4 37 37 57 84","first_published_date":"26/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003640-pip01-24"},{"decision_number":"P/0210/2024","pip_number":"EMEA-003582-PIP01-24","active_substance":"rosuvastatin;ezetimibe","invented_name":"","therapeutic_area":"Cardiac disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events;Treatment of hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Verisfield Single Member S.A.Email: pharmacovigilance@verisfield.gr; economou@verisfield.gr Tel: +30 2107475196&nbsp","first_published_date":"26/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003582-pip01-24"},{"decision_number":"P/0216/2024","pip_number":"EMEA-003577-PIP01-24","active_substance":"certepetide","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of pancreatic cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Lisata Therapeutics Ireland LimitedE-mail: info@lisata.comTel: +1 9495352391","first_published_date":"26/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003577-pip01-24"},{"decision_number":"P/0209/2024","pip_number":"EMEA-003581-PIP01-24","active_substance":"derivative of 1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer (small cell and non-small cell lung cancer)","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer AG; Email: pediatrics.medical-affairs-europe@bayer.com; Tel. +49 (0)3046815333;  ","first_published_date":"26/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003581-pip01-24"},{"decision_number":"P/0223/2024","pip_number":"EMEA-003525-PIP01-23","active_substance":"mirdametinib","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Capsule, hard;Tablet","condition_indication":"Treatment of neurofibromatosis type 1","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"20/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"SpringWorks Therapeutics, Inc; clinical.inquiries@springworkstx.com;  +1 9197901002","first_published_date":"26/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003525-pip01-23"},{"decision_number":"P/0214/2024","pip_number":"EMEA-003459-PIP01-23","active_substance":"recombinant adeno-associated virus Olig001 containing human aspartoacylase cDNA","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Canavan disease","routes_of_administration":"Intracerebral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Myrtelle Inc. E-mail: info@myrtellegtx.comTel: +1 7816212381","first_published_date":"26/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003459-pip01-23"},{"decision_number":"P/0197/2024","pip_number":"EMEA-003462-PIP01-23","active_substance":"radiprodil","invented_name":"","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Oral suspension","condition_indication":"Treatment of GRIN-related disorder","routes_of_administration":"Oral use;Naso-gastric use;Gastric use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"E-mail: michael.panzara@grintherapeutics.com Tel. +1 6467776723","first_published_date":"26/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003462-pip01-23"},{"decision_number":"P/0196/2024","pip_number":"EMEA-003572-PIP01-23","active_substance":"sitagliptin;dapagliflozin","invented_name":"","therapeutic_area":"Endocrine disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Althera Laboratories LimitedEmail: regulatory.eu@altherainc.comTel.: +353 1 906 0479","first_published_date":"26/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003572-pip01-23"},{"decision_number":"P/0194/2024","pip_number":"EMEA-002572-PIP02-19-M05","active_substance":"soticlestat","invented_name":"","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral formulation","condition_indication":"Treatment of Dravet syndrome;Treatment of Lennox-Gastaut syndrome","routes_of_administration":"Oral use;Gastric use;Intestinal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Pharma A/STel. +44 (0)3333000181E-mail: medinfoEMEA@takeda.com","first_published_date":"22/06/2021","last_updated_date":"26/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002572-pip02-19-m05"},{"decision_number":"P/0193/2024","pip_number":"EMEA-003576-PIP01-24","active_substance":"actinium-225-2-(4,7,10-tris-carboxymethyl-1,4,7,10 tetraaza-cyclododec-1-yl)-pentanedioic acid 3- iodo-D-Tyr-D-Phe-D-Lys-OH)-8-oyl-ε-(HO-Glu-ureido-Lys-OH)","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of PSMA-expressing prostate cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"05/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"E-mail: regulatory@fusionpharma.com Tel. +1 (617)4205698","first_published_date":"25/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003576-pip01-24"},{"decision_number":"P/0192/2024","pip_number":"EMEA-003574-PIP01-24","active_substance":"telisotuzumab conjugated to (2S)-2-(2-bromoacetamido)-N-[(2S)-1-({3-[(7S)-7-ethyl-7-hydroxy- 8,11-dioxo-7,8,11,13-tetrahydro-2H,10H-[1,3]dioxolo[4,5-g]pyrano[3',4':6,7]indolizino[1,2- b]quinolin-14-yl]bicyclo[1.1.1]pentan-1-yl}amino)-1-oxopropan-2-yl]-3-methylbutanamide","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of colorectal carcinoma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"25/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003574-pip01-24"},{"decision_number":"P/0190/2024","pip_number":"EMEA-001809-PIP01-15-M05","active_substance":"imipenem monohydrate;cilastatin sodium;relebactam (MK-7655A)","invented_name":"Recarbrio","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of infections caused by gram-negative organisms","routes_of_administration":"Parenteral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"26/08/2016","last_updated_date":"25/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001809-pip01-15-m05"},{"decision_number":"P/0191/2024","pip_number":"EMEA-002489-PIP02-24","active_substance":"rivoceranib","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hepatocellular carcinoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"E-mail: elevar-medical@elevartherapeutics.com Tel. +49 8374480","first_published_date":"25/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002489-pip02-24"},{"decision_number":"P/0189/2024","pip_number":"EMEA-001533-PIP01-13-M03","active_substance":"Ertugliflozin","invented_name":"Steglatro","therapeutic_area":"Metabolism and nutrition disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"30/09/2014","last_updated_date":"25/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001533-pip01-13-m03"},{"decision_number":"P/0187/2024","pip_number":"EMEA-000534-PIP03-17-M01","active_substance":"Mecasermin rinfabate","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Solution for infusion","condition_indication":"Prevention of chronic lung disease of prematurity","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ohb Neonatology LimitedE-mail: info@oakhillbio.com Tel. +44 1865966499","first_published_date":"04/06/2020","last_updated_date":"25/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000534-pip03-17-m01"},{"decision_number":"P/0208/2024","pip_number":"EMEA-001222-PIP01-11-M01","active_substance":"olokizumab","invented_name":"","therapeutic_area":"Musculoskeletal and connective tissue disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis)","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Accelsiors GmbH; Russian Federation; Email: serebryakova@rpharm.ru; Tel. +7 (495) 956-79-37","first_published_date":"18/09/2012","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001222-pip01-11-m01"},{"decision_number":"P/0529/2022","pip_number":"EMEA-000927-PIP01-10-M08","active_substance":"linaclotide","invented_name":"Constella","therapeutic_area":"Gastrointestinal disorders","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of functional constipation","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"09/06/2011","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000927-pip01-10-m08"},{"decision_number":"P/0206/2024","pip_number":"EMEA-001911-PIP02-22-M01","active_substance":"inebilizumab","invented_name":"Uplizna","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of myasthenia gravis","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Horizon Therapeutics Ireland DAC  E-mail: medinfointernational@amgen.com Tel.  +44 (0)1223420305","first_published_date":"07/03/2025","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001911-pip02-22-m01"},{"decision_number":"P/0205/2024","pip_number":"EMEA-003196-PIP01-22-M01","active_substance":"obefazimod","invented_name":"","therapeutic_area":"Gastrointestinal disorders","pharmaceutical_forms":"Capsule, hard;Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of ulcerative colitis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbivaxE-mail: Didier.Blondel@abivax.comTel. +33 153830839","first_published_date":"09/11/2023","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003196-pip01-22-m01"},{"decision_number":"P/0203/2024","pip_number":"EMEA-001821-PIP01-15-M08","active_substance":"quizartinib","invented_name":"Vanflyta","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Film-coated tablet;Powder for oral solution","condition_indication":"Treatment of acute myeloid leukaemia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Daiichi Sankyo Europe GmbH; Tel. +49 8978080; E-mail: service@daiichi-sankyo.eu","first_published_date":"22/09/2016","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001821-pip01-15-m08"},{"decision_number":"P/0204/2024","pip_number":"EMEA-003480-PIP01-23","active_substance":"Derivative of pyrindin-2-yl)cyclopropanecarboxamide hydrochloride","invented_name":"","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Film-coated tablet;Age-appropriate oral dosage form","condition_indication":"Treatment of psoriasis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alumis Inc.; E-mail: info@alumis.com; Tel. +1 (650)2316625","first_published_date":"24/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003480-pip01-23"},{"decision_number":"P/0202/2024","pip_number":"EMEA-003586-PIP01-24","active_substance":"(5aSa,17aRa)-20-Chloro-2-[(2S,5R)-2,5-dimethyl-4-(prop-2-enoyl)piperazin-1-yl]-14,17-difluoro-6- (propan-2-yl)-11,12-dihydro-4H-1,18-(ethanediylidene)pyrido[4,3-e]pyrimido[1,6- g][1,4,7,9]benzodioxadiazacyclododecin-4-one (MK-1084)","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of all solid and haematological malignancies","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"24/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003586-pip01-24"},{"decision_number":"P/0201/2024","pip_number":"EMEA-003535-PIP02-24","active_substance":"autologous T-cells from a melanoma metastasis (TM001)","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of melanoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Netherlands Cancer Institute; E-mail: i.jedema@nki.nl; Tel. +31 205124002","first_published_date":"24/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003535-pip02-24"},{"decision_number":"P/0213/2024","pip_number":"EMEA-003408-PIP02-24","active_substance":"gallium (68Ga) boclatixafortide","invented_name":"","therapeutic_area":"Endocrine disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Subtype diagnosis of primary aldosteronism","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pentixapharm AGE-mail: info@pentixapharm.com Tel: +49 93199136076","first_published_date":"24/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003408-pip02-24"},{"decision_number":"P/0212/2024","pip_number":"EMEA-002536-PIP02-24","active_substance":"Lebrikizumab","invented_name":"Ebglyss","therapeutic_area":"Respiratory, thoracic and mediastinal disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of nasal polyposis","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Almirall S.A.; Tel.  +34 932912958; E-mail: sonia.barange@almirall.com","first_published_date":"24/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002536-pip02-24"},{"decision_number":"P/0224/2024","pip_number":"EMEA-002907-PIP01-20-M03","active_substance":"Epcoritamab","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps);Oncology","pharmaceutical_forms":"Concentrate for solution for injection;Solution for injection","condition_indication":"Treatment of mature B-cell malignancies","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628925033","first_published_date":"12/09/2022","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002907-pip01-20-m03"},{"decision_number":"P/0222/2024","pip_number":"EMEA-002705-PIP01-19-M02","active_substance":"iptacopan","invented_name":"","therapeutic_area":"Renal and urinary disorders","pharmaceutical_forms":"Capsule, hard;Age appropriate oral solid dosage form","condition_indication":"Treatment of C3 glomerulopathy","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"20/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"28/07/2021","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002705-pip01-19-m02"},{"decision_number":"P/0218/2024","pip_number":"EMEA-002418-PIP01-18-M04","active_substance":"recombinant Influenza Hemagglutinin-strain A (H1N1 subtype);recombinant Influenza Hemagglutinin-strain A (H3N2 subtype);recombinant Influenza Hemagglutinin-strain B (Victoria lineage);recombinant Influenza Hemagglutinin-strain B (Yamagata lineage) (RIV4)","invented_name":"Supemtek Tetra (previously Supemtek)","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Solution for injection in pre-filled syringe","condition_indication":"Prevention of influenza infection","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi Winthrop Industrie; E-mail: contact-us@sanofi.com; Tel: +33 4 37 37 57 84","first_published_date":"24/06/2019","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002418-pip01-18-m04"},{"decision_number":"P/0211/2024","pip_number":"EMEA-002093-PIP02-17-M02","active_substance":"calcifediol","invented_name":"Rayaldee","therapeutic_area":"Endocrine disorders;Uro-nephrology","pharmaceutical_forms":"Prolonged-release capsule","condition_indication":"Treatment of secondary hyperparathyroidism (SHPT)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vifor Fresenius Medical Care Renal Pharma France; E-mail: rayaldee_ra@viforpharma.com; Tel.  +41 5885 18000","first_published_date":"14/02/2019","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002093-pip02-17-m02"},{"decision_number":"P/0221/2024","pip_number":"EMEA-001862-PIP01-15-M04","active_substance":"brexucabtagene autoleucel","invented_name":"Tecartus","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps);Oncology","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of acute lymphoblastic leukaemia","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"20/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kite Pharma EU B.V.; Tel. +1 4242091332; E-mail: regulatory@kitepharma.com","first_published_date":"28/09/2017","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001862-pip01-15-m04"},{"decision_number":"P/0271/2024","pip_number":"EMEA-002740-PIP01-19-M01","active_substance":"lenacapavir sodium","invented_name":"Sunlenca","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Age appropriate oral solid dosage form;Film-coated tablet;Solution for injection","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd.; Tel. +44 (0)1223 897 300; E-mail: regulatory.pip@gilead.com","first_published_date":"29/09/2021","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002740-pip01-19-m01"},{"decision_number":"P/0269/2024","pip_number":"EMEA-002827-PIP01-20-M03","active_substance":"botaretigene sparoparvovec","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Retinitis Pigmentosa","routes_of_administration":"Ophthalmic use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen Cilag International Email: contact@Janssen-emea.com Tel. +32 14602111","first_published_date":"19/11/2021","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002827-pip01-20-m03"},{"decision_number":"P/0268/2024","pip_number":"EMEA-002707-PIP01-19-M02","active_substance":"doravirine;Islatravir","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Age appropriate oral solid dosage form;Tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"19/11/2021","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002707-pip01-19-m02"},{"decision_number":"P/0200/2024","pip_number":"EMEA-003591-PIP01-24","active_substance":"fenofibrate;rosuvastatin calcium","invented_name":"","therapeutic_area":"Metabolism and nutrition disorders","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of  elevated cholesterol with elevated triglycerides","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Verisfield Single Member S.A.Email: pharmacovigilance@verisfield.gr; economou@verisfield.gr Tel: +30 2107475196&nbsp","first_published_date":"24/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003591-pip01-24"},{"decision_number":"P/0266/2024","pip_number":"EMEA-002765-PIP02-21-M01","active_substance":"ribociclib","invented_name":"Kisqali","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Age appropriate oral liquid dosage formulation;Film-coated tablet","condition_indication":"Treatment of neuroblastoma","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"05/04/2023","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002765-pip02-21-m01"},{"decision_number":"P/0260/2024","pip_number":"EMEA-002463-PIP01-18-M02","active_substance":"dostarlimab","invented_name":"Jemperli","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of all conditions contained in the category of malignant neoplasms (except haematopoietic and lymphoid tissue)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline (Ireland) Limited; E-mail: eu.paediatric-plans@gsk.com; Tel: +1 4388998201","first_published_date":"25/03/2020","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002463-pip01-18-m02"},{"decision_number":"P/0254/2024","pip_number":"EMEA-002889-PIP02-20-M01","active_substance":"ublituximab","invented_name":"Briumvi","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of multiple sclerosis","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Neuraxpharm Pharmaceuticals S.L.E-mail: nxregulatory@neuraxpharm.com Tel.:  +34 934759600","first_published_date":"12/09/2022","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002889-pip02-20-m01"},{"decision_number":"P/0249/2024","pip_number":"EMEA-003302-PIP01-22-M01","active_substance":"gefurulimab","invented_name":"","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of myasthenia gravis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alexion Europe SAS; E-mail: pip.enquiries.eu@alexion.com; Tel: +33 147100615","first_published_date":"07/06/2024","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003302-pip01-22-m01"},{"decision_number":"P/0247/2024","pip_number":"EMEA-000835-PIP01-10-M01","active_substance":"Dermatophagoides pteronyssinus","invented_name":"","therapeutic_area":"Immune system disorders","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergopharma GmbH & Co. KGEmail: allergopharma@info.com Tel.:  +49 4072765600","first_published_date":"11/01/2011","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000835-pip01-10-m01"},{"decision_number":"P/0199/2024","pip_number":"EMEA-003260-PIP03-23","active_substance":"brigimadlin","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of soft tissue sarcoma excluding liposarcoma","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"24/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003260-pip03-23"},{"decision_number":"P/0198/2024","pip_number":"EMEA-002338-PIP05-23","active_substance":"lanalumab","invented_name":"","therapeutic_area":"Blood and lymphatic system disorders","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of immune thrombocytopenia","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"24/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002338-pip05-23"},{"decision_number":"P/0246/2024","pip_number":"EMEA-003112-PIP01-21-M01","active_substance":"donidalorsen","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of hereditary angioedema","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Otsuka Pharmaceutical Netherlands B.V.Email: paediatrics-info@otsuka-europe.com Tel.:  +49 691700860","first_published_date":"28/08/2023","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003112-pip01-21-m01"},{"decision_number":"P/0245/2024","pip_number":"EMEA-000834-PIP01-10-M01","active_substance":"Dermatophagoides farinae","invented_name":"","therapeutic_area":"Immune system disorders","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergopharma GmbH & Co. KGEmail: allergopharma@info.com Tel.:  +49 4072765600","first_published_date":"11/01/2011","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000834-pip01-10-m01"},{"decision_number":"P/0244/2024","pip_number":"EMEA-000645-PIP01-09-M09","active_substance":"vedolizumab","invented_name":"Entyvio","therapeutic_area":"Gastrointestinal disorders","pharmaceutical_forms":"Powder for concentrate for solution for infusion;Solution for injection","condition_indication":"Treatment of Crohn's disease;Treatment of ulcerative colitis","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Pharma A/S; Tel. +44 2031168000; E-mail: paediatrics@tgrd.com","first_published_date":"21/07/2021","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000645-pip01-09-m09"},{"decision_number":"P/0243/2024","pip_number":"EMEA-001940-PIP01-16-M06","active_substance":"lamivudine;dolutegravir","invented_name":"Dovato","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Dispersible tablet;Film-coated tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ViiV Healthcare UK LimitedE-mail: eu.paediatric-plans@gsk.com Tel: +1 4388998201","first_published_date":"21/04/2017","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001940-pip01-16-m06"},{"decision_number":"P/0248/2024","pip_number":"EMEA-000836-PIP01-10-M01","active_substance":"Dermatophagoides pteronyssinus;Dermatophagoides farinae","invented_name":"","therapeutic_area":"Respiratory, thoracic and mediastinal disorders","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergopharma GmbH & Co. KGEmail: allergopharma@info.com Tel.:  +49 4072765600","first_published_date":"11/01/2011","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000836-pip01-10-m01"},{"decision_number":"P/0255/2024","pip_number":"EMEA-002941-PIP01-20-M05","active_substance":"severe acute respiratory syndrome coronavirus 2 recombinant spike protein nanoparticle vaccine/ matrix-M1 adjuvant (NVX-CoV2373)","invented_name":"Nuvaxovid","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novavax CZ, a.s.; E-mail:  ahanzlikova@novavax.com   Tel: +420 601 699 433","first_published_date":"16/03/2021","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002941-pip01-20-m05"},{"decision_number":"P/0253/2024","pip_number":"EMEA-003191-PIP01-22-M01","active_substance":"SARS-CoV-2 virus recombinant spike protein receptor binding domain fusion homodimer - XBB.1.16-XBB.1.16 variant;SARS-CoV-2 virus recombinant spike protein receptor binding domain fusion heterodimer (B.1.351 and B.1.1.7 strains) (beta-alpha variants)","invented_name":"Bimervax","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Emulsion for injection","condition_indication":"Prevention of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Hipra Human Health S.L.Email: medicalinformation@hipra.comTel.  +34 972430660","first_published_date":"12/10/2023","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003191-pip01-22-m01"},{"decision_number":"P/0241/2024","pip_number":"EMEA-001951-PIP01-16-M03","active_substance":"pegvaliase","invented_name":"Palynziq","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of hyperphenylalaninaemia","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BioMarin International Limited; Tel. +44 (0)20 7420 0800; E-mail: biomarin-europe@bmrn.com","first_published_date":"17/03/2017","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001951-pip01-16-m03"},{"decision_number":"P/0239/2024","pip_number":"EMEA-000576-PIP01-09-M16","active_substance":"tofacitinib","invented_name":"Xeljanz","therapeutic_area":"Musculoskeletal and connective tissue disorders","pharmaceutical_forms":"Film-coated tablet;Prolonged-release tablet;Prolonged-release age-appropriate oral formulation;Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIGE-mail: medical.information@pfizer.com Tel. +44 1304646607","first_published_date":"26/04/2012","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000576-pip01-09-m16"},{"decision_number":"P/0238/2024","pip_number":"EMEA-000410-PIP01-08-M07","active_substance":"regadenoson","invented_name":"Rapiscan","therapeutic_area":"Cardiac disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Diagnosis of myocardial perfusion disturbances","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GE Healthcare AS Email: petra.jeevaratnam@gehealthcare.com  Tel. +44 (0)1494 544000","first_published_date":"10/06/2009","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000410-pip01-08-m07"},{"decision_number":"P/0236/2024","pip_number":"EMEA-001164-PIP01-11-M08","active_substance":"vonicog alfa","invented_name":"Veyvondi","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of von Willebrand disease","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Baxalta Innovations GmbHE-mail: medinfoEMEA@takeda.comTel. +44 (0)3333 000181","first_published_date":"25/06/2012","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001164-pip01-11-m08"},{"decision_number":"P/0235/2024","pip_number":"EMEA-001652-PIP01-14-M06","active_substance":"cariprazine hydrochloride","invented_name":"Reagila","therapeutic_area":"Psychiatric disorders","pharmaceutical_forms":"Capsule, hard;Orodispersible tablet","condition_indication":"Treatment of schizophrenia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gedeon Richter Plc.Email: cprichter@richter.hu Tel.:  +362 04162804","first_published_date":"25/08/2015","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001652-pip01-14-m06"},{"decision_number":"P/0230/2024","pip_number":"EMEA-002432-PIP02-20-M01","active_substance":"ralinepag","invented_name":"","therapeutic_area":"Respiratory, thoracic and mediastinal disorders","pharmaceutical_forms":"Age appropriate oral liquid dosage formulation;Age appropriate oral solid dosage form","condition_indication":"Treatment of pulmonary arterial hypertension","routes_of_administration":"Enteral use;Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"United Therapeutics Corporation; Tel. +1 9194858530; Email: info1@unither.com    ","first_published_date":"22/07/2022","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002432-pip02-20-m01"},{"decision_number":"P/0229/2024","pip_number":"EMEA-002268-PIP02-18-M02","active_substance":"niraparib (tosilate monohydrate)","invented_name":"Zejula","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Capsule, hard;Tablet for oral suspension;Tablet","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline (Ireland) Limited; E-mail: eu.paediatric-plans@gsk.com; Tel: +1 4388998201","first_published_date":"23/03/2020","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002268-pip02-18-m02"},{"decision_number":"P/0228/2024","pip_number":"EMEA-002021-PIP01-16-M01","active_substance":"rAAV8 viral vector encoding the human UGT1A1 transgene (rAAV8-hUGT1A1)","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Crigler-Najjar syndrome","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GenethonE-mail: clinical_development@genethon.frTel: +33 169472828","first_published_date":"11/02/2022","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002021-pip01-16-m01"},{"decision_number":"P/0227/2024","pip_number":"EMEA-002012-PIP01-16-M05","active_substance":"Mexiletine hydrochloride","invented_name":"Namuscla","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Capsule, hard;Oral solution","condition_indication":"Treatment of myotonic disorders","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Lupin Europe GmbHTel.   +44 1565751378E-mail: preetamathur@lupin.com&nbsp","first_published_date":"24/07/2017","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002012-pip01-16-m05"},{"decision_number":"P/0225/2024","pip_number":"EMEA-002169-PIP01-17-M03","active_substance":"setrusumab","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of osteogenesis imperfecta","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mereo Biopharma Ireland LimitedEmail: bharti.navsariwala@mereobiopharma.com Tel.:  +44 3330237342","first_published_date":"28/01/2019","last_updated_date":"24/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002169-pip01-17-m03"},{"decision_number":"P/0256/2024","pip_number":"EMEA-003598-PIP01-24","active_substance":"anti-human LAG-3 monoclonal antibody, human IgG4 isotype","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Beone Medicines Ireland LimitedEmail: RegEU@beigene.com Tel.:  +353 015667660","first_published_date":"24/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003598-pip01-24"},{"decision_number":"P/0257/2024","pip_number":"EMEA-003597-PIP01-24","active_substance":"4-Benzoyl-D-phenylalanyl-D-seryl-D-tryptophyl-D-seryl-2,3,4,5,6-pentafluoro-D-phenylalanyl-3- cyclohexyl-D-alanyl-D-arginyl-D-arginyl-D-arginyl-D-glutaminyl-D-arginyl-D arginine acetate","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of pancreatic cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Canbas Co. Ltd.Email: cbp2401@canbas.co.jp Tel.:  +81 559543666","first_published_date":"24/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003597-pip01-24"},{"decision_number":"P/0232/2024","pip_number":"EMEA-003596-PIP01-24","active_substance":"3-tert-butyl-N-{(1R)-1-[4-(6-{6-[4-({1-[4-(2,4-dioxo-1,3-diazinan-1-yl)phenyl]piperidin-4-yl}methyl)piperazin-1-yl]pyridin-3-yl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2-methylphenyl]ethyl}-1,2,4-oxadiazole-5-carboxamide","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of mature B-cell neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Beone Medicines Ireland LimitedEmail: RegEU@beigene.com Tel.:  +353 015667660","first_published_date":"24/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003596-pip01-24"},{"decision_number":"P/0231/2024","pip_number":"EMEA-003594-PIP01-24","active_substance":"fulzerasib","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of colorectal cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Zhejiang Genfleet Therapeutics Co. Ltd.Email: hgrac@genfleet.com Tel.:  +86 57582586890","first_published_date":"23/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003594-pip01-24"},{"decision_number":"P/0233/2024","pip_number":"EMEA-003593-PIP01-24","active_substance":"autologous CD3-positive T cells transduced with a retroviral vector containing an anti-B cell maturation agent chimeric antigen receptor gene","invented_name":"","therapeutic_area":"Immune system disorders","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of systemic light chain amyloidosis","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Nexcella Inc.Email: chris@raremoonconsulting.com Tel.:  +34 934880972","first_published_date":"23/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003593-pip01-24"},{"decision_number":"P/0234/2024","pip_number":"EMEA-003593-PIP02-24","active_substance":"autologous CD3-positive T cells transduced with a retroviral vector containing an anti-B cell maturation agent chimeric antigen receptor gene","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of Multiple Myeloma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Nexcella Inc.Email: chris@raremoonconsulting.com Tel.:  +34 934880972","first_published_date":"23/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003593-pip02-24"},{"decision_number":"P/0242/2024","pip_number":"EMEA-003192-PIP02-23","active_substance":"ensitrelvir","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Age appropriate oral solid dosage form;Tablet","condition_indication":"Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"19/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Shionogi B.V.E-mail: contact@shionogi.eu Tel:  +31 (0)204917439","first_published_date":"23/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003192-pip02-23"},{"decision_number":"P/0237/2024","pip_number":"EMEA-002875-PIP02-24","active_substance":"allogeneic skin-derived ABCB5-positive dermal mesenchymal stromal cells","invented_name":"Amesanar","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of venous leg ulcer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Rheacell GmbH & Co. KGTel: +49 6221718330Email: office@rheacell.com","first_published_date":"23/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002875-pip02-24"},{"decision_number":"P/0226/2024","pip_number":"EMEA-002354-PIP03-24","active_substance":"zanubrutinib","invented_name":"Brukinsa","therapeutic_area":"Blood and lymphatic system disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of lymphoplasmacytic lymphoma;Treatment of mature B-cell neoplasms (excluding lymphoplasmacytic lymphoma)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Beone Medicines Ireland LimitedE-mail: bg.ireland@beigene.com Tel.: +353 1 566 7660","first_published_date":"20/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002354-pip03-24"},{"decision_number":"P/0250/2024","pip_number":"EMEA-003613-PIP01-24","active_substance":"Ifinatamab deruxtecan","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer (small cell and non-small cell lung cancer)","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Daiichi Sankyo Europe GmbH; E-mail: service@daiichi-sankyo.eu; Tel.: +49 8978080","first_published_date":"20/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003613-pip01-24"},{"decision_number":"P/0251/2024","pip_number":"EMEA-003611-PIP01-24","active_substance":"diclofenac (sodium);thiocolchicoside","invented_name":"","therapeutic_area":"Musculoskeletal and connective tissue disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of musculoskeletal and connective tissue pain and discomfort","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Doc Generici S.r.l.E-mail: marta.bragheri@genericidoc.it Tel.:  +39 0265534261","first_published_date":"20/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003611-pip01-24"},{"decision_number":"P/0272/2024","pip_number":"EMEA-003606-PIP01-24","active_substance":"acasunlimab","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer (small cell and non-small cell lung cancer)","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Genmab A/S; Tel.: +45 70202728; E-mail: clinicaltrials@genmab.com","first_published_date":"20/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003606-pip01-24"},{"decision_number":"P/0258/2024","pip_number":"EMEA-003605-PIP01-24","active_substance":"alvelestat","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of congenital alpha-1 antitrypsin deficiency","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mereo Biopharma Ireland LimitedE-mail: paediatrics@mereobiopharma.com Tel.:  +1 6509958341","first_published_date":"20/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003605-pip01-24"},{"decision_number":"P/0267/2024","pip_number":"EMEA-003600-PIP01-24","active_substance":"Indapamide;ramipril","invented_name":"","therapeutic_area":"Vascular disorders","pharmaceutical_forms":"Modified-release tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Adamed Pharma S.A.E-mail: RA-EU@adamed.comTel: +48 697063916","first_published_date":"20/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003600-pip01-24"},{"decision_number":"P/0270/2024","pip_number":"EMEA-003599-PIP01-24","active_substance":"trastuzumab-exatecan derivative antibody-drug conjugate","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of breast cancer;Treatment of endometrial cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BioNTech SEE-mail: service@biontech.de Tel: +49 (0) 6131 90840","first_published_date":"20/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003599-pip01-24"},{"decision_number":"P/0164/2024","pip_number":"EMEA-002724-PIP01-19-M03","active_substance":"Giroctocogene fitelparvovec","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Haemophilia A","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG  E-mail: medical.information@pfizer.com Tel: +44 (0)1304 616161","first_published_date":"30/06/2021","last_updated_date":"16/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002724-pip01-19-m03"},{"decision_number":"P/0152/2024","pip_number":"EMEA-002665-PIP02-20-M01","active_substance":"Loncastuximab tesirine","invented_name":"Zynlonta","therapeutic_area":"Blood and lymphatic system disorders","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of mature B-cell neoplasms","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Swedish Oprhan Biovitrum AB (publ); Email: info@sobi.com; Tel. +46 8 697 20 00","first_published_date":"14/02/2023","last_updated_date":"16/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002665-pip02-20-m01"},{"decision_number":"P/0163/2024","pip_number":"EMEA-002474-PIP02-18-M02","active_substance":"levonorgestrel","invented_name":"","therapeutic_area":"Surgical and medical procedures","pharmaceutical_forms":"Vaginal delivery system","condition_indication":"Prevention of pregnancy","routes_of_administration":"Vaginal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Chemo Research S.L.E-mail: naomi.nunez@exeltis.com Tel.:  +34 653535412","first_published_date":"25/03/2020","last_updated_date":"16/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002474-pip02-18-m02"},{"decision_number":"P/0151/2024","pip_number":"EMEA-002449-PIP02-18-M02","active_substance":"Berotralstat","invented_name":"Orladeyo","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Capsule, hard;Age appropriate oral solid dosage form","condition_indication":"Treatment of hereditary angioedema","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biocryst Ireland LimitedE-mail: eurow_ra@biocryst.com Tel.:  +49 (0)15172444722","first_published_date":"09/06/2020","last_updated_date":"16/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002449-pip02-18-m02"},{"decision_number":"P/0168/2024","pip_number":"EMEA-002068-PIP01-16-M05","active_substance":"influenza vaccine (surface antigen, inactivated, prepared in cell cultures) [QIVc]","invented_name":"Flucelvax Tetra","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of influenza","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Seqirus Netherlands B.V.; E-mail: seqirus.clinicaltrials@seqirus.com; Tel: +1 9088587365","first_published_date":"28/09/2017","last_updated_date":"16/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002068-pip01-16-m05"},{"decision_number":"P/0167/2024","pip_number":"EMEA-001875-PIP02-18-M04","active_substance":"beclometasone dipropionate;formoterol fumarate dihydrate;glycopyrronium bromide","invented_name":"Trimbow; Trimbow and associated names","therapeutic_area":"Respiratory, thoracic and mediastinal disorders","pharmaceutical_forms":"Pressurised inhalation (solution);Inhalation powder","condition_indication":"Treatment of asthma","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Chiesi Farmaceutici S.p.A; Tel. +39 05212791; E-mail: info@chiesi.com","first_published_date":"29/10/2019","last_updated_date":"16/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001875-pip02-18-m04"},{"decision_number":"P/0176/2024","pip_number":"EMEA-001862-PIP03-20-M02","active_substance":"brexucabtagene autoleucel","invented_name":"Tecartus","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of mature B-cell neoplasms","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kite Pharma EU B.V.; Tel. +1 4242091332; E-mail: regulatory@kitepharma.com","first_published_date":"29/09/2021","last_updated_date":"16/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001862-pip03-20-m02"},{"decision_number":"P/0172/2024","pip_number":"EMEA-001716-PIP07-22-M01","active_substance":"venglustat","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Chewable tablet","condition_indication":"Treatment of Gaucher disease, type 2;Treatment of Gaucher disease, type 3","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi B.V.E-mail: eumedinfo.gz@sanofi.comTel: +31 (0) 20 245 3917","first_published_date":"22/09/2016","last_updated_date":"16/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001716-pip07-22-m01"},{"decision_number":"P/0171/2024","pip_number":"EMEA-001666-PIP02-21-M01","active_substance":"atrasentan","invented_name":"","therapeutic_area":"Renal and urinary disorders","pharmaceutical_forms":"Tablet;Age appropriate formulation","condition_indication":"Treatment of primary IgA nephropathy","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Chinook Therapeutics, Inc.; Email: info@chinooktx.com","first_published_date":"30/05/2024","last_updated_date":"16/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001666-pip02-21-m01"},{"decision_number":"P/0252/2024","pip_number":"EMEA-003451-PIP01-23","active_substance":"derivative of azabicycloheptane-carboxamide","invented_name":"","therapeutic_area":"Respiratory, thoracic and mediastinal disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of bronchiectasis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"19/07/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"13/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003451-pip01-23"},{"decision_number":"P/0462/2023","pip_number":"EMEA-002963-PIP01-21-M01","active_substance":"bemnifosbuvir","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Age appropriate oral dosage formulation;Tablet","condition_indication":"Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Atea Pharmaceuticals Inc. Tel. +1 8572848891 Email: ateaclinicaltrials@ateapharma.com","first_published_date":"20/02/2023","last_updated_date":"13/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002963-pip01-21-m01"},{"decision_number":"P/0149/2024","pip_number":"EMEA-002168-PIP01-17-M06","active_substance":"onasemnogene abeparvovec","invented_name":"Zolgensma","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of spinal muscular atrophy","routes_of_administration":"Intravenous use;Intrathecal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"28/01/2019","last_updated_date":"13/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002168-pip01-17-m06"},{"decision_number":"P/0165/2024","pip_number":"EMEA-002999-PIP01-21-M01","active_substance":"Live, attenuated, dengue virus, serotype 1 (DENV1);live, attenuated, chimeric dengue virus, serotype 2 (DENV2);Live, attenuated, dengue virus, serotype 3 (DENV3);Live, attenuated, dengue virus, serotype 4 (DENV4)","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Powder and solvent for concentrate for solution for infusion","condition_indication":"Prevention of dengue disease","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"MSD Europe Belgium S.R.L.E-mail: pip.information@msd.comTel. +33 180464738","first_published_date":"13/11/2023","last_updated_date":"12/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002999-pip01-21-m01"},{"decision_number":"P/0148/2024","pip_number":"EMEA-002269-PIP01-17-M03","active_substance":"olaparib","invented_name":"Lynparza","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB (Sweden); Tel. +46 8 5532791; E-mail: paediatrics@astrazeneca.com","first_published_date":"17/01/2019","last_updated_date":"12/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002269-pip01-17-m03"},{"decision_number":"P/0138/2024","pip_number":"EMEA-001407-PIP02-15-M07","active_substance":"nivolumab","invented_name":"Opdivo","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of malignant neoplasms of lymphoid tissue;Treatment of malignant neoplasms of the central nervous system","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"25/04/2016","last_updated_date":"12/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001407-pip02-15-m07"},{"decision_number":"P/0137/2024","pip_number":"EMEA-001136-PIP01-11-M03","active_substance":"avatrombopag maleate","invented_name":"Doptelet","therapeutic_area":"Blood and lymphatic system disorders;Haematology-Hemostaseology","pharmaceutical_forms":"Film-coated tablet;Powder for oral suspension","condition_indication":"Treatment of Idiopathic Thrombocytopenia Purpura (ITP);Treatment of Thrombocytopenic Purpura Secondary to Liver Disease","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Swedish Orphan Biovitrum ABE-mail: medical.info@sobi.comTel. +46 8697 2000","first_published_date":"19/01/2012","last_updated_date":"12/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001136-pip01-11-m03"},{"decision_number":"P/0119/2024","pip_number":"EMEA-001619-PIP04-17-M03","active_substance":"filgotinib","invented_name":"Jyseleca","therapeutic_area":"Musculoskeletal and connective tissue disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis,  psoriatic arthritis, and juvenile idiopathic arthritis)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Galapagosemail: medicalinfo@glpg.comphone: +32 (0)15342900","first_published_date":"12/02/2018","last_updated_date":"12/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001619-pip04-17-m03"},{"decision_number":"P/0117/2024","pip_number":"EMEA-001220-PIP01-11-M10","active_substance":"Baricitinib","invented_name":"Olumiant","therapeutic_area":"Musculoskeletal and connective tissue disorders","pharmaceutical_forms":"Oral suspension;Film-coated tablet","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis and juvenile idiopathic arthritis)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly And Company Limitedemail: EU_PAEDIATRIC@lilly.comphone: +44 1256315000","first_published_date":"03/05/2013","last_updated_date":"11/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001220-pip01-11-m10"},{"decision_number":"P/0115/2024","pip_number":"EMEA-002362-PIP02-19-M03","active_substance":"fidanacogene elaparvovec","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of congenital factor IX deficiency (haemophilia B)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG; Tel. +44 (0)1304 646 607; E-mail: pip_enquiries@pfizer.com","first_published_date":"05/03/2021","last_updated_date":"11/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002362-pip02-19-m03"},{"decision_number":"P/0114/2024","pip_number":"EMEA-001823-PIP01-15-M03","active_substance":"in vitro expanded autologous human articular chondrocytes","invented_name":"","therapeutic_area":"Musculoskeletal and connective tissue disorders","pharmaceutical_forms":"Implantation matrix","condition_indication":"Treatment of cartilage disorders","routes_of_administration":"Intra-articular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"TETEC Tissue Engineering Technologies AG; Email: info@tetec-ag.de; Tel. +49 712116260;  ","first_published_date":"27/10/2016","last_updated_date":"11/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001823-pip01-15-m03"},{"decision_number":"P/0110/2024","pip_number":"EMEA-002486-PIP04-21-M01","active_substance":"catequentinib","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Age appropriate oral liquid dosage formulation;Capsule, hard","condition_indication":"Treatment of Ewing sarcoma;Treatment of soft tissue sarcomas","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Advenchen Laboratories, LLC; info@advenchen.com;  +1 8055301550","first_published_date":"17/04/2023","last_updated_date":"11/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002486-pip04-21-m01"},{"decision_number":"P/0177/2024","pip_number":"EMEA-000813-PIP01-09-M01","active_substance":"13 Grass Aqueous Extract","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergy Therapeutics (UK) Ltd; Tel. +44(0)1903 844 700; E-mail: infoservices@allergytherapeutics.com","first_published_date":"25/11/2010","last_updated_date":"11/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000813-pip01-09-m01"},{"decision_number":"P/0135/2024","pip_number":"EMEA-000183-PIP02-12-M05","active_substance":"apixaban","invented_name":"Eliquis","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral liquid dosage formulation;Age appropriate dosage form, other","condition_indication":"Treatment of venous thromboembolism","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG; Email: medical.information@bms.com; Tel. +44 1895523740","first_published_date":"03/04/2013","last_updated_date":"11/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000183-pip02-12-m05"},{"decision_number":"P/0181/2024","pip_number":"EMEA-003623-PIP01-24","active_substance":"Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H1N1);Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2);Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Victoria lineage)","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Suspension for injection in pre-filled syringe","condition_indication":"Prevention of influenza infection","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Seqirus Netherlands B.V.; E-mail: seqirus.clinicaltrials@seqirus.com; Tel: +1 9088587365","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003623-pip01-24"},{"decision_number":"P/0180/2024","pip_number":"EMEA-003624-PIP01-24","active_substance":"Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H1N1);Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2);Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Victoria lineage)","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Suspension for injection in pre-filled syringe","condition_indication":"Prevention of influenza infection","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Seqirus Netherlands B.V.; E-mail: seqirus.clinicaltrials@seqirus.com; Tel: +1 9088587365","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003624-pip01-24"},{"decision_number":"P/0143/2024","pip_number":"EMEA-003573-PIP01-23","active_substance":"pitavastatin (calcium);ezetimibe","invented_name":"","therapeutic_area":"Metabolism and nutrition disorders","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"KRKA tovarna zdravil d.d. Novo mesto E-mail: Regulatory.Affairs@krka.biz Tel. + 386 73312111","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003573-pip01-23"},{"decision_number":"P/0156/2024","pip_number":"EMEA-003570-PIP01-23","active_substance":"human alpha-1-proteinase inhibitor immunoglobulin G fusion protein, recombinant","invented_name":"","therapeutic_area":"Respiratory, thoracic and mediastinal disorders","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of emphysema secondary to congenital deficiency of alpha-1 antitrypsin","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Inhibrx Inc.E-mail: clinicaltrials@inhibrx.com Tel.:  +1 (858)7954220","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003570-pip01-23"},{"decision_number":"P/0155/2024","pip_number":"EMEA-003567-PIP01-23","active_substance":"volixibat potassium","invented_name":"","therapeutic_area":"Hepatobiliary disorders","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of primary biliary cholangitis","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mirum PharmaceuticalsE-mail: medinfo@mirumpharma.com Tel.  +1 6506674085","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003567-pip01-23"},{"decision_number":"P/0111/2024","pip_number":"EMEA-002597-PIP10-23","active_substance":"Efgartigimod alfa","invented_name":"Vyvgart","therapeutic_area":"Eye disorders","pharmaceutical_forms":"Concentrate for solution for infusion;Solution for injection","condition_indication":"Treatment of thyroid eye disease","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Argenx BVE-mail: regulatory@argenx.comTel: +32 93103400","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002597-pip10-23"},{"decision_number":"P/0154/2024","pip_number":"EMEA-003566-PIP01-23","active_substance":"camrelizumab","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of hepatocellular carcinoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Luzsana Biotechnology EuropeE-mail: regulatoryeu@luzsana.com Tel.:  +41 792406071","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003566-pip01-23"},{"decision_number":"P/0109/2024","pip_number":"EMEA-000520-PIP03-23","active_substance":"belimumab","invented_name":"Benlysta","therapeutic_area":"Musculoskeletal and connective tissue disorders","pharmaceutical_forms":"Powder for concentrate for solution for infusion;Solution for injection","condition_indication":"Treatment of systemic sclerosis","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline (Ireland) Limitedeu.paediatrics-plans@gsk.com+1 4388998201","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000520-pip03-23"},{"decision_number":"P/0108/2024","pip_number":"EMEA-003546-PIP01-23","active_substance":"zongertinib","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of non-small cell lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003546-pip01-23"},{"decision_number":"P/0162/2024","pip_number":"EMEA-003563-PIP01-23","active_substance":"atorvastatin calcium;fenofibrate","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hyperlipidaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Althera Laboratories LimitedEmail: regulatory.eu@altherainc.comTel.: +353 1 906 0479","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003563-pip01-23"},{"decision_number":"P/0185/2023","pip_number":"EMEA-003390-PIP01-23","active_substance":"pitavastatin;ezetimibe","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Verisfield Single Member S.A.Email: pharmacovigilance@verisfield.gr; economou@verisfield.gr Tel: +30 2107475196&nbsp","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003390-pip01-23"},{"decision_number":"P/0161/2024","pip_number":"EMEA-003562-PIP01-23","active_substance":"ezetimibe;fenofibrate;rosuvastatin calcium","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hyperlipidaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Althera Laboratories LtdEmail: regulatory.eu@altheralabs.com Tel: +353 861838865","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003562-pip01-23"},{"decision_number":"P/0160/2024","pip_number":"EMEA-003561-PIP01-23","active_substance":"carbachol;brimonidine tartrate","invented_name":"","therapeutic_area":"Eye disorders","pharmaceutical_forms":"Eye drops, solution","condition_indication":"Treatment of presbyopia","routes_of_administration":"Ophthalmic use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Visus Therapeutics Inc.E-mail: nathan.wheeler@visustx.com Tel.:  +1 (949)2592259","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003561-pip01-23"},{"decision_number":"P/0146/2024","pip_number":"EMEA-003559-PIP01-23","active_substance":"baxdrostat;dapagliflozin propanediol monohydrate","invented_name":"","therapeutic_area":"Renal and urinary disorders","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of chronic kidney disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca ABEmail: paediatrics@astrazeneca.comTel. +46 855324400","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003559-pip01-23"},{"decision_number":"P/0147/2024","pip_number":"EMEA-003557-PIP01-23","active_substance":"petosemtamab","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of head and neck epithelial malignant neoplasms","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merus N.V. E-mail: enquiries@merus.nlTel: +31 850162500","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003557-pip01-23"},{"decision_number":"P/0140/2024","pip_number":"EMEA-003555-PIP01-23","active_substance":"alrefimotide;tapderimotide;riletamotide","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of mesothelioma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ultimovacs ASAE-mail: mail@ultimovacs.comTel.:  +47 41380080","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003555-pip01-23"},{"decision_number":"P/0139/2024","pip_number":"EMEA-003554-PIP01-23","active_substance":"acetylcysteine amide","invented_name":"","therapeutic_area":"Vascular disorders","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hereditary cystatin C amyloid angiopathy","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Arctic Therapeutics ehf.E-mail: info@arctictherapeutics.com Tel.:  +354 8643476","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003554-pip01-23"},{"decision_number":"P/0175/2024","pip_number":"EMEA-003552-PIP01-23","active_substance":"human rabies immunoglobulin","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of rabies viral infection","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kamada Ireland LimitedEmail: oritp@kamada.com    Tel: +972 89406472;  +972 522660030","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003552-pip01-23"},{"decision_number":"P/0107/2024","pip_number":"EMEA-003534-PIP01-23","active_substance":"sitagliptin;dapagliflozin","invented_name":"","therapeutic_area":"Metabolism and nutrition disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Rontis Hellas Medical And Pharmaceutical Products S.A.emakrodouli@pharosgr.gr+30 2106664667","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003534-pip01-23"},{"decision_number":"P/0106/2024","pip_number":"EMEA-003530-PIP01-23","active_substance":"nebivolol;ramipril","invented_name":"","therapeutic_area":"Cardiac disorders","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of coronary artery disease;Treatment of heart failure;Treatment of hypertension;Treatment of hypertension with coexisting coronary artery disease;Treatment of hypertension with coexisting heart failure","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Zakłady Farmaceutyczne Polpharma S.A.; E-mail: regulatory@polpharma.com; Tel.  +48 585631600","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003530-pip01-23"},{"decision_number":"P/0174/2024","pip_number":"EMEA-003485-PIP01-23","active_substance":"N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)- 6-(2,2,2-trifluoroethoxy)pyridin-3-yl)acrylamide methanesulfonate","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of non-small cell lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Arrivent Biopharma Inc.E-mail: info@arrivent.com Tel.:  +1 6282774836","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003485-pip01-23"},{"decision_number":"P/0150/2024","pip_number":"EMEA-003481-PIP01-23","active_substance":"lutikizumab","invented_name":"","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of hidradenitis suppurativa","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003481-pip01-23"},{"decision_number":"P/0182/2024","pip_number":"EMEA-003478-PIP01-23","active_substance":"zasocitinib","invented_name":"","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral formulation","condition_indication":"Treatment of psoriasis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Pharma A/STel. +44 (0)3333000181E-mail: medinfoEMEA@takeda.com","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003478-pip01-23"},{"decision_number":"P/0142/2024","pip_number":"EMEA-003465-PIP01-23","active_substance":"messenger RNA encoding Cas9, single guide RNA targeting the human KLKB1 gene","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of hereditary angioedema","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Intellia Therapeutics Inc.E-mail: medicalinformation@intelliatx.com Tel: +1 8338880387","first_published_date":"11/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003465-pip01-23"},{"decision_number":"P/0123/2024","pip_number":"EMEA-002958-PIP01-21-M01","active_substance":"aficamten","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertrophic cardiomyopathy","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cytokinetics, Inc.; Tel.: +1 650 624 3000; E-mail: regaffairs@cytokinetics.com","first_published_date":"05/04/2023","last_updated_date":"10/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002958-pip01-21-m01"},{"decision_number":"P/0134/2024","pip_number":"EMEA-001585-PIP01-13-M06","active_substance":"selumetinib","invented_name":"Koselugo","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Age appropriate oral dosage formulation;Capsule, hard","condition_indication":"Treatment of melanoma;Treatment of neurofibromatosis type 1;Treatment of thyroid cancer","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"25/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel. +46 8553 27591","first_published_date":"25/08/2015","last_updated_date":"10/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001585-pip01-13-m06"},{"decision_number":"P/0130/2024","pip_number":"EMEA-002208-PIP01-17-M04","active_substance":"Mirikizumab","invented_name":"Omvoh","therapeutic_area":"Gastrointestinal disorders","pharmaceutical_forms":"Concentrate for solution for infusion;Solution for injection","condition_indication":"Treatment of Crohn's disease","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; EU_PAEDIATRIC@LILLY.COM; +44 1276483000","first_published_date":"28/01/2019","last_updated_date":"10/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002208-pip01-17-m04"},{"decision_number":"P/0133/2024","pip_number":"EMEA-003453-PIP01-23","active_substance":"enlicitide (decanoate)","invented_name":"","therapeutic_area":"Metabolism and nutrition disorders","pharmaceutical_forms":"Age appropriate formulation;Film-coated tablet","condition_indication":"Treatment of hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"MSD Europe Belgium S.R.L.E-mail: pip.information@msd.comTel. +33 180464738","first_published_date":"10/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003453-pip01-23"},{"decision_number":"P/0132/2024","pip_number":"EMEA-001198-PIP04-23","active_substance":"netupitant;palonosetron","invented_name":"Akynzeo","therapeutic_area":"Surgical and medical procedures","pharmaceutical_forms":"Oral suspension","condition_indication":"Prevention of chemotherapy-induced nausea and vomiting","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Helsinn Birex Pharmaceuticals Limited; ailbhe.henderson@helsinn.com; +353 18089615","first_published_date":"10/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001198-pip04-23"},{"decision_number":"P/0131/2024","pip_number":"EMEA-003439-PIP02-23","active_substance":"GIPR antagonist/GLP-1R agonist (AMG 133)","invented_name":"","therapeutic_area":"Metabolism and nutrition disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of obesity","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V. ; E-mail: medinfointernational@amgen.com; Tel. +44 (0)1223 420305","first_published_date":"10/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003439-pip02-23"},{"decision_number":"P/0129/2024","pip_number":"EMEA-002208-PIP02-24","active_substance":"Mirikizumab","invented_name":"Omvoh","therapeutic_area":"Gastrointestinal disorders","pharmaceutical_forms":"Concentrate for solution for infusion;Solution for injection","condition_indication":"Treatment of ulcerative colitis","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly And Company Limited; EU_PAEDIATRIC@LILLY.COM; +44 1276483000","first_published_date":"10/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002208-pip02-24"},{"decision_number":"P/0128/2024","pip_number":"EMEA-003543-PIP01-23","active_substance":"autologous T-cells expressing a chimeric antigenic receptor against G protein coupled receptor class C, group 5, member D (GPRC5D) (BMS-986393)","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of Multiple Myeloma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/04/2025","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"10/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003543-pip01-23"},{"decision_number":"P/0127/2024","pip_number":"EMEA-003542-PIP01-23","active_substance":"propylene glycol","invented_name":"","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Cutaneous emulsion","condition_indication":"Treatment of dry skin","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aco Hud Nordic AB; CHCINordicRegulatory@perrigo.com; +46 859002900","first_published_date":"10/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003542-pip01-23"},{"decision_number":"P/0126/2024","pip_number":"EMEA-003443-PIP02-23","active_substance":"disitamab vedotin","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of solid tumours, including central nervous system malignancies","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG  E-mail: medical.information@pfizer.com Tel: +44 (0)1304 616161","first_published_date":"10/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003443-pip02-23"},{"decision_number":"P/0125/2024","pip_number":"EMEA-003551-PIP01-23","active_substance":"maplirpacept","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of Multiple Myeloma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG  E-mail: medical.information@pfizer.com Tel: +44 (0)1304 616161","first_published_date":"10/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003551-pip01-23"},{"decision_number":"P/0159/2024","pip_number":"EMEA-003457-PIP01-23","active_substance":"laruparetigene zovaparvovec","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of X-linked retinitis pigmentosa","routes_of_administration":"Intraocular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"FGK Representative Service GmbHE-mail: angela.denzel@fgk-rs.com Tel.:  +49 8989311938","first_published_date":"10/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003457-pip01-23"},{"decision_number":"P/0122/2024","pip_number":"EMEA-003395-PIP02-23","active_substance":"iodine (131I) apamistamab","invented_name":"","therapeutic_area":"Surgical and medical procedures","pharmaceutical_forms":"Solution for infusion","condition_indication":"","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Immedica Pharma AB; E-mail: info@immedica.comTel. +46 (0)853339500","first_published_date":"10/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003395-pip02-23"},{"decision_number":"P/0184/2024","pip_number":"EMEA-003454-PIP01-23","active_substance":"mometasone furoate","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Implant","condition_indication":"Treatment of chronic rhinosinusitis","routes_of_administration":"Endosinusial use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"17/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Orphix Consulting GmbHE-mail: contactus@lyratx.com Tel.:  +1 6173934600","first_published_date":"10/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003454-pip01-23"},{"decision_number":"P/0121/2024","pip_number":"EMEA-003248-PIP02-23","active_substance":"suvecaltamide hydrochloride","invented_name":"","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of tremor in patients with Parkinson’s disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Jazz Pharmaceuticals Ireland LimitedE-mail: corporateaffairsmediainfo@jazzpharma.comTel: +353 16347800","first_published_date":"10/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003248-pip02-23"},{"decision_number":"P/0173/2024","pip_number":"EMEA-003434-PIP02-23","active_substance":"modified messenger ribonucleic acid encoding individual patient-specific tumour neoantigens (V940/ mRNA-4157)","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Dispersion for injection","condition_indication":"Treatment of cutaneous squamous cell carcinoma;Treatment of renal cell carcinoma (RCC);Treatment of urothelial carcinoma","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"10/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003434-pip02-23"},{"decision_number":"P/0120/2024","pip_number":"EMEA-002883-PIP03-23","active_substance":"trimodulin (human IgM, IgA, IgG solution)","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of lower respiratory tract and lung infections","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biotest AG; Tel. +49 6103801497; E-mail: Andrea.Wartenberg-Demand@biotest.com","first_published_date":"10/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002883-pip03-23"},{"decision_number":"P/0170/2024","pip_number":"EMEA-003393-PIP01-23","active_substance":"tanimilast","invented_name":"","therapeutic_area":"Respiratory, thoracic and mediastinal disorders","pharmaceutical_forms":"Inhalation powder","condition_indication":"Treatment of asthma","routes_of_administration":"Inhalation use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Chiesi Farmaceutici S.p.A; Tel. +39 05212791; E-mail: info@chiesi.com","first_published_date":"10/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003393-pip01-23"},{"decision_number":"P/0141/2024","pip_number":"EMEA-003333-PIP01-22","active_substance":"Hemopexin","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of sickle cell disease","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CSL Behring GmbHEmail: PIP.CSLBehring@cslbehring.com Tel: +49 (0)64213912","first_published_date":"10/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003333-pip01-22"},{"decision_number":"P/0178/2024","pip_number":"EMEA-003299-PIP01-22","active_substance":"orforglipron","invented_name":"","therapeutic_area":"Endocrine disorders","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of type 2 diabetes mellitus","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly and Company LtdE-mail: eu_paediatric@lilly.com Phone: +44 1256315000","first_published_date":"10/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003299-pip01-22"},{"decision_number":"P/0153/2024","pip_number":"EMEA-003277-PIP02-23","active_substance":"live attenuated respiratory syncytial virus (RSV)","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Nasal spray (solution)","condition_indication":"Prevention of respiratory syncytial virus disease","routes_of_administration":"Nasal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi Winthrop IndustrieE-mail: contact-us@sanofi.comTel: +33 1 69 74 56 95","first_published_date":"10/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003277-pip02-23"},{"decision_number":"P/0158/2024","pip_number":"EMEA-002924-PIP02-23","active_substance":"etavopivat","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of sickle cell disease","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; E-mail: paediatrics@novonordisk.com ; Tel.: +45 44448888","first_published_date":"06/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002924-pip02-23"},{"decision_number":"P/0169/2024","pip_number":"EMEA-002727-PIP03-23","active_substance":"nivolumab;relatlimab","invented_name":"Opdualag","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of melanoma","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb EEIG; E-mail: medical.information@bms.com; Tel: +44 1423533610","first_published_date":"06/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002727-pip03-23"},{"decision_number":"P/0166/2024","pip_number":"EMEA-002573-PIP02-23","active_substance":"amivantamab","invented_name":"Rybrevant","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of colorectal carcinoma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen Cilag International Email: contact@Janssen-emea.com Tel. +32 14602111","first_published_date":"06/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002573-pip02-23"},{"decision_number":"P/0185/2024","pip_number":"EMEA-002490-PIP01-18","active_substance":"Mavorixafor","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Capsule, hard;Age appropriate oral liquid dosage formulation;Age appropriate oral solid dosage form","condition_indication":"Treatment of WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"23/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"E-mail: clinicaltrialinfo@x4pharma.com Tel.:  +1 18575295779","first_published_date":"06/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002490-pip01-18"},{"decision_number":"P/0145/2024","pip_number":"EMEA-002042-PIP03-23","active_substance":"Erdafitinib","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of urothelial carcinoma","routes_of_administration":"Intravesical use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen Cilag International Email: contact@Janssen-emea.com Tel. +32 14602111","first_published_date":"06/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002042-pip03-23"},{"decision_number":"P/0136/2024","pip_number":"EMEA-001039-PIP04-23","active_substance":"Clostridium Botulinum neurotoxin type A (150 kD), free from complexing proteins","invented_name":"Bocouture; Xeomin","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of essential tremor","routes_of_administration":"Intramuscular use;Intraglandular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merz Pharmaceuticals GmbH; Tel. +49 6915031; E-mail: contact@merz.de","first_published_date":"06/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001039-pip04-23"},{"decision_number":"P/0105/2024","pip_number":"EMEA-002861-PIP02-20-M07","active_substance":"tozinameran;raxtozinameran","invented_name":"Comirnaty","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Concentrate for dispersion for injection;Dispersion for injection","condition_indication":"Prevention of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BioNTech Manufacturing GmbH Tel.  +49 613190847507 E-mail: Constanze.Blume.Comirnaty@biontech.de","first_published_date":"18/12/2020","last_updated_date":"06/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002861-pip02-20-m07"},{"decision_number":"P/0104/2024","pip_number":"EMEA-002746-PIP01-20-M03","active_substance":"seltorexant","invented_name":"","therapeutic_area":"Psychiatric disorders","pharmaceutical_forms":"Film-coated tablet;Age appropriate dosage form","condition_indication":"Treatment of major depressive disorder","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; E-mail: contact@janssen-emea.com; Tel: +40 744383413","first_published_date":"19/11/2021","last_updated_date":"06/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002746-pip01-20-m03"},{"decision_number":"P/0103/2024","pip_number":"EMEA-002736-PIP02-23","active_substance":"garetosmab","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of fibrodysplasia ossificans progressiva","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Regeneron Ireland Designated Activity Company E-mail: clinicaltrials@regeneron.com  Tel. +1 9048475385","first_published_date":"06/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002736-pip02-23"},{"decision_number":"P/0102/2024","pip_number":"EMEA-002618-PIP02-20-M01","active_substance":"ruxolitinib (phosphate)","invented_name":"Jakavi; Opzelura","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Cream","condition_indication":"Treatment of vitiligo","routes_of_administration":"Cutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Incyte Biosciences Distribution B.V.; E-mail: globalmedinfo@incyte.com; Tel. +800 0002 7423","first_published_date":"13/01/2022","last_updated_date":"06/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002618-pip02-20-m01"},{"decision_number":"P/0100/2024","pip_number":"EMEA-003569-PIP01-23","active_substance":"raludotatug deruxtecan","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of fallopian tube cancer;Treatment of ovarian cancer;Treatment of primary peritoneal cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"05/04/2025","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Daiichi Sankyo Europe GmbH; E-mail: service@daiichi-sankyo.eu; Tel.: +49 8978080","first_published_date":"06/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003569-pip01-23"},{"decision_number":"P/0097/2024","pip_number":"EMEA-003405-PIP01-23","active_substance":"CX-000359 mRNA encoding the UL128 protein in the CMV glycoprotein complex pentamer;CX- 000594 mRNA encoding the gL protein in the CMV glycoprotein complex pentamer;CX- 000712 mRNA encoding the UL130 protein in the CMV glycoprotein complex pentamer;CX-005128 mRNA encoding the UL131A protein in the CMV glycoprotein complex pentamer;CX-005282 m-RNA encoding the gH protein in the CMV glycoprotein complex pentamer;CX-000667 mRNA encoding CMV gB (mRNA- 1647)","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Powder for suspension for injection","condition_indication":"Prevention of cytomegalovirus infection","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Moderna Biotech Spain, S.L.E-mail: EMEAMedInfo@modernatx.comTel.  +34 900031015","first_published_date":"06/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003405-pip01-23"},{"decision_number":"P/0096/2024","pip_number":"EMEA-003313-PIP03-23","active_substance":"povorcitinib","invented_name":"","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of prurigo nodularis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Incyte Biosciences Distribution B.V.; E-mail: RA@incyte.com","first_published_date":"06/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003313-pip03-23"},{"decision_number":"P/0095/2024","pip_number":"EMEA-003540-PIP01-23","active_substance":"vixarelimab","invented_name":"","therapeutic_area":"Respiratory, thoracic and mediastinal disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of idiopathic pulmonary fibrosis","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"06/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003540-pip01-23"},{"decision_number":"P/0094/2024","pip_number":"EMEA-003537-PIP01-23","active_substance":"human hydroxysteroid-17ß-dehydrogenase type 1 (HSD17B1) enzyme inhibitor","invented_name":"","therapeutic_area":"Reproductive system and breast disorders","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of endometriosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/04/2025","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Organon N.V. E-mail: regaffairseurope@organon.com Tel. +358 401585669","first_published_date":"06/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003537-pip01-23"},{"decision_number":"P/0093/2024","pip_number":"EMEA-003528-PIP01-23","active_substance":"empasiprubart","invented_name":"","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of multifocal motor neuropathy (MMN)","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Argenx BVE-mail: regulatory@argenx.comTel: +32 93103400","first_published_date":"06/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003528-pip01-23"},{"decision_number":"P/0090/2024","pip_number":"EMEA-002016-PIP05-23","active_substance":"alpelisib","invented_name":"Piqray","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Film-coated tablet;Age appropriate formulation","condition_indication":"Treatment of lymphatic malformations associated with a PIK3CA mutation","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"06/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002016-pip05-23"},{"decision_number":"P/0099/2024","pip_number":"EMEA-002600-PIP01-19-M02","active_substance":"pegcetacoplan","invented_name":"Aspaveli","therapeutic_area":"Renal and urinary disorders","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of paroxysmal nocturnal haemoglobinuria","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Swedish Orphan Biovitrum ABE-mail: medical.info@sobi.comTel. +46 8697 2000","first_published_date":"03/08/2020","last_updated_date":"05/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002600-pip01-19-m02"},{"decision_number":"P/0092/2024","pip_number":"EMEA-003220-PIP01-22-M01","active_substance":"milvexian","invented_name":"","therapeutic_area":"Vascular disorders","pharmaceutical_forms":"Age appropriate oral dosage formulation;Film-coated tablet","condition_indication":"Prevention of thromboembolism in patients with cardiovascular diseases","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen Cilag International NV; Tel. +3214602111; E-mail: contact@Janssen-emea.com","first_published_date":"02/10/2024","last_updated_date":"05/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003220-pip01-22-m01"},{"decision_number":"P/0091/2024","pip_number":"EMEA-003215-PIP01-22-M01","active_substance":"vamikibart","invented_name":"","therapeutic_area":"Eye disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of uveitic macular oedema","routes_of_administration":"Intravitreal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbH; E-mail: global.eu_regulatory_office@roche.comTel. +49 7624142892","first_published_date":"05/04/2024","last_updated_date":"05/06/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003215-pip01-22-m01"},{"decision_number":"P/0179/2024","pip_number":"EMEA-003394-PIP01-23","active_substance":"sevasemten","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Tablet;Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of dystrophinopathy","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"FGK Representative Service GmbHE-mail: regulatory@edgewisetx.comTel.:  +1 7202627002","first_published_date":"05/06/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003394-pip01-23"},{"decision_number":"P/0226/2023","pip_number":"EMEA-003306-PIP01-22","active_substance":"obeldesivir","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Age appropriate oral dosage formulation;Film-coated tablet","condition_indication":"Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd; E-mail: regulatory.pip@gilead.com; Tel. +44 (0)1223 897300","first_published_date":"10/07/2024","last_updated_date":"27/05/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003306-pip01-22"},{"decision_number":"P/0424/2023","pip_number":"EMEA-003063-PIP03-22","active_substance":"vibostolimab;pembrolizumab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of melanoma","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"15/11/2024","last_updated_date":"26/05/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003063-pip03-22"},{"decision_number":"P/0364/2022","pip_number":"EMEA-001220-PIP07-20-M01","active_substance":"Baricitinib","invented_name":"Olumiant","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Age appropriate oral liquid dosage formulation;Film-coated tablet","condition_indication":"Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Gastric use;Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"16/02/2021","last_updated_date":"20/05/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001220-pip07-20-m01"},{"decision_number":"P/0120/2022","pip_number":"EMEA-001501-PIP09-21","active_substance":"dupilumab","invented_name":"Dupixent","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic inducible cold urticaria","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi-Aventis Groupe; contact-us@sanofi.com;  +33 169745695","first_published_date":"17/04/2023","last_updated_date":"20/05/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001501-pip09-21"},{"decision_number":"P/0038/2022","pip_number":"EMEA-001214-PIP07-21","active_substance":"Benralizumab","invented_name":"Fasenra","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Age appropriate dosage form for parenteral use;Solution for injection;Solution for injection/infusion","condition_indication":"Treatment of eosinophilic gastritis/eosinophilic gastroenteritis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca ABEmail: paediatrics@astrazeneca.comTel.  +46 855326000","first_published_date":"13/03/2024","last_updated_date":"20/05/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001214-pip07-21"},{"decision_number":"P/0305/2023","pip_number":"EMEA-003185-PIP01-22","active_substance":"MVA-BN-RSV vaccine (construct MVA-mBN294B)","invented_name":"","therapeutic_area":"Infectious diseases;Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of lower respiratory tract disease caused by respiratory syncytial virus","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bavarian Nordic A/S; Email: info@bavarian-nordic.com ; Tel:  +45 61774743","first_published_date":"02/10/2024","last_updated_date":"20/05/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003185-pip01-22"},{"decision_number":"P/0083/2024","pip_number":"EMEA-003049-PIP01-21-M01","active_substance":"L-carnitine;glucose;calcium chloride dihydrate;sodium lactate;sodium chloride;magnesium chloride hexahydrate","invented_name":"","therapeutic_area":"Renal and urinary disorders","pharmaceutical_forms":"Solution for peritoneal dialysis","condition_indication":"Treatment of renal failure with carnitine deficiency","routes_of_administration":"Intraperitoneal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Iperboreal Pharma Srl; E-mail: info@iperboreal.com; Tel: +39 0852034834","first_published_date":"19/04/2023","last_updated_date":"15/05/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003049-pip01-21-m01"},{"decision_number":"P/0084/2024","pip_number":"EMEA-000639-PIP03-16-M03","active_substance":"chloroprocaine hydrochloride","invented_name":"Ampres","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Peripheral nerve block (local anaesthesia by perineural injection)","routes_of_administration":"Perineural use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sintetica GmbH; Tel. +41 916404250E-mail: corporate_clinical_rd@sintetica.com","first_published_date":"17/04/2018","last_updated_date":"15/05/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000639-pip03-16-m03"},{"decision_number":"P/0085/2024","pip_number":"EMEA-000597-PIP03-15-M06","active_substance":"Mirabegron","invented_name":"Betmiga; Betmiga","therapeutic_area":"Renal and urinary disorders","pharmaceutical_forms":"Prolonged-release granules for oral suspension;Prolonged-release tablet","condition_indication":"Treatment of neurogenic detrusor overactivity","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Astellas Pharma Europe B.V.Tel. +31 7154 55878E-mail: contact.nl@astellas.com&nbsp","first_published_date":"03/07/2015","last_updated_date":"14/05/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000597-pip03-15-m06"},{"decision_number":"P/0086/2024","pip_number":"EMEA-003170-PIP01-21-M02","active_substance":"glucagon analogue linked to a human immunoglobulin Fc fragment (HM15136)","invented_name":"","therapeutic_area":"Metabolism and nutrition disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of congenital hyperinsulinism","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"21/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Hanmi Pharm. Co., Ltd.; Email: hjkim8802@hanmi.co.kr; Tel. +82 24108771","first_published_date":"12/10/2023","last_updated_date":"14/05/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003170-pip01-21-m02"},{"decision_number":"P/0089/2024","pip_number":"EMEA-003568-PIP01-23","active_substance":"sargramostim","invented_name":"","therapeutic_area":"Injury, poisoning and procedural complications","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of acute radiation syndrome","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Partner Therapeutics Inc.; E-mail: partnertx@medcomminc.com; United States; Tel: +1 857 347 5730 (outside US);       +1 888 479 5385 (within US)","first_published_date":"13/05/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003568-pip01-23"},{"decision_number":"P/0088/2024","pip_number":"EMEA-003603-PIP01-24","active_substance":"split influenza virus, inactivated containing antigens equivalent to the A/H1N1-like strain/Split influenza virus, inactivated containing antigens equivalent to the A/H3N2-like strain/Split influenza virus, inactivated containing antigens equivalent to B-like strain","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of influenza","routes_of_administration":"Subcutaneous use;Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi Winthrop Industrie; E-mail: contact-us@sanofi.com; Tel: +33 4 37 37 57 84","first_published_date":"13/05/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003603-pip01-24"},{"decision_number":"P/0087/2024","pip_number":"EMEA-002876-PIP02-23","active_substance":"sodium phenylbutyrate / ursodoxicoltaurine","invented_name":"","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of progressive supranuclear palsy","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amylyx Pharmaceuticals EMEA B.V.; the Netherlands; E-mail: Amylyx_EMEA@amylyx.com; Tel: +31 20 369 8199","first_published_date":"13/05/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002876-pip02-23"},{"decision_number":"P/0081/2024","pip_number":"EMEA-003176-PIP02-22","active_substance":"cannabidiol","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Gel","condition_indication":"Treatment of fragile-X syndrome","routes_of_administration":"Transdermal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Zynerba Pharmaceuticals Inc.; United States; E-mail: medicalinformation@zynerba.com; Tel: +1 (484) 581-7505","first_published_date":"13/05/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003176-pip02-22"},{"decision_number":"P/0079/2024","pip_number":"EMEA-001741-PIP04-17-M05","active_substance":"upadacitinib","invented_name":"Rinvoq","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Age appropriate oral liquid dosage formulation;Age appropriate oral solid dosage form;Prolonged-release capsule;Prolonged-release tablet","condition_indication":"Treatment of atopic dermatitis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"20/02/2019","last_updated_date":"12/05/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001741-pip04-17-m05"},{"decision_number":"P/0080/2024","pip_number":"EMEA-003130-PIP02-23","active_substance":"borrelia outer surface protein A (OspA) serotypes (ST1-6) lipidated, fusion protein vaccine","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Suspension for injection in pre-filled syringe","condition_indication":"Prevention of Lyme disease","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIGE-mail: PIP_Enquiries@pfizer.com Tel.:  +44 (0)1304616161","first_published_date":"12/05/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003130-pip02-23"},{"decision_number":"P/0069/2024","pip_number":"EMEA-001625-PIP02-21-M03","active_substance":"satralizumab","invented_name":"Enspryng","therapeutic_area":"Nervous system disorders;Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of myasthenia gravis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbH; E-mail: global.eu_regulatory_office@roche.comTel. +49 7624142892","first_published_date":"06/03/2023","last_updated_date":"25/04/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001625-pip02-21-m03"},{"decision_number":"P/0063/2024","pip_number":"EMEA-002282-PIP01-17-M02","active_substance":"molgramostim","invented_name":"","therapeutic_area":"Respiratory, thoracic and mediastinal disorders;Pneumology-allergology","pharmaceutical_forms":"Nebuliser solution","condition_indication":"Treatment of pulmonary alveolar proteinosis","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Savara ApS; Email: charles.lapree@savarapharma.com    ; Tel. +1 2672499491","first_published_date":"24/06/2019","last_updated_date":"25/04/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002282-pip01-17-m02"},{"decision_number":"P/0064/2024","pip_number":"EMEA-002493-PIP01-18-M06","active_substance":"nedosiran","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders;Uro-nephrology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of primary hyperoxaluria","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; E-mail: paediatrics@novonordisk.com ; Tel.: +45 44444848","first_published_date":"03/04/2020","last_updated_date":"25/04/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002493-pip01-18-m06"},{"decision_number":"P/0074/2024","pip_number":"EMEA-001270-PIP01-12-M07","active_substance":"oritavancin (diphosphate)","invented_name":"Tenkasi (previously Orbactiv)","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Powder for concentrate for solution for infusion;Age appropriate dosage form for parenteral use","condition_indication":"Treatment of acute bacterial skin and skin structure infections","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Menarini International Operations Luxembourg S.A.; E-mail: scappellini@menarini-ricerche.it; Tel. +39 05556807607/458; +39 3289896201","first_published_date":"03/05/2013","last_updated_date":"14/04/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001270-pip01-12-m07"},{"decision_number":"P/0076/2024","pip_number":"EMEA-001314-PIP01-12-M02","active_substance":"Dinutuximab beta","invented_name":"Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron)","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for infusion;Concentrate for solution for infusion;Powder and solvent for solution for injection;Powder for solution for infusion","condition_indication":"Treatment of neuroblastoma","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"EUSA Pharma (Netherlands) B.V.; Tel. +44 (0)3305 001155; E-mail: Ignacio.AlvarezRojo@eusapharma.com","first_published_date":"12/05/2014","last_updated_date":"14/04/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001314-pip01-12-m02"},{"decision_number":"P/0077/2024","pip_number":"EMEA-001539-PIP01-13-M06","active_substance":"sodium zirconium cyclosilicate","invented_name":"Lokelma; Lokelma","therapeutic_area":"Metabolism and nutrition disorders","pharmaceutical_forms":"Powder for oral suspension","condition_indication":"Treatment of hyperkalaemia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca ABEmail: paediatrics@astrazeneca.comTel. +46 855324400","first_published_date":"30/09/2014","last_updated_date":"14/04/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001539-pip01-13-m06"},{"decision_number":"P/0078/2024","pip_number":"EMEA-001579-PIP01-13-M06","active_substance":"eluxadoline","invented_name":"","therapeutic_area":"Gastrointestinal disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of diarrhoea-predominant irritable bowel Syndrome","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628925033","first_published_date":"05/03/2015","last_updated_date":"14/04/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001579-pip01-13-m06"},{"decision_number":"P/0073/2024","pip_number":"EMEA-002741-PIP01-20-M02","active_substance":"Fordadistrogene movaparvovec","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Duchenne muscular dystrophy","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIGE-mail: medical.information@pfizer.com Tel. +44 1304646607","first_published_date":"22/09/2021","last_updated_date":"14/04/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002741-pip01-20-m02"},{"decision_number":"P/0075/2024","pip_number":"EMEA-002338-PIP04-23","active_substance":"lanalumab","invented_name":"","therapeutic_area":"Blood and lymphatic system disorders","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of autoimmune haemolytic anaemia","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"14/04/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002338-pip04-23"},{"decision_number":"P/0072/2024","pip_number":"EMEA-002915-PIP01-20-M03","active_substance":"SARS-CoV2 prefusion Spike delta TM (CoV-2 preS dTM) adjuvanted with AS03","invented_name":"VidPrevtyn Beta","therapeutic_area":"Vaccines","pharmaceutical_forms":"Solution and emulsion for emulsion for injection","condition_indication":"Prevention of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi PasteurE-mail: contact-us@sanofi.comTel. +33 1 6974 5695","first_published_date":"19/05/2021","last_updated_date":"14/04/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002915-pip01-20-m03"},{"decision_number":"P/0071/2024","pip_number":"EMEA-003420-PIP01-23","active_substance":"synthetic double-stranded siRNA oligonucleotide directed against apolipoprotein C-III mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Concentrate for solution for injection","condition_indication":"Treatment of familial chylomicronaemia syndrome (type I hyperlipoproteinaemia","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"E-mail: smullins@arrowheadpharma.comTel. +1 (626)7346186","first_published_date":"14/04/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003420-pip01-23"},{"decision_number":"P/0070/2024","pip_number":"EMEA-003423-PIP02-23","active_substance":"volrustomig","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Concentrate for solution for injection/infusion","condition_indication":"Treatment of head and neck epithelial malignant neoplasms","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com","first_published_date":"14/04/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003423-pip02-23"},{"decision_number":"P/0058/2024","pip_number":"EMEA-002565-PIP02-19-M01","active_substance":"Difelikefalin","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of chronic kidney disease associated pruritus","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vifor Fresenius Medical Care Renal Pharma France; Tel. +41 588518000; E-mail: difelikefalin_ra@viforpharma.com","first_published_date":"05/03/2021","last_updated_date":"02/04/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002565-pip02-19-m01"},{"decision_number":"P/0059/2024","pip_number":"EMEA-002656-PIP01-19-M01","active_substance":"Chikungunya Virus Virus-Like Particle Vaccine / aluminum hydroxide","invented_name":"","therapeutic_area":"Infections and infestations;Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of chikungunya disease","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bavarian Nordic A/S; E-mail: regulatory@bavarian-nordic.com; Tel. +49 89255446300","first_published_date":"13/01/2022","last_updated_date":"02/04/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002656-pip01-19-m01"},{"decision_number":"P/0055/2024","pip_number":"EMEA-000551-PIP04-21-M03","active_substance":"Givinostat","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Oral suspension","condition_indication":"Treatment of Duchenne muscular dystrophy","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Italfarmaco S.p.A. E-mail: ITFPIP@italfarmacogroup.comTel. +39 0264432500 &nbsp","first_published_date":"30/03/2023","last_updated_date":"02/04/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000551-pip04-21-m03"},{"decision_number":"P/0054/2024","pip_number":"EMEA-002121-PIP03-19-M02","active_substance":"Daridorexant","invented_name":"Quviviq","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Age appropriate oral solid dosage form;Film-coated tablet","condition_indication":"Treatment of insomnia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Idorsia Pharmaceuticals Deutschland GmbH  E-mail: clinical-trials-disclosure@idorsia.com  Tel. +41 588440000 &nbsp","first_published_date":"03/03/2021","last_updated_date":"02/04/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002121-pip03-19-m02"},{"decision_number":"P/0053/2024","pip_number":"EMEA-000237-PIP01-08-M12","active_substance":"azilsartan medoxomil","invented_name":"Edarbi","therapeutic_area":"Vascular disorders","pharmaceutical_forms":"Tablet;Granules for oral suspension","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Development Centre Europe Limited Email: medinfoEMEA@takeda.com Tel.  +44 (0)3333 000181 &nbsp","first_published_date":"04/01/2013","last_updated_date":"02/04/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000237-pip01-08-m12"},{"decision_number":"P/0051/2024","pip_number":"EMEA-002234-PIP01-17-M02","active_substance":"purified inactivated rabies virus (WISTAR PM/WI 38-1503-3M strain)","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Powder and solvent for suspension for injection","condition_indication":"Prevention of rabies viral infection","routes_of_administration":"Intramuscular use;Intradermal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi Pasteur Europe Email: contact-us@sanofi.com Tel.  +33 169745789 &nbsp","first_published_date":"27/11/2018","last_updated_date":"02/04/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002234-pip01-17-m02"},{"decision_number":"P/0057/2024","pip_number":"EMEA-003523-PIP01-23","active_substance":"Interleukin-2/Interleukin-1 beta, human/Granulocyte colony-stimulating factor/Tumour necrosis factoralpha/ Interferon gamma","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of head and neck epithelial malignant neoplasms","routes_of_administration":"Peritumoral and perilymphatic use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cel-Sci Corp. Email: feedback@cel-sci.com Tel.  +1 7035069460 &nbsp","first_published_date":"01/04/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003523-pip01-23"},{"decision_number":"P/0056/2024","pip_number":"EMEA-003515-PIP01-23","active_substance":"2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)- 1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone monohydrate","invented_name":"","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of Parkinson's disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"UCB Pharma Email: UCBCares.IE@ucb.com Tel.  +35 314632371 &nbsp","first_published_date":"01/04/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003515-pip01-23"},{"decision_number":"P/0052/2024","pip_number":"EMEA-003299-PIP02-22","active_substance":"orforglipron","invented_name":"","therapeutic_area":"Metabolism and nutrition disorders","pharmaceutical_forms":"Capsule, hard;Age appropriate oral solid dosage form","condition_indication":"Treatment of obesity","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly and Company LtdE-mail: eu_paediatric@lilly.com Phone: +44 1256315000","first_published_date":"01/04/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003299-pip02-22"},{"decision_number":"P/0050/2024","pip_number":"EMEA-003522-PIP01-23","active_substance":"zanzalintinib","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of colorectal cancer;Treatment of head and neck epithelial malignant neoplasms;Treatment of renal cell carcinoma (RCC)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Exelixis Inc. Email: druginfo@exelixis.com Tel.  +1 6508377400 &nbsp","first_published_date":"01/04/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003522-pip01-23"},{"decision_number":"P/0049/2024","pip_number":"EMEA-002205-PIP02-23","active_substance":"Isatuximab","invented_name":"Sarclisa","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi Winthrop IndustrieE-mail: contact-us@sanofi.comTel: +33 1 69 74 56 95","first_published_date":"01/04/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002205-pip02-23"},{"decision_number":"P/0048/2024","pip_number":"EMEA-003516-PIP01-23","active_substance":"IIgG-like T cell engager binding to DLL3 and CD3","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of neuroendocrine carcinoma (excluding neuroblastoma);Treatment of small cell lung carcinoma","routes_of_administration":"Parenteral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"01/04/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003516-pip01-23"},{"decision_number":"P/0045/2024","pip_number":"EMEA-003589-PIP01-24","active_substance":"influenza virus type B, Victoria lineage;Influenza A virus subtype H3N2 haemagglutinin, recombinant;Influenza A virus subtype H1N1 haemagglutinin, recombinant","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Nasal spray suspension","condition_indication":"Prevention of influenza infection","routes_of_administration":"Nasal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/02/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com","first_published_date":"26/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003589-pip01-24"},{"decision_number":"P/0016/2024","pip_number":"EMEA-003512-PIP01-23","active_substance":"tifcemalimab","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer (small cell and non-small cell lung cancer)","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/02/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"E-mail: regulatory@topalliancebio.comTel. +13 016 405 166&nbsp","first_published_date":"26/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003512-pip01-23"},{"decision_number":"P/0042/2024","pip_number":"EMEA-003458-PIP01-23","active_substance":"clobetasol propionate","invented_name":"","therapeutic_area":"Eye disorders","pharmaceutical_forms":"Eye drops, emulsion","condition_indication":"Treatment of ocular inflammations and manifestations associated with ocular surgery","routes_of_administration":"Ocular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/02/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Laboratorios Salvat, S.A.E-mail: regulatory@svt.com Tel. +34 933946400","first_published_date":"26/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003458-pip01-23"},{"decision_number":"P/0022/2024","pip_number":"EMEA-003402-PIP01-23","active_substance":"fibroblast growth factor 21 analogue (NNC194-0499) / semaglutide","invented_name":"","therapeutic_area":"Hepatobiliary disorders","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of non-alcoholic steatohepatitis (NASH)","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/02/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; E-mail: paediatrics@novonordisk.com ; Tel.: +45 44448888","first_published_date":"26/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003402-pip01-23"},{"decision_number":"P/0041/2024","pip_number":"EMEA-003027-PIP02-23","active_substance":"sepiapterin","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Oral powder","condition_indication":"Treatment of hyperphenylalaninaemia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"02/02/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"PTC Therapeutics International Limited; Tel. +353 19068700; E-mail: medinfo@ptcbio.com","first_published_date":"26/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003027-pip02-23"},{"decision_number":"P/0047/2024","pip_number":"EMEA-002945-PIP03-23","active_substance":"frexalimab","invented_name":"","therapeutic_area":"Endocrine disorders","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of type 1 diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"23/02/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi Winthrop Industrie; Email: contact-us@sanofi.com; Tel: +31 202 453 703","first_published_date":"25/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002945-pip03-23"},{"decision_number":"P/0023/2024","pip_number":"EMEA-002886-PIP02-23","active_substance":"rocatinlimab","invented_name":"","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"","condition_indication":"Treatment of prurigo nodularis","routes_of_administration":"","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/02/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V.; Tel. +44 (0)1223 420305; E-mail: pipenquiry@amgen.com","first_published_date":"25/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002886-pip02-23"},{"decision_number":"P/0043/2024","pip_number":"EMEA-002796-PIP01-20-M02","active_substance":"acetyl-L-leucine ((s)-(acetylamino)-4-methylpentanoic acid) (IB1001)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of Niemann-Pick disease, type C","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/02/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"IntraBio Ltd.E-mail: info@intrabio.com Tel.: +44 (0)7426 956368","first_published_date":"12/04/2023","last_updated_date":"25/03/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002796-pip01-20-m02"},{"decision_number":"P/0039/2024","pip_number":"EMEA-002744-PIP01-19-M01","active_substance":"atropine sulfate","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution","condition_indication":"Treatment of myopia","routes_of_administration":"Topical use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/02/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Nevakar Inc.; E-mail: info@nevakar.com; Tel: +1 9083677400","first_published_date":"26/04/2022","last_updated_date":"25/03/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002744-pip01-19-m01"},{"decision_number":"P/0038/2024","pip_number":"EMEA-002342-PIP02-18-M03","active_substance":"abemaciclib","invented_name":"Verzenios","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of glioma;Treatment of neuroblastoma","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/02/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly and Company Limited; E-mail: EU_PAEDIATRIC@LILLY.COM; Tel.   +44 1344382427","first_published_date":"09/06/2020","last_updated_date":"25/03/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002342-pip02-18-m03"},{"decision_number":"P/0044/2024","pip_number":"EMEA-002734-PIP01-19-M01","active_substance":"adeno-associated viral vector serotype 8 containing the human glucose-6-phosphatase gene (DTX401)","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Concentrate and diluent for solution for infusion","condition_indication":"Treatment of glycogen storage disease type Ia","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/02/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ultragenyx Germany GmbH; Tel. +49 30590083651; Email: inquiries@ultragenyx.com","first_published_date":"22/07/2022","last_updated_date":"25/03/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002734-pip01-19-m01"},{"decision_number":"P/0021/2024","pip_number":"EMEA-000877-PIP03-17-M05","active_substance":"bupivacaine","invented_name":"Exparel liposomal","therapeutic_area":"Pain","pharmaceutical_forms":"Prolonged-release dispersion for injection;Dispersion for injection","condition_indication":"Postsurgical analgesia","routes_of_administration":"Perineural use;Infiltration use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/02/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pacira Ltd; Tel.  +1 9732544600; E-mail: expareleurope@pacira.com","first_published_date":"20/02/2019","last_updated_date":"24/03/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000877-pip03-17-m05"},{"decision_number":"P/0037/2024","pip_number":"EMEA-002342-PIP01-18-M04","active_substance":"abemaciclib","invented_name":"Verzenios","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of Ewing sarcoma","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/02/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly and Company Limited; E-mail: EU_PAEDIATRIC@LILLY.COM; Tel.   +44 1344382427","first_published_date":"24/06/2019","last_updated_date":"24/03/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002342-pip01-18-m04"},{"decision_number":"P/0040/2024","pip_number":"EMEA-000574-PIP03-23","active_substance":"blinatumomab","invented_name":"Blincyto","therapeutic_area":"Blood and lymphatic system disorders","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of B-lymphoblastic leukaemia/lymphoma","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"07/02/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V.; Tel. +44 (0)1223 420305; E-mail: pipenquiry@amgen.com","first_published_date":"24/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000574-pip03-23"},{"decision_number":"P/0062/2024","pip_number":"EMEA-001741-PIP10-23","active_substance":"upadacitinib","invented_name":"Rinvoq","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Prolonged-release tablet;Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of alopecia areata","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"21/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001741-pip10-23"},{"decision_number":"P/0060/2024","pip_number":"EMEA-003225-PIP01-22","active_substance":"tinlarebant","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Tablet;Age appropriate oral formulation","condition_indication":"Treatment of Stargardt disease","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"07/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Belite Bio Inc. E-mail: clinicaltrial@belitebio.comTel: +1 8586925980","first_published_date":"21/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003225-pip01-22"},{"decision_number":"P/0065/2024","pip_number":"EMEA-003425-PIP01-23","active_substance":"belumosudil","invented_name":"","therapeutic_area":"Immune system disorders","pharmaceutical_forms":"Film-coated tablet;Oral suspension","condition_indication":"Treatment of graft versus host disease","routes_of_administration":"Oral use;Naso-gastric use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi Winthrop IndustrieE-mail: contact-us@sanofi.comTel: +33 1 69 74 56 95","first_published_date":"21/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003425-pip01-23"},{"decision_number":"P/0061/2024","pip_number":"EMEA-003519-PIP01-23","active_substance":"zenocutuzumab","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer;Treatment of pancreatic cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merus N.V. E-mail: enquiries@merus.nlTel: +31 850162500","first_published_date":"21/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003519-pip01-23"},{"decision_number":"P/0066/2024","pip_number":"EMEA-003520-PIP01-23","active_substance":"motugivatrep","invented_name":"","therapeutic_area":"Eye disorders","pharmaceutical_forms":"Eye drops, suspension","condition_indication":"Treatment of dry eye disease","routes_of_administration":"Ophthalmic use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Senju Pharmaceutical Co. LtdE-mail: andre.sousa@ppd.com Tel: +351 308804284","first_published_date":"21/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003520-pip01-23"},{"decision_number":"P/0067/2024","pip_number":"EMEA-003541-PIP01-23","active_substance":"anti-alpha-synuclein recombinant humanised monoclonal antibody","invented_name":"","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of Parkinson's disease","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"UCB Pharma S.A.; E-mail: UCBCares.IE@ucb.com; Tel. +353 1463 2371","first_published_date":"21/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003541-pip01-23"},{"decision_number":"P/0005/2024","pip_number":"EMEA-003149-PIP01-21-M02","active_substance":"odronextamab","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of mature B cell malignancies","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/01/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Regeneron Ireland Designated Activity Company Email: ClinicalTrialDisclosureTeam@regeneron.com Tel.  +1 9048475385","first_published_date":"04/10/2023","last_updated_date":"19/03/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003149-pip01-21-m02"},{"decision_number":"P/0035/2024","pip_number":"EMEA-003514-PIP02-23","active_substance":"obicetrapib;ezetimibe","invented_name":"","therapeutic_area":"Metabolism and nutrition disorders","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of elevated cholesterol","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"NewAmsterdam Pharma B.V. Email: Marc.ditmarsch@newamsterdampharma.com Tel.  +31 352062971","first_published_date":"18/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003514-pip02-23"},{"decision_number":"P/0017/2024","pip_number":"EMEA-003514-PIP01-23","active_substance":"obicetrapib;ezetimibe","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of mixed hyperlipidaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"NewAmsterdam Pharma B.V. Email: Marc.ditmarsch@newamsterdampharma.com Tel.  +31 352062971","first_published_date":"18/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003514-pip01-23"},{"decision_number":"P/0031/2024","pip_number":"EMEA-003504-PIP01-23","active_substance":"tinengotinib","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of cholangiocarcinoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Transthera Sciences (Nanjing) Inc. Email: TT420C2308clinfo@transtherabio.com Tel.  +1 3018590848","first_published_date":"18/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003504-pip01-23"},{"decision_number":"P/0025/2024","pip_number":"EMEA-003438-PIP02-23","active_substance":"obicetrapib","invented_name":"","therapeutic_area":"Metabolism and nutrition disorders","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of elevated cholesterol","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"NewAmsterdam Pharma B.V. Email: Marc.ditmarsch@newamsterdampharma.com Tel.  +31 352062971","first_published_date":"18/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003438-pip02-23"},{"decision_number":"P/0015/2024","pip_number":"EMEA-003389-PIP01-23","active_substance":"Dordaviprone","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Capsule, hard;Age appropriate oral solid dosage form","condition_indication":"Treatment of glioma","routes_of_administration":"Oral use;Gastric use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Chimerix IRL Limited Email: clinicaltrials@chimerix.com Tel.  +1 9198061074","first_published_date":"17/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003389-pip01-23"},{"decision_number":"P/0033/2024","pip_number":"EMEA-003300-PIP01-22","active_substance":"zigakibart","invented_name":"","therapeutic_area":"Renal and urinary disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of primary IgA nephropathy","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/01/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"17/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003300-pip01-22"},{"decision_number":"P/0006/2024","pip_number":"EMEA-002817-PIP05-23","active_substance":"Faricimab","invented_name":"Vabysmo","therapeutic_area":"Eye disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of choroidal neovascularisation secondary to pathologic myopia","routes_of_administration":"Intravitreal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/01/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbH E-mail: global.eu_regulatory_office@roche.comTel: +41 616879411","first_published_date":"17/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002817-pip05-23"},{"decision_number":"P/0034/2024","pip_number":"EMEA-002618-PIP04-23","active_substance":"ruxolitinib (phosphate)","invented_name":"Jakavi; Opzelura","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Cream","condition_indication":"Treatment of prurigo nodularis","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Incyte Biosciences Distribution B.V. E-mail: RA@incyte.comTel. +1 3024252734","first_published_date":"17/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002618-pip04-23"},{"decision_number":"P/0020/2024","pip_number":"EMEA-002582-PIP03-23","active_substance":"remibrutinib","invented_name":"","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of chronic inducible urticaria","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"17/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002582-pip03-23"},{"decision_number":"P/0002/2024","pip_number":"EMEA-002578-PIP01-19-M01","active_substance":"mozafancogene autotemcel","invented_name":"","therapeutic_area":"Blood and lymphatic system disorders","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of Fanconi anaemia subtype A","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/01/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Rocket Pharmaceuticals, Inc. Email: mz@rocketpharma.com Tel.  +34 682675494","first_published_date":"29/07/2020","last_updated_date":"14/03/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002578-pip01-19-m01"},{"decision_number":"P/0032/2024","pip_number":"EMEA-002559-PIP09-23","active_substance":"nipocalimab","invented_name":"","therapeutic_area":"Blood and lymphatic system disorders","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Prevention of foetal and neonatal alloimmune thrombocytopenia","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen Cilag International Email: contact@Janssen-emea.com Tel. +32 14602111","first_published_date":"14/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002559-pip09-23"},{"decision_number":"P/0026/2024","pip_number":"EMEA-002451-PIP01-18-M02","active_substance":"ritlecitinib","invented_name":"Litfulo","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Tablet;Capsule, hard","condition_indication":"Treatment of alopecia areata","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"26/01/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG  E-mail: medical.information@pfizer.com Tel: +44 (0)1304 616161","first_published_date":"12/01/2022","last_updated_date":"14/03/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002451-pip01-18-m02"},{"decision_number":"P/0008/2024","pip_number":"EMEA-002350-PIP01-18-M03","active_substance":"deucravacitinib","invented_name":"Sotyktu","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of psoriasis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/01/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"13/11/2019","last_updated_date":"14/03/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002350-pip01-18-m03"},{"decision_number":"P/0011/2024","pip_number":"EMEA-002303-PIP01-17-M04","active_substance":"Etripamil","invented_name":"","therapeutic_area":"Cardiac disorders","pharmaceutical_forms":"Nasal spray (solution)","condition_indication":"Treatment of supraventricular arrhythmia","routes_of_administration":"Intranasal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/01/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Milestone Pharmaceuticals Inc. Email: info@milestonepharma.com Tel.  +1 5143360444","first_published_date":"12/04/2019","last_updated_date":"14/03/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002303-pip01-17-m04"},{"decision_number":"P/0004/2024","pip_number":"EMEA-002141-PIP01-17-M04","active_substance":"Crizanlizumab","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of sickle cell disease","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/01/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"19/06/2018","last_updated_date":"14/03/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002141-pip01-17-m04"},{"decision_number":"P/0354/2024","pip_number":"EMEA-001741-PIP01-14-M08","active_substance":"upadacitinib","invented_name":"Rinvoq","therapeutic_area":"Musculoskeletal and connective tissue disorders","pharmaceutical_forms":"Age appropriate oral solid dosage form;Age appropriate oral liquid dosage formulation;Prolonged-release tablet","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis and juvenile idiopathic arthritis)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"25/10/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"07/01/2016","last_updated_date":"13/03/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001741-pip01-14-m08"},{"decision_number":"P/0036/2024","pip_number":"EMEA-001213-PIP03-23","active_substance":"Ferric citrate coordination complex (FCCC)","invented_name":"","therapeutic_area":"Renal and urinary disorders","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of anaemias due to chronic kidney disorders","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Averoa Email: info@averoa-pharma.com Tel. +33 789047130; &nbsp","first_published_date":"13/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001213-pip03-23"},{"decision_number":"P/0009/2024","pip_number":"EMEA-000383-PIP04-23","active_substance":"Cladribine","invented_name":"","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of myasthenia gravis","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Europe B.V.; Tel.: +49 6151725200; E-mail: service@merckgroup.com","first_published_date":"13/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000383-pip04-23"},{"decision_number":"P/0028/2024","pip_number":"EMEA-000309-PIP07-21-M01","active_substance":"tocilizumab","invented_name":"RoActemra","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbH E-mail: global.eu_regulatory_office@roche.comTel: +41 616879411","first_published_date":"19/08/2021","last_updated_date":"12/03/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000309-pip07-21-m01"},{"decision_number":"P/0499/2023","pip_number":"EMEA-003043-PIP01-21-M01","active_substance":"alprazolam","invented_name":"","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Inhalation powder","condition_indication":"Treatment of epileptic seizures","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"UCB Pharma SA.; E-mail: UCBCares.IE@ucb.com; Tel.:  + 353 14632371","first_published_date":"13/06/2023","last_updated_date":"12/03/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003043-pip01-21-m01"},{"decision_number":"P/0474/2023","pip_number":"EMEA-003470-PIP01-23","active_substance":"derivative of a benzoimidazole substituted pyrimidine","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of breast malignant neoplasms","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG E-mail: medical.information@pfizer.com Tel: +44 (0)1304 616161","first_published_date":"07/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003470-pip01-23"},{"decision_number":"P/0473/2023","pip_number":"EMEA-003476-PIP01-23","active_substance":"Fusion protein consisting of relaxin and Fc domain of IgG1","invented_name":"","therapeutic_area":"Cardiac disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of pulmonary hypertension due to left heart disease","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB Email: paediatrics@astrazeneca.com Tel. +46 855324400","first_published_date":"07/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003476-pip01-23"},{"decision_number":"P/0472/2023","pip_number":"EMEA-003475-PIP01-23","active_substance":"naproxen;paracetamol","invented_name":"","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of acute pain;Treatment of febrile disorders;Treatment of rheumatoid arthritis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GSK Consumer Healthcare Export Limited Email: CHPK.MEDINFO@haleon.com Tel. +0800 7838881","first_published_date":"07/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003475-pip01-23"},{"decision_number":"P/0466/2023","pip_number":"EMEA-003498-PIP01-23","active_substance":"ramipril;Indapamide","invented_name":"","therapeutic_area":"Vascular disorders","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Egis Pharmaceuticals Plc. E-mail: registry@regis.hu Tel. +36 18032414","first_published_date":"07/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003498-pip01-23"},{"decision_number":"P/0465/2023","pip_number":"EMEA-003466-PIP01-23","active_substance":"amlodipine;atorvastatin;Candesartan","invented_name":"","therapeutic_area":"Cardiac disorders","pharmaceutical_forms":"Tablet","condition_indication":"Prevention of cardiovascular events","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Teva B.V. Email: MedAffGenTevaEurope@tevapharm.com Tel. +385 13722001","first_published_date":"07/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003466-pip01-23"},{"decision_number":"P/0464/2023","pip_number":"EMEA-003238-PIP02-22","active_substance":"pozelimab","invented_name":"","therapeutic_area":"Blood and lymphatic system disorders","pharmaceutical_forms":"Solution for injection;Concentrate for solution for infusion","condition_indication":"Treatment of paroxysmal nocturnal haemoglobinuria","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Regeneron Ireland DAC; Tel. +1 9148 475385; E-mail: clinicaltrials@regeneron.com","first_published_date":"06/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003238-pip02-22"},{"decision_number":"P/0463/2023","pip_number":"EMEA-003237-PIP02-22","active_substance":"cemdisiran","invented_name":"","therapeutic_area":"Blood and lymphatic system disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of paroxysmal nocturnal haemoglobinuria","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Regeneron Ireland DAC; Tel. +1 9148 475385; E-mail: clinicaltrials@regeneron.com","first_published_date":"06/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003237-pip02-22"},{"decision_number":"P/0470/2023","pip_number":"EMEA-000402-PIP03-17-M08","active_substance":"lacosamide","invented_name":"Vimpat","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Film-coated tablet;Solution for infusion;Syrup","condition_indication":"Treatment of generalised epilepsy and epileptic syndromes","routes_of_administration":"Oral use;Intravenous use","decision_type":"RPM: decision refers to a refusal on the application for modification of an agreed PIP","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"UCB Pharma S.A.; E-mail: UCBCares.IE@ucb.com; Tel. +353 1463 2371","first_published_date":"24/07/2017","last_updated_date":"06/03/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000402-pip03-17-m08"},{"decision_number":"P/0469/2023","pip_number":"EMEA-000325-PIP01-08-M11","active_substance":"tapentadol hydrochloride","invented_name":"","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Prolonged-release tablet;Prolonged-release granules","condition_indication":"Treatment of chronic pain","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Grünenthal GmbH; Tel.: +49 2415690; E-mail: pediatrics@grunenthal.com ","first_published_date":"24/06/2021","last_updated_date":"06/03/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000325-pip01-08-m11"},{"decision_number":"P/0468/2023","pip_number":"EMEA-000128-PIP02-09-M05","active_substance":"liraglutide","invented_name":"Saxenda","therapeutic_area":"Endocrine disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of obesity","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; Denmark; Tel. +45 44448888; E-mail: paediatrics@novonordisk.com","first_published_date":"25/06/2012","last_updated_date":"06/03/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000128-pip02-09-m05"},{"decision_number":"P/0467/2023","pip_number":"EMEA-000016-PIP01-07-M09","active_substance":"dalbavancin hydrochloride","invented_name":"Xydalba","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of acute bacterial skin and skin structure infections","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"21/07/2008","last_updated_date":"06/03/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000016-pip01-07-m09"},{"decision_number":"P/0461/2023","pip_number":"EMEA-002950-PIP01-20-M01","active_substance":"lutetium (177Lu) oxodotreotide","invented_name":"Lutathera","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of gastroenteropancreatic neuroendocrine tumours","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Advanced Accelerator Applications Tel. +41 613241111  Email: paediatric.enquiries@novartis.com","first_published_date":"10/03/2023","last_updated_date":"06/03/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002950-pip01-20-m01"},{"decision_number":"P/0457/2023","pip_number":"EMEA-001032-PIP01-10-M07","active_substance":"macitentan","invented_name":"Opsumit","therapeutic_area":"Cardiac disorders","pharmaceutical_forms":"Dispersible tablet;Film-coated tablet","condition_indication":"Treatment of idiopathic pulmonary fibrosis;Treatment of pulmonary arterial hypertension;Treatment of systemic sclerosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen Cilag International NV; Tel. +3214602111; E-mail: contact@Janssen-emea.com","first_published_date":"19/01/2012","last_updated_date":"06/03/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001032-pip01-10-m07"},{"decision_number":"P/0458/2023","pip_number":"EMEA-002727-PIP02-23","active_substance":"relatlimab;nivolumab","invented_name":"Opdualag","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Concentrate for solution for infusion;Solution for injection","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, hematopoietic and lymphoid tissue neoplasms and melanoma)","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Services Unlimited Company Email: medical.information@bms.com Tel: +44 (0)1423 533610 &nbsp","first_published_date":"04/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002727-pip02-23"},{"decision_number":"P/0456/2023","pip_number":"EMEA-003484-PIP01-23","active_substance":"povidone iodinated","invented_name":"","therapeutic_area":"Eye disorders","pharmaceutical_forms":"Eye drops, solution","condition_indication":"Preoperative treatment for ophthalmic surgeries","routes_of_administration":"Ophthalmic use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Medivis S.r.l. E-mail: regolatorio.medivis@legalmail.it Tel. +39 0957229111","first_published_date":"04/03/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003484-pip01-23"},{"decision_number":"P/0174/2023","pip_number":"EMEA-003063-PIP02-22","active_substance":"vibostolimab;pembrolizumab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Hodgkin lymphoma","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"30/05/2024","last_updated_date":"26/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003063-pip02-22"},{"decision_number":"P/0260/2016","pip_number":"EMEA-000786-PIP01-09-M02","active_substance":"autologous CD34+ cells transduced with lentiviral vector containing the human Wiskott Aldrich Syndrom Protein gene","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Cell suspension for infusion","condition_indication":"Treatment of Wiskott Aldrich Syndrome","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/10/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Genethon; France; Tel. +33 169472900; Fax +33 169471946; E-mail: clinical_development@genethon.fr","first_published_date":"15/11/2013","last_updated_date":"26/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000786-pip01-09-m02"},{"decision_number":"P/0507/2023","pip_number":"EMEA-003501-PIP01-23","active_substance":"rilvegostomig","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of biliary tract cancer;Treatment of lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel. +46 8553 27591","first_published_date":"19/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003501-pip01-23"},{"decision_number":"P/0506/2023","pip_number":"EMEA-003500-PIP01-23","active_substance":"elinzanetant","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism;Neurology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of vasomotor symptoms caused by endocrine therapy related to breast cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer AG; Tel. +49 30300139003; E-mail: clinical-trials-contact@bayer.com","first_published_date":"19/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003500-pip01-23"},{"decision_number":"P/0505/2023","pip_number":"EMEA-003392-PIP01-23","active_substance":"broadly neutralizing anti-HIV human monoclonal antibody (VH3810109)","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Powder for solution for injection or infusion","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ViiV Healthcare UK LimitedE-mail: eu.paediatric-plans@gsk.com Tel: +1 4388998201","first_published_date":"19/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003392-pip01-23"},{"decision_number":"P/0500/2023","pip_number":"EMEA-003182-PIP01-22-M01","active_substance":"treprostinil sodium","invented_name":"Trisuva and associated names","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of pulmonary arterial hypertension","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AOP Orphan Pharmaceuticals AGE-mail: office@aoporphan.comTel. +43 150372440","first_published_date":"05/10/2023","last_updated_date":"19/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003182-pip01-22-m01"},{"decision_number":"P/0504/2023","pip_number":"EMEA-003350-PIP01-23","active_substance":"AstraZeneca Anti-SARS-CoV-2 monoclonal antibody (AZD3152)","invented_name":"","therapeutic_area":"Immune system disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intramuscular use;Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com","first_published_date":"19/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003350-pip01-23"},{"decision_number":"P/0508/2023","pip_number":"EMEA-002904-PIP01-20-M01","active_substance":"respiratory syncytial virus (RSV) PreF3 recombinant fusion protein/AS01 (RSVPreF3 OA)","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Powder and suspension for suspension for injection","condition_indication":"Prevention of lower respiratory tract disease caused by respiratory syncytial virus","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Biologicalse-mail: eu.paediatric-plans@gsk.com tel. +1 4388998201","first_published_date":"14/02/2023","last_updated_date":"19/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002904-pip01-20-m01"},{"decision_number":"P/0503/2023","pip_number":"EMEA-001195-PIP01-11-M07","active_substance":"ferric maltol","invented_name":"Feraccru","therapeutic_area":"Blood and lymphatic system disorders","pharmaceutical_forms":"Capsule, hard;Oral suspension","condition_indication":"Treatment of iron deficiency","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Norgine BVTel. +33 141399415E-mail: lifecyclemanagement@norgine.com","first_published_date":"26/07/2017","last_updated_date":"19/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001195-pip01-11-m07"},{"decision_number":"P/0523/2023","pip_number":"EMEA-002755-PIP01-19-M02","active_substance":"Fully human IgG1 RB-1 YTE anti-RSV F monoclonal antibody (MK-1654)","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of lower respiratory tract infection caused by respiratory syncytial virus","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"20/09/2021","last_updated_date":"17/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002755-pip01-19-m02"},{"decision_number":"P/0490/2023","pip_number":"EMEA-003472-PIP01-23","active_substance":"rosuvastatin;ezetimibe","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events;Treatment of hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pharmaplot P.C.; E-mail: info@pharmaplot.com; Tel.  +30 2160047700","first_published_date":"17/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003472-pip01-23"},{"decision_number":"P/0475/2023","pip_number":"EMEA-003471-PIP01-23","active_substance":"humanised IgG1 monoclonal antibody against integrin beta-6 conjugated to monomethyl auristatin E via a valine-citrulline linker (SGN-B6A)","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of non-small cell lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG  E-mail: medical.information@pfizer.com Tel: +44 (0)1304 616161","first_published_date":"17/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003471-pip01-23"},{"decision_number":"P/0491/2023","pip_number":"EMEA-003468-PIP01-23","active_substance":"Ilginatinib maleate","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of myelofibrosis","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"E-mail: info@nspharma.com Tel.:  +1 8666774276","first_published_date":"17/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003468-pip01-23"},{"decision_number":"P/0481/2023","pip_number":"EMEA-003404-PIP01-23","active_substance":"decitabine;tetrahydrouridine","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Capsule, hard;Tablet;Age appropriate oral formulation","condition_indication":"Treatment of sickle cell disease","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; E-mail: paediatrics@novonordisk.com ; Tel.: +45 44448888","first_published_date":"17/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003404-pip01-23"},{"decision_number":"P/0524/2023","pip_number":"EMEA-002438-PIP02-19-M03","active_substance":"rilzabrutinib","invented_name":"","therapeutic_area":"Immune system disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of immune thrombocytopenia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi B.V.E-mail: eumedinfo.GZ@sanofi.com Tel. +31 2024 54000&nbsp","first_published_date":"18/06/2021","last_updated_date":"14/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002438-pip02-19-m03"},{"decision_number":"P/0477/2023","pip_number":"EMEA-002762-PIP02-20-M02","active_substance":"denecimig","invented_name":"","therapeutic_area":"Blood and lymphatic system disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Haemophilia A","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; E-mail: paediatrics@novonordisk.com ; Tel.: +45 44448888","first_published_date":"20/09/2021","last_updated_date":"14/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002762-pip02-20-m02"},{"decision_number":"P/0511/2023","pip_number":"EMEA-002198-PIP01-21-M01","active_substance":"alisitol;retinyl palmitate;zinc gluconate","invented_name":"","therapeutic_area":"Gastrointestinal disorders","pharmaceutical_forms":"Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of microvillus inclusion disease","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vanessa Research Magyarorszag Kft/Vanessa Research Hungary ltd; Email: vrregulatory@vanessaresearch.com Tel.  +1 2038368424 x 114","first_published_date":"10/05/2023","last_updated_date":"14/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002198-pip01-21-m01"},{"decision_number":"P/0476/2023","pip_number":"EMEA-002723-PIP01-19-M02","active_substance":"sebetralstat","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of hereditary angioedema","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"KalVista Pharmaceuticals Ltd; E-mail: regulatory@kalvista.com; Tel: +44 1980753002","first_published_date":"21/07/2021","last_updated_date":"14/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002723-pip01-19-m02"},{"decision_number":"P/0529/2023","pip_number":"EMEA-001716-PIP04-19-M01","active_substance":"venglustat","invented_name":"","therapeutic_area":"Endrocrine disorders","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of galactosialidosis;Treatment of GM1 gangliosidosis;Treatment of GM2 gangliosidosis;Treatment of sialidosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi B.V.E-mail: eumedinfo.gz@sanofi.comTel: +31 (0) 20 245 3917","first_published_date":"17/09/2021","last_updated_date":"14/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001716-pip04-19-m01"},{"decision_number":"P/0519/2023","pip_number":"EMEA-001625-PIP01-14-M07","active_substance":"satralizumab","invented_name":"","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of neuromyelitis optica","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"25/08/2015","last_updated_date":"14/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001625-pip01-14-m07"},{"decision_number":"P/0526/2023","pip_number":"EMEA-001619-PIP03-16-M02","active_substance":"filgotinib","invented_name":"","therapeutic_area":"Gastrointestinal disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of ulcerative colitis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alfasigma S.p.A. E-mail: medicalinfo@glpg.comTel: +32 15342900","first_published_date":"12/04/2019","last_updated_date":"14/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001619-pip03-16-m02"},{"decision_number":"P/0478/2023","pip_number":"EMEA-002360-PIP02-22-M02","active_substance":"tirzepatide","invented_name":"Mounjaro","therapeutic_area":"Other","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of obesity","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"06/02/2024","last_updated_date":"14/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002360-pip02-22-m02"},{"decision_number":"P/0493/2023","pip_number":"EMEA-001812-PIP01-15-M02","active_substance":"Indacaterol (acetate);mometasone (furoate);glycopyrronium bromide","invented_name":"Enerzair Breezhaler; Zimbus Breezhaler","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Inhalation powder;Capsule, hard","condition_indication":"Treatment of asthma","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"22/09/2016","last_updated_date":"14/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001812-pip01-15-m02"},{"decision_number":"P/0485/2023","pip_number":"EMEA-001318-PIP01-12-M05","active_substance":"zanamivir","invented_name":"Relenza","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Inhalation powder (pre-dispensed);Solution for infusion","condition_indication":"Prevention of influenza;Treatment of influenza","routes_of_administration":"Inhalation use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Glaxosmithkline Trading Services LimitedE-mail: eu.paediatric-plans@gsk.comTel.:  +44 2089903650","first_published_date":"23/07/2021","last_updated_date":"14/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001318-pip01-12-m05"},{"decision_number":"P/0498/2023","pip_number":"EMEA-003467-PIP01-23","active_substance":"gotistobart","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/02/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"E-mail: admin@oncoc4.comTel. +1 (202)7516823; &nbsp","first_published_date":"14/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003467-pip01-23"},{"decision_number":"P/0527/2023","pip_number":"EMEA-003507-PIP01-23","active_substance":"baxdrostat","invented_name":"","therapeutic_area":"Vascular disorders","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca ABEmail: paediatrics@astrazeneca.comTel. +46 855324400","first_published_date":"13/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003507-pip01-23"},{"decision_number":"P/0525/2023","pip_number":"EMEA-003499-PIP01-23","active_substance":"humanised IgG1kappa Monoclonal Antibody directed against IGF-1R","invented_name":"","therapeutic_area":"Eye disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of thyroid eye disease","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Viridian Therapeutics Inc. E-mail: viridian-clinical-trials@viridiantherapeutics.comTel: +1 6172724609","first_published_date":"13/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003499-pip01-23"},{"decision_number":"P/0514/2023","pip_number":"EMEA-003497-PIP01-23","active_substance":"oregovomab","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of fallopian tube cancer;Treatment of ovarian cancer;Treatment of primary peritoneal cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Canariabio Inc. E-mail: ben.yoon@canariabio.comTel: +82 1042678593","first_published_date":"13/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003497-pip01-23"},{"decision_number":"P/0494/2023","pip_number":"EMEA-003469-PIP01-23","active_substance":"Humanized IgG1 blocking monoclonal antibody targeting CD39 (IPH5201)","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Innate Pharma SA; E-mail: info@innate-pharma.fr; Tel. +33 430303030","first_published_date":"13/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003469-pip01-23"},{"decision_number":"P/0521/2023","pip_number":"EMEA-003419-PIP01-23","active_substance":"modified messenger ribonucleic acid encoding human propionyl-coenzyme a carboxylase alpha and beta subunits encapsulated into lipid nanoparticles (mRNA-3927)","invented_name":"","therapeutic_area":"Endrocrine disorders","pharmaceutical_forms":"Dispersion for injection","condition_indication":"Treatment of propionic acidaemia","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Moderna Biotech Spain S.L. E-mail: medinfo@modernatx.comTel: +1 6177146500","first_published_date":"13/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003419-pip01-23"},{"decision_number":"P/0518/2023","pip_number":"EMEA-003496-PIP01-23","active_substance":"allogeneic cultured postnatal thymus-derived tissue","invented_name":"","therapeutic_area":"Surgical and medical procedures","pharmaceutical_forms":"Living tissue equivalent","condition_indication":"Treatment of congenital athymia","routes_of_administration":"Implant use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Enzyvant Therapeutics Ireland Limited E-mail: info@us.sumitomo-pharma.comTel: +(877) 3763830","first_published_date":"13/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003496-pip01-23"},{"decision_number":"P/0517/2023","pip_number":"EMEA-003396-PIP01-23","active_substance":"complement factor B antisense oligonucleotide (RO7434656)","invented_name":"","therapeutic_area":"Renal and urinary disorders","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of primary IgA nephropathy","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbH E-mail: global.eu_regulatory_office@roche.comTel: +41 616879411","first_published_date":"13/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003396-pip01-23"},{"decision_number":"P/0516/2023","pip_number":"EMEA-002674-PIP01-19","active_substance":"3-(4-acetamidophenyl)-2-(S)-methoxypropionic acid, or (S)-3-(4-acetamidophenyl)-2- methoxypropanoic acid (N-Acetyl-GED-0507-34-LEVO)","invented_name":"","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Gel","condition_indication":"Treatment of acne vulgaris","routes_of_administration":"Cutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Nogra Pharma Limited E-mail: sbellinvia@ppmservices.chTel: +41 916961712","first_published_date":"13/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002674-pip01-19"},{"decision_number":"P/0509/2023","pip_number":"EMEA-002022-PIP02-23","active_substance":"DNA plasmid encoding HPV type 16 consensus E6 and E7 proteins (pGX 3001);DNA plasmid encoding HPV type 18 consensus E6 and E7 proteins (pGX3002)","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of squamous intraepithelial lesions of the anus caused by HPV types 16 and 18","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Inovio Pharmaceuticals Inc E-mail: Clinical.Trials@inovio.com Tel:  +1 2674344080","first_published_date":"13/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002022-pip02-23"},{"decision_number":"P/0543/2023","pip_number":"EMEA-003071-PIP02-23","active_substance":"cedazuridine;decitabine","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of myelodysplastic syndromes, including juvenile myelomonocytic leukaemia","routes_of_administration":"Oral use;Gastric use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"21/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Otsuka Pharmaceutical Netherlands B.V.E-mail: communications@otsuka-europe.com Tel. +44 2037475001","first_published_date":"13/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003071-pip02-23"},{"decision_number":"P/0544/2023","pip_number":"EMEA-003025-PIP03-23-M01","active_substance":"haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R,4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate (ECT-001-CB)","invented_name":"","therapeutic_area":"Blood and lymphatic system disorders","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment in haematopoietic stem cell transplantation in patients with haematological malignancies","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"20/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ExCellTheraE-mail: david.millette@excellthera.comTel: +15143432369","first_published_date":"15/11/2024","last_updated_date":"13/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003025-pip03-23-m01"},{"decision_number":"P/0541/2023","pip_number":"EMEA-001299-PIP03-17-M03","active_substance":"birch bark","invented_name":"Filsuvez","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Gel","condition_indication":"Treatment of epidermolysis bullosa","routes_of_administration":"Cutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Chiesi Farmaceutici S.p.A.; Tel. +39 0521 2791; E-mail: info@chiesi.com","first_published_date":"23/07/2021","last_updated_date":"13/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001299-pip03-17-m03"},{"decision_number":"P/0540/2023","pip_number":"EMEA-003437-PIP01-23","active_substance":"modified mRNA encoding human methylmalonyl-coenzyme A mutase containing a polymorphism at position 671 (mRNA-3705)","invented_name":"","therapeutic_area":"Endocrine disorders","pharmaceutical_forms":"Dispersion for injection","condition_indication":"Treatment of methylmalonic acidaemia","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Moderna Biotech Spain S.L. E-mail: medinfo@modernatx.comTel: +1 6177146500","first_published_date":"13/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003437-pip01-23"},{"decision_number":"P/0539/2023","pip_number":"EMEA-003486-PIP01-23","active_substance":"sitagliptin;dapagliflozin","invented_name":"","therapeutic_area":"Endocrine disorders","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type 2 diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"KRKA tovarna zdravil d.d. Novo mesto E-mail: Regulatory.Affairs@krka.biz Tel. + 386 73312111","first_published_date":"13/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003486-pip01-23"},{"decision_number":"P/0538/2023","pip_number":"EMEA-003490-PIP01-23","active_substance":"diflunisal","invented_name":"","therapeutic_area":"Nervous system disorders","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of transthyretin amyloidosis (ATTR)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AO Pharma AB E-mail: info@envestia.com Tel. +44 (0)7940030277&nbsp","first_published_date":"13/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003490-pip01-23"},{"decision_number":"P/0537/2023","pip_number":"EMEA-003386-PIP01-22","active_substance":"taldefgrobep alfa","invented_name":"","therapeutic_area":"","pharmaceutical_forms":"Concentrate for solution for injection/infusion","condition_indication":"Treatment of spinal muscular atrophy","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biohaven Bioscience Ireland Limited E-mail: medinfo@biohavenpharma.com Tel. +1 2034040410","first_published_date":"13/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003386-pip01-22"},{"decision_number":"P/0536/2023","pip_number":"EMEA-003421-PIP01-23","active_substance":"olutasidenib","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of acute myeloid leukaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Rigel Pharmaceuticals B.V. E-mail: asiddiqui@rigel.com Tel. +1 6506241162","first_published_date":"13/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003421-pip01-23"},{"decision_number":"P/0535/2023","pip_number":"EMEA-003488-PIP01-23","active_substance":"lotilaner","invented_name":"","therapeutic_area":"Eye disorders","pharmaceutical_forms":"Eye drops, solution","condition_indication":"Treatment of Demodex blepharitis","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Tarsus Pharmaceuticals Inc. E-mail: info@tarsusrx.com Tel.  +1 9494099820","first_published_date":"13/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003488-pip01-23"},{"decision_number":"P/0532/2023","pip_number":"EMEA-002798-PIP04-23","active_substance":"retifanlimab","invented_name":"","therapeutic_area":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Incyte Biosciences Distribution B.V. E-mail: RA@incyte.comTel. +1 3024252734","first_published_date":"13/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002798-pip04-23"},{"decision_number":"P/0533/2023","pip_number":"EMEA-002329-PIP02-20-M03","active_substance":"Delgocitinib","invented_name":"","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Cream","condition_indication":"Treatment of chronic hand eczema","routes_of_administration":"Cutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/12/2023","compliance_outcome":"Positive","compliance_opinion_date":"20/09/2019","compliance_procedure_number":"","contact_for_public_enquiries":"LEO Pharma A/S E-mail: raleodk@leo-pharma.com Tel. +45 44945888","first_published_date":"05/11/2021","last_updated_date":"13/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002329-pip02-20-m03"},{"decision_number":"P/0530/2023","pip_number":"EMEA-001731-PIP01-14-M04","active_substance":"meropenem trihydrate;vaborbactam","invented_name":"Vaborem","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of Gram-negative bacterial infections","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Menarini International Operations Luxembourg S.A.; E-mail: prijli@menarini.it; Tel. +39 0555 680633","first_published_date":"22/12/2015","last_updated_date":"13/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001731-pip01-14-m04"},{"decision_number":"P/0273/2024","pip_number":"EMEA-002862-PIP01-20-M04","active_substance":"COVID-19 vaccine (ChAdOx1-S [recombinant]) (AZD1222)","invented_name":"Vaxzevria (previously COVID-19 Vaccine AstraZeneca)","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca ABEmail: paediatrics@astrazeneca.comTel. +46 855324400","first_published_date":"05/01/2021","last_updated_date":"12/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002862-pip01-20-m04"},{"decision_number":"P/0144/2024","pip_number":"EMEA-003360-PIP01-22","active_substance":"tozorakimab","invented_name":"","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of severe viral lower respiratory tract disease","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB Tel.  +44 7876398360 E-mail: paediatrics@astrazeneca.com &nbsp","first_published_date":"12/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003360-pip01-22"},{"decision_number":"P/0188/2024","pip_number":"EMEA-003587-PIP01-24","active_substance":"trofinetide","invented_name":"","therapeutic_area":"Congenital, familial and genetic disorders","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of Rett syndrome","routes_of_administration":"Oral use;Gastroenteral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/06/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ACADIA Pharmaceuticals Inc.; United States; E-mail: info@acadia-pharm.com; Tel.: +1 8585582871; Fax: +1 8585582872","first_published_date":"12/02/2025","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003587-pip01-24"},{"decision_number":"P/252/2010","pip_number":"EMEA-000802-PIP01-09","active_substance":"anti-BAFF monoclonal antibody (LY2127399)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic autoimmune arthritis;Treatment of multiple sclerosis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"21/12/2010","last_updated_date":"11/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000802-pip01-09"},{"decision_number":"P/87/2010","pip_number":"EMEA-000532-PIP01-09","active_substance":"bituminosulphonate (sodium);clindamycin phosphate","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution","condition_indication":"Treatment of acne vulgaris","routes_of_administration":"Cutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/06/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ichthyol -Gesellschaft Cordes, Hermanni & Co. (GmbH & Co.) KG,; E-mail: fe@ichthyol.de; Tel.: +49 4050714301","first_published_date":"27/07/2010","last_updated_date":"06/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000532-pip01-09"},{"decision_number":"P/0168/2020","pip_number":"EMEA-001434-PIP01-13-M03","active_substance":"Etrolizumab","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Crohn's disease;Treatment of ulcerative colitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/04/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"20/02/2014","last_updated_date":"05/02/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001434-pip01-13-m03"},{"decision_number":"P/0237/2018","pip_number":"EMEA-002161-PIP01-17","active_substance":"trimeric, recombinant HIV-1 envelope glycoprotein 140 of Clade C / trimeric, recombinant HIV-1 envelope glycoprotein 140 containing motifs of multiple HIV-1 variants, adjuvanted with aluminium phosphate [Clade C gp140/ Mosaic gp140]","invented_name":"","therapeutic_area":"Infectious diseases;Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/08/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; E-mail: contact@janssen-emea.com; Tel.: +32 14602111","first_published_date":"28/01/2019","last_updated_date":"31/01/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002161-pip01-17"},{"decision_number":"P/0238/2018","pip_number":"EMEA-002160-PIP01-17","active_substance":"serotype 26 adenovirus encoding mosaic 1 HIV-1 group-specific antigen and polymerase proteins (Ad26.Mos1.Gag-Pol);serotype 26 adenovirus encoding mosaic 2 HIV-1 group-specific antigen and polymerase proteins (Ad26.Mos2.Gag-Pol);serotype 26 adenovirus encoding mosaic 1 HIV-1 envelope protein (Ad26.Mos1.Env);serotype 26 adenovirus encoding mosaic 2S HIV-1 envelope protein (Ad26.Mos2S.Env) [Ad26.Mos4.HIV]","invented_name":"","therapeutic_area":"Infectious diseases;Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/08/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; E-mail: contact@janssen-emea.com; Tel.: +32 14602111","first_published_date":"28/01/2019","last_updated_date":"31/01/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002160-pip01-17"},{"decision_number":"P/0033/2013","pip_number":"EMEA-001354-PIP01-12","active_substance":"2,6-Bis-{(1-napthalenyl-3,6-disulfonic acid)-oxyacetamido}-2,6-bis-2,6-bis-2,6-bis-(2,6-diamino-hexanoylamino)-2,6-diamino-hexanoic acid (diphenylmethyl)-amide, polysodium salt","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Vaginal gel","condition_indication":"Treatment of bacterial vaginosis","routes_of_administration":"Vaginal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/02/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Starpharma Pty Ltd; E-mail: ben.rogers@starpharma.com; Country: Australia; Tel. + 61 385322702","first_published_date":"23/04/2013","last_updated_date":"29/01/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001354-pip01-12"},{"decision_number":"P/0316/2023","pip_number":"EMEA-003331-PIP02-23","active_substance":"mavodelpar","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of primary mitochondrial disorders","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Reneo Pharmaceuticals IncTel. :  +44 (0)1304809360E-mail: clintrialinfo@reneopharma.com&nbsp","first_published_date":"13/09/2024","last_updated_date":"29/01/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003331-pip02-23"},{"decision_number":"P/0254/2023","pip_number":"EMEA-003019-PIP01-21","active_substance":"sodium 2,2-dimethylbutyrate (HST5040)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of inborn errors of amino acid metabolism","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Hemoshear Therapeutics Inc.E-mail: info@hemoshear.com Tel.:  +1 4348720196","first_published_date":"15/07/2024","last_updated_date":"29/01/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003019-pip01-21"},{"decision_number":"P/0236/2018","pip_number":"EMEA-002221-PIP01-17","active_substance":"trimeric, recombinant HIV-1 envelope glycoprotein 140 of Clade C, adjuvanted with aluminium phosphate [Clade C gp140]","invented_name":"","therapeutic_area":"Infectious diseases;Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/08/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; Tel. +32 1460 2111; E-mail: contact@janssen-emea.com","first_published_date":"17/01/2019","last_updated_date":"28/01/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002221-pip01-17"},{"decision_number":"P/0277/2021","pip_number":"EMEA-002856-PIP01-20","active_substance":"recombinant monoclonal antibody to sialic acid-binding Ig-like lectin 8 (AK002)","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of eosinophilic gastrointestinal inflammatory disorders","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/07/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allakos Inc; Tel. +1 6505975002; Email: pip@allakos.com    ","first_published_date":"22/07/2022","last_updated_date":"28/01/2025","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002856-pip01-20"},{"decision_number":"P/0452/2023","pip_number":"EMEA-001741-PIP03-16-M04","active_substance":"upadacitinib","invented_name":"Rinvoq","therapeutic_area":"Gastroentology-Hepatology;Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Prolonged-release tablet;Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of Crohn's disease","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"18/04/2018","last_updated_date":"28/11/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001741-pip03-16-m04"},{"decision_number":"P/0448/2023","pip_number":"EMEA-001995-PIP01-16-M04","active_substance":"lisocabtagene maraleucel","invented_name":"Breyanzi","therapeutic_area":"Oncology","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of B-lymphoblastic leukaemia/lymphoma;Treatment of mature B-cell neoplasms","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"12/02/2018","last_updated_date":"28/11/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001995-pip01-16-m04"},{"decision_number":"P/0443/2023","pip_number":"EMEA-002705-PIP02-19-M01","active_substance":"iptacopan","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Age appropriate oral solid dosage form;Capsule, hard","condition_indication":"Treatment of primary IgA nephropathy","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"04/08/2021","last_updated_date":"27/11/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002705-pip02-19-m01"},{"decision_number":"P/0442/2023","pip_number":"EMEA-002763-PIP01-20-M01","active_substance":"tovorafenib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Age appropriate oral formulation;Tablet","condition_indication":"Treatment of paediatric low grade glioma","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ipsen PharmaE-mail: muriel.anselmi@ipsen.comTel: +1-206-931-2433","first_published_date":"20/09/2021","last_updated_date":"27/11/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002763-pip01-20-m01"},{"decision_number":"P/0440/2023","pip_number":"EMEA-002776-PIP01-20-M02","active_substance":"autologous tumour-infiltrating lymphocytes (LN-144/LN-145)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Iovance Biotherapeutics, Inc.; E-mail: iova_regulatory_affairs@iovance.com; Tel: +1 650 260 7120 Ext.366","first_published_date":"06/10/2021","last_updated_date":"27/11/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002776-pip01-20-m02"},{"decision_number":"P/0419/2023","pip_number":"EMEA-001129-PIP01-11-M06","active_substance":"peginterferon beta-1a","invented_name":"Plegridy","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of multiple sclerosis","routes_of_administration":"Subcutaneous use;Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"25/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biogen Idec Ltd; Tel. +44 (0)1628 501000; E-mail: pip.enquiries@biogen.com","first_published_date":"18/09/2012","last_updated_date":"25/11/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001129-pip01-11-m06"},{"decision_number":"P/0418/2023","pip_number":"EMEA-001198-PIP03-17-M05","active_substance":"Fosnetupitant;palonosetron","invented_name":"Akynzeo","therapeutic_area":"Other","pharmaceutical_forms":"Powder for concentrate for solution for infusion;Concentrate for solution for infusion","condition_indication":"Prevention of chemotherapy-induced nausea and vomiting","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"25/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Helsinn Birex Pharmaceuticals Limited; E-mail: paediatrics-netu@helsinn.com; Tel. +41 9198 51950","first_published_date":"27/11/2018","last_updated_date":"25/11/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001198-pip03-17-m05"},{"decision_number":"P/0417/2023","pip_number":"EMEA-000997-PIP01-10-M07","active_substance":"selexipag","invented_name":"Uptravi","therapeutic_area":"Other","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of pulmonary arterial hypertension","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"25/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen Cilag International NV; Tel. +3214602111; E-mail: contact@Janssen-emea.com","first_published_date":"28/11/2011","last_updated_date":"22/11/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000997-pip01-10-m07"},{"decision_number":"P/0415/2023","pip_number":"EMEA-001912-PIP02-16-M03","active_substance":"angiotensin II (LJPC-501)","invented_name":"Giapreza","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of hypotension associated with distributive or vasodilatory shock","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"25/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"PAION Deutschland GmbH; Tel. +49 241 44530E-mail: info@paion.com","first_published_date":"12/02/2018","last_updated_date":"22/11/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001912-pip02-16-m03"},{"decision_number":"P/0414/2023","pip_number":"EMEA-002007-PIP02-17-M03","active_substance":"cemiplimab","invented_name":"Libtayo","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Regeneron Ireland DAC; E-mail: clinicaltrials@regeneron.com","first_published_date":"05/03/2018","last_updated_date":"22/11/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002007-pip02-17-m03"},{"decision_number":"P/0486/2023","pip_number":"EMEA-003479-PIP01-23","active_substance":"glyceryl trinitrate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Sublingual spray","condition_indication":"Prevention of cardiac and vascular procedural complications;Treatment of heart failure;Treatment of ischaemic coronary artery disorders","routes_of_administration":"Sublingual use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/11/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Egis Gyogyszergyar Zrt.; E-mail: registry@egis.huTel.  +36 18032414&nbsp","first_published_date":"22/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003479-pip01-23"},{"decision_number":"P/0487/2023","pip_number":"EMEA-003365-PIP02-23","active_substance":"govorestat","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism;Neurology","pharmaceutical_forms":"Oral suspension","condition_indication":"Treatment of galactosaemia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"30/11/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"E-mail: info@appliedtherapeutics.comTel. +1 6462638662&nbsp","first_published_date":"22/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003365-pip02-23"},{"decision_number":"P/0501/2023","pip_number":"EMEA-002873-PIP01-20","active_substance":"Live-attenuated La Reunion strain of chikungunya virus (VLA1553)","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Powder and solvent for suspension for injection","condition_indication":"Prevention of chikungunya disease","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"24/11/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Valneva Austria GmbH; E-mail: medinfo@valneva.com; Tel. +43 20620-1124","first_published_date":"14/02/2023","last_updated_date":"22/11/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002873-pip01-20"},{"decision_number":"P/0482/2023","pip_number":"EMEA-001943-PIP04-20-M01","active_substance":"ravulizumab","invented_name":"Ultomiris","therapeutic_area":"Neurology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of neuromyelitis optica spectrum disorders","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/11/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alexion Europe SAS; E-mail: pip.enquiries.eu@alexion.com; Tel. +33 147100619","first_published_date":"06/03/2023","last_updated_date":"22/11/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001943-pip04-20-m01"},{"decision_number":"P/0484/2023","pip_number":"EMEA-001931-PIP01-16-M03","active_substance":"human fibrinogen concentrate (BT524)","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder for solution for injection or infusion","condition_indication":"Treatment of congenital fibrinogen deficiency","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/11/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biotest AG; Tel. +49 6103801497; E-mail: Andrea.Wartenberg-Demand@biotest.com","first_published_date":"29/05/2017","last_updated_date":"22/11/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001931-pip01-16-m03"},{"decision_number":"P/0483/2023","pip_number":"EMEA-001925-PIP02-19-M01","active_substance":"Pegzilarginase","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism;Neurology","pharmaceutical_forms":"Solution for infusion;Solution for injection","condition_indication":"Treatment of Hyperargininaemia","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/11/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Immedica Pharma AB; E-mail: info@immedica.comTel. +46 (0)853339500","first_published_date":"16/06/2021","last_updated_date":"22/11/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001925-pip02-19-m01"},{"decision_number":"P/0453/2023","pip_number":"EMEA-002582-PIP01-19-M03","active_substance":"remibrutinib","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Age appropriate oral solid dosage form;Coated tablet","condition_indication":"Treatment of chronic spontaneous urticaria","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/11/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"04/03/2021","last_updated_date":"22/11/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002582-pip01-19-m03"},{"decision_number":"P/0408/2023","pip_number":"EMEA-001806-PIP04-19-M02","active_substance":"carfilzomib","invented_name":"Kyprolis","therapeutic_area":"Haematology-Hemostaseology;Oncology","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of acute lymphoblastic leukaemia","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe BV; E-mail: medinfointernational@amgen.com; Tel. +44 (0)1223 420305","first_published_date":"29/09/2021","last_updated_date":"21/11/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001806-pip04-19-m02"},{"decision_number":"P/0399/2023","pip_number":"EMEA-002243-PIP01-17-M04","active_substance":"Eptinezumab","invented_name":"Vyepti","therapeutic_area":"Neurology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Prevention of migraine headaches","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"H. Lundbeck A/S E-mail: commres2738@lundbeck.com Tel: +45 36301311","first_published_date":"23/03/2020","last_updated_date":"21/11/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002243-pip01-17-m04"},{"decision_number":"P/0400/2023","pip_number":"EMEA-002519-PIP03-21-M01","active_substance":"evenamide","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of schizophrenia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Newron Pharmaceuticals S.p.A. E-mail: ravi@anand.chTel: +39026103461","first_published_date":"07/03/2023","last_updated_date":"21/11/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002519-pip03-21-m01"},{"decision_number":"P/0398/2023","pip_number":"EMEA-000332-PIP02-17-M05","active_substance":"Brivaracetam","invented_name":"Briviact (in Italy: Nubriveo)","therapeutic_area":"Neurology","pharmaceutical_forms":"Film-coated tablet;Oral solution;Solution for injection/infusion","condition_indication":"Treatment of neonatal seizures;Treatment of paediatric epilepsy syndromes","routes_of_administration":"Oral use;Intravenous use;Intravenous bolus use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"UCB Pharma S.A.; Tel. + 353 14632371; E-mail: ucbcares.ie@ucb.com","first_published_date":"18/04/2018","last_updated_date":"21/11/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000332-pip02-17-m05"},{"decision_number":"P/0397/2023","pip_number":"EMEA-001555-PIP01-13-M05","active_substance":"eravacycline","invented_name":"Xerava","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of complicated intra-abdominal infection","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"PAION Deutschland GmbH; Tel. +49 241 44530E-mail: info@paion.com","first_published_date":"23/03/2015","last_updated_date":"21/11/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001555-pip01-13-m05"},{"decision_number":"P/0396/2023","pip_number":"EMEA-001501-PIP02-13-M08","active_substance":"dupilumab","invented_name":"Dupixent","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of asthma","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi Winthrop IndustrieE-mail: contact-us@sanofi.comTel: +33 1 69 74 56 95","first_published_date":"22/08/2014","last_updated_date":"21/11/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001501-pip02-13-m08"},{"decision_number":"P/0451/2023","pip_number":"EMEA-001741-PIP09-23","active_substance":"upadacitinib","invented_name":"Rinvoq","therapeutic_area":"Dermatology","pharmaceutical_forms":"Age appropriate oral dosage formulation;Prolonged-release tablet","condition_indication":"Treatment of Systemic Lupus Erythematosus (SLE)","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"20/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001741-pip09-23"},{"decision_number":"P/0445/2023","pip_number":"EMEA-003379-PIP01-22","active_substance":"Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid carrier protein (MenABCWY);Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid carrier protein;Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid carrier protein;Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid carrier protein;recombinant Neisseria meningitidis serogroup B protein 1;recombinant Neisseria meningitidis serogroup B protein 2;recombinant Neisseria meningitidis serogroup B protein 3;Neisseria meningitidis serogroup B Protein-based active substance (MenPenta vaccine)","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of Meningococcal disease","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi PasteurE-mail: contact-us@sanofi.comTel. +33 1 6974 5695","first_published_date":"20/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003379-pip01-22"},{"decision_number":"P/0446/2023","pip_number":"EMEA-001741-PIP08-22","active_substance":"upadacitinib","invented_name":"Rinvoq","therapeutic_area":"Dermatology","pharmaceutical_forms":"Age appropriate oral liquid dosage formulation;Prolonged-release tablet","condition_indication":"Treatment of hidradenitis suppurativa","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"20/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001741-pip08-22"},{"decision_number":"P/0450/2023","pip_number":"EMEA-002705-PIP05-23","active_substance":"iptacopan","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Age appropriate oral dosage formulation;Capsule, hard","condition_indication":"Treatment of immune-complex mediated membranoproliferative glomerulonephritis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"20/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002705-pip05-23"},{"decision_number":"P/0437/2023","pip_number":"EMEA-003307-PIP01-22","active_substance":"uproleselan","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of acute myeloid leukaemia","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlycoMimetics, Inc.E-mail: erock@glycomimetics.comTel: +1 240 243 1201","first_published_date":"20/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003307-pip01-22"},{"decision_number":"P/0438/2023","pip_number":"EMEA-003033-PIP02-22","active_substance":"pabinafusp alfa","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of mucopolysaccharidosis II","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"JCR Pharmaceuticals Co., Ltd.E-mail: sarah.arbe-barnes@artemidapharma.comTel: +353 14372313","first_published_date":"20/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003033-pip02-22"},{"decision_number":"P/0441/2023","pip_number":"EMEA-001521-PIP03-22","active_substance":"Luspatercept","invented_name":"Reblozyl","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of alpha-thalassaemia","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG; Email: medical.information@bms.com; Tel. +44 1895523740","first_published_date":"20/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001521-pip03-22"},{"decision_number":"P/0444/2023","pip_number":"EMEA-003363-PIP01-22","active_substance":"ruzotolimod","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Age appropriate oral solid dosage form;Tablet","condition_indication":"Treatment of chronic hepatitis B","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"20/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003363-pip01-22"},{"decision_number":"P/0434/2023","pip_number":"EMEA-003452-PIP01-23","active_substance":"belrestotug","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Tel. +1 4388998201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"19/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003452-pip01-23"},{"decision_number":"P/0435/2023","pip_number":"EMEA-003362-PIP01-22","active_substance":"xalnesiran","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic hepatitis B","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"19/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003362-pip01-22"},{"decision_number":"P/0436/2023","pip_number":"EMEA-003446-PIP01-23","active_substance":"amlodipine;rosuvastatin","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Prevention of cardiovascular events;Treatment of hypertension;Treatment of ischemic cornary artery disorders","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Tel  +33 87509776Email: regulatory@lanovafarmaceutici.com","first_published_date":"19/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003446-pip01-23"},{"decision_number":"P/0430/2023","pip_number":"EMEA-003368-PIP01-22","active_substance":"Inaxaplin","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of apolipoprotein L1 (APOL1)-mediated kidney disease","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vertex Pharmaceuticals (Ireland) Limited; E-mail: vertexmedicalinfo@vrtx.com; Tel: +353 17617299","first_published_date":"19/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003368-pip01-22"},{"decision_number":"P/0431/2023","pip_number":"EMEA-003449-PIP01-23","active_substance":"modified, recombinant version of the human myeloid-derived growth factor","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of ischaemic coronary artery disorders","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"19/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003449-pip01-23"},{"decision_number":"P/0432/2023","pip_number":"EMEA-002830-PIP01-20","active_substance":"A self-complementary adeno-associated virus [AAV] serotype 8 virus particle encoding the human ornithine transcarbamylase [OTC] gene sequence (DTX301)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of ornithine transcarbamylase deficiency","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ultragenyx Germany GmbHE-mail: ameichle@ultragenyx.comTel: +49 172 8546908","first_published_date":"19/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002830-pip01-20"},{"decision_number":"P/0433/2023","pip_number":"EMEA-003450-PIP01-23","active_substance":"zanidatamab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of biliary tract cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Jazz Pharmaceuticals Ireland LimitedE-mail: corporateaffairsmediainfo@jazzpharma.comTel: +353 16347800","first_published_date":"19/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003450-pip01-23"},{"decision_number":"P/0427/2023","pip_number":"EMEA-003456-PIP01-23","active_substance":"2-[3-(dimethyl-1H-1,2,3-triazol-5-yl)-5-[(S)-oxan-4-yl(phenyl)methyl]-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of myelofibrosis","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG; Email: medical.information@bms.comTel. +44 1423 533 610","first_published_date":"19/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003456-pip01-23"},{"decision_number":"P/0428/2023","pip_number":"EMEA-003347-PIP01-22","active_substance":"derivative of 6‐(piperidine‐1‐carbonyl)pyridin‐3‐ol (BI 764198)","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Age appropriate oral solid dosage form;Film-coated tablet","condition_indication":"Treatment of glomerulonephritis and nephrotic syndrome","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"19/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003347-pip01-22"},{"decision_number":"P/0429/2023","pip_number":"EMEA-003461-PIP01-23","active_substance":"humanised IgG1 monoclonal antibody against TROP2, conjugated to a topoisomerase I inhibitor belotecan-derivative","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of breast cancer;Treatment of cervical cancer;Treatment of endometrial cancer;Treatment of gastric cancer;Treatment of lung cancer;Treatment of ovarian cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"19/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003461-pip01-23"},{"decision_number":"P/0425/2023","pip_number":"EMEA-003455-PIP01-23","active_substance":"Methyl-(1-{[6-{[(1S)-1-cyclopropylethyl]amino}-2-(pyrazolo[5,1-b][1,3]thiazol-7-yl)-pyrimidin-4-yl]carbonyl}piperidin-4-yl)carbamate mono(4-methylbenzenesulfonate)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"RAPT Therapeutics IncE-mail: inquiries@rapt.comTel: +1 650 489 9037; &nbsp","first_published_date":"15/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003455-pip01-23"},{"decision_number":"P/0421/2023","pip_number":"EMEA-003321-PIP01-22","active_substance":"ciraparantag","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of FXa inhibitor-associated haemorrhage;Treatment of FXa inhibitor-associated haemorrhage","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Norgine BVTel. +33 141399415E-mail: lifecyclemanagement@norgine.com","first_published_date":"15/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003321-pip01-22"},{"decision_number":"P/0420/2023","pip_number":"EMEA-002681-PIP03-21","active_substance":"rozanolixizumab","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of myelin oligodendrocyte glycoprotein antibody-associated disease","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"UCB Pharma S.A.; E-mail: UCBCares.IE@ucb.com; Tel. +353 1463 2371","first_published_date":"15/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002681-pip03-21"},{"decision_number":"P/0413/2023","pip_number":"EMEA-003474-PIP01-23","active_substance":"ulviprubart","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of inclusion body myositis","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"25/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Abcuro, Inc.E-mail: corporate.contact@abcuro.comTel: +1 (617) 714-9759","first_published_date":"14/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003474-pip01-23"},{"decision_number":"P/0409/2023","pip_number":"EMEA-003482-PIP01-23","active_substance":"actinium chloride (non-carrier added)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Radiopharmaceutical precursor;Solution","condition_indication":"Radiolabelling agent","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ITM Medical Isotopes GmbH; E-mail: info-medical-isotopes@itm.ag; Tel. +49 89 329 8986 600","first_published_date":"14/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003482-pip01-23"},{"decision_number":"P/0406/2023","pip_number":"EMEA-003442-PIP01-23","active_substance":"genetically detoxified pertussis toxin (PTgen);pertussis filamentous haemagglutinin (FHA)","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of Pertussis disease","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bionet EuropeE-mail: bsoubeyrand@bionet.oneTel: +33607582783","first_published_date":"14/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003442-pip01-23"},{"decision_number":"P/0405/2023","pip_number":"EMEA-002721-PIP04-23","active_substance":"tiragolumab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of hepatocellular carcinoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"14/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002721-pip04-23"},{"decision_number":"P/0404/2023","pip_number":"EMEA-003359-PIP01-22","active_substance":"recombinant neisseria meningitis group B Protein 936-741;meningococcal group W-135 oligosaccharides conjugated to corynebacterium diphtheriae CRM197 protein;recombinant neisseria meningitis group B Protein 287-953;meningococcal group A oligosaccharides conjugated to corynebacterium diphtheriae CRM197 protein;recombinant Neisseria meningitidis group B fHbp 2-3-1.13NB fusion protein;outer membrane vesicles (OMV) from n. meningitidis strain NZ 98/254;meningococcal group C oligosaccharides conjugated to corynebacterium diphtheriae CRM197 protein;meningococcal group Y oligosaccharides conjugated to corynebacterium diphtheriae CRM197 protein (MenABCWY);recombinant neisseria meningitis group B Protein 961c (MenACWY-7B vaccine)","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Powder and suspension for suspension for injection","condition_indication":"Prevention of Meningococcal disease","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Biologicals SA; Tel. +44 (0)20 8966 3220; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"13/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003359-pip01-22"},{"decision_number":"P/0402/2023","pip_number":"EMEA-003356-PIP01-22","active_substance":"Inhibitor of receptor-interacting protein kinase 1 (ABBV-668)","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Age appropriate oral dosage formulation;Capsule, hard","condition_indication":"Treatment of ulcerative colitis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"13/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003356-pip01-22"},{"decision_number":"P/0401/2023","pip_number":"EMEA-003342-PIP02-22","active_substance":"Enpatoran","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Age appropriate oral dosage formulation;Film-coated tablet","condition_indication":"Treatment of Systemic Lupus Erythematosus (SLE)","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Europe B.V.; Tel.: +49 6151725200; E-mail: service@merckgroup.com","first_published_date":"13/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003342-pip02-22"},{"decision_number":"P/0395/2023","pip_number":"EMEA-003445-PIP01-23","active_substance":"bezuclastinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of mastocytosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cogent Biosciences, Inc; Email: paediatrics@cogentbio.com    ; Tel. +1 6179455576","first_published_date":"13/11/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003445-pip01-23"},{"decision_number":"P/0324/2021","pip_number":"EMEA-002863-PIP01-20","active_substance":"(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3- methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (ALXN2050)","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of paroxysmal nocturnal haemoglobinuria","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alexion Europe SAS; E-mail: pip.enquiries.eu@alexion.com; Tel. +33 147103621","first_published_date":"08/09/2022","last_updated_date":"24/10/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002863-pip01-20"},{"decision_number":"P/0150/2017","pip_number":"EMEA-001043-PIP01-10-M03","active_substance":"sirukumab","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection in pre-filled pen;Age appropriate dosage form for parenteral use","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis and juvenile idiopathic arthritis)","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/06/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; United Kingdom; Tel. +44 1494567567; Fax +44 1494658084; E-mail: ldobell@its.jnj.com (Laura Dobell)","first_published_date":"26/07/2017","last_updated_date":"24/10/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001043-pip01-10-m03"},{"decision_number":"P/0376/2023","pip_number":"EMEA-001776-PIP03-17-M01","active_substance":"risankizumab","invented_name":"Skyrizi","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Concentrate for solution for infusion;Solution for injection;Age appropriate dosage form for parenteral use","condition_indication":"Treatment of Crohn's disease","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628925033","first_published_date":"28/01/2019","last_updated_date":"07/10/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001776-pip03-17-m01"},{"decision_number":"P/0380/2023","pip_number":"EMEA-001687-PIP01-14-M07","active_substance":"fostemsavir trometamol","invented_name":"Rukobia","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Prolonged-release tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ViiV Healthcare UK Ltd;  +44 (0)7467 443192; eu.paediatric-plans@gsk.com","first_published_date":"21/12/2015","last_updated_date":"07/10/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001687-pip01-14-m07"},{"decision_number":"P/0341/2023","pip_number":"EMEA-000311-PIP04-13-M06","active_substance":"ustekinumab","invented_name":"Stelara","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Solution for injection/infusion;Concentrate for solution for infusion","condition_indication":"Treatment of Crohn's disease","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen Cilag International NV; Tel. +3214602111; E-mail: contact@Janssen-emea.com","first_published_date":"16/04/2014","last_updated_date":"07/10/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000311-pip04-13-m06"},{"decision_number":"P/0363/2023","pip_number":"EMEA-003319-PIP02-22","active_substance":"substituted 3,7-dihydro-1H-purine-2,6-dione (BI 1358894)","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of major depressive disorder","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"07/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003319-pip02-22"},{"decision_number":"P/0364/2023","pip_number":"EMEA-003319-PIP03-22","active_substance":"substituted 3,7-dihydro-1H-purine-2,6-dione (BI 1358894)","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of posttraumatic stress disorder","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"07/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003319-pip03-22"},{"decision_number":"P/0370/2023","pip_number":"EMEA-003326-PIP01-22","active_substance":"Funobactam","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Age appropriate dosage form;Powder for solution for injection or infusion","condition_indication":"Treatment of infections caused by Gram-negative organisms (in combination with imipenem and cilastatin)","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"E-mail: info@evopointbio.com","first_published_date":"07/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003326-pip01-22"},{"decision_number":"P/0371/2023","pip_number":"EMEA-003328-PIP01-22","active_substance":"Dexpramipexole (dihydrochloride monohydrate)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of asthma","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"E-mail: info@areteiatx.com&nbsp","first_published_date":"07/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003328-pip01-22"},{"decision_number":"P/0369/2023","pip_number":"EMEA-003232-PIP01-22-M01","active_substance":"recombinant human ectonucleotide pyrophosphatase/phosphodiesterase 1 fused to the Fc fragment of IgG1","invented_name":"","therapeutic_area":"Cardiovascular diseases;Endocrinology-Gynaecology-Fertility-Metabolism;Other","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of ectonucleotide pyrophosphatase / phosphodiesterase 1 deficiency","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Inozyme Pharma IrelandE-mail: info@inozyme.com Tel.:  +1 8573304340","first_published_date":"19/07/2024","last_updated_date":"04/10/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003232-pip01-22-m01"},{"decision_number":"P/0373/2023","pip_number":"EMEA-002893-PIP01-20-M04","active_substance":"elasomeran;imelsomeram;davesomeran","invented_name":"Spikevax (previously COVID-19 Vaccine Moderna)","therapeutic_area":"Vaccines","pharmaceutical_forms":"Dispersion for injection","condition_indication":"Prevention of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Moderna Biotech Spain, S.L. Tel.  +41 795000903 E-mail: paediatrics@modernatx.com","first_published_date":"18/12/2020","last_updated_date":"04/10/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002893-pip01-20-m04"},{"decision_number":"P/0361/2023","pip_number":"EMEA-002681-PIP01-19-M02","active_substance":"rozanolixizumab","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of myasthenia gravis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"UCB Pharma S.A.; E-mail: UCBCares.IE@ucb.com; Tel. +353 1463 2371","first_published_date":"08/03/2021","last_updated_date":"04/10/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002681-pip01-19-m02"},{"decision_number":"P/0368/2023","pip_number":"EMEA-002722-PIP01-19-M03","active_substance":"Etranacogene dezaparvovec","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Haemophilia B","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CSL Behring GmbH; Email: PIP.CSLBehring@cslbehring.com; Tel. +49 6421392355;  ","first_published_date":"26/10/2021","last_updated_date":"04/10/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002722-pip01-19-m03"},{"decision_number":"P/0360/2023","pip_number":"EMEA-002485-PIP01-18-M01","active_substance":"Norursodeoxycholic acid","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Capsule;Age appropriate oral solid dosage form;Film-coated tablet","condition_indication":"Treatment of autoimmune sclerosing cholangitis;Treatment of primary sclerosing cholangitis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dr. Falk Pharma GmbH; Email: zentrale@drfalkpharma.de; Tel.: +49 76115140","first_published_date":"10/06/2020","last_updated_date":"04/10/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002485-pip01-18-m01"},{"decision_number":"P/0359/2023","pip_number":"EMEA-002440-PIP01-18-M05","active_substance":"Baloxavir marboxil","invented_name":"Xofluza","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Granules for oral suspension","condition_indication":"Prevention of influenza infection;Treatment of influenza","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"23/03/2020","last_updated_date":"04/10/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002440-pip01-18-m05"},{"decision_number":"P/0374/2023","pip_number":"EMEA-003436-PIP01-23","active_substance":"lerociclib (dihydrochloride)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of endometrial carcinoma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"EQRx International, Inc. Tel. 617 3152255 E-mail: info@eqrx.com","first_published_date":"04/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003436-pip01-23"},{"decision_number":"P/0375/2023","pip_number":"EMEA-003438-PIP01-23","active_substance":"obicetrapib","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of mixed dyslipidaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"NewAmsterdam Pharma BV Tel.  +31 352062971 E-mail: study.director@newamsterdampharma.com","first_published_date":"04/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003438-pip01-23"},{"decision_number":"P/0365/2023","pip_number":"EMEA-003444-PIP01-23","active_substance":"rosuvastatin;ezetimibe","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pharmazac S.A. Tel. +30 2103418890 (ext. 609) E-mail: regulatory@pharmazac.com","first_published_date":"04/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003444-pip01-23"},{"decision_number":"P/0356/2023","pip_number":"EMEA-003447-PIP01-23","active_substance":"5-{4-[(7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]-1-piperazinyl}-N-methyl-2-pyridinecarboxamide","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of breast cancer;Treatment of prostate cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca ABEmail: paediatrics@astrazeneca.comTel.  +46 855326000","first_published_date":"04/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003447-pip01-23"},{"decision_number":"P/0333/2023","pip_number":"EMEA-003305-PIP01-22","active_substance":"vesleteplirsen","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of Duchenne muscular dystrophy","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sarepta Therapeutics Ireland Limited; E-mail: ekelly@sarepta.com; Tel. +353 868792759","first_published_date":"04/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003305-pip01-22"},{"decision_number":"P/0344/2023","pip_number":"EMEA-003434-PIP01-23","active_substance":"modified messenger ribonucleic acid encoding individual patient-specific tumour neoantigens (V940/ mRNA-4157)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Dispersion for injection","condition_indication":"Treatment of lung cancer","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"04/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003434-pip01-23"},{"decision_number":"P/0362/2023","pip_number":"EMEA-003283-PIP01-22","active_substance":"dexmedetomidine","invented_name":"","therapeutic_area":"Anaesthesiology","pharmaceutical_forms":"Nasal spray (solution)","condition_indication":"Sedation","routes_of_administration":"Intranasal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cessatech A/S; E-mail: info@cessatech.com; Tel: +45 93872309  ","first_published_date":"04/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003283-pip01-22"},{"decision_number":"P/0394/2023","pip_number":"EMEA-003256-PIP02-23","active_substance":"valemetostat tosilate","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet;Capsule, hard","condition_indication":"Treatment of mature T-cell neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Daiichi Sankyo Europe GmbH; E-mail: service@daiichi-sankyo.eu; Tel.: +49 8978080","first_published_date":"04/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003256-pip02-23"},{"decision_number":"P/0355/2023","pip_number":"EMEA-003345-PIP01-22","active_substance":"acellular tubular graft composed of human collagen types I and III and other extracellular matrix proteins, including fibronectin and vitronectin","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Implant","condition_indication":"Treatment of vascular injuries","routes_of_administration":"Implant use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Humacyte Global, Inc. Tel.  +1 (919)3139633 E-mail: ccao@humacyte.com","first_published_date":"04/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003345-pip01-22"},{"decision_number":"P/0342/2023","pip_number":"EMEA-003378-PIP01-23","active_substance":"ivonescimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of lung cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Summit Therapeutics Sub Inc. Tel. + 18332560522 E-mail: medicalinformation@summitplc.com","first_published_date":"04/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003378-pip01-23"},{"decision_number":"P/0343/2023","pip_number":"EMEA-003430-PIP01-23","active_substance":"ramipril;nebivolol (hydrochloride)","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Menarini Ricerche S.p.A.; Tel:+39 05556807607/458Email:scappellini@menarini-ricerche.it","first_published_date":"04/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003430-pip01-23"},{"decision_number":"P/0366/2023","pip_number":"EMEA-002990-PIP02-23","active_substance":"3-[2-(Dimethylamino)ethyl]-1H-indol-4-yl dihydrogen phosphate","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Capsule, soft","condition_indication":"Treatment of major depressive disorder","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"E-mail: info@compasspathways.com&nbsp","first_published_date":"04/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002990-pip02-23"},{"decision_number":"P/0390/2023","pip_number":"EMEA-003343-PIP01-22","active_substance":"recombinant human tissue nonspecific alkaline phosphatase (TNSALP) fragment crystallizable (Fc) deca aspartate fusion protein (ALXN1850)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of hypophosphatasia","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alexion Europe SAS; E-mail: pip.enquiries.eu@alexion.com; Tel. +33 147100619","first_published_date":"04/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003343-pip01-22"},{"decision_number":"P/0314/2023","pip_number":"EMEA-003315-PIP01-22","active_substance":"mRNA encoding modified human ornithine transcarbamylase (ARCT-810)","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of ornithine transcarbamylase deficiency","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Arcturus Therapeutics Europe B.V.E-mail: regulatory@arcturusrx.com Tel.:  +1 (858)7320394","first_published_date":"02/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003315-pip01-22"},{"decision_number":"P/0311/2023","pip_number":"EMEA-003313-PIP01-22","active_substance":"povorcitinib","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hidradenitis suppurativa","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"07/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Incyte Biosciences Distribution B.V.; E-mail: RA@incyte.com","first_published_date":"02/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003313-pip01-22"},{"decision_number":"P/0310/2023","pip_number":"EMEA-003304-PIP01-22","active_substance":"mocravimod","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment in haematopoietic stem cell transplantation in patients with acute myeloid leukaemia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"07/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Email: info@priothera.com Telephone: +33 367510040","first_published_date":"02/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003304-pip01-22"},{"decision_number":"P/0306/2023","pip_number":"EMEA-003290-PIP01-22","active_substance":"dirloctocogene samoparvovec","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of moderate or severe haemophilia A without Factor VIII inhibitors","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Email: patients@sparktx.com Telephone: +1 2152209300; &nbsp","first_published_date":"02/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003290-pip01-22"},{"decision_number":"P/0292/2023","pip_number":"EMEA-003274-PIP01-22","active_substance":"enomimeran;gindameran;ontasameran;vibosameran (BNT111)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Dispersion for injection","condition_indication":"Treatment of melanoma","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BioNTech SEE-mail: service@biontech.de Tel: +49 (0) 6131 90840","first_published_date":"02/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003274-pip01-22"},{"decision_number":"P/0291/2023","pip_number":"EMEA-003271-PIP01-22","active_substance":"XEN1101","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Age appropriate intravenous dosage form;Age appropriate oral liquid dosage formulation;Capsule, hard","condition_indication":"Treatment of focal onset seizures","routes_of_administration":"Intravenous use;Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Email: info@xenon-pharma.com ; Telephone: +1 6044843300","first_published_date":"02/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003271-pip01-22"},{"decision_number":"P/0307/2023","pip_number":"EMEA-003059-PIP02-23","active_substance":"cagrilintide;semaglutide","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; E-mail: paediatrics@novonordisk.com ; Tel.: +45 44448888","first_published_date":"02/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003059-pip02-23"},{"decision_number":"P/0304/2023","pip_number":"EMEA-003154-PIP01-21","active_substance":"repagermanium","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of focal segmental glomerulosclerosis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dimerix Bioscience Pty LtdE-mail: info@dimerix.com Tel.:  +61 1300813321&nbsp","first_published_date":"02/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003154-pip01-21"},{"decision_number":"P/0290/2023","pip_number":"EMEA-002850-PIP03-22","active_substance":"dersimelagon","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Age appropriate oral formulation;Tablet","condition_indication":"Treatment of systemic sclerosis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mitsubishi Tanabe Pharma GmbHE-mail: regulatory@mt-pharma-eu.com Tel: +49 2115205440","first_published_date":"02/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002850-pip03-22"},{"decision_number":"P/0288/2023","pip_number":"EMEA-002438-PIP04-23","active_substance":"rilzabrutinib","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of autoimmune haemolytic aneamia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi B.V.E-mail: eumedinfo.GZ@sanofi.com Tel. +31 2024 54000&nbsp","first_published_date":"02/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002438-pip04-23"},{"decision_number":"P/0289/2023","pip_number":"EMEA-002451-PIP03-22","active_substance":"ritlecitinib","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Capsule, hard;Age appropriate oral solid dosage form;Tablet","condition_indication":"Treatment of vitiligo","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG; Tel. +44 (0)1304 646 607; E-mail: pip_enquiries@pfizer.com","first_published_date":"02/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002451-pip03-22"},{"decision_number":"P/0298/2023","pip_number":"EMEA-001625-PIP05-23","active_substance":"satralizumab","invented_name":"Enspryng","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of thyroid eye disease","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"02/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001625-pip05-23"},{"decision_number":"P/0296/2023","pip_number":"EMEA-001441-PIP08-23","active_substance":"semaglutide","invented_name":"Wegovy","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Prevention of cardiovascular events in patients with atherosclerosis","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; E-mail: paediatrics@novonordisk.com ; Tel.: +45 44448888","first_published_date":"02/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001441-pip08-23"},{"decision_number":"P/0303/2023","pip_number":"EMEA-002381-PIP02-23","active_substance":"autologous dendritic cells pulsed with allogeneic tumour cell lysate","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of pancreatic cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amphera BVTel.   +31 651032369E-mail: info@amphera.nl","first_published_date":"02/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002381-pip02-23"},{"decision_number":"P/0334/2023","pip_number":"EMEA-000142-PIP03-23","active_substance":"concentrate of proteolytic enzymes in bromelain","invented_name":"NexoBrid","therapeutic_area":"Other","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of diabetic foot ulcer;Treatment of venous leg ulcer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"MediWound Germany GmbH; Tel. +972 779714168; E-mail: ayaby@mediwound.com","first_published_date":"02/10/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000142-pip03-23"},{"decision_number":"P/0295/2023","pip_number":"EMEA-001397-PIP04-17-M02","active_substance":"Ibrutinib","invented_name":"Imbruvica","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Capsule, hard;Film-coated tablet;Oral suspension","condition_indication":"Treatment of chronic Graft versus Host Disease (cGvHD)","routes_of_administration":"Oral use;Gastric use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International N.V.; Tel.  +32 14602111; E-mail: contact@janssen-emea.com","first_published_date":"11/04/2019","last_updated_date":"02/10/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001397-pip04-17-m02"},{"decision_number":"P/0340/2023","pip_number":"EMEA-001379-PIP01-12-M08","active_substance":"tedizolid phosphate","invented_name":"Sivextro","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Powder for concentrate for solution for infusion;Powder for oral suspension","condition_indication":"Treatment of acute bacterial skin and skin structure infections","routes_of_administration":"Oral use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"15/11/2013","last_updated_date":"02/10/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001379-pip01-12-m08"},{"decision_number":"P/0287/2023","pip_number":"EMEA-001304-PIP02-13-M07","active_substance":"obeticholic acid","invented_name":"Ocaliva","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Coated tablet;Tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of biliary atresia;Treatment of primary biliary cirrhosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Advanz Pharma LimitedEmail: enquiries@advanzpharma.com Tel:   +44 (0)2085889441","first_published_date":"31/07/2014","last_updated_date":"02/10/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001304-pip02-13-m07"},{"decision_number":"P/0309/2023","pip_number":"EMEA-001143-PIP01-11-M06","active_substance":"cabozantinib","invented_name":"Cometriq; Cabometyx","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet;Capsule, hard","condition_indication":"Treatment of solid malignant tumours","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ipsen PharmaE-mail: GlobalMedInfo@ipsen.comTel.: +33 158335427","first_published_date":"09/08/2012","last_updated_date":"02/10/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001143-pip01-11-m06"},{"decision_number":"P/0073/2022","pip_number":"EMEA-000533-PIP01-08-M11","active_substance":"tenofovir disoproxil fumarate","invented_name":"Viread","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Granules","condition_indication":"Treatment of chronic viral hepatitis B;Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/03/2022","compliance_outcome":"Positive","compliance_opinion_date":"20/01/2023","compliance_procedure_number":"EMEA-C-000533-PIP01-08-M11","contact_for_public_enquiries":"Gilead Sciences International Limited; Tel. +44 (0)1223 897300; E-mail: regulatory.pip@gilead.com;  ","first_published_date":"15/09/2011","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000533-pip01-08-m11"},{"decision_number":"P/0337/2022","pip_number":"EMEA-000455-PIP02-10-M09","active_substance":"vortioxetine","invented_name":"Brintellix; Brintellix","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of major depressive disorder","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/08/2022","compliance_outcome":"Positive","compliance_opinion_date":"20/01/2023","compliance_procedure_number":"EMEA-C-000455-PIP02-10-M09","contact_for_public_enquiries":"H. Lumdbeck A/S; E-mail: commres2738@lundbeck.com; Tel.  +45 3083 3413","first_published_date":"21/12/2011","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000455-pip02-10-m09"},{"decision_number":"P/0002/2023","pip_number":"EMEA-000335-PIP01-08-M15","active_substance":"ivacaftor","invented_name":"Kalydeco","therapeutic_area":"Other","pharmaceutical_forms":"Film-coated tablet;Granules in sachet","condition_indication":"Treatment of cystic fibrosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/01/2023","compliance_outcome":"Positive","compliance_opinion_date":"20/01/2023","compliance_procedure_number":"EMEA-C-000335-PIP01-08-M15","contact_for_public_enquiries":"Vertex Pharmaceuticals (Europe) Limited; Tel. +1 8776348789; E-mail: medicalinfo@vrtx.com","first_published_date":"25/07/2017","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000335-pip01-08-m15"},{"decision_number":"P/0092/2021","pip_number":"EMEA-000431-PIP01-08-M12","active_substance":"vilanterol;fluticasone furoate","invented_name":"Relvar Ellipta; Relvar Ellipta and associated names","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Inhalation powder (pre-dispensed)","condition_indication":"Treatment of asthma","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/03/2021","compliance_outcome":"Positive","compliance_opinion_date":"20/01/2023","compliance_procedure_number":"EMEA-C-000431-PIP01-08-M12","contact_for_public_enquiries":"Glaxo Group Limited; E-mail: eu.paediatrics-plans@gsk.com; Tel. +1 4388998201","first_published_date":"25/07/2017","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000431-pip01-08-m12"},{"decision_number":"P/0135/2022","pip_number":"EMEA-001645-PIP01-14-M04","active_substance":"Bezlotoxumab","invented_name":"Zinplava; Zinplava","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Prevention of recurrence of Clostridioides difficile infection","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/04/2022","compliance_outcome":"Positive","compliance_opinion_date":"24/02/2023","compliance_procedure_number":"EMEA-C-001645-PIP01-14-M04","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"23/02/2015","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001645-pip01-14-m04"},{"decision_number":"P/0057/2023","pip_number":"EMEA-003189-PIP01-22-M01","active_substance":"Methylphenidate (hydrochloride)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Chewable tablet;Oral suspension","condition_indication":"Treatment of Attention Deficit Hyperactivity Disorder (ADHD)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"24/01/2023","compliance_outcome":"Positive","compliance_opinion_date":"02/02/2023","compliance_procedure_number":"EMEA-C-003189-PIP01-22-M01","contact_for_public_enquiries":"Laboratorios Lesvi, S.L.; E-Mail: info@lesvi.es; Tel. +34 936022404","first_published_date":"23/06/2023","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003189-pip01-22-m01"},{"decision_number":"P/0550/2021","pip_number":"EMEA-001169-PIP01-11-M05","active_substance":"alirocumab","invented_name":"Praluent; Praluent","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of elevated cholesterol","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/12/2021","compliance_outcome":"Positive","compliance_opinion_date":"24/02/2023","compliance_procedure_number":"EMEA-C-001169-PIP01-11-M05","contact_for_public_enquiries":"Sanofi-Aventis Recherche & Développement ; Tel. +33 169745695; E-mail: contact-us@sanofi.com","first_published_date":"06/01/2014","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001169-pip01-11-m05"},{"decision_number":"P/0351/2021","pip_number":"EMEA-002096-PIP01-16-M03","active_substance":"Entrectinib","invented_name":"Rozlytrek","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard;Coated granules","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)","routes_of_administration":"Oral use;Gastric use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2021","compliance_outcome":"Positive","compliance_opinion_date":"24/02/2023","compliance_procedure_number":"EMEA-C-002096-PIP01-16-M03","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"28/01/2019","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002096-pip01-16-m03"},{"decision_number":"P/0487/2021","pip_number":"EMEA-001971-PIP02-16-M04","active_substance":"Larotrectinib","invented_name":"Vitrakvi","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard;Oral solution","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)","routes_of_administration":"Gastric use;Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/12/2021","compliance_outcome":"Positive","compliance_opinion_date":"31/03/2023","compliance_procedure_number":"EMEA-C-001971-PIP02-16-M04","contact_for_public_enquiries":"Bayer AG; Tel. +49 3046815333; E-mail: pediatrics.medical-affairs-europe@bayer.com","first_published_date":"24/07/2017","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001971-pip02-16-m04"},{"decision_number":"P/0036/2021","pip_number":"EMEA-001493-PIP03-18-M01","active_substance":"crizotinib","invented_name":"Xalkori","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard;Age appropriate oral dosage formulation","condition_indication":"Treatment of anaplastic large cell lymphoma;Treatment of inflammatory myofibroblastic tumours","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/01/2021","compliance_outcome":"Positive","compliance_opinion_date":"31/03/2023","compliance_procedure_number":"EMEA-C-001493-PIP03-18-M01","contact_for_public_enquiries":"Pfizer Europe MA EEIG; Tel. +44 (0)1304 646 607; E-mail: pip_enquiries@pfizer.com","first_published_date":"30/03/2020","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001493-pip03-18-m01"},{"decision_number":"P/0382/2022","pip_number":"EMEA-002501-PIP01-18-M03","active_substance":"Efanesoctocog alfa","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of Haemophilia A","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/10/2022","compliance_outcome":"Positive","compliance_opinion_date":"26/04/2023","compliance_procedure_number":"EMEA-C-002501-PIP01-18-M03","contact_for_public_enquiries":"Swedish Orphan Biovitrum ABE-mail: medical.info@sobi.comTel. +46 8697 2000","first_published_date":"10/06/2020","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002501-pip01-18-m03"},{"decision_number":"P/0220/2021","pip_number":"EMEA-001835-PIP01-15-M05","active_substance":"Liquid ethanolic extract 30 per cent (w/w) of Allium cepa L. (fresh bulb) and Citrus limon (L.) Burm. f. (fresh fruit);paullinia cupana Kunth;Theobroma cacao L.","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Cutaneous solution","condition_indication":"Treatment of alopecia","routes_of_administration":"Cutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/06/2021","compliance_outcome":"Positive","compliance_opinion_date":"26/04/2023","compliance_procedure_number":"EMEA-C-001835-PIP01-15-M05","contact_for_public_enquiries":"Legacy Healthcare; E-mail: Pharma@legacyhealthcare.ch; Tel: +41 792943472","first_published_date":"18/07/2016","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001835-pip01-15-m05"},{"decision_number":"P/0052/2021","pip_number":"EMEA-001598-PIP01-13-M03","active_substance":"human fibrinogen;human thrombin","invented_name":"VeraSeal","therapeutic_area":"Other","pharmaceutical_forms":"Solution for sealant","condition_indication":"Treatment of haemorrhage resulting from a surgical procedure","routes_of_administration":"Epilesional use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/01/2021","compliance_outcome":"Positive","compliance_opinion_date":"26/04/2023","compliance_procedure_number":"EMEA-C-001598-PIP01-13-M03","contact_for_public_enquiries":"Instituto Grifols, S.A.E-mail: areatecnica.instituto@grifols.comTel. +34 935710700","first_published_date":"04/12/2014","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001598-pip01-13-m03"},{"decision_number":"P/0453/2021","pip_number":"EMEA-002934-PIP01-20","active_substance":"crisantaspase","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection;Solution for infusion","condition_indication":"Treatment of acute lymphoblastic leukaemia;Treatment of lymphoblastic lymphoma","routes_of_administration":"Intramuscular use;Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/10/2021","compliance_outcome":"Positive","compliance_opinion_date":"26/05/2023","compliance_procedure_number":"EMEA-C-002934-PIP01-20","contact_for_public_enquiries":"Jazz Pharmaceuticals Ireland Ltd. E-mail: corporateaffairsmediainfo@jazzpharma.com Tel: +1 35316347800","first_published_date":"22/03/2022","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002934-pip01-20"},{"decision_number":"P/0280/2022","pip_number":"EMEA-001119-PIP02-12-M08","active_substance":"lenvatinib","invented_name":"Lenvima; Kisplyx","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of follicular thyroid cancer;Treatment of osteosarcoma;Treatment of papillary thyroid cancer","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/08/2022","compliance_outcome":"Positive","compliance_opinion_date":"26/05/2023","compliance_procedure_number":"EMEA-C-001119-PIP02-12-M08","contact_for_public_enquiries":"Eisai Europe Ltd; E-mail: eumedinfo@eisai.net; Tel. +44 (0)8456 761400","first_published_date":"24/06/2013","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001119-pip02-12-m08"},{"decision_number":"P/0075/2023","pip_number":"EMEA-002435-PIP01-18-M03","active_substance":"Eladocagene exuparvovec","invented_name":"Upstaza","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of aromatic L-amino acid decarboxylase deficiency","routes_of_administration":"Intraputaminal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/03/2023","compliance_outcome":"Positive","compliance_opinion_date":"26/05/2023","compliance_procedure_number":"EMEA-C-002435-PIP01-18-M03","contact_for_public_enquiries":"PTC Therapeutics International Limited; Tel. +353 19068700; E-mail: medinfo@ptcbio.com","first_published_date":"23/03/2020","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002435-pip01-18-m03"},{"decision_number":"P/0189/2020","pip_number":"EMEA-000599-PIP01-09-M07","active_substance":"Influenza virus surface antigens - A/turkey/Turkey/1/05 (H5N1)","invented_name":"Aflunov","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of influenza","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/05/2020","compliance_outcome":"Positive","compliance_opinion_date":"26/05/2023","compliance_procedure_number":"EMEA-C-000599-PIP01-09-M07","contact_for_public_enquiries":"Seqirus S.r.l.; E-mail: pip.seq@seqirus.com; Tel.  +39 0577096405 / +39 0577096401","first_published_date":"13/07/2011","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000599-pip01-09-m07"},{"decision_number":"P/0049/2022","pip_number":"EMEA-002475-PIP02-19-M02","active_substance":"spesolimab","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution for infusion;Solution for injection","condition_indication":"Prevention of generalized pustular psoriasis;Treatment of generalized pustular psoriasis","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/02/2022","compliance_outcome":"Positive","compliance_opinion_date":"23/06/2023","compliance_procedure_number":"EMEA-C-002475-PIP02-19-M02","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"04/03/2021","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002475-pip02-19-m02"},{"decision_number":"P/0076/2023","pip_number":"EMEA-003330-PIP01-22","active_substance":"clascoterone","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Cream","condition_indication":"Treatment of acne vulgaris","routes_of_administration":"Topical use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/03/2023","compliance_outcome":"Positive","compliance_opinion_date":"23/06/2023","compliance_procedure_number":"EMEA-C-003330-PIP01-22","contact_for_public_enquiries":"E-mail: dermatology@cosmopharma.comTelephone: +39 0286891124","first_published_date":"29/02/2024","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003330-pip01-22"},{"decision_number":"P/0103/2023","pip_number":"EMEA-001734-PIP01-14-M06","active_substance":"defatted powder of Arachis hypogaea L., semen (peanuts)","invented_name":"Palforzia","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oral powder;Capsule, hard","condition_indication":"Treatment of peanut allergy","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"24/03/2023","compliance_outcome":"Positive","compliance_opinion_date":"23/06/2023","compliance_procedure_number":"EMEA-C-001734-PIP01-14-M06","contact_for_public_enquiries":"Aimmune Nestle Health Science US R&D LLCE-mail: USNHScPharmaregops@us.nestle.comPhone: +16508479108&nbsp","first_published_date":"19/11/2015","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001734-pip01-14-m06"},{"decision_number":"P/0165/2017","pip_number":"EMEA-001094-PIP01-10-M04","active_substance":"teriflunomide","invented_name":"Aubagio; Aubagio","therapeutic_area":"Neurology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of multiple sclerosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/07/2017","compliance_outcome":"Positive","compliance_opinion_date":"23/06/2023","compliance_procedure_number":"EMEA-C-001094-PIP01-10-M04","contact_for_public_enquiries":"Genzyme Europe B.V. / Sanofi-Aventis groupe; The Netherlands; Tel. +31 356991299; E-mail: eumedinfo@genzyme.com;  ","first_published_date":"26/07/2017","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001094-pip01-10-m04"},{"decision_number":"P/0170/2023","pip_number":"EMEA-000973-PIP01-10-M04","active_substance":"recombinant human N-acetylgalactosamine-6-sulfatase (elosulfase alfa)","invented_name":"Vimizim","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of mucopolysaccharidosis, type IVA (Morquio-A syndrome)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/05/2023","compliance_outcome":"Positive","compliance_opinion_date":"23/06/2023","compliance_procedure_number":"EMEA-C-000973-PIP01-10-M04","contact_for_public_enquiries":"BioMarin International Limited E-mail: girish.dhondge@bmrn.com Tel. +44 2071508590&nbsp","first_published_date":"12/05/2011","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000973-pip01-10-m04"},{"decision_number":"P/0507/2022","pip_number":"EMEA-000637-PIP02-10-M07","active_substance":"Lanthanum carbonate hydrate","invented_name":"Fosrenol and associated names","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Chewable tablet;Oral powder","condition_indication":"Treatment of hyperphosphataemia","routes_of_administration":"Oral use","decision_type":"RPM: decision refers to a refusal on the application for modification of an agreed PIP","decision_date":"02/12/2022","compliance_outcome":"Positive","compliance_opinion_date":"23/06/2023","compliance_procedure_number":"EMEA-C-000637-PIP02-10-M07","contact_for_public_enquiries":"Takeda Pharmaceuticals International AG Ireland Branch; E-mail: medinfoemea@takeda.com; Tel: +44 (0) 3333 000181","first_published_date":"27/10/2016","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000637-pip02-10-m07"},{"decision_number":"P/0101/2022","pip_number":"EMEA-000317-PIP01-08-M13","active_substance":"rilpivirine hydrochloride","invented_name":"Edurant","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Age appropriate solid oral formulation","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/08/2020","compliance_outcome":"Positive","compliance_opinion_date":"23/06/2023","compliance_procedure_number":"EMEA-C-000317-PIP01-08-M13","contact_for_public_enquiries":"Janssen-Cilag International NV; Tel. +32 1460 2111; E-mail: contact@janssen-emea.com","first_published_date":"17/10/2011","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000317-pip01-08-m13"},{"decision_number":"P/0541/2022","pip_number":"EMEA-001501-PIP04-19-M02","active_substance":"dupilumab","invented_name":"Dupixent","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of eosinophilic esophagitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/12/2022","compliance_outcome":"Positive","compliance_opinion_date":"21/07/2023","compliance_procedure_number":"EMEA-C-001501-PIP04-19-M02","contact_for_public_enquiries":"Regeneron Ireland DAC; Tel. +1 9148 475385; E-mail: clinicaltrials@regeneron.com","first_published_date":"09/06/2020","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001501-pip04-19-m02"},{"decision_number":"P/0479/2021","pip_number":"EMEA-001301-PIP02-12-M04","active_substance":"Isavuconazonium sulfate","invented_name":"Cresemba; Cresemba","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for solution for infusion;Capsule, hard","condition_indication":"Treatment of invasive aspergillosis;Treatment of mucormycosis","routes_of_administration":"Intravenous use;Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/12/2021","compliance_outcome":"Positive","compliance_opinion_date":"21/07/2023","compliance_procedure_number":"EMEA-C-001301-PIP02-12-M04","contact_for_public_enquiries":"Basilea Pharmaceutica International Ltd.; Tel. +41 616061400; E-mail: medical.information@basilea.com","first_published_date":"26/07/2017","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001301-pip02-12-m04"},{"decision_number":"P/0066/2022","pip_number":"EMEA-001082-PIP02-11-M03","active_substance":"Ex vivo expanded autologous human corneal epithelium cells containing stem cells","invented_name":"Holoclar","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Living tissue equivalent","condition_indication":"Treatment of limbal stem cell deficiency due to ocular burns","routes_of_administration":"Ophthalmic use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/03/2022","compliance_outcome":"Positive","compliance_opinion_date":"21/07/2023","compliance_procedure_number":"EMEA-C-001082-PIP02-11-M03","contact_for_public_enquiries":"Holostem Terapie Avanzate S.r.l.;  +39 3492403930; regulatory@holostem.com","first_published_date":"18/09/2012","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001082-pip02-11-m03"},{"decision_number":"P/0478/2022","pip_number":"EMEA-000200-PIP01-08-M10","active_substance":"saxagliptin","invented_name":"Onglyza; Onglyza","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"02/12/2022","compliance_outcome":"Positive","compliance_opinion_date":"21/07/2023","compliance_procedure_number":"EMEA-C-000200-PIP01-08-M10","contact_for_public_enquiries":"AstraZeneca ABEmail: paediatrics@astrazeneca.comTel. +46 855324400","first_published_date":"19/04/2010","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000200-pip01-08-m10"},{"decision_number":"P/0270/2022","pip_number":"EMEA-002399-PIP01-18-M01","active_substance":"bulevirtide","invented_name":"Hepcludex","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of chronic hepatitis D infection","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/08/2022","compliance_outcome":"Positive","compliance_opinion_date":"08/09/2023","compliance_procedure_number":"EMEA-C-002399-PIP01-18-M01","contact_for_public_enquiries":"Gilead Sciences International Ltd.; Tel. +44 (0)1223 897 300; E-mail: regulatory.pip@gilead.com","first_published_date":"20/11/2019","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002399-pip01-18-m01"},{"decision_number":"P/0038/2023","pip_number":"EMEA-001219-PIP01-11-M06","active_substance":"dolutegravir;abacavir;lamivudine","invented_name":"Triumeq; Triumeq","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Dispersible tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/01/2023","compliance_outcome":"Positive","compliance_opinion_date":"08/09/2023","compliance_procedure_number":"EMEA-C-001219-PIP01-11-M06","contact_for_public_enquiries":"ViiV Healthcare UK LimitedE-mail: eu.paediatric-plans@gsk.com Tel: +1 4388998201","first_published_date":"07/01/2012","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001219-pip01-11-m06"},{"decision_number":"P/0019/2022","pip_number":"EMEA-000322-PIP01-08-M06","active_substance":"cysteamine hydrochloride","invented_name":"Cystadrops; Cystadrops","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution","condition_indication":"Treatment of corneal cystine crystal deposits in cystinosis","routes_of_administration":"Ocular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/02/2022","compliance_outcome":"Positive","compliance_opinion_date":"08/09/2023","compliance_procedure_number":"EMEA-C-000322-PIP01-08-M06","contact_for_public_enquiries":"Recordati Rare Diseases SARL; fortun.m@recordati.com;  +33 147739373","first_published_date":"18/05/2009","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000322-pip01-08-m06"},{"decision_number":"P/0296/2021","pip_number":"EMEA-001784-PIP01-15-M04","active_substance":"nirsevimab","invented_name":"Beyfortus","therapeutic_area":"Vaccines","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of lower respiratory tract disease caused by respiratory syncytial virus","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/07/2022","compliance_outcome":"Positive","compliance_opinion_date":"13/10/2023","compliance_procedure_number":"EMEA-C-001784-PIP01-15-M04","contact_for_public_enquiries":"AstraZeneca AB; Tel. +46 855259283; E-mail: paediatrics@astrazeneca.com","first_published_date":"18/07/2016","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001784-pip01-15-m04"},{"decision_number":"P/0528/2022","pip_number":"EMEA-001119-PIP03-19-M03","active_substance":"lenvatinib","invented_name":"Kisplyx; Lenvima","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms except haematopoietic and lymphoid tissue neoplasms, papillary thyroid cancer, follicular thyroid cancer and osteosarcoma","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/12/2022","compliance_outcome":"Positive","compliance_opinion_date":"13/10/2023","compliance_procedure_number":"EMEA-C-001119-PIP03-19-M03","contact_for_public_enquiries":"Eisai GmbH; E-mail: EUMedInfo@eisai.net; Tel.  +44  8456761400","first_published_date":"04/03/2021","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001119-pip03-19-m03"},{"decision_number":"P/0087/2020","pip_number":"EMEA-001050-PIP01-10-M05","active_substance":"ixekizumab","invented_name":"Taltz","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of psoriasis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/03/2020","compliance_outcome":"Positive","compliance_opinion_date":"13/10/2023","compliance_procedure_number":"EMEA-C-001050-PIP01-10-M05","contact_for_public_enquiries":"Eli Lilly Nederland B.V.; E-mail: EU_paediatric@lilly.com; Tel.  +44 1276483000","first_published_date":"25/06/2012","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001050-pip01-10-m05"},{"decision_number":"P/0449/2023","pip_number":"EMEA-000574-PIP02-12-M04","active_substance":"blinatumomab","invented_name":"Blincyto","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of acute lymphoblastic leukaemia","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/10/2023","compliance_outcome":"Positive","compliance_opinion_date":"23/02/2024","compliance_procedure_number":"EMEA-C-000574-PIP02-12-M04","contact_for_public_enquiries":"Amgen Europe B.V. ; E-mail: medinfointernational@amgen.com; Tel. +44 (0)1223 420305","first_published_date":"18/07/2014","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000574-pip02-12-m04"},{"decision_number":"P/0527/2021","pip_number":"EMEA-000901-PIP04-17-M02","active_substance":"ruxolitinib (phosphate)","invented_name":"Jakavi","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of chronic Graft versus Host Disease (cGvHD)","routes_of_administration":"Oral use;Gastric use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/12/2021","compliance_outcome":"Positive","compliance_opinion_date":"13/10/2023","compliance_procedure_number":"EMEA-C-000901-PIP04-17-M02","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"19/06/2018","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000901-pip04-17-m02"},{"decision_number":"P/0172/2021","pip_number":"EMEA-000901-PIP03-16-M02","active_substance":"ruxolitinib (phosphate)","invented_name":"Jakavi","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet;Age appropriate dosage form","condition_indication":"Treatment of acute graft-versus-host disease (aGvHD)","routes_of_administration":"Oral use;Gastric use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/04/2021","compliance_outcome":"Positive","compliance_opinion_date":"13/10/2023","compliance_procedure_number":"EMEA-C-000901-PIP03-16-M02","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"05/03/2018","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000901-pip03-16-m02"},{"decision_number":"P/0196/2023","pip_number":"EMEA-000115-PIP01-07-M13","active_substance":"ataluren","invented_name":"Translarna","therapeutic_area":"Neurology","pharmaceutical_forms":"Granules for oral suspension","condition_indication":"Treatment of dystrophinopathy","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/05/2023","compliance_outcome":"Positive","compliance_opinion_date":"13/10/2023","compliance_procedure_number":"EMEA-C-000115-PIP01-07-M13","contact_for_public_enquiries":"PTC Therapeutics International Limited; Tel. +353 19068700; E-mail: medinfo@ptcbio.com","first_published_date":"26/08/2010","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000115-pip01-07-m13"},{"decision_number":"P/0551/2022","pip_number":"EMEA-001313-PIP01-12-M13","active_substance":"ceftazidime;avibactam","invented_name":"Zavicefta; Zavicefta","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of infections due to aerobic Gram-negative bacteria;Treatment of intra-abdominal infections;Treatment of pneumonia;Treatment of urinary tract infections","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/01/2023","compliance_outcome":"Positive","compliance_opinion_date":"10/11/2023","compliance_procedure_number":"EMEA-C-001313-PIP01-12-M13","contact_for_public_enquiries":"Pfizer Europe MA EEIG; Tel. +44 (0)1304 646 607; E-mail: pip_enquiries@pfizer.com","first_published_date":"31/05/2013","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001313-pip01-12-m13"},{"decision_number":"P/0562/2021","pip_number":"EMEA-001662-PIP01-14-M05","active_substance":"palovarotene","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of fibrodysplasia ossificans progressiva","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/12/2021","compliance_outcome":"Positive","compliance_opinion_date":"10/11/2023","compliance_procedure_number":"EMEA-C-001662-PIP01-14-M05","contact_for_public_enquiries":"Ipsen Pharma; E-mail: abdelali.majdi@ipsen.com; Tel.: +33 158335427","first_published_date":"06/07/2015","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001662-pip01-14-m05"},{"decision_number":"P/0469/2020","pip_number":"EMEA-000715-PIP03-11-M06","active_substance":"apremilast","invented_name":"Otezla; Otezla","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Tablet;Oral liquid","condition_indication":"Treatment of psoriasis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2020","compliance_outcome":"Positive","compliance_opinion_date":"10/11/2023","compliance_procedure_number":"EMEA-C-000715-PIP03-11-M06","contact_for_public_enquiries":"Amgen Europe B.V. ; E-mail: medinfointernational@amgen.com; Tel. +44 (0)1223 420305","first_published_date":"25/07/2017","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000715-pip03-11-m06"},{"decision_number":"P/0440/2022","pip_number":"EMEA-000461-PIP02-11-M05","active_substance":"Eliglustat (tartrate)","invented_name":"Cerdelga","therapeutic_area":"Other","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of Gaucher disease Type 1 and Type 3;Treatment of Gaucher disease, type 2","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"28/10/2022","compliance_outcome":"Positive","compliance_opinion_date":"10/11/2023","compliance_procedure_number":"EMEA-C-000461-PIP02-11-M05","contact_for_public_enquiries":"Sanofi B.V.E-mail: eumedinfo.GZ@sanofi.com Tel. +31 2024 54000&nbsp","first_published_date":"26/03/2012","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000461-pip02-11-m05"},{"decision_number":"P/0488/2023","pip_number":"EMEA-001475-PIP03-17-M04","active_substance":"Maralixibat chloride","invented_name":"Livmarli","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of Progressive Familial Intrahepatic Cholestasis","routes_of_administration":"Oral use;Tablet","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/12/2023","compliance_outcome":"Positive","compliance_opinion_date":"26/04/2024","compliance_procedure_number":"EMEA-C-001475-PIP03-17-M04","contact_for_public_enquiries":"Mirum PharmaceuticalsE-mail: medinfo@mirumpharma.com Tel.  +1 6506674085","first_published_date":"18/04/2018","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001475-pip03-17-m04"},{"decision_number":"P/0007/2022","pip_number":"EMEA-002932-PIP02-21","active_substance":"vorasidenib hemicitrate hemihydrate","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of low grade glioma","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2022","compliance_outcome":"Positive","compliance_opinion_date":"15/12/2023","compliance_procedure_number":"EMEA-C-002932-PIP02-21","contact_for_public_enquiries":"Les Laboratoires ServierE-mail: mail.pip.enquiries@servier.comTel.: +33 155726000","first_published_date":"05/04/2023","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002932-pip02-21"},{"decision_number":"P/0439/2023","pip_number":"EMEA-002826-PIP01-20-M04","active_substance":"remdesivir","invented_name":"Veklury","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/10/2023","compliance_outcome":"Positive","compliance_opinion_date":"15/12/2023","compliance_procedure_number":"EMEA-C-002826-PIP01-20-M04","contact_for_public_enquiries":"Gilead Sciences International Ltd; E-mail: regulatory.pip@gilead.com; Tel. +44 (0)1223 897300","first_published_date":"08/06/2020","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002826-pip01-20-m04"},{"decision_number":"P/0144/2023","pip_number":"EMEA-002205-PIP01-17-M04","active_substance":"Isatuximab","invented_name":"Sarclisa","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"21/04/2023","compliance_outcome":"Positive","compliance_opinion_date":"15/12/2023","compliance_procedure_number":"EMEA-C-002205-PIP01-17-M04","contact_for_public_enquiries":"Sanofi-Aventis Recherche & Développement ; Tel. +33 169745695; E-mail: contact-us@sanofi.com","first_published_date":"07/11/2019","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002205-pip01-17-m04"},{"decision_number":"P/0297/2022","pip_number":"EMEA-001258-PIP01-11-M08","active_substance":"Dermatophagoides pteronyssinus;Dermatophagoides farinae","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oral lyophilisate","condition_indication":"Treatment of allergic rhinitis;Treatment of asthma","routes_of_administration":"Sublingual use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/04/2021","compliance_outcome":"Positive","compliance_opinion_date":"15/12/2023","compliance_procedure_number":"EMEA-C-001258-PIP01-11-M08","contact_for_public_enquiries":"ALK Abelló A/S; Tel. +45 4574 7576; E-mail: alkmrp@alk.net","first_published_date":"27/11/2012","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001258-pip01-11-m08"},{"decision_number":"P/0336/2023","pip_number":"EMEA-000727-PIP01-09-M07","active_substance":"Bosutinib","invented_name":"Bosulif; Bosulif","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard;Film-coated tablet","condition_indication":"Treatment of chronic myeloid leukaemia (CML)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/08/2023","compliance_outcome":"Positive","compliance_opinion_date":"15/12/2023","compliance_procedure_number":"EMEA-C-000727-PIP01-09-M07","contact_for_public_enquiries":"Pfizer Europe MA EEIG; Tel. +44 (0)1304 646 607; E-mail: pip_enquiries@pfizer.com","first_published_date":"29/10/2010","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000727-pip01-09-m07"},{"decision_number":"P/0395/2022","pip_number":"EMEA-000520-PIP02-13-M04","active_substance":"belimumab","invented_name":"Benlysta","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Systemic Lupus Erythematosus (SLE)","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/09/2022","compliance_outcome":"Positive","compliance_opinion_date":"15/12/2023","compliance_procedure_number":"EMEA-C-000520-PIP02-13-M04","contact_for_public_enquiries":"Glaxo Group Limited; E-mail: eu.paediatrics-plans@gsk.com; Tel. +1 4388998201","first_published_date":"04/12/2014","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000520-pip02-13-m04"},{"decision_number":"P/0358/2023","pip_number":"EMEA-002326-PIP04-20-M01","active_substance":"concizumab","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for injection in pre-filled pen","condition_indication":"Treatment of congenital haemophilia A;Treatment of congenital haemophilia B","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; E-mail: paediatrics@novonordisk.com; Tel: +45 44448888;  ","first_published_date":"10/01/2023","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002326-pip04-20-m01"},{"decision_number":"P/0392/2023","pip_number":"EMEA-002324-PIP01-17-M05","active_substance":"elexacaftor;tezacaftor;ivacaftor","invented_name":"Kaftrio; Kaftrio","therapeutic_area":"Other","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of cystic fibrosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"28/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vertex Pharmaceuticals (Ireland) Limited; E-mail: vertexmedicalinfo@vrtx.com; Tel:  +353 (0)17617299","first_published_date":"24/06/2019","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002324-pip01-17-m05"},{"decision_number":"P/0357/2023","pip_number":"EMEA-002310-PIP01-17-M01","active_substance":"Danicopan","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of paroxysmal nocturnal haemoglobinuria","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alexion Europe SAS; E-mail: pip.enquiries.eu@alexion.com; Tel: +33 147100615","first_published_date":"22/07/2021","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002310-pip01-17-m01"},{"decision_number":"P/0353/2023","pip_number":"EMEA-002077-PIP01-16-M06","active_substance":"ravulizumab","invented_name":"Ultomiris","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Concentrate for solution for infusion;Solution for injection","condition_indication":"Treatment of paroxysmal nocturnal haemoglobinuria","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alexion Europe SAS; E-mail: pip.enquiries.eu@alexion.com; Tel: +33 147100615","first_published_date":"05/03/2018","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002077-pip01-16-m06"},{"decision_number":"P/0352/2023","pip_number":"EMEA-002023-PIP01-16-M07","active_substance":"avacopan","invented_name":"Tavneos","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Capsule, hard;Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V. ; E-mail: medinfointernational@amgen.com; Tel. +44 (0)1223 420305","first_published_date":"03/07/2017","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002023-pip01-16-m07"},{"decision_number":"P/0379/2023","pip_number":"EMEA-001943-PIP01-16-M08","active_substance":"ravulizumab","invented_name":"Ultomiris","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Concentrate for solution for infusion;Solution for injection","condition_indication":"Treatment of atypical haemolytic uremic syndrome","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alexion Europe SAS; E-mail: pip.enquiries.eu@alexion.com; Tel: +33 147100615","first_published_date":"17/03/2017","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001943-pip01-16-m08"},{"decision_number":"P/0378/2023","pip_number":"EMEA-001877-PIP01-15-M04","active_substance":"fremanezumab","invented_name":"Ajovy","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of migraine headaches","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Teva GmbHE-mail: MedInfo@tevaeu.comTel: +44 (0)2075407117","first_published_date":"06/01/2017","last_updated_date":"19/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001877-pip01-15-m04"},{"decision_number":"P/0372/2023","pip_number":"EMEA-002883-PIP02-22","active_substance":"trimodulin","invented_name":"","therapeutic_area":"Infectious diseases;Neonatology-Paediatric Intensive Care","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biotest AG; Tel. + 49 6103 801497E-mail: clinical.trials@biotest.com","first_published_date":"19/09/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002883-pip02-22"},{"decision_number":"P/0367/2023","pip_number":"EMEA-002342-PIP05-23","active_substance":"abemaciclib","invented_name":"Verzenios","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of prostate cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly and Company Limited; E-mail: EU_PAEDIATRIC@LILLY.COM; Tel.   +44 1344382427","first_published_date":"19/09/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002342-pip05-23"},{"decision_number":"P/0385/2023","pip_number":"EMEA-002299-PIP02-23","active_substance":"Enfortumab vedotin","invented_name":"Padcev","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of head and neck epithelial malignant neoplasms","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Astellas Pharma Europe B.V.E-mail: regulatory.eu@astellas.comTel: +31 715454006","first_published_date":"19/09/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002299-pip02-23"},{"decision_number":"P/0381/2023","pip_number":"EMEA-001973-PIP02-23","active_substance":"teprotumumab","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Powder for concentrate for solution for infusion;Solution for injection","condition_indication":"Treatment of thyroid eye disease","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V. ; E-mail: medinfointernational@amgen.com; Tel. +44 (0)1223 420305","first_published_date":"19/09/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001973-pip02-23"},{"decision_number":"P/0383/2023","pip_number":"EMEA-001741-PIP07-22","active_substance":"upadacitinib","invented_name":"Rinvoq","therapeutic_area":"Dermatology","pharmaceutical_forms":"Age appropriate oral dosage formulation;Prolonged-release tablet","condition_indication":"Treatment of vitiligo","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"07/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"19/09/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001741-pip07-22"},{"decision_number":"P/0388/2023","pip_number":"EMEA-001943-PIP06-23","active_substance":"ravulizumab","invented_name":"Ultomiris","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Prevention of kidney injury in high-risk patients with chronic kidney disease undergoing cardiopulmonary bypass","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alexion Europe SAS; E-mail: pip.enquiries.eu@alexion.com; Tel: +33 147100615","first_published_date":"19/09/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001943-pip06-23"},{"decision_number":"P/0351/2023","pip_number":"EMEA-001588-PIP04-23","active_substance":"Encorafenib","invented_name":"Braftovi","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pierre Fabre Médicament; E-mail: medical_information@pierre-fabre.com; Tel. +33 800326326","first_published_date":"19/09/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001588-pip04-23"},{"decision_number":"P/0349/2023","pip_number":"EMEA-001454-PIP06-23","active_substance":"binimetinib","invented_name":"Mektovi","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pierre Fabre Médicament; E-mail: medical_information@pierre-fabre.com; Tel. +33 800326326","first_published_date":"19/09/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001454-pip06-23"},{"decision_number":"P/0350/2023","pip_number":"EMEA-001573-PIP03-23","active_substance":"pemafibrate","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of primary biliary cholangitis","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kowa Pharmaceuticals Europe AG; Email: paediatrics@kowapharma.ch; Tel. +41 (0)442055989","first_published_date":"19/09/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001573-pip03-23"},{"decision_number":"P/0345/2023","pip_number":"EMEA-001207-PIP05-22","active_substance":"obinutuzumab","invented_name":"Gazyvaro","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of glomerulonephritis and nephrotic syndrome","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"19/09/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001207-pip05-22"},{"decision_number":"P/0513/2023","pip_number":"EMEA-001911-PIP01-15-M05","active_substance":"inebilizumab","invented_name":"Uplizna","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for infusion;Concentrate for solution for infusion","condition_indication":"Treatment of neuromyelitis optica spectrum disorders","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Horizon Therapeutics Ireland DAC  E-mail: medinfointernational@amgen.com Tel.  +44 (0)1223420305","first_published_date":"30/01/2017","last_updated_date":"16/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001911-pip01-15-m05"},{"decision_number":"P/0315/2023","pip_number":"EMEA-003316-PIP01-22","active_substance":"Furosemide","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Age appropriate oral dosage formulation","condition_indication":"Treatment of fluid retention","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Proveca Pharma Limited; Tel. +353 15136233; E-mail: info@proveca.com","first_published_date":"13/09/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003316-pip01-22"},{"decision_number":"P/0327/2023","pip_number":"EMEA-003346-PIP01-22","active_substance":"single-stranded 5' capped mRNA encoding the HAs of the influenza virus strains A and B (mRNA-1010)","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Dispersion for injection","condition_indication":"Prevention of influenza","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Moderna Biotech Spain, S.L.E-mail: EMEAMedInfo@modernatx.comTel.  +34 900031015","first_published_date":"13/09/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003346-pip01-22"},{"decision_number":"P/0317/2023","pip_number":"EMEA-003415-PIP01-23","active_substance":"sotuletinib","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of amyotrophic lateral sclerosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"13/09/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003415-pip01-23"},{"decision_number":"P/0328/2023","pip_number":"EMEA-003418-PIP01-23","active_substance":"tiragolumab;atezolizumab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung carcinoma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"13/09/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003418-pip01-23"},{"decision_number":"P/0293/2023","pip_number":"EMEA-003423-PIP01-23","active_substance":"volrustomig","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for injection/infusion","condition_indication":"Treatment of cervical cancer;Treatment of lung cancer;Treatment of mesothelioma;Treatment of renal cell carcinoma (RCC)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel. +46 8553 27591","first_published_date":"13/09/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003423-pip01-23"},{"decision_number":"P/318/2023","pip_number":"EMEA-003427-PIP01-23","active_substance":"zimberelimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Limited; Tel. +44 (0)1223 897300; E-mail: regulatory.pip@gilead.com","first_published_date":"13/09/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003427-pip01-23"},{"decision_number":"P/0319/2023","pip_number":"EMEA-003427-PIP02-23","active_substance":"zimberelimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of gastric and gastroesophageal junction adenocarcinoma;Treatment of oesophageal carcinoma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Limited; Tel. +44 (0)1223 897300; E-mail: regulatory.pip@gilead.com","first_published_date":"13/09/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003427-pip02-23"},{"decision_number":"P/0329/2023","pip_number":"EMEA-003429-PIP01-23","active_substance":"domvanalimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Limited; Tel. +44 (0)1223 897300; E-mail: regulatory.pip@gilead.com","first_published_date":"13/09/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003429-pip01-23"},{"decision_number":"P/0330/2023","pip_number":"EMEA-003429-PIP02-23","active_substance":"domvanalimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of gastric and gastroesophageal junction adenocarcinoma;Treatment of oesophageal carcinoma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Limited; Tel. +44 (0)1223 897300; E-mail: regulatory.pip@gilead.com","first_published_date":"13/09/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003429-pip02-23"},{"decision_number":"P/0332/2023","pip_number":"EMEA-003431-PIP01-23","active_substance":"clotrimazole","invented_name":"","therapeutic_area":"Oto-rhino-laryngology","pharmaceutical_forms":"Ear drops, solution","condition_indication":"Treatment of acute otitis externa","routes_of_administration":"Auricular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Laboratorios Salvat, S.A.E-mail: regulatory@svt.com Tel. +34 933946400","first_published_date":"13/09/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003431-pip01-23"},{"decision_number":"P/0326/2023","pip_number":"EMEA-002773-PIP01-20-M01","active_substance":"(S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran 3 yl) pyrimidine-5-carboxamide (PF-06865571)","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of non-alcoholic steatohepatitis (NASH)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG  E-mail: medical.information@pfizer.com Tel: +44 (0)1304 616161","first_published_date":"19/11/2021","last_updated_date":"13/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002773-pip01-20-m01"},{"decision_number":"P/0331/2023","pip_number":"EMEA-002699-PIP01-19-M01","active_substance":"bilayer engineered collagen hydrogel-based skin graft composed of autologous keratinocytes and fibroblasts","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Living tissue equivalent","condition_indication":"Treatment of burns","routes_of_administration":"Implant use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CUTISS AGTel. + 41 442443660E-mail: info@cutiss.swiss&nbsp","first_published_date":"06/07/2021","last_updated_date":"13/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002699-pip01-19-m01"},{"decision_number":"P/0325/2023","pip_number":"EMEA-002677-PIP01-19-M03","active_substance":"delandistrogene moxeparvovec","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of Duchenne muscular dystrophy","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"22/07/2021","last_updated_date":"13/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002677-pip01-19-m03"},{"decision_number":"P/0335/2023","pip_number":"EMEA-002635-PIP02-21-M02","active_substance":"repotrectinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Age appropriate oral liquid dosage formulation;Capsule, hard","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic neoplasms)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"07/03/2023","last_updated_date":"13/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002635-pip02-21-m02"},{"decision_number":"P/0322/2023","pip_number":"EMEA-002214-PIP01-17-M02","active_substance":"Inclisiran sodium","invented_name":"Leqvio","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of elevated cholesterol","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"17/01/2019","last_updated_date":"13/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002214-pip01-17-m02"},{"decision_number":"P/0302/2023","pip_number":"EMEA-002029-PIP01-16-M04","active_substance":"tremelimumab","invented_name":"Imjudo; Tremelimumab AstraZeneca","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except central nervous system, haematopoietic and lymphoid tissue);Treatment of malignant neoplasms of lymphoid tissue","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel. +46 8553 27591","first_published_date":"19/06/2018","last_updated_date":"13/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002029-pip01-16-m04"},{"decision_number":"P/0301/2023","pip_number":"EMEA-002028-PIP01-16-M04","active_substance":"durvalumab","invented_name":"Imfinzi","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except central nervous system, haematopoietic and lymphoid tissue);Treatment of malignant neoplasms of lymphoid tissue","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel. +46 8553 27591","first_published_date":"19/06/2018","last_updated_date":"13/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002028-pip01-16-m04"},{"decision_number":"P/0299/2023","pip_number":"EMEA-001664-PIP02-15-M06","active_substance":"erenumab","invented_name":"Aimovig","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of migraine headaches","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/08/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"17/03/2017","last_updated_date":"13/09/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001664-pip02-15-m06"},{"decision_number":"P/0455/2023","pip_number":"EMEA-001631-PIP01-14-M05","active_substance":"Letermovir","invented_name":"Prevymis","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Granules;Concentrate for solution for infusion","condition_indication":"Prevention of cytomegalovirus infection","routes_of_administration":"Oral use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/11/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"25/08/2015","last_updated_date":"25/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001631-pip01-14-m05"},{"decision_number":"P/0101/2024","pip_number":"EMEA-000737-PIP02-11-M03","active_substance":"afamelanotide","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Implant;Age appropriate prolonged release formulation","condition_indication":"Treatment of erythropoietic protoporphyria","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"mail@clinuvel.com; tel: +61 396604900","first_published_date":"19/01/2012","last_updated_date":"25/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000737-pip02-11-m03"},{"decision_number":"P/0129/2023","pip_number":"EMEA-003369-PIP01-22","active_substance":"utreloxastat","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of amyotrophic lateral sclerosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"PTC Therapeutics International Limited; Tel. +353 19068700; E-mail: medinfo@ptcbio.com","first_published_date":"22/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003369-pip01-22"},{"decision_number":"P/0140/2023","pip_number":"EMEA-003366-PIP01-22","active_substance":"ciclosporin","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution","condition_indication":"Treatment of dry eye disease","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novaliq GmbHE-mail: Info@novaliq.com Tel.:  +49 6221502590","first_published_date":"22/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003366-pip01-22"},{"decision_number":"P/0138/2023","pip_number":"EMEA-003358-PIP01-22","active_substance":"","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of breast malignant neoplasms","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG; Tel. +44 (0)1304 646 607; E-mail: pip_enquiries@pfizer.com","first_published_date":"22/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003358-pip01-22"},{"decision_number":"P/0137/2023","pip_number":"EMEA-003353-PIP01-22","active_substance":"Lutetium 177-labelled radiohybrid prostate-specific membrane antigen-10.1 ((177Lu) rhPSMA-10.1)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of prostate cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Blue Earth Therapeutics LtdE-mail: contact@blueearthTx.com Tel.:  +44 (0)1865634500","first_published_date":"22/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003353-pip01-22"},{"decision_number":"P/0108/2023","pip_number":"EMEA-003352-PIP01-22","active_substance":"Efzofitimod","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of pulmonary sarcoidosis","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"FGK Representative Service GmbHE-mail: info@atyrpharma.com Tel.:  011 9085244843","first_published_date":"22/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003352-pip01-22"},{"decision_number":"P/0122/2023","pip_number":"EMEA-003351-PIP01-22","active_substance":"acoltremon","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution","condition_indication":"Treatment of dry eye disease","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aerie Pharmaceuticals Ireland Ltd; Tel. +1 9495268700; E-mail: info@aeriepharma.com","first_published_date":"22/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003351-pip01-22"},{"decision_number":"P/0127/2023","pip_number":"EMEA-003344-PIP02-22","active_substance":"sodium ({(2S)-1,4-bis[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[2.2.2]octan-2-yl}oxy)methyl hydrogen phosphate-2-amino-2-(hydroxymethyl)propane-1,3-diol (1/1/1)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Granules","condition_indication":"Treatment of amyotrophic lateral sclerosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628925033","first_published_date":"22/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003344-pip02-22"},{"decision_number":"P/0120/2023","pip_number":"EMEA-003323-PIP01-22","active_substance":"tadalafil;Finasteride","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of benign prostatic hyperplasia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dr. Pfleger Arzneimittel GmbHE-mail: regaffairs@dr-pfleger.de Tel.:  +49 (0)9516043291","first_published_date":"22/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003323-pip01-22"},{"decision_number":"P/0148/2023","pip_number":"EMEA-001588-PIP01-13-M03","active_substance":"Encorafenib","invented_name":"Braftovi","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of melanoma","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"21/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pierre Fabre Médicament; Tel. +33 800326326; E-mail: medical_information@pierre-fabre.com","first_published_date":"22/04/2016","last_updated_date":"22/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001588-pip01-13-m03"},{"decision_number":"P/0147/2023","pip_number":"EMEA-001454-PIP03-15-M03","active_substance":"binimetinib","invented_name":"Mektovi","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of melanoma","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"21/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pierre Fabre Médicament; Tel. +33 800326326; E-mail: medical_information@pierre-fabre.com","first_published_date":"25/04/2016","last_updated_date":"22/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001454-pip03-15-m03"},{"decision_number":"P/0149/2023","pip_number":"EMEA-001435-PIP02-16-M02","active_substance":"anifrolumab","invented_name":"Saphnelo","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection;Concentrate for solution for infusion","condition_indication":"Treatment of Systemic Lupus Erythematosus (SLE)","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"21/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca ABEmail: paediatrics@astrazeneca.comTel. +46 855324400","first_published_date":"19/06/2018","last_updated_date":"22/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001435-pip02-16-m02"},{"decision_number":"P/0130/2023","pip_number":"EMEA-003257-PIP01-22","active_substance":"zilovertamab vedotin","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue);Treatment of malignant neoplasms of haematopoietic and lymphoid tissue","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"19/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003257-pip01-22"},{"decision_number":"P/0141/2023","pip_number":"EMEA-002747-PIP01-20-M01","active_substance":"zilucoplan","invented_name":"","therapeutic_area":"Neurology;Other","pharmaceutical_forms":"Solution for injection in pre-filled syringe;Age appropriate dosage form for parenteral use","condition_indication":"Treatment of myasthenia gravis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"UCB Pharma S.A.; Tel. + 353 14632371; E-mail: ucbcares.ie@ucb.com","first_published_date":"14/01/2022","last_updated_date":"19/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002747-pip01-20-m01"},{"decision_number":"002634-PIP01-19","pip_number":"EMEA-002634-PIP01-19-M02","active_substance":"temozolomide","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for oral suspension","condition_indication":"Treatment of malignant glioma","routes_of_administration":"Gastric use;Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Accord Healthcare S.L.U.; E-mail: regulatory_EU@accord-healthcare.com; Tel. +34 933010064","first_published_date":"05/03/2021","last_updated_date":"19/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002634-pip01-19-m02"},{"decision_number":"P/0133/2023","pip_number":"EMEA-002544-PIP01-18-M02","active_substance":"selpercatinib","invented_name":"Retsevmo","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard;Age appropriate dosage form","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"27/03/2020","last_updated_date":"19/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002544-pip01-18-m02"},{"decision_number":"P/0145/2023","pip_number":"EMEA-001984-PIP02-20-M01","active_substance":"sparsentan","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Tablet;Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of focal segmental glomerulosclerosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"21/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vifor (International) AG; Email: sparsentan_ra@viforpharma.com; Tel: +41588518000","first_published_date":"16/06/2021","last_updated_date":"19/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001984-pip02-20-m01"},{"decision_number":"P/0128/2023","pip_number":"EMEA-001943-PIP02-20-M02","active_substance":"ravulizumab","invented_name":"Ultomiris","therapeutic_area":"Haematology-Hemostaseology;Uro-nephrology","pharmaceutical_forms":"Concentrate for solution for infusion;Solution for injection","condition_indication":"Treatment in haematopoietic stem cell transplantation","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alexion Europe SAS; E-mail: pip.enquiries.eu@alexion.com; Tel: +33 147100615","first_published_date":"10/01/2023","last_updated_date":"19/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001943-pip02-20-m02"},{"decision_number":"P/0110/2023","pip_number":"EMEA-001880-PIP02-19-M04","active_substance":"remimazolam besilate","invented_name":"Byfavo","therapeutic_area":"Anaesthesiology","pharmaceutical_forms":"Powder for solution for injection or infusion;Orodispersible film;Age appropriate formulation","condition_indication":"General anaesthesia;Sedation","routes_of_administration":"Intravenous use;Buccal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"PAION Deutschland GmbH; E-mail: info@paion.com; Tel: +49 2414453128","first_published_date":"27/03/2020","last_updated_date":"19/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001880-pip02-19-m04"},{"decision_number":"P/0273/2023","pip_number":"EMEA-003413-PIP01-23","active_substance":"povidone;iodine","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Nasal spray (solution)","condition_indication":"Treatment of acute nasopharyngitis (common cold)","routes_of_administration":"Nasal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ESPL Regulatory Consulting LimitedE-mail: smt@espl-regulatory.com Tel.:  +44 1806242851","first_published_date":"16/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003413-pip01-23"},{"decision_number":"P/0244/2023","pip_number":"EMEA-003412-PIP01-23","active_substance":"amlodipine besilate;rivaroxaban","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of thromboembolic events;Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Teva B.V. Email: MedAffGenTevaEurope@tevapharm.com Tel. +385 13722001","first_published_date":"16/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003412-pip01-23"},{"decision_number":"P/0266/2023","pip_number":"EMEA-003410-PIP01-23","active_substance":"acetylsalicylic acid;rosuvastatin calcium","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Prevention of cardiovascular events","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Swyssi AGE-mail: info@swyssi.com Tel: +49 6966554162","first_published_date":"16/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003410-pip01-23"},{"decision_number":"P/0260/2023","pip_number":"EMEA-003406-PIP01-23","active_substance":"opicapone","invented_name":"Ongentys; Ontilyv","therapeutic_area":"Neurology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of Parkinson's disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BIAL - Portela & Ca, SA; E-mail: info@bial.com; Tel. +351 229866100","first_published_date":"16/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003406-pip01-23"},{"decision_number":"P/0256/2023","pip_number":"EMEA-003403-PIP01-23","active_substance":"therapeutic DNA plasmid vaccine targeting HPV16 E6 and E7 proteins (VB10.16)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of human papilloma virus (HPV) type 16 positive malignancies","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Nykode Therapeutics ASAE-mail: info@nykode.com Tel.:  +47 22958193","first_published_date":"16/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003403-pip01-23"},{"decision_number":"P/0271/2023","pip_number":"EMEA-003367-PIP01-22","active_substance":"nizaracianine triflutate","invented_name":"","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Curadel Surgical Innovations, Inc.E-mail: regulatory@curadel.com Tel.:  +1 5083052355","first_published_date":"16/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003367-pip01-22"},{"decision_number":"P/0265/2023","pip_number":"EMEA-003324-PIP01-22","active_substance":"bictegravir;lenacapavir","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of human immunodeficiency virus type 1 (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Limited; Tel. +44 (0)1223 897300; E-mail: regulatory.pip@gilead.com","first_published_date":"16/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003324-pip01-22"},{"decision_number":"P/0261/2023","pip_number":"EMEA-003409-PIP01-23","active_substance":"Benzo[b]thiophene-3-carbonitrile, 2-amino-4-[(4aS)-8-chloro-10-fluoro-2,3,4,4a,5,6-hexahydro-12-oxo-3-(1-oxo-2-propen-1-yl)-1H,12H-pyrazino[2,1-d][1,5]benzoxazocin-9-yl]-7-fluoro-, (4R)- (LY3537982)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoetic, and lymphoid tissue neoplasms);Treatment of malignant neoplasms of the central nervous system","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"16/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003409-pip01-23"},{"decision_number":"P/0268/2023","pip_number":"EMEA-003325-PIP01-22","active_substance":"izokibep","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis,  psoriatic arthritis, and juvenile idiopathic arthritis)","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Acelyrin Inc.E-mail: info@acelyrin.com Tel.:  +1 8054564393","first_published_date":"16/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003325-pip01-22"},{"decision_number":"P/0262/2023","pip_number":"EMEA-003422-PIP01-23","active_substance":"fuzuloparib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of prostate cancer","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Luzsana Biotechnology EuropeE-mail: regulatoryeu@luzsana.com Tel.:  +41 792406071","first_published_date":"16/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003422-pip01-23"},{"decision_number":"P/0255/2023","pip_number":"EMEA-003318-PIP01-22","active_substance":"modRNA encoding 4 influenza HA antigens (2 for influenza A and 2 for influenza B strains) (qIRV)","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Concentrate for solution for injection","condition_indication":"Prevention of influenza","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europa MA EEIG; Email: PIP_Enquiries@pfizer.com; Tel. +44 1304646607","first_published_date":"16/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003318-pip01-22"},{"decision_number":"P/0283/2023","pip_number":"EMEA-003314-PIP01-22","active_substance":"Influenza recombinant H7 haemagglutinin","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of influenza infection","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi PasteurE-mail: contact-us@sanofi.comTel. +33 1 6974 5695","first_published_date":"16/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003314-pip01-22"},{"decision_number":"P/0280/2023","pip_number":"EMEA-003276-PIP01-22","active_substance":"±3,4-methylenedioxymethamphetamine hydrochloride (MDMA)","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of post-traumatic stress disorder","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"MAPS Europe B.V.E-mail: legalrep@mapseurope.eu Tel.:  425 9220389","first_published_date":"16/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003276-pip01-22"},{"decision_number":"P/0245/2023","pip_number":"EMEA-003267-PIP02-23","active_substance":"Influenza virus Type A H3N2, whole virion, inactivated;Influenza virus Type B, whole virion, inactivated;Influenza virus Type A H1N1, whole virion, inactivated","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of influenza","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Fluart Innovative Vaccines KftE-mail: info@fluart.hu Tel.: +36 204197020","first_published_date":"16/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003267-pip02-23"},{"decision_number":"P/0269/2023","pip_number":"EMEA-003263-PIP01-22","active_substance":"clindamycin phosphate;benzoyl peroxide;adapalene","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Gel","condition_indication":"Treatment of acne vulgaris","routes_of_administration":"Cutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bausch Health Ireland Limited; Tel. +48 22 203 90 45; E-mail: EMEA.Regulatory@bauschhealth.com","first_published_date":"16/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003263-pip01-22"},{"decision_number":"P/0286/2023","pip_number":"EMEA-003055-PIP02-23","active_substance":"tazemetostat","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of follicular lymphoma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"25/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ipsen PharmaE-mail: GlobalMedInfo@ipsen.comTel.: +33 158335427","first_published_date":"16/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003055-pip02-23"},{"decision_number":"P/0270/2023","pip_number":"EMEA-003268-PIP01-22","active_substance":"1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3- fluorophenyl)ethan-1-one (BBP-671)","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Oral suspension;Tablet","condition_indication":"Treatment of Pantothenate Kinase Associated Neurodegeneration","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BridgeBio Europe B.V.E-mail: jennifer.pavillard@bridgebio.comTel.:  +01 6107166391","first_published_date":"15/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003268-pip01-22"},{"decision_number":"P/0248/2023","pip_number":"EMEA-003270-PIP01-22","active_substance":"immunoglobulin G4 [224-proline], anti-(Betula alleghaniensis allergen Bet v 1) (human monoclonal REGN5713 γ4-chain), disulphide with human monoclonal REGN5713 κ-chain, dimer (REGN5713);immunoglobulin G4 [227-proline], anti-(Betula alleghaniensis allergen Bet v 1) (human monoclonal REGN5714 γ4-chain), disulphide with human monoclonal REGN5714 κ-chain, dimer (REGN5714);immunoglobulin G4 [228-proline], anti-(Betula alleghaniensis allergen Bet v 1) (human monoclonal REGN5715 γ4-chain), disulphide with human monoclonal REGN5715 κ-chain, dimer (REGN5715)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of allergic rhinitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Regeneron Ireland DAC; Tel. +1 9148 475385; E-mail: clinicaltrials@regeneron.com","first_published_date":"15/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003270-pip01-22"},{"decision_number":"P/0279/2023","pip_number":"EMEA-002908-PIP02-22","active_substance":"Posoleucel","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Prevention of viral disease in haematopoietic stem cell transplantation (HCT)","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AlloVir International DACE-mail: pipinformation@allovir.com Tel.:  +1 6174332605","first_published_date":"15/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002908-pip02-22"},{"decision_number":"P/0272/2023","pip_number":"EMEA-002559-PIP08-23","active_substance":"nipocalimab","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of idiopathic inflammatory myopathies","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International N.V.; Tel.  +32 14602111; E-mail: contact@janssen-emea.com","first_published_date":"15/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002559-pip08-23"},{"decision_number":"P/0250/2023","pip_number":"EMEA-002350-PIP05-23","active_substance":"deucravacitinib","invented_name":"Sotyktu","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of Sjögren's syndrome","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"12/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002350-pip05-23"},{"decision_number":"P/0282/2023","pip_number":"EMEA-000380-PIP11-23","active_substance":"secukinumab","invented_name":"Cosentyx","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection;Powder for solution for injection or infusion","condition_indication":"Treatment of rotator cuff tendinopathy","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"12/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000380-pip11-23"},{"decision_number":"P/0264/2023","pip_number":"EMEA-002886-PIP01-20-M03","active_substance":"rocatinlimab","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of atopic dermatitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V. ; E-mail: medinfointernational@amgen.com; Tel. +44 (0)1223 420305","first_published_date":"07/03/2022","last_updated_date":"12/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002886-pip01-20-m03"},{"decision_number":"P/0253/2023","pip_number":"EMEA-002631-PIP01-19-M02","active_substance":"","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of acute myeloid leukaemia","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V; Tel.: +44 (0)1223 420305; E-mail: medinfointernational@amgen.com","first_published_date":"24/06/2021","last_updated_date":"12/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002631-pip01-19-m02"},{"decision_number":"P/0252/2023","pip_number":"EMEA-002597-PIP04-21-M01","active_substance":"Efgartigimod alfa","invented_name":"Vyvgart","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for injection;Concentrate for solution for infusion","condition_indication":"Treatment of immune thrombocytopenia","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Argenx BVE-mail: regulatory@argenx.comTel: +32 93103400","first_published_date":"13/04/2023","last_updated_date":"12/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002597-pip04-21-m01"},{"decision_number":"P/0249/2023","pip_number":"EMEA-002472-PIP03-22-M01","active_substance":"Beremagene geperpavec","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Gel","condition_indication":"Treatment of dystrophic epidermolysis bullosa","routes_of_administration":"Topical use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Krystal Biotech, Inc.E-mail: inquiries@krystalbio.com Tel.:  +1 4125865830","first_published_date":"12/10/2023","last_updated_date":"12/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002472-pip03-22-m01"},{"decision_number":"P/0246/2023","pip_number":"EMEA-002330-PIP01-18-M03","active_substance":"Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)","invented_name":"Prevenar 20 (previously Apexxnar)","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of disease caused by Streptococcus pneumoniae","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIGE-mail: PIP_Enquiries@pfizer.com Tel.:  +44 (0)1304616161","first_published_date":"05/03/2021","last_updated_date":"12/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002330-pip01-18-m03"},{"decision_number":"P/0278/2023","pip_number":"EMEA-002231-PIP01-17-M01","active_substance":"Mavacamten","invented_name":"Camzyos","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypertrophic cardiomyopathy","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"24/06/2019","last_updated_date":"12/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002231-pip01-17-m01"},{"decision_number":"P/0277/2023","pip_number":"EMEA-001624-PIP01-14-M06","active_substance":"nemolizumab","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of atopic dermatitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Galderma International S.A.SE-mail: regulatoryaffairsrx@galderma.com Tel.: +41 219249046","first_published_date":"16/06/2015","last_updated_date":"12/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001624-pip01-14-m06"},{"decision_number":"P/0276/2023","pip_number":"EMEA-001526-PIP01-13-M06","active_substance":"recombinant parathyroid hormone","invented_name":"Natpar","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of hypoparathyroidism","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Pharmaceuticals International AG Ireland Branch; E-mail: medinfoEMEA@takeda.com; Tel: +41 79 758 4815","first_published_date":"22/08/2014","last_updated_date":"12/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001526-pip01-13-m06"},{"decision_number":"P/0257/2023","pip_number":"EMEA-001280-PIP01-12-M06","active_substance":"darunavir;cobicistat","invented_name":"Rezolsta","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Dispersible tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; Tel. + 32 1460 2111; E-mail: contact@janssen-emea.com","first_published_date":"23/04/2013","last_updated_date":"12/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001280-pip01-12-m06"},{"decision_number":"P/0275/2023","pip_number":"EMEA-001251-PIP01-11-M06","active_substance":"talimogene laherparepvec","invented_name":"Imlygic","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of melanoma","routes_of_administration":"Intralesional use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V. ; E-mail: medinfointernational@amgen.com; Tel. +44 (0)1223 420305","first_published_date":"30/04/2013","last_updated_date":"12/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001251-pip01-11-m06"},{"decision_number":"P/0284/2023","pip_number":"EMEA-001161-PIP02-11-M03","active_substance":"Modified Vaccinia Ankara - Bavarian Nordic virus (smallpox)","invented_name":"Imvanex","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of smallpox, monkeypox and related orthopoxvirus infection and disease","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bavarian Nordic A/S; E-mail: regulatory@bavarian-nordic.com; Tel. +49 89255446300","first_published_date":"26/03/2012","last_updated_date":"12/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001161-pip02-11-m03"},{"decision_number":"P/0049/2023","pip_number":"EMEA-001050-PIP02-18-M02","active_substance":"ixekizumab","invented_name":"Taltz","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis)","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly Nederland B.V.; E-mail: EU_paediatric@lilly.com; Tel.  +44 1276483000","first_published_date":"20/02/2019","last_updated_date":"12/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001050-pip02-18-m02"},{"decision_number":"P/0258/2023","pip_number":"EMEA-001045-PIP01-10-M03","active_substance":"sarilumab","invented_name":"Kevzara","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, spondylarthritis, psoriatic arthritis and juvenile idiopathic arthritis)","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/07/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi-Aventis Recherche & Développement; Tel. +33 169745695; E-mail: contact-us@sanofi.com","first_published_date":"03/05/2013","last_updated_date":"12/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001045-pip01-10-m03"},{"decision_number":"P/0241/2023","pip_number":"EMEA-003416-PIP01-23","active_substance":"irinotecan","invented_name":"onivyde","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of pancreatic cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierE-mail: mail.pip.enquiries@servier.comTel.: +33 155726000","first_published_date":"10/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003416-pip01-23"},{"decision_number":"P/0227/2023","pip_number":"EMEA-003408-PIP01-23","active_substance":"gallium (68Ga) boclatixafortide","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Solution for injection","condition_indication":"Diagnosis of marginal zone lymphoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"PentixaPharm GmbHE-mail: info@pentixapharm.com Tel.:  +49 93199136076","first_published_date":"10/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003408-pip01-23"},{"decision_number":"P/0224/2023","pip_number":"EMEA-003401-PIP01-23","active_substance":"Candesartan cilexetil;Indapamide","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"KRKA, d.d., Novo mestoE-mail: Regulatory.Affairs@krka.bizTel. + 38 673312111","first_published_date":"10/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003401-pip01-23"},{"decision_number":"P/0223/2023","pip_number":"EMEA-003398-PIP01-23","active_substance":"salbutamol sulfate","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Inhalation powder","condition_indication":"Treatment of asthma","routes_of_administration":"Inhalation use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"26/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Teva B.V.; E-mail: MedInfo@tevaeu.com; Tel: +44 (0)2075407117","first_published_date":"10/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003398-pip01-23"},{"decision_number":"P/0199/2023","pip_number":"EMEA-003391-PIP01-23","active_substance":"amphotericin B","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Oral suspension","condition_indication":"Treatment of cryptococcosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Matinas BioPharma Holdings Inc.E-mail: info@matinasbiopharma.com Tel.:  +1 9084848805","first_published_date":"10/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003391-pip01-23"},{"decision_number":"P/0207/2023","pip_number":"EMEA-003387-PIP01-22","active_substance":"xylometazoline hydrochloride;sodium hyaluronate","invented_name":"","therapeutic_area":"Oto-rhino-laryngology","pharmaceutical_forms":"Nasal spray (solution)","condition_indication":"Treatment of acute rhinosinusitis","routes_of_administration":"Nasal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Jadran galenski laboratorij d.d.E-mail: karina.vukelic@jglpharma.com Tel.:  +385 51546399","first_published_date":"10/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003387-pip01-22"},{"decision_number":"P/0220/2023","pip_number":"EMEA-003384-PIP02-23","active_substance":"levodopa;carbidopa monohydrate","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Concentrate and solvent for solution for infusion","condition_indication":"Treatment of Parkinson's disease","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dizlin Pharmaceuticals ABE-mail: info@dizlin.se Tel.:  +46 (0)768792325","first_published_date":"10/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003384-pip02-23"},{"decision_number":"P/0218/2023","pip_number":"EMEA-003383-PIP02-23","active_substance":"Inhibitor of receptor-interacting serine/threonine-protein kinase 1 (SAR443820)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of amyotrophic lateral sclerosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi Winthrop Industrie; Email: contact-us@sanofi.com; Tel: +31 202 453 703","first_published_date":"10/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003383-pip02-23"},{"decision_number":"P/0204/2023","pip_number":"EMEA-003349-PIP01-22","active_substance":"zapomeran","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Powder for dispersion for injection","condition_indication":"Prevention of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"05/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Arcturus Therapeutics Europe B.V.E-mail: regulatory@arcturusrx.com Tel.:  +1 (858)7320394","first_published_date":"10/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003349-pip01-22"},{"decision_number":"P/0222/2023","pip_number":"EMEA-003296-PIP01-22","active_substance":"crofelemer","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Powder for oral solution","condition_indication":"Treatment of short bowel syndrome","routes_of_administration":"Oral use;Gastroenteral use;Naso-gastric use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Napo Therapeutics S.p.A.E-mail: regulatory.napo@legalmail.it Tel.:  +39 3270664003","first_published_date":"10/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003296-pip01-22"},{"decision_number":"P/0228/2023","pip_number":"EMEA-003280-PIP01-22","active_substance":"Fosmanogepix","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Solution for infusion;Age appropriate dosage form for parenteral use;Tablet;Age appropriate oral formulation","condition_indication":"Treatment of invasive fungal infections","routes_of_administration":"Intravenous use;Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIGE-mail: medical.information@basilea.com Tel.:  +49 76211639475","first_published_date":"10/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003280-pip01-22"},{"decision_number":"P/0225/2023","pip_number":"EMEA-003264-PIP01-22","active_substance":"adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z (ARI-0001","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of B-lymphoblastic leukaemia/lymphoma","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Hospital Clinic of BarcelonaTel.: +34 932275400 (ext. 3343)E-mail: svarea@clinic.cat&nbsp","first_published_date":"10/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003264-pip01-22"},{"decision_number":"P/0236/2023","pip_number":"EMEA-003260-PIP02-23","active_substance":"derivative of (3S,3'S,3a'S,10a'S)-3'-phenyl-3',3a',10',10a'-tetrahydro-1'H-spiro[indoline-3,2'- pyrrolo[2',3':4,5]pyrrolo[1,2-b]indazol]-2-one","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of biliary tract cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"10/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003260-pip02-23"},{"decision_number":"P/0216/2023","pip_number":"EMEA-003247-PIP02-23","active_substance":"(S)-lactic acid","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of intervertebral disc disorder","routes_of_administration":"Intradiscal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Stayble Therapeutics ABE-mail: info@stayble.se Tel.:  +46 (0)730808397","first_published_date":"10/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003247-pip02-23"},{"decision_number":"P/0219/2023","pip_number":"EMEA-003201-PIP01-22","active_substance":"asunercept","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Apogenix AGTel.:+49 6221586080E-mail: webmaster@apogenix.com&nbsp","first_published_date":"10/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003201-pip01-22"},{"decision_number":"P/0239/2023","pip_number":"EMEA-002619-PIP02-23","active_substance":"belzutifan","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of neuroendocrine tumours (excluding neuroblastoma);Treatment of von Hippel-Lindau disease (excluding von Hippel-Lindau disease- associated renal cell carcinoma)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"10/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002619-pip02-23"},{"decision_number":"P/0208/2023","pip_number":"EMEA-002597-PIP08-22","active_substance":"Efgartigimod alfa","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of dermatomycosis;Treatment of immune-mediated necrotising myopathy;Treatment of polymyositis (including antisynthetase syndrome)","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Argenx BVE-mail: regulatory@argenx.comTel: +32 93103400","first_published_date":"10/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002597-pip08-22"},{"decision_number":"P/0205/2023","pip_number":"EMEA-002052-PIP02-23","active_substance":"deutetrabenazine","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of tardive dyskinesia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Teva B.V.; E-mail: MedInfo@tevaeu.com; Tel: +44 (0)2075407117","first_published_date":"05/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002052-pip02-23"},{"decision_number":"P/0194/2023","pip_number":"EMEA-001338-PIP02-23","active_substance":"isopropyl alcohol;chlorhexidine digluconate","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Cutaneous solution;Cutaneous spray, solution","condition_indication":"Prevention of infections prior to invasive procedures","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ecolab Deutschland GmbHE-mail: eurregaffairs@ecolab.com Tel.:  +49 21735991150","first_published_date":"05/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001338-pip02-23"},{"decision_number":"P/0201/2023","pip_number":"EMEA-000380-PIP10-23","active_substance":"secukinumab","invented_name":"Cosentyx","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of polymyalgia rheumatica","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"05/07/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000380-pip10-23"},{"decision_number":"P/0238/2023","pip_number":"EMEA-002961-PIP01-21-M02","active_substance":"regdanvimab","invented_name":"Regkirona","therapeutic_area":"Vaccines","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Celltrion Healthcare Hungary Kft.; Email: regulatory_eu@celltrion.com; Tel. +82 328505913","first_published_date":"17/06/2021","last_updated_date":"05/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002961-pip01-21-m02"},{"decision_number":"P/0213/2023","pip_number":"EMEA-002735-PIP03-20-M02","active_substance":"histidine;tryptophan;aspartic acid;n-acetyl-histidine (monohydrate);glycine;alpha-ketoglutaric acid;arginine;potassium chloride;calcium chloride (dihydrate);sodium chloride;alanine;3,4-dimethoxy-N-methylbenzohydroxamic acid (Custodiol-N);magnesium chloride hexahydrate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Solution for organ preservation","condition_indication":"Heart transplantation","routes_of_administration":"","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dr. Franz Köhler Chemie GmbH; E-mail: C-Npaediatric@koehler-chemie.de; Tel: +49 62511083332","first_published_date":"14/02/2022","last_updated_date":"05/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002735-pip03-20-m02"},{"decision_number":"P/0210/2023","pip_number":"EMEA-002735-PIP01-19-M01","active_substance":"Deferoxamine (mesylate);histidine;tryptophan;aspartic acid;n-acetyl-histidine (monohydrate);glycine;arginine;potassium chloride;calcium chloride (dihydrate);sodium chloride;alanine;3,4-dimethoxy-N-methylbenzohydroxamic;magnesium chloride hexahydrate;alpha-ketoglutaric acid","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Concentrate and solvent for solution for infusion","condition_indication":"Cardioplegia","routes_of_administration":"Intracoronary use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dr. Franz Köhler Chemie GmbH; E-mail: C-Npaediatric@koehler-chemie.de; Tel: +49 62511083332","first_published_date":"26/04/2022","last_updated_date":"05/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002735-pip01-19-m01"},{"decision_number":"P/0217/2023","pip_number":"EMEA-002229-PIP02-21-M01","active_substance":"Dienogest;ethinylestradiol","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Prolonged-release tablet","condition_indication":"Treatment of hirsutism associated with polycystic ovary syndrome","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Chemo Research S.L.E-mail: enrico.coli@exeltis.com Tel.: +34 913021560","first_published_date":"13/03/2024","last_updated_date":"05/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002229-pip02-21-m01"},{"decision_number":"P/0242/2023","pip_number":"EMEA-001766-PIP01-15-M05","active_substance":"bictegravir;emtricitabine;tenofovir alafenamide","invented_name":"Biktarvy","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Age appropriate oral formulation;Film-coated tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd. ; Tel. +44 (0)1223 897 300 ; E-mail: regulatory.pip@gilead.com","first_published_date":"02/02/2016","last_updated_date":"05/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001766-pip01-15-m05"},{"decision_number":"P/0203/2023","pip_number":"EMEA-001627-PIP01-14-M03","active_substance":"Efinaconazole","invented_name":"","therapeutic_area":"Dermatology;Infectious diseases","pharmaceutical_forms":"Cutaneous solution","condition_indication":"Treatment of onychomycosis","routes_of_administration":"Cutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Almirall, S.A.E-mail: global.regulatory@almirall.comTel.:  +34 933128699","first_published_date":"24/03/2015","last_updated_date":"05/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001627-pip01-14-m03"},{"decision_number":"P/0221/2023","pip_number":"EMEA-001150-PIP02-13-M05","active_substance":"landiolol hydrochloride","invented_name":"Rapibloc; Landiobloc; Raploc; Runrapiq","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Powder for solution for injection;Concentrate for solution for injection","condition_indication":"Treatment of supraventricular arrhythmias","routes_of_administration":"Intravenous use;Intravenous bolus use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AOP Orphan Pharmaceuticals AGE-mail: office@aoporphan.comTel. +43 150372440","first_published_date":"22/09/2016","last_updated_date":"05/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001150-pip02-13-m05"},{"decision_number":"P/0212/2023","pip_number":"EMEA-001089-PIP02-13-M04","active_substance":"brodalumab","invented_name":"Kyntheum","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of psoriasis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LEO Pharma A/S E-mail: raleodk@leo-pharma.com Tel. +45 44945888","first_published_date":"09/10/2014","last_updated_date":"05/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001089-pip02-13-m04"},{"decision_number":"P/0211/2023","pip_number":"EMEA-000902-PIP01-10-M01","active_substance":"Dermatophagoides pteronyssinus;Dermatophagoides farinae","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"HAL Allergy BVE-mail: RA@hal-allergy.nlTel.: +31 881959092","first_published_date":"10/01/2011","last_updated_date":"05/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000902-pip01-10-m01"},{"decision_number":"P/0234/2023","pip_number":"EMEA-000798-PIP01-09-M04","active_substance":"ponesimod","invented_name":"Ponvory","therapeutic_area":"Neurology;Other","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of multiple sclerosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NVE-mail: contact@janssen-emea.comTel.:  +44 (0)1494567358","first_published_date":"07/01/2013","last_updated_date":"05/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000798-pip01-09-m04"},{"decision_number":"P/0209/2023","pip_number":"EMEA-000347-PIP02-16-M05","active_substance":"bilastine","invented_name":"Bilaxten and associated names","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution","condition_indication":"Treatment of allergic conjunctivitis","routes_of_administration":"Ocular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Faes Farma S.A.Tel. +34 944818300E-mail: ieguidazu@faes.es; mjarenal@faes.es","first_published_date":"11/04/2019","last_updated_date":"05/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000347-pip02-16-m05"},{"decision_number":"P/0206/2023","pip_number":"EMEA-000207-PIP01-08-M08","active_substance":"treprostinil","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of pulmonary arterial hypertension","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ferrer Internacional, S.A.; E-mail: registros@ferrer.comTel.:  +34 935044423","first_published_date":"24/05/2012","last_updated_date":"05/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000207-pip01-08-m08"},{"decision_number":"P/0167/2023","pip_number":"EMEA-003001-PIP01-21-M01","active_substance":"autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) genetically modified with the lentiviral vector IDUA LV, encoding for the human α-L-iduronidase (IDUA) gene (OTL-203)","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of mucopolysaccharidosis type I, Hurler syndrome","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Orchard Therapeutics (Netherlands) B.V.; regulatory@orchard-tx.com; Tel. +44 (0) 20 3808 8286","first_published_date":"17/04/2023","last_updated_date":"04/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003001-pip01-21-m01"},{"decision_number":"P/0165/2023","pip_number":"EMEA-002935-PIP01-20-M03","active_substance":"Idrevloride","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Inhalation solution","condition_indication":"Treatment of primary ciliary dyskinesia","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Parion Sciences, Inc.; E-mail: clinicaltrials@parion.com; Tel: +1 919 313 1187","first_published_date":"11/01/2023","last_updated_date":"04/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002935-pip01-20-m03"},{"decision_number":"P/0155/2023","pip_number":"EMEA-002443-PIP01-18-M02","active_substance":"Gepotidacin","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral formulation","condition_indication":"Treatment of uncomplicated urinary tract infections","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Consumer Trading Services Limited; United Kingdom; E-mail: rd.gskch-paediatric-plans@gsk.com; Tel. +44 (0)19 3282 6987","first_published_date":"05/03/2021","last_updated_date":"04/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002443-pip01-18-m02"},{"decision_number":"P/0159/2023","pip_number":"EMEA-002597-PIP05-21-M01","active_substance":"Efgartigimod alfa","invented_name":"Vyvgart","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of myasthenia gravis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Argenx BVE-mail: regulatory@argenx.comTel: +32 93103400","first_published_date":"10/01/2023","last_updated_date":"04/07/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002597-pip05-21-m01"},{"decision_number":"P/0180/2023","pip_number":"EMEA-003376-PIP01-22","active_substance":"recombinant humanized monoclonal antibody (immunoglobulin gamma-1 with kappa light chains, IgG1κ) directed against integrin αvβ8 produced in Chinese Hamster Ovary (CHO) cells","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of head and neck squamous cell carcinoma (HNSCC);Treatment of renal cell carcinoma (RCC)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/05/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG  E-mail: medical.information@pfizer.com Tel: +44 (0)1304 616161","first_published_date":"18/06/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003376-pip01-22"},{"decision_number":"P/0188/2023","pip_number":"EMEA-003374-PIP01-22","active_substance":"adeno-associated viral vector serotype 9 expressing codon-optimized human GRN gene (LY3884963)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of frontotemporal dementia","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"18/06/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003374-pip01-22"},{"decision_number":"P/0158/2023","pip_number":"EMEA-003373-PIP01-22","active_substance":"atorvastatin;ezetimibe","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pharmaplot P.C.; E-mail: info@pharmaplot.com; Tel.  +30 2160047700","first_published_date":"18/06/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003373-pip01-22"},{"decision_number":"P/0157/2023","pip_number":"EMEA-003372-PIP01-22","active_substance":"ramipril;Indapamide","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Zakłady Farmaceutyczne Polpharma S.A.; E-mail: regulatory@polpharma.com; Tel.  +48 585631600","first_published_date":"18/06/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003372-pip01-22"},{"decision_number":"P/0139/2023","pip_number":"EMEA-003184-PIP01-22","active_substance":"AV2-cVLP-RBD SARS-CoV-2 (ABNCoV2)","invented_name":"","therapeutic_area":"Infectious diseases;Vaccines","pharmaceutical_forms":"Dispersion for injection","condition_indication":"Prevention of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bavarian Nordic A/S; Email: info@bavarian-nordic.com ; Tel:  +45 61774743","first_published_date":"07/06/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003184-pip01-22"},{"decision_number":"P/0117/2023","pip_number":"EMEA-003099-PIP01-21","active_substance":"pudexacianinium chloride","invented_name":"","therapeutic_area":"Diagnostic;Endocrinology-Gynaecology-Fertility-Metabolism;Gastroentology-Hepatology;Oncology;Uro-nephrology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"","routes_of_administration":"Intravascular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Astellas Pharma Europe B.V.Tel. +31 7154 55878E-mail: contact.nl@astellas.com&nbsp","first_published_date":"07/06/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003099-pip01-21"},{"decision_number":"P/0118/2023","pip_number":"EMEA-003080-PIP03-22","active_substance":"vilobelimab","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"InflaRx GmbH; Email: info@inflarx.de; Tel:  +49 894141897800","first_published_date":"07/06/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003080-pip03-22"},{"decision_number":"P/0151/2023","pip_number":"EMEA-002612-PIP02-22","active_substance":"2-amino-5-(carbamylamino)pentanoic acid (L-citrulline)","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of sickle cell disease","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"24/04/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ASK Pharmaceuticals GmbH (ASK); Email: public-enquiry@asklepionpharm.com; Tel:  +1 4105450494 ext 113","first_published_date":"07/06/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002612-pip02-22"},{"decision_number":"P/0119/2023","pip_number":"EMEA-003079-PIP01-22","active_substance":"tixagevimab;cilgavimab","invented_name":"Evusheld","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of Coronavirus disease 2019 (COVID-19);Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intramuscular use;Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel. +46 8553 27591","first_published_date":"07/06/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003079-pip01-22"},{"decision_number":"P/0116/2023","pip_number":"EMEA-000032-PIP02-22","active_substance":"Meningococcal group A oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenA-CRM) Meningococcal group C oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenC-CRM) Meningococcal group W-135 oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenW-CRM) Meningococcal group Y oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenY-CRM)","invented_name":"Menveo","therapeutic_area":"Vaccines","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of meningococcal meningitis","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Biologicals Srl; Email: eu.paediatric-plans@gsk.com; Tel: +1 4388998201","first_published_date":"07/06/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000032-pip02-22"},{"decision_number":"P/0169/2023","pip_number":"EMEA-003370-PIP01-22","active_substance":"Palmitoyl-KSS-MHGDTPTLHEYMLDLQPETT (HPV-16 E7 1-20);Palmitoyl-KSS-YMLDLQPETT (HPV-16 E7 11-20);Palmitoyl-KSS-GQAEPDRAHYNIVTF (HPV-16 E7 43-57);Palmitoyl-KSSKKLLMGTLGIVCPICSQKP (HPV-16 E7 82-98);Palmitoyl-KSS-LLMGTLGIV (HPV-16 E7 82-90);Palmitoyl-KSS-ELQTTIHDIILECVYCKQQLL (HPV-16 E6 25-45) + [(2R)-2,3-bis[[(Z)-octadec-9- enoyl]oxy]propyl]-trimethylazanium chloride (R-DOTAP chloride)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of human papilloma virus (HPV) type 16 positive malignancies","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"PDS Biotechnology Corp.E-mail: greid@pdsbiotech.com Tel: +1 9083452980","first_published_date":"07/06/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003370-pip01-22"},{"decision_number":"P/0181/2023","pip_number":"EMEA-003364-PIP02-22","active_substance":"1-((S)-4-((R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro- 2-(((S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop- 2-en-1-one adipate","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of non-small cell lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbH; E-mail: global.eu_regulatory_office@roche.comTel. +49 7624142892","first_published_date":"07/06/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003364-pip02-22"},{"decision_number":"P/0161/2023","pip_number":"EMEA-003339-PIP02-23","active_substance":"diclofenac;thiocolchicoside","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Verisfield Single Member S.A.Email: pharmacovigilance@verisfield.gr; economou@verisfield.gr Tel: +30 2107475196&nbsp","first_published_date":"07/06/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003339-pip02-23"},{"decision_number":"P/0168/2023","pip_number":"EMEA-003279-PIP01-22","active_substance":"albaconazole","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of acute vulvovaginal candidiasis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Palau Pharma, S.L.E-mail: regulatory@noucor.com Tel: +34 937376690","first_published_date":"07/06/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003279-pip01-22"},{"decision_number":"P/0184/2023","pip_number":"EMEA-003251-PIP01-22","active_substance":"aticaprant","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of major depressive disorder","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"19/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; E-mail: contact@janssen-emea.com; Tel.: +32 14602111","first_published_date":"07/06/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003251-pip01-22"},{"decision_number":"P/0178/2023","pip_number":"EMEA-003208-PIP02-22","active_substance":"Itolizumab","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of acute graft versus host disease","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biocon Pharma Malta-I LimitedE-mail: Novel.Biologics@biocon.comTel: +91 9717166167","first_published_date":"07/06/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003208-pip02-22"},{"decision_number":"P/0177/2023","pip_number":"EMEA-001231-PIP02-13-M10","active_substance":"tolvaptan","invented_name":"Samsca and associated names","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism;Uro-nephrology","pharmaceutical_forms":"Tablet;Oral suspension","condition_indication":"Treatment of dilutional hyponatraemia;Treatment of polycystic kidney disease","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Otsuka Pharmaceutical Netherlands B.V.E-mail: paediatrics-info@otsuka-europe.com Tel.: +49 69955044321","first_published_date":"08/10/2013","last_updated_date":"07/06/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001231-pip02-13-m10"},{"decision_number":"P/0190/2023","pip_number":"EMEA-001523-PIP04-19-M02","active_substance":"Guselkumab","invented_name":"Tremfya","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Solution for injection in pre-filled pen;Solution for injection in pre-filled syringe","condition_indication":"Treatment of ulcerative colitis","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International N.V.; Tel. +32 14602111; E-mail: contact@Janssen-emea.com","first_published_date":"22/09/2021","last_updated_date":"07/06/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001523-pip04-19-m02"},{"decision_number":"P/0189/2023","pip_number":"EMEA-001490-PIP01-13-M04","active_substance":"Cholera vaccine, live attenuated, oral (strain CVD 103-HgR)","invented_name":"Vaxchora","therapeutic_area":"Vaccines","pharmaceutical_forms":"Powder for oral suspension;Age appropriate oral liquid dosage formulation","condition_indication":"Prevention of cholera","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bavarian Nordic A/SE-mail: BNBE-Regulatory@bavarian-nordic.com Tel: +41 (0)318885111","first_published_date":"04/12/2014","last_updated_date":"07/06/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001490-pip01-13-m04"},{"decision_number":"P/0192/2023","pip_number":"EMEA-001238-PIP03-21-M01","active_substance":"vatiquinone","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Oral solution;Capsule, hard","condition_indication":"Treatment of Friedreich's ataxia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"26/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"PTC Therapeutics International Limited; Tel. +353 19068700; E-mail: medinfo@ptcbio.com","first_published_date":"02/03/2023","last_updated_date":"07/06/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001238-pip03-21-m01"},{"decision_number":"P/0173/2023","pip_number":"EMEA-001214-PIP09-21-M01","active_substance":"Benralizumab","invented_name":"Fasenra","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of eosinophilic granulomatosis with polyangiitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel.  +46 855326000;  ","first_published_date":"19/06/2023","last_updated_date":"06/06/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001214-pip09-21-m01"},{"decision_number":"P/0172/2023","pip_number":"EMEA-001194-PIP01-11-M06","active_substance":"migalastat hydrochloride","invented_name":"Galafold; Galafold","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Capsule, hard;Dispersible tablet","condition_indication":"Treatment of Fabry disease","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amicus Therapeutics Europe Limited; E-mail: IR@amicusrx.com; Tel: +1 6096623809","first_published_date":"23/08/2012","last_updated_date":"06/06/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001194-pip01-11-m06"},{"decision_number":"P/0183/2023","pip_number":"EMEA-000353-PIP02-16-M03","active_substance":"Maribavir","invented_name":"Livtencity","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Powder for oral suspension","condition_indication":"Treatment of cytomegalovirus (CMV) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Pharmaceuticals International AG Ireland Branch; E-mail: medinfoemea@takeda.com; Tel: +44 (0) 3333 000181","first_published_date":"12/02/2018","last_updated_date":"06/06/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000353-pip02-16-m03"},{"decision_number":"P/0123/2023","pip_number":"EMEA-000145-PIP02-12-M05","active_substance":"denosumab","invented_name":"Xgeva; Prolia","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of osteoporosis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V. ; E-mail: medinfointernational@amgen.com; Tel. +44 (0)1223 420305","first_published_date":"31/05/2013","last_updated_date":"03/06/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000145-pip02-12-m05"},{"decision_number":"P/0154/2023","pip_number":"EMEA-003371-PIP01-22","active_substance":"N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2- yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d] pyrimidin-6-yl)phenyl)methacrylamide (hydrochloride) (RLY-4008)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of cholangiocarcinoma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Relay Therapeutics Inc.; E-mail: info@relaytx.com; Tel.  +1 (617)3708837","first_published_date":"03/06/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003371-pip01-22"},{"decision_number":"P/0124/2023","pip_number":"EMEA-000876-PIP03-14-M06","active_substance":"Eculizumab","invented_name":"Soliris","therapeutic_area":"Neurology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of neuromyelitis optica spectrum disorders","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alexion Europe SAS; E-mail: pip.enquiries.eu@alexion.com; Tel. +33 147103621","first_published_date":"30/01/2017","last_updated_date":"03/06/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000876-pip03-14-m06"},{"decision_number":"P/0182/2023","pip_number":"EMEA-003024-PIP01-21","active_substance":"2’-O-(2-methoxyethyl) modified antisense oligonucleotide targeting fused in sarcoma (FUS) pre-mRNA (ION363)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Concentrate for solution for injection","condition_indication":"Treatment of amyotrophic lateral sclerosis","routes_of_administration":"Intrathecal use","decision_type":"","decision_date":"","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ionis Pharmaceuticals; Email: globalregulatoryaffairs@ionisph.com; Tel. 7606032302","first_published_date":"30/05/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003024-pip01-21"},{"decision_number":"P/0163/2023","pip_number":"EMEA-002559-PIP07-22","active_substance":"nipocalimab","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Concentrate for solution for infusion;Concentrate for solution for injection","condition_indication":"Treatment of Sjögren's syndrome","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; Tel. +32 1460 2111; E-mail: contact@janssen-emea.com","first_published_date":"30/05/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002559-pip07-22"},{"decision_number":"P/0191/2023","pip_number":"EMEA-000310-PIP05-22","active_substance":"ocrelizumab","invented_name":"Ocrevus","therapeutic_area":"Neurology","pharmaceutical_forms":"Concentrate for solution for injection","condition_indication":"Treatment of multiple sclerosis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"30/05/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000310-pip05-22"},{"decision_number":"P/0156/2023","pip_number":"EMEA-002427-PIP01-18-M02","active_substance":"valoctocogene roxaparvovec","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of Haemophilia A","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BioMarin International Limited; Tel. +44 (0)20 7420 0800; E-mail: biomarin-europe@bmrn.com","first_published_date":"07/11/2019","last_updated_date":"28/05/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002427-pip01-18-m02"},{"decision_number":"P/0176/2023","pip_number":"EMEA-002233-PIP01-17-M02","active_substance":"Dasiglucagon","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of hypoglycaemia","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Zealand Pharma A/S; E-mail: info@zealandpharma.com; Tel: + 45 50603821","first_published_date":"27/11/2018","last_updated_date":"28/05/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002233-pip01-17-m02"},{"decision_number":"P/0193/2023","pip_number":"EMEA-001679-PIP01-14-M03","active_substance":"emtricitabine;rilpivirine;tenofovir alafenamide","invented_name":"Odefsey","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral formulation","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd ; United Kingdom; Tel. +44 (0)1223 897300 ; Fax +44 (0)1223 897284; E-mail: regulatory.pip@gilead.com","first_published_date":"16/06/2015","last_updated_date":"28/05/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001679-pip01-14-m03"},{"decision_number":"P/0411/2023","pip_number":"EMEA-003090-PIP02-22","active_substance":"deucrictibant","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Age appropriate oral solid dosage form;Capsule, soft;Prolonged-release tablet","condition_indication":"Treatment of hereditary angioedema","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"25/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pharvaris Netherlands BVE-mail: info@pharvaris.comTel:  +31 (0)7120336410","first_published_date":"21/05/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003090-pip02-22"},{"decision_number":"P/0422/2023","pip_number":"EMEA-003355-PIP01-22","active_substance":"fazirsiran","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of congenital alpha-1 antitrypsin deficiency","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Pharma A/STel. +44 (0)3333000181E-mail: medinfoEMEA@takeda.com","first_published_date":"21/05/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003355-pip01-22"},{"decision_number":"P/0001/2024","pip_number":"EMEA-002247-PIP03-17-M01","active_substance":"Ivosidenib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of acute myeloid leukaemia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/01/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierE-mail: caroline.pascal@servier.com Tel: +33 155724905","first_published_date":"17/01/2019","last_updated_date":"21/05/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002247-pip03-17-m01"},{"decision_number":"P/0017/2021","pip_number":"EMEA-002754-PIP01-19","active_substance":"allopurinol;verinurad","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Capsule, hard;Age appropriate oral formulation","condition_indication":"Treatment of chronic kidney disease","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/01/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca ABEmail: paediatrics@astrazeneca.comTel. +46 855324400","first_published_date":"29/09/2021","last_updated_date":"03/05/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002754-pip01-19"},{"decision_number":"P/0418/2020","pip_number":"EMEA-002693-PIP01-19","active_substance":"N-(3-cyano-4-fluorophenyl)-1-methyl-4-[[(2S)-1,1,1-trifluoro-2-propanyl]sulfamoyl]-1H-pyrrole-2- carboxamide (JNJ-56136379)","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of chronic viral hepatitis B","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/10/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; Tel. +32 1460 2111; E-mail: contact@janssen-emea.com","first_published_date":"28/07/2021","last_updated_date":"03/05/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002693-pip01-19"},{"decision_number":"P/0431/2022","pip_number":"EMEA-003157-PIP01-21","active_substance":"Fusion protein composed of the first 2 immunoglobulin (Ig)-like domains of the human ROBO2 fused to human IgG1 Fc (PF-06730512)","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of focal segmental glomerulosclerosis","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"28/10/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG  E-mail: medical.information@pfizer.com Tel: +44 (0)1304 616161","first_published_date":"04/10/2023","last_updated_date":"03/05/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003157-pip01-21"},{"decision_number":"P/0171/2016","pip_number":"EMEA-001666-PIP01-14-M01","active_substance":"atrasentan (hydrochloride)","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Tablet;Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of nephropathy","routes_of_administration":"Oral use;Gastric use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/06/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)791 988 1614","first_published_date":"22/09/2015","last_updated_date":"03/05/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001666-pip01-14-m01"},{"decision_number":"P/0504/2021","pip_number":"EMEA-002981-PIP01-21","active_substance":"2'-O-(2-methoxyethyl) phosphorothioate antisense oligonucleotide targeting CD49d RNA (ATL1102)","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Duchenne muscular dystrophy","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Percheron Therapeutics LimitedE-mail: info@percherontx.com","first_published_date":"13/03/2023","last_updated_date":"17/04/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002981-pip01-21"},{"decision_number":"P/0086/2023","pip_number":"EMEA-002070-PIP01-16-M07","active_substance":"risdiplam","invented_name":"Evrysdi","therapeutic_area":"Neurology","pharmaceutical_forms":"Powder for oral solution;Film-coated tablet","condition_indication":"Treatment of spinal muscular atrophy","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/03/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"12/02/2018","last_updated_date":"08/04/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002070-pip01-16-m07"},{"decision_number":"P/0070/2023","pip_number":"EMEA-002079-PIP01-16-M03","active_substance":"Lumasiran (ALN-GO1)","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of hyperoxaluria","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/03/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alnylam UK Limited; Tel. +1  8663300326; E-mail: clinicaltrials@alnylam.com","first_published_date":"05/03/2018","last_updated_date":"08/04/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002079-pip01-16-m03"},{"decision_number":"P/0080/2023","pip_number":"EMEA-000334-PIP01-08-M11","active_substance":"Methoxyflurane","invented_name":"Penthrox","therapeutic_area":"Pain","pharmaceutical_forms":"Inhalation vapour (liquid)","condition_indication":"Treatment of acute pain","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/03/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Medical Developments UK Ltd; Email: regulatory@medicaldev.com; Tel. + 61 395471888","first_published_date":"25/07/2017","last_updated_date":"05/04/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000334-pip01-08-m11"},{"decision_number":"P/0084/2023","pip_number":"EMEA-003245-PIP01-22","active_substance":"Lutetium (177Lu) edotreotide","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of gastro-entero-pancreatic neuroendocrine tumours","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/03/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"email: ciaran.greene@itm-radiopharma.com tel: +49 8932989864557","first_published_date":"05/04/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003245-pip01-22"},{"decision_number":"P/0066/2023","pip_number":"EMEA-003317-PIP02-22","active_substance":"varicella virus OKA strain (live, attenuated)","invented_name":"","therapeutic_area":"Infectious diseases;Vaccines","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Prevention of Varicella Zoster virus disease","routes_of_administration":"Parenteral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Biologicals SA; E-mail: eu.paediatric-plans@gsk.com; Tel:  +1 4388998201","first_published_date":"05/04/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003317-pip02-22"},{"decision_number":"P/0073/2023","pip_number":"EMEA-003032-PIP01-21-M01","active_substance":"Ibutamoren mesilate","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of growth hormone deficiency","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/03/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Lumos Pharma, Inc.; Email: medicalinformation@lumos-pharma.com    ; Tel: 512 3879872","first_published_date":"10/05/2023","last_updated_date":"05/04/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003032-pip01-21-m01"},{"decision_number":"P/0078/2023","pip_number":"EMEA-001744-PIP01-14-M02","active_substance":"begelomab","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of acute graft-versus-host disease (aGvHD)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/03/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Adienne S.r.l. S.U. ; Italy; Tel. +39 0240 700445; Fax +39 0295 745179; E-mail: adienne@adienne.com","first_published_date":"19/11/2015","last_updated_date":"05/04/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001744-pip01-14-m02"},{"decision_number":"P/0079/2023","pip_number":"EMEA-001429-PIP01-13-M07","active_substance":"Inotuzumab ozogamicin","invented_name":"Besponsa","therapeutic_area":"Haematology-Hemostaseology;Oncology","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of B cell acute lymphoblastic leukaemia","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/03/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG; Tel. +44 (0)1304 646 607; E-mail: pip_enquiries@pfizer.com","first_published_date":"12/12/2014","last_updated_date":"05/04/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001429-pip01-13-m07"},{"decision_number":"P/0071/2023","pip_number":"EMEA-001332-PIP01-12-M06","active_substance":"Estetrol;drospirenone","invented_name":"Lydisilka","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of pregnancy","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Estetra SPRL; Tel. +32 (0)4 349 28 22; Email: estetra.regulatory@mithra.com","first_published_date":"09/08/2013","last_updated_date":"05/04/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001332-pip01-12-m06"},{"decision_number":"P/0094/2023","pip_number":"EMEA-003171-PIP01-21","active_substance":"obecabtagene autoleucel","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of acute lymphoblastic leukaemia","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/03/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Autolus GmbH; Email: clinicaltrials@autolus.comTel. +44 2039114385","first_published_date":"05/04/2024","last_updated_date":"05/04/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003171-pip01-21"},{"decision_number":"P/0092/2023","pip_number":"EMEA-003218-PIP01-22","active_substance":"zilebesiran (sodium)","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Concentrate for solution for injection","condition_indication":"Treatment of hypertension","routes_of_administration":"Subcutaneous use","decision_type":"","decision_date":"10/03/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alnylam Netherlands BV; E-mail: clinicaltrials@alnylam.com; Tel. +1 8663 300326","first_published_date":"05/04/2024","last_updated_date":"05/04/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003218-pip01-22"},{"decision_number":"P/0065/2023","pip_number":"EMEA-003237-PIP01-22","active_substance":"cemdisiran","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Concentrate for solution for injection","condition_indication":"Treatment of myasthenia gravis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/03/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Regeneron Ireland DAC; Tel. +1 9148 475385; E-mail: clinicaltrials@regeneron.com","first_published_date":"05/04/2024","last_updated_date":"05/04/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003237-pip01-22"},{"decision_number":"P/0099/2023","pip_number":"EMEA-001371-PIP03-22","active_substance":"clazakizumab","invented_name":"","therapeutic_area":"Cardiovascular diseases;Uro-nephrology","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of cardiovascular events in patients with atherosclerosis","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/03/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CSL Behring GmbH; Tel. 41 313445118E-mail: PIP-CSLBehring@cslbehring.com; &nbsp","first_published_date":"05/04/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001371-pip03-22"},{"decision_number":"P/0096/2023","pip_number":"EMEA-001474-PIP03-22","active_substance":"pembrolizumab","invented_name":"Keytruda","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Hodgkin lymphoma, treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue)","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/03/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"05/04/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001474-pip03-22"},{"decision_number":"P/0089/2023","pip_number":"EMEA-002690-PIP02-22","active_substance":"sotorasib","invented_name":"Lumykras","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of colorectal carcinoma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/03/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V ; United Kingdom ; pipenquiry@amgen.com ; + 44 1223420305 ; + 44 1223426814","first_published_date":"05/04/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002690-pip02-22"},{"decision_number":"P/0064/2023","pip_number":"EMEA-003166-PIP01-21","active_substance":"Insulin lispro (BC222)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of type 1 diabetes mellitus / Treatment of type 2 diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/03/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"email: v.janet@adocia.comtel: +33 472610610","first_published_date":"05/04/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003166-pip01-21"},{"decision_number":"P/0029/2022","pip_number":"EMEA-002239-PIP02-21","active_substance":"acetylsalicylic acid;rosuvastatin calcium","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Prevention of cardiovascular events","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Tel  +33 87509776Email: regulatory@lanovafarmaceutici.com","first_published_date":"13/03/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002239-pip02-21"},{"decision_number":"P/0027/2022","pip_number":"EMEA-001196-PIP03-21","active_substance":"Fostamatinib","invented_name":"Tavlesse","therapeutic_area":"Haematology-Hemostaseology;Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of autoimmune haemolytic anaemia","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Instituto Grifols, S.A.E-mail: areatecnica.instituto@grifols.comTel. +34 935710700","first_published_date":"13/03/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001196-pip03-21"},{"decision_number":"P/0006/2022","pip_number":"EMEA-002431-PIP02-21","active_substance":"alectinib","invented_name":"Alecensa","therapeutic_area":"Oncology","pharmaceutical_forms":"Age appropriate oral liquid dosage formulation;Capsule, hard","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"13/03/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002431-pip02-21"},{"decision_number":"P/0095/2023","pip_number":"EMEA-002839-PIP01-20-M01","active_substance":"hydroxypropyl-β-cyclodextrin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of Niemann-Pick disease, type C","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/03/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cyclo Therapeutics Inc.; Tel.:  +1 6178387851E-mail: info@cyclotherapeutics.com; &nbsp","first_published_date":"17/01/2022","last_updated_date":"13/03/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002839-pip01-20-m01"},{"decision_number":"P/0134/2020","pip_number":"EMEA-001312-PIP02-19","active_substance":"alpha1-proteinase inhibitor (human)","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder and solvent for solution for injection;Powder and solvent for solution for infusion","condition_indication":"Prevention of graft versus host disease","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/04/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CSL Behring GmbH; Tel. 41 313445118E-mail: PIP-CSLBehring@cslbehring.com; &nbsp","first_published_date":"03/03/2021","last_updated_date":"08/03/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001312-pip02-19"},{"decision_number":"P/0442/2020","pip_number":"EMEA-001312-PIP03-19","active_substance":"alpha1-proteinase inhibitor (human)","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder and solvent for solution for injection/infusion","condition_indication":"Treatment of acute graft-versus-host disease (aGvHD)","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CSL Behring GmbH; Tel. 41 313445118E-mail: PIP-CSLBehring@cslbehring.com; &nbsp","first_published_date":"17/09/2021","last_updated_date":"08/03/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001312-pip03-19"},{"decision_number":"P/0087/2023","pip_number":"EMEA-002298-PIP01-17-M05","active_substance":"Evinacumab","invented_name":"Evkeeza","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of elevated cholesterol","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/03/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ultragenyx Germany GmbH; E-mail: medinfo@ultragenyx.com; Tel. : +4930590083651","first_published_date":"14/02/2019","last_updated_date":"07/03/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002298-pip01-17-m05"},{"decision_number":"P/0082/2023","pip_number":"EMEA-003341-PIP01-22","active_substance":"rubella virus Wistar RA 27/3 strain (live, attenuated);varicella virus OKA strain (live, attenuated);mumps virus RIT 4385 strain, derived from Jeryl Lynn strain (live, attenuated);Measles virus Schwarz strain (live, attenuated)","invented_name":"","therapeutic_area":"Infectious diseases;Vaccines","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Prevention of measles, mumps, rubella and varicella","routes_of_administration":"Parenteral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/03/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Biologicals SA; E-mail: eu.paediatric-plans@gsk.com; Tel:  +1 4388998201","first_published_date":"07/03/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003341-pip01-22"},{"decision_number":"P/0081/2023","pip_number":"EMEA-003342-PIP01-22","active_substance":"Enpatoran","invented_name":"","therapeutic_area":"Dermatology;Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Age appropriate oral solid dosage form;Film-coated tablet","condition_indication":"Treatment of cutaneous lupus erythemathosus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/03/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Europe B.V.; Tel.: +49 6151725200; E-mail: service@merckgroup.com","first_published_date":"07/03/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003342-pip01-22"},{"decision_number":"P/0083/2023","pip_number":"EMEA-003340-PIP01-22","active_substance":"upifitamab rilsodotin","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of fallopian tube cancer;Treatment of ovarian cancer;Treatment of primary peritoneal cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/03/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mersana Therapeutics IncE-mail:  medicalinformation@mersana.comTel: +1 8446377262","first_published_date":"07/03/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003340-pip01-22"},{"decision_number":"P/0067/2023","pip_number":"EMEA-003334-PIP01-22","active_substance":"camlipixant","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of unexplained or chronic refractory cough","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"E-mail: eu.paediatric-plans@gsk.comTelephone: +1 (514)2100409; (908)5892480","first_published_date":"29/02/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003334-pip01-22"},{"decision_number":"P/0059/2023","pip_number":"EMEA-002024-PIP02-22","active_substance":"Candesartan cilexetil;amlodipine;hydrochlorothiazide","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/02/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Adamed Pharma S.A.; E-mail: adamed@adamed.com; Tel: +48 227327700","first_published_date":"28/02/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002024-pip02-22"},{"decision_number":"P/0040/2023","pip_number":"EMEA-003051-PIP05-22","active_substance":"depemokimab","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of hypereosinophilic syndrome","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/02/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Tel. +1 4388998201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"28/02/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003051-pip05-22"},{"decision_number":"P/0385/2022","pip_number":"EMEA-001757-PIP02-15-M03","active_substance":"Copanlisib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue);Treatment of mature B-cell neoplasms","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer AG; E-mail: pediatrics.medical-affairs-europe@bayer.com; Tel. +49 3046815333","first_published_date":"23/11/2016","last_updated_date":"22/02/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001757-pip02-15-m03"},{"decision_number":"P/0518/2022","pip_number":"EMEA-002058-PIP01-16-M01","active_substance":"Entospletinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of acute myeloid leukaemia","routes_of_administration":"Oral use;Gastric use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kronos Bio Inc.; email: info@kronosbio.com; tel: +1 (650)7815200","first_published_date":"12/02/2018","last_updated_date":"20/02/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002058-pip01-16-m01"},{"decision_number":"P/0269/2022","pip_number":"EMEA-003098-PIP01-21","active_substance":"(1R,2R)-2-[4-(5-methyl-1H-pyrazol-3-yl) benzoyl]-N-(4-oxo-6,7-dihydro-5H-pyrazolo [1,5-a]pyrazin-3-yl)cyclohexanecarboxamide (AZD5718)","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Age appropriate oral solid pharmaceutical form;Film-coated tablet","condition_indication":"Proteinuric chronic kidney disease","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca ABEmail: paediatrics@astrazeneca.comTel. +46 855324400","first_published_date":"25/08/2023","last_updated_date":"20/02/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003098-pip01-21"},{"decision_number":"P/0244/2014","pip_number":"EMEA-001352-PIP01-12-M01","active_substance":"metformin hydrochloride","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Effervescent tablet","condition_indication":"Treatment of polycystic ovary syndrome","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/09/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"EffRx Pharmaceuticals SA; Switzerland; Tel. +41 791268584; E-mail: adowling@effrx.com","first_published_date":"13/08/2013","last_updated_date":"20/02/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001352-pip01-12-m01"},{"decision_number":"P/0157/2015","pip_number":"EMEA-001656-PIP01-14","active_substance":"Momelotinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral dosage formulation","condition_indication":"Treatment of acute lymphoblastic leukaemia;Treatment of essential thrombocythaemia;Treatment of polycythaemia vera;Treatment of post-essential thrombocythaemia myelofibrosis;Treatment of post-polycythaemia vera myelofibrosis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/07/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Tel. +1 438-899-8201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"25/08/2015","last_updated_date":"20/02/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001656-pip01-14"},{"decision_number":"P/0407/2021","pip_number":"EMEA-002938-PIP01-20","active_substance":"Islatravir","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Tablet","condition_indication":"Prevention of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"20/02/2023","last_updated_date":"20/02/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002938-pip01-20"},{"decision_number":"P/0502/2023","pip_number":"EMEA-000597-PIP02-10-M10","active_substance":"Mirabegron","invented_name":"Betmiga","therapeutic_area":"Renal and urinary disorders","pharmaceutical_forms":"Polonged-release granules for oral suspension;Prolonged-release tablet","condition_indication":"Treatment of idiopathic overactive bladder","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Astellas Pharma Europe B.V.Tel. +31 7154 55878E-mail: contact.nl@astellas.com&nbsp","first_published_date":"29/10/2010","last_updated_date":"14/02/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000597-pip02-10-m10"},{"decision_number":"P/0009/2023","pip_number":"EMEA-001079-PIP01-10-M06","active_substance":"fibrinogen;thrombin;aprotinin;calcium chloride","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Powder and solvent for sealant","condition_indication":"Prevention of haemorrhage resulting from a surgical procedure;Treatment of haemorrhage resulting from a surgical procedure","routes_of_administration":"Epilesional use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kedrion S.p.A.; E-mail: info@kedrion.com ; Tel. +30 0583 1969697","first_published_date":"26/03/2012","last_updated_date":"14/02/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001079-pip01-10-m06"},{"decision_number":"P/0056/2023","pip_number":"EMEA-002709-PIP01-19-M01","active_substance":"Crovalimab","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of atypical haemolytic uremic syndrome;Treatment of paroxysmal nocturnal haemoglobinuria","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/01/2023","compliance_outcome":"Positive","compliance_opinion_date":"20/09/2019","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbH; E-mail: global.eu_regulatory_office@roche.comTel. +49 7624142892","first_published_date":"05/11/2021","last_updated_date":"14/02/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002709-pip01-19-m01"},{"decision_number":"P/0340/2022","pip_number":"EMEA-002240-PIP02-17-M02","active_substance":"Enmetazobactam;cefepime","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of infections caused by gram-negative organisms","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"24/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allecra Therapeutics GmbH; E-mail: oml@allecra.com; Tel. +49 7621 5104915","first_published_date":"24/06/2019","last_updated_date":"14/02/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002240-pip02-17-m02"},{"decision_number":"P/0031/2023","pip_number":"EMEA-002320-PIP01-17-M03","active_substance":"Isoflurane","invented_name":"Sedaconda and associated names","therapeutic_area":"Neonatology-Paediatric Intensive Care","pharmaceutical_forms":"Inhalation vapour (liquid)","condition_indication":"Sedation of mechanically ventilated patients","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sedana Medical AB; regulatoryaffairs@sedanamedical.com ; +46 707710364","first_published_date":"24/06/2019","last_updated_date":"14/02/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002320-pip01-17-m03"},{"decision_number":"P/0037/2023","pip_number":"EMEA-001864-PIP03-19-M01","active_substance":"lanadelumab","invented_name":"Takhzyro","therapeutic_area":"Other","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of attacks of Idiopathic non-histaminergic angioedema (INHA)","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Pharmaceuticals International AG Ireland Branch; E-mail: medinfoemea@takeda.com; Tel: +44 (0) 3333 000181","first_published_date":"17/09/2021","last_updated_date":"14/02/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001864-pip03-19-m01"},{"decision_number":"P/0024/2023","pip_number":"EMEA-003212-PIP01-22","active_substance":"autologous CD4+ and CD8+ T cells transduced with lentiviral vector encoding a chimeric antigen receptor (CAR) directed against CD19 and preserving the T cell phenotype of the leukapheresis starting material (YTB323)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of mature B-cell neoplasms","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"14/02/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003212-pip01-22"},{"decision_number":"P/0045/2023","pip_number":"EMEA-003207-PIP01-22","active_substance":"Fianlimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of melanoma","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Regeneron Ireland DAC; E-mail: clinicaltrials@regeneron.com","first_published_date":"14/02/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003207-pip01-22"},{"decision_number":"P/0041/2023","pip_number":"EMEA-003177-PIP01-21","active_substance":"2'-MOE antisense oligonucleotide targeting apoC-III (ISIS 678354)","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of familial chylomicronaemia syndrome (type I hyperlipoproteinaemia","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ionis Pharmaceuticals, Inc; E-mail: clinicaltrials@ionisph.com; Tel.  +1 4423393268; &nbsp","first_published_date":"14/02/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003177-pip01-21"},{"decision_number":"P/0497/2023","pip_number":"EMEA-002383-PIP01-18-M03","active_substance":"glycopyrronium bromide","invented_name":"Axhidrox","therapeutic_area":"Skin and subcutaneous tissue disorders","pharmaceutical_forms":"Cream","condition_indication":"Treatment of hyperhidrosis","routes_of_administration":"Topical use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dr. August Wolff GmbH & Co. KG - Arzneimittel; Email: AW-Info@drwolffgroup.com    ; Tel. +49 521880805;  ","first_published_date":"22/07/2021","last_updated_date":"14/02/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002383-pip01-18-m03"},{"decision_number":"P/0553/2022","pip_number":"EMEA-002283-PIP01-17-M04","active_substance":"aztreonam (ATM);avibactam (AVI)","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of infections caused by aerobic gram-negative bacteria","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG; Tel. +44 (0)1304 646 607; E-mail: pip_enquiries@pfizer.com","first_published_date":"09/06/2020","last_updated_date":"14/02/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002283-pip01-17-m04"},{"decision_number":"P/0020/2023","pip_number":"EMEA-003122-PIP01-21-M01","active_substance":"azelastine (hydrochloride);mometasone furoate","invented_name":"","therapeutic_area":"Oto-rhino-laryngology","pharmaceutical_forms":"Nasal spray suspension","condition_indication":"Treatment of allergic rhinitis","routes_of_administration":"Nasal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Lek Pharmaceuticals d.d.; Tel.  +41 613241111; E-mail: enquiries.paediatrics@sandoz.com; &nbsp","first_published_date":"29/08/2023","last_updated_date":"14/02/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003122-pip01-21-m01"},{"decision_number":"P/0021/2023","pip_number":"EMEA-003144-PIP01-21","active_substance":"asundexian","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Age appropriate oral dosage formulation;Film-coated tablet","condition_indication":"Prevention of arterial thromboembolism","routes_of_administration":"Gastric use;Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer AG; E-mail: clinical-trials-contact@bayer.com; Tel. +49 30300139003","first_published_date":"13/02/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003144-pip01-21"},{"decision_number":"P/0023/2023","pip_number":"EMEA-003125-PIP02-21","active_substance":"avexitide acetate","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of congenital hyperinsulinism","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"EigerBio Europe Limited; E-mail: info@eigerbio.com; Tel: +1 8778992051","first_published_date":"13/02/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003125-pip02-21"},{"decision_number":"P/0018/2023","pip_number":"EMEA-003077-PIP01-21","active_substance":"SARS-CoV-2 virus, beta-propiolactone inactivated adjuvanted with CpG 1018 (VLA2001)","invented_name":"COVID-19 Vaccine (inactivated, adjuvanted) Valneva","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Valneva Austria GmbH; E-mail: medinfo@valneva.com; Tel. +43 20620-1124","first_published_date":"14/07/2022","last_updated_date":"13/02/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003077-pip01-21"},{"decision_number":"P/0028/2023","pip_number":"EMEA-001625-PIP04-22","active_substance":"satralizumab","invented_name":"Enspryng","therapeutic_area":"","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of autoimmune encephalitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"13/02/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001625-pip04-22"},{"decision_number":"P/0013/2023","pip_number":"EMEA-002597-PIP09-22","active_substance":"Efgartigimod alfa","invented_name":"Vyvgart","therapeutic_area":"","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of bullous pemphigoid","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/03/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Argenx BVE-mail: regulatory@argenx.comTel: +32 93103400","first_published_date":"06/02/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002597-pip09-22"},{"decision_number":"P/0505/2022","pip_number":"EMEA-001676-PIP01-14-M05","active_substance":"doravirine","invented_name":"Pifeltro","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Tablet;Granules","condition_indication":"Treatment of human immunodeficiency virus type 1 (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"02/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"MSD Europe Belgium S.R.L.E-mail: pip.information@msd.comTel. +33 180464738","first_published_date":"18/07/2016","last_updated_date":"30/01/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001676-pip01-14-m05"},{"decision_number":"P/0504/2022","pip_number":"EMEA-001695-PIP01-14-M05","active_substance":"doravirine;lamivudine;tenofovir disoproxil fumarate","invented_name":"Delstrigo","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Tablet;Granules","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"02/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"MSD Europe Belgium S.R.L.E-mail: pip.information@msd.comTel. +33 180464738","first_published_date":"18/07/2016","last_updated_date":"30/01/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001695-pip01-14-m05"},{"decision_number":"P/0275/2019","pip_number":"EMEA-002464-PIP01-18","active_substance":"human immunoglobulin (Ig) G4-variant monoclonal antibody that binds and neutralizes soluble human interleukin (IL-) 33","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of atopic dermatitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"16/08/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"20/11/2019","last_updated_date":"22/01/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002464-pip01-18"},{"decision_number":"P/0089/2019","pip_number":"EMEA-002351-PIP01-18","active_substance":"spartalizumab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of melanoma","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"24/06/2019","last_updated_date":"22/01/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002351-pip01-18"},{"decision_number":"P/0015/2023","pip_number":"EMEA-001150-PIP03-22","active_substance":"rapibloc;landiobloc;raploc;runrapiq","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Concentrate for solution for injection;Powder for solution for infusion","condition_indication":"Treatment of ventricular tachycardia and ventricular fibrillation","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AOP Orphan Pharmaceuticals AG ; Austria ; E-mail: office@aoporphan.com ; Tel. +43 15037244 ; Fax +43 150372445","first_published_date":"11/01/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001150-pip03-22"},{"decision_number":"P/0022/2023","pip_number":"EMEA-003339-PIP01-22","active_substance":"diclofenac;thiocolchicoside","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Orodispersible tablet;Concentrate for solution for injection","condition_indication":"Treatment of pain","routes_of_administration":"Oral use;Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Verisfield Single Member S.A.Email: pharmacovigilance@verisfield.gr; economou@verisfield.gr Tel: +30 2107475196&nbsp","first_published_date":"11/01/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003339-pip01-22"},{"decision_number":"P/0044/2023","pip_number":"EMEA-003084-PIP03-22","active_substance":"troriluzole hydrochloride","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Capsule, hard;Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of hereditary spinocerebellar ataxia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biohaven Pharmaceutical Ireland DAC; Email: medinfo@biohavenpharma.com; Tel. +1 2034040410","first_published_date":"11/01/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003084-pip03-22"},{"decision_number":"P/0101/2023","pip_number":"EMEA-003380-PIP01-22","active_substance":"Finasteride;doxazosin (mesylate)","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of benign prostatic hyperplasia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Midas Pharma GmbH; E-mail: info@midas-pharma.com; Tel. +49 6132 990583","first_published_date":"11/01/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003380-pip01-22"},{"decision_number":"P/0195/2023","pip_number":"EMEA-003309-PIP01-22","active_substance":"single-stranded 5' capped mRNA encoding the respiratory syncytial virus glycoprotein F stabilized in the prefusion conformation (mRNA-1345)","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Dispersion for injection","condition_indication":"Prevention of lower respiratory tract infection caused by respiratory syncytial virus","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Moderna Biotech Spain, S.L.E-mail: EMEAMedInfo@modernatx.comTel.  +34 900031015","first_published_date":"11/01/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003309-pip01-22"},{"decision_number":"P/0011/2023","pip_number":"EMEA-002840-PIP02-22","active_substance":"ziltivekimab","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of heart failure","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; E-mail: paediatrics@novonordisk.com ; Tel.: +45 44444848","first_published_date":"11/01/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002840-pip02-22"},{"decision_number":"P/0014/2023","pip_number":"EMEA-002798-PIP03-22","active_substance":"retifanlimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of Merkel cell carcinoma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Incyte Biosciences Distribution B.V.; E-mail: RA@incyte.com","first_published_date":"11/01/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002798-pip03-22"},{"decision_number":"P/0026/2023","pip_number":"EMEA-002698-PIP03-22","active_substance":"Eftilagimod alpha","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of non-small cell lung cancer","routes_of_administration":"All routes of administration","decision_type":"","decision_date":"","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Immutep SAS; E-mail: christian.mueller@immutep.com; Tel.: +49 3088716843","first_published_date":"11/01/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002698-pip03-22"},{"decision_number":"P/0025/2023","pip_number":"EMEA-002698-PIP02-22","active_substance":"Eftilagimod alpha","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of head and neck epithelial malignant neoplasms","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Immutep SAS; E-mail: christian.mueller@immutep.com; Tel.: +49 3088716843","first_published_date":"11/01/2024","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002698-pip02-22"},{"decision_number":"P/0019/2023","pip_number":"EMEA-003119-PIP01-21-M01","active_substance":"zuranolone","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of postpartum depression","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biogen Netherlands B.V.; E-mail: pip.enquiries@biogen.com; Tel: +44 (0)1628512586","first_published_date":"29/08/2023","last_updated_date":"11/01/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003119-pip01-21-m01"},{"decision_number":"P/0030/2023","pip_number":"EMEA-001860-PIP03-16-M08","active_substance":"Galcanezumab","invented_name":"Emgality","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of migraine headaches","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"27/01/2017","last_updated_date":"11/01/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001860-pip03-16-m08"},{"decision_number":"EMA/PE/0000221021","pip_number":"EMA/PE/0000221021","active_substance":"cobicistat;atazanavir (as sulfate)","invented_name":"Evotaz; Evotaz","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"26/07/2017","last_updated_date":"11/01/2024","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000221021"},{"decision_number":"P/0416/2022","pip_number":"EMEA-002545-PIP01-19-M01","active_substance":"atropine sulfate","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops","condition_indication":"Treatment of myopia","routes_of_administration":"Ocular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"E-mail: al@benzifoundation.org, rc@benzifoundation.org; Tel: +39 0809026797","first_published_date":"05/03/2021","last_updated_date":"04/12/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002545-pip01-19-m01"},{"decision_number":"P/0286/2022","pip_number":"EMEA-002350-PIP04-21","active_substance":"deucravacitinib","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Age appropriate oral solid dosage form;Film-coated tablet","condition_indication":"Treatment of ulcerative colitis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb International Corporation; E-mail: medical.information@bms.com; Tel. +44 1423 533 610","first_published_date":"24/08/2023","last_updated_date":"04/12/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002350-pip04-21"},{"decision_number":"P/0081/2014","pip_number":"EMEA-001468-PIP01-13","active_substance":"(E)-4-[(5-Phenyl-1,3,4-thiadiazol-2-yl)oxy]-1-azoniatricyclo[3.3.1.13,7] decane 3,4-dicarboxy-3-hydroxybutanoate hydrate (ABT-126)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Capsule;Coated tablet","condition_indication":"Treatment of schizophrenia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"02/04/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"13/05/2014","last_updated_date":"04/12/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001468-pip01-13"},{"decision_number":"P/0480/2022","pip_number":"EMEA-003168-PIP01-21","active_substance":"sirolimus","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Cream","condition_indication":"Treatment of tuberous sclerosis complex","routes_of_administration":"Cutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"02/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Desitin Arzneimittel GmbH ; Germany ; E-mail: info@desitin.de ; Tel. +49 4059101525","first_published_date":"13/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003168-pip01-21-0"},{"decision_number":"P/0474/2022","pip_number":"EMEA-003165-PIP01-21","active_substance":"derivative of 3‐phenyl‐3H,4H,6H,7H‐pyrano[3,4‐d]imidazol‐4‐one","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral dosage formulation","condition_indication":"Treatment of chronic kidney disease","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"13/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003165-pip01-21"},{"decision_number":"P/0473/2022","pip_number":"EMEA-003162-PIP01-21","active_substance":"batoclimab","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Concentrate for solution for injection","condition_indication":"Treatment of myasthenia gravis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Immunovant Sciences, GmbH; E-mail: regulatoryaffairs@immunovant.com; Tel. +1 3174175110","first_published_date":"13/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003162-pip01-21"},{"decision_number":"P/0484/2022","pip_number":"EMEA-003160-PIP01-21","active_substance":"camidanlumab tesirine","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder and solvent for concentrate for solution for infusion","condition_indication":"Treatment of Hodgkin lymphoma","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"02/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ADC Therapeutics SA; Email: info@adctherapeutics.com; Tel. +41 216530200","first_published_date":"13/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003160-pip01-21"},{"decision_number":"P/0522/2022","pip_number":"EMEA-003100-PIP01-21","active_substance":"Humanized monoclonal antibody of IgG1 subtype targeting NRP1","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Concentrate for solution for injection","condition_indication":"Treatment of spinal muscular atrophy","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"30/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"13/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003100-pip01-21"},{"decision_number":"P/0540/2022","pip_number":"EMEA-001205-PIP02-19-M02","active_substance":"tecovirimat monohydrate","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for oral suspension;Capsule, hard","condition_indication":"Treatment of orthopoxvirus disease (smallpox, monkeypox, cowpox, and vaccinia)","routes_of_administration":"Oral use;Gastric use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"SIGA Technologies, Inc.; E-mail: PLong@siga.com; Tel. +1 5417584823;  ","first_published_date":"16/06/2021","last_updated_date":"13/11/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001205-pip02-19-m02"},{"decision_number":"P/0533/2022","pip_number":"EMEA-002908-PIP01-20","active_substance":"Posoleucel","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of bacterial community-acquired pneumonia","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"30/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Nabriva Therapeutics DAC; email: officeUS@nabriva.com; tel: +1 6102091499","first_published_date":"13/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002908-pip01-20"},{"decision_number":"P/0498/2022","pip_number":"EMEA-003035-PIP02-21","active_substance":"Manganese chloride tetrahydrate","invented_name":"","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Powder for oral solution","condition_indication":"Diagnostic evaluation of liver lesions by magnetic resonance imaging","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"02/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ascelia Pharma AB; email: info@ascelia.com; tel:  +46 735179118","first_published_date":"13/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003035-pip02-21"},{"decision_number":"P/0543/2022","pip_number":"EMEA-003051-PIP04-22","active_substance":"depemokimab","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of eosinophilic granulomatosis with polyangiitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"30/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Tel. +1 4388998201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"13/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003051-pip04-22"},{"decision_number":"P/0544/2022","pip_number":"EMEA-003096-PIP02-22","active_substance":"enzastaurin hydrochloride","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of Ehlers-Danlos Syndrome","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"30/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aytu BioPharma Inc.; email: info@aytubio.com; tel: +1 (855)2988246","first_published_date":"13/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003096-pip02-22"},{"decision_number":"P/0483/2022","pip_number":"EMEA-003281-PIP01-22","active_substance":"Lacutamab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of Cutaneous T-Cell Lymphoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Innate Pharma SA; E-mail: info@innate-pharma.fr; Tel. +33 430303030","first_published_date":"13/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003281-pip01-22"},{"decision_number":"P/0493/2022","pip_number":"EMEA-003278-PIP01-22","active_substance":"1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer (small cell and non-small cell lung cancer)","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"13/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003278-pip01-22"},{"decision_number":"P/0471/2022","pip_number":"EMEA-003275-PIP01-22","active_substance":"namilumab","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of sarcoidosis","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kinevant Sciences GmbH; E-mail: info@kinevant.com; Tel.  +1 6468873895","first_published_date":"13/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003275-pip01-22"},{"decision_number":"P/0511/2022","pip_number":"EMEA-003272-PIP01-22","active_substance":"tigulixostat","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hyperuricemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LG Chem, Ltd.; E-mail: jenny.yoon@lgchem.com; Tel.  +82 269874357","first_published_date":"13/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003272-pip01-22"},{"decision_number":"P/0514/2022","pip_number":"EMEA-001741-PIP02-16-M02","active_substance":"upadacitinib (ABT-494)","invented_name":"Rinvoq","therapeutic_area":"Gastroentology-Hepatology;Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Prolonged-release tablet;Age appropriate oral formulation","condition_indication":"Treatment of ulcerative colitis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"18/04/2018","last_updated_date":"13/11/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001741-pip02-16-m02"},{"decision_number":"P/0497/2022","pip_number":"EMEA-001776-PIP01-15-M01","active_substance":"risankizumab","invented_name":"Skyrizi","therapeutic_area":"Dermatology","pharmaceutical_forms":"Concentrate for solution for infusion;Solution for injection;Age appropriate dosage form for parenteral use","condition_indication":"Treatment of psoriasis","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"02/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"28/10/2016","last_updated_date":"13/11/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001776-pip01-15-m01"},{"decision_number":"P/0515/2022","pip_number":"EMEA-002054-PIP03-20-M02","active_substance":"odevixibat","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Capsule, hard;Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of Alagille syndrome","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Albireo AB; Tel. +46 31741 14 80; E-mail: info@albireopharma.com","first_published_date":"10/06/2022","last_updated_date":"13/11/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002054-pip03-20-m02"},{"decision_number":"P/0535/2022","pip_number":"EMEA-002075-PIP01-16-M03","active_substance":"Lefamulin","invented_name":"Xenleta","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Concentrate for solution for infusion;Age appropriate oral solid dosage form;Coated tablet","condition_indication":"Treatment of community-acquired pneumonia","routes_of_administration":"Intravenous use;Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Nabriva Therapeutics DAC; email: officeUS@nabriva.com; tel: +1 6102091499","first_published_date":"24/10/2017","last_updated_date":"13/11/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002075-pip01-16-m03"},{"decision_number":"P/0545/2022","pip_number":"EMEA-003219-PIP01-22","active_substance":"inclacumab","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of sickle cell disease","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"30/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG; Tel. +44 (0)1304 646 607; E-mail: pip_enquiries@pfizer.com","first_published_date":"10/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003219-pip01-22"},{"decision_number":"P/0525/2022","pip_number":"EMEA-003204-PIP01-22","active_substance":"treprostinil (palmitil)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Inhalation powder","condition_indication":"Treatment of pulmonary hypertension due to lung disease and/or hypoxia","routes_of_administration":"Inhalation use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Insmed Netherlands B.V.; E-mail: medicalinformation@insmed.com; Tel: +1 8 4444 67633","first_published_date":"10/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003204-pip01-22"},{"decision_number":"P/0486/2022","pip_number":"EMEA-002618-PIP03-21","active_substance":"ruxolitinib (phosphate)","invented_name":"Jakavi","therapeutic_area":"Dermatology","pharmaceutical_forms":"Cream","condition_indication":"Treatment of atopic dermatitis","routes_of_administration":"Cutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"02/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Incyte Biosciences Distribution B.V.; E-mail: globalmedinfo@incyte.com; Tel. +800 0002 7423","first_published_date":"10/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002618-pip03-21"},{"decision_number":"P/0509/2022","pip_number":"EMEA-002559-PIP06-22","active_substance":"nipocalimab","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic inflammatory demyelinating polyradiculoneuropathy","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen Cilag International NV; Tel. +3214602111; E-mail: contact@Janssen-emea.com","first_published_date":"10/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002559-pip06-22"},{"decision_number":"P/0472/2022","pip_number":"EMEA-002370-PIP03-22","active_substance":"pemigatinib","invented_name":"Pemazyre","therapeutic_area":"Oncology","pharmaceutical_forms":"","condition_indication":"Treatment of myeloid/lymphoid neoplasms with eosinophilia and gene rearrangement","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Incyte Biosciences Distribution B.V.; E-mail: RA@incyte.com","first_published_date":"10/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002370-pip03-22"},{"decision_number":"P/0347/2023","pip_number":"EMEA-001441-PIP07-21-M01","active_substance":"semaglutide","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of obesity","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; E-mail: paediatrics@novonordisk.com ; Tel.: +45 44448888","first_published_date":"10/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001441-pip07-21-m01"},{"decision_number":"P/0479/2022","pip_number":"EMEA-003269-PIP01-22","active_substance":"2-{4-[4-(4-{5-[(1S)-1-amino-1-(4-fluorophenyl) ethyl]pyrimidin-2-yl}piperazin-1-yl)pyrrolo[2,1-f] [1,2,4]triazin-6-yl]-1H-pyrazol-1-yl}ethan-1-ol","invented_name":"","therapeutic_area":"Haematology-Hemostaseology;Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of mastocytosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Blueprint Medicines (Netherlands) B.V.; E-mail: medinfo@blueprintmedicines.com; Tel. +31 858880230","first_published_date":"10/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003269-pip01-22"},{"decision_number":"P/0520/2022","pip_number":"EMEA-003200-PIP01-22","active_substance":"stiripentol","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Powder for oral suspension;Capsule, hard","condition_indication":"Treatment of primary hyperoxaluria","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"30/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biocodex SA; E-mail: reglementaire@biocodex.fr; Tel. +33 141243000","first_published_date":"10/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003200-pip01-22"},{"decision_number":"P/0016/2023","pip_number":"EMEA-002881-PIP01-20-M01","active_substance":"Evoncabtagene pazurgedleucel","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Dispersion for injection","condition_indication":"Treatment of B-lymphoblastic leukaemia/lymphoma;Treatment of mature B cell neoplasms","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CRISPR Therapeutics AG; Email: info@crisprtx.com; Tel. +1 6173154600","first_published_date":"08/09/2022","last_updated_date":"09/11/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002881-pip01-20-m01"},{"decision_number":"P/0055/2023","pip_number":"EMEA-002814-PIP02-21-M01","active_substance":"Neisseria meningitidis serogroup B fHbp subfamily A;Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid carrier protein;Neisseria meningitidis serogroup B fHbp subfamily B;Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid carrier protein;Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid carrier protein;Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid carrier protein (MenABCWY)","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Powder and suspension for suspension for injection","condition_indication":"Prevention of invasive disease caused by Neisseria meningitidis group A, B, C, W and Y","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIGE-mail: medical.information@pfizer.com Tel. +44 1304646607","first_published_date":"17/04/2023","last_updated_date":"09/11/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002814-pip02-21-m01"},{"decision_number":"P/0058/2023","pip_number":"EMEA-002795-PIP02-21-M01","active_substance":"Respiratory Syncytial Virus stabilised prefusion F subunit vaccine","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Prevention of lower respiratory tract disease caused by respiratory syncytial virus","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"24/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG  E-mail: medical.information@pfizer.com Tel: +44 (0)1304 616161","first_published_date":"13/06/2023","last_updated_date":"09/11/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002795-pip02-21-m01"},{"decision_number":"P/0046/2023","pip_number":"EMEA-002730-PIP04-21-M01","active_substance":"Exagamglogene autotemcel","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of beta-thalassemia intermedia and major","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"24/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vertex Pharmaceuticals (Ireland) Limited; E-mail: vertexmedicalinfo@vrtx.com; Tel: +353 17617299","first_published_date":"09/03/2023","last_updated_date":"09/11/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002730-pip04-21-m01"},{"decision_number":"P/0048/2023","pip_number":"EMEA-002726-PIP01-19-M03","active_substance":"garadacimab","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of hereditary angioedema attacks","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CSL Behring GmbH; E-mail: PIP.CSLBehring@cslbehring.com; Tel.:  +41 (0)794670392","first_published_date":"22/09/2021","last_updated_date":"09/11/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002726-pip01-19-m03"},{"decision_number":"P/0036/2023","pip_number":"EMEA-003337-PIP01-22","active_substance":"diclofenac;orphenadrine (citrate)","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Solution for infusion;Tablet","condition_indication":"Treatment of pain","routes_of_administration":"Intravenous use;Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Verisfield Single Member S.A.Email: pharmacovigilance@verisfield.gr; economou@verisfield.gr Tel: +30 2107475196&nbsp","first_published_date":"09/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003337-pip01-22"},{"decision_number":"P/0043/2023","pip_number":"EMEA-003311-PIP01-22","active_substance":"tetanus toxoid","invented_name":"Tetana","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of infectious disease caused by Clostridium tetani","routes_of_administration":"Intramuscular use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"IBSS Biomed S.A.; E-mail: katarzyna.forys@biomed.pl; Tel: +48 123769306","first_published_date":"09/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003311-pip01-22"},{"decision_number":"P/0032/2023","pip_number":"EMEA-003310-PIP01-22","active_substance":"setanaxib","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of primary biliary cholangitis","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Calliditas Therapeutics France SAS; E-mail: info@calliditas.com; Tel: +46 84113005","first_published_date":"09/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003310-pip01-22"},{"decision_number":"P/0042/2023","pip_number":"EMEA-003308-PIP01-22","active_substance":"rivaroxaban;acetylsalicylic acid","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Prevention of atherothrombotic events","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alfred E. Tiefenbacher (GmbH & Co. KG); Tel. +49 404418090; E-mail: regaffairs@aet.eu","first_published_date":"09/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003308-pip01-22"},{"decision_number":"P/0001/2023","pip_number":"EMEA-003295-PIP01-22","active_substance":"rosuvastatin calcium;fenofibrate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of  elevated cholesterol with elevated triglycerides","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Althera Laboratories LtdEmail: regulatory.eu@altheralabs.com Tel: +353 861838865","first_published_date":"09/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003295-pip01-22"},{"decision_number":"P/0035/2023","pip_number":"EMEA-003292-PIP02-22","active_substance":"diclofenac (sodium);pyridoxine (hydrochloride);cyanocobalamin","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Treatment of familial Mediterranean fever","condition_indication":"Treatment of inflammatory pain;Treatment of inflammatory rheumatic diseases","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Verisfield Single Member S.A.Email: pharmacovigilance@verisfield.gr; economou@verisfield.gr Tel: +30 2107475196&nbsp","first_published_date":"09/11/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003292-pip02-22"},{"decision_number":"P/0164/2022","pip_number":"EMEA-002232-PIP02-19-M02","active_substance":"bis-choline tetrathiomolybdate","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Age appropriate oral solid dosage form;Coated tablet","condition_indication":"Treatment of Wilson Disease","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alexion Europe SAS; E-mail: pip.enquiries.eu@alexion.com; Tel. +33 147103621","first_published_date":"05/03/2021","last_updated_date":"09/11/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002232-pip02-19-m02"},{"decision_number":"P/0242/2022","pip_number":"EMEA-001452-PIP01-13-M04","active_substance":"daprodustat","invented_name":"","therapeutic_area":"Haematology-Hemostaseology;Uro-nephrology","pharmaceutical_forms":"Dispersible tablet;Tablet","condition_indication":"Treatment of anaemia due to chronic disorders","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Tel. +1 438-899-8201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"22/08/2014","last_updated_date":"07/11/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001452-pip01-13-m04"},{"decision_number":"P/0153/2015","pip_number":"EMEA-001606-PIP02-14","active_substance":"calcipotriol","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Medicated nail lacquer","condition_indication":"Treatment of psoriasis","routes_of_administration":"Cutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/07/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Polichem SA ; Luxembourg ; Tel. + 41 919864024; E-mail: maurizio.caserini@polichem.com","first_published_date":"25/08/2015","last_updated_date":"07/11/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001606-pip02-14"},{"decision_number":"P/0480/2022","pip_number":"EMEA-003168-PIP01-21","active_substance":"sirolimus","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Cream","condition_indication":"Treatment of tuberous sclerosis complex","routes_of_administration":"Cutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"02/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Desitin Arzneimittel GmbH ; Germany ; E-mail: info@desitin.de ; Tel. +49 4059101525","first_published_date":"26/10/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003168-pip01-21"},{"decision_number":"P/0510/2022","pip_number":"EMEA-003172-PIP01-21","active_substance":"emactuzumab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of tenosynovial giant cell tumour","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"02/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Synox Therapeutics Limited; E-mail: enquiries@synoxtherapeutics.com; Tel:  +44 7376066175","first_published_date":"26/10/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003172-pip01-21"},{"decision_number":"P/0475/2022","pip_number":"EMEA-003183-PIP02-22","active_substance":"exanatide","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of idiopathic intracranial hypertension","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Invex Therapeutics Ltd; E-mail: info@invextherapeutics.com; Tel:  +61 (08)63820137","first_published_date":"26/10/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003183-pip02-22"},{"decision_number":"P/0512/2022","pip_number":"EMEA-003273-PIP01-22","active_substance":"cobolimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Glaxo Group Limited; Tel. +1 4388998201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"26/10/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003273-pip01-22"},{"decision_number":"P/0548/2022","pip_number":"EMEA-000662-PIP02-09-M05","active_substance":"aluminium hydroxide adsorbed;depigmented glutaraldehyde polymerised;alder pollen;birch pollen;hazel pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Subcutaneous use","decision_type":"RPM: decision refers to a refusal on the application for modification of an agreed PIP","decision_date":"30/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Leti Pharma GmbH; Germany; E-mail: paediatrics@leti.de; Tel. +49 230 2202 860; Fax +49 230 2202 8623","first_published_date":"20/12/2010","last_updated_date":"25/10/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000662-pip02-09-m05"},{"decision_number":"P/0531/2022","pip_number":"EMEA-000716-PIP01-09-M05","active_substance":"siponimod (hemifumarate)","invented_name":"Mayzent","therapeutic_area":"Neurology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of multiple sclerosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"29/07/2010","last_updated_date":"25/10/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000716-pip01-09-m05"},{"decision_number":"P/0526/2022","pip_number":"EMEA-000838-PIP01-10-M02","active_substance":"aluminium hydroxide adsorbed;depigmented glutaraldehyde polymerised;birch pollen;alder pollen;hazel pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"RPM: decision refers to a refusal on the application for modification of an agreed PIP","decision_date":"30/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LETI Pharma GmbH; paediatrics@leti.de; Germany; Phone: +49 2302202860; Fax: +49 23022028620","first_published_date":"21/12/2010","last_updated_date":"25/10/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000838-pip01-10-m02"},{"decision_number":"P/0527/2022","pip_number":"EMEA-000837-PIP01-10-M02","active_substance":"aluminium hydroxide adsorbed;depigmented glutaraldehyde polymerised;birch pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"RPM: decision refers to a refusal on the application for modification of an agreed PIP","decision_date":"30/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LETI Pharma GmbH; paediatrics@leti.de; Germany; Phone: +49 2302202860; Fax: +49 23022028620","first_published_date":"21/12/2010","last_updated_date":"25/10/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000837-pip01-10-m02"},{"decision_number":"P/0538/2022","pip_number":"EMEA-003320-PIP01-22","active_substance":"ezeprogind","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of progressive supranuclear palsy","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alzprotect S.A.S., France; E-mail: contact@alzprotect.com; Tel: +33 359537045","first_published_date":"24/10/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003320-pip01-22"},{"decision_number":"P/0532/2022","pip_number":"EMEA-003298-PIP01-22","active_substance":"Messenger RNA encoding Cas9 and single guide RNA targeting the human TTR gene","invented_name":"","therapeutic_area":"Cardiovascular diseases;Neurology","pharmaceutical_forms":"Suspension for infusion","condition_indication":"Treatment of transthyretin amyloidosis (ATTR)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Intellia Therapeutics Inc.E-mail: medicalinformation@intelliatx.com Tel: +1 8338880387","first_published_date":"24/10/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003298-pip01-22"},{"decision_number":"P/0534/2022","pip_number":"EMEA-003294-PIP01-22","active_substance":"eplontersen","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of transthyretin amyloidosis (ATTR)","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca ABEmail: paediatrics@astrazeneca.comTel. +46 855324400","first_published_date":"24/10/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003294-pip01-22"},{"decision_number":"P/0499/2022","pip_number":"EMEA-003292-PIP01-22","active_substance":"cyanocobalamin;diclofenac (potassium);pyridoxine (hydrochloride);thiamine hydrochloride","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation;Pain","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of inflammatory pain;Treatment of inflammatory rheumatic diseases","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Verisfield Single Member S.A.Email: pharmacovigilance@verisfield.gr; economou@verisfield.gr Tel: +30 2107475196&nbsp","first_published_date":"24/10/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003292-pip01-22"},{"decision_number":"P/0516/2022","pip_number":"EMEA-003291-PIP01-22","active_substance":"acetylsalicylic acid;rivaroxaban","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Prevention of atherothrombotic events","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"PharOS Pharmaceutical Oriented Services Single Member Ltd; Tel:  +30 2106664667; E-mail: pharmacovigilance@pharosgr.gr","first_published_date":"24/10/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003291-pip01-22"},{"decision_number":"P/0530/2022","pip_number":"EMEA-003289-PIP01-22","active_substance":"eplerenone;torasemide","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of heart failure","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Win Medica S.A.; E-mail: info@winmedica.gr; Tel. +30 2107488821","first_published_date":"24/10/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003289-pip01-22"},{"decision_number":"P/0547/2022","pip_number":"EMEA-003285-PIP01-22","active_substance":"Indapamide;valsartan","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Modified-release tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"KRKA, d.d., Novo mesto; E-mail: Regulatory.Affairs@krka.biz; Tel: +386 73312055","first_published_date":"24/10/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003285-pip01-22"},{"decision_number":"P/0482/2022","pip_number":"EMEA-003282-PIP01-22","active_substance":"2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indan-2-carboxylic acid","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of systemic sclerosis","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Horizon Therapeutics Ireland DAC; E-mail: customerservice@horizontherapeutics.com; Tel.: +1 866 479 6742","first_published_date":"24/10/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003282-pip01-22"},{"decision_number":"P/0462/2022","pip_number":"EMEA-003087-PIP01-21","active_substance":"resmetirom","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Age appropriate oral solid dosage form","condition_indication":"Treatment of non-alcoholic steatohepatitis (NASH)","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Madrigal Pharmaceuticals EU Limited; Tel.  +353 18851710; E-mail: info@transcrip-group.com","first_published_date":"12/10/2023","last_updated_date":"20/10/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003087-pip01-21"},{"decision_number":"P/0142/2019","pip_number":"EMEA-002480-PIP01-18","active_substance":"tislelizumab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (excluding central nervous system, haematopoietic and lymphoid tissue neoplasms)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/04/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BeiGene Ireland Ltd.; E-mail: bg.ireland@beigene.com; Tel. +353 15667660","first_published_date":"24/06/2019","last_updated_date":"20/10/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002480-pip01-18"},{"decision_number":"P/0542/2022","pip_number":"EMEA-002880-PIP01-20-M01","active_substance":"COVID-19 vaccine (Ad26.COV2-S (recombinant))","invented_name":"Jcovden (previously COVID-19 Vaccine Janssen)","therapeutic_area":"Infectious diseases;Vaccines","pharmaceutical_forms":"Suspension for injection in cartridge","condition_indication":"Prevention of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International N.V.; Tel. +32 14602111; E-mail: contact@Janssen-emea.com","first_published_date":"16/02/2021","last_updated_date":"13/10/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002880-pip01-20-m01"},{"decision_number":"P/0476/2022","pip_number":"EMEA-002807-PIP01-20-M01","active_substance":"Durlobactam / sulbactam (SUL-DUR)","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of infections due to organisms of the Acinetobacter baumannii-calcoaceticus complex","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Entasis Therapeutics Inc.; Email: Enquiries@entasistx.com; Tel. +1 7818108940;  ","first_published_date":"20/09/2021","last_updated_date":"13/10/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002807-pip01-20-m01"},{"decision_number":"P/0500/2022","pip_number":"EMEA-002778-PIP01-20-M01","active_substance":"Gadoquatrane (BAY 1747846)","invented_name":"","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Solution for injection","condition_indication":"Diagnosis by evaluation of any known or suspected clinical condition with contrast enhanced magnetic resonance imaging","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer AG; Tel. +49 30300139003; E-mail: clinical-trials-contact@bayer.com","first_published_date":"21/07/2021","last_updated_date":"13/10/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002778-pip01-20-m01"},{"decision_number":"P/0537/2022","pip_number":"EMEA-002397-PIP01-18-M03","active_substance":"ofatumumab","invented_name":"Kesimpta","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of multiple sclerosis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Ireland Limited; E-mail: paediatric.enquiries@novartis.com; Tel: +41 613241111","first_published_date":"29/10/2019","last_updated_date":"13/10/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002397-pip01-18-m03"},{"decision_number":"P/0491/2022","pip_number":"EMEA-002356-PIP02-20-M01","active_substance":"voxelotor","invented_name":"Oxbryta","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Tablet;Dispersible tablet","condition_indication":"Treatment of sickle cell disease","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"02/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Global Blood Therapeutics Netherlands B. V.E-mail: medical.information@pfizer.com","first_published_date":"17/09/2021","last_updated_date":"13/10/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002356-pip02-20-m01"},{"decision_number":"P/0430/2022","pip_number":"EMEA-003250-PIP01-22","active_substance":"Fluorine (18F) PSMA-1007","invented_name":"","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Solution for injection","condition_indication":"Visualisation of prostate specific membrane antigen in prostate cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BIOKOSMOS S.A.; email: ra.team@pharmassist-cro.com; tel: +30 2106560700","first_published_date":"12/10/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003250-pip01-22"},{"decision_number":"P/0451/2022","pip_number":"EMEA-002534-PIP03-22","active_substance":"trilaciclib (dihydrochloride)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of breast cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"G1 Therapeutics, Inc.; email: regulatory@g1therapeutics.com; tel: +1 9087833356","first_published_date":"12/10/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002534-pip03-22"},{"decision_number":"P/0450/2022","pip_number":"EMEA-002338-PIP03-21","active_substance":"lanalumab","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Systemic Lupus Erythematosus (SLE)","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"12/10/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002338-pip03-21"},{"decision_number":"P/0449/2022","pip_number":"EMEA-002204-PIP02-20","active_substance":"branaplam","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of Huntington's disease","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"12/10/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002204-pip02-20"},{"decision_number":"P/0448/2022","pip_number":"EMEA-001625-PIP03-21","active_substance":"satralizumab","invented_name":"Enspryng","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of myelin oligodendrocyte glycoprotein antibody-associated disease","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"12/10/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001625-pip03-21"},{"decision_number":"P/0382/2023","pip_number":"EMEA-000645-PIP04-20-M02","active_substance":"vedolizumab","invented_name":"Entyvio","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Powder for concentrate for solution for infusion;Solution for injection","condition_indication":"Treatment of pouchitis","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Pharma A/S; E-mail: paediatrics@tgrd.com; Tel. +44 2031168000","first_published_date":"11/02/2022","last_updated_date":"12/10/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000645-pip04-20-m02"},{"decision_number":"P/0463/2022","pip_number":"EMEA-003117-PIP02-21","active_substance":"Freeze-dried allergen extract of Betula pendula pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Solution for skin-prick test","condition_indication":"Diagnosis of IgE mediated allergy to tree pollen of the birch group","routes_of_administration":"Epicutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"12/10/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003117-pip02-21"},{"decision_number":"P/0433/2022","pip_number":"EMEA-003108-PIP01-21","active_substance":"cenerimod","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Age appropriate oral solid dosage form;Film-coated tablet","condition_indication":"Treatment of Systemic Lupus Erythematosus (SLE)","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Idorsia Pharmaceuticals Deutschland GmbH  E-mail: clinical-trials-disclosure@idorsia.com  Tel. +41 588440000 &nbsp","first_published_date":"12/10/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003108-pip01-21"},{"decision_number":"P/0425/2022","pip_number":"EMEA-003030-PIP02-21","active_substance":"Yellow fever virus, strain vYF-247","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Prevention of Yellow Fever disease","routes_of_administration":"Intramuscular use;Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi PasteurE-mail: contact-us@sanofi.comTel. +33 1 6974 5695","first_published_date":"12/10/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003030-pip02-21"},{"decision_number":"P/0429/2022","pip_number":"EMEA-002845-PIP01-20","active_substance":"recombinant fusion protein linking iduronate 2-sulfatase to engineered Fc with binding site for transferrin receptor (DNL310)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of mucopolysaccharidosis II (Hunter syndrome)","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Denali Therapeutics Inc.E-mail: DNL310Inquiries-team@dnli.comTel.  +1 6508668548 ext 1033","first_published_date":"12/10/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002845-pip01-20"},{"decision_number":"P/0457/2022","pip_number":"EMEA-001983-PIP01-16-M01","active_substance":"3,6-diamino-2,5-bis{N-[(1R)-1-carboxy-2-hydroxyethyl]carbamoyl}pyrazine (MB-102)","invented_name":"","therapeutic_area":"Diagnostic;Uro-nephrology","pharmaceutical_forms":"Solution for injection","condition_indication":"Monitoring of renal function","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"MediBeacon Inc.; United States; Tel.: +1 3147350971; E-mail: hanley@medibeacon.com","first_published_date":"03/07/2017","last_updated_date":"05/10/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001983-pip01-16-m01"},{"decision_number":"P/0456/2022","pip_number":"EMEA-001798-PIP02-16-M01","active_substance":"Enasidenib","invented_name":"","therapeutic_area":"Haematology-Hemostaseology;Oncology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of acute myeloid leukaemia","routes_of_administration":"Oral use;Gastric use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"13/02/2018","last_updated_date":"05/10/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001798-pip02-16-m01"},{"decision_number":"P/0455/2022","pip_number":"EMEA-001765-PIP02-15-M04","active_substance":"atidarsagene autotemcel","invented_name":"Libmeldy","therapeutic_area":"Other","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of metachromatic leukodystrophy (MLD)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Orchard Therapeutics (Netherlands) B.V.; regulatory@orchard-tx.com; Tel. +44 (0) 20 3808 8286","first_published_date":"26/07/2017","last_updated_date":"05/10/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001765-pip02-15-m04"},{"decision_number":"P/0179/2023","pip_number":"EMEA-001623-PIP01-14-M06","active_substance":"Finerenone","invented_name":"Kerendia","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral dosage formulation","condition_indication":"Treatment of chronic kidney disease","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/05/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer AG; Tel. +49 30300139003; E-mail: clinical-trials-contact@bayer.com","first_published_date":"05/03/2015","last_updated_date":"05/10/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001623-pip01-14-m06"},{"decision_number":"P/0384/2023","pip_number":"EMEA-001523-PIP03-18-M03","active_substance":"Guselkumab","invented_name":"Tremfya","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis)","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; Tel. +32 1460 2111; E-mail: contact@janssen-emea.com","first_published_date":"11/04/2019","last_updated_date":"05/10/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001523-pip03-18-m03"},{"decision_number":"P/0418/2022","pip_number":"EMEA-003174-PIP02-22","active_substance":"pridopidine hydrochloride","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of amyotrophic lateral sclerosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Prilenia Therapeutics B.V.E-mail: info@prilenia.comTel. +31 358080509","first_published_date":"05/10/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003174-pip02-22"},{"decision_number":"P/0452/2022","pip_number":"EMEA-003162-PIP02-22","active_substance":"batoclimab","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of thyroid eye disease","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Immunovant Sciences, GmbH; E-mail: regulatoryaffairs@immunovant.com; Tel. +1 3174175110","first_published_date":"04/10/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003162-pip02-22"},{"decision_number":"P/0375/2022","pip_number":"EMEA-003137-PIP01-21","active_substance":"Ex vivo expanded autologous human keratinocytes containing epidermal stem cells genetically modified with a gamma-retroviral (RV) vector expressing the full-length LAMB3 cDNA (Hologene 5)","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Living tissue equivalent","condition_indication":"Treatment of epidermolysis bullosa","routes_of_administration":"Implant use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Holostem Terapie Avanzate S.r.l.;  +39 3492403930; regulatory@holostem.com","first_published_date":"28/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003137-pip01-21"},{"decision_number":"P/0403/2022","pip_number":"EMEA-002600-PIP04-22","active_substance":"pegcetacoplan","invented_name":"Aspaveli","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of amyotrophic lateral sclerosis","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Apellis Netherlands B.V.; email: Regulatory-Info@apellis.com; tel: +33 643746980","first_published_date":"28/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002600-pip04-22"},{"decision_number":"P/0393/2022","pip_number":"EMEA-001371-PIP02-21","active_substance":"clazakizumab","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for infusion","condition_indication":"Prevention and treatment of rejection of transplanted kidney","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CSL Behring GmbHEmail: PIP.CSLBehring@cslbehring.com Tel: +49 (0)64213912","first_published_date":"28/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001371-pip02-21"},{"decision_number":"P/0249/2019","pip_number":"EMEA-001656-PIP02-19","active_substance":"Momelotinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of myelofibrosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/06/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Tel. +1 438-899-8201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"08/11/2019","last_updated_date":"28/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001656-pip02-19"},{"decision_number":"P/0443/2022","pip_number":"EMEA-002285-PIP02-19-M02","active_substance":"marstacimab","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of congenital haemophilia A;Treatment of congenital haemophilia B","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG; Tel. +44 (0)1304 646 607; E-mail: pip_enquiries@pfizer.com","first_published_date":"18/06/2021","last_updated_date":"28/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002285-pip02-19-m02"},{"decision_number":"P/0442/2022","pip_number":"EMEA-002172-PIP02-17-M02","active_substance":"monovalent, recombinant, replication-incompetent human adenovirus serotype 26-vectored vaccine encoding the pre-fusion conformation-stabilised F protein derived from the RSV A2 strain","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV)","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; E-mail: contact@janssen-emea.com; Tel.: +32 14602111","first_published_date":"28/01/2019","last_updated_date":"28/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002172-pip02-17-m02"},{"decision_number":"P/0458/2022","pip_number":"EMEA-002116-PIP01-17-M01","active_substance":"Insulin human (NTRA-2112)","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Powder for oral solution","condition_indication":"Treatment of intestinal malabsorption in preterm infants","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ELGAN Pharma Ltd; E-mail: RA@elganpharma.com; Tel: +972 532437322","first_published_date":"19/06/2018","last_updated_date":"28/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002116-pip01-17-m01"},{"decision_number":"P/0453/2022","pip_number":"EMEA-002033-PIP01-16-M03","active_substance":"vosoritide","invented_name":"Voxzogo","therapeutic_area":"Other","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of achondroplasia","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"24/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BioMarin International Limited; Tel. +44 (0)20 7420 0800; E-mail: biomarin-europe@bmrn.com","first_published_date":"05/03/2018","last_updated_date":"28/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002033-pip01-16-m03"},{"decision_number":"P/0461/2022","pip_number":"EMEA-003261-PIP01-22","active_substance":"Finasteride;tadalafil","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of patients with benign prostatic hyperplasia","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Adamed Pharma S.A.E-mail: RA-EU@adamed.comTel: +48 697063916","first_published_date":"28/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003261-pip01-22"},{"decision_number":"P/0460/2022","pip_number":"EMEA-003262-PIP01-22","active_substance":"rosuvastatin calcium;telmisartan","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events;Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Adamed Pharma S.A.; E-mail: adamed@adamed.com; Tel: +48 227327700","first_published_date":"28/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003262-pip01-22"},{"decision_number":"P/0459/2022","pip_number":"EMEA-003260-PIP01-22","active_substance":"derivative of (3S,3'S,3a'S,10a'S)-3'-phenyl-3',3a',10',10a'-tetrahydro-1'H-spiro[indoline-3,2'- pyrrolo[2',3':4,5]pyrrolo[1,2-b]indazol]-2-one","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of liposarcoma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"28/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003260-pip01-22"},{"decision_number":"P/0419/2022","pip_number":"EMEA-003255-PIP01-22","active_substance":"lidocaine hydrochloride","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Dental gel","condition_indication":"Local anaesthesia","routes_of_administration":"Oromucosal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Acumen Dental Limited; E-mail: ra.team@pharmassist-cro.com; Tel: +30 2106560700","first_published_date":"27/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003255-pip01-22"},{"decision_number":"P/0420/2022","pip_number":"EMEA-003252-PIP01-22","active_substance":"3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of multiple system atrophy","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Teva B.V.; E-mail: MedInfo@tevaeu.com; Tel: +44 (0)2075407117","first_published_date":"27/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003252-pip01-22"},{"decision_number":"P/0055/2017","pip_number":"EMEA-000576-PIP02-11-M04","active_substance":"tofacitinib","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Film-coated tablet;Oral solution","condition_indication":"Treatment of psoriasis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/03/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Limited; Tel. + 44 1304646607; E-mail: pip_enquiries@pfizer.com","first_published_date":"27/11/2012","last_updated_date":"27/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000576-pip02-11-m04"},{"decision_number":"P/0180/2022","pip_number":"EMEA-001904-PIP03-18-M02","active_substance":"brincidofovir","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Oral suspension;Film-coated tablet","condition_indication":"Treatment of smallpox","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Emergent Operations Ireland, Ltd; Email: oreillyk@ebsi.com; Tel. +353 1 634 3214","first_published_date":"20/02/2019","last_updated_date":"26/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001904-pip03-18-m02"},{"decision_number":"P/0374/2022","pip_number":"EMEA-003235-PIP01-22","active_substance":"xevinapant","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of head and neck epithelial malignant neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Healthcare KGaAEmail: service@merckgroup.comTel.: +49 6151725200","first_published_date":"25/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003235-pip01-22"},{"decision_number":"P/0388/2022","pip_number":"EMEA-003234-PIP01-22","active_substance":"oleclumab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer;Treatment of pancreatic cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel. +46 8553 27591","first_published_date":"25/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003234-pip01-22"},{"decision_number":"P/0389/2022","pip_number":"EMEA-003231-PIP01-22","active_substance":"autologous CD4+ and CD8+ T cells transduced with lentiviral vector encoding a chimeric antigen receptor (CAR) directed against human B cell maturation antigen (BCMA) and preserving the T cell phenotype of the leukapheresis starting material (PHE885)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of Multiple Myeloma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"25/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003231-pip01-22"},{"decision_number":"P/0406/2022","pip_number":"EMEA-003230-PIP01-22","active_substance":"vepsitamab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of colorectal carcinoma;Treatment of gastric and gastro-oesophageal junction cancer;Treatment of pancreatic cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V; Tel.: +44 (0)1223 420305; E-mail: medinfointernational@amgen.com","first_published_date":"25/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003230-pip01-22"},{"decision_number":"P/0377/2022","pip_number":"EMEA-003229-PIP01-22","active_substance":"amlodipine;hydrochlorothiazide;telmisartan","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Krka, d.d., Novo mesto; E-mail: stasa.taferner@krka.biz; Country: Slovenia; Tel. + 386 73312657","first_published_date":"25/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003229-pip01-22"},{"decision_number":"P/0376/2022","pip_number":"EMEA-003228-PIP01-22","active_substance":"rosuvastatin;perindopril","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated dispersible tablet","condition_indication":"Prevention of cardiovascular events;Treatment of dyslipidaemia;Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"KRKA, d.d., Novo mestoE-mail: Regulatory.Affairs@krka.bizTel. + 38 673312111","first_published_date":"22/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003228-pip01-22"},{"decision_number":"P/2/2010","pip_number":"EMEA-000458-PIP01-08","active_substance":"(1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy- 10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,- 14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]- oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyldimethyl-phosphinate (MK-8669, or AP23573)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Gastro-resistant tablet;Age appropriate dosage form, other;Age appropriate dosage form for parenteral use","condition_indication":"Treatment of solid malignant tumours","routes_of_administration":"Oral use;Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"25/01/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp and Dohme (Europe), Inc.; Belgium; E-mail: axel_breitstadt@merck.com; Tel. +32 2776 6045; Fax +32 2776 6288","first_published_date":"25/02/2010","last_updated_date":"22/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000458-pip01-08"},{"decision_number":"P/0409/2022","pip_number":"EMEA-002713-PIP01-19-M02","active_substance":"Etrasimod L-arginine","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of ulcerative colitis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Arena Pharmaceuticals, Inc.; E-mail: PIP_Enquiries@pfizer.com; Tel: +44 (0)1304656607","first_published_date":"22/09/2021","last_updated_date":"21/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002713-pip01-19-m02"},{"decision_number":"P/0414/2022","pip_number":"EMEA-002756-PIP01-19-M01","active_substance":"sotatercept","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of pulmonary arterial hypertension","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"26/04/2022","last_updated_date":"21/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002756-pip01-19-m01"},{"decision_number":"P/0405/2022","pip_number":"EMEA-002751-PIP02-22","active_substance":"monalizumab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; Tel. +46 855259283; E-mail: paediatrics@astrazeneca.com","first_published_date":"21/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002751-pip02-22"},{"decision_number":"P/0384/2022","pip_number":"EMEA-003097-PIP01-21","active_substance":"corticotropin","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of infantile spasms","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"23/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amzell B.V.; email: laetitia.delpy@amzell.com; tel: +41 764914132","first_published_date":"21/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003097-pip01-21"},{"decision_number":"P/0413/2022","pip_number":"EMEA-002685-PIP02-19-M01","active_substance":"Diroximel fumarate (BIIB098)","invented_name":"Vumerity","therapeutic_area":"Neurology","pharmaceutical_forms":"Gastro-resistant capsule (hard)","condition_indication":"Treatment of multiple sclerosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biogen Netherlands B.V.; E-mail: pip.enquiries@biogen.com; Tel. +44 1628 512669","first_published_date":"06/07/2021","last_updated_date":"20/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002685-pip02-19-m01"},{"decision_number":"P/0371/2022","pip_number":"EMEA-003224-PIP01-22","active_substance":"bismuth (subcitrate);Metronidazole (benzoate);tetracycline hydrochloride","invented_name":"","therapeutic_area":"Gastroentology-Hepatology;Infectious diseases","pharmaceutical_forms":"Granules","condition_indication":"Treatment of Helicobacter pylori infection","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Verisfield Single Member S.A.Email: pharmacovigilance@verisfield.gr; economou@verisfield.gr Tel: +30 2107475196&nbsp","first_published_date":"19/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003224-pip01-22"},{"decision_number":"P/0396/2022","pip_number":"EMEA-001418-PIP01-13-M05","active_substance":"cabotegravir","invented_name":"Vocabria","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Age appropriate oral dosage formulation;Film-coated tablet;Prolonged-release suspension for injection","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Intramuscular use;Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ViiV Healthcare UK Limited; E-mail: eu.paediatric-plans@gsk.com; Tel.: +44 (0)2089903650","first_published_date":"26/11/2021","last_updated_date":"19/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001418-pip01-13-m05"},{"decision_number":"P/0400/2022","pip_number":"EMEA-001557-PIP01-13-M06","active_substance":"roxadustat","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of anaemia due to chronic disorders","routes_of_administration":"Oral use;Gastric use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Astellas Pharma Europe B.V.Tel. +31 7154 55878E-mail: contact.nl@astellas.com&nbsp","first_published_date":"05/03/2015","last_updated_date":"19/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001557-pip01-13-m06"},{"decision_number":"P/0402/2022","pip_number":"EMEA-001577-PIP02-14-M05","active_substance":"emtricitabine;tenofovir alafenamide","invented_name":"Descovy; Descovy","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Age appropriate oral formulation;Film-coated tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd; E-mail: regulatory.pip@gilead.com; Tel. +44 (0)1223 897300","first_published_date":"05/03/2015","last_updated_date":"19/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001577-pip02-14-m05"},{"decision_number":"P/0390/2022","pip_number":"EMEA-001990-PIP01-16-M05","active_substance":"fenfluramine hydrochloride","invented_name":"Fintepla","therapeutic_area":"Neurology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of Dravet syndrome","routes_of_administration":"Oral use;Gastric use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"UCB Pharma SA; Email: ucbcares.uk@ucb.com; Tel. +44 175777100;  ","first_published_date":"24/10/2017","last_updated_date":"18/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001990-pip01-16-m05"},{"decision_number":"P/0412/2022","pip_number":"EMEA-002016-PIP03-19-M02","active_substance":"alpelisib","invented_name":"Piqray","therapeutic_area":"Other","pharmaceutical_forms":"Film-coated tablet;Granules","condition_indication":"Treatment of PIK3CA related overgrowth spectrum","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"18/06/2021","last_updated_date":"18/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002016-pip03-19-m02"},{"decision_number":"P/0369/2022","pip_number":"EMEA-002087-PIP01-16-M01","active_substance":"anti-CD7 mAb conjugated to ricin toxin A chain;anti-CD3 mAb conjugated to ricin toxin A chain","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of acute graft versus host disease","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Xenikos BV; Tel. +31 243000100; E-mail: y.vanoosterhout@xenikos.com","first_published_date":"09/06/2020","last_updated_date":"18/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002087-pip01-16-m01"},{"decision_number":"P/0392/2022","pip_number":"EMEA-001710-PIP02-14-M07","active_substance":"Ozanimod (hydrochloride)","invented_name":"Zeposia","therapeutic_area":"Neurology","pharmaceutical_forms":"Capsule, hard;Age appropriate oral solid dosage form","condition_indication":"Treatment of multiple sclerosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Celgene Europe B.V.; Tel. +41 327298500; E-mail: medinfo.emea@celgene.com","first_published_date":"26/07/2017","last_updated_date":"18/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001710-pip02-14-m07"},{"decision_number":"P/0411/2022","pip_number":"EMEA-001659-PIP01-15-M06","active_substance":"burosumab","invented_name":"Crysvita","therapeutic_area":"Other","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of X-linked hypophosphataemia","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kyowa Kirin Holdings B.V.; Tel. +44 (0)1896 664000; E-mail: regulatorygroup@kyowakirin.com","first_published_date":"26/07/2017","last_updated_date":"18/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001659-pip01-15-m06"},{"decision_number":"P/0190/2022","pip_number":"EMEA-002042-PIP02-20-M01","active_substance":"Erdafitinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet;Age appropriate dosage form","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except urothelial carcinoma, haematopoietic and lymphoid tissue neoplasms)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/06/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International N.V.; E-mail: contact@Janssen-emea.com; Tel: +44 7824545660","first_published_date":"26/04/2022","last_updated_date":"15/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002042-pip02-20-m01"},{"decision_number":"P/24/2011","pip_number":"EMEA-000093-PIP02-10","active_substance":"sotrastaurin acetate","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Film-coated tablet;Age appropriate dosage form, other","condition_indication":"Prevention of rejection of transplanted kidney","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"26/01/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"24/02/2011","last_updated_date":"15/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000093-pip02-10"},{"decision_number":"P/155/2011","pip_number":"EMEA-000093-PIP01-07-M01","active_substance":"sotrastaurin acetate","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of chronic plaque psoriasis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/07/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"09/08/2011","last_updated_date":"15/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000093-pip01-07-m01"},{"decision_number":"P/0365/2022","pip_number":"EMEA-001623-PIP03-20-M01","active_substance":"Finerenone","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet;Age appropriate formulation","condition_indication":"Treatment of heart failure","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer AG; Tel. +49 202364913; Email: clinical-trials-contact@bayer.com    ","first_published_date":"22/07/2022","last_updated_date":"15/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001623-pip03-20-m01"},{"decision_number":"P/0373/2022","pip_number":"EMEA-000181-PIP02-13-M01","active_substance":"cannabidiol;delta-9-tetrahydrocannabinol","invented_name":"Sativex","therapeutic_area":"Pain","pharmaceutical_forms":"Oromucosal spray","condition_indication":"Treatment of pain","routes_of_administration":"Oromucosal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GW Pharma Ltd; United Kingdom; Tel. +44 (0)1223 266800; E-mail: medinfo@gwpharm.com","first_published_date":"12/12/2014","last_updated_date":"14/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000181-pip02-13-m01"},{"decision_number":"P/0397/2022","pip_number":"EMEA-000317-PIP02-18-M01","active_substance":"rilpivirine","invented_name":"Rekambys","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Prolonged release suspension for injection","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International N.V.; Tel.  +32 14602111; E-mail: contact@janssen-emea.com","first_published_date":"11/04/2019","last_updated_date":"14/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000317-pip02-18-m01"},{"decision_number":"P/0372/2022","pip_number":"EMEA-003248-PIP01-22","active_substance":"suvecaltamide hydrochloride","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of essential tremor","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Jazz Pharmaceuticals Ireland Ltd. E-mail: corporateaffairsmediainfo@jazzpharma.com Tel: +1 35316347800","first_published_date":"14/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003248-pip01-22"},{"decision_number":"P/0386/2022","pip_number":"EMEA-003246-PIP01-22","active_substance":"Golidocitinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of peripheral T cell lymphoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dizal (Jiangsu) Pharmaceuticals Co., Ltd.; E-mail: info@dizalpharma.com; Tel: +86 2161097840","first_published_date":"14/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003246-pip01-22"},{"decision_number":"P/0408/2022","pip_number":"EMEA-003243-PIP01-22","active_substance":"toripalimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of all conditions in the category of malignant neoplasms (except CNS, haematopoietic and lymphoid tissue and melanoma)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"TopAlliance Biosciences, Inc.; E-mail: regulatory@topalliancebio.com; Tel: +1 3016405166","first_published_date":"14/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003243-pip01-22"},{"decision_number":"P/0387/2022","pip_number":"EMEA-003240-PIP01-22","active_substance":"rosuvastatin;valsartan","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events;Treatment of dyslipidaemia;Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Teva B.V. Email: MedAffGenTevaEurope@tevapharm.com Tel. +385 13722001","first_published_date":"14/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003240-pip01-22"},{"decision_number":"P/0407/2022","pip_number":"EMEA-003239-PIP01-22","active_substance":"Dimeric protein comprised of two disulfide-linked monomers, each being a fully human fusion protein consisting of a modified extracellular domain of the human activin receptor type IIA fused to the fragment crystallizable domain of human IgG1 Fc including the hinge region, CH2 and CH3 domains (KER-050)","invented_name":"","therapeutic_area":"Haematology-Hemostaseology;Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of myelodysplastic syndromes;Treatment of myelofibrosis","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Keros Therapeutics, Inc.; E-mail: etreece@kerostx.com; Tel: +1 (617)3146297","first_published_date":"14/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003239-pip01-22"},{"decision_number":"P/0361/2022","pip_number":"EMEA-003236-PIP01-22","active_substance":"Gallium 68-labelled Prostate-Specific Membrane Antigen-11 (68Ga-PSMA-11)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Visualisation of prostate specific membrane antigen in prostate cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROTOP Pharmaka GmbH; Tel.  +49 35126310251; E-mail: reg-affairs@rotop-pharmaka.de","first_published_date":"14/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003236-pip01-22"},{"decision_number":"P/0352/2022","pip_number":"EMEA-000715-PIP02-11-M06","active_substance":"apremilast","invented_name":"Otezla","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Tablet;Oral liquid","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V. ; E-mail: medinfointernational@amgen.com; Tel. +44 (0)1223 420305","first_published_date":"23/08/2012","last_updated_date":"13/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000715-pip02-11-m06"},{"decision_number":"P/0353/2022","pip_number":"EMEA-000715-PIP05-13-M05","active_substance":"apremilast","invented_name":"Otezla; Otezla","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Tablet;Oral suspension","condition_indication":"Treatment of Behcet disease","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V. ; E-mail: medinfointernational@amgen.com; Tel. +44 (0)1223 420305","first_published_date":"25/07/2017","last_updated_date":"13/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000715-pip05-13-m05"},{"decision_number":"P/0360/2022","pip_number":"EMEA-000969-PIP01-10-M06","active_substance":"cobicistat","invented_name":"Tybost; Tybost","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Age appropriate dispersible tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"22/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd.; Tel. +44 (0)1223 897 300; E-mail: regulatory.pip@gilead.com","first_published_date":"14/07/2011","last_updated_date":"13/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000969-pip01-10-m06"},{"decision_number":"P/0296/2022","pip_number":"EMEA-001207-PIP02-19-M01","active_substance":"obinutuzumab","invented_name":"Gazyvaro","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Systemic Lupus Erythematosus (SLE)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"29/09/2021","last_updated_date":"13/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001207-pip02-19-m01"},{"decision_number":"P/0298/2022","pip_number":"EMEA-001475-PIP02-13-M02","active_substance":"Maralixibat chloride","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Oral liquid;Tablet","condition_indication":"Treatment of Alagille syndrome","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/04/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mirum PharmaceuticalsE-mail: medinfo@mirumpharma.com Tel.  +1 6506674085","first_published_date":"25/08/2015","last_updated_date":"13/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001475-pip02-13-m02"},{"decision_number":"P/0283/2022","pip_number":"EMEA-003214-PIP01-22","active_substance":"Humanized monoclonal antibody of IgG1 subtype targeting NRP1","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of diabetic retinopathy","routes_of_administration":"Intravitreal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"13/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003214-pip01-22-0"},{"decision_number":"P/0273/2022","pip_number":"EMEA-003216-PIP01-22","active_substance":"Magnesium lactate dihydrate Tramadol (hydrochloride)","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Orphinic Scientific Bis Sp. z o.o.; Email: office@orphinic.com","first_published_date":"13/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003216-pip01-22"},{"decision_number":"P/0282/2022","pip_number":"EMEA-003217-PIP01-22","active_substance":"modakafusp alfa","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of Multiple Myeloma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Pharma A/STel. +44 (0)3333000181E-mail: medinfoEMEA@takeda.com","first_published_date":"13/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003217-pip01-22"},{"decision_number":"P/0275/2022","pip_number":"EMEA-003223-PIP01-22","active_substance":"N-(6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)-2-((4-fluorobenzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide (RIST-4721)","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of palmoplantar pustulosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aristea Therapeutics, Inc.; Email: pediatrics@aristeatx.com; tel:+1 8589874089","first_published_date":"13/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003223-pip01-22"},{"decision_number":"P/0338/2022","pip_number":"EMEA-003226-PIP01-22","active_substance":"nebivolol (hydrochloride);amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Menarini Ricerche S.p.A. ; Italy; Tel. +39 0555680633; E-mail: prijli@menarini.it","first_published_date":"13/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003226-pip01-22"},{"decision_number":"P/0276/2022","pip_number":"EMEA-003227-PIP01-22","active_substance":"nebivolol (hydrochloride)","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Menarini Ricerche S.p.A.; Tel:+39 05556807607/458Email:scappellini@menarini-ricerche.it","first_published_date":"13/09/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003227-pip01-22"},{"decision_number":"P/0285/2022","pip_number":"EMEA-003148-PIP01-21","active_substance":"Oxytocin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Nasal spray (solution)","condition_indication":"Treatment of Prader-Willi syndrome","routes_of_administration":"Nasal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"OT4B; E-mail: media@ot4b.com; Tel: +33 189164311","first_published_date":"29/08/2023","last_updated_date":"06/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003148-pip01-21"},{"decision_number":"P/0222/2012","pip_number":"EMEA-001197-PIP01-11","active_substance":"Ioforminol","invented_name":"","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Solution for injection","condition_indication":"Visualisation of anatomical structures of the body during computed tomography for diagnostic purposes","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/10/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GE Healthcare; Norway; jelena.dunkel@ge.com; Phone: +47 23185755; Fax: +47 23186005","first_published_date":"27/11/2012","last_updated_date":"04/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001197-pip01-11"},{"decision_number":"P/0482/2020","pip_number":"EMEA-001136-PIP02-19-M01","active_substance":"avatrombopag","invented_name":"Doptelet","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Film-coated tablet;Powder for oral suspension","condition_indication":"Treatment of chemotherapy-induced thrombocytopenia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dova Pharmaceuticals Ireland Limited; E-mail: medical.info@sobi.com; Tel:  +46 86972000","first_published_date":"23/09/2021","last_updated_date":"01/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001136-pip02-19-m01"},{"decision_number":"P/0243/2019","pip_number":"EMEA-002310-PIP02-17","active_substance":"(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4- fluoropyrrolidine-2-carboxamide (ACH-0144471)","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of C3 glomerulopathy","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"17/07/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Achillion Pharmaceuticals, Inc.; Tel.+1 203 624 7000; E-mail: C3gpatientinquiries@achillion.com","first_published_date":"13/11/2019","last_updated_date":"01/09/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002310-pip02-17"},{"decision_number":"P/0335/2022","pip_number":"EMEA-001644-PIP02-14-M03","active_substance":"fluciclovine (18F)","invented_name":"Axumin; Axumin","therapeutic_area":"Diagnostic;Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Diagnosis of amino acid metabolism in solid malignant tumours","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Blue Earth Diagnostics Ireland Ltd; E-mail: contact@blueearthdx.com; Tel. +353 17617403","first_published_date":"21/12/2015","last_updated_date":"31/08/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001644-pip02-14-m03"},{"decision_number":"P/0290/2022","pip_number":"EMEA-001828-PIP01-15-M03","active_substance":"pegunigalsidase alfa","invented_name":"Elfabrio","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of Fabry disease","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Chiesi Farmaceutici S.p.A.; E-mail: m.toschi@chiesi.com; Tel: +39 05211689124","first_published_date":"02/06/2016","last_updated_date":"31/08/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001828-pip01-15-m03"},{"decision_number":"P/0343/2022","pip_number":"EMEA-002965-PIP01-21-M02","active_substance":"Imdevimab","invented_name":"Ronapreve","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Prevention of Coronavirus disease 2019 (COVID-19);Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"19/08/2021","last_updated_date":"31/08/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002965-pip01-21-m02"},{"decision_number":"P/0300/2022","pip_number":"EMEA-002964-PIP01-21-M02","active_substance":"casirivimab","invented_name":"Ronapreve","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Prevention of Coronavirus disease 2019 (COVID-19);Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"19/08/2021","last_updated_date":"31/08/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002964-pip01-21-m02"},{"decision_number":"P/0339/2022","pip_number":"EMEA-002189-PIP01-17-M03","active_substance":"bimekizumab","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of psoriasis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"UCB Biopharma SRL; Tel.  +44 1753777100; E-mail: UCBCares.UK@ucb.com","first_published_date":"27/11/2018","last_updated_date":"30/08/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002189-pip01-17-m03"},{"decision_number":"P/0351/2022","pip_number":"EMEA-001872-PIP01-15-M02","active_substance":"bempedoic acid (ETC-1002)","invented_name":"","therapeutic_area":"Cardiovascular diseases;Other","pharmaceutical_forms":"Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of elevated cholesterol","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Esperion Therapeutics, Inc.; E-mail: ahall@esperion.com; Tel.: +1 7346346816","first_published_date":"29/05/2017","last_updated_date":"30/08/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001872-pip01-15-m02"},{"decision_number":"P/0289/2022","pip_number":"EMEA-001971-PIP03-18-M02","active_substance":"Larotrectinib","invented_name":"Vitrakvi","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard;Oral solution","condition_indication":"Treatment of malignant neoplasms of the central nervous system","routes_of_administration":"Gastric use;Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer AG; Tel. +49 3046815333; E-mail: pediatrics.medical-affairs-europe@bayer.com","first_published_date":"31/03/2020","last_updated_date":"30/08/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001971-pip03-18-m02"},{"decision_number":"P/0301/2022","pip_number":"EMEA-003211-PIP01-22","active_substance":"Gold (Au)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Oral suspension","condition_indication":"Treatment of amyotrophic lateral sclerosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Clene Netherlands B.V.; email: info@CleneNanomedicine.com; tel: +1 8016769695","first_published_date":"30/08/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003211-pip01-22"},{"decision_number":"P/0287/2022","pip_number":"EMEA-003210-PIP01-22","active_substance":"Doxecitine;Doxribtimine","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Powder for oral solution","condition_indication":"Treatment of thymidine kinase 2 deficiency","routes_of_administration":"Oral use;Gastric use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"UCB Pharma S.A.; E-mail: UCBCares.UK@ucb.comTel: +44 (0)1753777100","first_published_date":"30/08/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003210-pip01-22"},{"decision_number":"P/0281/2022","pip_number":"EMEA-003206-PIP01-22","active_substance":"acetylsalicylic acid;rosuvastatin calcium","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Prevention of cardiovascular events","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CIPROS S.r.l.; email: regolatorio@ciprossrl.it; tel: +39 057320877","first_published_date":"30/08/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003206-pip01-22"},{"decision_number":"P/0272/2022","pip_number":"EMEA-003205-PIP01-22","active_substance":"atorvastatin;ezetimibe","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events;Treatment of hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Verisfield Single Member S.A.Email: pharmacovigilance@verisfield.gr; economou@verisfield.gr Tel: +30 2107475196&nbsp","first_published_date":"30/08/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003205-pip01-22"},{"decision_number":"P/0336/2022","pip_number":"EMEA-003064-PIP01-21","active_substance":"lademirsen","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Alport syndrome","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Genzyme Europe B.V.; E-mail: eumedinfo.GZ@sanofi.com; Tel: 31 202454000","first_published_date":"28/08/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003064-pip01-21"},{"decision_number":"P/0345/2022","pip_number":"EMEA-002582-PIP02-21","active_substance":"remibrutinib","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of multiple sclerosis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"28/08/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002582-pip02-21"},{"decision_number":"P/0344/2022","pip_number":"EMEA-002559-PIP05-22","active_substance":"nipocalimab","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Concentrate for solution for infusion;Solution for injection","condition_indication":"Treatment of bullous pemphigoid","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; E-mail: contact@janssen-emea.com; Tel.: +32 14602111","first_published_date":"28/08/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002559-pip05-22"},{"decision_number":"P/0302/2022","pip_number":"EMEA-003114-PIP01-21","active_substance":"Efruxifermin","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of non-alcoholic steatohepatitis (NASH)","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"28/08/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003114-pip01-21"},{"decision_number":"P/0030/2021","pip_number":"EMEA-001838-PIP01-15-M03","active_substance":"3-[[5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl]methyl]-1-(2,2,2-trifluoroethyl)-1,3-dihydro-3-[[5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl]methyl]-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridine-2-one (JNJ-53718678)","invented_name":"Rilematovir","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder and solvent for oral suspension","condition_indication":"Treatment of lower respiratory tract disease caused by human respiratory syncytial virus (RSV)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/01/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; Tel.: +32 14602111; E-mail: contact@janssen-emea.com","first_published_date":"28/10/2016","last_updated_date":"25/08/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001838-pip01-15-m03"},{"decision_number":"P/0266/2020","pip_number":"EMEA-001882-PIP02-16-M02","active_substance":"recombinant human monoclonal antibody to GM-CSF (GSK3196165)","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis)","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/07/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Tel. +1 4388998201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"13/02/2018","last_updated_date":"25/08/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001882-pip02-16-m02"},{"decision_number":"P/0350/2022","pip_number":"EMEA-003094-PIP02-21","active_substance":"RSV preF protein","invented_name":"","therapeutic_area":"Infectious diseases;Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of lower respiratory tract disease caused by respiratory syncytial virus","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen Cilag International NV; Tel. +3214602111; E-mail: contact@Janssen-emea.com","first_published_date":"25/08/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003094-pip02-21"},{"decision_number":"P/0333/2022","pip_number":"EMEA-002451-PIP02-21","active_substance":"ritlecitinib","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Age appropriate oral solid dosage form;Capsule, hard;Tablet","condition_indication":"Treatment of ulcerative colitis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIGE-mail: medical.information@pfizer.com Tel. +44 1304646607","first_published_date":"24/08/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002451-pip02-21"},{"decision_number":"P/0354/2022","pip_number":"EMEA-000309-PIP09-21","active_substance":"tocilizumab","invented_name":"RoActemra","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of systemic sclerosis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/08/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbH; E-mail: global.eu_regulatory_office@roche.comTel. +49 7624142892","first_published_date":"24/08/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000309-pip09-21"},{"decision_number":"P/0222/2021","pip_number":"EMEA-002842-PIP01-20","active_substance":"Iscalimab","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection;Concentrate for solution for infusion","condition_indication":"Prophylaxis of solid organ transplant rejection","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/06/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"28/04/2022","last_updated_date":"22/08/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002842-pip01-20"},{"decision_number":"P/0454/2021","pip_number":"EMEA-002927-PIP01-20","active_substance":"adalimumab conjugated with (4S)-4-[2-(2-bromoacetamido)acetamido]-5-{3-[(4-{(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-4a,6a-dimethyl-2-oxo-6b-[(phosphonooxy)acetyl]-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H,8H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8-yl}phenyl)methyl] anilino}-5-oxopentanoic acid; (ABBV-154)","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection in pre-filled syringe","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis)","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/10/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"14/02/2023","last_updated_date":"03/08/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002927-pip01-20"},{"decision_number":"P/0285/2020","pip_number":"EMEA-002812-PIP01-20","active_substance":"rimegepant","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Orodispersible tablet","condition_indication":"Prevention of migraine headaches","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG  E-mail: medical.information@pfizer.com Tel: +44 (0)1304 616161","first_published_date":"22/06/2021","last_updated_date":"01/08/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002812-pip01-20"},{"decision_number":"P/0553/2021","pip_number":"EMEA-002940-PIP02-21","active_substance":"Molnupiravir","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Capsule, hard;Age appropriate dosage form","condition_indication":"Prevention of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Oral use;Gastric use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"10/03/2023","last_updated_date":"07/07/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002940-pip02-21"},{"decision_number":"P/0465/2021","pip_number":"EMEA-002962-PIP01-21","active_substance":"AZD8233 sodium, PCSK9-targeted, antisense oligonucleotide (ASO)","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of elevated cholesterol;Treatment of mixed dyslipidaemia","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca ABEmail: paediatrics@astrazeneca.comTel. +46 855324400","first_published_date":"20/02/2023","last_updated_date":"06/07/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002962-pip01-21"},{"decision_number":"P/0125/2022","pip_number":"EMEA-002974-PIP01-21","active_substance":"Benzylamine derivative of benzofuran (BCX9930)","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Age appropriate oral solid dosage form;Tablet","condition_indication":"Treatment of paroxysmal nocturnal haemoglobinuria","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BioCryst Ireland LimitedE-mail: pip.enquiries@biocryst.com Tel: +1 9842450602","first_published_date":"17/04/2023","last_updated_date":"06/07/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002974-pip01-21"},{"decision_number":"P/0355/2021","pip_number":"EMEA-001811-PIP04-21","active_substance":"ligelizumab","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution for injection;Age appropriate dosage form for parenteral use","condition_indication":"Treatment of chronic inducible urticaria","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"10/01/2023","last_updated_date":"06/07/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001811-pip04-21"},{"decision_number":"P/0102/2022","pip_number":"EMEA-001418-PIP02-15-M03","active_substance":"cabotegravir","invented_name":"Vocabria","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Prolonged-release suspension for injection","condition_indication":"Prevention of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use;Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/03/2022","compliance_outcome":"Positive","compliance_opinion_date":"20/05/2022","compliance_procedure_number":"EMEA-C-001418-PIP02-15-M03","contact_for_public_enquiries":"ViiV Healthcare UK Limited; E-mail: eu.paediatric-plans@gsk.com; Tel. +44 (0)208 990 3650","first_published_date":"20/04/2023","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001418-pip02-15-m03"},{"decision_number":"P/0327/2021","pip_number":"EMEA-000316-PIP02-11-M05","active_substance":"sacubitril;valsartan","invented_name":"Entresto","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet;Age appropriate solid oral formulation","condition_indication":"Treatment of heart failure","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/08/2021","compliance_outcome":"Positive","compliance_opinion_date":"20/05/2022","compliance_procedure_number":"EMEA-C-000316-PIP02-11-M05","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"25/06/2012","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000316-pip02-11-m05"},{"decision_number":"P/0057/2021","pip_number":"EMEA-001176-PIP01-11-M06","active_substance":"pitolisant","invented_name":"Wakix","therapeutic_area":"Neurology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of narcolepsy","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/01/2021","compliance_outcome":"Positive","compliance_opinion_date":"20/05/2022","compliance_procedure_number":"EMEA-C-001176-PIP01-11-M06","contact_for_public_enquiries":"Bioprojet PHARMA; E-mail: contact@bioprojet.com; Tel: +33 147036600;  ","first_published_date":"18/09/2012","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001176-pip01-11-m06"},{"decision_number":"P/0317/2017","pip_number":"EMEA-000172-PIP01-07-M03","active_substance":"Methoxy polyethylene glycol-epoetin beta","invented_name":"Mircera","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of symptomatic anaemia associated with chronic kidney disease","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"RPM: decision refers to a refusal on the application for modification of an agreed PIP","decision_date":"31/10/2017","compliance_outcome":"Positive","compliance_opinion_date":"20/05/2022","compliance_procedure_number":"EMEA-C-000172-PIP01-07-M03","contact_for_public_enquiries":"Roche Registration Limited; Tel. +41 616879411; E-mail: info.paediatrics@roche.com","first_published_date":"04/01/2013","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000172-pip01-07-m03"},{"decision_number":"P/0097/2022","pip_number":"EMEA-000553-PIP01-09-M05","active_substance":"Lisdexamfetamine dimesilate","invented_name":"Elvanse and associated names","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of Attention Deficit Hyperactivity Disorder (ADHD)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/03/2022","compliance_outcome":"Positive","compliance_opinion_date":"25/05/2022","compliance_procedure_number":"EMEA-C-000553-PIP01-09-M05","contact_for_public_enquiries":"Takeda Pharmaceuticals International AG, Ireland Branch;  +44 (0)3333 000181; medinfoEMEA@takeda.com","first_published_date":"26/04/2012","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000553-pip01-09-m05"},{"decision_number":"P/0334/2021","pip_number":"EMEA-002308-PIP01-17-M02","active_substance":"multivalent, live, recombinant, non-replicating in human cells, Modified Vaccinia Ankara vectored vaccine, expressing the EBOV Mayinga glycoprotein, the Sudan virus Gulu GP, the Marburg virus Musoke GP, and the Taï Forest virus nucleoprotein [MVA-BN-Filo]","invented_name":"Mvabea","therapeutic_area":"Infectious diseases;Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of Ebola virus disease","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/08/2021","compliance_outcome":"Positive","compliance_opinion_date":"24/06/2022","compliance_procedure_number":"EMEA-C-002308-PIP01-17-M02","contact_for_public_enquiries":"Janssen Cilag International NV; Tel. +3214602111; E-mail: contact@Janssen-emea.com","first_published_date":"25/06/2019","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002308-pip01-17-m02"},{"decision_number":"P/0307/2021","pip_number":"EMEA-002307-PIP01-17-M02","active_substance":"monovalent, live, recombinant, replication-incompetent adenoviral serotype 26 vectored vaccine expressing the full length glycoprotein of the Ebola virus Mayinga variant [Ad26.ZEBOV]","invented_name":"Zabdeno","therapeutic_area":"Infectious diseases;Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of Ebola virus disease","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/08/2021","compliance_outcome":"Positive","compliance_opinion_date":"24/06/2022","compliance_procedure_number":"EMEA-C-002307-PIP01-17-M02","contact_for_public_enquiries":"Janssen Cilag International NV; Tel. +3214602111; E-mail: contact@Janssen-emea.com","first_published_date":"25/06/2019","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002307-pip01-17-m02"},{"decision_number":"P/0323/2019","pip_number":"EMEA-001654-PIP02-17-M01","active_substance":"tisagenlecleucel","invented_name":"Kymriah","therapeutic_area":"Oncology","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of mature B-cell neoplasms","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/09/2019","compliance_outcome":"Positive","compliance_opinion_date":"24/06/2022","compliance_procedure_number":"EMEA-C-001654-PIP02-17-M01","contact_for_public_enquiries":"Novartis Europharm Limited; E-mail: paediatric.enquiries@novartis.com; Tel. +41 6132 46715","first_published_date":"24/10/2017","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001654-pip02-17-m01"},{"decision_number":"P/0258/2017","pip_number":"EMEA-001208-PIP01-11-M03","active_substance":"human fibrinogen","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for infusion","condition_indication":"Treatment of congenital fibrinogen deficiency","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/09/2017","compliance_outcome":"Positive","compliance_opinion_date":"24/06/2022","compliance_procedure_number":"EMEA-C-001208-PIP01-11-M03","contact_for_public_enquiries":"Octapharma Pharmazeutika Produktionsges.m.b.H; Tel. +41 5545 12189; E-mail: cristina.solomon@octapharma.com","first_published_date":"18/09/2012","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001208-pip01-11-m03"},{"decision_number":"P/0198/2020","pip_number":"EMEA-000183-PIP01-08-M08","active_substance":"apixaban","invented_name":"Eliquis; Eliquis","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral liquid dosage formulation;Age appropriate dosage form, other","condition_indication":"Prevention of arterial thromboembolism;Prevention of venous thromboembolism","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"20/05/2020","compliance_outcome":"Positive","compliance_opinion_date":"24/06/2022","compliance_procedure_number":"EMEA-C-000183-PIP01-08-M08","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"27/04/2012","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000183-pip01-08-m08"},{"decision_number":"P/0409/2021","pip_number":"EMEA-000783-PIP01-09-M06","active_substance":"dulaglutide","invented_name":"Trulicity","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection in pre-filled pen","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/10/2021","compliance_outcome":"Positive","compliance_opinion_date":"24/06/2022","compliance_procedure_number":"EMEA-C-000783-PIP01-09-M06","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"24/02/2011","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000783-pip01-09-m06"},{"decision_number":"P/0438/2021","pip_number":"EMEA-001006-PIP05-18-M01","active_substance":"nintedanib","invented_name":"Ofev; Vargatef","therapeutic_area":"Oncology;Pneumology-allergology","pharmaceutical_forms":"Capsule, soft","condition_indication":"Treatment of fibrosing Interstitial Lung Diseases (ILD)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/10/2021","compliance_outcome":"Positive","compliance_opinion_date":"22/07/2022","compliance_procedure_number":"EMEA-C-001006-PIP05-18-M01","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"20/06/2019","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001006-pip05-18-m01"},{"decision_number":"P/0081/2022","pip_number":"EMEA-003134-PIP01-21","active_substance":"nifurtimox","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of Chagas disease","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/03/2022","compliance_outcome":"Positive","compliance_opinion_date":"09/09/2022","compliance_procedure_number":"EMEA-C-003134-PIP01-21","contact_for_public_enquiries":"Bayer AG, Leverkusen; E-mail: clinical-trials-contact@bayer.com; Tel: +49 30300139003","first_published_date":"20/04/2023","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003134-pip01-21"},{"decision_number":"P/0328/2020","pip_number":"EMEA-002710-PIP01-19","active_substance":"artesunate","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of malaria","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/08/2020","compliance_outcome":"Positive","compliance_opinion_date":"09/09/2022","compliance_procedure_number":"EMEA-C-002710-PIP01-19","contact_for_public_enquiries":"Amivas Ireland Ltd; E-mail: info@amivas.com; Tel.: + 353 51 347 322","first_published_date":"22/06/2021","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002710-pip01-19"},{"decision_number":"P/0141/2022","pip_number":"EMEA-002869-PIP03-21","active_substance":"Influenza virus A/turkey/Turkey/1/2005 (H5N1) NIBRG-23 strain, HA surface antigen","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of zoonotic influenza","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/04/2022","compliance_outcome":"Positive","compliance_opinion_date":"09/09/2022","compliance_procedure_number":"EMEA-C-002869-PIP03-21","contact_for_public_enquiries":"Seqirus Netherlands B.V.; E-mail: seqirus.clinicaltrials@seqirus.com; Tel: +1 9088587365","first_published_date":"17/04/2023","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002869-pip03-21-0"},{"decision_number":"P/0214/2022","pip_number":"EMEA-001864-PIP01-15-M07","active_substance":"Lanadelumab (DX-2930)","invented_name":"Takhzyro","therapeutic_area":"Other","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of hereditary angioedema attacks","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/06/2022","compliance_outcome":"Positive","compliance_opinion_date":"09/09/2022","compliance_procedure_number":"EMEA-C-001864-PIP01-15-M07","contact_for_public_enquiries":"Takeda Pharmaceuticals International AG Ireland Branch; E-mail: medinfoemea@takeda.com; Tel: +44 (0) 3333 000181","first_published_date":"23/11/2016","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001864-pip01-15-m07"},{"decision_number":"P/0423/2020","pip_number":"EMEA-001147-PIP02-20","active_substance":"dabrafenib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard;Dispersible tablet","condition_indication":"Treatment of glioma","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"23/10/2020","compliance_outcome":"Positive","compliance_opinion_date":"27/09/2022","compliance_procedure_number":"EMEA-C-001147-PIP02-20","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"22/07/2021","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001147-pip02-20"},{"decision_number":"P/0424/2020","pip_number":"EMEA-001177-PIP02-20","active_substance":"trametinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet;Powder for oral solution","condition_indication":"Treatment of glioma","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"23/10/2020","compliance_outcome":"Positive","compliance_opinion_date":"27/09/2022","compliance_procedure_number":"EMEA-C-001177-PIP02-20","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"22/07/2021","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001177-pip02-20"},{"decision_number":"P/0115/2021","pip_number":"EMEA-001181-PIP01-11-M06","active_substance":"agomelatine","invented_name":"Valdoxan and associated names","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of major depressive episodes","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/03/2021","compliance_outcome":"Positive","compliance_opinion_date":"14/10/2022","compliance_procedure_number":"EMEA-C-001181-PIP01-11-M06","contact_for_public_enquiries":"Les Laboratoires ServierE-mail: mail.pip.enquiries@servier.comTel.: +33 155726000","first_published_date":"25/06/2012","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001181-pip01-11-m06"},{"decision_number":"P/0209/2022","pip_number":"EMEA-001105-PIP01-10-M06","active_substance":"Dopamine (hydrochloride)","invented_name":"","therapeutic_area":"Cardiovascular diseases;Neonatology-Paediatric Intensive Care","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of vascular hypotensive disorders","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/06/2023","compliance_outcome":"Positive","compliance_opinion_date":"14/10/2022","compliance_procedure_number":"EMEA-C-001105-PIP01-10-M06","contact_for_public_enquiries":"Brepco Biopharma Limited; E-mail: info@ivowen.com; Tel.: +353 526180664","first_published_date":"19/01/2012","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001105-pip01-10-m06"},{"decision_number":"P/0074/2022","pip_number":"EMEA-000876-PIP05-15-M05","active_substance":"Eculizumab","invented_name":"Soliris; Soliris","therapeutic_area":"Neurology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of myasthenia gravis","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/03/2022","compliance_outcome":"Positive","compliance_opinion_date":"14/10/2022","compliance_procedure_number":"EMEA-C-000876-PIP05-15-M05","contact_for_public_enquiries":"Alexion Europe SAS; E-mail: pip.enquiries.eu@alexion.com; Tel: +33 147100615","first_published_date":"25/04/2016","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000876-pip05-15-m05"},{"decision_number":"P/0174/2021","pip_number":"EMEA-000332-PIP01-08-M16","active_substance":"Brivaracetam","invented_name":"Briviact (in Italy: Nubriveo)","therapeutic_area":"Neurology","pharmaceutical_forms":"Film-coated tablet;Oral solution;Solution for injection","condition_indication":"Treatment of epilepsy with partial-onset seizures","routes_of_administration":"Oral use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/04/2021","compliance_outcome":"Positive","compliance_opinion_date":"14/10/2022","compliance_procedure_number":"EMEA-C-000332-PIP01-08-M16","contact_for_public_enquiries":"UCB Pharma S.A.; E-mail: UCBCares.IE@ucb.com; Tel. +353 1463 2371","first_published_date":"17/10/2011","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000332-pip01-08-m16"},{"decision_number":"P/0311/2021","pip_number":"EMEA-001220-PIP03-16-M02","active_substance":"Baricitinib","invented_name":"Olumiant","therapeutic_area":"Dermatology","pharmaceutical_forms":"Oral suspension;Tablet","condition_indication":"Treatment of atopic dermatitis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/08/2021","compliance_outcome":"Positive","compliance_opinion_date":"11/11/2022","compliance_procedure_number":"EMEA-C-001220-PIP03-16-M02","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"11/01/2019","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001220-pip03-16-m02"},{"decision_number":"P/0188/2016","pip_number":"EMEA-001156-PIP01-11-M07","active_substance":"recombinant dimer of 6 kD early secretory antigenic target;recombinant 10 kD culture filtrate protein","invented_name":"","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Solution for injection","condition_indication":"Diagnosis of tuberculosis","routes_of_administration":"Intradermal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/07/2016","compliance_outcome":"Positive","compliance_opinion_date":"11/11/2022","compliance_procedure_number":"EMEA-C-001156-PIP01-11-M07","contact_for_public_enquiries":"Statens Serum Institut; Denmark; Tel. +45 32688617; E-mail: lsst@ssi.dk","first_published_date":"24/02/2012","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001156-pip01-11-m07"},{"decision_number":"P/0392/2020","pip_number":"EMEA-001177-PIP01-11-M06","active_substance":"trametinib dimethyl sulfoxide","invented_name":"Mekinist","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet;Powder for oral solution","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except melanoma, haematopoietic and lymphoid tissue, and glioma);Treatment of melanoma","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"23/10/2020","compliance_outcome":"Positive","compliance_opinion_date":"11/11/2022","compliance_procedure_number":"EMEA-C-001177-PIP01-11-M06","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"26/03/2012","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001177-pip01-11-m06"},{"decision_number":"P/0410/2020","pip_number":"EMEA-001147-PIP01-11-M07","active_substance":"dabrafenib mesilate","invented_name":"Tafinlar","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard;Dispersible tablet","condition_indication":"Treatment of melanoma;Treatment of solid malignant tumours (excluding melanoma)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"23/10/2020","compliance_outcome":"Positive","compliance_opinion_date":"11/11/2022","compliance_procedure_number":"EMEA-C-001147-PIP01-11-M07","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"24/02/2012","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001147-pip01-11-m07"},{"decision_number":"P/0493/2021","pip_number":"EMEA-001146-PIP01-11-M07","active_substance":"naloxegol","invented_name":"Moventig","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Tablet;Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of opioid-induced constipation","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/12/2021","compliance_outcome":"Positive","compliance_opinion_date":"11/11/2022","compliance_procedure_number":"EMEA-C-001146-PIP01-11-M07","contact_for_public_enquiries":"Kyowa Kirin Pharmaceutical Development Limited; Tel. +44 1896664000; E-mail: medinfo@kyowakirin.com","first_published_date":"18/09/2012","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001146-pip01-11-m07"},{"decision_number":"P/0423/2021","pip_number":"EMEA-000788-PIP02-11-M11","active_substance":"edoxaban tosilate","invented_name":"Lixiana","therapeutic_area":"Cardiovascular diseases;Haematology-Hemostaseology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral dosage formulation","condition_indication":"Prevention of arterial thromboembolism;Prevention of venous thromboembolism;Treatment of venous thromboembolism","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/10/2021","compliance_outcome":"Positive","compliance_opinion_date":"11/11/2022","compliance_procedure_number":"EMEA-C-000788-PIP02-11-M11","contact_for_public_enquiries":"Daiichi Sankyo Europe GmbH; Tel. +49 8978080; E-mail: service@daiichi-sankyo.eu","first_published_date":"14/07/2011","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000788-pip02-11-m11"},{"decision_number":"P/0257/2020","pip_number":"EMEA-000496-PIP01-08-M08","active_substance":"alogliptin","invented_name":"Vipidia","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/07/2020","compliance_outcome":"Positive","compliance_opinion_date":"11/11/2022","compliance_procedure_number":"EMEA-C-000496-PIP01-08-M08","contact_for_public_enquiries":"Takeda Pharma A/STel. +44 (0)3333000181E-mail: medinfoEMEA@takeda.com","first_published_date":"09/07/2009","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000496-pip01-08-m08"},{"decision_number":"P/0460/2021","pip_number":"EMEA-002392-PIP01-18-M02","active_substance":"oteseconazole","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of vulvovaginal candidiasis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/10/2021","compliance_outcome":"Positive","compliance_opinion_date":"16/12/2022","compliance_procedure_number":"EMEA-C-002392-PIP01-18-M02","contact_for_public_enquiries":"Gedeon Richter Plc.; Tel.  +36 14314675; E-mail: cprichter@richter.hu","first_published_date":"24/06/2019","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002392-pip01-18-m02"},{"decision_number":"P/0188/2020","pip_number":"EMEA-001830-PIP01-15-M02","active_substance":"Pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)","invented_name":"Foclivia; Foclivia and associated names","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of influenza infection","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/05/2020","compliance_outcome":"Positive","compliance_opinion_date":"16/12/2022","compliance_procedure_number":"EMEA-C-001830-PIP01-15-M02","contact_for_public_enquiries":"Seqirus S.r.l.; Tel. +39 0577096405; +39 0577096401; E-mail: pip.seq@seqirus.com","first_published_date":"25/04/2016","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001830-pip01-15-m02"},{"decision_number":"P/0283/2021","pip_number":"EMEA-000828-PIP01-09-M09","active_substance":"empagliflozin","invented_name":"Jardiance; Jardiance","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/10/2021","compliance_outcome":"Positive","compliance_opinion_date":"16/12/2022","compliance_procedure_number":"EMEA-C-000828-PIP01-09-M09","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"23/02/2011","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000828-pip01-09-m09"},{"decision_number":"P/0446/2021","pip_number":"EMEA-000498-PIP01-08-M10","active_substance":"linagliptin","invented_name":"Trajenta; Trajenta","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/10/2021","compliance_outcome":"Positive","compliance_opinion_date":"16/12/2022","compliance_procedure_number":"EMEA-C-000498-PIP01-08-M10","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"11/08/2009","last_updated_date":"30/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000498-pip01-08-m10"},{"decision_number":"P/0259/2022","pip_number":"EMEA-002989-PIP01-21-M01","active_substance":"Leniolisib","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Capsule, hard;Film-coated tablet;Granules","condition_indication":"Treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pharming Group N.V.; Tel. +31 715247400; E-mail: info@pharming.com","first_published_date":"13/03/2023","last_updated_date":"29/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002989-pip01-21-m01"},{"decision_number":"P/0248/2022","pip_number":"EMEA-002758-PIP01-19-M02","active_substance":"Dexmedetomidine hydrochloride","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Oromucosal film","condition_indication":"Treatment of bipolar disorder;Treatment of schizophrenia","routes_of_administration":"Sublingual use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BioXcel Therapeutics, Inc.E-mail: info@bioxceltherapeutics.comTel.: +1 475 2386837","first_published_date":"06/10/2021","last_updated_date":"29/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002758-pip01-19-m02"},{"decision_number":"P/0205/2022","pip_number":"EMEA-002354-PIP02-18-M01","active_substance":"zanubrutinib","invented_name":"Brukinsa","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of lymphoplasmacytic lymphoma;Treatment of mature B-cell neoplasms (excluding lymphoplasmacytic lymphoma)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/06/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BeiGene Ireland Ltd.; E-mail: bg.ireland@beigene.com; Tel. +353 15667660","first_published_date":"03/04/2020","last_updated_date":"29/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002354-pip02-18-m01"},{"decision_number":"P/0162/2022","pip_number":"EMEA-003008-PIP01-21","active_substance":"virus-like particle of SARS-CoV-2 spike protein (recombinant, adjuvant) (CoVLP)","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension and emulsion for emulsion for injection","condition_indication":"Prevention of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Medicago Inc.; Email: atkinsj@medicago.com; Tel. +1 4185694616","first_published_date":"11/05/2023","last_updated_date":"29/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003008-pip01-21"},{"decision_number":"P/0387/2021","pip_number":"EMEA-002887-PIP01-20","active_substance":"ribitol","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Powder for oral use;Age appropriate oral dosage formulation","condition_indication":"Treatment of limb-girdle muscular dystrophy","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BridgeBio Europe B.V.; E-mail: info@mlbiosolutions.comTel: (704) 285-8153","first_published_date":"10/01/2023","last_updated_date":"27/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002887-pip01-20"},{"decision_number":"P/0231/2022","pip_number":"EMEA-002344-PIP02-18-M01","active_substance":"liposomal ciclosporin A (L-CsA)","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder for nebuliser solution","condition_indication":"Treatment of bronchiolitis obliterans syndrome","routes_of_administration":"Inhalation use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Zambon S.p.A.; E-mail: marzia.michieletto@zambongroup.com ; Tel.:  +39 0266524256","first_published_date":"23/03/2020","last_updated_date":"27/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002344-pip02-18-m01"},{"decision_number":"P/0208/2022","pip_number":"EMEA-001030-PIP01-10-M10","active_substance":"canagliflozin","invented_name":"Invokana; Invokana","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/06/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International N.V.; Tel. +32 14602111; E-mail: contact@Janssen-emea.com","first_published_date":"09/08/2011","last_updated_date":"27/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001030-pip01-10-m10"},{"decision_number":"P/0200/2022","pip_number":"EMEA-001115-PIP01-10-M08","active_substance":"loxapine","invented_name":"Adasuve","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Inhalation powder (pre-dispensed)","condition_indication":"Treatment of bipolar disorder;Treatment of schizophrenia","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/06/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ferrer Internacional, S.A.; E-mail: registros@ferrer.comTel.:  +34 935044423","first_published_date":"18/10/2011","last_updated_date":"27/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001115-pip01-10-m08"},{"decision_number":"P/0260/2022","pip_number":"EMEA-001696-PIP01-14-M02","active_substance":"omecamtiv mecarbil","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Modified-release tablet","condition_indication":"Treatment of heart failure","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"22/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cytokinetics, Inc.; Tel.: +1 650 624 3000; E-mail: regaffairs@cytokinetics.com","first_published_date":"20/10/2015","last_updated_date":"23/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001696-pip01-14-m02"},{"decision_number":"P/0237/2022","pip_number":"EMEA-001410-PIP02-17-M04","active_substance":"Ixazomib","invented_name":"Ninlaro","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution for injection or infusion;Capsule, hard","condition_indication":"Treatment of lymphoid malignancies (excluding multiple myeloma);Treatment of Multiple Myeloma","routes_of_administration":"Intravenous use;Oral use;Gastric use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Pharm A/S; E-mail: medinfoEMEA@takeda.com​; Tel. +44 (0)3333 000181","first_published_date":"26/07/2018","last_updated_date":"23/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001410-pip02-17-m04"},{"decision_number":"P/0226/2022","pip_number":"EMEA-001217-PIP01-11-M08","active_substance":"Indacaterol (acetate);mometasone furoate","invented_name":"Atectura Breezhaler; Bemrist Breezhaler","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Inhalation powder;Capsule, hard","condition_indication":"Treatment of asthma","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"07/06/2018","last_updated_date":"23/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001217-pip01-11-m08"},{"decision_number":"P/0245/2022","pip_number":"EMEA-001127-PIP02-11-M02","active_substance":"Hepatitis B (rDNA) surface antigen adjuvanted","invented_name":"Heplisav B","therapeutic_area":"Vaccines","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of hepatitis B virus infection","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dynavax GmbH; E-mail: dynavaxmedinfo@lashgroup.com; Tel. +49 21175845126","first_published_date":"10/04/2012","last_updated_date":"23/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001127-pip02-11-m02"},{"decision_number":"P/0223/2022","pip_number":"EMEA-003190-PIP01-22","active_substance":"Botulinum toxin type E","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of skin wrinkling","routes_of_administration":"All routes of administration","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergan Pharmaceuticals Ireland; ML-EU_Reg_Affairs@Allergan.com ; +44 (0)1628494444","first_published_date":"21/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003190-pip01-22"},{"decision_number":"P/0227/2022","pip_number":"EMEA-003181-PIP01-22","active_substance":"Peptide KLBPVQLWV / Peptide SMPPPGTRV / Peptide YLQLVFGIEV / Peptide RLLQETELV / Peptide YLSGADLNL / Peptide LLTFWNPPV / Peptide IMIGHLVGV / Peptide KVAEIVHFL / Peptide KVFGSLAFV / Pan HLA DR-binding epitope D-Ala-Lys-Cha-Val-Ala-Ala-Trp-Thr-Leu-Lys-Ala-Ala-D-Ala (OSE2101)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer (small cell and non-small cell lung cancer)","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"OSE Immunotherapeutics; gra@ose-immuno.com ; +33 (0)228291010","first_published_date":"21/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003181-pip01-22"},{"decision_number":"P/0261/2022","pip_number":"EMEA-003115-PIP01-21","active_substance":"recombinant COVID-19 subunit nanoparticle (adjuvanted with AS03) (GBP510)","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Emulsion and suspension for emulsion for injection","condition_indication":"Prevention of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"SK Chemicals GmBH; raulhead@skdiscovery.com; +82 220082557","first_published_date":"21/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003115-pip01-21"},{"decision_number":"P/0232/2022","pip_number":"EMEA-003085-PIP01-21","active_substance":"sibeprenlimab","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of primary immunoglobulin A nephropathy","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Otsuka Pharmaceutical Netherlands B.V.E-mail: paediatrics-info@otsuka-europe.com Tel.: +49 69955044321","first_published_date":"21/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003085-pip01-21"},{"decision_number":"P/0212/2022","pip_number":"EMEA-003186-PIP01-22","active_substance":"Indapamide;perindopril arginine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/06/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires Servier; E-mail: mail.dcp-contact@servier.com; Tel: +33 1 55 72 60 00","first_published_date":"21/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003186-pip01-22"},{"decision_number":"P/0198/2018","pip_number":"EMEA-001310-PIP01-12-M03","active_substance":"gabapentin","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of chronic pain","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/07/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Consorzio per Valutazioni Biologiche e Farmacologiche; Email: ricercaclinica@cvbf.net; Tel. +39 0382 25075","first_published_date":"03/05/2013","last_updated_date":"21/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001310-pip01-12-m03"},{"decision_number":"P/0194/2022","pip_number":"EMEA-003179-PIP01-22","active_substance":"sugemalimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/06/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"SFL Pharmaceuticals Deutschland GmbH; Email: RA@sfl-services.com; Tel. +49 7621 5500 250;  ","first_published_date":"21/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003179-pip01-22"},{"decision_number":"P/0207/2022","pip_number":"EMEA-003178-PIP01-21","active_substance":"anti-TGFbeta fully human monoclonal antibody (NIS793)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of pancreatic cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/06/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"21/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003178-pip01-21"},{"decision_number":"P/0240/2022","pip_number":"EMEA-002696-PIP03-22","active_substance":"Parsaclisib (hydrochloride)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Coated tablet","condition_indication":"Treatment of myelofibrosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Incyte Biosciences Distribution B.V.; E-mail: RA@incyte.com","first_published_date":"20/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002696-pip03-22"},{"decision_number":"P/0228/2022","pip_number":"EMEA-002694-PIP02-21","active_substance":"mixture of 2 synthetic double-stranded N-Acetyl-galactosamine conjugated siRNA oligonucleotides that are directed against hepatitis B virus (JNJ-73763989)","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Age appropriate dosage form for parenteral use;Age appropriate formulation","condition_indication":"Treatment of chronic hepatitis D infection","routes_of_administration":"Subcutaneous use;Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Ltd; Tel. +1 4388998201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"20/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002694-pip02-21"},{"decision_number":"P/0246/2022","pip_number":"EMEA-002516-PIP02-21","active_substance":"Lonafarnib","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Hepatitis D virus infection","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"EigerBio Europe Limited; E-mail: info@eigerbio.com; Tel: +1 8778992051","first_published_date":"20/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002516-pip02-21"},{"decision_number":"P/0233/2022","pip_number":"EMEA-003202-PIP01-22","active_substance":"Botulinum toxin type A","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of skin wrinkling","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Galderma International S.A.S.; E-mail: info@galderma.com; Tel. +41 584558592","first_published_date":"19/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003202-pip01-22"},{"decision_number":"P/0252/2022","pip_number":"EMEA-003199-PIP01-22","active_substance":"224 Radium adsorbed in calcium carbonate microparticles","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of peritoneal carcinomatosis","routes_of_administration":"Intraperitoneal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Oncoinvent AS; E-Mail: oncoinvent@oncoinvent.com; Tel. +47 22183305","first_published_date":"19/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003199-pip01-22"},{"decision_number":"P/0224/2022","pip_number":"EMEA-003193-PIP01-22","active_substance":"autologous bone marrow-derived mononuclear cell enriched white blood cells","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of chronic limb-threatening ischemia","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ixaka Iberia SLU; E-Mail: jimmy.wong@ixaka.com ; Tel. +44 2038769808","first_published_date":"19/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003193-pip01-22"},{"decision_number":"P/0202/2022","pip_number":"EMEA-003198-PIP01-22","active_substance":"clonidine","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Prolonged-release tablet","condition_indication":"Treatment of Attention Deficit Hyperactivity Disorder (ADHD)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/06/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Proveca LimitedTel. +44 7913048665E-mail: simon@proveca.co.uk","first_published_date":"19/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003198-pip01-22"},{"decision_number":"P/0210/2022","pip_number":"EMEA-001693-PIP03-21","active_substance":"reparixin","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Tablet;Age appropriate oral formulation","condition_indication":"Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/06/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dompé farmaceutici S.p.A.; E-mail: DAR@dompe.com; Tel. +39 3669018586","first_published_date":"19/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001693-pip03-21"},{"decision_number":"P/0199/2022","pip_number":"EMEA-003187-PIP01-22","active_substance":"Flortaucipir F18","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Diagnosis of Alzheimer's disease","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/06/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly and Co. Ltd.E-mail: eu_paediatric@lilly.com Tel. +44 1344382659","first_published_date":"19/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003187-pip01-22"},{"decision_number":"P/0234/2022","pip_number":"EMEA-001964-PIP03-21","active_substance":"cannabidiol","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Oral solution","condition_indication":"Epilepsy with myoclonic atonic seizures","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GW Pharma (International) B.V.; E-mail: info@gwpharm.com; Tel: +44 1223266800","first_published_date":"19/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001964-pip03-21"},{"decision_number":"P/0220/2020","pip_number":"EMEA-002752-PIP01-19","active_substance":"IMG-2789","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of myeloproliferative neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/06/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"09/03/2021","last_updated_date":"14/06/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002752-pip01-19"},{"decision_number":"P/0254/2022","pip_number":"EMEA-003082-PIP01-21","active_substance":"bepirovirsen","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic hepatitis B infection","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Tel. +1 4388998201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"13/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003082-pip01-21"},{"decision_number":"P/0253/2022","pip_number":"EMEA-003072-PIP01-21","active_substance":"autologous tumour-infiltrating lymphocytes (TILs) isolated from a patient's cancer tissue and expanded ex vivo (ITIL-168)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of melanoma","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Instil Bio, Inc.; E-mail: info@propharmagroup.com; Tel.:  +44 (0)2039119410","first_published_date":"13/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003072-pip01-21"},{"decision_number":"P/0241/2022","pip_number":"EMEA-003059-PIP01-21","active_substance":"cagrilintide;semaglutide","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection in pre-filled pen","condition_indication":"Treatment of obesity","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; E-mail: paediatrics@novonordisk.com ; Tel.: +45 44448888","first_published_date":"13/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003059-pip01-21"},{"decision_number":"P/0229/2022","pip_number":"EMEA-002846-PIP02-22","active_substance":"Lurbinectedin","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of malignant mesothelioma","routes_of_administration":"All routes of administration","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pharma Mar, S.A.; Email: regulatory@pharmamar.com; Tel. +34 918466000;  ","first_published_date":"13/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002846-pip02-22"},{"decision_number":"P/0251/2022","pip_number":"EMEA-002737-PIP01-19","active_substance":"autologous CD3+CD4+CD25+CD127-FoxP3+ polyclonal regulatory T cells ex vivo expanded","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism;Other","pharmaceutical_forms":"Suspension for infusion","condition_indication":"Treatment of type 1 diabetes mellitus","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/07/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"PolTreg SA; E-mail: office@poltreg.tech; Tel.:  +48 504978536","first_published_date":"13/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002737-pip01-19"},{"decision_number":"P/0211/2022","pip_number":"EMEA-003026-PIP02-21","active_substance":"whole-cell heat-inactivated bacterial strains of Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris and Enterococcus faecalis","invented_name":"","therapeutic_area":"Infectious diseases;Uro-nephrology;Vaccines","pharmaceutical_forms":"Sublingual spray","condition_indication":"Prevention of urinary tract infections","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/06/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Inmunotek S.L.; E-mail: medical@inmunotek.com; Tel.: +34 691490175","first_published_date":"13/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003026-pip02-21"},{"decision_number":"P/0197/2022","pip_number":"EMEA-003016-PIP01-21","active_substance":"apraglutide","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of short bowel syndrome","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/06/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"VectivBio AG; E-mail: clinicaltrials@vectivbio.com; Tel.:  +41 615513030","first_published_date":"13/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003016-pip01-21"},{"decision_number":"P/0193/2022","pip_number":"EMEA-002983-PIP01-21","active_substance":"recombinant adeno-associated viral (rAAV) vector expressing the human ornithine transcarbamylase (hOTC) gene","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Suspension for infusion","condition_indication":"Treatment of ornithine transcarbamylase deficiency","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/06/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Selecta Biosciences, Inc.; E-mail: ptraber@selectabio.com; Tel.:  +1 6179231400","first_published_date":"13/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002983-pip01-21"},{"decision_number":"P/0192/2022","pip_number":"EMEA-002982-PIP01-21","active_substance":"sirolimus","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Suspension for infusion","condition_indication":"Treatment of ornithine transcarbamylase deficiency","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/06/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Selecta Biosciences, Inc.; E-mail: ptraber@selectabio.com; Tel.:  +1 6179231400","first_published_date":"13/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002982-pip01-21"},{"decision_number":"P/0216/2022","pip_number":"EMEA-002850-PIP02-21","active_substance":"dersimelagon","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Film-coated tablet;Age appropriate dosage form","condition_indication":"Treatment of erythropoietic protoporphyria;Treatment of X-linked protoporphyria","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/06/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mitsubishi Tanabe Pharma GmbHE-mail: regulatory@mt-pharma-eu.com Tel: +49 2115205440","first_published_date":"13/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002850-pip02-21"},{"decision_number":"P/0204/2022","pip_number":"EMEA-002487-PIP01-18","active_substance":"omaveloxolone","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Capsule, hard;Age appropriate oral formulation","condition_indication":"Treatment of Friedreich's ataxia","routes_of_administration":"Gastric use;Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/06/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Reata Ireland Limited; E-mail: neila.benabadji@reatapharma.com; Tel. +41 782316350","first_published_date":"12/06/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002487-pip01-18"},{"decision_number":"P/0312/2020","pip_number":"EMEA-001742-PIP01-14-M01","active_substance":"derivative of 4H-pyrazolo[3,4-d]pyrimidin-4-one","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of schizophrenia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"27/10/2016","last_updated_date":"22/05/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001742-pip01-14-m01"},{"decision_number":"P/0175/2022","pip_number":"EMEA-001665-PIP01-14-M06","active_substance":"betibeglogene autotemcel","invented_name":"Zynteglo","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of β-thalassaemia","routes_of_administration":"Intravenous use","decision_type":"RPM: decision refers to a refusal on the application for modification of an agreed PIP","decision_date":"13/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"bluebird bio (Netherlands) B.V.; E-mail: patient.advocacy@bluebirdbio.com; Tel. +1 3394999300","first_published_date":"21/12/2015","last_updated_date":"16/05/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001665-pip01-14-m06"},{"decision_number":"P/0174/2022","pip_number":"EMEA-002360-PIP01-18-M02","active_substance":"tirzepatide","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly and Company LtdE-mail: eu_paediatric@lilly.com Phone: +44 1256315000","first_published_date":"23/03/2020","last_updated_date":"16/05/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002360-pip01-18-m02"},{"decision_number":"P/0161/2022","pip_number":"EMEA-000694-PIP02-14-M03","active_substance":"dapagliflozin","invented_name":"Forxiga; Forxiga","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral dosage formulation","condition_indication":"Treatment of type I diabetes mellitus","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca ABEmail: paediatrics@astrazeneca.comTel. +46 855324400","first_published_date":"07/05/2015","last_updated_date":"12/05/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000694-pip02-14-m03"},{"decision_number":"P/0160/2022","pip_number":"EMEA-000696-PIP02-10-M08","active_substance":"eslicarbazepine acetate","invented_name":"Zebinix; Zebinix","therapeutic_area":"Neurology","pharmaceutical_forms":"Oral suspension;Tablet","condition_indication":"Treatment of epilepsy with partial-onset seizures","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BIAL - Portela & Ca, SA; E-mail: info@bial.com; Tel. +351 229866100","first_published_date":"04/01/2013","last_updated_date":"12/05/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000696-pip02-10-m08"},{"decision_number":"P/0159/2022","pip_number":"EMEA-000816-PIP02-10-M03","active_substance":"magnesium sulfate heptahydrate (BLI800);sodium sulphate anhydrous;potassium sulfate","invented_name":"Izinova (and associated names)","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Concentrate for oral solution","condition_indication":"Diagnostic of organic and/or functional bowel diseases","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"IPSEN Consumer Healthcare; Email: ch_ra@ipsen.com; Tel. +33 158335500","first_published_date":"18/10/2011","last_updated_date":"12/05/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000816-pip02-10-m03"},{"decision_number":"P/0155/2022","pip_number":"EMEA-001521-PIP01-13-M06","active_substance":"Luspatercept","invented_name":"Reblozyl","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of beta-thalassaemia;Treatment of myelodysplastic syndromes","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG; Email: medical.information@bms.com; Tel. +44 1895523740","first_published_date":"05/11/2014","last_updated_date":"12/05/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001521-pip01-13-m06"},{"decision_number":"P/0148/2022","pip_number":"EMEA-002018-PIP02-16-M05","active_substance":"venetoclax","invented_name":"Venclyxto","therapeutic_area":"Haematology-Hemostaseology;Oncology","pharmaceutical_forms":"Film-coated tablet;Tablet for oral suspension;Powder for oral suspension","condition_indication":"Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue;Treatment of solid malignant tumours","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628925033","first_published_date":"28/09/2017","last_updated_date":"12/05/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002018-pip02-16-m05"},{"decision_number":"P/0147/2022","pip_number":"EMEA-002054-PIP01-16-M03","active_substance":"odevixibat","invented_name":"Bylvay","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of Progressive Familial Intrahepatic Cholestasis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Albireo AB; Tel. +46 31741 14 80; E-mail: info@albireopharma.com","first_published_date":"12/02/2018","last_updated_date":"12/05/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002054-pip01-16-m03"},{"decision_number":"P/0149/2022","pip_number":"EMEA-002113-PIP01-16-M01","active_substance":"(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride (KH176)","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Age appropriate oral liquid dosage formulation;Capsule, hard","condition_indication":"Treatment of mitochondrial respiratory chain/oxidative phosphorylation defects","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Khondrion BV; Email: info@khondrion.com; Tel. +31 243617505","first_published_date":"29/09/2021","last_updated_date":"12/05/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002113-pip01-16-m01"},{"decision_number":"P/0176/2022","pip_number":"EMEA-003158-PIP01-21","active_substance":"zandelisib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of mature B-cell neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/05/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kyowa Kirin Holdings B.V.; Email: comms@kyowakirin.com; Tel. +44 (0)1896664000","first_published_date":"11/05/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003158-pip01-21"},{"decision_number":"P/0178/2022","pip_number":"EMEA-001501-PIP11-21","active_substance":"dupilumab","invented_name":"Dupixent","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic puritus of unknown origin","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/05/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi-Aventis Groupe; contact-us@sanofi.com;  +33 169745695","first_published_date":"11/05/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001501-pip11-21"},{"decision_number":"P/0167/2022","pip_number":"EMEA-002945-PIP02-21","active_substance":"anti-CD40L humanized monoclonal antibody (SAR441344)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of progressive multiple sclerosis","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi Winthrop Industrie; Email: contact-us@sanofi.com; Tel: +31 202 453 703","first_published_date":"11/05/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002945-pip02-21"},{"decision_number":"P/0169/2022","pip_number":"EMEA-002594-PIP03-21","active_substance":"Infigratinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of urothelial carcinoma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Helsinn Birex Pharmaceuticals Ltd.; Email: Info-HHC@helsinn.com; Tel. +353 18225404","first_published_date":"11/05/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002594-pip03-21"},{"decision_number":"P/0165/2022","pip_number":"EMEA-003040-PIP02-21","active_substance":"Izaflortaucipir (18F)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Diagnosis of Alzheimer's disease","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Life Molecular Imaging GmbH; Email: gra@life-mi.com; Tel. +49 30461124603","first_published_date":"11/05/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003040-pip02-21"},{"decision_number":"P/0158/2022","pip_number":"EMEA-003159-PIP01-21","active_substance":"(2S) 4 [2 methoxyethyl [4 (5,6,7,8 tetrahydro 1,8 naphthyridin 2 yl)butyl] amino] 2 (quinazolin 4 ylamino)butanoic acid","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of idiopathic pulmonary fibrosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pliant Therapeutics Inc.; Email: info@pliantrx.com; Tel. +1 6504816770","first_published_date":"11/05/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003159-pip01-21"},{"decision_number":"P/0186/2022","pip_number":"EMEA-003058-PIP01-21","active_substance":"Humanised KLB/FGFR1c monoclonal antibody (MK-3655)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of non-alcoholic steatohepatitis (NASH)","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"16/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe), Inc.; Email: pip.information@merck.com; Tel. +31 412663179","first_published_date":"11/05/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003058-pip01-21"},{"decision_number":"P/0181/2022","pip_number":"EMEA-002645-PIP03-21","active_substance":"sacituzumab govitecan","invented_name":"Trodelvy","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung carcinoma (small cell and non-small cell carcinoma)","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd. ; Tel. +44 (0)1223 897 300 ; E-mail: regulatory.pip@gilead.com","first_published_date":"11/05/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002645-pip03-21"},{"decision_number":"P/0182/2022","pip_number":"EMEA-003167-PIP01-21","active_substance":"","invented_name":"deno-associated virus vector serotype 1 containing the human GRN","therapeutic_area":"Neurology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of frontotemporal dementia","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Passage Bio, Inc.; Email: info@passagebio.com; Tel. +1 2678660311","first_published_date":"11/05/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003167-pip01-21"},{"decision_number":"P/0183/2022","pip_number":"EMEA-003169-PIP01-21","active_substance":"3,4-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazole-5-carboxamide","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of gastrointestinal stromal tumours","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cogent Biosciences, Inc; Email: paediatrics@cogentbio.com    ; Tel. +1 6179455576","first_published_date":"11/05/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003169-pip01-21"},{"decision_number":"P/0172/2022","pip_number":"EMEA-003164-PIP01-21","active_substance":"bilastine;pseudoephedrine","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Prolonged-release tablet","condition_indication":"Treatment of allergic rhinitis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Faes Farma S.A.Tel. +34 944818300E-mail: ieguidazu@faes.es; mjarenal@faes.es","first_published_date":"10/05/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003164-pip01-21"},{"decision_number":"P/0145/2022","pip_number":"EMEA-003020-PIP01-21","active_substance":"Adeno-associated viral vector serotype rh.10 expressing beta-galactosidase (LYS-GM101)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of GM1 gangliosidosis","routes_of_administration":"Intracisternal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Lysogene; E-mail: contact@lysogene.com; Tel. +33 141430390","first_published_date":"10/05/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003020-pip01-21"},{"decision_number":"P/0146/2022","pip_number":"EMEA-002997-PIP02-22","active_substance":"Latozinemab","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of amyotrophic lateral sclerosis","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alector, Inc.; E-mail: info@alector.com; Tel: +1 4152315660","first_published_date":"10/05/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002997-pip02-22"},{"decision_number":"P/0152/2022","pip_number":"EMEA-003173-PIP01-21","active_substance":"amlodipine;atorvastatin;Indapamide;perindopril arginine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires Servier; E-mail: mail.dcp-contact@servier.com; Tel: +33 1 55 72 60 00","first_published_date":"10/05/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003173-pip01-21"},{"decision_number":"P/0153/2022","pip_number":"EMEA-003175-PIP01-21","active_substance":"human IgG4-based bispecific antibody binding to both B-cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3) (REGN5458)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of Multiple Myeloma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/05/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Regeneron Ireland DAC; Tel. +1 9148 475385; E-mail: clinicaltrials@regeneron.com","first_published_date":"10/05/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003175-pip01-21"},{"decision_number":"P/0127/2022","pip_number":"EMEA-003017-PIP01-21","active_substance":"abelacimab","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Concentrate for solution for injection","condition_indication":"Prevention of thromboembolic events;Treatment of thromboembolic events","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Anthos Therapeutics, Inc.; E-mail: info@anthostherapeutics.com; Tel: +1 6174604000","first_published_date":"14/09/2022","last_updated_date":"25/04/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003017-pip01-21"},{"decision_number":"P/0090/2022","pip_number":"EMEA-003138-PIP01-21","active_substance":"tarlatamab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of prostate malignant neoplasms;Treatment of small cell lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe BV; E-mail: medinfointernational@amgen.com; Tel. +44 (0)1223 420305","first_published_date":"20/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003138-pip01-21"},{"decision_number":"P/0059/2022","pip_number":"EMEA-003135-PIP01-21","active_substance":"nemtabrutinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of mature B-cell malignancies","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"20/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003135-pip01-21"},{"decision_number":"P/0058/2022","pip_number":"EMEA-003132-PIP01-21","active_substance":"sunvozertinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of non-small cell lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dizal (Jiangsu) Pharmaceutical Co., Ltd; E-mail: info@dizalpharma.com; Tel: +86 2161097800","first_published_date":"20/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003132-pip01-21"},{"decision_number":"P/0064/2022","pip_number":"EMEA-003127-PIP01-21","active_substance":"ceralasertib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung carcinoma (small cell and non-small cell carcinoma)","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel. +46 8553 27591","first_published_date":"20/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003127-pip01-21"},{"decision_number":"P/0057/2022","pip_number":"EMEA-003125-PIP01-21","active_substance":"avexitide acetate","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of postbariatric hypoglycaemia","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"EigerBio Europe Limited; E-mail: info@eigerbio.com; Tel: +1 8778992051","first_published_date":"20/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003125-pip01-21"},{"decision_number":"P/0094/2022","pip_number":"EMEA-003121-PIP01-21","active_substance":"human normal immunoglobulin","invented_name":"Flebogamma DIF (previously Flebogammadif)","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of post-polio syndrome","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Instituto Grifols, S.A.E-mail: areatecnica.instituto@grifols.comTel. +34 935710700","first_published_date":"20/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003121-pip01-21"},{"decision_number":"P/0063/2022","pip_number":"EMEA-003120-PIP01-21","active_substance":"dapagliflozin;2-{(3S)-7-fluoro-4-[(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-3-yl}-N-methylacetamide (AZD9977)","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Prevention of cardiovascular events in patients with chronic heart failure","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca ABEmail: paediatrics@astrazeneca.comTel. +46 855324400","first_published_date":"20/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003120-pip01-21"},{"decision_number":"P/0068/2022","pip_number":"EMEA-001996-PIP02-16-M01","active_substance":"Glutamine","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Oral powder","condition_indication":"Treatment of sickle cell disease","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Emmaus Medical Europe Ltd.; +1 310 214 0075; cstark@emmausmedical.com","first_published_date":"17/04/2018","last_updated_date":"19/04/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001996-pip02-16-m01"},{"decision_number":"P/0065/2022","pip_number":"EMEA-001523-PIP05-19-M01","active_substance":"Guselkumab","invented_name":"Tremfya","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Solution for injection in pre-filled pen;Solution for injection in pre-filled syringe;Solution for injection","condition_indication":"Treatment of Crohn's disease","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International N.V.; Tel.  +32 14602111; E-mail: contact@janssen-emea.com","first_published_date":"18/06/2021","last_updated_date":"19/04/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001523-pip05-19-m01"},{"decision_number":"P/0099/2022","pip_number":"EMEA-002492-PIP01-18-M02","active_substance":"bempegaldesleukin","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoetic, and lymphoid tissue neoplasms)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Nektar Therapeutics; E-mail: studyinquiry@nektar.com; Tel. +1 8554 828676","first_published_date":"20/11/2019","last_updated_date":"19/04/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002492-pip01-18-m02"},{"decision_number":"P/0087/2022","pip_number":"EMEA-002250-PIP02-17-M01","active_substance":"ridinilazole (hydrate)","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral formulation","condition_indication":"Treatment of Clostridium difficile infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Summit Limited; david.gancarz@summitplc.com;  +1 (508)4500187","first_published_date":"24/06/2019","last_updated_date":"19/04/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002250-pip02-17-m01"},{"decision_number":"P/0092/2022","pip_number":"EMEA-002229-PIP01-17-M03","active_substance":"Dienogest;Ethinyl estradiol","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Prolonged-release tablet","condition_indication":"Prevention of pregnancy","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Chemo Research S.L.E-mail: enrico.coli@exeltis.com Tel.: +34 913021560","first_published_date":"17/04/2018","last_updated_date":"19/04/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002229-pip01-17-m03"},{"decision_number":"P/0075/2022","pip_number":"EMEA-000932-PIP01-10-M02","active_substance":"modified allergen extract of birch pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Subcutaneous use","decision_type":"RPM: decision refers to a refusal on the application for modification of an agreed PIP","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"24/01/2011","last_updated_date":"19/04/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000932-pip01-10-m02"},{"decision_number":"P/0072/2022","pip_number":"EMEA-003053-PIP01-21","active_substance":"Phospholipid esters from herring roe (HRO350)","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Age appropriate oral liquid dosage formulation;Age appropriate oral solid dosage form;Capsule, soft","condition_indication":"Treatment of psoriasis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Arctic Bioscience (previously Arctic Nutrition AS); E-mail: runhild@arctic-bioscience.com; Tel: +47 95933436","first_published_date":"19/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003053-pip01-21"},{"decision_number":"P/0117/2022","pip_number":"EMEA-002146-PIP01-17-M04","active_substance":"Palbociclib","invented_name":"Ibrance","therapeutic_area":"Oncology","pharmaceutical_forms":"Age appropriate oral dosage formulation;Capsule, hard;Film-coated tablet","condition_indication":"Treatment of Ewing sarcoma","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG; Tel. +44 (0)1304 646 607; E-mail: pip_enquiries@pfizer.com","first_published_date":"27/11/2018","last_updated_date":"19/04/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002146-pip01-17-m04"},{"decision_number":"P/0114/2022","pip_number":"EMEA-002010-PIP01-16-M03","active_substance":"axicabtagene ciloleucel","invented_name":"Yescarta","therapeutic_area":"Oncology","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of mature B-cell neoplasms","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kite Pharma EU B.V.; Tel. +1 4242091332; E-mail: regulatory@kitepharma.com","first_published_date":"28/09/2017","last_updated_date":"19/04/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002010-pip01-16-m03"},{"decision_number":"P/0061/2022","pip_number":"EMEA-003041-PIP01-21","active_substance":"cosibelimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of cutaneous squamous cell carcinoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Checkpoint Therapeutics, Inc.; E-mail: info@checkpointtx.com; Tel: +1 7816524500","first_published_date":"19/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003041-pip01-21"},{"decision_number":"P/0131/2022","pip_number":"EMEA-001710-PIP04-17-M03","active_substance":"Ozanimod (hydrochloride)","invented_name":"Zeposia","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Capsule, hard;Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of Crohn's disease","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"12/04/2019","last_updated_date":"19/04/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001710-pip04-17-m03"},{"decision_number":"P/0056/2022","pip_number":"EMEA-003003-PIP01-21","active_substance":"ralmitaront","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of schizophrenia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"19/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003003-pip01-21"},{"decision_number":"P/0133/2022","pip_number":"EMEA-001554-PIP01-13-M03","active_substance":"Etelcalcetide","invented_name":"Parsabiv; Parsabiv","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of hyperparathyroidism","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V. ; E-mail: medinfointernational@amgen.com; Tel. +44 (0)1223 420305","first_published_date":"05/11/2014","last_updated_date":"19/04/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001554-pip01-13-m03"},{"decision_number":"P/0070/2022","pip_number":"EMEA-002987-PIP01-21","active_substance":"CpG 1018/Alum-adjuvanted recombinant SARS-CoV-2 Trimeric Spike (S) protein subunit vaccine (SCB- 2019)","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Clover Biopharmaceuticals Ireland Limited; E-mail: info.ireland@cloverbiopharma.com; Tel: +86 13601009684","first_published_date":"19/04/2023","last_updated_date":"19/04/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002987-pip01-21"},{"decision_number":"P/0132/2022","pip_number":"EMEA-001491-PIP01-13-M02","active_substance":"fosdenopterin (ORGN001)","invented_name":"Nulibry","therapeutic_area":"Other","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of molybdenum cofactor deficiency type A","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/04/2022","compliance_outcome":"Positive","compliance_opinion_date":"15/10/2021","compliance_procedure_number":"EMEA-C-001491-PIP01-13-M01","contact_for_public_enquiries":"Zydus France S.A.S.; philippe.dupont@zydusfrance.com;  +33 141191860","first_published_date":"13/05/2014","last_updated_date":"19/04/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001491-pip01-13-m02"},{"decision_number":"P/0082/2022","pip_number":"EMEA-002946-PIP01-20","active_substance":"MIJ821","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of major depressive disorder","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"19/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002946-pip01-20"},{"decision_number":"P/0108/2022","pip_number":"EMEA-003147-PIP01-21","active_substance":"human IgG4 monoclonal antibody against BCMA and CD3 (ABBV-383)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of Multiple Myeloma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628925033","first_published_date":"19/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003147-pip01-21"},{"decision_number":"P/0136/2022","pip_number":"EMEA-001428-PIP03-15-M02","active_substance":"esketamine hydrochloride","invented_name":"Spravato","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Nasal spray (solution)","condition_indication":"Treatment of major depressive disorder","routes_of_administration":"Intranasal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; Tel. +32 1460 2111; E-mail: contact@janssen-emea.com","first_published_date":"17/03/2017","last_updated_date":"19/04/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001428-pip03-15-m02"},{"decision_number":"P/0129/2022","pip_number":"EMEA-001214-PIP01-11-M11","active_substance":"Benralizumab","invented_name":"Fasenra","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of asthma","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca ABEmail: paediatrics@astrazeneca.comTel. +46 855324400","first_published_date":"24/06/2013","last_updated_date":"19/04/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001214-pip01-11-m11"},{"decision_number":"P/0111/2022","pip_number":"EMEA-003151-PIP01-21","active_substance":"Indapamide;telmisartan","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Modified-release tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"KRKA, d.d., Novo mesto;  +386 73312657; stasa.taferner@krka.biz","first_published_date":"19/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003151-pip01-21"},{"decision_number":"P/0122/2022","pip_number":"EMEA-001186-PIP01-11-M03","active_substance":"Ponatinib","invented_name":"Iclusig","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet;Capsule, hard;Age appropriate formulation","condition_indication":"Treatment of chronic myeloid leukaemia;Treatment of Philadelphia chromosome positive acute lymphoblastic leukaemia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Incyte Biosciences Distribution B.V.; E-mail: globalmedinfo@incyte.com; Tel. +800 0002 7423","first_published_date":"09/08/2012","last_updated_date":"19/04/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001186-pip01-11-m03"},{"decision_number":"P/0113/2022","pip_number":"EMEA-003146-PIP01-21","active_substance":"acetylsalicylic acid;ticagrelor","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Prevention of atherothrombotic events","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"PharOS Pharmaceutical Oriented Services Single Member Ltd; Tel:  +30 2106664667; E-mail: pharmacovigilance@pharosgr.gr","first_published_date":"17/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003146-pip01-21"},{"decision_number":"P/0107/2022","pip_number":"EMEA-000525-PIP01-08-M08","active_substance":"amikacin sulfate","invented_name":"Arikayce liposomal","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Nebuliser dispersion","condition_indication":"Treatment of nontuberculous mycobacterial lung infection;Treatment of Pseudomonas aeruginosa lung infection/colonisation in cystic fibrosis patients","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Insmed Netherlands B.V.E-mail: medicalinformation@insmed.comTel.: +1 9089474303","first_published_date":"23/02/2011","last_updated_date":"17/04/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000525-pip01-08-m08"},{"decision_number":"P/0112/2022","pip_number":"EMEA-003145-PIP01-21","active_substance":"cevostamab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of Multiple Myeloma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"17/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003145-pip01-21"},{"decision_number":"P/0124/2022","pip_number":"EMEA-002927-PIP02-21","active_substance":"adalimumab conjugated with (4S)-4-[2-(2-bromoacetamido)acetamido]-5-{3-[(4-{(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-4a,6a-dimethyl-2-oxo-6b-[(phosphonooxy)acetyl]-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H,8H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8-yl}phenyl)methyl] anilino}-5-oxopentanoic acid; (ABBV-154)","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of polymyalgia rheumatica","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"17/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002927-pip02-21"},{"decision_number":"P/0140/2022","pip_number":"EMEA-002919-PIP02-21","active_substance":"sintilimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of oesophageal cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"17/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002919-pip02-21"},{"decision_number":"P/0083/2022","pip_number":"EMEA-002853-PIP01-20","active_substance":"viltolarsen","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of Duchenne muscular dystrophy","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"NS Pharma, Inc.; E-mail: regulatory@nspharma.com; Tel: 2013229148","first_published_date":"17/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002853-pip01-20"},{"decision_number":"P/0460/2023","pip_number":"EMEA-002925-PIP01-20-M02","active_substance":"cilgavimab (AZD1061)","invented_name":"Evusheld","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Prevention or treatment of COVID-19;Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intramuscular use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel. +46 8553 27591","first_published_date":"17/06/2021","last_updated_date":"17/04/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002925-pip01-20-m02"},{"decision_number":"P/0139/2022","pip_number":"EMEA-002798-PIP02-21","active_substance":"retifanlimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of endometrial carcinoma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Incyte Biosciences Distribution B.V. E-mail: RA@incyte.comTel. +1 3024252734","first_published_date":"17/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002798-pip02-21"},{"decision_number":"P/0459/2023","pip_number":"EMEA-002900-PIP01-20-M02","active_substance":"tixagevimab","invented_name":"Evusheld","therapeutic_area":"Infections and infestations","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Prevention or treatment of COVID-19;Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intramuscular use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel. +46 8553 27591","first_published_date":"17/06/2021","last_updated_date":"17/04/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002900-pip01-20-m02"},{"decision_number":"P/0118/2022","pip_number":"EMEA-002681-PIP02-21","active_substance":"rozanolixizumab","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of immune thrombocytopenia","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"UCB Pharma S.A.; E-mail: UCBCares.IE@ucb.com; Tel. +353 1463 2371","first_published_date":"17/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002681-pip02-21"},{"decision_number":"P/0084/2022","pip_number":"EMEA-002802-PIP02-21","active_substance":"vimseltinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of tenosynovial giant cell tumour","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Deciphera Pharmaceuticals; E-mail: info@deciphera.com; Tel.: +1 7812096400","first_published_date":"17/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002802-pip02-21"},{"decision_number":"P/0137/2022","pip_number":"EMEA-002317-PIP02-21","active_substance":"Invimestrocel","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of ischaemic stroke","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ReGenesys BVBA (Athersys); pip@athersys.com;  +1 2162153071","first_published_date":"17/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002317-pip02-21"},{"decision_number":"P/0034/2022","pip_number":"EMEA-003105-PIP01-21","active_substance":"Insulin efsitora alfa","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Type 1 diabetes mellitus;Type 2 diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/02/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly and Company LtdE-mail: eu_paediatric@lilly.com Phone: +44 1256315000","first_published_date":"14/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003105-pip01-21"},{"decision_number":"P/0130/2022","pip_number":"EMEA-000380-PIP09-21","active_substance":"secukinumab","invented_name":"Cosentyx","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder for solution for injection;Solution for injection","condition_indication":"Treatment of lichen planus (including mucosal lichen planus)","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"14/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000380-pip09-21"},{"decision_number":"P/0109/2022","pip_number":"EMEA-000373-PIP02-09-M05","active_substance":"Ferumoxytol","invented_name":"Rienso; Rienso","therapeutic_area":"Haematology-Hemostaseology;Uro-nephrology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of iron deficiency anaemia (IDA)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Covis Pharma Europe B.V.; Email: medinfoEMEA@covispharma.com; Tel. 08000270008","first_published_date":"18/05/2010","last_updated_date":"13/04/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000373-pip02-09-m05"},{"decision_number":"P/0110/2022","pip_number":"EMEA-000181-PIP01-08-M06","active_substance":"cannabidiol;delta-9-tetrahydrocannabinol","invented_name":"Sativex","therapeutic_area":"Neurology","pharmaceutical_forms":"Oromucosal spray","condition_indication":"Spasticity","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GW Pharma (International) B.V; Email: medinfo@gwpharm.com    ; Tel. +44 (0)1223266800","first_published_date":"18/05/2009","last_updated_date":"13/04/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000181-pip01-08-m06"},{"decision_number":"P/0085/2022","pip_number":"EMEA-002696-PIP02-21","active_substance":"Parsaclisib (as hydrochloride)","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of autoimmune haemolytic anaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Incyte Biosciences Distribution B.V.; E-mail: RA@incyte.com","first_published_date":"13/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002696-pip02-21"},{"decision_number":"P/0055/2022","pip_number":"EMEA-002555-PIP02-21","active_substance":"recombinant humanized anti-blood dendritic cell antigen 2 (BDCA2) monoclonal antibody (BIIB059)","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of lupus erythematosus","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biogen Netherlands B.V.; E-mail: pip.enquiries@biogen.com; Tel: +44 (0)1628512586","first_published_date":"13/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002555-pip02-21"},{"decision_number":"P/0077/2022","pip_number":"EMEA-002242-PIP02-21","active_substance":"tucatinib","invented_name":"Tukysa","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of solid tumours","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"PfizerE-mail: medical.information@pfizer.comTel: +44 (0)1304616161","first_published_date":"13/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002242-pip02-21"},{"decision_number":"P/0079/2022","pip_number":"EMEA-001649-PIP02-21","active_substance":"(1S,3S)-3-({2-methyl-6-[1-methyl-5-({[methyl(propyl)carbamoyl]oxy}methyl)-1H-1,2,3-triazol-4-yl]pyridin-3-yl}oxy)cyclohexane-1-carboxylic acid (BMS-986278)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of fibrosing Interstitial Lung Diseases (ILD)","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb EEIG; E-mail: medical.information@bms.com; Tel: +44 1423533610","first_published_date":"13/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001649-pip02-21"},{"decision_number":"P/0030/2022","pip_number":"EMEA-002684-PIP01-19-M01","active_substance":"Mitapivat","invented_name":"Pyrukynd","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of pyruvate kinase deficiency","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/01/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Agios Pharmaceuticals, Inc.Tel.  +1 8332288474E-mail: medinfo@agios.com","first_published_date":"06/07/2021","last_updated_date":"12/04/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002684-pip01-19-m01"},{"decision_number":"P/0301/2021","pip_number":"EMEA-002532-PIP01-18-M02","active_substance":"phenobarbital","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Oral suspension","condition_indication":"Treatment of epilepsy","routes_of_administration":"Oral use;Gastric use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/01/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Proveca LimitedTel. +44 7913048665E-mail: simon@proveca.co.uk","first_published_date":"03/04/2020","last_updated_date":"12/04/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002532-pip01-18-m02"},{"decision_number":"P/0012/2022","pip_number":"EMEA-003109-PIP01-21","active_substance":"derivative of pyrrolopyrimidine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events in patients with heart failure","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca ABEmail: paediatrics@astrazeneca.comTel. +46 855324400","first_published_date":"12/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003109-pip01-21"},{"decision_number":"P/0011/2022","pip_number":"EMEA-003107-PIP01-21","active_substance":"gantenerumab","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Prevention of Alzheimer's disease","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"12/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003107-pip01-21"},{"decision_number":"P/0010/2022","pip_number":"EMEA-003106-PIP01-21","active_substance":"aumolertinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"SFL Pharmaceuticals Deutschland GmbH; sfl@sfl-services.com, info@sfl-pharma.eu;  +41 787842804","first_published_date":"12/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003106-pip01-21"},{"decision_number":"P/0009/2022","pip_number":"EMEA-003104-PIP01-21","active_substance":"Favezelimab;pembrolizumab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue neoplasms and melanoma)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck, Sharp & Dohme (Europe) Inc.; Tel. +33 180464738; E-mail: pip.information@merck.com","first_published_date":"12/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003104-pip01-21"},{"decision_number":"P/0028/2022","pip_number":"EMEA-003101-PIP01-21","active_substance":"colchicine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pharmascience International Limited; fduchesna@pharmascience.com;  +33 272247361","first_published_date":"12/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003101-pip01-21"},{"decision_number":"P/0037/2022","pip_number":"EMEA-003002-PIP01-21","active_substance":"derivative of 6-[2-(pyridin-2-yl)phenoxy]methyl}-1,2,3,4-tetrahydroisoquinoline","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Age appropriate formulation;Modified-release tablet;Modified release granules","condition_indication":"Treatment of chronic kidney disease","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"12/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003002-pip01-21"},{"decision_number":"P/0025/2022","pip_number":"EMEA-002992-PIP01-21","active_substance":"2-Amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-((1R,5S)-3- (tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1- yl)phenyl)nicotinamide fumarate dihydrate (INCB-00928)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Age appropriate oral solid dosage form;Film-coated tablet","condition_indication":"Treatment of fibrodysplasia ossificans progressiva","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Incyte Biosciences Distribution B.V.; E-mail: globalmedinfo@incyte.com; Tel. +800 0002 7423","first_published_date":"05/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002992-pip01-21"},{"decision_number":"P/0008/2022","pip_number":"EMEA-002933-PIP01-20","active_substance":"single strain of non-genetically modified Prevotella histicola (EDP1815)","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Age appropriate oral solid dosage form;Capsule, hard","condition_indication":"Treatment of psoriasis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Evelo Biosciences, Inc.; info@evelobio.com;  +1 6175770300","first_published_date":"05/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002933-pip01-20"},{"decision_number":"P/0032/2022","pip_number":"EMEA-002971-PIP01-21","active_substance":"nirogacestat hydrobromide","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of soft tissue sarcoma","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"SpringWorks Therapeutics, Inc; clinical.inquiries@springworkstx.com;  +1 9197901002","first_published_date":"05/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002971-pip01-21"},{"decision_number":"P/0036/2022","pip_number":"EMEA-002970-PIP01-21","active_substance":"tildacerfont","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet;Granules","condition_indication":"Treatment of congenital adrenal hyperplasia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Spruce Biosciences, Inc.; E-mail: info@scendea.com; Tel: +31 0208 949169","first_published_date":"05/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002970-pip01-21-0"},{"decision_number":"P/0018/2022","pip_number":"EMEA-002757-PIP02-21","active_substance":"izencitinib","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Age appropriate oral dosage formulation;Tablet","condition_indication":"Treatment of Crohn's disease","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Theravance Biopharma Ireland Limited; Email: medinfo@theravance.com; Tel. +1 8556338479 ;  ","first_published_date":"05/04/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002757-pip02-21"},{"decision_number":"P/0454/2022","pip_number":"EMEA-001636-PIP01-14-M03","active_substance":"vericiguat","invented_name":"Verquvo","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet;Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of left ventricular failure","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer AG; Email: pediatrics.medical-affairs-europe@bayer.com; Tel. +49 (0)3046815333;  ","first_published_date":"03/07/2015","last_updated_date":"30/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001636-pip01-14-m03"},{"decision_number":"P/0490/2020","pip_number":"EMEA-002025-PIP04-19","active_substance":"tabelecleucel","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Dispersion for injection","condition_indication":"Treatment of Epstein-Barr virus associated post-transplant lymphoproliferative disorder","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"21/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pierre Fabre Médicament; E-mail: medical_information@pierre-fabre.com; Tel. +33 800326326","first_published_date":"17/09/2021","last_updated_date":"29/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002025-pip04-19"},{"decision_number":"P/0490/2021","pip_number":"EMEA-002644-PIP01-19-M01","active_substance":"cyclophosphamide","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for oral solution","condition_indication":"Treatment of all malignant neoplasms","routes_of_administration":"Oral use;Gastric use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Accord Healthcare S.L.U.; E-mail: regulatory_EU@accord-healthcare.com; Tel. +34 933010064","first_published_date":"05/03/2021","last_updated_date":"29/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002644-pip01-19-m01"},{"decision_number":"P/0121/2021","pip_number":"EMEA-001501-PIP08-20","active_substance":"dupilumab","invented_name":"Dupixent","therapeutic_area":"Oto-rhino-laryngology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic rhinosinusitis without nasal polyposis","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/03/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi Winthrop Industrie; Email: contact-us@sanofi.com; Tel: +31 202 453 703","first_published_date":"15/11/2021","last_updated_date":"28/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001501-pip08-20"},{"decision_number":"P/0103/2022","pip_number":"EMEA-003075-PIP01-21","active_substance":"censavudine","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Age appropriate oral solid dosage form;Age appropriate oral suspension formulation","condition_indication":"Treatment of Aicardi-Goutières syndrome","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"21/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Transposon Therapeutics, Inc.; E-mail: clinicaltrials@transposonrx.com; Tel: +1 9494229676","first_published_date":"23/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003075-pip01-21"},{"decision_number":"P/0076/2022","pip_number":"EMEA-002183-PIP01-17-M01","active_substance":"imlifidase","invented_name":"Idefirix","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Prevention of graft rejection following solid organ transplantation","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/03/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Hansa Biopharma AB; E-mail: info@hansabiopharma.com; Tel: +46 46165670","first_published_date":"27/11/2018","last_updated_date":"23/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002183-pip01-17-m01"},{"decision_number":"P/0246/2018","pip_number":"EMEA-002072-PIP01-16-M01","active_substance":"(Z)-N-(3-bromo-4- fluorophenyl)-N-hydroxy-4-(2-(sulfamoylamino)ethylamino)-1,2,5-oxadiazole-3-carboximidamide","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet;Age appropriate oral formulation","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms including Hodgkin lymphoma (except nervous system, haematopoietic and lymphoid tissue other than Hodgkin lymphoma)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/08/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Incyte Corporation; Tel. +44 3301003677; E-mail: globalmedinfo@incyte.com","first_published_date":"12/02/2018","last_updated_date":"22/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002072-pip01-16-m01"},{"decision_number":"P/0535/2021","pip_number":"EMEA-001261-PIP01-11-M07","active_substance":"Eribulin","invented_name":"Halaven; Halaven","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of soft tissue sarcoma","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/12/2021","compliance_outcome":"Positive","compliance_opinion_date":"25/02/2022","compliance_procedure_number":"EMEA-C-001261-PIP01-11-M07","contact_for_public_enquiries":"Eisai Europe Ltd; Tel. +44 (0)20 8600 1400; E-mail: EUMedInfo@eisai.net","first_published_date":"23/04/2013","last_updated_date":"16/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001261-pip01-11-m07"},{"decision_number":"P/0521/2021","pip_number":"EMEA-000467-PIP01-08-M15","active_substance":"perampanel","invented_name":"Fycompa","therapeutic_area":"Neurology","pharmaceutical_forms":"Tablet;Oral suspension","condition_indication":"Treatment of treatment-resistant epilepsies","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eisai Europe Limited; E-mail: eumedinfo@eisai.net; Tel. +44 (0)20 8600 1400","first_published_date":"27/07/2010","last_updated_date":"15/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000467-pip01-08-m15"},{"decision_number":"P/0557/2021","pip_number":"EMEA-003091-PIP01-21","active_substance":"acetylcysteine;paracetamol;phenylephrine","invented_name":"","therapeutic_area":"Infectious diseases;Oto-rhino-laryngology","pharmaceutical_forms":"Granules for oral solution","condition_indication":"Treatment of upper respiratory tract infections","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"HEXAL AG; Email: enquiries.paediatrics@sandoz.com; Tel. +31 365241710","first_published_date":"14/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003091-pip01-21"},{"decision_number":"P/0513/2021","pip_number":"EMEA-003070-PIP01-21","active_substance":"ramipril;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"1A Pharma GmbHEmail: enquiries.paediatrics@sandoz.com Tel. +31 365241710","first_published_date":"14/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003070-pip01-21"},{"decision_number":"P/0511/2021","pip_number":"EMEA-003068-PIP01-21","active_substance":"adagrasib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet;Capsule, hard","condition_indication":"Treatment of all solid and haematological malignancies","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mirati Therapeutics, Inc.; Email: albrighta@mirati.com     ; Tel. +1 8583323525","first_published_date":"14/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003068-pip01-21"},{"decision_number":"P/0512/2021","pip_number":"EMEA-003069-PIP01-21","active_substance":"adavosertib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of malignant endometrial neoplasms;Treatment of pancreatic cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel. +46 8553 27591","first_published_date":"14/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003069-pip01-21"},{"decision_number":"P/0501/2021","pip_number":"EMEA-003076-PIP01-21","active_substance":"human normal immunoglobulin","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Primary Immunodeficiency (PID)","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Octapharma Pharmazeutika Produktionsges.m.b.H; Email: at1CRDGeneral@octapharma.com; Tel. +43 1610321201;  ","first_published_date":"14/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003076-pip01-21"},{"decision_number":"P/0564/2021","pip_number":"EMEA-003083-PIP01-21","active_substance":"Humanised IgG2k Fc-modified bispecific antibody against CD3 and BCMA (PF-06863135)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Multiple Myeloma","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIGE-mail: medical.information@pfizer.com Tel. +44 1304646607","first_published_date":"14/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003083-pip01-21"},{"decision_number":"P/0485/2021","pip_number":"EMEA-003063-PIP01-21","active_substance":"pembrolizumab;vibostolimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue neoplasms and melanoma);Treatment of malignant neoplasms of the central nervous system","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck, Sharp & Dohme (Europe) Inc.; Tel. +33 180464738; E-mail: pip.information@merck.com","first_published_date":"13/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003063-pip01-21"},{"decision_number":"P/0471/2021","pip_number":"EMEA-003062-PIP01-21","active_substance":"ofranergene obadenovec","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for injection/infusion","condition_indication":"Treatment of fallopian tube cancer;Treatment of ovarian cancer;Treatment of peritoneal cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vascular Biogenics Ltd. (VBL Therapeutics); Email: clinical@vblrx.com     ; Tel. +972 89935000","first_published_date":"13/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003062-pip01-21"},{"decision_number":"P/0488/2021","pip_number":"EMEA-003065-PIP01-21","active_substance":"eplerenone;Furosemide","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of heart failure","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Przedsiębiorstwo Farmaceutyczne LEK-AM Sp. z o.o.; Email: biuro@lekam.pl; Tel. +48 224644500","first_published_date":"13/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003065-pip01-21"},{"decision_number":"P/0489/2021","pip_number":"EMEA-003066-PIP01-21","active_substance":"Bordetella pertussis antigen: Filamentous Haemagglutinin;Bordetella pertussis antigen: Pertactin;Bordetella pertussis antigen: Pertussis toxoid;Inactivated Type 1 Poliovirus (Mahoney);Inactivated Type 2 Poliovirus (MEF-1);Inactivated Type 3 Poliovirus (Saukett);tetanus toxoid","invented_name":"","therapeutic_area":"Infectious diseases;Vaccines","pharmaceutical_forms":"Solution for injection in pre-filled syringe","condition_indication":"Prevention of infectious diseases caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, Poliovirus types 1, 2 and 3","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vakzine Projekt Management GmbH; Email: info@vakzine-manager.de; Tel. +49 15111699080","first_published_date":"13/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003066-pip01-21"},{"decision_number":"P/0508/2021","pip_number":"EMEA-002979-PIP03-21","active_substance":"pamrevlumab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of pancreatic cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"FibroGen, Inc; Email: ecarrier@fibrogen.com; Tel. +1 4159781306","first_published_date":"13/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002979-pip03-21"},{"decision_number":"P/0472/2021","pip_number":"EMEA-003061-PIP01-21","active_substance":"otenaproxesul","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Antibe Therapeutics Inc.; Email: info@antibethera.com     ; Tel. +1 4169223460","first_published_date":"13/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003061-pip01-21"},{"decision_number":"P/0241/2021","pip_number":"EMEA-000365-PIP01-08-M12","active_substance":"oseltamivir (phosphate)","invented_name":"Tamiflu; Tamiflu","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Capsule, hard;Powder for oral suspension","condition_indication":"Treatment and prevention of influenza","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"25/06/2021","compliance_outcome":"Positive","compliance_opinion_date":"15/10/2021","compliance_procedure_number":"EMEA-C-000365-PIP01-08-M12","contact_for_public_enquiries":"Roche Registration GmbH; E-mail: global.eu_regulatory_office@roche.comTel. +49 7624142892","first_published_date":"23/02/2011","last_updated_date":"13/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000365-pip01-08-m12"},{"decision_number":"P/0175/2021","pip_number":"EMEA-000480-PIP01-08-M14","active_substance":"ticagrelor","invented_name":"Brilique","therapeutic_area":"Cardiovascular diseases;Haematology-Hemostaseology","pharmaceutical_forms":"Film-coated tablet;Orodispersible tablet;Tablet","condition_indication":"Prevention of thromboembolic events","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/04/2021","compliance_outcome":"Positive","compliance_opinion_date":"25/06/2021","compliance_procedure_number":"EMEA-C-000480-PIP01-08-M14","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel. +46 8553 27591","first_published_date":"25/07/2017","last_updated_date":"13/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000480-pip01-08-m14"},{"decision_number":"P/0115/2019","pip_number":"EMEA-000236-PIP05-18","active_substance":"aflibercept","invented_name":"Eylea","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of retinopathy of prematurity","routes_of_administration":"Intravitreal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/04/2019","compliance_outcome":"Positive","compliance_opinion_date":"15/10/2021","compliance_procedure_number":"EMEA-C-000236-PIP05-18","contact_for_public_enquiries":"Bayer AG; Tel. +49 30300139003; E-mail: clinical-trials-contact@bayer.com","first_published_date":"20/06/2019","last_updated_date":"13/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000236-pip05-18"},{"decision_number":"P/0352/2017","pip_number":"EMEA-000380-PIP01-08-M04","active_substance":"secukinumab","invented_name":"Cosentyx","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder for solution for injection;Solution for injection","condition_indication":"Treatment of psoriasis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2017","compliance_outcome":"Positive","compliance_opinion_date":"20/04/2021","compliance_procedure_number":"EMEA-C-000380-PIP01-08-M04","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"22/10/2009","last_updated_date":"13/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000380-pip01-08-m04"},{"decision_number":"P/0372/2018","pip_number":"EMEA-000380-PIP02-09-M04","active_substance":"secukinumab","invented_name":"Cosentyx; Cosentyx","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder for solution for injection or infusion;Solution for injection","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis and juvenile idiopathic arthritis)","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/12/2018","compliance_outcome":"Positive","compliance_opinion_date":"25/06/2021","compliance_procedure_number":"EMEA-C-000380-PIP02-09-M04","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"26/08/2010","last_updated_date":"13/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000380-pip02-09-m04"},{"decision_number":"P/0267/2021","pip_number":"EMEA-000409-PIP01-08-M06","active_substance":"Dolutegravir (DTG)","invented_name":"Tivicay","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Age appropriate formulation","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/07/2021","compliance_outcome":"Positive","compliance_opinion_date":"15/10/2021","compliance_procedure_number":"EMEA-C-000409-PIP01-08-M06","contact_for_public_enquiries":"ViiV Healthcare UK Ltd.; United Kingdom; E-mail: eu.paediatric-plans@gsk.com; Tel. +1 4388998201; Fax +44 (0)20 8990 3511","first_published_date":"24/11/2010","last_updated_date":"13/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000409-pip01-08-m06"},{"decision_number":"P/0143/2019","pip_number":"EMEA-000306-PIP01-08-M04","active_substance":"corifollitropin alfa","invented_name":"Elonva","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of hypogonadotrophic hypogonadism","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/04/2019","compliance_outcome":"Positive","compliance_opinion_date":"29/01/2021","compliance_procedure_number":"EMEA-C-000306-PIP01-08-M04","contact_for_public_enquiries":"Merck, Sharp & Dohme (Europe) Inc.; Tel. +31 412770000; E-mail: regaffairseurope@organon.com","first_published_date":"22/09/2016","last_updated_date":"13/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000306-pip01-08-m04"},{"decision_number":"P/0473/2021","pip_number":"EMEA-002954-PIP02-21","active_substance":"Neisseria meningitidis serogroup B Protein-based active substance;recombinant Neisseria meningitidis serogroup B protein 1;recombinant Neisseria meningitidis serogroup B protein 2;recombinant Neisseria meningitidis serogroup B protein 3","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of Meningococcal disease","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi PasteurE-mail: contact-us@sanofi.comTel. +33 1 6974 5695","first_published_date":"10/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002954-pip02-21"},{"decision_number":"P/0539/2021","pip_number":"EMEA-002822-PIP01-20","active_substance":"2’-O-(2-methoxyethyl) modified antisense oligonucleotide targeting glial fibrillary acidic protein pre-mRNA (ION373)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Alexander disease","routes_of_administration":"Intrathecal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ionis Pharmaceuticals; Email: globalregulatoryaffairs@ionisph.com; Tel. 7606032302","first_published_date":"10/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002822-pip01-20"},{"decision_number":"P/0500/2021","pip_number":"EMEA-002942-PIP01-20","active_substance":"Peptide derivative of glucagon-like-peptide 1 and glucagon with fatty acid side chain (BI 456906)","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of non-alcoholic steatohepatitis (NASH)","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"10/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002942-pip01-20"},{"decision_number":"P/0537/2021","pip_number":"EMEA-002947-PIP01-20","active_substance":"Exebacase","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of Staphylococcus aureus bacteraemia","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ContraFect Corporation; Email: clinicalstudies@contrafect.com; Tel. +1 (914)2072300;  ","first_published_date":"10/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002947-pip01-20"},{"decision_number":"P/0329/2019","pip_number":"EMEA-001215-PIP01-11-M07","active_substance":"lonoctocog alfa","invented_name":"Afstyla","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Haemophilia A (congenital Factor VIII deficiency)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/09/2019","compliance_outcome":"Positive","compliance_opinion_date":"10/09/2021","compliance_procedure_number":"EMEA-C-001215-PIP01-11-M07","contact_for_public_enquiries":"CSL Behring GmbH; Tel. +49 6421393290; E-mail: marburg.rfVIII@cslbehring.com;  ","first_published_date":"26/07/2017","last_updated_date":"10/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001215-pip01-11-m07"},{"decision_number":"P/0142/2017","pip_number":"EMEA-001174-PIP02-12-M02","active_substance":"turoctocog alfa pegol","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of hereditary factor VIII deficiency","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/06/2017","compliance_outcome":"Positive","compliance_opinion_date":"23/07/2021","compliance_procedure_number":"EMEA-C-001174-PIP02-12-M02","contact_for_public_enquiries":"Novo Nordisk A/S; Denmark; Tel. +45 44448888; E-mail: paediatrics@novonordisk.com","first_published_date":"26/07/2017","last_updated_date":"10/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001174-pip02-12-m02"},{"decision_number":"P/0248/2016","pip_number":"EMEA-001362-PIP01-12-M03","active_substance":"cerliponase alfa","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Neuronal Ceroid Lipofuscinosis type 2","routes_of_administration":"Intracerebral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/09/2016","compliance_outcome":"Positive","compliance_opinion_date":"26/02/2021","compliance_procedure_number":"EMEA-C-001362-PIP01-12-M03","contact_for_public_enquiries":"BioMarin International Limited; Ireland; Tel. +44 2074200800; Fax +44 2074200829; E-mail: biomarin-europe@bmrn.com","first_published_date":"15/11/2013","last_updated_date":"10/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001362-pip01-12-m03"},{"decision_number":"P/0479/2020","pip_number":"EMEA-000482-PIP01-08-M06","active_substance":"teduglutide","invented_name":"Revestive; Revestive","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of short bowel syndrome","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2020","compliance_outcome":"Positive","compliance_opinion_date":"26/03/2021","compliance_procedure_number":"EMEA-C-000482-PIP01-08-M06","contact_for_public_enquiries":"Takeda Pharmaceuticals International AG Ireland Branch; E-mail: medinfoemea@takeda.com; Tel: +44 (0) 3333 000181","first_published_date":"20/12/2010","last_updated_date":"10/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000482-pip01-08-m06"},{"decision_number":"P/0134/2021","pip_number":"EMEA-001356-PIP02-12-M04","active_substance":"citric acid (as citric acid anhydrous);macrogol 4000;potassium chloride;simeticone;sodium chloride;sodium citrate;sodium sulfate (as sodium sulfate anhydrous)","invented_name":"Clensia","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Powder for oral suspension","condition_indication":"Bowel cleansing prior to clinical procedures","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/04/2021","compliance_outcome":"Positive","compliance_opinion_date":"17/12/2021","compliance_procedure_number":"EMEA-C-001356-PIP02-12-M04","contact_for_public_enquiries":"Alfasigma S.p.A.; E-mail: Antonietta.Pazardjiklian@alfasigma.com; Tel.: +39 0516489602","first_published_date":"16/04/2014","last_updated_date":"10/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001356-pip02-12-m04"},{"decision_number":"P/0432/2020","pip_number":"EMEA-001407-PIP01-12-M03","active_substance":"nivolumab","invented_name":"Opdivo","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/11/2020","compliance_outcome":"Positive","compliance_opinion_date":"21/01/2022","compliance_procedure_number":"EMEA-C-001407-PIP01-12-M03","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"16/04/2014","last_updated_date":"10/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001407-pip01-12-m03"},{"decision_number":"P/0031/2020","pip_number":"EMEA-001107-PIP01-10-M04","active_substance":"albutrepenonacog alfa","invented_name":"Idelvion","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for infusion;Powder and solvent for solution for injection","condition_indication":"Treatment of hereditary factor IX deficiency","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/01/2020","compliance_outcome":"","compliance_opinion_date":"21/01/2022","compliance_procedure_number":"EMEA-C-001107-PIP01-10-M04","contact_for_public_enquiries":"CSL Behring GmbH; Tel.: +49 6421393304; E-mail: rix-fp@cslbehring.com","first_published_date":"29/11/2011","last_updated_date":"10/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001107-pip01-10-m04"},{"decision_number":"P/0014/2020","pip_number":"EMEA-001024-PIP01-10-M02","active_substance":"Human-cell-line recombinant human factor VIII (human-cl rhFVIII);human Coagulation Factor VIII (rDNA)","invented_name":"Nuwiq and associated names","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of haemophilia A (congenital factor-VIII deficiency)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/01/2020","compliance_outcome":"Positive","compliance_opinion_date":"26/03/2021","compliance_procedure_number":"EMEA-C-001024-PIP01-10-M02","contact_for_public_enquiries":"Octapharma Pharmazeutika Produktionsges.m.b.H; E-mail: sigurd.knaub@octapharma.ch; Tel. +41 554512141","first_published_date":"12/05/2011","last_updated_date":"10/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001024-pip01-10-m02"},{"decision_number":"P/0436/2020","pip_number":"EMEA-001142-PIP01-11-M04","active_substance":"ceftolozane;tazobactam","invented_name":"Zerbaxa","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of intra-abdominal infections;Treatment of urinary tract infections","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/11/2020","compliance_outcome":"Positive","compliance_opinion_date":"25/06/2021","compliance_procedure_number":"EMEA-C-001142-PIP01-11-M04","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"07/01/2012","last_updated_date":"10/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001142-pip01-11-m04"},{"decision_number":"P/0119/2021","pip_number":"EMEA-001425-PIP01-13-M05","active_substance":"Cobimetinib","invented_name":"Cotellic","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral formulation","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue) with Ras, Raf or MEK pathway activation","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/03/2021","compliance_outcome":"Positive","compliance_opinion_date":"25/06/2021","compliance_procedure_number":"EMEA-C-001425-PIP01-13-M05","contact_for_public_enquiries":"Roche Registration GmbH; E-mail: global.eu_regulatory_office@roche.comTel. +49 7624142892","first_published_date":"20/02/2014","last_updated_date":"10/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001425-pip01-13-m05"},{"decision_number":"P/0407/2020","pip_number":"EMEA-001056-PIP02-12-M01","active_substance":"velmanase alfa","invented_name":"Lamzede","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of alpha-mannosidosis","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"23/10/2020","compliance_outcome":"Positive","compliance_opinion_date":"23/04/2021","compliance_procedure_number":"EMEA-C-001056-PIP02-12-M01","contact_for_public_enquiries":"Chiesi Farmaceutici S.p.A.; Tel. +39 0521 2791; E-mail: info@chiesi.com","first_published_date":"05/06/2014","last_updated_date":"10/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001056-pip02-12-m01"},{"decision_number":"P/0177/2020","pip_number":"EMEA-000832-PIP01-10-M05","active_substance":"dimethyl fumarate","invented_name":"Tecfidera","therapeutic_area":"Neurology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of multiple sclerosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/05/2020","compliance_outcome":"Positive","compliance_opinion_date":"14/06/2021","compliance_procedure_number":"EMEA-C-000832-PIP01-10-M05","contact_for_public_enquiries":"Biogen Idec LtdTel.  +01 628501000E-mail: pip.enquiries@biogen.com","first_published_date":"25/07/2017","last_updated_date":"10/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000832-pip01-10-m05"},{"decision_number":"P/0060/2018","pip_number":"EMEA-001064-PIP01-10-M03","active_substance":"octocog alfa","invented_name":"Iblias; Kovaltry; Iblias; Kovaltry","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of hereditary factor VIII deficiency","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/03/2018","compliance_outcome":"Positive","compliance_opinion_date":"23/07/2021","compliance_procedure_number":"EMEA-C-001064-PIP01-10-M03","contact_for_public_enquiries":"Bayer AG; E-mail: clinical-trials-contact@bayer.com; Tel. +49 30300139003","first_published_date":"14/07/2011","last_updated_date":"10/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001064-pip01-10-m03"},{"decision_number":"P/0346/2020","pip_number":"EMEA-000883-PIP01-10-M05","active_substance":"treosulfan","invented_name":"Trecondi","therapeutic_area":"Immunology-Rheumatology-Transplantation;Oncology","pharmaceutical_forms":"Powder for solution","condition_indication":"Conditioning treatment prior to haematopoietic-progenitor-cell transplantation","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/09/2020","compliance_outcome":"Positive","compliance_opinion_date":"25/03/2022","compliance_procedure_number":"EMEA-C-000883-PIP01-10-M05","contact_for_public_enquiries":"medac Gesellschaft für klinische Spezialpräparate mbH; Germany; Tel. +49 (0) 401380060; E-mail: dra@medac.de","first_published_date":"14/07/2011","last_updated_date":"10/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000883-pip01-10-m05"},{"decision_number":"P/0013/2021","pip_number":"EMEA-000980-PIP01-10-M07","active_substance":"Brentuximab vedotin","invented_name":"Adcetris","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of anaplastic large cell lymphoma;Treatment of Hodgkin lymphoma","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"28/01/2021","compliance_outcome":"Positive","compliance_opinion_date":"25/06/2021","compliance_procedure_number":"EMEA-C-000980-PIP01-10-M07","contact_for_public_enquiries":"Takeda Pharma A/S; Tel.  +45(0) 46771111; E-mail: paediatrics@tgrd.com","first_published_date":"07/01/2013","last_updated_date":"10/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000980-pip01-10-m07"},{"decision_number":"P/0064/2021","pip_number":"EMEA-000689-PIP01-09-M11","active_substance":"exenatide","invented_name":"Bydureon; Byetta","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection;Powder and solvent for prolonged-release suspension for injection;Solution for injection in pre-filled injector","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/02/2021","compliance_outcome":"Positive","compliance_opinion_date":"21/05/2021","compliance_procedure_number":"EMEA-C-000689-PIP01-09-M11","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel. +46 8553 27591","first_published_date":"17/10/2011","last_updated_date":"10/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000689-pip01-09-m11"},{"decision_number":"P/0257/2021","pip_number":"EMEA-001856-PIP02-16-M02","active_substance":"peramivir","invented_name":"Alpivab","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of influenza","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/07/2021","compliance_outcome":"Positive","compliance_opinion_date":"17/12/2021","compliance_procedure_number":"EMEA-C-001856-PIP02-16-M02","contact_for_public_enquiries":"BioCryst Ireland Limited; Tel. +1 9194505809; E-mail: pip.enquiries@biocryst.com","first_published_date":"06/01/2017","last_updated_date":"09/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001856-pip02-16-m02"},{"decision_number":"P/0070/2021","pip_number":"EMEA-002727-PIP01-19-M01","active_substance":"nivolumab;relatlimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of melanoma","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/03/2021","compliance_outcome":"Positive","compliance_opinion_date":"10/09/2021","compliance_procedure_number":"EMEA-C-002727-PIP01-19-M01","contact_for_public_enquiries":"Bristol-Myers Squibb International Corporation; E-mail: medical.information@bms.com; Tel. +44 1423 533 610","first_published_date":"22/06/2021","last_updated_date":"09/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002727-pip01-19-m01"},{"decision_number":"P/0329/2021","pip_number":"EMEA-001501-PIP01-13-M07","active_substance":"dupilumab","invented_name":"Dupixent; Dupixent","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of atopic dermatitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/08/2021","compliance_outcome":"Positive","compliance_opinion_date":"25/02/2022","compliance_procedure_number":"EMEA-C-001501-PIP01-13-M07","contact_for_public_enquiries":"Regeneron Pharmaceuticals Inc; E-mail: clinicaltrials@regeneron.com; Tel. +914 8475385","first_published_date":"31/07/2014","last_updated_date":"09/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001501-pip01-13-m07"},{"decision_number":"P/0150/2018","pip_number":"EMEA-001646-PIP01-14-M02","active_substance":"sofosbuvir;velpatasvir","invented_name":"Epclusa; Epclusa","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral formulation","condition_indication":"Treatment of chronic hepatitis C","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/05/2018","compliance_outcome":"Positive","compliance_opinion_date":"26/02/2021","compliance_procedure_number":"EMEA-C-001646-PIP01-14-M02","contact_for_public_enquiries":"Gilead Sciences International Ltd; E-mail: regulatory.pip@gilead.com; Tel. +44 (0)1223 897300","first_published_date":"26/07/2017","last_updated_date":"09/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001646-pip01-14-m02"},{"decision_number":"P/0435/2020","pip_number":"EMEA-001460-PIP01-13-M05","active_substance":"elvitegravir;cobicistat;emtricitabine;tenofovir alafenamide","invented_name":"Genvoya","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/11/2020","compliance_outcome":"Positive","compliance_opinion_date":"25/06/2021","compliance_procedure_number":"EMEA-C-001460-PIP01-13-M05","contact_for_public_enquiries":"Gilead Sciences International Ltd; Tel. +44 (0)1223 897300; E-mail: regulatory.pip@gilead.com","first_published_date":"20/02/2014","last_updated_date":"09/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001460-pip01-13-m05"},{"decision_number":"P/0093/2021","pip_number":"EMEA-001706-PIP01-14-M03","active_substance":"Enalapril (maleate)","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Age appropriate oral solid dosage form","condition_indication":"Treatment of heart failure","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/03/2021","compliance_outcome":"Positive","compliance_opinion_date":"25/06/2021","compliance_procedure_number":"EMEA-C-001706-PIP01-14-M03","contact_for_public_enquiries":"Proveca Pharma Limited; Tel. +353 15136233; E-mail: info@proveca.com","first_published_date":"26/07/2017","last_updated_date":"09/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001706-pip01-14-m03"},{"decision_number":"P/0184/2020","pip_number":"EMEA-001596-PIP02-17-M02","active_substance":"afatinib","invented_name":"Giotrif","therapeutic_area":"Oncology","pharmaceutical_forms":"Oral use","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (excluding central nervous system, haematopoietic and lymphoid tissue neoplasms);Treatment of malignant neoplasms of the central nervous system","routes_of_administration":"","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/05/2020","compliance_outcome":"Positive","compliance_opinion_date":"23/04/2021","compliance_procedure_number":"EMEA-C-001596-PIP02-17-M02","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"28/01/2019","last_updated_date":"09/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001596-pip02-17-m02"},{"decision_number":"P/0244/2019","pip_number":"EMEA-002215-PIP01-17-M03","active_substance":"pneumococcal polysaccharide serotype 1- diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 3 - diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 4 - diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 5 - diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 6A- diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 6B - diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 7F - diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 9V - diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 14 - diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 18C - diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 19A - diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 19F - diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 22F - diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 23F - diphtheria CRM197 conjugate;pneumococcal polysaccharide serotype 33F – diphtheria CRM197 conjugate (15-valent pneumococcal polysaccharide conjugate vaccine [V114])","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of disease caused by Streptococcus pneumoniae","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/08/2021","compliance_outcome":"Positive","compliance_opinion_date":"17/12/2021","compliance_procedure_number":"EMEA-C-002215-PIP01-17-M03","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"12/02/2018","last_updated_date":"09/03/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002215-pip01-17-m03"},{"decision_number":"P/0523/2021","pip_number":"EMEA-002708-PIP02-21","active_substance":"verdiperstat","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Modified-release tablet","condition_indication":"Treatment of amyotrophic lateral sclerosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biohaven Pharmaceutical Ireland DAC; Email: medinfo@biohavenpharma.com; Tel. +1 2034040410","first_published_date":"07/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002708-pip02-21"},{"decision_number":"P/0548/2021","pip_number":"EMEA-002730-PIP03-21","active_substance":"autologous CD34+ hematopoietic stem cells with a CRISPR-edited erythroid enhancer region of the BCL11A gene","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of sickle cell disease","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vertex Pharmaceuticals (Ireland) Limited; E-mail: vertexmedicalinfo@vrtx.com; Tel: +353 17617299","first_published_date":"07/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002730-pip03-21"},{"decision_number":"P/0563/2021","pip_number":"EMEA-002506-PIP03-21","active_substance":"human monoclonal antibody targeting Staphylococcus aureus alpha-toxin (tosatoxumab)","invented_name":"","therapeutic_area":"Infectious diseases;Pneumology-allergology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of Staphylococcus aureus pneumonia","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aridis Pharmaceuticals Inc; Email: mmscltd@gmail.com    ; Tel. +1 9252003089","first_published_date":"07/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002506-pip03-21"},{"decision_number":"P/0538/2021","pip_number":"EMEA-002597-PIP07-21","active_substance":"Efgartigimod alfa","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of pemphigus","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Argenx BVE-mail: regulatory@argenx.comTel: +32 93103400","first_published_date":"07/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002597-pip07-21"},{"decision_number":"P/0482/2021","pip_number":"EMEA-002270-PIP04-20","active_substance":"Marzeptacog alfa (activated)","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of Haemophilia B","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Catalyst Biosciences, Inc.; Email: cdemocko@catbio.com    ; Tel. +1 4153054942","first_published_date":"06/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002270-pip04-20"},{"decision_number":"P/0481/2021","pip_number":"EMEA-002270-PIP03-20","active_substance":"Marzeptacog alfa (activated)","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of Haemophilia A","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Catalyst Biosciences, Inc.; Email: cdemocko@catbio.com    ; Tel. +1 4153054942","first_published_date":"06/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002270-pip03-20"},{"decision_number":"P/0499/2021","pip_number":"EMEA-001525-PIP02-21","active_substance":"human alpha1-proteinase inhibitor","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of emphysema secondary to congenital deficiency of alpha-1 antitrypsin","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kamada Ireland LimitedEmail: oritp@kamada.com    Tel: +972 89406472;  +972 522660030","first_published_date":"02/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001525-pip02-21"},{"decision_number":"P/0560/2021","pip_number":"EMEA-000380-PIP08-21","active_substance":"secukinumab","invented_name":"Cosentyx","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder for solution for injection;Solution for injection","condition_indication":"Treatment of vasculitides","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"02/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000380-pip08-21"},{"decision_number":"P/0497/2021","pip_number":"EMEA-001214-PIP08-21","active_substance":"Benralizumab","invented_name":"Fasenra","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Age appropriate dosage form for parenteral use;Solution for injection","condition_indication":"Treatment of non-cystic fibrosis bronchiectasis with an eosinophilic phenotype","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB (Sweden); Tel.  +46 855326000; E-mail: paediatrics@astrazeneca.com","first_published_date":"02/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001214-pip08-21"},{"decision_number":"P/0544/2021","pip_number":"EMEA-000095-PIP02-21","active_substance":"plitidepsin","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder and solvent for concentrate for solution for infusion","condition_indication":"Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/12/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pharma Mar, S.A.; Email: clinicaltrials@pharmamar.com; Tel. +34 918466000","first_published_date":"02/03/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000095-pip02-21"},{"decision_number":"P/0036/2022","pip_number":"EMEA-002970-PIP01-21","active_substance":"tildacerfont","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Granules;Tablet","condition_indication":"Treatment of congenital adrenal hyperplasia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Spruce Biosciences, Inc.; E-mail: info@scendea.com; Tel: +31 0208 949169","first_published_date":"22/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002970-pip01-21"},{"decision_number":"P/0467/2021","pip_number":"EMEA-003048-PIP01-21","active_substance":"pyridine-3-carboxamide derivative (K-161)","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution","condition_indication":"Treatment of dry eye disease","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kowa Pharmaceuticals Europe AG; Email: paediatrics@kowapharma.ch; Tel. +41 (0)442055989","first_published_date":"22/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003048-pip01-21"},{"decision_number":"P/0417/2021","pip_number":"EMEA-003051-PIP01-21","active_substance":"depemokimab","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of nasal polyposis","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services LimitedE-mail: eu.paediatric-plans@gsk.comTel.  +1 4388998201","first_published_date":"22/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003051-pip01-21"},{"decision_number":"P/0422/2021","pip_number":"EMEA-003045-PIP01-21","active_substance":"rusfertide","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of polycythaemia vera","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Protagonist Therapeutics, Inc.; Email: ptgxclintrials@ptgx-inc.com; Tel. +1 5104740170","first_published_date":"22/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003045-pip01-21"},{"decision_number":"P/0421/2021","pip_number":"EMEA-003046-PIP01-21","active_substance":"alnuctamab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection;Solution for infusion","condition_indication":"Treatment of mature B cell malignancies","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb International Corporation; E-mail: medical.information@bms.com; Tel. +44 1423 533 610","first_published_date":"22/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003046-pip01-21"},{"decision_number":"P/0420/2021","pip_number":"EMEA-003047-PIP01-21","active_substance":"B cell maturation antigen antibody-drug conjugate comprised of an immunoglobulin G1 humanized antibody conjugated covalently to the dibenzocyclooctyne noncleavable linker maytansinoid warhead (BMS-986352)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of mature B cell neoplasms","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb International Corporation; E-mail: medical.information@bms.com; Tel. +44 1423 533 610","first_published_date":"22/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003047-pip01-21"},{"decision_number":"P/0431/2021","pip_number":"EMEA-003042-PIP01-21","active_substance":"batiraxcept","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of fallopian tube cancer;Treatment of ovarian cancer;Treatment of primary peritoneal cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aravive, Inc; Email: jgould@aravive.com; Tel. +1 4847438790;  ","first_published_date":"21/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003042-pip01-21"},{"decision_number":"P/0425/2021","pip_number":"EMEA-003044-PIP01-21","active_substance":"anti-CD123 IgG1 humanised monoclonal antibody conjugated to N1-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-N6-((S)-1-(((S)-1-((3-((((S)-8-methoxy-6-oxo-11,12,12a,13-tetrahydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)-5-((((S)-8-methoxy-6-oxo-12a,13-dihydro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)phenyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)adipamide","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of blastic plasmacytoid dendritic cell neoplasm","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Immunogen BioPharma (Ireland) Limited; Email: regulatory.affairs@immunogen.com; Tel. +1 2249442128","first_published_date":"21/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003044-pip01-21"},{"decision_number":"P/0436/2021","pip_number":"EMEA-003036-PIP01-21","active_substance":"amlodipine;zofenopril","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Menarini Ricerche S.p.A. ; Italy; Tel. +39 0555680633; E-mail: prijli@menarini.it","first_published_date":"21/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003036-pip01-21"},{"decision_number":"P/0433/2021","pip_number":"EMEA-003038-PIP01-21","active_substance":"lutetium (177Lu) chloride","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Radiopharmaceutical precursor","condition_indication":"Radiolabelling agent","routes_of_administration":"","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eckert & Ziegler Radiopharma GmbH; Email: regaffairs.radiopharma@ezag.de; Tel. +49 30941084211","first_published_date":"21/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003038-pip01-21"},{"decision_number":"P/0432/2021","pip_number":"EMEA-003040-PIP01-21","active_substance":"Izaflortaucipir (18F)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Diagnosis of corticobasal degeneration;Treatment of progressive supranuclear palsy","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Life Molecular Imaging GmbH; Email: gra@life-mi.com; Tel. +49 30461124603","first_published_date":"21/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003040-pip01-21"},{"decision_number":"P/0337/2021","pip_number":"EMEA-001397-PIP03-14-M06","active_substance":"Ibrutinib","invented_name":"Imbruvica","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet;Capsule, hard","condition_indication":"Treatment of mature B-cell neoplasms","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/08/2021","compliance_outcome":"Positive","compliance_opinion_date":"25/02/2022","compliance_procedure_number":"EMEA-C-001397-PIP03-14-M06","contact_for_public_enquiries":"Janssen-Cilag International N.V.; E-mail: contact@Janssen-emea.com; Tel: +32 14641125","first_published_date":"18/12/2015","last_updated_date":"21/02/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001397-pip03-14-m06"},{"decision_number":"P/0104/2018","pip_number":"EMEA-001268-PIP01-12-M05","active_substance":"Evolocumab","invented_name":"Repatha; Repatha","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of elevated cholesterol;Treatment of mixed dyslipidaemia","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/04/2018","compliance_outcome":"Positive","compliance_opinion_date":"24/06/2022","compliance_procedure_number":"EMEA-C-001268-PIP01-12-M05","contact_for_public_enquiries":"Amgen Europe B.V; Tel. +44 (0)1223 420305; E-mail: medinfointernational@amgen.com","first_published_date":"24/06/2013","last_updated_date":"21/02/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001268-pip01-12-m05"},{"decision_number":"P/0144/2022","pip_number":"EMEA-002869-PIP01-21","active_substance":"Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A/H5N1","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of pandemic influenza","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/04/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Seqirus Netherlands B.V.; E-mail: seqirus.clinicaltrials@seqirus.com; Tel: +1 9088587365","first_published_date":"21/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002869-pip01-21"},{"decision_number":"P/0448/2021","pip_number":"EMEA-003031-PIP01-21","active_substance":"Dexamethasone (sodium phosphate);ofloxacin","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution","condition_indication":"Prevention and treatment of ocular infections, inflammations and associated manifestations","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Laboratório Edol - Produtos Farmacêuticos S.A.; Email: registos@edol.pt    ; Tel. +351 214158130","first_published_date":"20/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003031-pip01-21"},{"decision_number":"P/0445/2021","pip_number":"EMEA-003034-PIP01-21","active_substance":"senaparib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of metastatic castrate-resistant prostate cancer","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"IMPACT Therapeutics US, Inc.; Email: regulatoryaffairs@impacttherapeutics.com; Tel. +86 2168411121;  ","first_published_date":"20/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003034-pip01-21"},{"decision_number":"P/0462/2021","pip_number":"EMEA-003018-PIP01-21","active_substance":"ezetimibe;rosuvastatin","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events;Treatment of hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"QualipharmaCon Kft.; Tel. +36 302110337; E-mail: turjanyi@qualipharmacon.hu","first_published_date":"20/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003018-pip01-21"},{"decision_number":"P/0450/2021","pip_number":"EMEA-002984-PIP01-21","active_substance":"terbinafine hydrochloride","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Cutaneous solution","condition_indication":"Treatment of onychomycosis","routes_of_administration":"Topical use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Moberg Pharma AB; Email: info@mobergpharma.se    ; Tel. +46 0852230700;  ","first_published_date":"20/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002984-pip01-21"},{"decision_number":"P/0437/2021","pip_number":"EMEA-002957-PIP02-21","active_substance":"Humanized monoclonal antibody of IgG1 sub-type targeting the human SEMA3A polypeptide","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of diabetic retinopathy","routes_of_administration":"Intravitreal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"20/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002957-pip02-21"},{"decision_number":"P/0453/2021","pip_number":"EMEA-002934-PIP01-20","active_substance":"crisantaspase","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection;Solution for infusion","condition_indication":"Treatment of acute lymphoblastic leukaemia;Treatment of lymphoblastic lymphoma","routes_of_administration":"Intramuscular use;Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Jazz Pharmaceuticals Ireland Ltd. E-mail: corporateaffairsmediainfo@jazzpharma.com Tel: +1 35316347800","first_published_date":"20/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002934-pip01-20-0"},{"decision_number":"P/0434/2021","pip_number":"EMEA-002903-PIP03-21","active_substance":"anti-C1s Humanized IgG4 Monoclonal Antibody","invented_name":"","therapeutic_area":"Haematology-Hemostaseology;Immunology-Rheumatology-Transplantation;Neurology","pharmaceutical_forms":"Solution for injection;Solution for infusion","condition_indication":"Treatment of chronic inflammatory demyelinating polyradiculo-neuropathy","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Genzyme Europe B.V.; E-mail: eumedinfo.gz@sanofi.com; Tel: +31 202453917","first_published_date":"20/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002903-pip03-21"},{"decision_number":"P/0459/2021","pip_number":"EMEA-002901-PIP01-20","active_substance":"thienopyrimidine derivative","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Age appropriate oral solid dosage form;Film-coated tablet","condition_indication":"Treatment of fibrosing Interstitial Lung Diseases (ILD)","routes_of_administration":"Gastric use;Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"20/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002901-pip01-20"},{"decision_number":"P/0469/2021","pip_number":"EMEA-003039-PIP01-21","active_substance":"ezetimibe;rosuvastatin","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events;Treatment of hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/11/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sandoz s.r.o.; Tel.: +31 365241710; E-mail: enquiries.paediatrics@sandoz.com","first_published_date":"20/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003039-pip01-21"},{"decision_number":"P/0435/2021","pip_number":"EMEA-003037-PIP01-21","active_substance":"perflubutane","invented_name":"","therapeutic_area":"Diagnostic;Oncology","pharmaceutical_forms":"Powder and solvent for dispersion for injection","condition_indication":"Diagnostic evaluation of focal hepatic lesions","routes_of_administration":"Intravenous use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"22/11/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GE Healthcare AS; Tel.: +1494 544000; E-mail: CustomerServiceNorway@ge.com","first_published_date":"20/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003037-pip01-21"},{"decision_number":"P/0265/2013","pip_number":"EMEA-000745-PIP01-09-M03","active_substance":"guanfacine hydrochloride","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Prolonged-release tablet","condition_indication":"Treatment of Attention Deficit Hyperactivity Disorder (ADHD)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/10/2013","compliance_outcome":"Positive","compliance_opinion_date":"06/12/2013","compliance_procedure_number":"EMEA-C-000745-PIP01-09-M03","contact_for_public_enquiries":"Takeda Pharmaceuticals International AG Ireland Branch; E-mail: medinfoemea@takeda.com; Tel: +44 (0) 3333 000181","first_published_date":"10/04/2012","last_updated_date":"20/02/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000745-pip01-09-m03"},{"decision_number":"P/0142/2021","pip_number":"EMEA-002750-PIP01-19","active_substance":"surufatinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard;Powder for oral suspension","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms);Treatment of malignant neoplasms of haematopoietic and lymphoid tissue","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/04/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Hutchison MediPharma Ltd; E-mail: marjoh@hmplglobal.com; Tel: +358 408425802","first_published_date":"14/01/2022","last_updated_date":"17/02/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002750-pip01-19"},{"decision_number":"P/0021/2022","pip_number":"EMEA-002955-PIP01-21","active_substance":"Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-methoxy, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-teriparatide (2:1) (TransCon PTH)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of hypoparathyroidism","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ascendis Pharma Bone Diseases A/S; Email: medicalaffairs@ascendispharma.com; Tel. +45 70222244;  ","first_published_date":"14/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002955-pip01-21"},{"decision_number":"P/0461/2021","pip_number":"EMEA-001441-PIP03-17-M02","active_substance":"semaglutide","invented_name":"Ozempic","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection in pre-filled pen","condition_indication":"Treatment of obesity","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; E-mail: paediatrics@novonordisk.com ; Tel.: +45 44448888","first_published_date":"11/04/2019","last_updated_date":"13/02/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001441-pip03-17-m02"},{"decision_number":"P/0443/2021","pip_number":"EMEA-002597-PIP06-21","active_substance":"Efgartigimod alfa","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic inflammatory demyelinating polyradiculo-neuropathy","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Argenx BVE-mail: regulatory@argenx.comTel: +32 93103400","first_published_date":"13/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002597-pip06-21"},{"decision_number":"P/0428/2021","pip_number":"EMEA-002575-PIP03-21","active_substance":"pralsetinib","invented_name":"Gavreto","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms [except lung cancer (small cell and non-small cell cancer), thyroid neoplasms, central nervous system tumours, haematopoietic and lymphoid tissue neoplasms];Treatment of malignant neoplasms of haematopoietic and lymphoid tissue;Treatment of malignant neoplasms of the central nervous system","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"13/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002575-pip03-21"},{"decision_number":"P/0442/2021","pip_number":"EMEA-000801-PIP03-16-M01","active_substance":"Fluocinolone acetonide","invented_name":"ILUVIEN 190 micrograms intravitreal implant in applicator and associated names","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Intravitreal implant in applicator","condition_indication":"Secondary prevention of non-infectious uveitis;Treatment of chronic non-infectious uveitis","routes_of_administration":"Intravitreal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alimera Sciences Limited; Tel.: +44 (0)8001488274; E-mail: medicalinformation@alimerasciences.com","first_published_date":"24/07/2017","last_updated_date":"13/02/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000801-pip03-16-m01"},{"decision_number":"P/0424/2021","pip_number":"EMEA-002643-PIP01-19-M01","active_substance":"imatinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for oral solution","condition_indication":"Treatment of acute lymphoblastic leukaemia;Treatment of chronic myeloid leukaemia","routes_of_administration":"Naso-gastric use;Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Accord Healthcare S.L.U.; E-mail: regulatory_EU@accord-healthcare.com; Tel. +34 933010064","first_published_date":"05/03/2021","last_updated_date":"13/02/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002643-pip01-19-m01"},{"decision_number":"P/0413/2021","pip_number":"EMEA-001943-PIP05-21","active_substance":"ravulizumab","invented_name":"Ultomiris","therapeutic_area":"Neurology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of amyotrophic lateral sclerosis","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alexion Europe SAS; E-mail: pip.enquiries.eu@alexion.com; Tel. +33 147100619","first_published_date":"13/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001943-pip05-21"},{"decision_number":"P/0458/2021","pip_number":"EMEA-002180-PIP02-19","active_substance":"pritelivir (mesylate monohydrate)","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment and prevention of Herpes simplex virus disease","routes_of_administration":"Gastric use;Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AiCuris Anti-infective Cures AG; Email: info@AiCuris.com    ; Tel. +49 (0)202317630;  ","first_published_date":"13/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002180-pip02-19"},{"decision_number":"P/0458/2021","pip_number":"EMEA-002180-PIP02-19","active_substance":"pritelivir (mesylate monohydrate)","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment and prevention of Herpes simplex virus disease","routes_of_administration":"Gastric use;Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AiCuris Anti-infective Cures AG; Email: info@AiCuris.com    ; Tel. +49 (0)202317630;  ","first_published_date":"13/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002180-pip02-19-0"},{"decision_number":"P/0419/2021","pip_number":"EMEA-002559-PIP04-21","active_substance":"anti-neonatal Fc receptor human monoclonal antibody","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of chronic inflammatory demyelinating polyradiculo-neuropathy","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; E-mail: contact@janssen-emea.com; Tel.: + +32 473112810","first_published_date":"13/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002559-pip04-21"},{"decision_number":"P/0410/2021","pip_number":"EMEA-001608-PIP02-21","active_substance":"Doxylamine (succinate);pyridoxine (hydrochloride)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Prolonged-release tablet","condition_indication":"Treatment of nausea and vomiting in pregnancy","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"EXELTIS HEALTHCARE S.L.; Email: RASolids@chemogroup.com    ; Tel: +34 949349700;  ","first_published_date":"13/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001608-pip02-21"},{"decision_number":"P/0405/2021","pip_number":"EMEA-002296-PIP01-17-M03","active_substance":"brigatinib","invented_name":"Alunbrig","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of anaplastic large cell lymphoma;Treatment of inflammatory myofibroblastic tumours;Treatment of non-small cell lung cancer","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Pharm A/S; E-mail: medinfoEMEA@takeda.com​; Tel. +44 (0)3333 000181","first_published_date":"14/02/2019","last_updated_date":"13/02/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002296-pip01-17-m03"},{"decision_number":"P/0451/2021","pip_number":"EMEA-001495-PIP02-21","active_substance":"drospirenone","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of endometriosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Chemo Research, S.L.; Email: Barbara.Herranz@exeltis.com ; Tel: +34 917711500;  ","first_published_date":"13/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001495-pip02-21"},{"decision_number":"P/0441/2021","pip_number":"EMEA-000609-PIP01-09-M03","active_substance":"recombinant human glutamic acid decarboxylase (rhGAD65)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of type I diabetes mellitus","routes_of_administration":"Intralymphatic use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Diamyd Medical AB; E-mail: ulf.hannelius@diamyd.com; Tel: +46 736354241","first_published_date":"29/10/2010","last_updated_date":"13/02/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000609-pip01-09-m03"},{"decision_number":"P/0111/2023","pip_number":"EMEA-001796-PIP03-16-M03","active_substance":"acalabrutinib","invented_name":"Calquence","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard;Film-coated tablet","condition_indication":"Treatment of mature B-cell neoplasms","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/04/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Acerta Pharma, BVE-mail: paediatrics@astrazeneca.com Tel.: +46 855327591","first_published_date":"12/02/2018","last_updated_date":"13/02/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001796-pip03-16-m03"},{"decision_number":"P/0447/2021","pip_number":"EMEA-000370-PIP02-18-M01","active_substance":"oxalobacter formigenes strain HC-1","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism;Uro-nephrology","pharmaceutical_forms":"Powder for oral suspension;Gastro-resistant tablet;Gastro-resistant granules for oral suspension;Gastro-resistant capsule (hard)","condition_indication":"Treatment of hyperoxaluria","routes_of_administration":"Oral use;Gastric use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"OxThera AB; E-mail: orla.mccallion@oxthera.com, bastian.dehmel@oxthera.com ; Tel. +46 (0)8660 0223","first_published_date":"20/11/2019","last_updated_date":"13/02/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000370-pip02-18-m01"},{"decision_number":"P/0411/2021","pip_number":"EMEA-001447-PIP02-21","active_substance":"ezetimibe;rosuvastatin","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Prevention of cardiovascular disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"EGIS Pharmaceuticals PLC; Hungary; registry@egis.hu ; Tel. +361 18032414","first_published_date":"13/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001447-pip02-21"},{"decision_number":"P/0464/2021","pip_number":"EMEA-001441-PIP05-20","active_substance":"semaglutide","invented_name":"Ozempic","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Solution for injection in pre-filled pen","condition_indication":"Treatment of non-alcoholic steatohepatitis (NASH)","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; Email: paediatrics@novonordisk.com; Tel: +45 44444848;  ","first_published_date":"10/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001441-pip05-20"},{"decision_number":"P/0466/2021","pip_number":"EMEA-000309-PIP06-21","active_substance":"tocilizumab","invented_name":"RoActemra","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of systemic sclerosis","routes_of_administration":"Subcutaneous use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbH; E-mail: global.eu_regulatory_office@roche.comTel. +49 7624142892","first_published_date":"10/02/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000309-pip06-21"},{"decision_number":"P/0367/2018","pip_number":"EMEA-001553-PIP01-13-M02","active_substance":"nanobody directed towards the fusion protein of human respiratory syncytial virus (ALX-0171)","invented_name":"","therapeutic_area":"Neonatology-Paediatric Intensive Care","pharmaceutical_forms":"Nebuliser solution","condition_indication":"Treatment of lower respiratory tract disease caused by human respiratory syncytial virus (RSV)","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/12/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ablynx NV ; Tel. +32 92620000 ; E-mail: regulatory@ablynx.com","first_published_date":"05/11/2014","last_updated_date":"06/02/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001553-pip01-13-m02"},{"decision_number":"P/0377/2017","pip_number":"EMEA-001865-PIP02-16","active_substance":"omega-3-carboxylic acids","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, soft;Age appropriate dosage form, other","condition_indication":"Treatment of dyslipidaemia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel. +46 8553 27591","first_published_date":"05/03/2018","last_updated_date":"06/02/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001865-pip02-16"},{"decision_number":"P/0309/2020","pip_number":"EMEA-002571-PIP01-19","active_substance":"adeno-associated viral vector serotype 8 containing the human MTM1 gene (resamirigene bilparvovec)","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of X linked myotubular myopathy","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Astellas Pharma Europe B.V.Tel. +31 7154 55878E-mail: contact.nl@astellas.com&nbsp","first_published_date":"18/06/2021","last_updated_date":"31/01/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002571-pip01-19"},{"decision_number":"P/0400/2018","pip_number":"EMEA-001974-PIP01-16-M02","active_substance":"autologous CD34+ hematopoietic stem cells transduced ex vivo with EFS lentiviral vector encoding for the human adenosine deaminase gene","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of severe combined immunodeficiency due to adenosine deaminase deficiency","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"26/11/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AdRes EU B.V.; Tel. +44 2033846700; E-mail: regulatory@orchard-tx.com","first_published_date":"21/04/2017","last_updated_date":"24/01/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001974-pip01-16-m02"},{"decision_number":"P/0071/2022","pip_number":"EMEA-003052-PIP01-21","active_substance":"(14S)-8-[3-(2-{dispiro[2.0.2^(4).1^(3)]heptan-7-yl}ethoxy)-1H-pyrazol-1-yl]-12,12-dimethyl- 2lambda^(6)-thia-3,9,11,18,23-penta-azatetracyclo[17.3.1.1^(11,14).0^(5,10)]tetracosa- 1(22),5,7,9,19(23),20-hexaene-2,2,4-trione calcium salt hydrate / tezacaftor / deutivacaftor (VX-121/ TEZ/D-IVA)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of cystic fibrosis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/11/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vertex Pharmaceuticals (Ireland) Limited; E-mail: vertexmedicalinfo@vrtx.com; Tel: +353 17617299","first_published_date":"19/01/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003052-pip01-21"},{"decision_number":"P/0248/2021","pip_number":"EMEA-002311-PIP01-17-M02","active_substance":"Ibalizumab","invented_name":"Trogarzo","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/07/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Theratechnologies International Limited; Tel. +1 5143367800; E-mail: regulatoryaffairs@theratech.com","first_published_date":"17/01/2019","last_updated_date":"16/01/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002311-pip01-17-m02"},{"decision_number":"P/0394/2021","pip_number":"EMEA-002184-PIP01-17-M01","active_substance":"solriamfetol","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of narcolepsy;Treatment of obstructive sleep apnoea","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Jazz Pharmaceuticals Ireland Limited; E-mail: medinfo-int@jazzpharma.com; Tel: 00 44 1865 399 777","first_published_date":"27/11/2018","last_updated_date":"13/01/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002184-pip01-17-m01"},{"decision_number":"P/0374/2021","pip_number":"EMEA-002112-PIP01-16-M01","active_substance":"recombinant Clostridioides difficile toxoid A;recombinant Clostridioides difficile toxoid B","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Powder and suspension for suspension for injection","condition_indication":"Prevention of Clostridium difficile infection (CDI)","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG  E-mail: medical.information@pfizer.com Tel: +44 (0)1304 616161","first_published_date":"17/04/2018","last_updated_date":"12/01/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002112-pip01-16-m01"},{"decision_number":"P/0379/2021","pip_number":"EMEA-001893-PIP01-15-M02","active_substance":"naldemedine","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Tablet;Powder for oral suspension","condition_indication":"Treatment of opioid-induced constipation (OIC)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Shionogi Limited; E-mail: shionogiclintrials-admin@shionogi.co.jp; Tel. +44 (0)20 3534 200","first_published_date":"10/01/2017","last_updated_date":"12/01/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001893-pip01-15-m02"},{"decision_number":"P/0389/2021","pip_number":"EMEA-001701-PIP01-14-M02","active_substance":"Metreleptin","invented_name":"Myalepta","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of lipodystrophy","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amryt Pharmaceuticals DAC; Tel. +44 1604 549 952; E-mail: medinfo@amrytpharma.com","first_published_date":"19/09/2016","last_updated_date":"12/01/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001701-pip01-14-m02"},{"decision_number":"P/0406/2021","pip_number":"EMEA-001640-PIP01-14-M06","active_substance":"tezacaftor;ivacaftor","invented_name":"Symkevi","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of cystic fibrosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vertex Pharmaceuticals (Ireland) Limited; E-mail: medicalinfo@vrtx.com; Tel: +1 877 634 8789","first_published_date":"26/07/2017","last_updated_date":"12/01/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001640-pip01-14-m06"},{"decision_number":"P/0367/2020","pip_number":"EMEA-002323-PIP02-19","active_substance":"relamorelin","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Age appropriate oral dosage formulation;Solution for injection","condition_indication":"Treatment of gastroparesis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergan Pharmaceuticals International Limited; E-mail: ml-eu_reg_affairs@allergan.com; Tel. +44 (0)1628 4944444","first_published_date":"06/07/2021","last_updated_date":"12/01/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002323-pip02-19"},{"decision_number":"P/0397/2021","pip_number":"EMEA-001149-PIP01-11-M07","active_substance":"human fibrinogen;human thrombin","invented_name":"Evarrest; Evicel","therapeutic_area":"Other","pharmaceutical_forms":"Solution for sealant;Sealant matrix","condition_indication":"Treatment of cerebrospinal fluid leakage resulting from a neurosurgical procedure;Treatment of haemorrhage resulting from a surgical procedure","routes_of_administration":"Epilesional use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Omrix Biopharmaceuticals N.V.; Email: DL-OMRilRAAllStaff@ITS.JNJ.com; Tel. +32 27463000;  ","first_published_date":"24/02/2012","last_updated_date":"12/01/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001149-pip01-11-m07"},{"decision_number":"P/0356/2021","pip_number":"EMEA-000882-PIP03-11-M05","active_substance":"rubidium (82Rb) chloride","invented_name":"Ruby-Fill (82Sr/82Rb Generator)","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Radionuclide generator","condition_indication":"Visualisation of myocardial perfusion for diagnostic purposes","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Jubilant DraxImage Inc., dba Jubilant Radiopharma; E-mail: Ra@jdi.jubl.com; Tel: 1-514-694-8220, ext.7045","first_published_date":"26/07/2017","last_updated_date":"12/01/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000882-pip03-11-m05"},{"decision_number":"P/0354/2021","pip_number":"EMEA-003028-PIP01-21","active_substance":"ociperlimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of breast cancer;Treatment of cervical cancer;Treatment of endometrial carcinoma;Treatment of gastric and gastroesophageal junction adenocarcinoma;Treatment of head and neck epithelial malignant neoplasms;Treatment of hepatocellular carcinoma;Treatment of intestinal malignant neoplasms;Treatment of lung cancer;Treatment of oesophageal carcinoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BeiGene Ireland Limited; E-mail: BeigeneClinicalSupportUS@beigene.com; Tel: +1 833 969 2463","first_published_date":"11/01/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003028-pip01-21"},{"decision_number":"P/0401/2021","pip_number":"EMEA-003023-PIP01-21","active_substance":"5’-capped mRNA encoding HPV16 oncoprotein E6 and E7","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of head and neck squamous cell carcinoma (HNSCC)","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BioNTech SEE-mail: service@biontech.de Tel: +49 (0) 6131 90840","first_published_date":"11/01/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003023-pip01-21"},{"decision_number":"P/0381/2021","pip_number":"EMEA-003021-PIP01-21","active_substance":"azithromycin","invented_name":"","therapeutic_area":"Neonatology-Paediatric Intensive Care","pharmaceutical_forms":"Age appropriate dosage form for parenteral use","condition_indication":"Prevention of bronchopulmonary dysplasia","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aspire Pharma Limited; E-mail: info@aspirepharma.co.uk; Tel: +44 1730 231148","first_published_date":"11/01/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003021-pip01-21"},{"decision_number":"P/0366/2021","pip_number":"EMEA-003015-PIP01-21","active_substance":"Indapamide;perindopril arginine;amlodipine;bisoprolol (fumarate)","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires Servier; E-mail: mail.dcp-contact@servier.com; Tel: +33 1 55 72 60 00","first_published_date":"11/01/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003015-pip01-21"},{"decision_number":"P/0230/2015","pip_number":"EMEA-001740-PIP01-14","active_substance":"vaborbactam","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of Gram-negative bacterial infections","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/10/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Rempex Pharmaceuticals, a wholly-owned subsidiary of The Medicines Company; Tel. +39 0555680633; E-mail: prijli@menarini.it","first_published_date":"22/12/2015","last_updated_date":"11/01/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001740-pip01-14"},{"decision_number":"P/0376/2021","pip_number":"EMEA-003004-PIP01-21","active_substance":"prednisolone","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of prostate malignant neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alfred E. Tiefenbacher (GmbH & Co. KG); Tel. +49 404418090; E-mail: regaffairs@aet.eu","first_published_date":"11/01/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003004-pip01-21"},{"decision_number":"P/0359/2021","pip_number":"EMEA-002960-PIP02-21","active_substance":"prasterone;levonorgestrel;ethinylestradiol","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypoactive sexual desire disorder secondary to combined oral contraceptive use in women requiring contraception","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gedeon Richter Plc.; E-mail: cprichter@richter.hu; Tel: +36 1 431 4675","first_published_date":"11/01/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002960-pip02-21"},{"decision_number":"P/0378/2021","pip_number":"EMEA-002917-PIP01-20","active_substance":"L-Lactic acid;citric acid;potassium bitartrate","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Vaginal gel","condition_indication":"Prevention of Neisseria gonorrhoeae (GC) infection;Prevention of urogenital Chlamydia trachomatis (CT) infection","routes_of_administration":"Vaginal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Evofem, Inc.; E-mail: regulatory@evofem.com; Tel: +1 919 749 0328","first_published_date":"11/01/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002917-pip01-20"},{"decision_number":"P/0391/2021","pip_number":"EMEA-002896-PIP01-20","active_substance":"single chain urokinase plasminogen activator (scuPA)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of pleural effusion","routes_of_administration":"Intrapleural use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Lung Therapeutics, Inc.; E-mail: info@lungtx.com; Tel: +1 737 802 1989","first_published_date":"10/01/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002896-pip01-20"},{"decision_number":"P/0364/2021","pip_number":"EMEA-002387-PIP02-21","active_substance":"selinexor","invented_name":"Nexpovio","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of endometrial carcinoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Karyopharm Europe GmbH; E-mail: cnippgen@karyopharm.com; Tel: +4915118568262","first_published_date":"10/01/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002387-pip02-21"},{"decision_number":"P/0372/2021","pip_number":"EMEA-001811-PIP03-20","active_substance":"ligelizumab","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Solution for injection;Age appropriate dosage form for parenteral use","condition_indication":"Treatment of food allergy","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"09/01/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001811-pip03-20"},{"decision_number":"P/0110/2019","pip_number":"EMEA-002378-PIP01-18","active_substance":"N-hydroxy-5-methylfuran-2-sulfonamide (BMS-986231)","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Powder for concentrate for solution for infusion;Age appropriate dosage form for parenteral use","condition_indication":"Treatment of acute heart failure","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb International Corporation; Tel. +44 (0)1895 523740; E-mail: medical.information@bms.com","first_published_date":"24/06/2019","last_updated_date":"09/01/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002378-pip01-18"},{"decision_number":"P/0384/2021","pip_number":"EMEA-001638-PIP02-21","active_substance":"atezolizumab","invented_name":"Tecentriq","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, hematopoietic and lymphoid tissue neoplasms and melanoma)","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"09/01/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001638-pip02-21"},{"decision_number":"P/0070/2020","pip_number":"EMEA-001220-PIP05-19","active_substance":"Baricitinib","invented_name":"Olumiant","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Tablet;Age appropriate oral formulation","condition_indication":"Treatment of Systemic Lupus Erythematosus (SLE)","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"18/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"28/07/2020","last_updated_date":"09/01/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001220-pip05-19"},{"decision_number":"P/0352/2021","pip_number":"EMEA-001090-PIP02-21","active_substance":"florbetaben (18F)","invented_name":"Neuraceq","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Solution for injection","condition_indication":"Diagnosis of cardiac amyloidosis","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Life Molecular Imaging GmbH; E-mail: GRA@life-mi.com; Tel: +49030461124604","first_published_date":"09/01/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001090-pip02-21"},{"decision_number":"P/0306/2021","pip_number":"EMEA-000828-PIP07-21","active_substance":"empagliflozin","invented_name":"Jardiance","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of ischaemic heart disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH E-mail: COMMSPaediatrics@boehringer-ingelheim.comTel. +49 (0)6132 77 8271","first_published_date":"09/01/2023","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000828-pip07-21"},{"decision_number":"P/0346/2021","pip_number":"EMEA-002448-PIP01-18-M02","active_substance":"pegylated-fibroblast growth factor 21 (BMS-986036)","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"","condition_indication":"Treatment of non-alcoholic steatohepatitis (NASH)","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb International Corporation; Tel. +44 1895523740; E-mail: medical.information@bms.com","first_published_date":"25/03/2020","last_updated_date":"05/01/2023","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002448-pip01-18-m02"},{"decision_number":"P/0378/2019","pip_number":"EMEA-001869-PIP01-15-M02","active_substance":"rivogenlecleucel","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Adjunctive treatment in haematopoietic stem cell transplantation","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/12/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bellicum Pharma Ltd; Tel. +1 8323841100; E-mail: mansari@bellicum.com","first_published_date":"24/07/2017","last_updated_date":"22/12/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001869-pip01-15-m02"},{"decision_number":"P/0388/2021","pip_number":"EMEA-001214-PIP05-19","active_substance":"Benralizumab","invented_name":"Fasenra","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Solution for injection;Solution for injection/infusion;Age appropriate dosage form for parenteral use","condition_indication":"Treatment of eosinophilic esophagitis","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel.  +46 855326000;  ","first_published_date":"10/06/2022","last_updated_date":"22/12/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001214-pip05-19"},{"decision_number":"P/0120/2014","pip_number":"EMEA-001333-PIP02-13","active_substance":"pradigastat","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of familial chylomicronaemia syndrome (type I hyperlipoproteinaemia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"07/05/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"05/06/2014","last_updated_date":"22/12/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001333-pip02-13"},{"decision_number":"P/0418/2019","pip_number":"EMEA-001870-PIP01-15-M02","active_substance":"rimiducid","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of graft versus host disease","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/12/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bellicum Pharma Ltd; Tel. +1 8323841100; E-mail: mansari@bellicum.com","first_published_date":"24/07/2017","last_updated_date":"13/12/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001870-pip01-15-m02"},{"decision_number":"P/0101/2019","pip_number":"EMEA-001014-PIP01-10-M01","active_substance":"Dermatophagoides pteronyssinus;Dermatophagoides farinae","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Coated tablet","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Sublingual use","decision_type":"RPM: decision refers to a refusal on the application for modification of an agreed PIP","decision_date":"22/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"14/07/2011","last_updated_date":"13/12/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001014-pip01-10-m01"},{"decision_number":"P/0084/2019","pip_number":"EMEA-001016-PIP01-10-M01","active_substance":"chemically modified extract of grass pollen from Holcus lanatus, Phleum pratense and Poa pratensis","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Coated tablet","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Sublingual use","decision_type":"RPM: decision refers to a refusal on the application for modification of an agreed PIP","decision_date":"22/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"14/07/2011","last_updated_date":"13/12/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001016-pip01-10-m01"},{"decision_number":"P/0086/2019","pip_number":"EMEA-001012-PIP01-10-M01","active_substance":"birch pollen;alder pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Coated tablet","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Sublingual use","decision_type":"RPM: decision refers to a refusal on the application for modification of an agreed PIP","decision_date":"22/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"14/07/2011","last_updated_date":"13/12/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001012-pip01-10-m01"},{"decision_number":"P/0508/2020","pip_number":"EMEA-001529-PIP02-14-M03","active_substance":"testosterone","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Nasal gel","condition_indication":"Treatment of male hypogonadism","routes_of_administration":"Nasal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"22/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Acerus Biopharma Inc.; Email: fholagh@aceruspharma.com    ; Tel. +1 9058178195;  ","first_published_date":"18/04/2017","last_updated_date":"13/12/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001529-pip02-14-m03"},{"decision_number":"P/0396/2019","pip_number":"EMEA-002588-PIP01-19","active_substance":"ritonavir;atazanavir (as sulfate)","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/12/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pharmaceutical Oriented Services Ltd; E-mail: emakrodouli@pharosgr.gr; skoukaki@pharosgr.gr; Tel. +30 2106664667","first_published_date":"03/04/2020","last_updated_date":"06/12/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002588-pip01-19"},{"decision_number":"P/0043/2019","pip_number":"EMEA-001793-PIP01-15-M03","active_substance":"Bivalent anti-human myostatin adnectin recombinant human IgG1-Fc fusion protein (RO7239361)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection;Solution for injection in pre-filled syringe","condition_indication":"Treatment of Duchenne muscular dystrophy","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/01/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"27/10/2016","last_updated_date":"02/12/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001793-pip01-15-m03"},{"decision_number":"P/0023/2012","pip_number":"EMEA-001057-PIP01-10-M01","active_substance":"(S)-3-(OH)-desazadesferrithiocin-polyether, magnesium salt (FBS0701)","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder for oral solution;Capsule, hard","condition_indication":"Treatment of chronic iron overload requiring chelation therapy","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/01/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Shire Pharmaceutical Development Ltd; E-mail: medinfoEMEA@shire.com; Tel. 00800 6683 8470","first_published_date":"14/07/2011","last_updated_date":"02/12/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001057-pip01-10-m01"},{"decision_number":"P/0233/2021","pip_number":"EMEA-001710-PIP03-17-M03","active_substance":"Ozanimod (hydrochloride)","invented_name":"Zeposia","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Capsule, hard;Age appropriate oral solid dosage form","condition_indication":"Treatment of ulcerative colitis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/06/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"20/06/2019","last_updated_date":"02/12/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001710-pip03-17-m03"},{"decision_number":"P/0152/2019","pip_number":"EMEA-002264-PIP01-17","active_substance":"voclosporin","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Capsule, soft","condition_indication":"Treatment of Systemic Lupus Erythematosus (SLE)","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"17/04/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Otsuka Pharmaceutical Netherlands B.V.E-mail: communications@otsuka-europe.com Tel. +44 2037475001","first_published_date":"24/06/2019","last_updated_date":"02/12/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002264-pip01-17"},{"decision_number":"P/0390/2018","pip_number":"EMEA-001970-PIP02-17","active_substance":"SER-109 (Eubacterial Spores, Purified Suspension, Encapsulated)","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Capsule, hard;Oral suspension","condition_indication":"Treatment of Clostridium difficile infection","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"07/12/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aimmune Nestle Health Science US R&D LLCE-mail: USNHScPharmaregops@us.nestle.comPhone: +16508479108&nbsp","first_published_date":"14/02/2019","last_updated_date":"23/11/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001970-pip02-17"},{"decision_number":"P/0276/2019","pip_number":"EMEA-000645-PIP03-18","active_substance":"vedolizumab","invented_name":"Entyvio","therapeutic_area":"Gastroentology-Hepatology;Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder for concentrate for solution for infusion;Solution for injection","condition_indication":"Prevention of acute graft-versus-host disease","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/08/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Pharma A/S; Tel. +44 2031168000; E-mail: paediatrics@tgrd.com","first_published_date":"20/11/2019","last_updated_date":"09/11/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000645-pip03-18"},{"decision_number":"P/0024/2021","pip_number":"EMEA-001984-PIP03-20","active_substance":"sparsentan","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Age appropriate oral liquid dosage formulation;Tablet","condition_indication":"Treatment of primary IgA nephropathy","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/01/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vifor (International) AG; Email: sparsentan_ra@viforpharma.com; Tel: +41588518000","first_published_date":"29/09/2021","last_updated_date":"07/11/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001984-pip03-20"},{"decision_number":"P/0021/2016","pip_number":"EMEA-001139-PIP01-11-M02","active_substance":"nonacog alfa","invented_name":"Rixubis","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of haemophilia B (congenital factor IX deficiency)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/01/2016","compliance_outcome":"Positive","compliance_opinion_date":"29/06/2018","compliance_procedure_number":"EMEA-C-001139-PIP01-11-M02","contact_for_public_enquiries":"Baxalta Innovations GmbHE-mail: medinfoEMEA@takeda.comTel. +44 (0)3333 000181","first_published_date":"19/01/2012","last_updated_date":"10/10/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001139-pip01-11-m02"},{"decision_number":"P/0040/2012","pip_number":"EMEA-000753-PIP01-11","active_substance":"recombinant porcine factor VIII, B-domain deleted","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder for solution for injection;Powder and solvent for solution for injection","condition_indication":"Treatment of acquired haemophilia A","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/02/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Baxalta Innovations GmbHE-mail: medinfoEMEA@takeda.comTel. +44 (0)3333 000181","first_published_date":"26/03/2012","last_updated_date":"10/10/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000753-pip01-11"},{"decision_number":"P/0326/2021","pip_number":"EMEA-003010-PIP01-21","active_substance":"sivopixant","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of unexplained or refractory chronic cough","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Shionogi B.V.; E-mail: shionogiclintrials-admin@shionogi.co.jp; Tel: +44 203534200","first_published_date":"13/09/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003010-pip01-21"},{"decision_number":"P/0288/2021","pip_number":"EMEA-003007-PIP01-21","active_substance":"gemcitabine hydrochloride","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of urothelial carcinoma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; E-mail: contact@janssen-emea.com; Tel.: +32 14602111","first_published_date":"13/09/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003007-pip01-21"},{"decision_number":"P/0289/2021","pip_number":"EMEA-003006-PIP01-21","active_substance":"cetrelimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of urothelial carcinoma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; E-mail: contact@janssen-emea.com; Tel.: +32 14602111","first_published_date":"13/09/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003006-pip01-21"},{"decision_number":"P/0294/2021","pip_number":"EMEA-003005-PIP01-21","active_substance":"aldafermin","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of non-alcoholic steatohepatitis (NASH)","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"NGM Biopharmaceuticals, Inc.; E-mail: info@ngmbio.com; Tel: +1 6502435555","first_published_date":"13/09/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003005-pip01-21-0"},{"decision_number":"P/0297/2021","pip_number":"EMEA-003005-PIP01-21","active_substance":"ramipril;amlodipine;hydrochlorothiazide","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Swyssi AGE-mail: info@swyssi.com Tel: +49 6966554162","first_published_date":"12/09/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003005-pip01-21"},{"decision_number":"P/0299/2021","pip_number":"EMEA-002997-PIP01-21","active_substance":"Immunoglobulin G1 anti-SORT1 human monoclonal antibody","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of clinically symptomatic or pre-symptomatic frontotemporal dementia","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alector, Inc.; E-mail: info@alector.com; Tel: +1 4152315660","first_published_date":"12/09/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002997-pip01-21"},{"decision_number":"P/0335/2021","pip_number":"EMEA-002994-PIP01-21","active_substance":"gabapentin","invented_name":"","therapeutic_area":"Neurology;Pain","pharmaceutical_forms":"Prolonged-release tablet","condition_indication":"Treatment of postherpetic neuralgia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alvogen Malta Out-licensing Ltd; E-mail: regulatory@adalvo.com; Tel: +356 22485944","first_published_date":"12/09/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002994-pip01-21"},{"decision_number":"P/0312/2021","pip_number":"EMEA-002988-PIP01-21","active_substance":"insulin icodec;semaglutide","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection in pre-filled pen","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; E-mail: paediatrics@novonordisk.com; Tel: +45 44448888;  ","first_published_date":"12/09/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002988-pip01-21"},{"decision_number":"P/0330/2021","pip_number":"EMEA-002892-PIP01-20","active_substance":"cefepime;zidebactam","invented_name":"","therapeutic_area":"Infectious diseases;Neonatology-Paediatric Intensive Care;Uro-nephrology","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of complicated urinary tract infections","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Wockhardt Bio AG; E-mail: EUDataRepresentative@wockhardt.com; Tel: +48 221105473","first_published_date":"12/09/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002892-pip01-20"},{"decision_number":"P/0323/2021","pip_number":"EMEA-002867-PIP01-20","active_substance":"afamitresgene autoleucel","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of soft tissue sarcoma","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"12/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Adaptimmune Ltd; E-mail: info@adaptimmune.com; Tel: +44 123543000","first_published_date":"08/09/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002867-pip01-20"},{"decision_number":"P/0290/2021","pip_number":"EMEA-002766-PIP02-21","active_substance":"bentracimab","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Solution for infusion","condition_indication":"Prevention of ticagrelor associated haemorrhage;Treatment of ticagrelor associated haemorrhage","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"PhaseBio Pharmaceuticals Inc.; E-mail: phasebioregulatory@phasebio.com; Tel: +1 6109816507","first_published_date":"08/09/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002766-pip02-21"},{"decision_number":"P/0331/2021","pip_number":"EMEA-002594-PIP02-20","active_substance":"Infigratinib","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of achondroplasia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"QED Therapeutics Inc.; E-mail: info@qedtx.com; Tel: +1 65202314088","first_published_date":"08/09/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002594-pip02-20"},{"decision_number":"P/0325/2021","pip_number":"EMEA-002350-PIP03-20","active_substance":"deucravacitinib","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Age appropriate oral solid dosage form;Film-coated tablet","condition_indication":"Treatment of Systemic Lupus Erythematosus (SLE)","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"12/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb International Corporation; E-mail: medical.information@bms.com; Tel. +44 1423 533 610","first_published_date":"08/09/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002350-pip03-20"},{"decision_number":"P/0319/2021","pip_number":"EMEA-002349-PIP03-20","active_substance":"Fenebrutinib","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Age appropriate oral solid dosage form;Tablet","condition_indication":"Treatment of multiple sclerosis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"08/09/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002349-pip03-20"},{"decision_number":"P/0318/2021","pip_number":"EMEA-001238-PIP02-20","active_substance":"vatiquinone","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of mitochondrial disease","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"PTC Therapeutics International Limited; Tel. +353 19068700; E-mail: medinfo@ptcbio.com","first_published_date":"08/09/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001238-pip02-20"},{"decision_number":"P/0339/2021","pip_number":"EMEA-001220-PIP08-20","active_substance":"Baricitinib","invented_name":"Olumiant","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Tablet;Oral suspension","condition_indication":"Treatment of alopecia areata","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"08/09/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001220-pip08-20"},{"decision_number":"P/0215/2022","pip_number":"EMEA-001654-PIP01-14-M04","active_substance":"tisagenlecleucel","invented_name":"Kymriah; Kymriah","therapeutic_area":"Oncology","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of B cell acute lymphoblastic leukaemia/lymphoblastic lymphoma","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/06/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm Limited; E-mail: paediatric.enquiries@novartis.com; Tel. +41 6132 46715","first_published_date":"16/06/2015","last_updated_date":"07/09/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001654-pip01-14-m04"},{"decision_number":"P/0315/2021","pip_number":"EMEA-002217-PIP01-17-M02","active_substance":"in vitro expanded autologous human articular chondrocytes","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Implant","condition_indication":"Treatment of cartilage disorders","routes_of_administration":"Intraarticular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"TETEC Tissue Engineering Technologies AG; E-mail: info@tetec-ag.de; Tel: +49 712116260","first_published_date":"17/01/2019","last_updated_date":"01/09/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002217-pip01-17-m02"},{"decision_number":"P/0313/2021","pip_number":"EMEA-002127-PIP01-17-M01","active_substance":"temelimab","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of multiple sclerosis","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GeNeuro SA; Tel. +41  225524800; E-mail: contact@geneuro.com","first_published_date":"05/03/2018","last_updated_date":"01/09/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002127-pip01-17-m01"},{"decision_number":"P/0287/2021","pip_number":"EMEA-002059-PIP02-19-M01","active_substance":"Fasinumab","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic musculoskeletal pain;Treatment of chronic non-musculoskeletal pain","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Regeneron Ireland DAC; Tel. +1 9148 475385; E-mail: clinicaltrials@regeneron.com","first_published_date":"18/06/2021","last_updated_date":"01/09/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002059-pip02-19-m01"},{"decision_number":"P/0314/2021","pip_number":"EMEA-001895-PIP01-15-M01","active_substance":"Lactobacillus reuteri (IBP-9414)","invented_name":"","therapeutic_area":"Gastroentology-Hepatology;Neonatology-Paediatric Intensive Care;Other","pharmaceutical_forms":"Powder for oral suspension","condition_indication":"Prevention of necrotising enterocolitis","routes_of_administration":"Gastroenteral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Infant Bacterial Therapeutics AB; Tel. +46841014555; E-mail: info@ibtherapeutics.com","first_published_date":"13/02/2018","last_updated_date":"01/09/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001895-pip01-15-m01"},{"decision_number":"P/0308/2021","pip_number":"EMEA-001811-PIP02-15-M04","active_substance":"ligelizumab","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution for injection;Age appropriate dosage form for parenteral use","condition_indication":"Treatment of chronic spontaneous urticaria","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"13/02/2018","last_updated_date":"01/09/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001811-pip02-15-m04"},{"decision_number":"P/0336/2021","pip_number":"EMEA-001416-PIP01-12-M03","active_substance":"sirolimus","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic non-infectious uveitis","routes_of_administration":"Intravitreal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Santen Incorporated; Tel. +44 1727 615110; E-mail: regulatoryaffairs@santen.com","first_published_date":"13/05/2014","last_updated_date":"01/09/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001416-pip01-12-m03"},{"decision_number":"P/0302/2021","pip_number":"EMEA-001296-PIP01-12-M04","active_substance":"rurioctocog alfa pegol","invented_name":"Adynovi","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Baxalta Innovations GmbHE-mail: medinfoEMEA@takeda.comTel. +44 (0)3333 000181","first_published_date":"03/05/2013","last_updated_date":"01/09/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001296-pip01-12-m04"},{"decision_number":"P/0295/2021","pip_number":"EMEA-001171-PIP01-11-M02","active_substance":"procaine (hydrochloride);xylitol;potassium chloride;magnesium sulfate heptahydrate","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Solution for injection","condition_indication":"Cardioplegia","routes_of_administration":"Intracoronary use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"MIT Gesundheit GmbH; Switzerland; Tel. +41 763804835; E-mail: info@swisscardiotech.com","first_published_date":"22/08/2012","last_updated_date":"31/08/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001171-pip01-11-m02"},{"decision_number":"P/0424/2022","pip_number":"EMEA-000310-PIP03-10-M06","active_substance":"ocrelizumab","invented_name":"Ocrevus","therapeutic_area":"Neurology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of multiple sclerosis","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"08/08/2011","last_updated_date":"31/08/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000310-pip03-10-m06"},{"decision_number":"P/0303/2021","pip_number":"EMEA-000309-PIP04-17-M03","active_substance":"tocilizumab","invented_name":"RoActemra","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection;Concentrate for solution for infusion","condition_indication":"Treatment of cytokine release syndrome associated with chimeric antigen receptor (CAR) T cell therapy or T-cell-engaging bispecific antibody therapy","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"13/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"28/09/2017","last_updated_date":"31/08/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000309-pip04-17-m03"},{"decision_number":"P/0295/2020","pip_number":"EMEA-001857-PIP02-20","active_substance":"Elafibranor","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of primary biliary cholangitis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ipsen Pharma; E-mail: elafibranor.enquiries@ipsen.com; Tel. +1 857-600-8195","first_published_date":"18/06/2021","last_updated_date":"10/08/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001857-pip02-20"},{"decision_number":"P/0386/2023","pip_number":"EMEA-001584-PIP01-13-M07","active_substance":"tenofovir alafenamide fumarate","invented_name":"Vemlidy","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Age appropriate non-tablet formulation","condition_indication":"Treatment of chronic viral hepatitis B","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd. ; Tel. +44 (0)1223 897 300 ; E-mail: regulatory.pip@gilead.com","first_published_date":"30/09/2014","last_updated_date":"22/07/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001584-pip01-13-m07"},{"decision_number":"P/0280/2021","pip_number":"EMEA-002488-PIP01-18","active_substance":"Bardoxolone methyl","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of Alport syndrome","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"16/07/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Reata Pharmaceuticals Inc.; Tel. +1 4694424837; Email: paediatric.enquiries@reatapharma.com    ","first_published_date":"22/07/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002488-pip01-18"},{"decision_number":"P/0245/2021","pip_number":"EMEA-001475-PIP04-20","active_substance":"Maralixibat chloride","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of biliary atresia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/07/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mirum Pharmaceuticals Inc.; E-mail: medinfo@mirumpharma.com; Tel. +1 3104291626","first_published_date":"22/07/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001475-pip04-20"},{"decision_number":"P/0265/2021","pip_number":"EMEA-002844-PIP01-20","active_substance":"autologous selected renal cells","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of chronic kidney disease","routes_of_administration":"Percutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"07/07/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ProKidney; Tel. +1 336-462-2293; Email: info@prokidney.com","first_published_date":"22/07/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002844-pip01-20"},{"decision_number":"P/0251/2021","pip_number":"EMEA-001055-PIP02-21","active_substance":"human papilloma virus type 16 E6 071-095;human papilloma virus type 16 E6 001-032;human papilloma virus type 16 E6 055-080;human papilloma virus type 16 E6 091-122;human Papilloma Virus Type 16 E6 109-140;human Papilloma Virus Type 16 E6 019-050;human Papilloma Virus Type 16 E6 041-065;human Papilloma Virus Type 16 E6 085-109;human Papilloma Virus Type 16 E6 127-158;human papilloma virus type 16 E7 064-098;human Papilloma Virus Type 16 E7 022-056;human Papilloma Virus Type 16 E7 001-035","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of HPV16 positive malignancies","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/07/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ISA Therapeutics B.V.; E-mail:info@isa-pharma.com; Tel. +31 713322310","first_published_date":"22/07/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001055-pip02-21"},{"decision_number":"P/0242/2021","pip_number":"EMEA-001032-PIP03-19","active_substance":"macitentan","invented_name":"Opsumit","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet;Dispersible tablet","condition_indication":"Treatment of functional single ventricle heart disease with total cavo-pulmonary connection","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/07/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International N.V.; E-mail:clinical-trials-disclosure@its.jnj.com ; Tel. +41 615656565","first_published_date":"20/07/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001032-pip03-19"},{"decision_number":"P/0275/2021","pip_number":"EMEA-002978-PIP01-21","active_substance":"trastuzumab deruxtecan","invented_name":"Enhertu","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/07/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Daiichi Sankyo Europe GmbH; E-mail: service@daiichi-sankyo.eu; Tel.: +49 8978080","first_published_date":"19/07/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002978-pip01-21"},{"decision_number":"P/0284/2021","pip_number":"EMEA-002995-PIP01-21","active_substance":"human immunoglobulin G1 constant region - human ectodysplasin-A1 receptor-binding domain fusion protein","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution for injection","condition_indication":"X-linked hypohidrotic ectodermal dysplasia (XLHED)","routes_of_administration":"Intraamniotic use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"28/07/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"EspeRare Foundation; Tel. +41 227944004; Email: info.er004@esperare.org","first_published_date":"19/07/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002995-pip01-21"},{"decision_number":"P/0259/2021","pip_number":"EMEA-002976-PIP01-21","active_substance":"trastuzumab deruxtecan","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/07/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Daiichi Sankyo Europe GmbH; E-mail: service@daiichi-sankyo.eu; Tel.: +49 8978080","first_published_date":"19/07/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002976-pip01-21"},{"decision_number":"P/0279/2021","pip_number":"EMEA-002976-PIP02-21","active_substance":"trastuzumab deruxtecan","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of breast cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/07/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Daiichi Sankyo Europe GmbH; E-mail: service@daiichi-sankyo.eu; Tel.: +49 8978080","first_published_date":"19/07/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002976-pip02-21"},{"decision_number":"P/0276/2021","pip_number":"EMEA-002977-PIP01-21","active_substance":"patritumab deruxtecan","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/07/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Daiichi Sankyo Europe GmbH; E-mail: service@daiichi-sankyo.eu; Tel.: +49 8978080","first_published_date":"19/07/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002977-pip01-21"},{"decision_number":"P/0256/2021","pip_number":"EMEA-002973-PIP01-21","active_substance":"vupanorse","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of cardiovascular events;Treatment of hypertriglyceridaemia","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/07/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG; Tel. +44 (0)1304 646 607; E-mail: pip_enquiries@pfizer.com","first_published_date":"19/07/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002973-pip01-21"},{"decision_number":"P/0249/2021","pip_number":"EMEA-002969-PIP01-21","active_substance":"zibotentan;dapagliflozin propanediol monohydrate","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Capsule, hard;Tablet","condition_indication":"Treatment of chronic kidney disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/07/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca ABEmail: paediatrics@astrazeneca.comTel. +46 855324400","first_published_date":"19/07/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002969-pip01-21"},{"decision_number":"P/0258/2021","pip_number":"EMEA-002975-PIP01-21","active_substance":"[18F]CTT1057","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Visualisation of prostate-specific membrane antigen in adenocarcinoma of the prostate","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/07/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Advanced Accelerator Applications SA; Tel: +41 6132 41111; Email: paediatric.enquiries@novartis.com","first_published_date":"19/07/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002975-pip01-21"},{"decision_number":"P/0262/2021","pip_number":"EMEA-002968-PIP01-21","active_substance":"mannitol","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Powder for oral solution","condition_indication":"Bowel cleansing prior to clinical procedures","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/07/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"NTC srl; Tel. +39 3404221497; Email: regulatory-ph@ntcpharma.net","first_published_date":"19/07/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002968-pip01-21"},{"decision_number":"P/0263/2021","pip_number":"EMEA-002967-PIP01-21","active_substance":"selatogrel","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Solution for injection in pre-filled syringe","condition_indication":"Treatment of acute myocardial infarction","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/07/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Idorsia Pharmaceuticals Deutschland GmbH  E-mail: clinical-trials-disclosure@idorsia.com  Tel. +41 588440000 &nbsp","first_published_date":"19/07/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002967-pip01-21"},{"decision_number":"P/0252/2021","pip_number":"EMEA-002903-PIP02-21","active_substance":"anti-C1s Humanized IgG4 Monoclonal Antibody","invented_name":"","therapeutic_area":"Haematology-Hemostaseology;Immunology-Rheumatology-Transplantation;Neurology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of cold agglutinin disease","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/07/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Genzyme Europe B.V.; Tel. +31 20 245 3917; E-mail: eumedinfo@genzyme.com","first_published_date":"19/07/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002903-pip02-21"},{"decision_number":"P/0247/2021","pip_number":"EMEA-002875-PIP01-20","active_substance":"allogeneic skin-derived ATP-binding cassette, sub-family B, member 5 (ABCB5)-positive mesenchymal stem cells (allo-APZ2-EB)","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of epidermolysis bullosa","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/07/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Rheacell GmbH & Co. KGTel: +49 6221718330Email: office@rheacell.com","first_published_date":"19/07/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002875-pip01-20"},{"decision_number":"P/13/2010","pip_number":"EMEA-000375-PIP01-08-M02","active_substance":"human papillomavirus type 6 L1 protein;human papillomavirus type 11 L1 protein;human papillomavirus type 16 L1 protein;human papillomavirus type 18 L1 protein","invented_name":"Gardasil; Gardasil","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection;Suspension for injection in pre-filled syringe","condition_indication":"Infection by Human Papillomavirus","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"22/01/2010","compliance_outcome":"Positive","compliance_opinion_date":"16/04/2010","compliance_procedure_number":"EMEA-C-000375-PIP01-08-M02","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"25/02/2010","last_updated_date":"12/07/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000375-pip01-08-m02"},{"decision_number":"P/0236/2020","pip_number":"EMEA-001933-PIP01-16-M01","active_substance":"autologous CD34+ cells transduced with lentiviral vector encoding the human beta-globin gene","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Dispersion for injection","condition_indication":"Treatment of beta-thalassemia","routes_of_administration":"Intraosseous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"12/06/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Fondazione Telethon ETS; E-mail: regulatory@telethon.it; Tel: +39 06 440151","first_published_date":"17/03/2017","last_updated_date":"01/07/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001933-pip01-16-m01"},{"decision_number":"P/0134/2013","pip_number":"EMEA-001301-PIP01-12","active_substance":"Isavuconazonium sulfate","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for solution for infusion;Capsule, hard","condition_indication":"Treatment of Candida infections","routes_of_administration":"Intravenous use;Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/06/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Basilea Medical Ltd; E-mail: medical.information@basilea.com; Tel. +41 616061400; Fax +41 616061216","first_published_date":"23/07/2013","last_updated_date":"29/06/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001301-pip01-12"},{"decision_number":"P/0202/2016","pip_number":"EMEA-001540-PIP01-13-M01","active_substance":"recombinant human beta-glucuronidase (rhGUS, UX003)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of Mucopolysaccharidosis type VII","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"28/07/2016","compliance_outcome":"Positive","compliance_opinion_date":"11/12/2019","compliance_procedure_number":"EMEA-C-001540-PIP01-13-M01","contact_for_public_enquiries":"Ultragenyx Germany GmbH; E-mail: medinfo@ultragenyx.com; Tel. : +4930590083651","first_published_date":"22/07/2014","last_updated_date":"16/06/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001540-pip01-13-m01"},{"decision_number":"P/0274/2019","pip_number":"EMEA-002414-PIP01-18","active_substance":"Humanized anti-CD19, Fc engineered, monoclonal antibody (XmAb5871)","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of immunoglobulin G4-related disease","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"16/08/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"20/11/2019","last_updated_date":"16/06/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002414-pip01-18"},{"decision_number":"P/0268/2014","pip_number":"EMEA-000802-PIP02-11-M01","active_substance":"tabalumab","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Systemic Lupus Erythematosus (SLE)","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/10/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"25/06/2012","last_updated_date":"14/06/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000802-pip02-11-m01"},{"decision_number":"P/20/2010","pip_number":"EMEA-000635-PIP01-09","active_substance":"expanded human autologous mesenchymal adult stem cells extracted from adipose tissue (CX-401)","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of anal fistula of Crohn´s disease associated aetiology;Treatment of anal fistula of cryptoglandular aetiology (Non-Crohn);Treatment of non-inflammatory anal fistula","routes_of_administration":"Intralesional use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"19/02/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"TiGenix S.A.U.; E-mail: info@tigenix.com; Tel: +34 918049264; Fax:+34 918049263","first_published_date":"19/04/2010","last_updated_date":"14/06/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000635-pip01-09"},{"decision_number":"P/0168/2014","pip_number":"EMEA-001097-PIP01-10-M02","active_substance":"Insulin peglispro","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of type I diabetes mellitus;Treatment of type II diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/07/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"25/06/2012","last_updated_date":"14/06/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001097-pip01-10-m02"},{"decision_number":"P/0027/2015","pip_number":"EMEA-001634-PIP01-14","active_substance":"recombinant human heparan-N-sulfatase","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)","routes_of_administration":"Intrathecal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"30/01/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Shire Human Genetic Therapies AB; Sweden; E-mail: medinfoeuceemea@shire.com; Tel. +80066838470; Fax +01 245 550 389","first_published_date":"05/03/2015","last_updated_date":"14/06/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001634-pip01-14"},{"decision_number":"P/0115/2014","pip_number":"EMEA-000698-PIP02-10-M01","active_substance":"Methyl aminolevulinate hydrochloride","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Cream","condition_indication":"Treatment of acne vulgaris","routes_of_administration":"Cutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/05/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Photocure AS; Norway; E-mail: info@photocur.no; Tel. +47 2206 2210; Fax +47 2206 2218","first_published_date":"24/02/2012","last_updated_date":"14/06/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000698-pip02-10-m01"},{"decision_number":"P/0012/2021","pip_number":"EMEA-001748-PIP03-19","active_substance":"arimoclomol citrate","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of amyotrophic lateral sclerosis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"28/01/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Orphazyme A/S; Email: contact@orphazyme.com; Tel. +45 39178272","first_published_date":"29/09/2021","last_updated_date":"10/06/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001748-pip03-19"},{"decision_number":"P/0240/2013","pip_number":"EMEA-001389-PIP01-12","active_substance":"Deleobuvir","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Oral solution","condition_indication":"Treatment of chronic viral hepatitis C","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"24/09/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"15/11/2013","last_updated_date":"09/06/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001389-pip01-12"},{"decision_number":"P/0252/2017","pip_number":"EMEA-001868-PIP03-16","active_substance":"selonsertib","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of non-alcoholic steatohepatitis (NASH)","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/09/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd; Tel. +44 (0)1223 897300; E-mail: regulatory.pip@gilead.com","first_published_date":"24/10/2017","last_updated_date":"07/06/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001868-pip03-16"},{"decision_number":"P/0455/2021","pip_number":"EMEA-002926-PIP01-20","active_substance":"Glepaglutide","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of short bowel syndrome","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/10/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Zealand Pharma A/S; Zealand Pharma A/S; Tel. +45 88 77 36 00; E-mail: info@zealandpharma.com","first_published_date":"12/05/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002926-pip01-20"},{"decision_number":"P/0226/2021","pip_number":"EMEA-001517-PIP02-14-M03","active_substance":"sotagliflozin","invented_name":"Zynquista","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Granules;Film-coated tablet","condition_indication":"Treatment of type I diabetes mellitus","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/06/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Guidehouse Germany GmbH; E-mail: KKasslerTaub@lexpharma.com; Tel: +1 9089638536","first_published_date":"25/08/2015","last_updated_date":"28/04/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001517-pip02-14-m03"},{"decision_number":"P/0218/2021","pip_number":"EMEA-002956-PIP01-21","active_substance":"synthetic hypericin","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Ointment","condition_indication":"Treatment of Cutaneous T-Cell Lymphoma","routes_of_administration":"Topical use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/06/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Soligenix NL B.V; E-mail: arumage@soligenix.com; Tel: +1 6095388200","first_published_date":"28/04/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002956-pip01-21"},{"decision_number":"P/0219/2021","pip_number":"EMEA-002895-PIP02-21","active_substance":"immunoglobulin G4 [449-cysteine];anti-(human vascular endothelial growth factor A) (human-Mus musculus monoclonal OG1950 gamma-4-chain);disulfide with human-Mus musculus monoclonal OG1950 kappa-chain;(232 - 232’),(235 - 235’)-bis(disulfide) with immunoglobulin G4 anti-(human vascular endothelial growth factor A) (human-Mus musculus monoclonal OG1950 gamma-4-chain) disulfide with human-Mus musculus monoclonal OG1950 kappa-chain;449-thioether with 1,1’-[2-[11,11-bis[15-bromo-11,11-bis[(2-bromo-2-methyl- 1-oxopropoxy)methyl]-15-methyl-3,7,14-trioxo-9,13-dioxa-2,6-diazahexadec-1-yl]-44-(3-mercapto- 2,5-dioxo-1-pyrrolidinyl)-4,8,26,42-tetraoxo-2,13,16,19,22,29,32,35,38-nonaoxa-5,9,25,41- tetraazatetratetracont-1-yl]-2-[(2-bromo-2-methyl-1-oxopropoxy)methyl]-1,3-propanediyl] bis(2- bromo-2-methylpropanoate) core 9-arm star compd. with 4-hydroxy-N,N,N,10-tetramethyl-9-oxo- 3,5,8-trioxa-4-phosphaundec-10-en-1-aminium inner salt 4-oxide homopolymer (KSI-301)","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of choroidal neovascularisation;Treatment of diabetic retinopathy;Treatment of retinal vein occlusion","routes_of_administration":"Intravitreal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/06/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kodiak Sciences Inc.; E-mail: info@kodiak.com; Tel: +1 6502810850","first_published_date":"28/04/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002895-pip02-21"},{"decision_number":"P/0231/2021","pip_number":"EMEA-002627-PIP02-21","active_substance":"savolitinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of renal neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/06/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel. +46 8553 27591","first_published_date":"26/04/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002627-pip02-21"},{"decision_number":"P/0224/2021","pip_number":"EMEA-002066-PIP01-20","active_substance":"talazoparib","invented_name":"Talzenna","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of Ewing sarcoma","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/06/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIGE-mail: medical.information@pfizer.com Tel. +44 1304646607","first_published_date":"26/04/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002066-pip01-20"},{"decision_number":"P/0293/2022","pip_number":"EMEA-001943-PIP03-20-M01","active_substance":"ravulizumab","invented_name":"Ultomiris","therapeutic_area":"Neurology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of myasthenia gravis","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/08/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alexion Europe SAS; E-mail: pip.enquiries.eu@alexion.com; Tel: +33 147100615","first_published_date":"26/04/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001943-pip03-20-m01"},{"decision_number":"P/0070/2018","pip_number":"EMEA-001635-PIP03-17","active_substance":"tanezumab","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic musculoskeletal pain;Treatment of chronic pain (excluding musculoskeletal pain)","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"16/03/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Limited; Tel. + 44 1304646607; E-mail: pip_enquiries@pfizer.com","first_published_date":"19/06/2018","last_updated_date":"12/04/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001635-pip03-17"},{"decision_number":"P/0212/2021","pip_number":"EMEA-002986-PIP01-21","active_substance":"zorecimeran","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Concentrate and solvent for dispersion for injection","condition_indication":"Prevention of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"17/05/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CureVac AG; Tel.  +49 7071 9880-0; E-mail: info@curevac.com","first_published_date":"17/06/2021","last_updated_date":"11/04/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002986-pip01-21"},{"decision_number":"P/0357/2021","pip_number":"EMEA-002117-PIP01-17-M02","active_substance":"pevonedistat","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of acute myeloid leukaemia;Treatment of myelodysplastic syndromes","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Pharma A/S; Tel.  +45(0) 46771111; E-mail: paediatrics@tgrd.com","first_published_date":"19/06/2018","last_updated_date":"25/03/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002117-pip01-17-m02"},{"decision_number":"P/0003/2019","pip_number":"EMEA-001975-PIP01-16-M02","active_substance":"Pimodivir","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Age appropriate oral solid dosage form","condition_indication":"Treatment of influenza","routes_of_administration":"Oral use;Gastric use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/01/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; Tel.: +32 14602111; E-mail: contact@janssen-emea.com","first_published_date":"24/07/2017","last_updated_date":"24/03/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001975-pip01-16-m02"},{"decision_number":"P/0505/2020","pip_number":"EMEA-001716-PIP05-20","active_substance":"venglustat","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism;Uro-nephrology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of autosomal dominant polycystic kidney disease","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Genzyme Europe B.V.; E-mail: eumedinfo.gz@sanofi.com; Tel: +31 202453917","first_published_date":"17/09/2021","last_updated_date":"24/03/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001716-pip05-20"},{"decision_number":"P/0029/2014","pip_number":"EMEA-001371-PIP01-12","active_substance":"clazakizumab","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis)","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/02/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CSL Behring GmbH; Tel. +49 151 44162443; E-mail: PIP.CSLBehring@cslbehring.com","first_published_date":"20/03/2014","last_updated_date":"21/03/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001371-pip01-12"},{"decision_number":"P/0204/2021","pip_number":"EMEA-002447-PIP01-18-M01","active_substance":"Cipaglucosidase alfa","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of glycogen storage disease Type II (Pompe's disease)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/05/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amicus Therapeutics Europe Limited; E-mail: IR@amicusrx.com; Tel: +1 6096623809","first_published_date":"17/09/2021","last_updated_date":"17/02/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002447-pip01-18-m01"},{"decision_number":"P/0207/2021","pip_number":"EMEA-001879-PIP01-15-M03","active_substance":"Birch pollen extract (Betula verrucosa)","invented_name":"ITULAZAX","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oral lyophilisate","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Sublingual use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/05/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ALK Abelló A/S; Tel. +45 4574 7576; E-mail: alkmrp@alk.net","first_published_date":"10/01/2017","last_updated_date":"17/02/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001879-pip01-15-m03"},{"decision_number":"P/0196/2021","pip_number":"EMEA-001207-PIP01-11-M01","active_substance":"obinutuzumab","invented_name":"Gazyvaro","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of acute lymphoblastic leukaemia;Treatment of mature B-cell lymphoma","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/05/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbH; E-mail: global.eu_regulatory_office@roche.comTel. +49 7624142892","first_published_date":"30/04/2013","last_updated_date":"17/02/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001207-pip01-11-m01"},{"decision_number":"P/0189/2021","pip_number":"EMEA-000142-PIP02-09-M11","active_substance":"concentrate of proteolytic enzymes in bromelain","invented_name":"NexoBrid","therapeutic_area":"Other","pharmaceutical_forms":"Powder and gel for gel","condition_indication":"Treatment for burns","routes_of_administration":"Cutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/05/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"MediWound Germany GmbH; Tel. +972 779714168; E-mail: ayaby@mediwound.com","first_published_date":"20/12/2010","last_updated_date":"16/02/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000142-pip02-09-m11"},{"decision_number":"P/0208/2021","pip_number":"EMEA-002959-PIP01-21","active_substance":"sumatriptan;naproxen (sodium)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of migraine headaches","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/05/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Orion Corporation; E-mail: orionra@orionpharma.com; Tel: +358 982564248","first_published_date":"15/02/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002959-pip01-21"},{"decision_number":"P/0192/2021","pip_number":"EMEA-002949-PIP01-20","active_substance":"quavonlimab;pembrolizumab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue neoplasms and melanoma);Treatment of malignant neoplasms of the central nervous system","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/05/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck, Sharp & Dohme (Europe) Inc.; Tel. +33 180464738; E-mail: pip.information@merck.com","first_published_date":"15/02/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002949-pip01-20"},{"decision_number":"P/0183/2021","pip_number":"EMEA-002948-PIP01-20","active_substance":"(S)-N-(1-amino-4-(dimethylamino)-1-oxobutan-2-yl)-5-(2,4-difluorophenoxy)-1-isobutyl-1H-indazole- 6-carboxamide","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of dilated cardiomyopathy due to lamin A/C gene mutations","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/05/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIGE-mail: medical.information@pfizer.com Tel. +44 1304646607","first_published_date":"15/02/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002948-pip01-20"},{"decision_number":"P/0200/2021","pip_number":"EMEA-002945-PIP01-20","active_substance":"anti-CD40L humanized monoclonal antibody (SAR441344)","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Sjögren's syndrome","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/05/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi-aventis recherche & développement; E-mail: contact-us@sanofi.com; Tel: +31 202453703","first_published_date":"15/02/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002945-pip01-20"},{"decision_number":"P/0197/2021","pip_number":"EMEA-002943-PIP01-20","active_substance":"(S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1H-pyrazole-4-carboxamide","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of mature B-cell malignancies","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/05/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly and Company LtdE-mail: eu_paediatric@lilly.com Phone: +44 1256315000","first_published_date":"15/02/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002943-pip01-20"},{"decision_number":"P/0187/2021","pip_number":"EMEA-002921-PIP01-20","active_substance":"argon;oxygen","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Medicinal gas (compressed)","condition_indication":"Treatment of acute ischaemic stroke due to large intracranial vessel occlusion as add-on to thrombectomy","routes_of_administration":"Inhalation use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/05/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Air Liquide Santé International; E-mail: fralsi-paediatric@airliquide.com; Tel: +33 625775019","first_published_date":"15/02/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002921-pip01-20"},{"decision_number":"P/0202/2021","pip_number":"EMEA-002795-PIP01-20","active_substance":"Respiratory Syncytial Virus stabilised prefusion f subunit vaccine (RSVpreF)","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Prevention of lower respiratory tract disease caused by respiratory syncytial virus via maternal immunisation","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/05/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG  E-mail: medical.information@pfizer.com Tel: +44 (0)1304 616161","first_published_date":"14/02/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002795-pip01-20"},{"decision_number":"P/0203/2021","pip_number":"EMEA-002785-PIP01-20","active_substance":"edaravone","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Granules for oral suspension","condition_indication":"Treatment of amyotrophic lateral sclerosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/05/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Treeway B.V.; E-mail: info@treeway.nl; Tel: +31 135348272","first_published_date":"14/02/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002785-pip01-20"},{"decision_number":"P/0199/2021","pip_number":"EMEA-002775-PIP01-20","active_substance":"human anti-interleukin-15 (IL-15) monoclonal antibody","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of coeliac disease","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/05/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Provention Bio, Inc.; E-mail: info@proventionbio.com; Tel: + 1 908 336 0360","first_published_date":"14/02/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002775-pip01-20"},{"decision_number":"P/0206/2021","pip_number":"EMEA-002671-PIP02-20","active_substance":"pegfilgrastim","invented_name":"Pelgraz","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for injection in pre-filled syringe","condition_indication":"Prevention of chemotherapy-induced febrile neutropenia;Treatment of chemotherapy-induced neutropenia","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/05/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Accord Healthcare S.L.U.; E-mail: regulatory_EU@accord-healthcare.com; Tel. +34 933010064","first_published_date":"11/02/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002671-pip02-20"},{"decision_number":"P/0188/2021","pip_number":"EMEA-001693-PIP02-20","active_substance":"reparixin","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Tablet;Solution for infusion","condition_indication":"Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Oral use;Intravenous use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"07/05/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dompé farmaceutici S.p.A.; E-mail: DAR@dompe.com; Tel: +39 0258383230","first_published_date":"11/02/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001693-pip02-20"},{"decision_number":"P/0234/2019","pip_number":"EMEA-001665-PIP02-17","active_substance":"autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human βA-T87Q-globin gene","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of sickle cell disease","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"16/07/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bluebird Bio France; Tel. +1 857 331 5169; E-mail: pgeoffroy@bluebirdbio.com","first_published_date":"08/11/2019","last_updated_date":"09/02/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001665-pip02-17"},{"decision_number":"P/0146/2018","pip_number":"EMEA-001567-PIP01-13-M03","active_substance":"naloxone (hydrochloride)","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Prolonged-release tablet;Age appropriate dosage form, other","condition_indication":"Treatment of opioid-induced constipation","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/05/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Develco Pharma GmbH; E-mail: n.burger@develco.ch; Tel.  +41 6142 55020","first_published_date":"12/12/2014","last_updated_date":"08/02/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001567-pip01-13-m03"},{"decision_number":"P/0340/2021","pip_number":"EMEA-001303-PIP01-12-M04","active_substance":"bumetanide","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of autism spectrum disorder","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierTel. +33 1 55 72 60 00E-mail: mail.pip.enquiries@fr.netgrs.com","first_published_date":"31/05/2013","last_updated_date":"03/02/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001303-pip01-12-m04"},{"decision_number":"P/0144/2021","pip_number":"EMEA-002642-PIP01-19-M03","active_substance":"Ladarixin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Age appropriate oral liquid dosage formulation;Capsule, hard","condition_indication":"Treatment of type I diabetes mellitus","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/04/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dompé farmaceutici S.p.A; E-mail: dar@dompe.com; Tel.: +39 02583831","first_published_date":"29/07/2020","last_updated_date":"18/01/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002642-pip01-19-m03"},{"decision_number":"P/0131/2021","pip_number":"EMEA-001915-PIP01-15-M03","active_substance":"volanesorsen","invented_name":"Waylivra","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of familial chylomicronemia syndrome","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/04/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Akcea Therapeutics; Tel. +1 6172070202; E-mail: info@akceatx.com","first_published_date":"17/03/2017","last_updated_date":"18/01/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001915-pip01-15-m03"},{"decision_number":"P/0421/2022","pip_number":"EMEA-000265-PIP02-11-M04","active_substance":"golimumab","invented_name":"Simponi","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of ulcerative colitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen Biologics B.V.; Tel. +32 1460 2111; E-mail: contact@janssen-emea.com","first_published_date":"19/07/2012","last_updated_date":"18/01/2022","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000265-pip02-11-m04"},{"decision_number":"P/0135/2021","pip_number":"EMEA-002939-PIP01-20","active_substance":"Humanised recombinant IgG4, Anti-PD-1 monoclonal antibody (CS1003)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection;Solution for infusion","condition_indication":"Treatment of hepatocellular carcinoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/04/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CStone Pharmaceuticals (Suzhou) CO., Ltd.; E-mail: CStoneRA@cstonepharma.com; Tel.:  +86 2160333496","first_published_date":"17/01/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002939-pip01-20"},{"decision_number":"P/0165/2021","pip_number":"EMEA-002937-PIP01-20","active_substance":"ensartinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of non-small cell lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/04/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Xcovery Holdings, Inc.; E-mail: info@xcovery.com; Tel.: +1 5618359356","first_published_date":"17/01/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002937-pip01-20"},{"decision_number":"P/0136/2021","pip_number":"EMEA-002936-PIP01-20","active_substance":"anti-alpha-synuclein human monoclonal antibody","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of multiple system atrophy;Treatment of Parkinson's disease","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/04/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"H. Lundbeck A/S; E-mail: tsbr@lundbeck.com; Tel.  +45 30834928","first_published_date":"17/01/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002936-pip01-20"},{"decision_number":"P/0164/2021","pip_number":"EMEA-002931-PIP01-20","active_substance":"sabatolimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of myelodysplastic syndromes","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/04/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"17/01/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002931-pip01-20"},{"decision_number":"P/0163/2021","pip_number":"EMEA-002930-PIP01-20","active_substance":"anti-IL-7Rα monoclonal antibody (S95011/ OSE-127)","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Sjögren's syndrome","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/04/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierE-mail: mail.pip.enquiries@servier.comTel.: +33 155726000","first_published_date":"17/01/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002930-pip01-20"},{"decision_number":"P/0137/2021","pip_number":"EMEA-002923-PIP01-20","active_substance":"2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl) acetamide monohydrate","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of myelofibrosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/04/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Constellation Pharmaceuticals Inc.; Tel.: +1 6177140585 ; E-mail: Shrenik.Desai@constellationpharma.com","first_published_date":"17/01/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002923-pip01-20"},{"decision_number":"P/0138/2021","pip_number":"EMEA-002920-PIP01-20","active_substance":"tavapadon","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of Parkinson's disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/04/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cerevel Therapeutics, LLC; Tel.: +1 8603894140; E-mail: Jonathon.Parker@cerevel.com","first_published_date":"17/01/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002920-pip01-20"},{"decision_number":"P/0139/2021","pip_number":"EMEA-002919-PIP01-20","active_substance":"sintilimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of lung cancer","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/04/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"17/01/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002919-pip01-20"},{"decision_number":"P/0140/2021","pip_number":"EMEA-002913-PIP01-20","active_substance":"encequidar","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of breast cancer;Treatment of soft tissue sarcoma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/04/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Athenex Inc.; Tel.:  +1 7164272860; E-mail: pteegarden@athenex.com","first_published_date":"17/01/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002913-pip01-20"},{"decision_number":"P/0109/2021","pip_number":"EMEA-002902-PIP01-20","active_substance":"povidone;isopropyl alcohol","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Cutaneous solution","condition_indication":"Prevention of infection prior to invasive procedures","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/03/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BD Switzerland Sàrl; Tel.: +41 215563259; E-mail: GMB-IP-RA-EU@bd.com","first_published_date":"17/01/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002902-pip01-20"},{"decision_number":"P/0141/2021","pip_number":"EMEA-002894-PIP01-20","active_substance":"paclitaxel","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of soft tissue sarcoma","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/04/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Athenex Inc.; Tel.:  +1 7164272860; E-mail: pteegarden@athenex.com","first_published_date":"17/01/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002894-pip01-20"},{"decision_number":"P/0128/2021","pip_number":"EMEA-002779-PIP01-20","active_substance":"adeno-associated virus, serotype 9 (AAV9)-based non-replicating, self-complementary recombinant vector containing an expression cassette for the human ASPA transgene (scAAV9-CB6-hASPAopt)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Canavan disease","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/04/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aspa Therapeutics, Inc.; Tel.: +1 7073723949; E-mail: ks@bridgebio.com","first_published_date":"17/01/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002779-pip01-20"},{"decision_number":"P/0146/2021","pip_number":"EMEA-002542-PIP03-20","active_substance":"sutimlimab","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of cold agglutinin disease","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/04/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Genzyme Europe B.V.; Tel. +31 (0) 20 245 3917; E-mail: EUmedinfo@genzyme.com;  ","first_published_date":"13/01/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002542-pip03-20"},{"decision_number":"P/0129/2021","pip_number":"EMEA-002717-PIP02-20","active_substance":"sepofarsen","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection in a cartridge","condition_indication":"Treatment of Leber's Congenital Amaurosis","routes_of_administration":"Intravitreal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/04/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ProQR Therapeutics; Tel.: +31 881667000 ; E-mail: info@proqr.com","first_published_date":"12/01/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002717-pip02-20"},{"decision_number":"P/0149/2021","pip_number":"EMEA-002376-PIP02-20","active_substance":"nadofaragene firadenovec","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of malignant bladder neoplasms","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/04/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ferring Pharmaceuticals A/S; Tel.: +1 8622865200; E-mail: Dk0-Disclosure@ferring.com","first_published_date":"12/01/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002376-pip02-20"},{"decision_number":"P/0456/2020","pip_number":"EMEA-002189-PIP03-19","active_substance":"bimekizumab","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondylarthritis and juvenile idiopathic arthritis)","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"UCB Biopharma SRL; Tel.  +44 1753777100; E-mail: UCBCares.UK@ucb.com","first_published_date":"12/01/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002189-pip03-19"},{"decision_number":"P/130/2021","pip_number":"EMEA-002066-PIP02-20","active_substance":"talazoparib","invented_name":"Talzenna","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard;Capsule, soft","condition_indication":"Treatment of breast malignant neoplasms;Treatment of prostate malignant neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/04/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG; Tel. +44 (0)1304 646 607; E-mail: pip_enquiries@pfizer.com","first_published_date":"12/01/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002066-pip02-20"},{"decision_number":"P/150/2021","pip_number":"EMEA-002187-PIP01-17","active_substance":"pioglitazone hydrochloride;spironolactone metformin hydrochloride","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of polycystic ovary syndrome","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"16/04/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Katholieke Universiteit Leuven (KUL) Research & Development; Tel.: +32 16 32 65 00; E-mail: lrd.ip@kuleuven.be","first_published_date":"12/01/2022","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002187-pip01-17"},{"decision_number":"P/0058/2020","pip_number":"EMEA-002153-PIP01-17-M01","active_substance":"fluticasone furoate;umeclidinium bromide;vilanterol trifenatate","invented_name":"Trelegy Ellipta; Temybric Ellipta; Elebrato Ellipta","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Inhalation powder (pre-dispensed)","condition_indication":"Treatment of asthma","routes_of_administration":"Inhalation use","decision_type":"RPM: decision refers to a refusal on the application for modification of an agreed PIP","decision_date":"14/02/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Tel. +1 438-899-8201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"19/06/2018","last_updated_date":"10/12/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002153-pip01-17-m01"},{"decision_number":"P/0363/2016","pip_number":"EMEA-001780-PIP01-15","active_substance":"Dipalmitoylphosphatidylcholine;1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol sodium salt;synthetic surfactant protein C analogue;synthetic surfactant protein B analogue (CHF 5633)","invented_name":"","therapeutic_area":"Neonatology-Paediatric Intensive Care","pharmaceutical_forms":"Endotracheopulmonary instillation;Suspension","condition_indication":"Treatment of respiratory distress syndrome","routes_of_administration":"Endotracheopulmonary use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"21/12/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Chiesi Farmaceutici SpA; Italy; E-mail: info@chiesi.com; Tel.: 39 05212791; Fax: 39 0521774468","first_published_date":"30/01/2017","last_updated_date":"10/12/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001780-pip01-15"},{"decision_number":"P/0325/2013","pip_number":"EMEA-000720-PIP01-09-M02","active_substance":"anagrelide","invented_name":"Xagrid; Xagrid","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of essential thrombocythaemia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/12/2013","compliance_outcome":"Positive","compliance_opinion_date":"14/02/2014","compliance_procedure_number":"EMEA-C-000720-PIP01-09-M02","contact_for_public_enquiries":"Takeda Pharmaceuticals International AG Ireland Branch; E-mail: medinfoemea@takeda.com; Tel. +80066838470","first_published_date":"15/09/2011","last_updated_date":"09/12/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000720-pip01-09-m02"},{"decision_number":"P/0162/2016","pip_number":"EMEA-001359-PIP01-12-M03","active_substance":"retosiban","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of spontaneous preterm labour","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/06/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Tel. +1 4388998201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"07/10/2013","last_updated_date":"01/12/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001359-pip01-12-m03"},{"decision_number":"P/0055/2020","pip_number":"EMEA-002515-PIP01-18","active_substance":"human immunoglobulin G2 isotype antibody to IL-33R","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of asthma","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/02/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Tel. +1 438-899-8201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"10/06/2020","last_updated_date":"01/12/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002515-pip01-18"},{"decision_number":"P/0360/2016","pip_number":"EMEA-001384-PIP01-12","active_substance":"octenidine dihydrochloride","invented_name":"","therapeutic_area":"Neonatology-Paediatric Intensive Care","pharmaceutical_forms":"Cutaneous solution","condition_indication":"Skin disinfection","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/12/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Schülke & Mayr GmbH; Germany; E-mail: mail@schuelke.com; Tel.: +49 40521000","first_published_date":"30/01/2017","last_updated_date":"29/11/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001384-pip01-12"},{"decision_number":"EMEA-000753-PIP02-16","pip_number":"EMEA-000753-PIP02-16","active_substance":"susoctocog alfa","invented_name":"Obizur; Obizur","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of congenital haemophilia A with antibodies (inhibitors) to human factor VIII","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"19/12/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Baxalta Innovations GmbHE-mail: medinfoEMEA@takeda.comTel. +44 (0)3333 000181","first_published_date":"05/03/2018","last_updated_date":"29/11/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000753-pip02-16"},{"decision_number":"P/0148/2020","pip_number":"EMEA-002333-PIP02-19","active_substance":"2-[[2-ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl](methyl)amino]-4-(4-fluorophenyl)-1,3-thiazole-5-carbonitrile","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Film-coated tablet;Age appropriate formulation","condition_indication":"Treatment of interstitial pulmonary diseases with fibrosis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"18/04/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Galapagos NV; Tel. +32 15342900; E-mail: medicalinfo@glpg.com","first_published_date":"03/03/2021","last_updated_date":"29/11/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002333-pip02-19"},{"decision_number":"P/108/2009","pip_number":"Carisbamate","active_substance":"carisbamate","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Film-coated tablet;Oral suspension;Intravenous formulation","condition_indication":"Infantile spasms (West Syndrome);Lennox-Gastaut Syndrome;Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures;Neonatal seizures;Other paediatric epilepsy syndromes such as Dravet Syndrome, myoclonic astatic syndrome, epilepsy with continuous sharp-waves in sleep, idiopathic partial epilepsy, absence epilepsy","routes_of_administration":"Oral use;Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/06/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen Cilag International NV (Belgium); E-mail: bbyl@its.jnj.com; Country: Belgium; Phone: +32 14607172; Fax: +3214606377","first_published_date":"11/08/2009","last_updated_date":"22/11/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/carisbamate"},{"decision_number":"P/0097/2021","pip_number":"EMEA-002824-PIP01-20","active_substance":"telitacicept","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of Systemic Lupus Erythematosus (SLE)","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"19/03/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"RemeGen, Ltd.; E-mail: long.cheng@remegen.cn; Tel: +86 18663830001","first_published_date":"19/11/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002824-pip01-20"},{"decision_number":"P/0090/2021","pip_number":"EMEA-002586-PIP01-19-M01","active_substance":"bintrafusp alfa","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/03/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Europe B.V.; Tel.: +49 6151725200; E-mail: service@merckgroup.com","first_published_date":"04/03/2021","last_updated_date":"19/11/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002586-pip01-19-m01"},{"decision_number":"P/0096/2021","pip_number":"EMEA-002238-PIP01-17-M01","active_substance":"interferon beta-1a","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of Acute Respiratory Distress Syndrome (ARDS)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/03/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Faron Pharmaceuticals Ltd.; E-mail: regulatory.affairs@faron.com; Tel: +358 24695151","first_published_date":"17/01/2019","last_updated_date":"19/11/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002238-pip01-17-m01"},{"decision_number":"P/243/2010","pip_number":"EMEA-000734-PIP01-09","active_substance":"[(3S)-6-({2',6'-Dimethyl-4'-[3-(methylsulfonyl) propoxy] biphenyl-3-yl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid hydrate (TAK-875)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Global Research and Development Centre (Europe) Ltd.; paediatrics@tgrd.com; Phone: +44 2031168237; Fax: +44 2031168250","first_published_date":"20/12/2010","last_updated_date":"19/11/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000734-pip01-09"},{"decision_number":"P/0423/2022","pip_number":"EMEA-000380-PIP06-19-M01","active_substance":"secukinumab","invented_name":"Cosentyx","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection;Powder for solution for injection","condition_indication":"Treatment of Systemic Lupus Erythematosus (SLE)","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"15/11/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000380-pip06-19-m01"},{"decision_number":"P/0111/2021","pip_number":"EMEA-000380-PIP07-20","active_substance":"secukinumab","invented_name":"Cosentyx","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder for solution for injection;Solution for injection","condition_indication":"Treatment of thyroid eye disease","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/03/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"15/11/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000380-pip07-20"},{"decision_number":"P/0101/2021","pip_number":"EMEA-001642-PIP02-20","active_substance":"tacrolimus","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Age appropriate dosage form, other","condition_indication":"Prevention of solid organ transplant rejection;Treatment of solid organ transplant rejection","routes_of_administration":"Oral use;Gastric use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"17/03/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Proveca Pharma Limited; Tel. +353 15136233; E-mail: info@proveca.com","first_published_date":"15/11/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001642-pip02-20"},{"decision_number":"P/0517/2022","pip_number":"EMEA-001910-PIP03-20-M01","active_substance":"imetelstat","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of acute myeloid leukemia;Treatment of myelodysplastic syndromes, including juvenile myelomonocytic leukemia","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Geron Corporation; E-mail:  euregulatory@geron.com; Tel.   +1 6504737725","first_published_date":"15/11/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001910-pip03-20-m01"},{"decision_number":"P/0075/2021","pip_number":"EMEA-000060-PIP09-20","active_substance":"Canakinumab","invented_name":"Ilaris","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder for solution for injection;Solution for injection","condition_indication":"Treatment of Schnitzler Syndrome","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/03/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"15/11/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000060-pip09-20"},{"decision_number":"P/0281/2020","pip_number":"EMEA-000311-PIP05-17-M02","active_substance":"ustekinumab","invented_name":"Stelara; Stelara","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Concentrate for solution for infusion;Solution for injection/infusion","condition_indication":"Treatment of ulcerative colitis","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/03/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen Cilag International NV; Tel. +3214602111; E-mail: contact@Janssen-emea.com","first_published_date":"22/11/2018","last_updated_date":"09/11/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000311-pip05-17-m02"},{"decision_number":"P/0127/2021","pip_number":"EMEA-002918-PIP01-20","active_substance":"Fluoride 18-labelled Prostate-Specific Membrane Antigen-1007 ([18F]PSMA-1007)","invented_name":"","therapeutic_area":"Diagnostic;Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Visualisation of prostate specific membrane antigen in prostate cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"26/03/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"09/11/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002918-pip01-20"},{"decision_number":"P/0081/2021","pip_number":"EMEA-002910-PIP01-20","active_substance":"Olpasiran","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of cardiovascular events","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/03/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V. ; E-mail: medinfointernational@amgen.com; Tel. +44 (0)1223 420305","first_published_date":"09/11/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002910-pip01-20"},{"decision_number":"P/0082/2021","pip_number":"EMEA-002909-PIP01-20","active_substance":"autologous CD4+ and CD8+ T cells genetically modified with a lentiviral vector encoding a B cell maturation antigen-specific chimeric antigen receptor (JCARH125)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Dispersion for injection","condition_indication":"Treatment of mature B cell neoplasms","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/03/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Celgene Europe B.V.; Tel. +41 327298500; E-mail: medinfo.emea@celgene.com","first_published_date":"09/11/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002909-pip01-20"},{"decision_number":"P/0085/2021","pip_number":"EMEA-002906-PIP01-20","active_substance":"amlodipine;hydrochlorothiazide;ramipril","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/03/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sandoz GmbH; E-mail: caroline.kleinjan@sandoz.com; Tel:  +31 365241710","first_published_date":"09/11/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002906-pip01-20"},{"decision_number":"P/0087/2021","pip_number":"EMEA-002903-PIP01-20","active_substance":"anti-C1s Humanized IgG4 Monoclonal Antibody (BIVV020)","invented_name":"","therapeutic_area":"Haematology-Hemostaseology;Immunology-Rheumatology-Transplantation;Neurology","pharmaceutical_forms":"Solution for infusion;Solution for injection","condition_indication":"Treatment of immune thrombocytopenia purpura","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/03/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Genzyme Europe B.V.; E-mail: eumedinfo.gz@sanofi.com; Tel: +31 202453917","first_published_date":"09/11/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002903-pip01-20"},{"decision_number":"P/0095/2021","pip_number":"EMEA-002897-PIP01-20","active_substance":"edaravone","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for infusion;Oral suspension","condition_indication":"Treatment of amyotrophic lateral sclerosis","routes_of_administration":"Oral use;Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/03/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mitsubishi Tanabe Pharma GmbHE-mail: regulatory@mt-pharma-eu.com Tel: +49 2115205440","first_published_date":"09/11/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002897-pip01-20"},{"decision_number":"P/0078/2021","pip_number":"EMEA-002189-PIP04-20","active_substance":"bimekizumab","invented_name":"","therapeutic_area":"Dermatology;Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of hidradenitis suppurativa","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"17/03/2021","compliance_outcome":"Positive","compliance_opinion_date":"20/09/2019","compliance_procedure_number":"","contact_for_public_enquiries":"UCB Biopharma SRL; Tel.  +44 1753777100; E-mail: UCBCares.UK@ucb.com","first_published_date":"05/11/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002189-pip04-20"},{"decision_number":"P/0123/2021","pip_number":"EMEA-002243-PIP02-20","active_substance":"Eptinezumab","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Prevention of cluster headaches","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/03/2021","compliance_outcome":"Positive","compliance_opinion_date":"20/09/2019","compliance_procedure_number":"","contact_for_public_enquiries":"H. Lundbeck A/S; E-mail: tsbr@lundbeck.com; Tel.  +45 30834928","first_published_date":"05/11/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002243-pip02-20"},{"decision_number":"P/0104/2021","pip_number":"EMEA-002700-PIP01-19","active_substance":"crinecerfont","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Capsule, hard;Oral solution","condition_indication":"Treatment of atypical haemolytic uremic syndrome;Treatment of paroxysmal nocturnal haemoglobinuria","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"17/03/2021","compliance_outcome":"Positive","compliance_opinion_date":"20/09/2019","compliance_procedure_number":"","contact_for_public_enquiries":"Neurocrine Therapeutics Ltd; E-mail: medinfo@neurocrine.com; Tel. +01 8776 413461","first_published_date":"05/11/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002700-pip01-19"},{"decision_number":"P/0122/2021","pip_number":"EMEA-002016-PIP04-20","active_substance":"alpelisib","invented_name":"Piqray","therapeutic_area":"Oncology","pharmaceutical_forms":"All pharmaceutical forms","condition_indication":"Treatment of Fallopian tube carcinoma (excluding rhabdomyosarcoma and germ cell tumours);Treatment of ovarian carcinoma (excluding rhabdomyosarcoma and germ cell tumours);Treatment of peritoneal carcinoma (excluding blastomas and sarcomas)","routes_of_administration":"All routes of administration","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/03/2021","compliance_outcome":"Positive","compliance_opinion_date":"20/09/2019","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm Limited; E-mail: paediatric.enquiries@novartis.com; Tel. +41 6132 46715","first_published_date":"05/11/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002016-pip04-20"},{"decision_number":"P/0345/2019","pip_number":"EMEA-000828-PIP04-16-M03","active_substance":"empagliflozin","invented_name":"Jardiance","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet;Age appropriate dosage form, other","condition_indication":"Treatment of type I diabetes mellitus","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/09/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"24/07/2017","last_updated_date":"12/10/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000828-pip04-16-m03"},{"decision_number":"P/0068/2021","pip_number":"EMEA-002369-PIP01-18-M02","active_substance":"idecabtagene vicleucel","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Dispersion for injection","condition_indication":"Treatment of mature B-cell neoplasms","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/02/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Celgene Europe B.V.; Tel. +41 327298500; E-mail: medinfo.emea@celgene.com","first_published_date":"24/06/2019","last_updated_date":"08/10/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002369-pip01-18-m02"},{"decision_number":"P/0112/2019","pip_number":"EMEA-001760-PIP01-15-M03","active_substance":"olaratumab","invented_name":"Lartruvo","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of osteosarcoma;Treatment of soft tissue sarcoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"07/01/2016","last_updated_date":"08/10/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001760-pip01-15-m03"},{"decision_number":"P/0061/2021","pip_number":"EMEA-002884-PIP01-20","active_substance":"recombinant humanised monoclonal immunoglobulin G4, with specificity for human tau (UCB0107)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of progressive supranuclear palsy","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/02/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"UCB Pharma S.A.; E-mail: UCBCares.IE@ucb.com; Tel. +353 1463 2371","first_published_date":"08/10/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002884-pip01-20"},{"decision_number":"P/0058/2021","pip_number":"EMEA-002808-PIP01-20","active_substance":"Docosahexaenoic acid","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Capsule, soft","condition_indication":"Treatment of Retinitis Pigmentosa","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/02/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Natac Pharma S.L.; E-mail: spomposiello@natac.es; Tel: +34 682657367","first_published_date":"08/10/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002808-pip01-20"},{"decision_number":"P/0218/2022","pip_number":"EMEA-001964-PIP01-16-M04","active_substance":"cannabidiol","invented_name":"Epidyolex","therapeutic_area":"Neurology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of seizures associated with Dravet Syndrome (DS);Treatment of seizures associated with Lennox-Gastaut Syndrome (LGS);Treatment of seizures associated with Tuberous Sclerosis Complex (TSC)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/06/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GW Pharma (International) B.V.; E-mail: info@gwpharm.com; Tel: +44 1223266800","first_published_date":"24/07/2017","last_updated_date":"06/10/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001964-pip01-16-m04"},{"decision_number":"P/0026/2021","pip_number":"EMEA-001561-PIP01-13-M02","active_substance":"darvadstrocel","invented_name":"Alofisel","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of perianal fistula","routes_of_administration":"Other use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/01/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Pharma A/STel. +44 (0)3333000181E-mail: medinfoEMEA@takeda.com","first_published_date":"05/11/2014","last_updated_date":"06/10/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001561-pip01-13-m02"},{"decision_number":"P/0035/2021","pip_number":"EMEA-002888-PIP01-20","active_substance":"alpha1-proteinase inhibitor (human)","invented_name":"","therapeutic_area":"Haematology-Hemostaseology;Pneumology-allergology","pharmaceutical_forms":"Powder and solvent for solution for infusion","condition_indication":"Treatment of emphysema secondary to alpha 1-proteinase inhibitor deficiency","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/01/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Baxalta Innovations GmbH (owned by Takeda); Email: medinfoEMEA@takeda.com ; Tel. +41 797584815 ;  ","first_published_date":"06/10/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002888-pip01-20"},{"decision_number":"P/0046/2021","pip_number":"EMEA-002889-PIP01-20","active_substance":"ublituximab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of mature B cell malignancies","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/01/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CambPharma Solutions (CY) Ltd; Email: anne.frederick@tgtxinc.com ; Tel. +1 9736996629 ;  ","first_published_date":"06/10/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002889-pip01-20"},{"decision_number":"P/0044/2021","pip_number":"EMEA-002890-PIP01-20","active_substance":"umbralisib tosylate","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of mature B cell malignancies","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/01/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CambPharma Solutions (CY) Ltd; Email: anne.frederick@tgtxinc.com ; Tel. +1 9736996629 ;  ","first_published_date":"06/10/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002890-pip01-20"},{"decision_number":"P/0045/2021","pip_number":"EMEA-002891-PIP01-20","active_substance":"rosuvastatin calcium;acetylsalicylic acid","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Prevention of cardiovascular events","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/01/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Neopharmed Gentili S.p.A.; Email: g.sozzi@neogen.it; Tel. +39 0289132254;  ","first_published_date":"06/10/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002891-pip01-20"},{"decision_number":"P/0053/2021","pip_number":"EMEA-002879-PIP01-20","active_substance":"catumaxomab","invented_name":"Remun","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of malignant ascites","routes_of_administration":"Intraperitoneal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/01/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Lindis Biotech GmbH; Email: info@lindisbiotech.de; Tel. +49 8945239600;  ","first_published_date":"06/10/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002879-pip01-20"},{"decision_number":"P/0031/2021","pip_number":"EMEA-002882-PIP01-20","active_substance":"Eliapixant","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of unexplained or chronic refractory cough","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/01/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer AG; Tel. +49 3046815333; E-mail: pediatrics.medical-affairs-europe@bayer.com","first_published_date":"06/10/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002882-pip01-20"},{"decision_number":"P/0015/2021","pip_number":"EMEA-002885-PIP01-20","active_substance":"heparin sodium","invented_name":"","therapeutic_area":"Cardiovascular diseases;Haematology-Hemostaseology","pharmaceutical_forms":"Powder for solution for injection or infusion","condition_indication":"Prevention of thromboembolic events;Treatment of thromboembolic events","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"YES Pharmaceutical Development Services GmbH; Email: caren.martini@pharmalex.com ; Tel. +49 61727646418 ;  ","first_published_date":"06/10/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002885-pip01-20"},{"decision_number":"P/0023/2021","pip_number":"EMEA-002790-PIP01-20","active_substance":"retinol","invented_name":"","therapeutic_area":"Neonatology-Paediatric Intensive Care","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Prevention of bronchopulmonary dysplasia","routes_of_administration":"Intramuscular use;Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"28/01/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"orphanix GmbH; Email: dr.no@orphanix.com; Tel. +43 6769663799","first_published_date":"06/10/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002790-pip01-20"},{"decision_number":"P/0025/2021","pip_number":"EMEA-002868-PIP01-20","active_substance":"reldesemtiv","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of amyotrophic lateral sclerosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/01/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cytokinetics, Inc.; Tel.: +1 650 624 3000; E-mail: regaffairs@cytokinetics.com","first_published_date":"06/10/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002868-pip01-20"},{"decision_number":"P/0055/2021","pip_number":"EMEA-002877-PIP01-20","active_substance":"nefopam (hydrochloride);paracetamol","invented_name":"METAPAIN","therapeutic_area":"Pain","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of acute pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/01/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aptys Pharmaceuticals; Email: fb@aptys-pharmaceuticals.com; Tel.+33 473670670","first_published_date":"06/10/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002877-pip01-20"},{"decision_number":"P/0020/2021","pip_number":"EMEA-002772-PIP01-20","active_substance":"esketamine hydrochloride","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Inhalation powder (pre-dispensed)","condition_indication":"Treatment of bipolar depression;Treatment of major depressive disorder","routes_of_administration":"Inhalation use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/01/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Celon Pharma S.A.; Email: info@celonpharma.com; Tel. +48 227515933 ","first_published_date":"06/10/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002772-pip01-20"},{"decision_number":"P/0439/2022","pip_number":"EMEA-000576-PIP03-12-M06","active_substance":"tofacitinib","invented_name":"Xeljanz","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Film-coated tablet;Oral solution","condition_indication":"Treatment of ulcerative colitis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"28/10/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG; Tel. +44 (0)1304 646 607; E-mail: pip_enquiries@pfizer.com","first_published_date":"22/08/2014","last_updated_date":"29/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000576-pip03-12-m06"},{"decision_number":"P/0018/2021","pip_number":"EMEA-002757-PIP01-19","active_substance":"3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile (TD-1473)","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Tablet;Age appropriate oral dosage formulation","condition_indication":"Treatment of ulcerative colitis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/01/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Theravance Biopharma Ireland Limited; Email: medinfo@theravance.com; Tel. +1 8556338479 ;  ","first_published_date":"29/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002757-pip01-19"},{"decision_number":"P/0011/2021","pip_number":"EMEA-002745-PIP02-20","active_substance":"18-(p-[131I]-iodophenyl)octadecyl phosphocholine","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of lymphoplasmacytic lymphoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/01/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cellectar Biosciences, Inc.; E-mail: clinical@cellectar.com; Tel. +1 6084418120","first_published_date":"29/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002745-pip02-20"},{"decision_number":"P/0054/2021","pip_number":"EMEA-002561-PIP02-20","active_substance":"acetylcysteine;Ibuprofen (sodium dihydrate)","invented_name":"","therapeutic_area":"Oto-rhino-laryngology;Pneumology-allergology","pharmaceutical_forms":"Granules for oral suspension","condition_indication":"Treatment of upper respiratory tract infections","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/01/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"E-Pharma Trento S.p.A.; Email: info@e-pharma.com; Tel. +39 461922818","first_published_date":"29/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002561-pip02-20"},{"decision_number":"P/0006/2021","pip_number":"EMEA-002669-PIP02-20","active_substance":"Lorlatinib","invented_name":"Lorviqua","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of lung cancer","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/01/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europa MA EEIG; Email: PIP_Enquiries@pfizer.com; Tel. +44 1304646607","first_published_date":"29/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002669-pip02-20"},{"decision_number":"EMA/PE/0000221751","pip_number":"EMA/PE/0000221751","active_substance":"ascorbic acid;Macrogol 3350;potassium chloride;sodium ascorbate;sodium chloride;sodium sulphate (Plenvu)","invented_name":"Plenvu","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Powder for oral solution","condition_indication":"Bowel cleansing prior to clinical procedures","routes_of_administration":"Oral use;Gastric use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Norgine Limited; Email: lifecyclemanagement@norgine.com    ; Tel. +44 1895453584; +44 1895826669;  ","first_published_date":"23/11/2016","last_updated_date":"27/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000221751"},{"decision_number":"P/0459/2020","pip_number":"EMEA-001600-PIP01-13-M02","active_substance":"olipudase alfa","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Powder for solution for injection or infusion","condition_indication":"Treatment of Niemann-Pick disease","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi B.V.E-mail: eumedinfo.GZ@sanofi.com Tel. +31 2024 54000&nbsp","first_published_date":"24/03/2015","last_updated_date":"27/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001600-pip01-13-m02"},{"decision_number":"P/0507/2020","pip_number":"EMEA-001544-PIP01-13-M02","active_substance":"captopril","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of heart failure","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"22/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Proveca LimitedTel. +44 7913048665E-mail: simon@proveca.co.uk","first_published_date":"22/08/2014","last_updated_date":"27/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001544-pip01-13-m02"},{"decision_number":"P/0506/2020","pip_number":"EMEA-001582-PIP01-13-M10","active_substance":"Lumacaftor;ivacaftor","invented_name":"Orkambi; Orkambi","therapeutic_area":"Other","pharmaceutical_forms":"Film-coated tablet;Granules","condition_indication":"Treatment of cystic fibrosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"22/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vertex Pharmaceuticals (Europe) Limited; Tel. +1 8776348789; E-mail: medicalinfo@vrtx.com","first_published_date":"06/06/2014","last_updated_date":"27/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001582-pip01-13-m10"},{"decision_number":"P/0511/2020","pip_number":"EMEA-001211-PIP01-11-M02","active_substance":"Levofloxacin hemihydrate","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Nebuliser suspension","condition_indication":"Treatment of cystic fibrosis","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"22/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Chiesi Farmaceutici S.p.A.; Tel. +39 0521 2791; E-mail: info@chiesi.com","first_published_date":"04/01/2013","last_updated_date":"24/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001211-pip01-11-m02"},{"decision_number":"P/0443/2020","pip_number":"EMEA-000916-PIP01-10-M07","active_substance":"lixisenatide","invented_name":"Lyxumia","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection in pre-filled pen","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi-Aventis R&D; E-mail: contact-us@sanofi.com; Tel. +33 1697 45264","first_published_date":"24/05/2012","last_updated_date":"23/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000916-pip01-10-m07"},{"decision_number":"P/0494/2020","pip_number":"EMEA-000827-PIP01-09-M05","active_substance":"aztreonam","invented_name":"Cayston; Cayston","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder and solvent for nebuliser solution","condition_indication":"Treatment of Pseudomonas aeruginosa pulmonary infection / colonisation in patients with cystic fibrosis","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"21/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Limited; Tel. +44 (0)1223 897300; E-mail: regulatory.pip@gilead.com","first_published_date":"07/06/2011","last_updated_date":"23/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000827-pip01-09-m05"},{"decision_number":"P/0465/2020","pip_number":"EMEA-000499-PIP02-10-M01","active_substance":"veliparib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule;Oral liquid","condition_indication":"Treatment of high-grade glioma","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628925033","first_published_date":"18/10/2011","last_updated_date":"23/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000499-pip02-10-m01"},{"decision_number":"P/0516/2020","pip_number":"EMEA-000170-PIP03-13-M04","active_substance":"eltrombopag","invented_name":"Revolade","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Film-coated tablet;Powder for oral suspension","condition_indication":"Treatment of aplastic anaemia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"22/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"22/09/2016","last_updated_date":"23/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000170-pip03-13-m04"},{"decision_number":"P/0484/2020","pip_number":"EMEA-002866-PIP01-20","active_substance":"N-[(1R)-1-(1H-indol-3-ylmethyl)pentyl]-2-(4-methylpiperazin-1-yl)thiazole-5-carboxamide (UCB0599)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of Parkinson's disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"UCB Pharma S.A.; Tel. + 353 14632371; E-mail: ucbcares.ie@ucb.com","first_published_date":"22/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002866-pip01-20"},{"decision_number":"P/0496/2020","pip_number":"EMEA-002871-PIP01-20","active_substance":"tipifarnib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of head and neck epithelial malignant neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kura Oncology, Inc.; Email: mkelly@kuraoncology.com; Tel. +1 6173029506 ;  ","first_published_date":"22/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002871-pip01-20"},{"decision_number":"P/0495/2020","pip_number":"EMEA-002876-PIP01-20","active_substance":"tauroursodeoxycholic acid;sodium phenylbutyrate","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Powder for oral suspension","condition_indication":"Treatment of amyotrophic lateral sclerosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Drug Development and Regulation SL; Email: info@ddrmedic.com; Tel. +34 935285385;  ","first_published_date":"22/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002876-pip01-20"},{"decision_number":"P/0472/2020","pip_number":"EMEA-002854-PIP01-20","active_substance":"(1R,2R,3S,4S,5R,6S)-cyclohexane-1,2,3,4,5,6-hexayl-hexakis (dihydrogen phosphate)","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of calciphylaxis","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanifit Therapeutics S.A.; Email: info@sanifit.com    ; Tel. +34 971439925;  ","first_published_date":"22/09/2021","last_updated_date":"22/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002854-pip01-20"},{"decision_number":"P/0488/2020","pip_number":"EMEA-002597-PIP03-20","active_substance":"Efgartigimod alfa","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of pemphigus","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Argenx BVE-mail: regulatory@argenx.comTel: +32 93103400","first_published_date":"22/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002597-pip03-20"},{"decision_number":"P/0439/2020","pip_number":"EMEA-002702-PIP01-19","active_substance":"Dapirolizumab pegol","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of Systemic Lupus Erythematosus (SLE)","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"UCB Biopharma SRL; Tel.  +44 1753777100; E-mail: UCBCares.UK@ucb.com","first_published_date":"22/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002702-pip01-19"},{"decision_number":"P/0445/2020","pip_number":"EMEA-002852-PIP01-20","active_substance":"atorvastatin;ezetimibe","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events;Treatment of hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sandoz B.V.; Email: caroline.kleinjan@sandoz.com    ; Tel. +31 365241710;  ","first_published_date":"22/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002852-pip01-20"},{"decision_number":"P/0471/2020","pip_number":"EMEA-002859-PIP01-20","active_substance":"serplulimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of lung cancer (small cell and non-small cell lung cancer)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Shanghai Henlius Biotech, Inc.; Email: Xiaodong_Shi1@henlius.com; Tel. +86 13810233555;  ","first_published_date":"22/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002859-pip01-20"},{"decision_number":"P/0497/2020","pip_number":"EMEA-002860-PIP01-20","active_substance":"ramipril;Bisoprolol fumarate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"EGIS Pharmaceuticals PLC; Hungary; registry@egis.hu ; Tel. +361 18032414","first_published_date":"22/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002860-pip01-20"},{"decision_number":"P/0485/2020","pip_number":"EMEA-002864-PIP01-20","active_substance":"Delolimogene mupadenorepvec","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of pancreatic cancer","routes_of_administration":"Intratumoral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Lokon Pharma AB; Email: info@lokonpharma.com ; Tel. +46 18507444 ;  ","first_published_date":"22/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002864-pip01-20"},{"decision_number":"P/0173/2015","pip_number":"EMEA-001331-PIP01-12-M02","active_substance":"sebelipase alfa","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of lysosomal acid-lipase deficiency","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/08/2015","compliance_outcome":"Positive","compliance_opinion_date":"01/03/2019","compliance_procedure_number":"EMEA-C-001331-PIP01-12-M02","contact_for_public_enquiries":"Alexion Europe SAS; France; E-mail: pip.enquiries.eu@alxn.com ; Tel. +33 1 47 10 06 06; Fax +33 1 47 10 06 11","first_published_date":"31/05/2013","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001331-pip01-12-m02"},{"decision_number":"P/0098/2018","pip_number":"EMEA-000145-PIP01-07-M09","active_substance":"denosumab","invented_name":"Prolia; Xgeva; Xgeva; Prolia","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of skeletal related events in patients with bone metastases;Treatment of bone loss associated with sex hormone ablative therapy;Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis);Treatment of giant cell tumour of bone;Treatment of hypercalcemia of malignancy","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/03/2018","compliance_outcome":"Positive","compliance_opinion_date":"01/03/2019","compliance_procedure_number":"EMEA-C-000145-PIP01-07-M09","contact_for_public_enquiries":"Amgen Europe B.V.; Tel. +44 (0)1223 420305; E-mail: pipenquiry@amgen.com","first_published_date":"13/09/2011","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000145-pip01-07-m09"},{"decision_number":"P/0060/2016","pip_number":"EMEA-000308-PIP02-11-M01","active_substance":"rituximab","invented_name":"MabThera; MabThera","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of microscopic polyangiitis","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/03/2016","compliance_outcome":"Positive","compliance_opinion_date":"01/02/2019","compliance_procedure_number":"EMEA-C-000308-PIP02-11-M01","contact_for_public_enquiries":"Roche Registration Limited; Switzerland; Tel. +41 616879411; Fax +44 616879411; E-mail: infopaediatrics@roche.com","first_published_date":"27/04/2012","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000308-pip02-11-m01"},{"decision_number":"P/0063/2017","pip_number":"EMEA-001411-PIP01-12-M04","active_substance":"sofosbuvir;ledipasvir","invented_name":"Harvoni; Harvoni","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form;Age appropriate dosage form, other","condition_indication":"Treatment of chronic hepatitis C","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/03/2017","compliance_outcome":"Positive","compliance_opinion_date":"26/04/2019","compliance_procedure_number":"EMEA-C-001411-PIP01-12-M04","contact_for_public_enquiries":"Gilead Sciences International Ltd.; United Kingdom; Tel. +44 (0)1223 897300; Fax +44 (0)1223897284; E-mail: regulatory.pip@gilead.com","first_published_date":"18/11/2013","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001411-pip01-12-m04"},{"decision_number":"P/0196/2016","pip_number":"EMEA-001839-PIP01-15","active_substance":"emicizumab","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of hereditary factor VIII deficiency","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/07/2016","compliance_outcome":"Positive","compliance_opinion_date":"26/04/2019","compliance_procedure_number":"EMEA-C-001839-PIP01-15","contact_for_public_enquiries":"Roche Registration Limited; Switzerland; Tel.+41 6 6879411; Fax +41 616881560; E-mail: info.paediatrics@roche.com","first_published_date":"22/09/2016","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001839-pip01-15"},{"decision_number":"P/0043/2018","pip_number":"EMEA-001474-PIP01-13-M01","active_substance":"anti-PD1 humanized monoclonal antibody of the IgG4/kappa class (MK-3475) (pembrolizumab)","invented_name":"Keytruda","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for concentrate for solution for infusion;Concentrate for solution for infusion","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/02/2018","compliance_outcome":"Positive","compliance_opinion_date":"01/02/2019","compliance_procedure_number":"EMEA-C-001474-PIP01-13-M01","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"16/04/2014","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001474-pip01-13-m01"},{"decision_number":"P/0207/2016","pip_number":"EMEA-000428-PIP01-08-M03","active_substance":"turoctocog alpha","invented_name":"NovoEight; NovoEight","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of hereditary factor-VIII deficiency","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/08/2016","compliance_outcome":"Positive","compliance_opinion_date":"26/04/2019","compliance_procedure_number":"EMEA-C-000428-PIP01-08-M03","contact_for_public_enquiries":"Novo Nordisk A/S; Denmark; Tel. +45 44448888; E-mail: paediatrics@novonordisk.com","first_published_date":"18/05/2010","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000428-pip01-08-m03"},{"decision_number":"P/0022/2019","pip_number":"EMEA-000669-PIP01-09-M02","active_substance":"split influenza virus, inactivated containing antigen equivalent to A/California/7/2009 (H1N1)-like strain (A/California/7/2009 (NYMC X-179A)), adjuvanted","invented_name":"Humenza; Humenza","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension and emulsion for injection","condition_indication":"Prevention of influenza","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/01/2019","compliance_outcome":"Positive","compliance_opinion_date":"26/04/2019","compliance_procedure_number":"EMEA-C-000669-PIP01-09-M02","contact_for_public_enquiries":"Sanofi Pasteur SA; E-mail: Piplan@sanofipasteur.com; Country: France; Phone: +33 437375038","first_published_date":"18/05/2010","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000669-pip01-09-m02"},{"decision_number":"P/0401/2018","pip_number":"EMEA-000055-PIP01-07-M06","active_substance":"rabeprazole (sodium)","invented_name":"Pariet and associated names","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Gastro-resistant granules;Gastro-resistant tablet","condition_indication":"Treatment of duodenal ulcer;Treatment of gastric ulcer;Treatment of gastro-oesophageal reflux disease;Treatment of Helicobacter pylori in patients with peptic ulcer disease;Treatment of Zollinger-Ellison syndrome","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/12/2018","compliance_outcome":"Positive","compliance_opinion_date":"01/02/2019","compliance_procedure_number":"EMEA-C-000055-PIP01-07-M06","contact_for_public_enquiries":"Eisai Limited; E-mail: eumedinfo@eisai.net; Tel.: +44 845 6765400","first_published_date":"20/04/2012","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000055-pip01-07-m06"},{"decision_number":"P/0159/2018","pip_number":"EMEA-000548-PIP01-09-M08","active_substance":"beclometasone dipropionate;formoterol fumarate dihydrate","invented_name":"Foster and associated names; Kantos and associated names; Kantos Master and associated names; Inuvair and associated names","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Inhalation powder;Pressurised inhalation (solution)","condition_indication":"Treatment of asthma","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/06/2018","compliance_outcome":"Positive","compliance_opinion_date":"26/04/2019","compliance_procedure_number":"EMEA-C-000548-PIP01-09-M08","contact_for_public_enquiries":"Chiesi Farmaceutici S.p.A.; Tel. +39 0521 2791; E-mail: info@chiesi.com","first_published_date":"15/09/2011","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000548-pip01-09-m08"},{"decision_number":"P/0053/2017","pip_number":"EMEA-000469-PIP01-08-M07","active_substance":"anidulafungin","invented_name":"Ecalta; Ecalta","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of invasive candidiasis","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/03/2017","compliance_outcome":"Positive","compliance_opinion_date":"26/04/2019","compliance_procedure_number":"EMEA-C-000469-PIP01-08-M07","contact_for_public_enquiries":"Pfizer Limited; Tel. + 44 1304646607; E-mail: pip_enquiries@pfizer.com","first_published_date":"12/05/2011","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000469-pip01-08-m07"},{"decision_number":"P/0343/2018","pip_number":"EMEA-000367-PIP01-08-M08","active_substance":"Conestat alfa","invented_name":"Ruconest; Ruconest","therapeutic_area":"Other","pharmaceutical_forms":"Powder for solution for injection;Powder and solvent for solution for injection","condition_indication":"Treatment of hereditary angioedema","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/11/2018","compliance_outcome":"Positive","compliance_opinion_date":"01/03/2019","compliance_procedure_number":"EMEA-C-000367-PIP01-08-M08","contact_for_public_enquiries":"Pharming Group N.V.; Tel. +31 715247400; E-mail: info@pharming.com","first_published_date":"16/09/2009","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000367-pip01-08-m08"},{"decision_number":"P/0172/2018","pip_number":"EMEA-001276-PIP01-12-M02","active_substance":"sofosbuvir","invented_name":"Sovaldi; Sovaldi","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form;Other","condition_indication":"Treatment of chronic hepatitis C","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/06/2018","compliance_outcome":"Positive","compliance_opinion_date":"26/04/2019","compliance_procedure_number":"EMEA-C-001276-PIP01-12-M02","contact_for_public_enquiries":"Gilead Sciences International Ltd; E-mail: regulatory.pip@gilead.com; Tel. +44 (0)1223 897300","first_published_date":"08/02/2013","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001276-pip01-12-m02"},{"decision_number":"P/0089/2015","pip_number":"EMEA-000429-PIP01-08-M04","active_substance":"Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group W polysaccharide conjugated to tetanus toxoid;N. meningitidis serogroup Y polysaccharide conjugated to tetanus toxoid","invented_name":"Nimenrix; Nimenrix","therapeutic_area":"Vaccines","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Prevention of Meningococcal disease","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/05/2015","compliance_outcome":"Positive","compliance_opinion_date":"26/04/2019","compliance_procedure_number":"EMEA-C-000429-PIP01-08-M04","contact_for_public_enquiries":"GlaxoSmithKline Biologicals SA; Tel. +44 (0)20 8966 3220; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"21/12/2011","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000429-pip01-08-m04"},{"decision_number":"P/0064/2019","pip_number":"EMEA-000308-PIP01-08-M04","active_substance":"rituximab","invented_name":"MabThera; MabThera","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion;Solution for injection","condition_indication":"Treatment of autoimmune arthritis;Treatment of diffuse large B-cell lymphoma","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"22/03/2019","compliance_outcome":"Positive","compliance_opinion_date":"29/05/2019","compliance_procedure_number":"EMEA-C-000308-PIP01-08-M04","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"17/10/2011","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000308-pip01-08-m04"},{"decision_number":"P/0003/2016","pip_number":"EMEA-000311-PIP01-08-M04","active_substance":"ustekinumab","invented_name":"Stelara; Stelara","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic plaque psoriasis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/01/2016","compliance_outcome":"Positive","compliance_opinion_date":"29/05/2019","compliance_procedure_number":"EMEA-C-000311-PIP01-08-M04","contact_for_public_enquiries":"Janssen-Cilag International NV; Belgium; E-mail: mojanen@its.jnj.com; Tel. +34 917228079","first_published_date":"29/10/2010","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000311-pip01-08-m04"},{"decision_number":"P/0149/2016","pip_number":"EMEA-001114-PIP01-10-M03","active_substance":"efmoroctocog alfa","invented_name":"Elocta","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of hereditary factor-VIII deficiency","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2016","compliance_outcome":"Positive","compliance_opinion_date":"29/05/2019","compliance_procedure_number":"EMEA-C-001114-PIP01-10-M03","contact_for_public_enquiries":"Biogen Idec LtdTel. +44 (0) 16285 12609 / 44 (0)7557057823E-mail: amit.patel@biogen.cpm","first_published_date":"09/08/2011","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001114-pip01-10-m03"},{"decision_number":"P/0143/2018","pip_number":"EMEA-000298-PIP01-08-M06","active_substance":"peginterferon alfa-2a","invented_name":"Pegasys; Pegasys","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic hepatitis B;Treatment of chronic hepatitis C","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/05/2018","compliance_outcome":"Positive","compliance_opinion_date":"29/05/2019","compliance_procedure_number":"EMEA-C-000298-PIP01-08-M06","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"21/12/2011","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000298-pip01-08-m06"},{"decision_number":"P/0126/2019","pip_number":"EMEA-000430-PIP01-08-M11","active_substance":"rivaroxaban","invented_name":"Xarelto","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Oral suspension;Film-coated tablet","condition_indication":"Prevention of thromboembolic events;Treatment of thromboembolic events","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/04/2019","compliance_outcome":"Positive","compliance_opinion_date":"20/09/2019","compliance_procedure_number":"EMEA-C-000430-PIP01-08-M11","contact_for_public_enquiries":"Bayer Pharma AG; Tel. +49 3046 815333; E-mail: pediatrics.medical-affairs-europe@bayer.com","first_published_date":"25/07/2017","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000430-pip01-08-m11"},{"decision_number":"P/0399/2018","pip_number":"EMEA-000081-PIP01-07-M11","active_substance":"dabigatran etexilate mesilate","invented_name":"Pradaxa; Pradaxa","therapeutic_area":"Cardiovascular diseases;Haematology-Hemostaseology","pharmaceutical_forms":"Capsule, hard;Age appropriate dosage form, other","condition_indication":"Prevention of thromboembolic events;Treatment of thromboembolic events","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/12/2018","compliance_outcome":"Positive","compliance_opinion_date":"23/08/2019","compliance_procedure_number":"EMEA-C-000081-PIP01-07-M11","contact_for_public_enquiries":"","first_published_date":"10/08/2011","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000081-pip01-07-m11"},{"decision_number":"P/0221/2019","pip_number":"EMEA-001259-PIP02-13-M02","active_substance":"terbinafine hydrochloride","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Medicated nail lacquer","condition_indication":"Treatment of onychomycosis","routes_of_administration":"Topical use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/06/2019","compliance_outcome":"Positive","compliance_opinion_date":"26/07/2019","compliance_procedure_number":"EMEA-C-001259-PIP02-13-M02","contact_for_public_enquiries":"Polichem S.A. (Spain); Tel.: +34 932913512; E-mail: anna.pares@almirall.com","first_published_date":"09/08/2013","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001259-pip02-13-m02"},{"decision_number":"P/0294/2018","pip_number":"EMEA-001157-PIP01-11-M02","active_substance":"Caplacizumab","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of thrombotic thrombocytopenic purpura (TTP)","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/09/2018","compliance_outcome":"Positive","compliance_opinion_date":"23/08/2019","compliance_procedure_number":"EMEA-C-001157-PIP01-11-M02","contact_for_public_enquiries":"Ablynx NV; E-mail: bernard.delaey@ablynx.com; Tel. +32 2620 000","first_published_date":"19/04/2012","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001157-pip01-11-m02"},{"decision_number":"P/0196/2018","pip_number":"EMEA-001061-PIP01-10-M03","active_substance":"sucroferric oxyhydroxide","invented_name":"Velphoro; Velphoro","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Powder for oral suspension;Chewable tablet","condition_indication":"Treatment of hyperphosphataemia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/07/2018","compliance_outcome":"Positive","compliance_opinion_date":"20/09/2019","compliance_procedure_number":"EMEA-C-001061-PIP01-10-M03","contact_for_public_enquiries":"Vifor Fresenius Medical Care Renal Pharma France; E-mail: info@viforpharma.com ; Tel. +41 5885 18000","first_published_date":"21/12/2011","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001061-pip01-10-m03"},{"decision_number":"P/0207/2019","pip_number":"EMEA-001638-PIP01-14-M02","active_substance":"atezolizumab","invented_name":"Tecentriq","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/06/2019","compliance_outcome":"Positive","compliance_opinion_date":"20/09/2019","compliance_procedure_number":"EMEA-C-001638-PIP01-14-M02","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"07/05/2015","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001638-pip01-14-m02"},{"decision_number":"P/0139/2018","pip_number":"EMEA-001577-PIP03-17","active_substance":"emtricitabine;tenofovir alafenamide","invented_name":"Descovy; Descovy","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"07/05/2018","compliance_outcome":"Positive","compliance_opinion_date":"20/09/2019","compliance_procedure_number":"EMEA-C-001577-PIP03-17","contact_for_public_enquiries":"Gilead Sciences International Ltd; E-mail: regulatory.pip@gilead.com; Tel. +44 (0)1223 897300","first_published_date":"27/11/2018","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001577-pip03-17"},{"decision_number":"P/0234/2017","pip_number":"EMEA-000555-PIP01-09-M06","active_substance":"decitabine","invented_name":"Dacogen; Dacogen","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of acute myeloid leukaemia","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/08/2017","compliance_outcome":"Positive","compliance_opinion_date":"18/10/2019","compliance_procedure_number":"EMEA-C-000555-PIP01-09-M06","contact_for_public_enquiries":"Janssen-Cilag International NV; Ireland; Tel. +353 857446696; E-mail: nbuhl@its.jnj.com;  ","first_published_date":"26/04/2012","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000555-pip01-09-m06"},{"decision_number":"P/0176/2019","pip_number":"EMEA-000987-PIP01-10-M04","active_substance":"asfotase alfa","invented_name":"Strensiq","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of hypophosphatasia","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/05/2019","compliance_outcome":"Positive","compliance_opinion_date":"18/10/2019","compliance_procedure_number":"EMEA-C-000987-PIP01-10-M04","contact_for_public_enquiries":"Alexion Europe SAS; Tel. +33 153643800; E-mail: pip.enquiries.eu@alexion.com","first_published_date":"02/05/2013","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000987-pip01-10-m04"},{"decision_number":"P/0016/2019","pip_number":"EMEA-000671-PIP01-09-M10","active_substance":"sildenafil","invented_name":"Revatio; Revatio","therapeutic_area":"Other","pharmaceutical_forms":"Film-coated tablet;Powder for oral solution;Solution for injection","condition_indication":"Treatment of pulmonary arterial hypertension","routes_of_administration":"Oral use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/01/2019","compliance_outcome":"Positive","compliance_opinion_date":"20/09/2019","compliance_procedure_number":"EMEA-C-000671-PIP01-09-M10","contact_for_public_enquiries":"Pfizer Europe MA EEIG; Tel. +44 (0)1304 646 607; E-mail: pip_enquiries@pfizer.com","first_published_date":"07/06/2011","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000671-pip01-09-m10"},{"decision_number":"P/0359/2019","pip_number":"EMEA-001230-PIP01-11-M05","active_substance":"Lurasidone hydrochloride","invented_name":"Latuda; Latuda","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of schizophrenia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/11/2019","compliance_outcome":"Positive","compliance_opinion_date":"11/12/2019","compliance_procedure_number":"EMEA-C-001230-PIP01-11-M05","contact_for_public_enquiries":"AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO - A.C.R.A.F. S.p.A.; Tel. +3906780531; E-mail: angeliniregulatoryaffairs@angelinipharma.com","first_published_date":"22/08/2012","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001230-pip01-11-m05"},{"decision_number":"P/0269/2019","pip_number":"EMEA-001514-PIP01-13-M01","active_substance":"octenidine dihydrochloride","invented_name":"Laryngomedin Octenidin Antisept and associated names","therapeutic_area":"Oto-rhino-laryngology","pharmaceutical_forms":"Lozenge","condition_indication":"Treatment of upper respiratory tract infections","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/08/2019","compliance_outcome":"Positive","compliance_opinion_date":"11/12/2019","compliance_procedure_number":"EMEA-C-001514-PIP01-13-M01","contact_for_public_enquiries":"Cassella-med GmbH & Co. KG; Tel. +49 221165200; E-mail: pediatrics@cassella-med.de; regulatory@Klosterfrau-Group.de","first_published_date":"25/04/2016","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001514-pip01-13-m01"},{"decision_number":"P/0128/2019","pip_number":"EMEA-001832-PIP01-15-M02","active_substance":"glecaprevir;pibrentasvir","invented_name":"Maviret","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of chronic hepatitis C","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/04/2019","compliance_outcome":"Positive","compliance_opinion_date":"11/12/2019","compliance_procedure_number":"EMEA-C-001832-PIP01-15-M02","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628925033","first_published_date":"26/08/2016","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001832-pip01-15-m02"},{"decision_number":"P/0368/2019","pip_number":"EMEA-002147-PIP02-17-M01","active_substance":"sodium thiosulfate","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Prevention of platinum-induced ototoxic hearing loss","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/11/2019","compliance_outcome":"Positive","compliance_opinion_date":"11/12/2019","compliance_procedure_number":"EMEA-C-002147-PIP02-17-M01","contact_for_public_enquiries":"Fennec Pharmaceuticals, Inc.; E-mail: info@s-cubed.co.uk; Tel. +44 1235772260","first_published_date":"28/01/2019","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002147-pip02-17-m01"},{"decision_number":"P/0299/2019","pip_number":"EMEA-000160-PIP01-07-M05","active_substance":"purified antigen fractions of inactivated split virion Influenza A/Vietnam/1194/2004 (H5N1) like strain used (NIBRG-14);purified antigen fractions of inactivated split virion Influenza A/Indonesia/05/2005 (H5N1) like strain used (PR8-IBCDC-RG2)","invented_name":"Prepandrix; Adjupanrix","therapeutic_area":"Vaccines","pharmaceutical_forms":"Emulsion and suspension for emulsion for injection","condition_indication":"Prevention of influenza infection","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/08/2019","compliance_outcome":"Positive","compliance_opinion_date":"31/01/2020","compliance_procedure_number":"EMEA-C-000160-PIP01-07-M05","contact_for_public_enquiries":"GlaxoSmithKline Biologicals S.A.; E-mail: eu.paediatric-plans@gsk.com; Tel.: +1 438 899 8201","first_published_date":"10/06/2009","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000160-pip01-07-m05"},{"decision_number":"P/0358/2019","pip_number":"EMEA-000470-PIP01-08-M11","active_substance":"sitagliptin","invented_name":"Januvia","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/10/2019","compliance_outcome":"Positive","compliance_opinion_date":"28/02/2020","compliance_procedure_number":"EMEA-C-000470-PIP01-08-M11","contact_for_public_enquiries":"Merck Sharp and Dohme (Europe), Inc.; Tel. +44 (0)1992 452396; E-mail: paul.robinson@merck.com;  ","first_published_date":"14/07/2011","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000470-pip01-08-m11"},{"decision_number":"P/0300/2018","pip_number":"EMEA-000069-PIP04-13-M02","active_substance":"Mepolizumab","invented_name":"Nucala","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Powder for solution for injection or infusion;Solution for injection","condition_indication":"Treatment of vasculitides","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/09/2018","compliance_outcome":"Positive","compliance_opinion_date":"28/02/2020","compliance_procedure_number":"EMEA-C-000069-PIP04-13-M02","contact_for_public_enquiries":"GSK Trading Services Limited; Tel. +1 4388998201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"23/02/2015","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000069-pip04-13-m02"},{"decision_number":"P/0363/2019","pip_number":"EMEA-000245-PIP01-08-M06","active_substance":"Lubiprostone","invented_name":"Amitiza","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Capsule, soft","condition_indication":"Treatment of constipation","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/11/2019","compliance_outcome":"Positive","compliance_opinion_date":"28/02/2020","compliance_procedure_number":"EMEA-C-000245-PIP01-08-M06","contact_for_public_enquiries":"Sucampo AG; E-mail: medinfo@mnk.com; Tel.  +800 55444777","first_published_date":"12/05/2011","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000245-pip01-08-m06"},{"decision_number":"P/0170/2019","pip_number":"EMEA-002514-PIP01-18","active_substance":"mometasone (furoate monohydrate);olopatadine (hydrochloride) (GSP 301 NS)","invented_name":"","therapeutic_area":"Oto-rhino-laryngology","pharmaceutical_forms":"","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Intranasal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/05/2019","compliance_outcome":"Positive","compliance_opinion_date":"27/03/2020","compliance_procedure_number":"EMEA-C-002514-PIP01-18","contact_for_public_enquiries":"Glenmark Pharmaceuticals Europe Ltd; Tel.: +44 1923202950; E-mail: PIP@glenmarkpharma.com","first_published_date":"29/10/2019","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002514-pip01-18"},{"decision_number":"P/0233/2017","pip_number":"EMEA-000653-PIP01-09-M05","active_substance":"romiplostim","invented_name":"Nplate; Nplate","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder for solution for injection;Powder and solvent for solution for injection","condition_indication":"Treatment of disease-related thrombocytopenia in myelodysplastic syndrome;Treatment of idiopathic thrombocytopenic purpura as a model for immunomodulation","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/08/2017","compliance_outcome":"Positive","compliance_opinion_date":"27/03/2020","compliance_procedure_number":"EMEA-C-000653-PIP01-09-M05","contact_for_public_enquiries":"Amgen Europe BV; E-mail: medinfointernational@amgen.com; Tel. +44 (0)1223 420305","first_published_date":"29/10/2010","last_updated_date":"21/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000653-pip01-09-m05"},{"decision_number":"P/0470/2020","pip_number":"EMEA-002849-PIP01-20","active_substance":"amlodipine besilate;Indapamide;perindopril arginine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Teva B.V. Email: MedAffGenTevaEurope@tevapharm.com Tel. +385 13722001","first_published_date":"20/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002849-pip01-20"},{"decision_number":"P/0446/2020","pip_number":"EMEA-002846-PIP01-20","active_substance":"Lurbinectedin","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of small cell lung cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pharma Mar, S.A.; Email: regulatory@pharmamar.com; Tel. +34 918466000;  ","first_published_date":"20/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002846-pip01-20"},{"decision_number":"P/0447/2020","pip_number":"EMEA-002843-PIP02-20","active_substance":"2-(6-azaspiro[2.5]octan-6-yl)-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]- 4-[(2- hydroxyethanesulfonyl)amino]benzamide hydrochloride","invented_name":"","therapeutic_area":"Haematology-Hemostaseology;Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of breast cancer","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe BV; E-mail: medinfointernational@amgen.com; Tel. +44 (0)1223 420305","first_published_date":"20/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002843-pip02-20"},{"decision_number":"P/0448/2020","pip_number":"EMEA-002843-PIP01-20","active_substance":"2-(6-azaspiro[2.5]octan-6-yl)-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]- 4-[(2- hydroxyethanesulfonyl)amino]benzamide hydrochloride","invented_name":"","therapeutic_area":"Haematology-Hemostaseology;Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of ovarian cancer","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe BV; E-mail: medinfointernational@amgen.com; Tel. +44 (0)1223 420305","first_published_date":"20/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002843-pip01-20"},{"decision_number":"P/0468/2020","pip_number":"EMEA-002841-PIP01-20","active_substance":"fasudil hydrochloride","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Concentrate for solution for infusion;Concentrate for solution for injection;Powder for solution for injection or infusion","condition_indication":"Treatment of non-traumatic subarachnoid haemorrhage","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aneuryst (Ireland) Limited; Email: mitchell.wong@aneuryst.com; Tel. +1 2126711068;  ","first_published_date":"20/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002841-pip01-20"},{"decision_number":"P/0449/2020","pip_number":"EMEA-002791-PIP01-20","active_substance":"chimeric fibril-reactive IgG1k monoclonal antibody 11-1F4","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of systemic light chain amyloidosis","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Real Regulatory Limited; Email: info@realregulatory.com   ; Tel. +353 18851710;  ","first_published_date":"20/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002791-pip01-20"},{"decision_number":"P/0438/2020","pip_number":"EMEA-002834-PIP01-20","active_substance":"allogeneic B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Dispersion for injection","condition_indication":"Treatment of Multiple Myeloma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CRISPR Therapeutics AG; Email: info@crisprtx.com; Tel. +1 6173154600","first_published_date":"20/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002834-pip01-20"},{"decision_number":"P/0498/2020","pip_number":"EMEA-002840-PIP01-20","active_substance":"ziltivekimab","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of cardiovascular events in patients with atherosclerosis","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; E-mail: paediatrics@novonordisk.com ; Tel.: +45 44444848","first_published_date":"20/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002840-pip01-20"},{"decision_number":"P/0501/2020","pip_number":"EMEA-002759-PIP01-19","active_substance":"olinciguat","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of sickle cell disease","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cyclerion Therapeutics Inc.; Emaill: mchristian@cyclerion.com    ; Tel. +1 8573383340;  ","first_published_date":"20/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002759-pip01-19"},{"decision_number":"P/0258/2019","pip_number":"EMEA-002516-PIP01-18","active_substance":"Lonafarnib","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of Hutchinson-Gilford Progeria Syndrome;Treatment of progeroid laminopathies","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"16/07/2019","compliance_outcome":"Positive","compliance_opinion_date":"27/03/2020","compliance_procedure_number":"EMEA-C-002516-PIP01-18","contact_for_public_enquiries":"Eiger BioPharmaceuticals Europe Limited; Tel. +(+1) 877 899 2051; E-mail: info@eigerbio.com","first_published_date":"13/11/2019","last_updated_date":"20/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002516-pip01-18"},{"decision_number":"P/0061/2017","pip_number":"EMEA-001187-PIP01-11-M04","active_substance":"tafluprost","invented_name":"Taflotan and associated names","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution in single-dose container;Eye drops, solution","condition_indication":"Treatment of glaucoma","routes_of_administration":"Ocular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/03/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Santen Oy; Finland; E-mail: auli.ropo@santen.fi; Tel. +358 3284 8111; Fax +358 9724 4355","first_published_date":"09/08/2012","last_updated_date":"17/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001187-pip01-11-m04"},{"decision_number":"P/0455/2020","pip_number":"EMEA-002576-PIP01-19","active_substance":"cefepime;taniborbactam","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of Gram-negative bacterial infections","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Venatorx Pharmaceuticals, Inc.; E-mail: abey@venatorx.com; Tel: +1 4843298625","first_published_date":"17/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002576-pip01-19"},{"decision_number":"P/0512/2020","pip_number":"EMEA-001207-PIP03-20","active_substance":"obinutuzumab","invented_name":"Gazyvaro","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of glomerulonephritis and nephrotic syndrome","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbH; E-mail: global.eu_regulatory_office@roche.comTel. +49 7624142892","first_published_date":"17/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001207-pip03-20"},{"decision_number":"P/0515/2020","pip_number":"EMEA-000694-PIP06-20","active_substance":"dapagliflozin","invented_name":"Forxiga","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of ischaemic heart disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca ABEmail: paediatrics@astrazeneca.comTel. +46 855324400","first_published_date":"17/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000694-pip06-20"},{"decision_number":"P/0028/2020","pip_number":"EMEA-000057-PIP01-07-M07","active_substance":"zoledronic acid","invented_name":"Aclasta","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of osteoporosis;Treatment of Paget’s disease of the bone","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/01/2020","compliance_outcome":"Positive","compliance_opinion_date":"30/04/2020","compliance_procedure_number":"EMEA-C-000057-PIP01-07-M07","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"07/10/2010","last_updated_date":"16/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000057-pip01-07-m07"},{"decision_number":"P/0174/2019","pip_number":"EMEA-000366-PIP02-09-M06","active_substance":"adalimumab","invented_name":"Humira","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of ulcerative colitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/05/2019","compliance_outcome":"Positive","compliance_opinion_date":"30/04/2020","compliance_procedure_number":"EMEA-C-000366-PIP02-09-M06","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628925033","first_published_date":"08/03/2011","last_updated_date":"16/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000366-pip02-09-m06"},{"decision_number":"P/0034/2020","pip_number":"EMEA-001019-PIP01-10-M05","active_substance":"lipegfilgrastim","invented_name":"Lonquex","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of chemotherapy-induced febrile neutropenia;Treatment of chemotherapy-induced neutropenia","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/01/2020","compliance_outcome":"Positive","compliance_opinion_date":"30/04/2020","compliance_procedure_number":"EMEA-C-001019-PIP01-10-M05","contact_for_public_enquiries":"UAB \"Sicor Biotech\"; Tel. +44 (0)20 7540 7117; E-mail: med.info@tevapharm.com","first_published_date":"09/06/2011","last_updated_date":"16/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001019-pip01-10-m05"},{"decision_number":"P/0065/2020","pip_number":"EMEA-001545-PIP01-13-M02","active_substance":"live, attenuated, chimeric dengue virus, serotype 1;live, attenuated, chimeric dengue virus, serotype 2;live, attenuated, chimeric dengue virus, serotype 3;live, attenuated, chimeric dengue virus, serotype 4","invented_name":"Dengvaxia","therapeutic_area":"Vaccines","pharmaceutical_forms":"Powder and solvent for suspension for injection","condition_indication":"Prevention of dengue fever","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"21/02/2020","compliance_outcome":"Positive","compliance_opinion_date":"29/05/2020","compliance_procedure_number":"EMEA-C-001545-PIP01-13-M02","contact_for_public_enquiries":"Sanofi PasteurE-mail: contact-us@sanofi.comTel. +33 1 6974 5695","first_published_date":"06/06/2014","last_updated_date":"16/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001545-pip01-13-m02"},{"decision_number":"P/0333/2019","pip_number":"EMEA-000601-PIP01-09-M06","active_substance":"pazopanib","invented_name":"Votrient","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral formulation","condition_indication":"Treatment of Ewing sarcoma family of tumours;Treatment of non-rhabdomyosarcoma soft tissue sarcoma;Treatment of rhabdomyosarcoma","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/09/2019","compliance_outcome":"Positive","compliance_opinion_date":"24/07/2020","compliance_procedure_number":"EMEA-C-000601-PIP01-09-M06","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"25/07/2017","last_updated_date":"16/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000601-pip01-09-m06"},{"decision_number":"P/0125/2020","pip_number":"EMEA-001039-PIP02-12-M04","active_substance":"Clostridium Botulinum neurotoxin type A (150 kD), free from complexing proteins","invented_name":"Xeomin; Bocouture","therapeutic_area":"Neurology;Ophthalmology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of sialorrhoea","routes_of_administration":"Intraglandular use;Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/03/2020","compliance_outcome":"Positive","compliance_opinion_date":"24/07/2020","compliance_procedure_number":"EMEA-C-001039-PIP02-12-M04","contact_for_public_enquiries":"Merz Pharmaceuticals GmbH; Tel. +49 6915031; E-mail: contact@merz.de","first_published_date":"09/08/2013","last_updated_date":"16/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001039-pip02-12-m04"},{"decision_number":"P/0271/2019","pip_number":"EMEA-001113-PIP01-10-M06","active_substance":"Delamanid","invented_name":"Deltyba; Deltyba","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Dispersible tablet","condition_indication":"Treatment of multi-drug-resistant tuberculosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/08/2019","compliance_outcome":"Positive","compliance_opinion_date":"24/07/2020","compliance_procedure_number":"EMEA-C-001113-PIP01-10-M06","contact_for_public_enquiries":"Otsuka Pharmaceutical Development & Commercialisation Europe GmbH; Tel. +49 6995 5044321; E-mail: paediatric-info@otsuka.de","first_published_date":"21/12/2011","last_updated_date":"16/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001113-pip01-10-m06"},{"decision_number":"P/0161/2018","pip_number":"EMEA-001264-PIP01-12-M02","active_substance":"spheroids of human autologous matrix-associated chondrocytes","invented_name":"Spherox","therapeutic_area":"Other","pharmaceutical_forms":"Implantation suspension","condition_indication":"Treatment of cartilage disorders","routes_of_administration":"Intra-articular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/06/2018","compliance_outcome":"Positive","compliance_opinion_date":"24/07/2020","compliance_procedure_number":"EMEA-C-001264-PIP01-12-M02","contact_for_public_enquiries":"CO.DON AG; Tel.  +49 30240352330; E-mail: pr@codon.de","first_published_date":"11/01/2013","last_updated_date":"16/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001264-pip01-12-m02"},{"decision_number":"P/0176/2013","pip_number":"EMEA-001391-PIP01-12","active_substance":"glucarpidase","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of methotrexate toxicity","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"30/07/2013","compliance_outcome":"Positive","compliance_opinion_date":"24/07/2020","compliance_procedure_number":"EMEA-C-001391-PIP01-12","contact_for_public_enquiries":"BTG International Ltd ; United Kingdom ; E-mail: ashley.tapp@btgplc.com ; Tel. +44 (0)20 7575 0000","first_published_date":"03/09/2013","last_updated_date":"16/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001391-pip01-12"},{"decision_number":"P/0151/2019","pip_number":"EMEA-001438-PIP01-13-M01","active_substance":"idarucizumab","invented_name":"Praxbind; Praxbind","therapeutic_area":"Other","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Prevention of dabigatran associated haemorrhage;Treatment of dabigatran associated haemorrhage","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/04/2019","compliance_outcome":"Positive","compliance_opinion_date":"24/07/2020","compliance_procedure_number":"EMEA-C-001438-PIP01-13-M01","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"16/04/2014","last_updated_date":"16/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001438-pip01-13-m01"},{"decision_number":"P/0290/2018","pip_number":"EMEA-001244-PIP01-11-M02","active_substance":"autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ATP-binding cassette, sub-family D (ALD), member 1 (ABCD1) from cDNA","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of adrenoleukodystrophy","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/09/2018","compliance_outcome":"Positive","compliance_opinion_date":"04/09/2020","compliance_procedure_number":"EMEA-C-001244-PIP01-11-M02","contact_for_public_enquiries":"Bluebird bio France; Tel. +1 41 415615437; E-mail: CDeCoster@bluebirdio.com","first_published_date":"21/06/2013","last_updated_date":"16/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001244-pip01-11-m02"},{"decision_number":"P/0211/2018","pip_number":"EMEA-001782-PIP01-15-M03","active_substance":"Influenza virus surface antigens (haemagglutinin and neuraminidase) of the following strains: A/(H1N1), A/(H3N2), B/Yamagata lineage, B/Victoria lineage","invented_name":"Influvac Tetra","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of influenza infection","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/07/2018","compliance_outcome":"Positive","compliance_opinion_date":"04/09/2020","compliance_procedure_number":"EMEA-C-001782-PIP01-15-M03","contact_for_public_enquiries":"Abbott Biologicals B.V.Email: hind.ounis@abbott.comTel. +41 6148 70374","first_published_date":"24/09/2015","last_updated_date":"16/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001782-pip01-15-m03"},{"decision_number":"P/0006/2020","pip_number":"EMEA-001822-PIP01-15-M01","active_substance":"sofosbuvir;velpatasvir;voxilaprevi","invented_name":"Vosevi","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of chronic hepatitis C","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/01/2020","compliance_outcome":"Positive","compliance_opinion_date":"16/10/2020","compliance_procedure_number":"EMEA-C-001822-PIP01-15-M01","contact_for_public_enquiries":"Gilead Sciences Ireland UC; E-mail: regulatory.pip@gilead.com; Tel. +44 1223897300","first_published_date":"02/06/2016","last_updated_date":"16/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001822-pip01-15-m01"},{"decision_number":"P/0264/2019","pip_number":"EMEA-001853-PIP01-15-M02","active_substance":"human normal immunoglobulin","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Primary Immunodeficiency (PID)","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/11/2019","compliance_outcome":"Positive","compliance_opinion_date":"13/11/2020","compliance_procedure_number":"EMEA-C-001853-PIP01-15-M02","contact_for_public_enquiries":"Grifols Therapeutics Inc.; Tel. +49 69660593405; E-mail: bernhard.lauven@grifols.com","first_published_date":"02/06/2016","last_updated_date":"16/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001853-pip01-15-m02"},{"decision_number":"P/0008/2017","pip_number":"EMEA-000294-PIP02-12-M01","active_substance":"idursulfase","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of mucopolysaccharidosis II (Hunter syndrome)","routes_of_administration":"Intrathecal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/01/2017","compliance_outcome":"Positive","compliance_opinion_date":"11/12/2020","compliance_procedure_number":"EMEA-C-000294-PIP02-12-M01","contact_for_public_enquiries":"Shire Human Genetic Therapies AB; United States; Tel. +1 7814826558; E-mail: dalexanderia@shire.com","first_published_date":"08/10/2013","last_updated_date":"16/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000294-pip02-12-m01"},{"decision_number":"P/0086/2020","pip_number":"EMEA-000694-PIP01-09-M08","active_substance":"dapagliflozin","invented_name":"Forxiga","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/03/2020","compliance_outcome":"Positive","compliance_opinion_date":"11/12/2020","compliance_procedure_number":"EMEA-C-000694-PIP01-09-M08","contact_for_public_enquiries":"AstraZeneca AB (Sweden); Tel. +46 8 5532791; E-mail: paediatrics@astrazeneca.com","first_published_date":"29/07/2010","last_updated_date":"16/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000694-pip01-09-m08"},{"decision_number":"P/0289/2016","pip_number":"EMEA-000718-PIP01-09-M06","active_substance":"riociguat","invented_name":"Adempas; Adempas","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet;Oral liquid","condition_indication":"Treatment of pulmonary hypertension","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/11/2016","compliance_outcome":"Positive","compliance_opinion_date":"11/12/2020","compliance_procedure_number":"EMEA-C-000718-PIP01-09-M06","contact_for_public_enquiries":"Bayer Pharma AG; Germany; Tel. +49 3030 0139003; Fax +49 3046 895333; E-mail: clinical-trials-contact@bayer.com","first_published_date":"03/10/2011","last_updated_date":"16/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000718-pip01-09-m06"},{"decision_number":"P/0255/2017","pip_number":"EMEA-001604-PIP01-13-M03","active_substance":"grazoprevir;elbasvir","invented_name":"Zepatier; Zepatier","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Granules","condition_indication":"Treatment of chronic hepatitis C","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/09/2017","compliance_outcome":"Positive","compliance_opinion_date":"11/12/2020","compliance_procedure_number":"EMEA-C-001604-PIP01-13-M03","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"05/03/2015","last_updated_date":"16/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001604-pip01-13-m03"},{"decision_number":"P/0214/2017","pip_number":"EMEA-001203-PIP02-14-M02","active_substance":"Coagulation Factor VIIa (Recombinant)","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of acquired haemophilia;Treatment of congenital coagulation disorders","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/08/2017","compliance_outcome":"Positive","compliance_opinion_date":"04/09/2020","compliance_procedure_number":"EMEA-C-001203-PIP02-14-M02","contact_for_public_enquiries":"LFB SA; France; Tel. +33 169827344; E-mail: nogierm@lfb.fr","first_published_date":"23/03/2015","last_updated_date":"16/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001203-pip02-14-m02"},{"decision_number":"P/0275/2020","pip_number":"EMEA-002692-PIP01-19","active_substance":"Lonapegsomatropin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of growth hormone deficiency","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/07/2020","compliance_outcome":"","compliance_opinion_date":"04/09/2020","compliance_procedure_number":"EMEA-C-002692-PIP01-19","contact_for_public_enquiries":"Ascendis Pharma Endocrinology Division A/S; E-mail: MedicalAffairs@ascendispharma.com; Tel. +45 70222244","first_published_date":"16/06/2021","last_updated_date":"16/09/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002692-pip01-19"},{"decision_number":"P/0398/2020","pip_number":"EMEA-002645-PIP02-20","active_substance":"sacituzumab govitecan","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder and solvent for solution for infusion","condition_indication":"Treatment of urothelial carcinoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/10/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Immunomedics GmbH; E-mail: Regulatory.Pip@gilead.com; Tel: +44 1223897300","first_published_date":"09/09/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002645-pip02-20"},{"decision_number":"P/0345/2021","pip_number":"EMEA-002940-PIP01-20","active_substance":"molnupiravir","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Capsule, hard;Age appropriate dosage form, other","condition_indication":"Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Oral use;Gastric use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"12/08/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"19/08/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002940-pip01-20"},{"decision_number":"P/0444/2020","pip_number":"EMEA-000694-PIP05-20","active_substance":"dapagliflozin","invented_name":"Forxiga","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel. +46 8553 27591","first_published_date":"19/08/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000694-pip05-20"},{"decision_number":"P/0412/2020","pip_number":"EMEA-002721-PIP02-20","active_substance":"tiragolumab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for suspension for infusion","condition_indication":"Treatment of cervical cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/10/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"04/08/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002721-pip02-20"},{"decision_number":"P/0409/2020","pip_number":"EMEA-002721-PIP03-20","active_substance":"tiragolumab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for suspension for infusion","condition_indication":"Treatment of oesophageal carcinoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/10/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"04/08/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002721-pip03-20"},{"decision_number":"P/0426/2020","pip_number":"EMEA-002694-PIP01-19","active_substance":"mixture of 2 synthetic double-stranded N-Acetyl-galactosamine conjugated siRNA oligonucleotides that are directed against hepatitis B virus (JNJ-73763989)","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Solution for injection;Age appropriate dosage form for parenteral use","condition_indication":"Treatment of chronic viral hepatitis B","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"23/10/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Ltd; Tel. +1 4388998201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"28/07/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002694-pip01-19"},{"decision_number":"P/0389/2020","pip_number":"EMEA-001481-PIP01-13-M04","active_substance":"peanut allergen extract","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Cutaneous patch","condition_indication":"Treatment of peanut allergy","routes_of_administration":"Cutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/10/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"DBV Technologies S.A.; Tel. +33 15559 78 94; E-mail: clindev@dbv-technologies.com;  ","first_published_date":"23/07/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001481-pip01-13-m04"},{"decision_number":"P/0408/2020","pip_number":"EMEA-002691-PIP02-20","active_substance":"Brolucizumab","invented_name":"Beovu","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of diabetic retinopathy","routes_of_administration":"Intravitreal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/10/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"22/07/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002691-pip02-20"},{"decision_number":"P/0422/2020","pip_number":"EMEA-002837-PIP01-20","active_substance":"colchicine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Prevention of cardiovascular events","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/10/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Disphar International B.V.; E-mail: ra@disphar.com; Tel: +31 355280400","first_published_date":"22/07/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002837-pip01-20"},{"decision_number":"P/0396/2020","pip_number":"EMEA-002836-PIP01-20","active_substance":"recombinant humanised monoclonal antibody (IgG1, Kappa) to IL-5","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of asthma","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/10/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; E-mail: eu.paediatric-plans@gsk.com; Tel: +44 2080476613","first_published_date":"22/07/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002836-pip01-20"},{"decision_number":"P/0405/2020","pip_number":"EMEA-002835-PIP01-20","active_substance":"fenofibrate;Pravastatin sodium;ezetimibe","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of mixed hyperlipidaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/10/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Laboratoires SMB S.A.; E-mail: regulatory@smb.be; Tel: +32 24114828","first_published_date":"22/07/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002835-pip01-20"},{"decision_number":"P/0411/2020","pip_number":"EMEA-002823-PIP01-20","active_substance":"autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human B cell maturation antigen with 4-1BB and CD3-zeta intracellular signalling domains (CT053)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Suspension for infusion","condition_indication":"Treatment of Multiple Myeloma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/10/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CARsgen Therapeutics Corporation; E-mail: RegulatoryUS@carsgen.com; Tel: +1 3462939390","first_published_date":"22/07/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002823-pip01-20"},{"decision_number":"P/0414/2020","pip_number":"EMEA-002507-PIP02-19","active_substance":"recombinant human granulocyte colony-stimulating factor – human immunoglobulin Fc fusion protein (rhG-CSF-Fc)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of chemotherapy-induced febrile neutropenia;Treatment of chemotherapy-induced neutropenia","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"23/10/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Generon (Shanghai) Corporation; Email: xiaoch@generonbiomed.com; Tel: +86 2161760866;  ","first_published_date":"22/07/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002507-pip02-19"},{"decision_number":"P/0394/2020","pip_number":"EMEA-001501-PIP06-20","active_substance":"dupilumab","invented_name":"Dupixent","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of prurigo nodularis","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/10/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi-Aventis Recherche & Développement; Tel. +33 169745695; E-mail: contact-us@sanofi.com","first_published_date":"22/07/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001501-pip06-20"},{"decision_number":"P/0413/2020","pip_number":"EMEA-002811-PIP01-20","active_substance":"alpha-R-lipoic acid choline ester tosilate","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops","condition_indication":"Treatment of presbyopia","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/10/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"22/07/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002811-pip01-20"},{"decision_number":"P/0390/2020","pip_number":"EMEA-002794-PIP01-20","active_substance":"ramipril;Bisoprolol fumarate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of coronary artery disease;Treatment of heart failure;Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/10/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Adamed Pharma S.A.E-mail: agnieszka.leszczynska@adamed.comTel:  + 48 532512603","first_published_date":"22/07/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002794-pip01-20"},{"decision_number":"P/0354/2020","pip_number":"EMEA-001418-PIP01-13-M02","active_substance":"cabotegravir","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Tablet;Suspension for injection;Age appropriate oral dosage formulation","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use;Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ViiV Healthcare UK LimitedE-mail: eu.paediatric-plans@gsk.com Tel: +1 4388998201","first_published_date":"04/12/2014","last_updated_date":"09/07/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001418-pip01-13-m02"},{"decision_number":"P/0376/2020","pip_number":"EMEA-000452-PIP02-10-M06","active_substance":"tadalafil","invented_name":"Cialis; Adcirca (previously Tadalafil Lilly); Adcirca; Cialis","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet;Oral suspension","condition_indication":"Treatment of pulmonary arterial hypertension","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"09/06/2011","last_updated_date":"08/07/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000452-pip02-10-m06"},{"decision_number":"P/0363/2020","pip_number":"EMEA-002559-PIP03-19","active_substance":"anti-neonatal Fe receptor human monoclonal antibody {M281)","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Concentrate for solution for infusion;Solution for infusion","condition_indication":"Treatment of autoimmune haemolytic aneamia","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Momenta Pharmaceuticals, Inc.; E-mail: byork@momentapharma.com; Tel. +1 6173954994","first_published_date":"06/07/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002559-pip03-19"},{"decision_number":"P/0369/2020","pip_number":"EMEA-002581-PIP01-19","active_substance":"emixustat hydrochloride","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Age appropriate oral solid dosage form;Tablet","condition_indication":"Treatment of Stargardt disease","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kubota Pharmaceutical Holdings Co. Limited; E-mail: ClinicalTrials@acucela.com; Tel. +1 2068058310","first_published_date":"06/07/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002581-pip01-19"},{"decision_number":"P/0366/2020","pip_number":"EMEA-002206-PIP02-19","active_substance":"rebisufligene etisparvovec","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ultragenyx Germany GmbH; E-mail: medinfo@ultragenyx.com; Tel. : +4930590083651","first_published_date":"06/07/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002206-pip02-19"},{"decision_number":"P/0368/2020","pip_number":"EMEA-002054-PIP02-18","active_substance":"odevixibat","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Age appropriate oral liquid dosage formulation;Capsule, hard","condition_indication":"Treatment of biliary atresia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Albireo AB; Tel. +46 31741 14 80; E-mail: info@albireopharma.com","first_published_date":"06/07/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002054-pip02-18"},{"decision_number":"P/0385/2020","pip_number":"EMEA-001799-PIP03-19","active_substance":"the whole range of unmanipulated autologous mononuclear cells derived from human umbilical cord blood (Hau-UCB-mnc)","invented_name":"","therapeutic_area":"Neonatology-Paediatric Intensive Care","pharmaceutical_forms":"Suspension for infusion","condition_indication":"Treatment of periventricular leukomalacia","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"25/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BrainRepair UG (haftungsbeschränkt); E-mail: arne.jensen@brainrepair.eu​​​​​​​; Tel. +49 2345881960","first_published_date":"06/07/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001799-pip03-19"},{"decision_number":"P/0378/2020","pip_number":"EMEA-001613-PIP02-20","active_substance":"tezepelumab","invented_name":"","therapeutic_area":"Oto-rhino-laryngology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of nasal polyposis","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel. +46 8553 27591","first_published_date":"06/07/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001613-pip02-20"},{"decision_number":"P/0344/2020","pip_number":"EMEA-000643-PIP02-20","active_substance":"Dronabinol","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of spasticity","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bionorica Ethics GmbH; E-mail: info@bionorica-ethics.de; Tel. +49 91812317490","first_published_date":"06/07/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000643-pip02-20"},{"decision_number":"P/0358/2020","pip_number":"EMEA-002305-PIP01-17-M01","active_substance":"hydrocortisone (hemisuccinate)","invented_name":"","therapeutic_area":"Neonatology-Paediatric Intensive Care","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Prevention of bronchopulmonary dysplasia","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Laboratoire Aguettant; E-mail: infoscientifique@aguettant.fr; Tel. +33 478615141","first_published_date":"03/04/2020","last_updated_date":"02/07/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002305-pip01-17-m01"},{"decision_number":"P/0356/2020","pip_number":"EMEA-001999-PIP02-17-M01","active_substance":"cenicriviroc","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Age appropriate oral liquid dosage formulation;Film-coated tablet","condition_indication":"Treatment of non-alcoholic steatohepatitis (NASH)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergan Pharmaceuticals International Limited; E-mail: UK_Medinfo@allergan.com; Tel: +44 1628494026","first_published_date":"14/02/2019","last_updated_date":"01/07/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001999-pip02-17-m01"},{"decision_number":"P/0349/2020","pip_number":"EMEA-001902-PIP01-15-M04","active_substance":"andexanet alfa","invented_name":"Ondexxya","therapeutic_area":"Other","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Prevention of factor Xa inhibitor associated haemorrhage;Treatment of factor Xa inhibitor associated haemorrhage","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca ABEmail: paediatrics@astrazeneca.comTel. +46 855324400","first_published_date":"22/09/2016","last_updated_date":"01/07/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001902-pip01-15-m04"},{"decision_number":"P/0355/2020","pip_number":"EMEA-001715-PIP01-14-M04","active_substance":"Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2);Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Yamagata lineage);Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Victoria lineage);Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H1N1)","invented_name":"Fluad Tetra","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of influenza infection","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Seqirus Netherlands B.V.; Tel. +31 646951054; E-mail: pip.seq@seqirus.com","first_published_date":"26/08/2016","last_updated_date":"01/07/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001715-pip01-14-m04"},{"decision_number":"P/0345/2020","pip_number":"EMEA-002832-PIP01-20","active_substance":"ranibizumab","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of diabetic retinopathy","routes_of_administration":"Implant use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"01/07/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002832-pip01-20"},{"decision_number":"P/0348/2020","pip_number":"EMEA-002831-PIP01-20","active_substance":"rosuvastatin calcium;acetylsalicylic acid","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Prevention of cardiovascular events","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"IBSA Farmaceutici Italia s.r.l.; E-mail: regolatorio@skillpharma.com; Tel: +39 0645479408","first_published_date":"01/07/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002831-pip01-20"},{"decision_number":"P/0352/2020","pip_number":"EMEA-002825-PIP01-20","active_substance":"Cluster of differentiation 40 (CD40) ligand antagonist comprising two identical Tn3 modules fused to human serum albumin, with each Tn3 module being an engineered form of the third fibronectin type III protein domain of human Tenascin C (VIB4920)","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Sjögren's syndrome","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Viela Bio Inc; E-mail: berzinsm@vielabio.com; Tel: +1 2405580038 X234","first_published_date":"01/07/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002825-pip01-20"},{"decision_number":"P/0338/2020","pip_number":"EMEA-002816-PIP01-20","active_substance":"Icosabutate","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Age appropriate oral solid dosage form;Capsule","condition_indication":"Treatment of non-alcoholic fatty liver disease including non-alcoholic steatohepatitis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"NorthSea Therapeutics BV; E-mail: patrick.round@northseatherapeutics.com; Tel: +44 7979502770","first_published_date":"01/07/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002816-pip01-20"},{"decision_number":"P/0337/2020","pip_number":"EMEA-002800-PIP01-20","active_substance":"Linerixibat","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of primary biliary cholangitis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline (Ireland) Limited; E-mail: eu.paediatric-plans@gsk.com; Tel.: +44 2089903650","first_published_date":"01/07/2021","last_updated_date":"01/07/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002800-pip01-20"},{"decision_number":"P/0348/2018","pip_number":"EMEA-001904-PIP02-17","active_substance":"brincidofovir","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Oral suspension;Film-coated tablet","condition_indication":"Treatment of adenovirus in immunocompromised patients","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"16/11/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"SymBio Pharmaceuticals Limited; E-mail: mkano.mk11@symbiopharma.com; Tel. +818039323354","first_published_date":"20/02/2019","last_updated_date":"01/07/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001904-pip02-17"},{"decision_number":"P/0288/2019","pip_number":"EMEA-002559-PIP01-19","active_substance":"anti-neonatal Fc receptor human monoclonal antibody","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Concentrate for solution for infusion;Solution for injection","condition_indication":"Prevention of haemolytic disease of the foetus and newborn","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/08/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; Tel. +32 1460 2111; E-mail: contact@janssen-emea.com","first_published_date":"20/11/2019","last_updated_date":"01/07/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002559-pip01-19"},{"decision_number":"P/0117/2020","pip_number":"EMEA-002559-PIP02-19","active_substance":"anti-neonatal Fc receptor human monoclonal antibody","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Solution for infusion;Concentrate for solution for infusion","condition_indication":"Treatment of myasthenia gravis","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"18/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; Tel. +32 1460 2111; E-mail: contact@janssen-emea.com","first_published_date":"29/07/2020","last_updated_date":"01/07/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002559-pip02-19"},{"decision_number":"P/0319/2018","pip_number":"EMEA-002266-PIP01-17","active_substance":"recombinant human acid ceramidase (RVT-801)","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Solution for infusion","condition_indication":"Farber disease","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"12/09/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aceragen Inc.; Tel. +15182583364; E-mail: regulatory@aceragen.com","first_published_date":"17/01/2019","last_updated_date":"30/06/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002266-pip01-17"},{"decision_number":"P/0322/2020","pip_number":"EMEA-002101-PIP02-18-M01","active_substance":"iodine (131-I) murine IgG1 monoclonal antibody against B7-H3 (131I-omburtamab)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of neuroblastoma","routes_of_administration":"Intracerebral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Y-mAbs Therapeutics A/S; E-mail: jow@ymabs.com; Tel. +45 70261414","first_published_date":"02/04/2020","last_updated_date":"30/06/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002101-pip02-18-m01"},{"decision_number":"P/0327/2020","pip_number":"EMEA-001992-PIP02-16-M01","active_substance":"lenadogene nolparvovec","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of Leber Hereditary Optic Neuropathy","routes_of_administration":"Intravitreal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GenSight-Biologics; E-mail: mtaiel@gensight-biologics.com; Tel. +33 176217226","first_published_date":"03/03/2021","last_updated_date":"30/06/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001992-pip02-16-m01"},{"decision_number":"P/0283/2020","pip_number":"EMEA-002122-PIP02-17-M01","active_substance":"oenasufligene relduparvovec","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)","routes_of_administration":"Intracerebral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Lysogene; E-mail: contact@lysogene.com; Tel. +33 141430390","first_published_date":"19/06/2018","last_updated_date":"30/06/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002122-pip02-17-m01"},{"decision_number":"P/0300/2020","pip_number":"EMEA-001903-PIP01-15-M01","active_substance":"Efpeglenatide","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Subcutaneous use","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Solution for injection","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"JVM Europe B.V; E-mail: contact-us@sanofi.com; Tel. +33 1 60 49 66 82","first_published_date":"29/10/2019","last_updated_date":"30/06/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001903-pip01-15-m01"},{"decision_number":"P/0301/2020","pip_number":"EMEA-001657-PIP01-14-M01","active_substance":"Glucagon","invented_name":"Baqsimi","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Nasal powder","condition_indication":"Treatment of hypoglycaemia","routes_of_administration":"Intranasal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"24/09/2015","last_updated_date":"30/06/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001657-pip01-14-m01"},{"decision_number":"P/0288/2020","pip_number":"EMEA-001440-PIP01-13-M03","active_substance":"ombitasvir;paritaprevir;ritonavir","invented_name":"Viekirax; Viekirax","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of chronic hepatitis C","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.com Tel. +44 (0)7341101902","first_published_date":"05/02/2014","last_updated_date":"30/06/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001440-pip01-13-m03"},{"decision_number":"P/0357/2020","pip_number":"EMEA-002799-PIP01-20","active_substance":"live attenuated poliovirus type 1;live attenuated poliovirus type 3","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Oral suspension for use in drinking water","condition_indication":"Prevention of poliomyelitis viral infection","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bilthoven Biologicals; E-mail: jacqueline.middel@bbio.nl; Tel: +31 308004800","first_published_date":"30/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002799-pip01-20"},{"decision_number":"P/0336/2020","pip_number":"EMEA-002798-PIP01-20","active_substance":"retifanlimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of squamous carcinoma of the anal canal","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Incyte Biosciences Distribution B.V.; E-mail: globalmedinfo@incyte.com; Tel. +800 0002 7423","first_published_date":"30/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002798-pip01-20"},{"decision_number":"P/0360/2020","pip_number":"EMEA-002784-PIP01-20","active_substance":"fruquintinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of colorectal carcinoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Hutchison MediPharma Ltd; E-mail: marjoh@hmplglobal.com; Tel: +358 408425802","first_published_date":"30/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002784-pip01-20"},{"decision_number":"P/0276/2020","pip_number":"EMEA-002065-PIP01-16-M03","active_substance":"Crisaborole","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Ointment","condition_indication":"Treatment of atopic dermatitis","routes_of_administration":"Topical use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/07/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG; Tel. +44 (0)1304 646 607; E-mail: pip_enquiries@pfizer.com","first_published_date":"12/02/2018","last_updated_date":"29/06/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002065-pip01-16-m03"},{"decision_number":"P/0289/2020","pip_number":"EMEA-001439-PIP01-13-M03","active_substance":"Dasabuvir (sodium monohydrate)","invented_name":"Exviera; Exviera","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of chronic hepatitis C","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.com Tel. +44 (0)7341101902","first_published_date":"05/02/2014","last_updated_date":"28/06/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001439-pip01-13-m03"},{"decision_number":"P/0305/2020","pip_number":"EMEA-001202-PIP02-13-M04","active_substance":"reslizumab","invented_name":"Cinqaero","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Concentrate for solution for infusion;Solution for injection","condition_indication":"Treatment of asthma","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Teva Pharmaceuticals Europe; Tel. +44 (0)20 7540 7117; E-mail: medinfo@tevauk.com","first_published_date":"05/03/2015","last_updated_date":"28/06/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001202-pip02-13-m04"},{"decision_number":"P/0324/2020","pip_number":"EMEA-000332-PIP01-08-M15","active_substance":"Brivaracetam","invented_name":"Briviact (in Italy: Nubriveo); QG01AA01","therapeutic_area":"Neurology","pharmaceutical_forms":"Film-coated tablet;Oral solution;Solution for injection","condition_indication":"Treatment of epilepsy with partial-onset seizures;Treatment of neonatal seizures","routes_of_administration":"Oral use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"UCB Pharma S.A.; E-mail: UCBCares.IE@ucb.com; Tel. +353 1463 2371","first_published_date":"17/10/2011","last_updated_date":"28/06/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000332-pip01-08-m15"},{"decision_number":"P/0269/2020","pip_number":"EMEA-001072-PIP01-10-M04","active_substance":"alemtuzumab","invented_name":"Lemtrada; Lemtrada","therapeutic_area":"Neurology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of multiple sclerosis","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/07/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Genzyme Europe B.V.; Tel: +49 (0) 800 52 52 010; E-mail: medinfo.de@sanofi.com","first_published_date":"19/01/2012","last_updated_date":"25/06/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001072-pip01-10-m04"},{"decision_number":"P/0303/2020","pip_number":"EMEA-002655-PIP02-20","active_substance":"half-life extended bispecific T-cell engager (BiTE) antibody construct that binds to prostate-specific membrane antigen and cluster of differentiation 3, with a single chain fragment crystallizable moiety","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of prostate cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe BV; E-mail: medinfointernational@amgen.com; Tel. +44 (0)1223 420305","first_published_date":"24/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002655-pip02-20"},{"decision_number":"P/268/2010","pip_number":"EMEA-000420-PIP01-10","active_substance":"duloxetine hydrochloride","invented_name":"Ariclaim; Yentreve; Nodetrip (previously Xeristar); Cymbalta; Cymbalta; Xeristar; Yentreve; Ariclaim","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Capsule, hard;Gastro-resistant capsule","condition_indication":"Treatment of chronic pain;Treatment of diabetic neuropathic pain;Treatment of generalised anxiety disorder;Treatment of major depressive disorder;Treatment of stress urinary incontinence","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"21/12/2010","last_updated_date":"22/06/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000420-pip01-10"},{"decision_number":"P/0333/2020","pip_number":"EMEA-002817-PIP04-20","active_substance":"Faricimab","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of retinal vein occlusion","routes_of_administration":"Intravitreal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbH; E-mail: global.eu_regulatory_office@roche.comTel. +49 7624142892","first_published_date":"22/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002817-pip04-20"},{"decision_number":"P/0332/2020","pip_number":"EMEA-002817-PIP03-20","active_substance":"Faricimab","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of diabetic retinopathy","routes_of_administration":"Intravitreal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbH; E-mail: global.eu_regulatory_office@roche.comTel. +49 7624142892","first_published_date":"22/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002817-pip03-20"},{"decision_number":"P/0323/2020","pip_number":"EMEA-002792-PIP01-20","active_substance":"prolgolimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of non-small cell lung cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"JSC \"BIOCAD\"; E-mail: paediatric@biocad.ru; Tel:  +7 8123804933","first_published_date":"22/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002792-pip01-20"},{"decision_number":"P/0286/2020","pip_number":"EMEA-002805-PIP01-20","active_substance":"Pravastatin sodium;ezetimibe","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Prevention of cardiovascular events;Treatment of hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Laboratoires SMB S.A.; E-mail: regulatory@smb.be; Tel: +32 24114828","first_published_date":"22/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002805-pip01-20"},{"decision_number":"P/0287/2020","pip_number":"EMEA-002797-PIP01-20","active_substance":"oportuzumab monatox","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Intravesical solution","condition_indication":"Treatment of urothelial carcinoma","routes_of_administration":"Intravesical use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sesen Bio, Inc; E-mail: glen.macdonald@sesenbio.com; Tel: +1 2042903131","first_published_date":"22/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002797-pip01-20"},{"decision_number":"P/0297/2020","pip_number":"EMEA-002718-PIP02-20","active_substance":"balixafortide","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of breast cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Polyphor Deutschland GmbH; E-mail: francois.ringeisen@polyphor.com; Tel. +41 615671626","first_published_date":"22/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002718-pip02-20"},{"decision_number":"P/0290/2020","pip_number":"EMEA-002777-PIP01-20","active_substance":"sasanlimab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection;Solution for injection in pre-filled syringe","condition_indication":"Treatment of ureter and bladder carcinoma","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG; Tel. +44 (0)1304 646 607; E-mail: pip_enquiries@pfizer.com","first_published_date":"22/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002777-pip01-20"},{"decision_number":"P/0244/2020","pip_number":"EMEA-002789-PIP01-20","active_substance":"niraparib (tosilate monohydrate);abiraterone acetate","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of prostate malignant neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/07/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen Research & Development; Tel. +353 857446696; E-mail: nbuhl@its.jnj.com","first_published_date":"21/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002789-pip01-20"},{"decision_number":"P/0308/2020","pip_number":"EMEA-002537-PIP02-19","active_substance":"darunavir;ritonavir","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"12/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"PharOS - Pharmaceutical Orientated Services Ltd; E-mail: emakrodouli@pharosgr.gr; E-mail: ngialou@pharosgr.gr; Tel: +30 2106664667","first_published_date":"18/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002537-pip02-19"},{"decision_number":"P/0315/2020","pip_number":"EMEA-000316-PIP03-20","active_substance":"sacubitril;valsartan","invented_name":"Entresto","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Age appropriate oral solid dosage form;Film-coated tablet;Granules","condition_indication":"Prevention of heart failure","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"18/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000316-pip03-20"},{"decision_number":"P/0304/2020","pip_number":"EMEA-001501-PIP05-20","active_substance":"dupilumab","invented_name":"Dupixent","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of bullous pemphigoid","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Regeneron Ireland DAC; Tel. +1 9148 475385; E-mail: clinicaltrials@regeneron.com","first_published_date":"18/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001501-pip05-20"},{"decision_number":"P/0314/2020","pip_number":"EMEA-001214-PIP06-20","active_substance":"Benralizumab","invented_name":"Fasenra","therapeutic_area":"Dermatology","pharmaceutical_forms":"Age appropriate dosage form for parenteral use;Solution for injection","condition_indication":"Treatment of bullous pemphigoid","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/08/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel.  +46 855326000;  ","first_published_date":"18/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001214-pip06-20"},{"decision_number":"P/0264/2020","pip_number":"EMEA-002546-PIP01-19","active_substance":"tominersen","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Huntington's disease","routes_of_administration":"Intrathecal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/07/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"18/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002546-pip01-19-0"},{"decision_number":"P/0245/2020","pip_number":"EMEA-002786-PIP01-20","active_substance":"Icosasodium{26-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-14,14-bis{[(3-{6-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]hexyl}amino)-3-oxopropoxy)]methyl}-8,12,19-trioxo-16-oxa-7,13,20-triazahexacosyl}2′-O-(2-methoxyethyl...","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of cardiovascular events due to atherosclerotic cardiovascular disease in patients with elevated lipoprotein(a)","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/07/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"17/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002786-pip01-20"},{"decision_number":"P/0249/2020","pip_number":"EMEA-002617-PIP02-19","active_substance":"ravagalimab","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of Sjögren's syndrome","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/07/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628 561 090","first_published_date":"17/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002617-pip02-19"},{"decision_number":"P/0265/2020","pip_number":"EMEA-002542-PIP02-19","active_substance":"sutimlimab","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of immune thromboctyopenia purpura","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/07/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Genzyme Europe B.V.; Tel. +31 (0) 20 245 3917; E-mail: EUmedinfo@genzyme.com;  ","first_published_date":"17/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002542-pip02-19"},{"decision_number":"P/0251/2020","pip_number":"EMEA-002202-PIP02-20","active_substance":"rosuvastatin;ezetimibe","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/07/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Krka, d.d., Novo mesto; Slovenia; Tel. +386 73319037; Fax +386 73322742; E-mail: dragan.priselac@krka.biz","first_published_date":"17/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002202-pip02-20"},{"decision_number":"P/0095/2020","pip_number":"EMEA-001964-PIP02-19","active_substance":"cannabidiol","invented_name":"Epidyolex","therapeutic_area":"Neurology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of Rett syndrome","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"18/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GW Pharma (International) B.V.; E-mail: info@gwpharm.com; Tel: +44 1223266800","first_published_date":"17/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001964-pip02-19"},{"decision_number":"P/0221/2021","pip_number":"EMEA-002952-PIP01-21","active_substance":"bamlanivimab","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/06/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly and Company LtdE-mail: eu_paediatric@lilly.com Phone: +44 1256315000","first_published_date":"17/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002952-pip01-21"},{"decision_number":"P/0214/2021","pip_number":"EMEA-002966-PIP01-21","active_substance":"Etesevimab","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Coronavirus disease 2019 (COVID-19)","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/06/2021","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly and Company LtdE-mail: eu_paediatric@lilly.com Phone: +44 1256315000","first_published_date":"17/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002966-pip01-21"},{"decision_number":"P/0280/2020","pip_number":"EMEA-001407-PIP03-20","active_substance":"nivolumab","invented_name":"Opdivo","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of all conditions in the category of malignant neoplasms (except central nervous system neoplasms, haematopoietic and lymphoid tissue neoplasms other than Hodgkin lymphoma)","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/07/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"17/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001407-pip03-20"},{"decision_number":"P/0246/2020","pip_number":"EMEA-002783-PIP01-20","active_substance":"neratinib","invented_name":"Nerlynx","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of breast cancer","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/07/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pierre Fabre Médicament; E-mail: medical_information@pierre-fabre.com; Tel. +33 800326326","first_published_date":"16/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002783-pip01-20"},{"decision_number":"P/0261/2020","pip_number":"EMEA-002768-PIP01-20","active_substance":"Bisoprolol fumarate;trimetazidine (dihydrochloride)","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of ischaemic coronary artery disorders","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/07/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires Servier; E-mail: mail.pip.enquiries@servier.com; Tel. +1 55727275","first_published_date":"16/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002768-pip01-20"},{"decision_number":"P/0260/2020","pip_number":"EMEA-002769-PIP01-20","active_substance":"human fibrinogen","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of congenital fibrinogen deficiency","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/07/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Instituto Grifols, S.A.E-mail: areatecnica.instituto@grifols.comTel. +34 935710700","first_published_date":"16/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002769-pip01-20"},{"decision_number":"P/0259/2020","pip_number":"EMEA-002781-PIP01-20","active_substance":"Humanised Antibody Targeting the Inducible T cell Co-Stimulatory receptor","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of head and neck epithelial malignant neoplasms","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/07/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline (Ireland) Limited; E-mail: eu.paediatric-plans@gsk.com; Tel.: +44 2089903650","first_published_date":"16/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002781-pip01-20"},{"decision_number":"P/0248/2020","pip_number":"EMEA-002623-PIP01-19","active_substance":"ondansetron (hydrochloride)","invented_name":"","therapeutic_area":"Neurology;Other","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of alcohol use disorder","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/07/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Adial Pharmaceuticals; E-mail: info@adialpharma.com; Tel. +1 4344229800","first_published_date":"16/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002623-pip01-19"},{"decision_number":"P/0247/2020","pip_number":"EMEA-002732-PIP02-20","active_substance":"sitagliptin (hydrochloride monohydrate);metformin hydrochloride","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Modified-release tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/07/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Adamed Pharma S.A.; E-mail: joanna.bokus@adamed.com; Tel. +48 513000208","first_published_date":"16/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002732-pip02-20"},{"decision_number":"P/0263/2020","pip_number":"EMEA-002761-PIP01-20","active_substance":"Insulin 287","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of type I diabetes mellitus;Treatment of type II diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/07/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; E-mail: paediatrics@novonordisk.com ; Tel.: +45 44444848","first_published_date":"16/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002761-pip01-20"},{"decision_number":"P/0262/2020","pip_number":"EMEA-002766-PIP01-20","active_substance":"recombinant human IgGlA monoclonal Fab antibody","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Solution for infusion","condition_indication":"Reversal of antiplatelet effects of ticagrelor in patients with uncontrolled major or life-threatening bleeding or requiring urgent surgery or invasive procedure","routes_of_administration":"Intravenous use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"15/07/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"PhaseBio Pharmaceuticals Inc.; E-mail: lauren.richardson@phasebio.com; Tel. +1 6109816507","first_published_date":"16/06/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002766-pip01-20"},{"decision_number":"P/0139/2020","pip_number":"EMEA-001857-PIP01-15-M01","active_substance":"Elafibranor","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Capsule, hard;Coated tablet","condition_indication":"Treatment of non-alcoholic fatty liver disease (NAFLD) including non-alcoholic steatohepatitis (NASH)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/04/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Genfit SA; Tel.+33 320164000; Email: contact@genfit.com","first_published_date":"27/10/2016","last_updated_date":"07/06/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001857-pip01-15-m01"},{"decision_number":"P/0174/2013","pip_number":"EMEA-001238-PIP01-12","active_substance":"alpha tocotrienol quinone","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of Leigh syndrome","routes_of_administration":"Oral use;Enteral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"30/07/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"PTC Therapeutics International Limited; Tel. +353 19068700; E-mail: medinfo@ptcbio.com","first_published_date":"03/09/2013","last_updated_date":"07/06/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001238-pip01-12"},{"decision_number":"P/146/2011","pip_number":"EMEA-001015-PIP01-10","active_substance":"Dermatophagoides pteronyssinus;Dermatophagoides farinae","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal drops","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/06/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"14/07/2011","last_updated_date":"21/04/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001015-pip01-10"},{"decision_number":"P/0251/2012","pip_number":"EMEA-000646-PIP01-09-M01","active_substance":"peginesatide","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of symptomatic anaemia associated with chronic kidney disease","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"24/10/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Global Research & Development Centre (Europe) Ltd; E-mail: medinfoEMEA@takeda.com; Tel.: +44 (0)3333 000181","first_published_date":"26/08/2010","last_updated_date":"17/03/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000646-pip01-09-m01"},{"decision_number":"P/0221/2020","pip_number":"EMEA-002095-PIP01-16-M01","active_substance":"lucerastat","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Capsule, hard;Age appropriate oral solid dosage form","condition_indication":"Treatment of Fabry disease","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/06/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Idorsia Pharmaceuticals Deutschland GmbH  E-mail: clinical-trials-disclosure@idorsia.com  Tel. +41 588440000 &nbsp","first_published_date":"18/04/2018","last_updated_date":"17/03/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002095-pip01-16-m01"},{"decision_number":"P/0192/2020","pip_number":"EMEA-001070-PIP01-10-M02","active_substance":"2-iminobiotin","invented_name":"","therapeutic_area":"Neonatology-Paediatric Intensive Care","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of perinatal asphyxia","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/05/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Neurophyxia BV ; E-mail: info@neurophyxia.com ; Tel. +31 (0)73 6242141","first_published_date":"15/03/2012","last_updated_date":"16/03/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001070-pip01-10-m02"},{"decision_number":"P/0218/2020","pip_number":"EMEA-002765-PIP01-19","active_substance":"ribociclib succinate","invented_name":"Kisqali","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of breast cancer","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/06/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"09/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002765-pip01-19"},{"decision_number":"P/0242/2020","pip_number":"EMEA-002760-PIP01-19","active_substance":"Rucaparib camsylate","invented_name":"Rubraca","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of fallopian tube cancer;Treatment of ovarian cancer;Treatment of primary peritoneal cancer;Treatment of prostate malignant neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/06/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Clovis Oncology Ireland Ltd; E-mail: regulatoryUK@clovisoncology.com; Tel. +44(0) 1223 645500","first_published_date":"09/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002760-pip01-19"},{"decision_number":"P/0205/2020","pip_number":"EMEA-002753-PIP01-19","active_substance":"Adeno-associated virus serotype 2 encoding human aromatic L-amino acid decarboxylase","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of Parkinson's disease","routes_of_administration":"Intracerebral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/06/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Neurocrine Therapeutics Ltd; E-mail: medinfo@neurocrine.com; Tel. +01 8776 413461","first_published_date":"09/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002753-pip01-19"},{"decision_number":"P/0206/2020","pip_number":"EMEA-002751-PIP01-19","active_substance":"monalizumab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of head and neck epithelial malignant neoplasms","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/06/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.comTel. +46 8553 27591","first_published_date":"08/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002751-pip01-19"},{"decision_number":"P/0230/2020","pip_number":"EMEA-002748-PIP01-20","active_substance":"adenovirus encoding vascular endothelial growth factor C","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Solution for injection","condition_indication":"Secondary lymphedema associated with the treatment of breast cancer","routes_of_administration":"Ex vivo intranodal injection","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/06/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Herantis Pharma Plc; E-mail: antti.vuolanto@herantis.com; Tel. +358 4075 17329","first_published_date":"08/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002748-pip01-20"},{"decision_number":"P/0223/2020","pip_number":"EMEA-002664-PIP01-19","active_substance":"autologous haptenised and irradiated cell lysates derived from glioma","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of glioma","routes_of_administration":"Intradermal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"17/06/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ERC Belgium; E-mail: lacroix@ercbelgium.eu; Tel. +32 81728610","first_published_date":"08/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002664-pip01-19"},{"decision_number":"P/0224/2020","pip_number":"EMEA-002663-PIP01-19","active_substance":"allogeneic haptenised and irradiated cell lysates derived from glioma","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of glioma","routes_of_administration":"Intradermal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"17/06/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ERC Belgium; E-mail: lacroix@ercbelgium.eu; Tel. +32 81728610","first_published_date":"08/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002663-pip01-19"},{"decision_number":"P/0225/2020","pip_number":"EMEA-002662-PIP01-19","active_substance":"allogeneic haptenised and irradiated cells derived from glioma","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of glioma","routes_of_administration":"Intradermal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"17/06/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ERC Belgium; E-mail: lacroix@ercbelgium.eu; Tel. +32 81728610","first_published_date":"08/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002662-pip01-19"},{"decision_number":"P/0226/2020","pip_number":"EMEA-002661-PIP01-19","active_substance":"autologous haptenised and irradiated cells derived from glioma","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of glioma","routes_of_administration":"Intradermal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"17/06/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ERC Belgium; E-mail: lacroix@ercbelgium.eu; Tel. +32 81728610","first_published_date":"08/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002661-pip01-19"},{"decision_number":"P/0228/2020","pip_number":"EMEA-002652-PIP01-19","active_substance":"betahistine","invented_name":"","therapeutic_area":"Neurology;Oto-rhino-laryngology","pharmaceutical_forms":"Nasal spray (solution)","condition_indication":"Treatment of peripheral vertigo","routes_of_administration":"Intranasal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/06/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Auris Medical Ltd; E-mail: tm@aurismedical.com; Tel. +41 6120 11350","first_published_date":"08/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002652-pip01-19"},{"decision_number":"P/0215/2020","pip_number":"EMEA-002649-PIP02-20","active_substance":"ezetimibe;atorvastatin","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/06/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ELPEN Pharmaceutical Co. Inc; E-mail: regulatoryaffairs@elpen.gr; Tel. +30 2106039326; &nbsp","first_published_date":"08/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002649-pip02-20"},{"decision_number":"P/0137/2020","pip_number":"EMEA-001441-PIP01-13-M03","active_substance":"semaglutide","invented_name":"Ozempic","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/04/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; E-mail: dtru@novonordisk.com; Tel. +45 3079 0499","first_published_date":"16/06/2015","last_updated_date":"05/03/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001441-pip01-13-m03"},{"decision_number":"P/0181/2020","pip_number":"EMEA-002739-PIP01-19","active_substance":"hydrocortisone;benzocaine","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Rectal ointment","condition_indication":"Treatment of haemorrhoidal disease","routes_of_administration":"Rectal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/05/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Faes Farma S.A.Tel. +34 944818300E-mail: ieguidazu@faes.es; mjarenal@faes.es","first_published_date":"05/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002739-pip01-19"},{"decision_number":"P/0170/2020","pip_number":"EMEA-002743-PIP01-19","active_substance":"rosuvastatin calcium;fenofibrate","invented_name":"","therapeutic_area":"Cardiovascular diseases;Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of mixed dyslipidaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/05/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Accord Healthcare S.L.U.; E-mail: regulatory_EU@accord-healthcare.com; Tel. +34 933010064","first_published_date":"05/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002743-pip01-19"},{"decision_number":"P/0169/2020","pip_number":"EMEA-002745-PIP01-19","active_substance":"18-(p-[131I]-iodophenyl)octadecyl phosphocholine","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of Multiple Myeloma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/05/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cellectar Biosciences, Inc.; E-mail: clinical@cellectar.com; Tel. +1 6084418120","first_published_date":"05/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002745-pip01-19"},{"decision_number":"P/0186/2020","pip_number":"EMEA-002721-PIP01-19","active_substance":"tiragolumab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of lung carcinoma (small cell and non-small cell carcinoma)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/05/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"05/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002721-pip01-19"},{"decision_number":"P/0241/2020","pip_number":"EMEA-002617-PIP01-19","active_substance":"ravagalimab","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection;Solution for infusion","condition_indication":"Treatment of ulcerative colitis","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"25/06/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628 561 090","first_published_date":"05/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002617-pip01-19"},{"decision_number":"P/0229/2020","pip_number":"EMEA-002601-PIP01-19","active_substance":"adeno-associated viral vector serotype 8 containing the human RPGR gene","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of X-linked retinitis pigmentosa","routes_of_administration":"Ophthalmic use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"17/06/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biogen Netherlands B.V.; E-mail: pip.enquiries@biogen.com; Tel: +44 (0)1628512586","first_published_date":"05/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002601-pip01-19"},{"decision_number":"P/0212/2020","pip_number":"EMEA-002443-PIP02-18","active_substance":"Gepotidacin","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral formulation","condition_indication":"Treatment of uncomplicated urogenital gonorrhea","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"16/06/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services LimitedE-mail: eu.paediatric-plans@gsk.comTel.  +1 4388998201","first_published_date":"05/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002443-pip02-18"},{"decision_number":"P/0156/2020","pip_number":"EMEA-000583-PIP01-09-M08","active_substance":"Boceprevir","invented_name":"Victrelis","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Granules;Capsule, hard","condition_indication":"Treatment of chronic hepatitis C","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/04/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"25/05/2012","last_updated_date":"05/03/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000583-pip01-09-m08"},{"decision_number":"P/0235/2020","pip_number":"EMEA-002321-PIP01-17","active_substance":"sodium alginate oligosaccharide","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Inhalation powder;Capsule, hard","condition_indication":"Treatment of cystic fibrosis","routes_of_administration":"Inhalation use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"19/06/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AlgiPharma AS; E-mail: jowita.sleboda@algipharma.com; Tel. +47 46694971","first_published_date":"05/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002321-pip01-17"},{"decision_number":"P/0153/2020","pip_number":"EMEA-002714-PIP01-19","active_substance":"4-[4-({4-[({2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-4-yl}oxy)methyl]phenyl}methyl)piperazin-1-yl]-3-fluorobenzonitrile","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of mature B-cell neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/04/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Celgene Europe B.V.; Tel. +41 327298500; E-mail: medinfo.emea@celgene.com","first_published_date":"05/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002714-pip01-19"},{"decision_number":"P/0146/2020","pip_number":"EMEA-002641-PIP01-19","active_substance":"Pneumococcal polysaccharides individually biotinylated and complexed with a carrier protein (recombinant fusion construct of rhizavidin and Streptococcus pneumoniae derived proteins), 24-valent","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of disease caused by Streptococcus pneumoniae","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"18/04/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Biologicals SA; E-mail: eu.paediatric-plans@gsk.com; Tel:  +1 4388998201","first_published_date":"05/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002641-pip01-19"},{"decision_number":"P/0154/2020","pip_number":"EMEA-002619-PIP01-19","active_substance":"3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5- fluorobenzonitrile","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of renal neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/04/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck, Sharp & Dohme (Europe) Inc.; Tel. +33 180464738; E-mail: pip.information@merck.com","first_published_date":"05/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002619-pip01-19"},{"decision_number":"P/0182/2020","pip_number":"EMEA-002223-PIP01-19","active_substance":"arfolitixorin","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of colorectal cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/05/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Isofol Medical AB; Tel. +46 760293911; E-mail: roger.tell@isofolmedical.com","first_published_date":"04/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002223-pip01-19"},{"decision_number":"P/0176/2020","pip_number":"EMEA-002455-PIP01-18","active_substance":"Livoletide","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Concentrate for solution for injection","condition_indication":"Treatment of Prader-Willi syndrome","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/05/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Millendo Therapeutics SAS; Tel. +33 472180924; E-mail: allas@millendo.com","first_published_date":"04/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002455-pip01-18"},{"decision_number":"P/0180/2020","pip_number":"EMEA-002060-PIP02-17-M01","active_substance":"alicaforsen","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Rectal solution","condition_indication":"Treatment of pouchitis","routes_of_administration":"Rectal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/05/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Atlantic Healthcare Europe B.V.; Tel. +44 1799513391; E-mail: ann.mccormack@atlantichc.com","first_published_date":"28/01/2019","last_updated_date":"04/03/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002060-pip02-17-m01"},{"decision_number":"P/0194/2020","pip_number":"EMEA-001768-PIP02-15-M03","active_substance":"rolapitant","invented_name":"Varuby; Varuby","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral dosage formulation","condition_indication":"Prevention of nausea and vomiting","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/05/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Tesaro Bio Netherlands B.V.; Tel. +41 415880618; E-mail: lenerose.x.arfelt@gsk.com","first_published_date":"22/04/2016","last_updated_date":"04/03/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001768-pip02-15-m03"},{"decision_number":"P/0216/2020","pip_number":"EMEA-000639-PIP06-20","active_substance":"chloroprocaine hydrochloride","invented_name":"Ampres","therapeutic_area":"Anaesthesiology","pharmaceutical_forms":"Eye gel","condition_indication":"Ocular surface anaesthesia","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/06/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sintetica GmbH; Tel. +41 916404250E-mail: corporate_clinical_rd@sintetica.com","first_published_date":"04/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000639-pip06-20"},{"decision_number":"P/0219/2020","pip_number":"EMEA-000347-PIP05-20","active_substance":"bilastine","invented_name":"Bilaxten and associated names","therapeutic_area":"Dermatology;Oto-rhino-laryngology;Pneumology-allergology","pharmaceutical_forms":"Oral solution;Orodispersible tablet;Solution for injection;Tablet","condition_indication":"Treatment of acute type I hypersensitivity reactions","routes_of_administration":"Oral use;Intramuscular use;Intravenous use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"17/06/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Faes Farma S.A.; E-mail: ieguidazu@faes.es, mjarenal@faes.es; Tel. +34 944818300","first_published_date":"04/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000347-pip05-20"},{"decision_number":"P/0157/2020","pip_number":"EMEA-002595-PIP01-19","active_substance":"Polymyxin B","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of infections due to aerobic Gram-negative bacteria","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"17/04/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"The GARDP Foundation; Tel.: +41 229077623; E-mail: sally.ellis@gardp.org","first_published_date":"04/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002595-pip01-19"},{"decision_number":"P/0126/2020","pip_number":"EMEA-002567-PIP01-19","active_substance":"pracinostat","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard;Granules for oral suspension","condition_indication":"Treatment of acute myeloid leukaemia","routes_of_administration":"Oral use;Gastric use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/04/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Helsinn Birex Pharmaceuticals limited; Tel.: +41 919852167; E-mail: giuseppina.fusetti@helsinn.com","first_published_date":"04/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002567-pip01-19"},{"decision_number":"P/0313/2015","pip_number":"EMEA-001603-PIP01-13-M01","active_substance":"elbasvir","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Granules","condition_indication":"Treatment of chronic hepatitis C","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"21/12/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"05/03/2015","last_updated_date":"04/03/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001603-pip01-13-m01"},{"decision_number":"P/0312/2015","pip_number":"EMEA-001602-PIP01-13-M01","active_substance":"grazoprevir","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Granules","condition_indication":"Treatment of chronic hepatitis C","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"21/12/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"05/03/2015","last_updated_date":"04/03/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001602-pip01-13-m01"},{"decision_number":"P/0128/2020","pip_number":"EMEA-002511-PIP02-19","active_substance":"glycerol;urea","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Cream","condition_indication":"Treatment of dry skin","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/04/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ACO Hud Nordic AB; Tel.: +46 732744113; E-mail: tina.holm@perrigo.com","first_published_date":"04/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002511-pip02-19"},{"decision_number":"P/0129/2020","pip_number":"EMEA-002364-PIP03-19","active_substance":"Dihomo-y-linolenic acid","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Age appropriate oral liquid dosage formulation;Capsule, soft","condition_indication":"Treatment of atopic dermatitis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/04/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"DS Biopharma Ltd; Tel.:  +353 12946383; E-mail: dsbiopharma.regulatory@dsbiopharma.com","first_published_date":"03/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002364-pip03-19"},{"decision_number":"P/0140/2020","pip_number":"EMEA-001864-PIP02-19","active_substance":"lanadelumab","invented_name":"Takhzyro","therapeutic_area":"Other","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of acquired angioedema attacks","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/04/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Pharmaceuticals International AG Ireland Branch; E-mail: medinfoemea@takeda.com; Tel: +44 (0) 3333 000181","first_published_date":"03/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001864-pip02-19"},{"decision_number":"P/0161/2020","pip_number":"EMEA-002716-PIP01-19","active_substance":"propan-2-yl 2-[5-( acryloylamino )-4-{ [2-( dimethylamino )ethyl] ( methyl)amino }-2-methoxyanilino ]-4- ( 1 methyl-1 H-indol-3-yl)pyrimidine-5-carboxylate","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/04/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Pharma A/STel. +44 (0)3333000181E-mail: medinfoEMEA@takeda.com","first_published_date":"03/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002716-pip01-19"},{"decision_number":"P/0127/2020","pip_number":"EMEA-002725-PIP01-19","active_substance":"lazertinib (mesilate)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of lung carcinoma (small cell and non-small cell carcinoma)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/04/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Pharma A/S; Tel.: +353 857446696; E-mail: nbuhl@its.jnj.com","first_published_date":"03/03/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002725-pip01-19"},{"decision_number":"P/0347/2019","pip_number":"EMEA-002468-PIP04-18","active_substance":"belantamab mafodotin","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of Multiple Myeloma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Tel. +1 438-899-8201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"25/03/2020","last_updated_date":"19/02/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002468-pip04-18"},{"decision_number":"P/0038/2017","pip_number":"EMEA-002030-PIP01-16","active_substance":"ambrisentan","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of pulmonary arterial hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/01/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Glaxo Group Limited; United Kingdom; Tel. +1 4388998201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"17/03/2017","last_updated_date":"19/02/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002030-pip01-16"},{"decision_number":"P/0272/2016","pip_number":"EMEA-001175-PIP01-11-M04","active_substance":"albiglutide","invented_name":"Eperzan; Eperzan","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/10/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Glaxo Group Limited; E-mail: eu.paediatrics-plans@gsk.com; Tel. +1 4388998201","first_published_date":"09/08/2012","last_updated_date":"19/02/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001175-pip01-11-m04"},{"decision_number":"P/0239/2017","pip_number":"EMEA-000069-PIP02-10-M08","active_substance":"Mepolizumab","invented_name":"Nucala","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Solution for injection;Powder for solution for injection or infusion","condition_indication":"Treatment of asthma","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/08/2017","compliance_outcome":"Positive","compliance_opinion_date":"10/11/2017","compliance_procedure_number":"EMEA-C-000069-PIP02-10-M08","contact_for_public_enquiries":"GlaxoSmithKline Trading Services; United Kingdom; Tel . +1 4388998201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"18/10/2011","last_updated_date":"19/02/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000069-pip02-10-m08"},{"decision_number":"P/0365/2020","pip_number":"EMEA-002684-PIP01-19","active_substance":"Mitapivat","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Age appropriate oral solid dosage form;Film-coated tablet","condition_indication":"Treatment of pyruvate kinase deficiency","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Agios Pharmaceuticals, Inc.Tel.  +1 8332288474E-mail: medinfo@agios.com","first_published_date":"16/02/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002684-pip01-19"},{"decision_number":"P/0087/2019","pip_number":"EMEA-001011-PIP01-10-M01","active_substance":"Dermatophagoides pteronyssinus;Dermatophagoides farinae","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Subcutaneous use","decision_type":"RPM: decision refers to a refusal on the application for modification of an agreed PIP","decision_date":"22/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"14/07/2011","last_updated_date":"12/02/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001011-pip01-10-m01"},{"decision_number":"P/0085/2019","pip_number":"EMEA-001013-PIP01-10-M01","active_substance":"birch pollen;alder pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal drops","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Sublingual use","decision_type":"RPM: decision refers to a refusal on the application for modification of an agreed PIP","decision_date":"22/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"14/07/2011","last_updated_date":"12/02/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001013-pip01-10-m01"},{"decision_number":"P/0083/2019","pip_number":"EMEA-001017-PIP01-10-M01","active_substance":"chemically modified extract of grass pollen from Holcus lanatus, Phleum pratense and Poa pratensis","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal drops","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Sublingual use","decision_type":"RPM: decision refers to a refusal on the application for modification of an agreed PIP","decision_date":"22/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"14/07/2011","last_updated_date":"12/02/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001017-pip01-10-m01"},{"decision_number":"P/0264/2020","pip_number":"EMEA-002546-PIP01-19","active_substance":"tominersen","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Huntington's disease","routes_of_administration":"Intrathecal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/07/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"08/02/2021","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002546-pip01-19"},{"decision_number":"P/0397/2017","pip_number":"EMEA-001929-PIP01-16","active_substance":"brazikumab","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Solution for injection;Solution for infusion","condition_indication":"Treatment of Crohn's disease;Treatment of ulcerative colitis","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"19/12/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca ABEmail: paediatrics@astrazeneca.comTel. +46 855324400","first_published_date":"05/03/2018","last_updated_date":"21/01/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001929-pip01-16"},{"decision_number":"P/0280/2015","pip_number":"EMEA-000860-PIP01-10-M01","active_substance":"Dermatophagoides farinae;Dermatophagoides pteronyssinus","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal solution","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Sublingual use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/11/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ALK Abelló A/S; Tel. +45 4574 7576; E-mail: alkmrp@alk.net","first_published_date":"07/02/2011","last_updated_date":"05/01/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000860-pip01-10-m01"},{"decision_number":"P/0279/2015","pip_number":"EMEA-000857-PIP01-10-M01","active_substance":"Pollen from Dactylis glomarata (16%), Lolium perenne (16%), Phleum pratense (16%), Poa pratensis (16%), Anthoxhantum odoratum (16 %) and Secale cereale (20%)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal solution","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Sublingual use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/11/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ALK-Abelló A/S; Denmark; Tel. +45 4574 78079; E-mail: alkmrp@alk.net","first_published_date":"24/01/2011","last_updated_date":"05/01/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000857-pip01-10-m01"},{"decision_number":"P/0278/2015","pip_number":"EMEA-000853-PIP01-10-M01","active_substance":"Betula pendula","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/11/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ALK Abelló A/S; Tel. +45 4574 7576; E-mail: alkmrp@alk.net","first_published_date":"07/02/2011","last_updated_date":"05/01/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000853-pip01-10-m01"},{"decision_number":"P/0277/2015","pip_number":"EMEA-000852-PIP01-10-M01","active_substance":"Betula pendula;corylus avellana;alnus glutinosa","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal solution","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Sublingual use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/11/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ALK Abelló A/S; Tel. +45 4574 7576; E-mail: alkmrp@alk.net","first_published_date":"07/02/2011","last_updated_date":"05/01/2021","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000852-pip01-10-m01"},{"decision_number":"P/79/2009","pip_number":"Purified antigen fractions of inactivated split virion Influenza A/Indonesia/5/05 (H5N1)","active_substance":"purified antigen fractions of inactivated split virion Influenza A/Indonesia/5/05 (H5N1)","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Emulsion and suspension for emulsion for injection","condition_indication":"Influenza infection caused by an influenza strain contained in the vaccine or related to a strain contained in the vaccine","routes_of_administration":"Intramuscular injection","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"24/04/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Biologicals S.A. (UK); E-mail: eu.paediatric-plans@gsk.com; Tel.: +1 438 899 8201","first_published_date":"10/06/2009","last_updated_date":"26/11/2020","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/purified-antigen-fractions-inactivated-split-virion-influenza-indonesia-5-05-h5n1"},{"decision_number":"P/0273/2014","pip_number":"EMEA-001546-PIP01-13","active_substance":"molidustat (sodium)","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Film-coated tablet;Oral liquid","condition_indication":"Treatment of anaemia due to chronic disorders","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/10/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer Pharma AG; Tel. +49 3046 815333; E-mail: pediatrics.medical-affairs-europe@bayer.com","first_published_date":"04/12/2014","last_updated_date":"25/11/2020","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001546-pip01-13"},{"decision_number":"P/0386/2017","pip_number":"EMEA-001877-PIP03-17","active_substance":"fremanezumab","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of cluster headaches","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"19/12/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Teva GmbH; Tel. +491726277979; E-mail: info.era-clinical@teva.de","first_published_date":"05/03/2018","last_updated_date":"25/11/2020","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001877-pip03-17"},{"decision_number":"P/0106/2018","pip_number":"EMEA-001255-PIP01-11-M03","active_substance":"tilmanocept","invented_name":"Lymphoseek","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Kit for radiopharmaceutical preparation","condition_indication":"Visualisation of lymphatic drainage of solid malignant tumours for diagnostic purposes","routes_of_administration":"Intradermal use;Subcutaneous use;Intratumoral use;Peritumoural use;Intralymphatic use;Interstitial use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/04/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Navidea Biopharmaceuticals Europe Ltd.; Navidea Biopharmaceuticals Europe Ltd.; Tel: +1 614-973-7560; Mail: safety@navidea.com","first_published_date":"08/02/2013","last_updated_date":"10/11/2020","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001255-pip01-11-m03"},{"decision_number":"P/0191/2019","pip_number":"EMEA-002398-PIP01-18","active_substance":"N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl) cyclobutyl)-3-phenylisoxazole-5-","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Age appropriate oral dosage formulation;Capsule, hard","condition_indication":"Treatment of cystic fibrosis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"17/05/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"SFL Pharmaceuticals Deutschland GmbH; Tel: +49 7621 5500 250; E-mail: RA@sfl-services.com","first_published_date":"29/10/2019","last_updated_date":"12/10/2020","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002398-pip01-18"},{"decision_number":"P/0281/2018","pip_number":"EMEA-002218-PIP01-17","active_substance":"anti-mucosal addressin cell adhesion molecule antibody (SHP647)","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Crohn's disease;Treatment of ulcerative colitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"12/09/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Shire Pharmaceuticals Ireland Limited; Tel. +44 (0)8008 38470; E-mail: medinfoeuceemea@shire.com","first_published_date":"17/01/2019","last_updated_date":"07/10/2020","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002218-pip01-17"},{"decision_number":"P/0341/2019","pip_number":"EMEA-001315-PIP02-16-M02","active_substance":"Fevipiprant","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Tablet;Chewable tablet;Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of asthma","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/09/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"26/07/2018","last_updated_date":"20/08/2020","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001315-pip02-16-m02"},{"decision_number":"P/0109/2020","pip_number":"EMEA-002031-PIP01-16-M03","active_substance":"emapalumab","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of haemophagocytic lymphohistiocytosis","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"20/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novimmune B.V.; Tel. +41 228397141; E-mail: pip@novimmune.com","first_published_date":"05/03/2018","last_updated_date":"04/08/2020","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002031-pip01-16-m03"},{"decision_number":"P/0071/2020","pip_number":"EMEA-000914-PIP01-10-M05","active_substance":"eftrenonacog alfa","invented_name":"Alprolix","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of hereditary factor-IX deficiency","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/03/2020","compliance_outcome":"Positive","compliance_opinion_date":"24/07/2020","compliance_procedure_number":"EMEA-C-000914-PIP01-10-M05","contact_for_public_enquiries":"Swedish Orphan Biovitrum ABE-mail: medical.info@sobi.comTel. +46 8697 2000","first_published_date":"14/07/2011","last_updated_date":"03/08/2020","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000914-pip01-10-m05"},{"decision_number":"P/0111/2020","pip_number":"EMEA-000880-PIP02-11-M04","active_substance":"sonidegib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard;Film-coated tablet;Powder and solvent for oral suspension","condition_indication":"Treatment of medulloblastoma","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"20/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sun Pharmaceutical Industries Europe B.V.; E-mail: juliette.omtzigt@sunpharma.com; Tel.  +31 233034307","first_published_date":"18/09/2012","last_updated_date":"03/08/2020","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000880-pip02-11-m04"},{"decision_number":"P/0110/2020","pip_number":"EMEA-002708-PIP01-19","active_substance":"verdiperstat","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Coated tablet","condition_indication":"Treatment of multiple system atrophy","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biohaven Pharmaceuticals, Inc.; E-mail: medinfo@biohavenpharma.com; Tel.: +1 203 404 0410","first_published_date":"31/07/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002708-pip01-19"},{"decision_number":"P/0118/2020","pip_number":"EMEA-002698-PIP01-19","active_substance":"Eftilagimod alpha","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of breast cancer","routes_of_administration":"Subcutaneous use;Intravenous use;Intratumoral use;Intraperitoneal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Immutep SAS; E-mail: christian.mueller@immutep.com; Tel.: +49 3088716843","first_published_date":"31/07/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002698-pip01-19"},{"decision_number":"P/0067/2020","pip_number":"EMEA-002696-PIP01-19","active_substance":"Parsaclisib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of mature B-cell malignancies","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Incyte Biosciences Distribution B.V.; E-mail: globalmedinfo@incyte.com; Tel. +800 0002 7423","first_published_date":"31/07/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002696-pip01-19"},{"decision_number":"P/0090/2020","pip_number":"EMEA-002695-PIP01-19","active_substance":"zolbetuximab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of gastric cancer and gastro-oesophageal junction adenocarcinoma;Treatment of pancreatic cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Astellas Pharma Europe B.V.Tel. +31 7154 55878E-mail: contact.nl@astellas.com&nbsp","first_published_date":"31/07/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002695-pip01-19"},{"decision_number":"P/0112/2020","pip_number":"EMEA-002691-PIP01-19","active_substance":"Brolucizumab","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of visual impairment due to macular edema associated with retinal vein occlusion (branch RVO or central RVO)","routes_of_administration":"Intravitreal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"31/07/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002691-pip01-19"},{"decision_number":"P/0091/2020","pip_number":"EMEA-002690-PIP01-19","active_substance":"6 fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2- methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of lung cancer","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V; Tel.: +44 (0)1223 420305; E-mail: medinfointernational@amgen.com","first_published_date":"31/07/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002690-pip01-19"},{"decision_number":"P/0068/2020","pip_number":"EMEA-002687-PIP01-19","active_substance":"levodopa;carbidopa","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Parkinson's disease","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Neuroderm Ltd; E-mail: ronitm@neuroderm.com; Tel.: +972 8 9462729","first_published_date":"30/07/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002687-pip01-19"},{"decision_number":"P/0113/2020","pip_number":"EMEA-002686-PIP01-19","active_substance":"(2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-oxazolidin3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet;Powder for oral solution","condition_indication":"Treatment of breast cancer","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"30/07/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002686-pip01-19"},{"decision_number":"P/0077/2020","pip_number":"EMEA-002668-PIP01-19","active_substance":"5%-Δ9-tetrahydrocannabinol standardised Cannabis extract","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of chronic pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vertanical GmbH; E-mail: A.Buchner@futrue.com; Tel.: +49 897879790300","first_published_date":"30/07/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002668-pip01-19"},{"decision_number":"P/0094/2020","pip_number":"EMEA-002648-PIP01-19","active_substance":"recombinant anti-human CD20 and anti-human CD3 monoclonal antibody (RO7082859; CD20 CD3 TCB)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of mature B-cell neoplasms","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"18/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"30/07/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002648-pip01-19"},{"decision_number":"P/0096/2018","pip_number":"EMEA-002259-PIP01-17","active_substance":"Levothyroxine (sodium)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of benign thyroid nodules;Treatment of goitre;Treatment of hypothyroidism","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/03/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"IBSA Institut Biochimique SA; Tel. +41 5836 01718; E-mail: giulia.petricca@ibsa.ch","first_published_date":"19/06/2018","last_updated_date":"29/07/2020","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002259-pip01-17"},{"decision_number":"P/0115/2020","pip_number":"EMEA-002572-PIP01-19","active_substance":"soticlestat","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral formulation","condition_indication":"Treatment of Chromosome 15q Duplication Syndrome;Treatment of Cyclin-Dependent Kinase-Like 5 deficiency disorder","routes_of_administration":"Oral use;Gastric use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"18/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Pharma A/S; Tel. +45 4677 1111; E-mail: paediatrics@tgrd.com","first_published_date":"29/07/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002572-pip01-19"},{"decision_number":"P/0106/2020","pip_number":"EMEA-002562-PIP01-19","active_substance":"autologous CD34+ haematopoietic stem cells transduced ex vivo with a lentiviral vector encoding for the human Beta 2 Integrin/CD18 gene","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of leukocyte adhesion deficiency type I","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"20/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Rocket Pharmaceuticals, Inc.; E-mail: mz@rocketpharma.com; Tel.: +1 6465815229","first_published_date":"29/07/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002562-pip01-19"},{"decision_number":"P/0098/2020","pip_number":"EMEA-002552-PIP01-19","active_substance":"tris(hydroxymethyl)aminomethane trihydrate (PF-05221304-82)","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of non-alcoholic steatohepatitis (NASH)","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"18/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG; Tel. +44 (0)1304 646 607; E-mail: pip_enquiries@pfizer.com","first_published_date":"29/07/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002552-pip01-19"},{"decision_number":"P/0122/2020","pip_number":"EMEA-002526-PIP02-19","active_substance":"1-[ 4-bromo-5-[ 1-ethyl-7-( methylamino )-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl ]-2-fluorophenyl]-3-","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of gastrointestinal stromal tumours","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Deciphera Pharmaceuticals; E-mail: info@deciphera.com; Tel.: +1 7812096400","first_published_date":"29/07/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002526-pip02-19"},{"decision_number":"P/0108/2020","pip_number":"EMEA-002524-PIP02-19","active_substance":"mosunetuzumab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of mature B-cell neoplasms","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"20/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"28/07/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002524-pip02-19"},{"decision_number":"P/0085/2020","pip_number":"EMEA-002430-PIP01-18","active_substance":"timrepigene emparvovec","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of choroideremia","routes_of_administration":"Ophthalmic use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"20/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Nightstar Europa Limited; E-mail: enquiries@nightstartx.com; Tel.:  +44 1628512604","first_published_date":"28/07/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002430-pip01-18"},{"decision_number":"P/0083/2020","pip_number":"EMEA-002358-PIP03-19","active_substance":"avapritinib","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of mastocytosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Blueprint Medicines (Netherlands) B.V.; E-mail: medinfo@blueprintmedicines.com; Tel. +31 858880230","first_published_date":"28/07/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002358-pip03-19"},{"decision_number":"P/0100/2020","pip_number":"EMEA-002267-PIP03-19","active_substance":"gefapixant (citrate)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of endometriosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck, Sharp & Dohme (Europe) Inc.; Tel. +33 180464738; E-mail: pip.information@merck.com","first_published_date":"28/07/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002267-pip03-19"},{"decision_number":"P/0079/2020","pip_number":"EMEA-002257-PIP02-19","active_substance":"rosuvastatin;ezetimibe","invented_name":"Rosuvastatin and associated names; Ezetimibe Elpen and associated names","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ELPEN Pharmaceutical Co. Inc; Tel. +30 2106 039326; E-mail: info@elpen.gr","first_published_date":"28/07/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002257-pip02-19"},{"decision_number":"P/0116/2020","pip_number":"EMEA-002152-PIP03-19","active_substance":"daratumumab","invented_name":"Darzalex","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion;Solution for injection","condition_indication":"Treatment of systemic light chain amyloidosis","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International N.V.; E-mail: nreymond@its.jnj.com; Tel.: +31 14641125","first_published_date":"28/07/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002152-pip03-19"},{"decision_number":"P/0099/2020","pip_number":"EMEA-001913-PIP02-18","active_substance":"allogeneic, ex vivo expanded, umbilical cord blood-derived, haematopoietic CD34+progenitor cells (CF);allogeneic, non-expanded, umbilical cord blood-derived, haematopoietic mature myeloid and lymphoid cells (NF)","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment in haematopoietic stem cell transplantation","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"18/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gamida Cell Ltd; E-mail: nelly@gamida-cell.com; Tel.: +972 26595570","first_published_date":"28/07/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001913-pip02-18"},{"decision_number":"P/0119/2020","pip_number":"EMEA-001624-PIP02-19","active_substance":"nemolizumab","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of prurigo nodularis","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Galderma International S.A.; Tel.: +41 219249046; E-mail: christophe.piketty@galderma.com","first_published_date":"28/07/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001624-pip02-19"},{"decision_number":"P/0123/2020","pip_number":"EMEA-001095-PIP03-19","active_substance":"natalizumab","invented_name":"Tysabri","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection in pre-filled syringe","condition_indication":"Treatment of multiple sclerosis","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/03/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biogen Idec LtdTel.  +01 628501000E-mail: pip.enquiries@biogen.com","first_published_date":"28/07/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001095-pip03-19"},{"decision_number":"P/0030/2020","pip_number":"EMEA-002164-PIP01-17-M02","active_substance":"(RS)-Bacoflen;D-Sorbitol (PXT3003);naltrexone hydrochloride","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of Charcot-Marie-Tooth disease Type 1A","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pharnext SA; Tel. +33 1 41 09 22 59; E-mail: sdorn@pharnext.com","first_published_date":"19/06/2018","last_updated_date":"12/06/2020","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002164-pip01-17-m02"},{"decision_number":"P/0012/2020","pip_number":"EMEA-001613-PIP01-14-M04","active_substance":"tezepelumab","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of asthma","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB (Sweden); Tel.  +46 855326000; E-mail: paediatrics@astrazeneca.com","first_published_date":"22/01/2015","last_updated_date":"12/06/2020","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001613-pip01-14-m04"},{"decision_number":"P/0005/2020","pip_number":"EMEA-001349-PIP01-12-M03","active_substance":"daclizumab","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of multiple sclerosis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biogen Idec Ltd; E-mail: pip.enquiries@biogen.com; Tel. +44 (0)1628 501014","first_published_date":"08/10/2013","last_updated_date":"12/06/2020","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001349-pip01-12-m03"},{"decision_number":"P/0253/2018","pip_number":"EMEA-001563-PIP02-15-M01","active_substance":"ciprofloxacin hydrochloride","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Nebuliser solution","condition_indication":"Treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/08/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Savara ApS; E-mail: mette.vinge@savarapharma.com; Tel. +45 2488 5979","first_published_date":"18/04/2017","last_updated_date":"12/06/2020","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001563-pip02-15-m01"},{"decision_number":"P/0038/2020","pip_number":"EMEA-002682-PIP01-19","active_substance":"3-[4-(4-Aminopiperidin-1-yl)-3-(3,5-difluorophenyl)quinolin-6-yl]-2-hydroxybenzonitrile (CRN00808)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of acromegaly","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Crinetics Pharmaceuticals Inc; E-mail: clinicaltrials@crinetics.com; Tel. +1 8338279714","first_published_date":"10/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002682-pip01-19"},{"decision_number":"P/0039/2020","pip_number":"EMEA-002679-PIP01-19","active_substance":"autologous dendritic cells activated by transient exposure to killed prostate cancer cells ex vivo","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of prostate cancer","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"SOTIO a.s.; E-mail: clinicaltrial@sotio.com; Tel. +42 0224175498","first_published_date":"10/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002679-pip01-19"},{"decision_number":"P/0040/2020","pip_number":"EMEA-002678-PIP01-19","active_substance":"physostigmine;hyoscine","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Transdermal patch","condition_indication":"Prevention of organophosphate poisoning","routes_of_administration":"Transdermal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Defence Science and Technology Laboratory; E-mail: centralenquiries@dstl.gov.uk; Tel. +44 1980950000","first_published_date":"10/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002678-pip01-19"},{"decision_number":"P/0054/2020","pip_number":"EMEA-002676-PIP01-19","active_substance":"ripasudil","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution","condition_indication":"Treatment of corneal dystrophy","routes_of_administration":"Ophthalmic use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/02/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kowa Pharmaceutical Europe Co. Ltd; Tel. +44 (0)1189229000; E-mail: regulatory@kowa.co.uk","first_published_date":"10/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002676-pip01-19"},{"decision_number":"P/0016/2020","pip_number":"EMEA-002672-PIP01-19","active_substance":"Ethanol","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of uncontrolled primary hypertension","routes_of_administration":"Intraarterial use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ablative Solutions Inc.; E-mail: taf@ablativesolutions.com, nharatani@ablativesolutions.com; Tel. +1 4084212496","first_published_date":"10/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002672-pip01-19"},{"decision_number":"P/0041/2020","pip_number":"EMEA-002658-PIP01-19","active_substance":"modified human papillomavirus capsid protein conjugated to the near-infrared dye silicate(5-),bis[N-[3- [(hydroxy-.kappa.O)dimethylsilyl]propyl]-3-sulfo-N,N-bis(3-sulfopropyl)-1-propanaminiumato(4-)][6- [[[3-[(29H,31H-phthalocyanin-yl-.kappa.N29,.kappa.N30,.kappa.N31,.kappa.N32)oxy]propoxy] carbonyl]amino]hexanoato(3-)]-, sodium (1:5)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of ocular melanoma","routes_of_administration":"Intravitreal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aura Biosciences Inc.; E-mail: paediatrics@aurabiosciences.com; Tel. +1 6175008864","first_published_date":"10/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002658-pip01-19"},{"decision_number":"P/0042/2020","pip_number":"EMEA-002657-PIP01-19","active_substance":"rhPSMA-7.3 (18F)","invented_name":"","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Solution for injection","condition_indication":"Visualisation of prostate-specific membrane antigen in adenocarcinoma of the prostate","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Blue Earth Diagnostics Ltd; E-mail: contact@blueearthdx.com; Tel. +44 1865784186","first_published_date":"10/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002657-pip01-19"},{"decision_number":"P/0035/2020","pip_number":"EMEA-002654-PIP02-19","active_substance":"benzocaine","invented_name":"","therapeutic_area":"Oto-rhino-laryngology","pharmaceutical_forms":"Lozenge","condition_indication":"Treatment of oropharyngeal pain","routes_of_administration":"Oromucosal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Johnson and Johnson; E-mail: rokeeff2@its.jnj.com; Tel: +1 628827192","first_published_date":"10/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002654-pip02-19"},{"decision_number":"P/0044/2020","pip_number":"EMEA-002650-PIP01-19","active_substance":"Humanized immunoglobulin (lg) G4 proline, alanine, alanine (IgG4 PAA) based bispecific antibody directed against cluster of differentiation (CD) 3 receptor complex and B-cell maturation antigen (BCMA)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of Multiple Myeloma","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International N.V.; E-mail: nbuhl@its.jnj.com; Tel. +353 8574 46696","first_published_date":"10/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002650-pip01-19"},{"decision_number":"P/0043/2020","pip_number":"EMEA-002651-PIP01-19","active_substance":"glibenclamide","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of large hemispheric infarction","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biogen Idec LimitedTel. +44 1628512586E-mail: pip.enquiries@biogen.com","first_published_date":"10/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002651-pip01-19"},{"decision_number":"P/0045/2020","pip_number":"EMEA-002647-PIP01-19","active_substance":"Futibatinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of cholangiocarcinoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Taiho Pharma Europe Ltd.; Tel. +1 609 250 7336; E-mail: clinicaltrialinfo@taihooncology.com","first_published_date":"10/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002647-pip01-19"},{"decision_number":"P/0056/2020","pip_number":"EMEA-002646-PIP01-19","active_substance":"levocetirizine;montelukast","invented_name":"","therapeutic_area":"Oto-rhino-laryngology;Pneumology-allergology","pharmaceutical_forms":"Tablet;Powder for oral solution","condition_indication":"Treatment of allergic rhinitis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/02/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Abbott Laboratories Limited; Tel.  +44 1628644132; E-mail: abbott-EPD-GRA@abbott.com","first_published_date":"10/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002646-pip01-19"},{"decision_number":"P/0018/2020","pip_number":"EMEA-002645-PIP01-19","active_substance":"sacituzumab govitecan","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder and solvent for solution","condition_indication":"Treatment of breast cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Immunomedics GmbH; Tel. +1 8622603582; E-mail: dwhiteley@immunomedics.com","first_published_date":"10/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002645-pip01-19"},{"decision_number":"P/0019/2020","pip_number":"EMEA-002636-PIP01-19","active_substance":"Iberdomide","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of mature B-cell neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Celgene Europe B.V.; Tel. +41 327298500; E-mail: medinfo.emea@celgene.com","first_published_date":"10/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002636-pip01-19"},{"decision_number":"P/0015/2020","pip_number":"EMEA-002606-PIP02-19","active_substance":"Bispecific T-cell engager antibody with a single-chain fragment crystallizable moiety that binds to B cell maturation antigen surface receptor on tumour cells and the cluster of differentiation 3 receptor on Tcells","invented_name":"","therapeutic_area":"Haematology-Hemostaseology;Oncology","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of Multiple Myeloma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V; Tel.: +44 (0)1223 420305; E-mail: medinfointernational@amgen.com","first_published_date":"10/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002606-pip02-19"},{"decision_number":"P/0057/2020","pip_number":"EMEA-002568-PIP01-19","active_substance":"anti-IL-17A/F nanobody (MK 1095)","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of psoriasis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/02/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bond Avillion 2 Development LP; Tel. +44 2037649536; E-mail: alun@avillionllp.com","first_published_date":"10/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002568-pip01-19"},{"decision_number":"P/0049/2020","pip_number":"EMEA-002500-PIP01-18","active_substance":"Budesonide","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Modified release capsule","condition_indication":"Treatment of primary IgA nephropathy","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Calliditas Therapeutics AB; Tel. +46 703119960; E-mail: mikael.widell@calliditas.com","first_published_date":"10/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002500-pip01-18"},{"decision_number":"P/0051/2020","pip_number":"EMEA-002484-PIP01-18","active_substance":"2-[[8-chloro-3-[(4-chlorophenyl)methyl]-4-(difluoromethoxy)-2-ethyl-5-quinolinyl]oxy]acetic acid Llysine salt (GB001)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of asthma","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GB001, Inc.; Tel. +1 8586841327; E-mail: jspinella@gossamerbio.com","first_published_date":"10/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002484-pip01-18"},{"decision_number":"P/0052/2020","pip_number":"EMEA-002347-PIP01-18","active_substance":"asciminib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Age appropriate oral solid dosage form;Film-coated tablet","condition_indication":"Treatment of chronic myeloid leukaemia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"09/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002347-pip01-18"},{"decision_number":"P/0001/2020","pip_number":"EMEA-001266-PIP04-19","active_substance":"Masitinib mesilate","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of amyotrophic lateral sclerosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AB Science; France; a.moussy@ab-science.com ; +33 147200014; +33 147202411","first_published_date":"09/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001266-pip04-19"},{"decision_number":"P/0046/2020","pip_number":"EMEA-002530-PIP01-18","active_substance":"atogepant","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Tablet;Age appropriate oral solid dosage form","condition_indication":"Prevention of migraine headaches","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628925033","first_published_date":"09/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002530-pip01-18"},{"decision_number":"P/0009/2020","pip_number":"EMEA-000639-PIP05-19","active_substance":"chloroprocaine hydrochloride","invented_name":"Ampres","therapeutic_area":"Anaesthesiology","pharmaceutical_forms":"Gel","condition_indication":"Ocular surface anaesthesia","routes_of_administration":"Ocular use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"06/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sintetica GmbH; Tel. +41 916404250E-mail: corporate_clinical_rd@sintetica.com","first_published_date":"04/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000639-pip05-19"},{"decision_number":"P/0010/2020","pip_number":"EMEA-000639-PIP04-19","active_substance":"chloroprocaine hydrochloride","invented_name":"Ampres","therapeutic_area":"Anaesthesiology","pharmaceutical_forms":"Solution for injection","condition_indication":"Epidural anaesthesia","routes_of_administration":"Epidural use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"06/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sintetica GmbH; Tel. +41 916404250E-mail: corporate_clinical_rd@sintetica.com","first_published_date":"04/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000639-pip04-19"},{"decision_number":"P/0029/2020","pip_number":"EMEA-000060-PIP08-19","active_substance":"Canakinumab","invented_name":"Ilaris","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution for injection;Solution for injection","condition_indication":"Treatment of lung carcinoma","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"04/06/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000060-pip08-19"},{"decision_number":"P/0125/2015","pip_number":"EMEA-001609-PIP01-14","active_substance":"norovirus GI.1 virus-like particle antigen;norovirus GII.4 virus-like particle antigen","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of acute norovirus gastroenteritis","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"05/06/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Vaccines, Inc. E-mail: amy.atwood@takeda.com Tel. +1 6174 442147","first_published_date":"03/07/2015","last_updated_date":"29/04/2020","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001609-pip01-14"},{"decision_number":"P/0429/2019","pip_number":"EMEA-002649-PIP01-19","active_substance":"ezetimibe;atorvastatin","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/12/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ELPEN Pharmaceutical Co. Inc; E-mail: regulatoryaffairs@elpen.gr; Tel. +30 2106039326; &nbsp","first_published_date":"06/04/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002649-pip01-19"},{"decision_number":"P/0416/2019","pip_number":"EMEA-002633-PIP01-19","active_substance":"sitravatinib (malate)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of non-small cell lung cancer","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/12/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mirati Therapeutics, Inc.; E-mail: cheni@mirati.com; Tel.  +1 8583323428","first_published_date":"06/04/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002633-pip01-19"},{"decision_number":"P/0392/2019","pip_number":"EMEA-002629-PIP01-19","active_substance":"","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of breast cancer;Treatment of lung cancer;Treatment of neuroendocrine tumours (excluding neuroblastoma)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/12/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ipsen Pharma; E-mail: caroline.pallardy@ipsen.com; Tel. +33 671197553","first_published_date":"06/04/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002629-pip01-19"},{"decision_number":"P/0390/2019","pip_number":"EMEA-002632-PIP01-19","active_substance":"satoreotide trizoxetan","invented_name":"","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Solution for injection","condition_indication":"Diagnosis of breast cancer;Diagnosis of lung cancer;Diagnosis of neuroendocrine tumours (excluding neuroblastoma)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/12/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ipsen Pharma; E-mail: caroline.pallardy@ipsen.com; Tel. +33 671197553","first_published_date":"06/04/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002632-pip01-19"},{"decision_number":"P/0427/2019","pip_number":"EMEA-002627-PIP01-19","active_substance":"savolitinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of lung cancer","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/12/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com","first_published_date":"06/04/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002627-pip01-19"},{"decision_number":"P/0417/2019","pip_number":"EMEA-002626-PIP01-19","active_substance":"loxoprofen (sodium hydrate)","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Medicated plaster","condition_indication":"Treatment of pain","routes_of_administration":"Topical use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/12/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Lead Chemical Co. Ltd; E-mail: a-numa@lead-chemical.co.jp; Tel.  +81 764645710","first_published_date":"06/04/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002626-pip01-19"},{"decision_number":"P/0393/2019","pip_number":"EMEA-002622-PIP01-19","active_substance":"(3S,7S)-22-(3-(((2-((5-(2-Carboxyethyl)-2-hydroxybenzyl)(carboxymethyl)amino)ethyl)(carboxymethyl)amino)methyl)-4-hydroxyphenyl)-5,13,20-trioxo-4,6,12,19-tetraazadocosane-1,3,7-tricarboxylic acid (PSMA-11)","invented_name":"","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Kit for radiopharmaceutical preparation","condition_indication":"Visualisation of prostate specific membrane antigen in prostate cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/12/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Advanced Nuclear Medicine Ingredients (ANMI); E-mail: fbruyere@anmi.be; Tel. +32 43663701","first_published_date":"03/04/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002622-pip01-19"},{"decision_number":"P/0395/2019","pip_number":"EMEA-002615-PIP01-19","active_substance":"A fully humanized immunoglobulin G4 proline, alanine, alanine (IgG4 PAA) based bispecific antibody directed against cluster of differentiation 3 (CD3) receptor complex and G Protein Coupled Receptor Family C Group 5 Member D (GPRC5D) (JNJ-64407564)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of Multiple Myeloma","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/12/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International N.V.; E-mail: nbuhl@its.jnj.com; Tel. +353 8574 46696","first_published_date":"03/04/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002615-pip01-19"},{"decision_number":"P/0428/2019","pip_number":"EMEA-002587-PIP01-19","active_substance":"duvelisib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of mature B cell malignancies","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/12/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Verastem, Inc.; E-mail: va@eraconsulting.com; Tel. +49 516198900","first_published_date":"03/04/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002587-pip01-19"},{"decision_number":"P/0397/2019","pip_number":"EMEA-002580-PIP01-19","active_substance":"diclofenac (sodium);thiocolchicoside","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of pain","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/12/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Win Medica S.A.; E-mail: info@winmedica.gr; Tel. +30 2107488821","first_published_date":"03/04/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002580-pip01-19"},{"decision_number":"P/0403/2019","pip_number":"EMEA-002452-PIP01-18","active_substance":"Marizomib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of malignant glial tumours","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/12/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Celgene Europe B.V.; Tel. +41 327298500; E-mail: medinfo.emea@celgene.com","first_published_date":"03/04/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002452-pip01-18"},{"decision_number":"P/0420/2019","pip_number":"EMEA-002391-PIP02-19","active_substance":"","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of acute bacterial skin and skin structure infections","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/12/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"03/04/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002391-pip02-19"},{"decision_number":"P/0423/2019","pip_number":"EMEA-002402-PIP02-18","active_substance":"artesunate","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of severe malaria caused by Plasmodium falciparum","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"05/12/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ACE Pharmaceuticals B.V.; Tel. +31 365227201; E-mail: ace@ace-pharm.nl","first_published_date":"03/04/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002402-pip02-18"},{"decision_number":"P/0380/2019","pip_number":"EMEA-002267-PIP02-19","active_substance":"gefapixant (citrate)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of unexplained or chronic refractory cough","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/12/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"03/04/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002267-pip02-19"},{"decision_number":"P/0406/2019","pip_number":"EMEA-002247-PIP02-17","active_substance":"Ivosidenib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms);Treatment of malignant neoplasms of the central nervous system","routes_of_administration":"Oral use;Naso-gastric use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"04/12/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierE-mail: mail.pip.enquiries@servier.comTel.: +33 155726000","first_published_date":"02/04/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002247-pip02-17"},{"decision_number":"P/0414/2019","pip_number":"EMEA-002178-PIP01-17-M01","active_substance":"Itacitinib","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Prolonged-release tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of acute graft versus host disease","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/12/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Incyte Biosciences Distribution B.V.; E-mail: globalmedinfo@incyte.com; Tel. +800 0002 7423","first_published_date":"27/11/2018","last_updated_date":"02/04/2020","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002178-pip01-17-m01"},{"decision_number":"P/0412/2019","pip_number":"EMEA-001066-PIP02-11-M03","active_substance":"aciclovir","invented_name":"Sitavig and associated names","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Muco-adhesive buccal tablet","condition_indication":"Treatment of herpes simplex labialis","routes_of_administration":"Gingival use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/12/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vectans Pharma; Tel. +33 631268926; E-mail: christiane.bober@vectans.com","first_published_date":"26/07/2017","last_updated_date":"01/04/2020","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001066-pip02-11-m03"},{"decision_number":"P/0402/2019","pip_number":"EMEA-001976-PIP02-18","active_substance":"3-[5-[(1R,2S)-2-(2,2-difluoropropanoylamino)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)propoxy]indazol-1- yl]-N-[(3R)-tetrahydrofuran-3-yl]benzamide (AZD7594)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Inhalation powder;Nebuliser suspension;Pressurised inhalation (suspension)","condition_indication":"Treatment of asthma","routes_of_administration":"Inhalation use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"20/12/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel.  +46 855326000;  ","first_published_date":"31/03/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001976-pip02-18"},{"decision_number":"P/0433/2019","pip_number":"EMEA-001862-PIP02-19","active_substance":"autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti CD19 CD28/CD3-zeta chimeric antigen receptor and cultured (KTE-X19)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of mantle cell lymphoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/12/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kite Pharma EU B.V.; Tel. +1 4242091332; E-mail: regulatory@kitepharma.com","first_published_date":"31/03/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001862-pip02-19"},{"decision_number":"P/0419/2019","pip_number":"EMEA-001518-PIP03-19","active_substance":"eflornithine hydrochloride;sulindac","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Coated tablet","condition_indication":"Treatment of Familial Adenomatous Polyposis","routes_of_administration":"Oral use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"06/12/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cancer Prevention Pharma (Ireland) Limited; E-mail: cbrannen@canprevent.com; Tel.  +1 5209087774","first_published_date":"30/03/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001518-pip03-19"},{"decision_number":"P/0372/2019","pip_number":"EMEA-001894-PIP01-15-M01","active_substance":"Influenza virus inactivated split virion (haemagglutinin and neuraminidase) of strain A (H1N1);Influenza virus inactivated split virion (haemagglutinin and neuraminidase) of strain A (H3N2);Influenza virus inactivated split virion (haemagglutinin and neuraminidase) of strain B (Victoria lineage);Influenza virus inactivated split virion (haemagglutinin and neuraminidase) of strain B (Yamagata lineage)","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of influenza infection","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/11/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Seqirus GmbH; Tel. +39 3462545935; E-mail: dalila.dolfi@seqirus.com","first_published_date":"10/01/2017","last_updated_date":"30/03/2020","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001894-pip01-15-m01"},{"decision_number":"P/0367/2019","pip_number":"EMEA-001191-PIP01-11-M03","active_substance":"Daclatasvir","invented_name":"Daklinza","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Chewable tablet;Film-coated tablet","condition_indication":"Treatment of chronic hepatitis C","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/11/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"23/08/2012","last_updated_date":"30/03/2020","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001191-pip01-11-m03"},{"decision_number":"P/0366/2019","pip_number":"EMEA-000060-PIP07-19","active_substance":"Canakinumab","invented_name":"Ilaris","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder for solution for injection;Solution for injection","condition_indication":"Treatment of gout","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/11/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"27/03/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000060-pip07-19"},{"decision_number":"P/0340/2019","pip_number":"EMEA-002027-PIP02-17-M01","active_substance":"Influenza virus surface antigens (haemagglutinin) of strain A (H1N1);influenza virus surface antigens (haemagglutinin) of strain A (H3N2);influenza virus surface antigens (haemagglutinin) of strain B  (Victoria lineage);influenza virus surface antigens (haemagglutinin) of strain B (Yamagata lineage)","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of influenza infection","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/09/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Adimmune Corporation (Taiwan); Tel.: +886 425381220 ext.1809; E-mail: wendy_tsen@adimmune.com.tw","first_published_date":"12/02/2018","last_updated_date":"26/03/2020","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002027-pip02-17-m01"},{"decision_number":"P/0348/2019","pip_number":"EMEA-001866-PIP01-15-M04","active_substance":"2-hydroxypropyl-ß-cyclodextrin (HP-ß-CD)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Niemann-Pick disease, type C","routes_of_administration":"Intrathecal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/09/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mandos, LLC; Tel. (323)747-7472; E-mail: support@mandoshealth.com","first_published_date":"17/03/2017","last_updated_date":"26/03/2020","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001866-pip01-15-m04"},{"decision_number":"P/0334/2019","pip_number":"EMEA-000139-PIP01-07-M03","active_substance":"recombinant Neisseria meningitidis group B NHBA fusion protein;recombinant Neisseria meningitidis group B NadA protein;recombinant Neisseria meningitidis group B fHbp fusion protein;Outer Membrane Vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254 measured as amount of total protein containing the PorA P1.4","invented_name":"Bexsero","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Meningococcal meningitis","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/09/2019","compliance_outcome":"Positive","compliance_opinion_date":"15/11/2019","compliance_procedure_number":"EMEA-C-000139-PIP01-07-M03","contact_for_public_enquiries":"GSK Vaccines S.r.l.; Tel. +1 438 899 8201; Email: eu.paediatric-plans@gsk.com","first_published_date":"28/07/2010","last_updated_date":"26/03/2020","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000139-pip01-07-m03"},{"decision_number":"P/0357/2019","pip_number":"EMEA-002608-PIP01-19","active_substance":"2-(3-(1-carboxy-5-[(6-[18F]fluoropyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Diagnosis of prostate cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/10/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Curium Netherlands B.V.; E-mail: regulatory.cyclopharma@curiumpharma.com; Tel. +33 473632713","first_published_date":"25/03/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002608-pip01-19"},{"decision_number":"P/0353/2019","pip_number":"EMEA-002585-PIP01-19","active_substance":"autologous human T cells genetically modified ex-vivo with a lentiviral vector encoding a chimeric antigen receptor (CAR) for B-cell maturation antigen (BCMA) (JNJ-68284528)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of Multiple Myeloma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/10/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International N.V; Tel.: +353 857446696; E-mail: nbuhl@ITS.JNJ.com","first_published_date":"25/03/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002585-pip01-19"},{"decision_number":"P/0355/2019","pip_number":"EMEA-002583-PIP01-19","active_substance":"","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"","condition_indication":"Treatment of glaucoma;Treatment of ocular hypertension","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/10/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"25/03/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002583-pip01-19"},{"decision_number":"P/0351/2019","pip_number":"EMEA-002564-PIP01-19","active_substance":"ecopipam hydrochloride","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Age appropriate oral solid dosage form","condition_indication":"Treatment of Tourette syndrome","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/10/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Emalex Biosciences, Inc.; E-mail: fda_emalex@emalexbiosciences.com; Tel. +1 3127773741","first_published_date":"25/03/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002564-pip01-19"},{"decision_number":"P/0307/2019","pip_number":"EMEA-002628-PIP01-19","active_substance":"Botulinum toxin type A","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Prevention of post-operative atrial fibrillation in patients undergoing open-chest cardiac surgery","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergan Pharmaceuticals International Limited; E-mail: ml-eu_reg_affairs@allergan.com; Tel. +44 (0)1628 4944444","first_published_date":"25/03/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002628-pip01-19"},{"decision_number":"P/0354/2019","pip_number":"EMEA-002424-PIP02-19","active_substance":"7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-[(3S)-tetrahydrofuran-3-yl]-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one maleate","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of dementia with Lewy bodies","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/10/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eisai Ltd; E-mail: lmedInfo@eisai.net; Tel. +44 2086001400","first_published_date":"25/03/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002424-pip02-19"},{"decision_number":"P/0356/2019","pip_number":"EMEA-001978-PIP02-19","active_substance":"aprocitentan","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/10/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Idorsia Pharmaceuticals Deutschland GmbH  E-mail: clinical-trials-disclosure@idorsia.com  Tel. +41 588440000 &nbsp","first_published_date":"25/03/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001978-pip02-19"},{"decision_number":"P/0301/2019","pip_number":"EMEA-002594-PIP01-19","active_substance":"Infigratinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of cholangiocarcinoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"QED Therapeutics; Tel. +1 6502314088; E-mail: susan.moran@qedtx.com","first_published_date":"25/03/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002594-pip01-19"},{"decision_number":"P/0346/2019","pip_number":"EMEA-002598-PIP01-19","active_substance":"Fexapotide (friflutate)","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of benign prostatic hyperplasia","routes_of_administration":"Intraprostatic use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"FGK Representative Service GmbH; E-mail: info@nymox.com; Tel. +1 8009369669","first_published_date":"25/03/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002598-pip01-19"},{"decision_number":"P/0308/2019","pip_number":"EMEA-002593-PIP01-19","active_substance":"zofenopril;nebivolol","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Menarini Ricerche S.p.A.; E-mail: prijli@menarini.it; Tel. + 39 0555680633","first_published_date":"25/03/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002593-pip01-19"},{"decision_number":"P/0309/2019","pip_number":"EMEA-002570-PIP01-19","active_substance":"atropine sulfate;obidoxime (chloride)","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"","condition_indication":"Treatment of organophosphorus poisoning","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Emergent Netherlands B.V.; Tel.: +1 2406313200; E-mail: productinquiries@ebsi.com","first_published_date":"25/03/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002570-pip01-19"},{"decision_number":"P/0352/2019","pip_number":"EMEA-001931-PIP02-19","active_substance":"human fibrinogen","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder for solution for injection or infusion","condition_indication":"Treatment of acquired fibrinogen deficiency","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/10/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biotest AG; Tel. + 49 6103 801497E-mail: clinical.trials@biotest.com","first_published_date":"25/03/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001931-pip02-19"},{"decision_number":"P/0343/2019","pip_number":"EMEA-002569-PIP04-19","active_substance":"rosuvastatin;ramipril","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Prevention of cardiovascular events;Treatment of hypertension;Treatment of lipid metabolism disorders","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"EGIS Pharmaceuticals PLC ; Tel. +36 18032414; E-mail: registry@registry.hu","first_published_date":"25/03/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002569-pip04-19"},{"decision_number":"P/0343/2019","pip_number":"EMEA-002569-PIP04-19","active_substance":"rosuvastatin;ramipril","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Prevention of cardiovascular events;Treatment of hypertension;Treatment of lipid metabolism disorders","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"EGIS Pharmaceuticals PLC ; Tel. +36 18032414; E-mail: registry@registry.hu","first_published_date":"25/03/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002569-pip04-19-0"},{"decision_number":"P/0304/2019","pip_number":"EMEA-002444-PIP02-18","active_substance":"Equine immunoglobulin F(ab')2 fragments targeting Shiga toxin","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Solution for infusion","condition_indication":"Prevention of haemolytic uraemic syndrome","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"10/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Chemo Research S.L.E-mail: enrico.coli@exeltis.com Tel.: +34 913021560","first_published_date":"23/03/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002444-pip02-18"},{"decision_number":"P/0342/2019","pip_number":"EMEA-002157-PIP01-17","active_substance":"recombinant hepatitis B vaccine","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of hepatitis B virus infection","routes_of_administration":"Intramuscular use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"10/09/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"VBI Vaccines Inc.; Tel. +1 6137494200 ext.151; E-mail: byassin-rajkumar@vbivaccines.com","first_published_date":"23/03/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002157-pip01-17"},{"decision_number":"P/0320/2019","pip_number":"EMEA-001883-PIP03-17","active_substance":"pegvorhyaluronidase alpha","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of all conditions contained in the category of malignant neoplasms (except haematopoietic and lymphoid tissue)","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Halozyme Inc.; Tel. +1 8448554256; E-mail: medinfo@halozyme.com","first_published_date":"20/03/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001883-pip03-17"},{"decision_number":"P/0317/2019","pip_number":"EMEA-002036-PIP01-16","active_substance":"fosmetpantotenate","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Powder for oral suspension;Granules for oral suspension","condition_indication":"Treatment of Pantothenate Kinase Associated Neurodegeneration","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Retrophin Europe Limited; Tel. +1 7602608600; E-mail: info@retrophin.com","first_published_date":"20/03/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002036-pip01-16"},{"decision_number":"P/0325/2019","pip_number":"EMEA-001492-PIP02-18","active_substance":"trifarotene","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Cream","condition_indication":"Treatment of ichthyoses","routes_of_administration":"Topical use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/09/2020","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Premier Research Group SLU; Tel. +61 386147707; E-mail: Niall.Morrissey@maynepharma.com","first_published_date":"20/03/2020","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001492-pip02-18"},{"decision_number":"P/0283/2019","pip_number":"EMEA-002547-PIP01-19","active_substance":"human chorionic gonadotrophin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of female infertility","routes_of_administration":"Intramuscular use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/08/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Regulis Consulting Europe Ltd; E-mail: regulatory@regulis.com; Tel. +44(0) 1442 890909","first_published_date":"20/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002547-pip01-19"},{"decision_number":"P/0270/2019","pip_number":"EMEA-002540-PIP01-18","active_substance":"Istradefylline","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of Parkinson's disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/08/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kyowa Kirin Limited; E-mail: kkd.6002@kyowakirin.com; Tel. +1 6099 191100","first_published_date":"20/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002540-pip01-18"},{"decision_number":"P/0281/2019","pip_number":"EMEA-002521-PIP01-18","active_substance":"Botulinum toxin type A","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of skin wrinkling","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/08/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergan Pharmaceuticals International Limited; E-mail: ml-eu_reg_affairs@allergan.com; Tel. +44 (0)1628 4944444","first_published_date":"20/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002521-pip01-18"},{"decision_number":"P/0286/2019","pip_number":"EMEA-001722-PIP01-14-M02","active_substance":"eteplirsen","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Duchenne muscular dystrophy","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sarepta Therapeutics Ireland Limited; E-mail: ekelly@sarepta.com; Tel. +353 868792759","first_published_date":"29/03/2016","last_updated_date":"20/11/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001722-pip01-14-m02"},{"decision_number":"P/0294/2019","pip_number":"EMEA-002499-PIP02-19","active_substance":"tafasitamab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of diffuse large B-cell lymphoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/08/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Incyte Biosciences Distribution B.V.; E-mail: globalmedinfo@incyte.com; Tel. +800 0002 7423","first_published_date":"20/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002499-pip02-19"},{"decision_number":"P/0293/2019","pip_number":"EMEA-002491-PIP02-19","active_substance":"ciclosporin","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution","condition_indication":"Treatment of dry eye disease","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/08/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sun Pharmaceutical Industries Europe BV; E-mail: juliette.omtzigt@sunpharma.com; Tel. +31 2356 85502","first_published_date":"20/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002491-pip02-19"},{"decision_number":"P/0290/2019","pip_number":"EMEA-002577-PIP01-19","active_substance":"Gallium 68-labelled Prostate-Specific Membrane Antigen-11 (68Ga-PSMA-11)","invented_name":"","therapeutic_area":"Diagnostic;Oncology","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Visualisation of prostate specific membrane antigen in prostate cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/08/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Endocyte, Inc.; E-mail: cjordan@endocyte.com; Tel. +1 7654 637175","first_published_date":"20/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002577-pip01-19"},{"decision_number":"P/0289/2019","pip_number":"EMEA-002573-PIP01-19","active_substance":"EGFR-cMET bispecific antibody","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion;Solution for injection","condition_indication":"Treatment of lung carcinoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/08/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; Ireland; Tel. +353 857446696; E-mail: nbuhl@its.jnj.com;  ","first_published_date":"20/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002573-pip01-19"},{"decision_number":"P/0278/2019","pip_number":"EMEA-002428-PIP02-18","active_substance":"relugolix;estradiol;norethisterone acetate","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of endometriosis","routes_of_administration":"Oral use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"16/08/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Myovant Sciences Ireland Limited; Tel.+1 6502380250; E-mail: PIPrelugolix@myovant.com","first_published_date":"20/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002428-pip02-18"},{"decision_number":"P/0295/2019","pip_number":"EMEA-001437-PIP02-19","active_substance":"mifepristone","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"","condition_indication":"Treatment of endometriosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/08/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Laboratorios Litaphar S.L.; E-mail: eencinas@dynakin.com; Tel. +34 9440 45504","first_published_date":"20/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001437-pip02-19"},{"decision_number":"P/0247/2019","pip_number":"EMEA-001918-PIP01-15-M02","active_substance":"balovaptan","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Dispersible tablet","condition_indication":"Treatment of autism spectrum disorder","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/07/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"21/04/2017","last_updated_date":"18/11/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001918-pip01-15-m02"},{"decision_number":"P/0237/2019","pip_number":"EMEA-001509-PIP01-13-M02","active_substance":"fentanyl hydrochloride","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Transdermal system","condition_indication":"Treatment of acute pain","routes_of_administration":"Transdermal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/07/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Incline Therapeutics Europe Ltd; Tel. +1 973 290 6000; E-mail: medical.information@themedco.com","first_published_date":"06/06/2014","last_updated_date":"14/11/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001509-pip01-13-m02"},{"decision_number":"P/225/2019","pip_number":"EMEA-000815-PIP01-09-M01","active_substance":"Dermatophagoides pteronyssinus;Dermatophagoides farinae","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/07/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergy Therapeutics (UK) Ltd; Tel. +44(0)1903 844 700; E-mail: infoservices@allergytherapeutics.com","first_published_date":"25/11/2010","last_updated_date":"14/11/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000815-pip01-09-m01"},{"decision_number":"P/224/2019","pip_number":"EMEA-000808-PIP01-09-M01","active_substance":"birch pollen;hazel pollen;alder pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal solution","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Sublingual use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/07/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergy Therapeutics (UK) Ltd; Tel. +44(0)1903 844 700; E-mail: infoservices@allergytherapeutics.com","first_published_date":"25/11/2010","last_updated_date":"14/11/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000808-pip01-09-m01"},{"decision_number":"P/0254/2019","pip_number":"EMEA-002560-PIP01-19","active_substance":"Bisoprolol fumarate;ramipril","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of heart failure;Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/07/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Neopharmed Gentili S.r.l; Tel. +39 06 77209020; E-mail: direnzo@direnzo.biz","first_published_date":"13/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002560-pip01-19"},{"decision_number":"P/0266/2019","pip_number":"EMEA-002575-PIP01-19","active_substance":"BLU-667","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of lung cancer (small cell and non-small cell lung cancer)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"26/07/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Blueprint Medicines (Netherlands) B.V.; E-mail: medinfo@blueprintmedicines.com; Tel. +31 858880230","first_published_date":"13/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002575-pip01-19"},{"decision_number":"P/0255/2019","pip_number":"EMEA-002558-PIP01-19","active_substance":"brimonidine","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution","condition_indication":"Treatment of conjunctival hyperaemia","routes_of_administration":"Ophthalmic use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"16/07/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bausch Health Ireland Limited; Tel. +48 22 203 90 45; E-mail: EMEA.Regulatory@bauschhealth.com","first_published_date":"13/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002558-pip01-19"},{"decision_number":"P/0257/2019","pip_number":"EMEA-002557-PIP01-19","active_substance":"heparin (sodium)","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"","condition_indication":"Prevention of thromboembolic events","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/07/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"B. Braun Melsungen AG; Tel. ++49 6172 76464 - 18; E-mail: caren.martini@pharmalex.com","first_published_date":"13/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002557-pip01-19"},{"decision_number":"P/0259/2019","pip_number":"EMEA-002541-PIP01-18","active_substance":"ezetimibe;rosuvastatin calcium","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of elevated cholesterol","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/07/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Abbott Laboratories Limited; Tel.  +44 (0) 1628 644513; E-mail: robyn.hall@abbott.com","first_published_date":"13/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002541-pip01-18"},{"decision_number":"P/0228/2019","pip_number":"EMEA-002525-PIP01-18","active_substance":"moxetumomab pasudotox","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of hairy cell leukaemia","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/07/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com","first_published_date":"13/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002525-pip01-18"},{"decision_number":"P/0227/2019","pip_number":"EMEA-002472-PIP02-19","active_substance":"genetically modified replication-incompetent herpes simplex virus-1 expressing collagen VII (beremagene geperpavec)","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Gel","condition_indication":"Treatment of dystrophic epidermolysis bullosa","routes_of_administration":"Topical use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"08/07/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Krystal Biotech, Inc.; Tel. +434 409 0176; E-mail: svinzant@krystalbio.com","first_published_date":"13/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002472-pip02-19"},{"decision_number":"P/0229/2019","pip_number":"EMEA-002471-PIP01-18","active_substance":"tropifexor","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Capsule, soft","condition_indication":"Treatment of non-alcoholic steatohepatitis (NASH)","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"16/07/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"13/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002471-pip01-18"},{"decision_number":"P/0230/2019","pip_number":"EMEA-002457-PIP01-18","active_substance":"Emricasan","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of non-alcoholic steatohepatitis (NASH)","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"16/07/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Conatus Pharmaceuticals, Inc.; 16745 West Bernardo Drive, San Diego; California 92127; U.S.A.; E-mail: aspada@conatuspharma.com; Tel.: +1 858-376-2623","first_published_date":"13/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002457-pip01-18"},{"decision_number":"P/0241/2019","pip_number":"EMEA-002401-PIP01-18","active_substance":"bemarituzumab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"","condition_indication":"Treatment of gastric and gastro-oesophageal junction cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/07/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Five Prime Therapeutics, Inc.; Tel. +001 415 365 5600; E-mail: Carmen.Ladner@fiveprime.com","first_published_date":"13/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002401-pip01-18"},{"decision_number":"P/0242/2019","pip_number":"EMEA-002375-PIP02-18","active_substance":"Dexamethasone (sodium phosphate);levofloxacin","invented_name":"","therapeutic_area":"Oto-rhino-laryngology","pharmaceutical_forms":"Ear drops, solution","condition_indication":"Treatment of acute otitis externa","routes_of_administration":"Auricular use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"17/07/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"NTC srl; Tel.  +39 024385041; E-mail: federico.bertocchi@ntcpharma.com","first_published_date":"13/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002375-pip02-18"},{"decision_number":"P/0231/2019","pip_number":"EMEA-002343-PIP01-18","active_substance":"Diphtheria toxoid;tetanus toxoid;pertussis toxoid;pertussis filamentous haemagglutinin;pertactin","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"","condition_indication":"Prevention of infectious diseases caused by Corynebacterium diphtheriae, Clostridium tetani and Bordetella pertussis","routes_of_administration":"Intramuscular use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"16/07/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vakzine Projekt Management GmbH; Tel.+4951116990819; E-mail: info@vakzine-manager.de","first_published_date":"13/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002343-pip01-18"},{"decision_number":"P/0232/2019","pip_number":"EMEA-002200-PIP02-19","active_substance":"bempedoic acid;ezetimibe","invented_name":"","therapeutic_area":"Cardiovascular diseases;Other","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of mixed dyslipidaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/07/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Esperion Therapeutics, Inc.; E-mail: ahall@esperion.com; Tel.: +1 7346346816","first_published_date":"12/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002200-pip02-19"},{"decision_number":"P/0268/2019","pip_number":"EMEA-001884-PIP03-18","active_substance":"Hydrogen peroxide","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Cutaneous solution","condition_indication":"Treatment of common warts (verrucae vulgaris)","routes_of_administration":"Cutaneous use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"25/07/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aclaris Therapeutics, Inc.; Tel. +1 484 540 6264; E-mail: cmatkowski@aclaristx.com ","first_published_date":"12/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001884-pip03-18"},{"decision_number":"P/0233/2019","pip_number":"EMEA-001872-PIP02-19","active_substance":"bempedoic acid","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of mixed dyslipidaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/07/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Esperion Therapeutics, Inc.; Tel. +1 7346346816; E-mail: ahall@esperion.com","first_published_date":"12/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001872-pip02-19"},{"decision_number":"P/0206/2019","pip_number":"EMEA-002152-PIP02-17-M01","active_substance":"daratumumab","invented_name":"Darzalex","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection;Concentrate for solution for infusion","condition_indication":"Treatment of lymphoid malignancies (except mature B-cell neoplasms)","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/06/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International N.V.; E-mail: nbuhl@its.jnj.com; Tel. +353 8574 46696","first_published_date":"24/10/2017","last_updated_date":"08/11/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002152-pip02-17-m01"},{"decision_number":"P/0197/2019","pip_number":"EMEA-001441-PIP02-15-M02","active_substance":"semaglutide","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/06/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk; Tel. +45 44448888; E-mail: paediatrics@novonordisk.com","first_published_date":"28/10/2016","last_updated_date":"08/11/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001441-pip02-15-m02"},{"decision_number":"P/0214/2019","pip_number":"EMEA-002551-PIP01-18","active_substance":"capivasertib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of breast cancer;Treatment of prostate cancer","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/06/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB (UK); Tel.: +44 7384522139; E-mail: lee.anderson2@astrazeneca.com","first_published_date":"07/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002551-pip01-18"},{"decision_number":"P/0211/2019","pip_number":"EMEA-002542-PIP01-18","active_substance":"sutimlimab","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of primary Cold Agglutinin Disease","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/06/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bioverativ USA, Inc., a Sanofi Company; Tel.: +31 202453917; E-mail: eumedinfo.gz@sanofi.com","first_published_date":"07/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002542-pip01-18"},{"decision_number":"P/0200/2019","pip_number":"EMEA-002539-PIP01-18","active_substance":"emiplacel","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Dispersion for injection","condition_indication":"Treatment of peripheral ischaemia","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/06/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pluristem Ltd.; Tel.: +972 7747108624; E-mail: iris@pluristem.com","first_published_date":"07/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002539-pip01-18"},{"decision_number":"P/0212/2019","pip_number":"EMEA-002531-PIP01-18","active_substance":"ramipril;bisoprolol","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of coronary artery disease;Treatment of heart failure;Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/06/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Midas Pharma GmbH; E-mail: info@midas-pharma.com; Tel. +49 6132 990583","first_published_date":"07/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002531-pip01-18"},{"decision_number":"P/0216/2019","pip_number":"EMEA-002522-PIP01-18","active_substance":"tisotumab vedotin","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of cervical cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/06/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Genmab A/S; Tel.: +45 70202728; E-mail: clinicaltrials@genmab.com","first_published_date":"07/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002522-pip01-18"},{"decision_number":"P/0215/2019","pip_number":"EMEA-002519-PIP02-18","active_substance":"2-(2-(3-Butoxy-phenyl)-ethylamino)-N,N-dimethyl-acetamide hydrochloride","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of schizophrenia","routes_of_administration":"Oral use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"14/06/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Newron Pharmaceuticals SpA; E-mail: ravi@anand.ch; Tel. +41 793741364","first_published_date":"07/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002519-pip02-18"},{"decision_number":"P/0208/2019","pip_number":"EMEA-002503-PIP01-18","active_substance":"Glu-NH-CO-NH-Lys-(Ahx)-[N,N9-bis[2-hydroxy-5-(carboxyethyl) benzyl]ethylenediamine-N,N9-diacetic acid (PSMA11-HBED-CC) (HBED Trasis)","invented_name":"HBED Trasis","therapeutic_area":"Oncology","pharmaceutical_forms":"Kit for radiopharmaceutical preparation","condition_indication":"Visualisation of prostate specific membrane antigen in prostate cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/06/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Trasis S.A.; Tel.: +32 4988780; E-mail: philippart@trasis.com","first_published_date":"07/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002503-pip01-18"},{"decision_number":"P/0210/2019","pip_number":"EMEA-002423-PIP01-18","active_substance":"dexamethasone","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Ophthalmic insert","condition_indication":"Treatment of postoperative pain and inflammation associated with ophthalmic surgery","routes_of_administration":"Ophthalmic use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"12/06/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ocular Therapeutix Inc.; Tel.: +44 1865670864; E-mail: carole.pugh@eudrac.com","first_published_date":"07/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002423-pip01-18"},{"decision_number":"P/0213/2019","pip_number":"EMEA-002407-PIP01-18","active_substance":"Lentiviral vector containing the human ABCA4 gene","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of inherited retinal disorders","routes_of_administration":"Intraocular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/06/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi-Aventis Recherche & Développement (France); Tel.: +31 202454000; E-mail: eumedinfo.gz@sanofi.com","first_published_date":"07/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002407-pip01-18"},{"decision_number":"P/0202/2019","pip_number":"EMEA-002342-PIP03-18","active_substance":"abemaciclib","invented_name":"Verzenios","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of breast cancer","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/06/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly and Company Limited (US); Tel.: +1 31 75448941; E-mail: wagle_asvari@lilly.com","first_published_date":"07/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002342-pip03-18"},{"decision_number":"P/0222/2019","pip_number":"EMEA-002318-PIP03-19","active_substance":"tilsotolimod","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of malignant melanoma","routes_of_administration":"Intratumoral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/06/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Idera Pharmaceuticals Inc.; Tel.: +1 4843481600; E-mail: info@iderpharma.com","first_published_date":"07/11/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002318-pip03-19"},{"decision_number":"P/0189/2019","pip_number":"EMEA-001126-PIP01-10-M03","active_substance":"Deferiprone","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of chronic iron overload","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/05/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Consorzio per Valutazioni Biologiche e Farmacologiche; Tel. + 39 08225075 ; E-mail: deep@cvbf.net","first_published_date":"19/01/2012","last_updated_date":"30/10/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001126-pip01-10-m03"},{"decision_number":"P/0182/2019","pip_number":"EMEA-002553-PIP01-19","active_substance":"colecalciferol","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of osteoporosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/05/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pharma Patent Kft.; E-mail: info@pharmapatent.hu; Tel. +36 16306182","first_published_date":"29/10/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002553-pip01-19"},{"decision_number":"P/0184/2019","pip_number":"EMEA-002548-PIP01-19","active_substance":"amoxicillin","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of Helicobacter spp. infections","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/05/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Micro Labs GmbH; Tel.:  +91 8025731936 / 37 Ext.302; E-mail: microeu@microlabs.in","first_published_date":"29/10/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002548-pip01-19"},{"decision_number":"P/0183/2019","pip_number":"EMEA-002549-PIP01-19","active_substance":"clarithromycin","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of Helicobacter spp. infections","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/05/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Micro Labs GmbH; Tel.:  +91 8025731936 / 37 Ext.302; E-mail: microeu@microlabs.in","first_published_date":"29/10/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002549-pip01-19"},{"decision_number":"P/0192/2019","pip_number":"EMEA-002527-PIP01-18","active_substance":"seladelpar","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of primary biliary cholangitis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/05/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CymaBay Ireland Limited; Tel.: +1 5102938800; E-mail: cbueno@cymabay.com","first_published_date":"29/10/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002527-pip01-18"},{"decision_number":"P/0185/2019","pip_number":"EMEA-002533-PIP01-18","active_substance":"salbutamol sulfate;Budesonide","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Pressurised inhalation (suspension)","condition_indication":"Treatment of asthma","routes_of_administration":"Inhalation use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/05/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB (UK); Tel. +44 2037496236; E-mail: paediatrics@astrazeneca.com","first_published_date":"29/10/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002533-pip01-18"},{"decision_number":"P/0187/2019","pip_number":"EMEA-002520-PIP01-18","active_substance":"Candesartan;atorvastatin;amlodipine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypercholesterolaemia;Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/05/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Midas Pharma GmbH; E-mail: pv@midas-pharma.com; Tel. +49 6132 990583","first_published_date":"29/10/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002520-pip01-18"},{"decision_number":"P/0188/2019","pip_number":"EMEA-002512-PIP01-18","active_substance":"pantoprazole","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of Helicobacter spp. infections","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/05/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Micro Labs GmbH; Tel.:  +91 8025731936 / 37 Ext.302; E-mail: microeu@microlabs.in","first_published_date":"29/10/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002512-pip01-18"},{"decision_number":"P/0175/2019","pip_number":"EMEA-002497-PIP01-18","active_substance":"recombinant human lecithin cholesterol acyltransferase","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of acute ST- elevation myocardial infarction","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/05/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB (Sweden); Tel.: +46 8553260000; E-mail: kontakt@astrazeneca.com","first_published_date":"29/10/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002497-pip01-18"},{"decision_number":"P/0168/2019","pip_number":"EMEA-002468-PIP02-18","active_substance":"Humanized antibody targeting B cell maturation antigen conjugated with maleimidocaproyl monomethyl auristatin F","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Intravenous use","condition_indication":"Treatment of Multiple Myeloma","routes_of_administration":"Solution for infusion","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/05/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Tel. +1 4388998201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"29/10/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002468-pip02-18"},{"decision_number":"P/0180/2019","pip_number":"EMEA-002331-PIP01-18","active_substance":"ibandronic acid","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Intravenous use","condition_indication":"Treatment of osteoporosis","routes_of_administration":"Solution for injection","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/05/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pharma Patent Kft.; E-mail: info@pharmapatent.hu; Tel. +36 16306182","first_published_date":"29/10/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002331-pip01-18"},{"decision_number":"P/0177/2019","pip_number":"EMEA-002306-PIP02-18","active_substance":"Dusquetide","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Intravenous use","condition_indication":"Prevention of oral mucositis","routes_of_administration":"Solution for infusion","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/05/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Soligenix UK Limited; Tel.: +1 609 538 8200; E-mail: arumage@soligenix.com ","first_published_date":"29/10/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002306-pip02-18"},{"decision_number":"P/0167/2019","pip_number":"EMEA-002268-PIP03-18","active_substance":"niraparib","invented_name":"Zejula","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of prostate malignant neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/05/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen Research & Development; Tel. +353 857446696; E-mail: nbuhl@its.jnj.com","first_published_date":"29/10/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002268-pip03-18"},{"decision_number":"P/0178/2019","pip_number":"EMEA-000311-PIP06-18","active_substance":"ustekinumab","invented_name":"Stelara","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Concentrate for solution for infusion;Solution for injection","condition_indication":"Treatment of Systemic Lupus Erythematosus (SLE)","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/05/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen Cilag International NV; Tel. +3214602111; E-mail: contact@Janssen-emea.com","first_published_date":"29/10/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000311-pip06-18"},{"decision_number":"P/0171/2019","pip_number":"EMEA-001806-PIP03-18","active_substance":"carfilzomib","invented_name":"Kyprolis","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of Multiple Myeloma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/05/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V; Tel.: +44 (0)1223 420305; E-mail: medinfointernational@amgen.com","first_published_date":"29/10/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001806-pip03-18"},{"decision_number":"P/0298/2016","pip_number":"EMEA-001732-PIP02-15","active_substance":"Humanised chimeric antibody with a humanised H chain and a chimeric (mouse V-domain, human C-domain) L chain against epidermal growth factor receptor conjugated to maleimidocaproyl monomethylauristatin F (ABT-414)L chain against epidermal growth factor receptor conjugated to maleimidocaproylmonomethylauristatin F (ABT-414)","invented_name":"","therapeutic_area":"","pharmaceutical_forms":"Powder for solution for injection or infusion","condition_indication":"Treatment of high-grade glioma","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/11/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"06/01/2017","last_updated_date":"07/08/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001732-pip02-15"},{"decision_number":"P/0369/2018","pip_number":"EMEA-001936-PIP01-16-M01","active_substance":"dexamethasone (SHP640);povidone;iodine","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Ocular use","condition_indication":"Treatment of infectious conjunctivitis","routes_of_administration":"Eye drops","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/12/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Shire Pharmaceuticals Ireland Ltd; E-mail: medinfoEMEA@shire.com; Tel.: +43 1 20 1002473461;  ","first_published_date":"27/01/2017","last_updated_date":"28/06/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001936-pip01-16-m01"},{"decision_number":"P/0286/2017","pip_number":"EMEA-002057-PIP01-16","active_substance":"5-(4-Fluoro-1-benzothiophen-2-yl)-8-methyl-1,9-dihydro-2H-[1,3]oxazolo[4,5-H][2,3]benzodiazepin-2-one (S44819)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Powder for oral suspension","condition_indication":"Treatment of ischemic stroke to improve recovery","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/10/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierE-mail: mail.pip.enquiries@servier.comTel.: +33 155726000","first_published_date":"12/02/2018","last_updated_date":"27/06/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002057-pip01-16"},{"decision_number":"P/0168/2018","pip_number":"EMEA-001834-PIP02-16-M01","active_substance":"Betrixaban","invented_name":"Dexxience","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard;Age appropriate oral solid dosage form","condition_indication":"Prevention of venous thromboembolism","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/06/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Portola Pharma UK Limited; E-mail: info@portola.com; Tel. +1 6502 467000","first_published_date":"30/01/2017","last_updated_date":"27/06/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001834-pip02-16-m01"},{"decision_number":"P/0139/2019","pip_number":"EMEA-000731-PIP01-09-M03","active_substance":"nonacog beta pegol","invented_name":"Refixia","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of hereditary factor IX deficiency","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/04/2019","compliance_outcome":"Positive","compliance_opinion_date":"15/11/2019","compliance_procedure_number":"EMEA-C-000731-PIP01-09-M03","contact_for_public_enquiries":"Novo Nordisk A/S; E-mail: paediatrics@novonordisk.com; Tel. +45 4444 8888","first_published_date":"24/01/2011","last_updated_date":"25/06/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000731-pip01-09-m03"},{"decision_number":"P/0072/2019","pip_number":"EMEA-002138-PIP01-17-M01","active_substance":"carotuximab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of soft tissue sarcoma","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"22/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"TRACON Pharma Limited; Tel. +1 8585500780; E-mail: pbitar@traconpharma.com; sbenedict@traconpharma.com; ppathak@traconpharma.com","first_published_date":"05/03/2018","last_updated_date":"25/06/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002138-pip01-17-m01"},{"decision_number":"P/0118/2019","pip_number":"EMEA-001729-PIP02-18","active_substance":"cenegermin","invented_name":"Oxervate","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution","condition_indication":"Treatment of dry eye disease","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/04/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dompé farmaceutici S.p.A.; E-mail: annabella.amatulli@dompe.com; Tel. +39 2583 83230","first_published_date":"25/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001729-pip02-18"},{"decision_number":"P/0098/2019","pip_number":"EMEA-001037-PIP02-11-M05","active_substance":"Neisseria meningitidis serogroup B recombinant lipoprotein (rLP2086; subfamily A; Escherichia coli);Neisseria meningitidis serogroup B recombinant lipoprotein (rLP2086; subfamily B; Escherichia coli)","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of invasive meningococcal disease caused by N. meningitidis serogroup B","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"22/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG; Tel. +44 (0)1304 646 607; E-mail: pip_enquiries@pfizer.com","first_published_date":"31/05/2013","last_updated_date":"24/06/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001037-pip02-11-m05"},{"decision_number":"P/0127/2019","pip_number":"EMEA-002419-PIP02-18","active_substance":"177Lu-PSMA-617","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of PSMA-expressing prostate cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/04/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Succurro Clinical Research Limited; Tel. +1 3176080769; E-Mail: cjordan@endocyte.com","first_published_date":"24/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002419-pip02-18"},{"decision_number":"P/0113/2019","pip_number":"EMEA-002380-PIP01-18","active_substance":"chemically modified human recombinant sulfamidase","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Swedish Orphan Biovitrum ABE-mail: medical.info@sobi.comTel. +46 8697 2000","first_published_date":"24/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002380-pip01-18"},{"decision_number":"P/0155/2019","pip_number":"EMEA-002365-PIP01-18","active_substance":"liposomal vinorelbine (tartrate)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of rhabdomyosarcoma","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"17/04/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"TLC Biopharmaceuticals B.V.; Tel.  +886 226557377; E-mail: carlb@tlcbio.com","first_published_date":"24/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002365-pip01-18"},{"decision_number":"P/0119/2019","pip_number":"EMEA-002510-PIP01-18","active_substance":"orvepitant","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of refractory chronic cough","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/04/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"NeRRe Therapeutics Ltd; Tel.  +44 1438906960; E-mail: steve.pawsey@nerretherapeutics.com","first_published_date":"24/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002510-pip01-18"},{"decision_number":"P/0120/2019","pip_number":"EMEA-002509-PIP01-18","active_substance":"rosuvastatin calcium;fenofibrate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of  elevated cholesterol with elevated triglycerides","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/04/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mylan Healthcare GmbH; Tel.  +49 51167502400; E-mail: mylan.healthcare@mylan.com","first_published_date":"24/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002509-pip01-18"},{"decision_number":"P/0132/2019","pip_number":"EMEA-002504-PIP01-18","active_substance":"N2’-Deacetyl-N2’-[4-methyl-4-(oxobutyldithio)-1-oxopentyl]-maytansine-hu769_4D4 Antibody","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (excluding central nervous system, haematopoietic and lymphoid tissue neoplasms)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/04/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi-Aventis Recherche & Développement; Tel. +33 169745695; E-mail: contact-us@sanofi.com","first_published_date":"24/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002504-pip01-18"},{"decision_number":"P/0148/2019","pip_number":"EMEA-002374-PIP01-18","active_substance":"anti-IL-21 humanized immunoglobulin G1-kappa monoclonal antibody (BOS161721)","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Systemic Lupus Erythematosus (SLE)","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"17/04/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boston Pharmaceuticals, Inc.; Tel. +1 6175884844; E-mail: richard@bostonpharmaceuticals.com","first_published_date":"24/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002374-pip01-18"},{"decision_number":"P/0135/2019","pip_number":"EMEA-002496-PIP01-18","active_substance":"serlopitant","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of prurigo nodularis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/04/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Menlo Therapeutics Inc.; Tel.  +1 6504861416; E-mail: info@menlotx.com","first_published_date":"24/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002496-pip01-18"},{"decision_number":"P/0090/2019","pip_number":"EMEA- 002191-PIP02-17","active_substance":"ivacaftor / tezacaftor/ potassium (benzenesulfonyl)({[6-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridin-3-yl]carbonyl})azanide (VX-659)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of cystic fibrosis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vertex Pharmaceuticals (Europe) Ltd.; Tel. +1 8776348789; E-mail: medicalinfo@vrtx.com","first_published_date":"24/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002191-pip02-17"},{"decision_number":"P/0140/2019","pip_number":"EMEA-002489-PIP01-18","active_substance":"rivoceranib (mesilate)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/04/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Elevar Therapeutics Limited; Tel. +1 (801) 833 1227; E-mail: garomin@elevartherapeutics.com","first_published_date":"24/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002489-pip01-18"},{"decision_number":"P/0105/2019","pip_number":"EMEA-002165-PIP02-18","active_substance":"(R)-azasetron (besilate) (SENS-401)","invented_name":"","therapeutic_area":"Oto-rhino-laryngology","pharmaceutical_forms":"Tablet;Powder for oral solution;Orodispersible tablet","condition_indication":"Prevention of platinum-induced ototoxic hearing loss","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sensorion SA; E-mail: contact@sensorion-pharma.com; Tel.  +33  4672 07730","first_published_date":"24/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002165-pip02-18"},{"decision_number":"P/0075/2019","pip_number":"EMEA-002470-PIP01-18","active_substance":"N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl) pyridin-2-yl) acetamide (KX2-391)","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Ointment","condition_indication":"Treatment of actinic keratosis","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Almirall S.A.; Tel.  +34 932912958; E-mail: sonia.barange@almirall.com","first_published_date":"24/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002470-pip01-18"},{"decision_number":"P/0102/2019","pip_number":"EMEA-002364-PIP02-18","active_substance":"Dihomo-γ-linolenic acid (DS107)","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Cream","condition_indication":"Treatment of atopic dermatitis","routes_of_administration":"Topical use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"DS Biopharma Ltd; Tel. +353 12998381; E-mail: dsbiopharmaregulatory@dsbiopharma.com","first_published_date":"24/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002364-pip02-18"},{"decision_number":"P/0099/2019","pip_number":"EMEA-002469-PIP01-18","active_substance":"pyrimidinyl-aminopyridine dual leucine zipper kinase inhibitor (GDC-0134)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of amyotrophic lateral sclerosis","routes_of_administration":"Oral use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"22/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"24/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002469-pip01-18"},{"decision_number":"P/0078/2019","pip_number":"EMEA-002461-PIP01-18","active_substance":"genetically modified Mycobacterium bovis BCG","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for intravesical suspension","condition_indication":"Treatment of ureter and bladder carcinoma","routes_of_administration":"Intravesical use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"medac Gesellschaft für klinische Spezialpräparate mbH Tel.  +49 410380060E-mail: contact@medac.de","first_published_date":"24/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002461-pip01-18"},{"decision_number":"P/0095/2019","pip_number":"EMEA-002069-PIP02-17","active_substance":"(6aR,10aR)-1-Hydroxy-6,6-dimethyl-3-(2-methyl-2-octanyl)-6a,7,10,10a-tetrahydro-6H- benzo[c]chromene-9-carboxylic acid (lenabasum)","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Age appropriate oral formulation;Tablet","condition_indication":"Treatment of systemic sclerosis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Corbus Pharmaceuticals Holdings Inc; E-mail: bwhite@corbuspharma.com; Tel. +1 9195 997426","first_published_date":"24/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002069-pip02-17"},{"decision_number":"P/0079/2019","pip_number":"EMEA-002456-PIP01-18","active_substance":"rosuvastatin calcium;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events;Treatment of dyslipidaemia;Treatment of hypertension;Treatment of ischemic coronary artery disorders","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Abbott Laboratories Limited; Tel.  +44 1628644132; E-mail: abbott-EPD-GRA@abbott.com","first_published_date":"24/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002456-pip01-18"},{"decision_number":"P/0161/2019","pip_number":"EMEA-002442-PIP01-18","active_substance":"inactivated patients own (autologous) microorganism (Escherichia coli, Candida spp., Enterococcus spp., Streptococcus spp., Staphylococcus spp., Prevotella intermedia, Fusobacterium nucleatum and others)","invented_name":"","therapeutic_area":"Dermatology;Oto-rhino-laryngology;Pneumology-allergology;Uro-nephrology","pharmaceutical_forms":"Oral drops (suspension);Oromucosal spray;Cutaneous spray, suspension;Suspension for injection","condition_indication":"Treatment and prevention of bacterial upper respiratory tract infections;Treatment and prevention of dermatitis and eczema;Treatment and prevention of genitourinary tract infections and inflammations","routes_of_administration":"Nasal use;Oral use;Cutaneous use;Intradermal use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/04/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"SymbioVaccin GmbH; Tel. +49 2772981354; E-mail: ina.pieter@symbio.de","first_published_date":"24/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002442-pip01-18"},{"decision_number":"P/0103/2019","pip_number":"EMEA-001741-PIP06-18","active_substance":"upadacitinib","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Prolonged-release tablet","condition_indication":"Treatment of vasculitides","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"25/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"24/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001741-pip06-18"},{"decision_number":"P/0156/2019","pip_number":"EMEA-002439-PIP01-18","active_substance":"rogaratinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of urothelial carcinoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/04/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer AG; Tel. +49 3046815333; E-mail: pediatrics.medical-affairs-europe@bayer.com","first_published_date":"24/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002439-pip01-18"},{"decision_number":"P/0108/2019","pip_number":"EMEA-002428-PIP01-18","active_substance":"relugolix;estradiol;norethisterone acetate","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of leiomyoma of uterus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Myovant Sciences Ireland Limited; Tel.+1 6502380250; E-mail: PIPrelugolix@myovant.com","first_published_date":"24/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002428-pip01-18"},{"decision_number":"P/0121/2019","pip_number":"EMEA-000222-PIP01-08-M09","active_substance":"Etravirine","invented_name":"Intelence; Intelence","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/04/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; Tel. +32 1460 2111; E-mail: contact@janssen-emea.com","first_published_date":"14/07/2011","last_updated_date":"20/06/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000222-pip01-08-m09"},{"decision_number":"P/0070/2019","pip_number":"EMEA-000170-PIP02-10-M03","active_substance":"eltrombopag","invented_name":"Revolade; Revolade","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder for oral suspension;Film-coated tablet","condition_indication":"Treatment of secondary thrombocytopenia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"18/10/2011","last_updated_date":"20/06/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000170-pip02-10-m03"},{"decision_number":"P/0125/2019","pip_number":"EMEA-001080-PIP03-18","active_substance":"Delafloxacin","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for concentrate for solution for infusion;Tablet","condition_indication":"Treatment of community-acquired pneumonia","routes_of_administration":"Oral use;Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"17/04/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"A.Menarini - IndustrieFarmaceutiche Riunite - s.r.I.; E-mail: prijli@menarini.it; Tel. +39 0555 680633","first_published_date":"20/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001080-pip03-18"},{"decision_number":"P/0082/2019","pip_number":"EMEA-000828-PIP06-18","active_substance":"empagliflozin","invented_name":"Jardiance","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of chronic kidney disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/03/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"20/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000828-pip06-18"},{"decision_number":"P/0144/2019","pip_number":"EMEA-000380-PIP05-18","active_substance":"secukinumab","invented_name":"Cosentyx","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of hidradenitis suppurativa","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/04/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"20/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000380-pip05-18"},{"decision_number":"P/0138/2019","pip_number":"EMEA-000341-PIP03-18","active_substance":"L-Asparaginase","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of pancreatic cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/04/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Erytech pharma S.A.; Tel. +33 4787 44438; E-mail: vsemareg@erytech.com","first_published_date":"20/06/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000341-pip03-18"},{"decision_number":"P/0051/2019","pip_number":"EMEA-002477-PIP01-18","active_substance":"human ciliary neurotrophic factor","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Implant","condition_indication":"Treatment of Macular Telangiectasia Type 2","routes_of_administration":"Intravitreal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Neurotech Pharmaceuticals Inc; Tel.  +1 6784272334; E-mail: k.mandell@neurotechusa.com","first_published_date":"26/04/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002477-pip01-18"},{"decision_number":"P/0032/2019","pip_number":"EMEA-002465-PIP01-18","active_substance":"Fibroblast activation protein alpha-targeted interleukin 2 variant immunocytokine","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for infusion","condition_indication":"","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"26/04/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002465-pip01-18"},{"decision_number":"P/0024/2019","pip_number":"EMEA-002462-PIP01-18","active_substance":"telmisartan;Indapamide","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/01/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"PRO.MED.CS a.s.; Tel.  +420 241013111; E-mail: promed@promedcs.com","first_published_date":"26/04/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002462-pip01-18"},{"decision_number":"P/0033/2019","pip_number":"EMEA-002460-PIP01-18","active_substance":"amantadine (hydrochloride)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Prolonged-release capsule (hard)","condition_indication":"Treatment of Parkinson's disease and parkinsonism","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Adamas Pharmaceuticals LLC; Tel.  +1 5104503500; E-mail: https://www.adamaspharma.com/contact-us/","first_published_date":"26/04/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002460-pip01-18"},{"decision_number":"P/0047/2019","pip_number":"EMEA-002450-PIP01-18","active_substance":"rifamycin","invented_name":"","therapeutic_area":"","pharmaceutical_forms":"Prolonged-release tablet","condition_indication":"Treatment of acute infectious diarrhoea","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CRINOS S.P.A.; Tel. +39 0289421721; E-mail: regulatory.affairs@eglab.it","first_published_date":"26/04/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002450-pip01-18"},{"decision_number":"P/0052/2019","pip_number":"EMEA-002441-PIP01-18","active_substance":"technetium (99mTc) trofolastat chloride","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Kit for radiopharmaceutical preparation","condition_indication":"Visualisation of prostate specific membrane antigen in prostate cancer","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROTOP Pharmaka GmbH; Tel.  +49 35126310251; E-mail: reg-affairs@rotop-pharmaka.de","first_published_date":"26/04/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002441-pip01-18"},{"decision_number":"P/0015/2019","pip_number":"EMEA-002425-PIP01-18","active_substance":"synthetic double-stranded siRNA oligonucleotide targeted against transthyretin mRNA, with six phosphorothioate linkages in the backbone, and nine 2’-fluoro and thirty-five 2’-O-methyl nucleoside residues in the sequence, which is covalently linked via a phosphodiester group to a ligand containing three N-acetylgalactosamine residues (ALN-65492)","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of transthyretin-related amyloidosis (ATTR amyloidosis)","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/01/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alnylam Netherlands BV; E-mail: clinicaltrials@alnylam.com; Tel. +1 8663 300326","first_published_date":"25/04/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002425-pip01-18"},{"decision_number":"P/0011/2019","pip_number":"EMEA-002421-PIP01-18","active_substance":"levodopa;carbidopa monohydrate;entacapone","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Intestinal gel","condition_indication":"","routes_of_administration":"Intestinal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/01/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LobSor Pharmaceuticals AB; E-mail: info@lobsor.com; Tel. +46 7222 24408","first_published_date":"25/04/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002421-pip01-18"},{"decision_number":"P/0012/2019","pip_number":"EMEA-002420-PIP01-18","active_substance":"anti-VEGF and anti-DLL4 dual variable domain immunoglobulin (ABT-165)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of malignant colorectal neoplasms","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/01/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628925033","first_published_date":"25/04/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002420-pip01-18"},{"decision_number":"P/0048/2019","pip_number":"EMEA-002416-PIP01-18","active_substance":"ramipril;atorvastatin;amlodipine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypercholesterolaemia;Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Midas Pharma GmbH; E-mail: info@midas-pharma.com; Tel. +49 6132 990583","first_published_date":"25/04/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002416-pip01-18"},{"decision_number":"P/0020/2019","pip_number":"EMEA-002438-PIP01-18","active_substance":"Bruton’s tyrosine kinase inhibitor","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of pemphigus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/01/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Principia Biopharma, Inc.; Tel.  +1 6504167700; E-mail: info@principiabio.com","first_published_date":"24/04/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002438-pip01-18"},{"decision_number":"P/0019/2019","pip_number":"EMEA-002436-PIP01-18","active_substance":"germanium (68Ge) chloride;gallium (68Ga) chloride","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Radionuclide generator","condition_indication":"Radiolabelling agent","routes_of_administration":"","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/01/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ITM Medical Isotopes GmbH; E-mail: info-medical-isotopes@itm.ag; Tel. +49 89 329 8986 600","first_published_date":"24/04/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002436-pip01-18"},{"decision_number":"P/0005/2019","pip_number":"EMEA-002146-PIP02-18","active_substance":"Palbociclib","invented_name":"Ibrance","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard;Age appropriate oral dosage formulation;Tablet","condition_indication":"Treatment of breast malignant neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/01/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG; Tel. +44 (0)1304 646 607; E-mail: pip_enquiries@pfizer.com","first_published_date":"12/04/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002146-pip02-18"},{"decision_number":"P/0038/2019","pip_number":"EMEA-002048-PIP02-18","active_substance":"Givosiran","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Acute Hepatic Porphyria","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alnylam UK Limited; Tel. +1  8663300326; E-mail: clinicaltrials@alnylam.com","first_published_date":"12/04/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002048-pip02-18"},{"decision_number":"P/0044/2019","pip_number":"EMEA-001939-PIP03-16","active_substance":"pexidartinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of benign soft tissue neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Daiichi Sankyo Inc; Tel. +49 8978080; E-mail: service@daiichi-sankyo.eu","first_published_date":"12/04/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001939-pip03-16"},{"decision_number":"P/0049/2019","pip_number":"EMEA-001588-PIP03-18","active_substance":"Encorafenib","invented_name":"Braftovi","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of colorectal carcinoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pierre Fabre Médicament; Tel. +33 800326326; E-mail: medical_information@pierre-fabre.com","first_published_date":"11/04/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001588-pip03-18"},{"decision_number":"P/0037/2019","pip_number":"EMEA-001454-PIP05-18","active_substance":"binimetinib","invented_name":"Mektovi","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of colorectal carcinoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pierre Fabre Médicament; Tel. +33 800326326; E-mail: medical_information@pierre-fabre.com","first_published_date":"11/04/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001454-pip05-18"},{"decision_number":"P/0046/2019","pip_number":"EMEA-001174-PIP03-18","active_substance":"turoctocog alfa pegol","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of congenital haemophilia A","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; Denmark; Tel. +45 44448888; E-mail: paediatrics@novonordisk.com","first_published_date":"11/04/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001174-pip03-18"},{"decision_number":"P/0029/2019","pip_number":"EMEA-000809-PIP01-09-M01","active_substance":"birch pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/01/2019","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergy Therapeutics (UK) Ltd; Tel. +44(0)1903 844 700; E-mail: infoservices@allergytherapeutics.com","first_published_date":"25/11/2010","last_updated_date":"11/04/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000809-pip01-09-m01"},{"decision_number":"P/87/2009","pip_number":"EMEA-000275-PIP01-08","active_substance":"rolofylline","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Emulsion for injection","condition_indication":"Heart Failure","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"18/05/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe), Inc.; E-mail: axel_breitstadt@merck.com; Country: Belgium; Phone: +32 27766045; Fax: +32 27766288","first_published_date":"09/07/2009","last_updated_date":"08/03/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000275-pip01-08"},{"decision_number":"P/0221/2015","pip_number":"EMEA-001684-PIP01-14","active_substance":"adenovirus associated viral vector serotype 2 containing the human RPE65 gene","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of genetic congenital retinal disorders","routes_of_administration":"Intraocular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"02/10/2015","compliance_outcome":"Positive","compliance_opinion_date":"21/04/2017","compliance_procedure_number":"EMEA-001684-PIP01-14","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"19/11/2015","last_updated_date":"07/03/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001684-pip01-14"},{"decision_number":"P/0160/2016","pip_number":"EMEA-001213-PIP02-12-M02","active_substance":"ferric citrate coordination complex","invented_name":"Fexeric; Fexeric","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Film-coated tablet;Powder for oral suspension","condition_indication":"Treatment of hyperphosphataemia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/06/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Akebia Therapeutics; Tel. +1 617-844-8676; E-mail: sbrady@akebia.com","first_published_date":"03/09/2013","last_updated_date":"07/03/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001213-pip02-12-m02"},{"decision_number":"P/0327/2017","pip_number":"EMEA-001763-PIP01-15-M01","active_substance":"Domagrozumab","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of Duchenne muscular dystrophy","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/10/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG; Tel. +44 (0)1304 646 607; E-mail: pip_enquiries@pfizer.com","first_published_date":"02/06/2016","last_updated_date":"27/02/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001763-pip01-15-m01"},{"decision_number":"P/0183/2014","pip_number":"EMEA-001527-PIP01-13","active_substance":"(S)-Pyrrolidine-2-carboxylic acid compound with (2S,3R,4R,5S,6R)-2-(3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-ethylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (2:1) ( LIK066)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"24/07/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"22/08/2014","last_updated_date":"27/02/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001527-pip01-13"},{"decision_number":"P/208/2010","pip_number":"EMEA-000149-PIP01-07-M02","active_substance":"Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A/H1N1Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A/H3N2Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B","invented_name":"Fluad and associated names","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of influenza","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/10/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Vaccines and Diagnostics S.r.l.; Tel. +39 0577 243046; E-mail: pip.seq@seqirus.com","first_published_date":"24/11/2010","last_updated_date":"27/02/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000149-pip01-07-m02"},{"decision_number":"P/0210/2012","pip_number":"EMEA-000124-PIP01-07-M02","active_substance":"Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following strains: A/Solomon Islands/3/2006 (H1N1)-like strain (A/Solomon Islands/3/2006, IVR-145); A/Wisconsin/67/2005 (H3N2)-like strain (A/Wisconsin/67/2005, NYMC X161B); B/Malaysia/2506/2004-like strain (B/Malaysia/2506/2004)","invented_name":"Optaflu; Optaflu","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection in pre-filled syringe","condition_indication":"Prevention of influenza","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"28/09/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Vaccines & Diagnostics GmbH & Co. KG; E-mail: pip.seq@seqirus.com","first_published_date":"21/12/2010","last_updated_date":"27/02/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000124-pip01-07-m02"},{"decision_number":"P/0338/2014","pip_number":"EMEA-001612-PIP01-14","active_substance":"Covalently closed DNA plasmids coding for cytomegalovirus phosphoprotein 65 and glycoprotein B genes (ASP0113)","invented_name":"Transvax","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of cytomegalovirus disease in patients with impaired cell-mediated immunity","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Astellas Pharma Europe B.V.Tel. +31 7154 55878E-mail: contact.nl@astellas.com&nbsp","first_published_date":"23/02/2015","last_updated_date":"27/02/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001612-pip01-14"},{"decision_number":"P/0356/2018","pip_number":"EMEA-001045-PIP04-18","active_substance":"sarilumab","invented_name":"Kevzara; Kevzara","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of polymyalgia rheumatica","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/12/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi-aventis recherche et développement; Tel. +33 169745695; E-mail: contact-us@sanofi.com","first_published_date":"20/02/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001045-pip04-18"},{"decision_number":"P/0373/2018","pip_number":"EMEA-000694-PIP04-18","active_substance":"dapagliflozin","invented_name":"Forxiga; Forxiga","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of chronic kidney disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/12/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB (UK); Tel. +44 2037496236; E-mail: paediatrics@astrazeneca.com","first_published_date":"20/02/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000694-pip04-18"},{"decision_number":"P/0361/2018","pip_number":"EMEA-001493-PIP02-18","active_substance":"crizotinib","invented_name":"Xalkori","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of lung malignant neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/12/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Europe MA EEIG; Tel. +44 (0)1304 646 607; E-mail: pip_enquiries@pfizer.com","first_published_date":"20/02/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001493-pip02-18"},{"decision_number":"P/0362/2018","pip_number":"EMEA-001256-PIP02-12-M02","active_substance":"phenylephrine hydrochloride;ketorolac trometamol (OMS302)","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Concentrate for solution for injection;Irrigation solution","condition_indication":"Lens therapeutic procedures","routes_of_administration":"Intraocular use;Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/12/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Omeros Corporation; E-mail: swhitaker@omeros.com ; Tel. +11 2066 765000","first_published_date":"23/07/2013","last_updated_date":"19/02/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001256-pip02-12-m02"},{"decision_number":"P/0355/2018","pip_number":"EMEA-001357-PIP01-12-M02","active_substance":"potassium citrate monohydrated;potassium hydrogen carbonate","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Prolonged-release granules","condition_indication":"Treatment of renal tubular acidosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/12/2018","compliance_outcome":"Positive","compliance_opinion_date":"15/11/2019","compliance_procedure_number":"EMEA-C-001357-PIP01-12-M02","contact_for_public_enquiries":"Advicenne Pharma ; E-mail: contact@advicenne.com; Tel. +33 4660 55420","first_published_date":"05/11/2014","last_updated_date":"19/02/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001357-pip01-12-m02"},{"decision_number":"P/0397/2018","pip_number":"EMEA-001071-PIP03-14-M01","active_substance":"certolizumab pegol","invented_name":"Cimzia","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of psoriasis","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/12/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"UCB Pharma S.A.; E-mail: ucbcares.uk@ucb.com; Tel.  +44 175777100","first_published_date":"02/06/2016","last_updated_date":"18/02/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001071-pip03-14-m01"},{"decision_number":"P/0386/2018","pip_number":"EMEA-002370-PIP01-18","active_substance":"pemigatinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of cholangiocarcinoma;Treatment of urothelial carcinoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/12/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Incyte Biosciences Distribution B.V.; E-mail: globalmedinfo@incyte.com; Tel. +800 0002 7423","first_published_date":"14/02/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002370-pip01-18"},{"decision_number":"P/0359/2018","pip_number":"EMEA-002431-PIP01-18","active_substance":"alectinib","invented_name":"Alecensa","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of non-small cell lung carcinoma (NSCLC)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/12/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"13/02/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002431-pip01-18"},{"decision_number":"P/0396/2018","pip_number":"EMEA-002413-PIP01-18","active_substance":"flurpiridaz (18F)","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Solution for injection","condition_indication":"Diagnosis of coronary artery disease","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/12/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GE Healthcare Inc.; Tel. +44 1494543483; E-mail: Gabriel.Brooks@ge.com","first_published_date":"13/02/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002413-pip01-18"},{"decision_number":"P/0374/2018","pip_number":"EMEA-002410-PIP01-18","active_substance":"atorvastatin;ezetimibe","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/12/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"QualipharmaCon Kft.; Tel. +36 302110337; E-mail: turjanyi@qualipharmacon.hu","first_published_date":"13/02/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002410-pip01-18"},{"decision_number":"P/0383/2018","pip_number":"EMEA-002396-PIP01-18","active_substance":"Ipatasertib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of breast cancer;Treatment of prostate cancer","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/12/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411","first_published_date":"13/02/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002396-pip01-18"},{"decision_number":"P/0375/2018","pip_number":"EMEA-002406-PIP01-18","active_substance":"molibresib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of breast cancer","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/12/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Tel. +1 4388998201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"13/02/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002406-pip01-18"},{"decision_number":"P/0379/2018","pip_number":"EMEA-002405-PIP01-18","active_substance":"avadomide","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of mature B-cell neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/12/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Celgene Europe LimitedTel.  +41 327298500E-mail: medinfo.intl@celgene.com","first_published_date":"13/02/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002405-pip01-18"},{"decision_number":"P/0382/2018","pip_number":"EMEA-002400-PIP01-18","active_substance":"Ibuprofen","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Medicated plaster","condition_indication":"Treatment of pain","routes_of_administration":"Topical use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/12/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Medherant Ltd; Tel. +44 2476323060; E-mail: info@medherant.co.uk","first_published_date":"13/02/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002400-pip01-18"},{"decision_number":"P/0384/2018","pip_number":"EMEA-002387-PIP01-18","active_substance":"selinexor","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of Multiple Myeloma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/12/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Karyopharm Europe GmbH; Tel. +1 6176580551; E-mail: kmalobisky@karyopharm.com","first_published_date":"13/02/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002387-pip01-18"},{"decision_number":"P/0277/2018","pip_number":"EMEA-002375-PIP01-18","active_substance":"levofloxacin;dexamethasone","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution in single-dose container","condition_indication":"Prevention and treatment of inflammation and prevention of infection associated with cataract surgery","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/09/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"NTC srl; Tel.  +39 024385041; E-mail: federico.bertocchi@ntcpharma.com","first_published_date":"18/01/2019","last_updated_date":"12/02/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002375-pip01-18"},{"decision_number":"P/0274/2018","pip_number":"EMEA-000774-PIP01-09-M03","active_substance":"emtricitabine;rilpivirine hydrochloride;tenofovir disoproxil fumarate","invented_name":"Eviplera","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/08/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd; E-mail: regulatory.pip@gilead.com; Tel. +44 (0)1223 897300","first_published_date":"06/10/2010","last_updated_date":"05/02/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000774-pip01-09-m03"},{"decision_number":"P/0325/2018","pip_number":"EMEA-000625-PIP01-09-M03","active_substance":"simeprevir","invented_name":"Olysio","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Capsule, hard;Age appropriate dosage form, other","condition_indication":"Treatment of chronic viral hepatitis C","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/09/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; Tel. +32 1460 2111; E-mail: contact@janssen-emea.com","first_published_date":"07/01/2013","last_updated_date":"05/02/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000625-pip01-09-m03"},{"decision_number":"P/0269/2018","pip_number":"EMEA-000560-PIP03-15-M01","active_substance":"omadacycline","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for concentrate for solution for infusion;Film-coated tablet;Granules","condition_indication":"Treatment of bacterial pneumonia","routes_of_administration":"Intravenous use;Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/08/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Paratek UK Limited; E-mail: info@paratekpharma.com; Tel. +1 6178 076600","first_published_date":"24/07/2017","last_updated_date":"05/02/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000560-pip03-15-m01"},{"decision_number":"P/0299/2018","pip_number":"EMEA-000116-PIP01-07-M09","active_substance":"retigabine","invented_name":"Trobalt; Trobalt","therapeutic_area":"Neurology","pharmaceutical_forms":"Film-coated tablet;Dispersible tablet;Powder for solution for injection;Powder for solution for infusion;Chewable tablet","condition_indication":"Treatment of epilepsy with partial-onset seizures;Treatment of Lennox-Gastaut syndrome","routes_of_administration":"Oral use;Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/09/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Glaxo Group Limited; E-mail: eu.paediatric-plans@gsk.com; Tel. +44 (0)20 8990 3650","first_published_date":"11/08/2011","last_updated_date":"30/01/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000116-pip01-07-m09"},{"decision_number":"P/0333/2018","pip_number":"EMEA-002395-PIP01-18","active_substance":"atorvastatin (calcium trihydrate);Indapamide;perindopril arginine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of cardiovascular disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/10/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierE-mail: mail.pip.enquiries@servier.comTel.: +33 155726000","first_published_date":"29/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002395-pip01-18"},{"decision_number":"P/0337/2018","pip_number":"EMEA-002403-PIP01-18","active_substance":"synthetic ribonucleic acid oligonucleotide directed against superoxide dismutase 1 messenger ribonucleic acid (tofersen)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of amyotrophic lateral sclerosis","routes_of_administration":"Intrathecal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/10/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biogen Idec Ltd; Tel. +44 (0)1628 512749; E-mail: pip.enquiries@biogenidec.com","first_published_date":"29/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002403-pip01-18"},{"decision_number":"P/0239/2018","pip_number":"EMEA-002199-PIP01-17","active_substance":"Glasdegib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of acute myeloid leukaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/08/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Limited; Tel. + 44 1304646607; E-mail: pip_enquiries@pfizer.com","first_published_date":"28/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002199-pip01-17"},{"decision_number":"P/0284/2018","pip_number":"EMEA-002185-PIP02-17","active_substance":"human donor haematopoietic stem and progenitor cells (HSPC) that have been treated ex vivo with the protein transduction domain of the HIV-1 transactivation protein fused to MYC transcription factor (TBX-1400)","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment in haematopoietic stem cell transplantation in patients with severe combined immunodeficiency syndrome (SCID)","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"12/09/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Taiga Biotechnologies, Inc; E-mail: refaeli@taigabiotech.com; Tel. +1 7208593547","first_published_date":"28/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002185-pip02-17"},{"decision_number":"P/0287/2018","pip_number":"EMEA-001808-PIP03-17","active_substance":"sarizotan hydrochloride","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Capsule, hard;Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of Rett syndrome","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"12/09/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Newron Pharmaceuticals SpA; E-mail: ravi@anand.ch; Tel. +41 793741364","first_published_date":"28/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001808-pip03-17"},{"decision_number":"P/0302/2018","pip_number":"EMEA-002059-PIP01-16","active_substance":"Fasinumab","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic pain","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/09/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Regeneron Ireland U.C.; Tel.  +1 9148475385; E-mail: clinicaltrials@regeneron.com","first_published_date":"28/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002059-pip01-16"},{"decision_number":"P/0317/2018","pip_number":"EMEA-001748-PIP02-18","active_substance":"arimoclomol citrate","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of amyotrophic lateral sclerosis;Treatment of sporadic inclusion body myositis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/09/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Orphazyme A/S; Tel. +45 20727120; E-mail: alk@orphazyme.com","first_published_date":"28/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001748-pip02-18"},{"decision_number":"P/0248/2018","pip_number":"EMEA-001716-PIP03-18","active_substance":"venglustat","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of polycystic kidney disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/08/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Genzyme Europe B.V.; E-mail: eumedinfo.gz@sanofi.com; Tel. +31 3569 91499","first_published_date":"28/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001716-pip03-18"},{"decision_number":"P/0289/2018","pip_number":"EMEA-001662-PIP03-17","active_substance":"palovarotene","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of multiple osteochondromas","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/09/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Clementia Pharmaceuticals Inc.; Clementia Pharmaceuticals Inc.; Tel: +33(0)158335427; Email: abdelali.majdi@ipsen.com","first_published_date":"28/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001662-pip03-17"},{"decision_number":"P/0345/2018","pip_number":"EMEA-001350-PIP02-13-M04","active_substance":"Idelalisib","invented_name":"Zydelig; Zydelig","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet;Age appropriate dispersible tablet","condition_indication":"Treatment of mature B-cell neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/11/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Limited; Tel. +44 (0)1223 897300; E-mail: regulatory.pip@gilead.com","first_published_date":"15/11/2013","last_updated_date":"28/01/2019","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001350-pip02-13-m04"},{"decision_number":"P/0328/2018","pip_number":"EMEA-002393-PIP01-18","active_substance":"cell-free solution of lysed Escherichia coli culture, strain Laves","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of irritable bowel syndrome (IBS);Treatment of ulcerative colitis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/10/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Laves-Arzneimittel GmbH; Tel. +49 511438740; E-mail: info@laves-pharma.de","first_published_date":"18/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002393-pip01-18"},{"decision_number":"P/0329/2018","pip_number":"EMEA-002389-PIP01-18","active_substance":"pamiparib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of gastric and gastroesophageal junction adenocarcinoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/10/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BeiGene, Ltd.; Tel.  +1 8312328117; E-mail: patty.carlos@beigene.com","first_published_date":"18/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002389-pip01-18"},{"decision_number":"P/0336/2018","pip_number":"EMEA-002385-PIP01-18","active_substance":"Eflapegrastim","invented_name":"","therapeutic_area":"Haematology-Hemostaseology;Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chemotherapy-induced neutropenia","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/10/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Spectrum Pharmaceuticals, Inc.; Tel.  +1 9497439228; E-mail: anil.hiteshi@sppirx.com","first_published_date":"18/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002385-pip01-18"},{"decision_number":"P/0309/2018","pip_number":"EMEA-002384-PIP01-18","active_substance":"omega-3-acid ethyl esters 90;rosuvastatin calcium","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, soft","condition_indication":"Treatment of hypercholesterolaemia;Treatment of hypertriglyceridaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/09/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kuhnil Pharm. CO.,Ltd.; Tel.  +82 221759756; E-mail: jypark3@kuhnil.com, anna.alonen@medfiles.fi","first_published_date":"18/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002384-pip01-18"},{"decision_number":"P/0334/2018","pip_number":"EMEA-002381-PIP01-18","active_substance":"autologous dendritic cells pulsed with allogeneic tumour cell lysate","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for injection","condition_indication":"Treatment of malignant mesothelioma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/10/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amphera BVTel.   +31 651032369E-mail: info@amphera.nl","first_published_date":"18/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002381-pip01-18"},{"decision_number":"P/0267/2018","pip_number":"EMEA-002377-PIP01-18","active_substance":"Elotuzumab","invented_name":"Empliciti","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of Multiple Myeloma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/08/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"18/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002377-pip01-18"},{"decision_number":"P/0276/2018","pip_number":"EMEA-002376-PIP01-18","active_substance":"nadofaragene firadenovec","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for suspension for infusion","condition_indication":"Treatment of mesothelioma","routes_of_administration":"Intrapleural use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/09/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Trizell Ltd.; Tel. +44 1844355625","first_published_date":"18/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002376-pip01-18"},{"decision_number":"P/0278/2018","pip_number":"EMEA-002367-PIP01-18","active_substance":"anti-alpha synuclein monoclonal antibody (BIIB054)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of Parkinson's disease","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/09/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biogen Idec LimitedTel. +44 1628512586E-mail: pip.enquiries@biogen.com","first_published_date":"18/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002367-pip01-18"},{"decision_number":"P/0311/2018","pip_number":"EMEA-002366-PIP01-18","active_substance":"acetylsalicylic acid;indapamide (hemihydrate);perindopril tert-butylamine;rosuvastatin calcium","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Prevention of cardiovascular events","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/09/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"SmartGenRx Pty Ltd; Tel.  +61 (2)80524375; E-mail: arodgers@georgeinstitute.org","first_published_date":"18/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002366-pip01-18"},{"decision_number":"P/0330/2018","pip_number":"EMEA-002363-PIP01-18","active_substance":"3-(3-(3,5-Dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid","invented_name":"","therapeutic_area":"Cardiovascular diseases;Neurology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of transthyretin amyloidosis (ATTR)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/10/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eidos Therapeutics, Inc.; Tel.  +1415 887 1471; E-mail: info@eidostx.com","first_published_date":"17/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002363-pip01-18"},{"decision_number":"P/0331/2018","pip_number":"EMEA-002361-PIP01-18","active_substance":"telisotuzumab vedotin","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of lung carcinoma (small cell and non-small cell carcinoma)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/10/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628925033","first_published_date":"17/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002361-pip01-18"},{"decision_number":"P/0245/2018","pip_number":"EMEA-002352-PIP01-18","active_substance":"irbesartan;amlodipine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/08/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi- Aventis Research & Development; Tel.  +33 169745695; E-mail: contact-us@sanofi.com","first_published_date":"17/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002352-pip01-18"},{"decision_number":"P/0279/2018","pip_number":"EMEA-002345-PIP01-18","active_substance":"tepotinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of non-small cell lung carcinoma (NSCLC)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/09/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck KGaA; Tel. +49 6151 725200; E-mail: service@merckgroup.com","first_published_date":"17/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002345-pip01-18"},{"decision_number":"P/0332/2018","pip_number":"EMEA-002338-PIP02-18","active_substance":"lanalumab","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Sjögren's syndrome","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/10/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"17/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002338-pip02-18"},{"decision_number":"P/0232/2018","pip_number":"EMEA-002335-PIP01-18","active_substance":"autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor (axicabtagene ciloleucel)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of mantle cell lymphoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/08/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kite Pharma EU B.V.; Tel. +1 4242091332; E-mail: regulatory@kitepharma.com","first_published_date":"17/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002335-pip01-18"},{"decision_number":"P/0263/2018","pip_number":"EMEA-002261-PIP01-17","active_substance":"Ferric pyrophosphate citrate","invented_name":"","therapeutic_area":"Haematology-Hemostaseology;Uro-nephrology","pharmaceutical_forms":"Solution for infusion;Solution for haemodialysis","condition_indication":"Treatment of anaemia of chronic kidney disease","routes_of_administration":"Intravenous use;Haemodialysis","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/08/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Rockwell Medical, Inc.; Tel.  +1 2489609009; E-mail: rpratt@rockwellmed.com","first_published_date":"17/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002261-pip01-17"},{"decision_number":"P/0326/2018","pip_number":"EMEA-002244-PIP02-18","active_substance":"diphtheria toxin interleukin-3 Fusion Protein","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for infusion;Powder for solution for infusion","condition_indication":"Treatment of blastic plasmacytoid dendritic cell neoplasm","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/09/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Stemline Therapeutics, Inc.; Tel.  +1 6465022310; E-mail: info@stemline.com","first_published_date":"17/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002244-pip02-18"},{"decision_number":"P/0254/2018","pip_number":"EMEA-001521-PIP02-18","active_substance":"Luspatercept","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of myelofibrosis","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/08/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG; Tel. +41 327298500; E-mail: medinfo.intl@celgene.com","first_published_date":"14/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001521-pip02-18"},{"decision_number":"P/0240/2018","pip_number":"EMEA-001384-PIP02-17","active_substance":"octenidine dihydrochloride","invented_name":"","therapeutic_area":"Infectious diseases;Other","pharmaceutical_forms":"Mouthwash","condition_indication":"Prevention of oral soft tissue infections","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/08/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Schülke & Mayr GmbH; Tel.  +49 4052100666; E-mail: info@schuelke.com","first_published_date":"11/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001384-pip02-17"},{"decision_number":"P/0335/2018","pip_number":"EMEA-001045-PIP02-18","active_substance":"sarilumab","invented_name":"Kevzara; Kevzara","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of vasculitides","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/10/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi-aventis recherche et développement; Tel. +33 169745695; E-mail: contact-us@sanofi.com","first_published_date":"11/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001045-pip02-18"},{"decision_number":"P/0338/2018","pip_number":"EMEA-001039-PIP03-17","active_substance":"Clostridium Botulinum neurotoxin type A (150 kD), free from complexing proteins","invented_name":"Xeomin; Bocouture","therapeutic_area":"Neurology;Ophthalmology","pharmaceutical_forms":"Powder for solution for injection;Solution for injection in pre-filled syringe","condition_indication":"Treatment of hemifacial spasm","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/10/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merz Pharmaceuticals GmbH; Tel.: +49 6915031; E-mail: contact@merz.de","first_published_date":"11/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001039-pip03-17-0"},{"decision_number":"P/0327/2018","pip_number":"EMEA-000980-PIP04-18","active_substance":"Brentuximab vedotin","invented_name":"Adcetris; Adcetris","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of Mature T and NK neoplasms (excluding anaplastic large-cell lymphoma and cutaneous Tcell lymphoma)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/10/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Pharma A/S; Tel. +44 2031168000; E-mail: paediatrics@tgrd.com","first_published_date":"11/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000980-pip04-18"},{"decision_number":"P/0256/2018","pip_number":"EMEA-000499-PIP05-18","active_substance":"veliparib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard;Age appropriate oral liquid dosage formulation;Tablet","condition_indication":"Treatment of fallopian tube cancer;Treatment of ovarian cancer;Treatment of peritoneal carcinoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/08/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628925033","first_published_date":"11/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000499-pip05-18"},{"decision_number":"P/0255/2018","pip_number":"EMEA-000478-PIP02-18","active_substance":"navitoclax","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of myelofibrosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/08/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"11/01/2019","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000478-pip02-18"},{"decision_number":"P/0257/2018","pip_number":"EMEA-001308-PIP01-12-M02","active_substance":"paclitaxel","invented_name":"Abraxane","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for suspension for infusion","condition_indication":"Treatment of solid malignant tumours","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/08/2018","compliance_outcome":"Positive","compliance_opinion_date":"21/09/2018","compliance_procedure_number":"EMEA-C-001308-PIP01-12-M02","contact_for_public_enquiries":"Celgene Europe LimitedTel.  +41 327298500E-mail: medinfo.intl@celgene.com","first_published_date":"31/05/2013","last_updated_date":"19/12/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001308-pip01-12-m02"},{"decision_number":"P/0201/2015","pip_number":"EMEA-001771-PIP01-15","active_substance":"Indapamide;rosuvastatin;perindopril tert-butylamine","invented_name":"","therapeutic_area":"Cardiovascular diseases;Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events;Treatment of hypertension;Treatment of lipid metabolism disorders","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/09/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Krka, d.d., Novo mesto; E-mail: dragan.priselac@krka.biz; Tel. +386 7331 9037","first_published_date":"11/12/2018","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001771-pip01-15"},{"decision_number":"P/0231/2018","pip_number":"EMEA-001776-PIP04-17","active_substance":"risankizumab","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Concentrate for solution for infusion;Solution for injection;Age appropriate dosage form for parenteral use","condition_indication":"Treatment of ulcerative colitis","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/08/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628925033","first_published_date":"30/11/2018","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001776-pip04-17"},{"decision_number":"P/0176/2018","pip_number":"EMEA-000769-PIP01-09-M08","active_substance":"ceftaroline fosamil","invented_name":"Zinforo; Zinforo","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of community-acquired pneumonia;Treatment of complicated skin and soft-tissue infections","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/06/2018","compliance_outcome":"Positive","compliance_opinion_date":"19/10/2018","compliance_procedure_number":"EMEA-C-000769-PIP01-09-M08","contact_for_public_enquiries":"Pfizer Limited; Tel. + 44 1304646607; E-mail: pip_enquiries@pfizer.com","first_published_date":"24/05/2012","last_updated_date":"28/11/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000769-pip01-09-m08"},{"decision_number":"P/0227/2018","pip_number":"EMEA-000713-PIP02-10-M05","active_substance":"pixantrone dimaleate","invented_name":"Pixuvri; Pixuvri","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of non-Hodgkin lymphoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/07/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CTI Life Sciences Limited; Tel. +1 2062724260; E-mail: bseeley@ctibiopharma.com","first_published_date":"20/12/2010","last_updated_date":"28/11/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000713-pip02-10-m05"},{"decision_number":"P/0192/2018","pip_number":"EMEA-002274-PIP01-17","active_substance":"trandolapril","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"17/07/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Abbott Laboratories Limited; Tel.  +44 (0) 1628 644513; E-mail: robyn.hall@abbott.com","first_published_date":"28/11/2018","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002274-pip01-17"},{"decision_number":"P/0228/2018","pip_number":"EMEA-002275-PIP01-17","active_substance":"moxonidine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"29/07/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Abbott Laboratories Limited; Tel.  +44 (0) 1628 644513; E-mail: robyn.hall@abbott.com","first_published_date":"28/11/2018","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002275-pip01-17"},{"decision_number":"P/0162/2018","pip_number":"EMEA-002276-PIP01-17","active_substance":"verapamil;trandolapril","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/06/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Abbott Laboratories Limited; Tel.  +44 (0) 1628 644513; E-mail: robyn.hall@abbott.com","first_published_date":"28/11/2018","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002276-pip01-17"},{"decision_number":"P/0134/2018","pip_number":"EMEA-002291-PIP01-17","active_substance":"(2R)-2-amino-1-[3-( {2-[p-( 4-{3-[ (3,S-diamino-6-chloro-2-pyrazinyl)ca rbonyl ]guanidino }butyl )phenoxy ]ethyl}{ 3-[ ( 2R)-2-am ino-6-guanidinohexanoyla mino] propyl }amino )propylamino ]-6-guanidino-1-hexanone hexahydrochloride","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution","condition_indication":"Treatment of dry eye disease","routes_of_administration":"Ophthalmic use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/05/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Shire Pharmaceuticals Ireland Limited; Tel. +44 (0)8008 38470; E-mail: medinfoeuceemea@shire.com","first_published_date":"28/11/2018","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002291-pip01-17"},{"decision_number":"P/0169/2018","pip_number":"EMEA-002304-PIP01-17","active_substance":"andecaliximab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of gastric cancer and gastro-oesophageal junction adenocarcinoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/06/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd; E-mail: regulatory.pip@gilead.com; Tel. +44 (0)1223 897300","first_published_date":"28/11/2018","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002304-pip01-17"},{"decision_number":"P/0133/2018","pip_number":"EMEA-002309-PIP01-17","active_substance":"eszopiclone","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of insomnia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/05/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alfred E. Tiefenbacher (GmbH & Co. KG); Tel. +49 404418090; E-mail: regaffairs@aet.eu","first_published_date":"28/11/2018","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002309-pip01-17"},{"decision_number":"P/0218/2018","pip_number":"EMEA-002322-PIP01-17","active_substance":"patidegib","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Gel","condition_indication":"Treatment of naevoid basal-cell carcinoma syndrome (Gorlin syndrome)","routes_of_administration":"Topical use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/07/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pellepharm, Inc; Tel.  +33 182731004; E-mail: leclere.marie-caroline@blue-reg.com","first_published_date":"28/11/2018","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002322-pip01-17"},{"decision_number":"P/0213/2018","pip_number":"EMEA-001748-PIP01-15-M01","active_substance":"arimoclomol citrate","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of Niemann-Pick disease, type C","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/07/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Orphazyme A/S; E-mail: amh@orphazyme.com; Tel. +45 2898 9056","first_published_date":"25/04/2016","last_updated_date":"28/11/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001748-pip01-15-m01"},{"decision_number":"P/0217/2018","pip_number":"EMEA-002340-PIP01-18","active_substance":"nitrous oxide","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Medicinal gas (liquefied)","condition_indication":"Sedation","routes_of_administration":"Inhalation use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/07/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Società Italiana Carburo Ossigeno Spa SICO; Tel. +39 0382530059; E-mail: regulatory@gbpharma.it, cvino@gbpharma.it","first_published_date":"28/11/2018","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002340-pip01-18"},{"decision_number":"P/0184/2018","pip_number":"EMEA-002344-PIP01-18","active_substance":"liposomal ciclosporin A (L-CsA)","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder for nebuliser solution","condition_indication":"Treatment of bronchiolitis obliterans syndrome","routes_of_administration":"Inhalation use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"17/07/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Zambon SpA; Tel.  +49 8990414910; E-mail: contact@breath-therapeutics.com","first_published_date":"27/11/2018","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002344-pip01-18"},{"decision_number":"P/0191/2018","pip_number":"EMEA-000297-PIP02-12-M02","active_substance":"Glycerol phenylbutyrate","invented_name":"Ravicti; Ravicti","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Oral liquid","condition_indication":"Treatment of urea cycle disorders","routes_of_administration":"Oral use;Gastroenteral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/07/2018","compliance_outcome":"Positive","compliance_opinion_date":"21/09/2018","compliance_procedure_number":"EMEA-C-000297-PIP02-12-M02","contact_for_public_enquiries":"Horizon Pharma Ireland Limited; E-mail: regulatory-eu@horizonpharma.com; Tel.  +353 1772 2100","first_published_date":"08/10/2013","last_updated_date":"27/11/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000297-pip02-12-m02"},{"decision_number":"P/0214/2018","pip_number":"EMEA-001535-PIP01-13-M01","active_substance":"potassium citrate monohydrated;potassium hydrogen carbonate (ADV7103)","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Prolonged-release granules","condition_indication":"Treatment of cystinuria","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"17/07/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Advicenne; E-mail: infomed@advicenne.com; Tel. +33 4660 55420","first_published_date":"05/11/2014","last_updated_date":"27/11/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001535-pip01-13-m01"},{"decision_number":"P/0155/2018","pip_number":"EMEA-002353-PIP01-18","active_substance":"split influenza virus, inactivated containing antigens equivalent to the A/H1N1-like strain;split influenza virus, inactivated containing antigens equivalent to the A/H3N2-like strain;split influenza virus, inactivated containing antigens equivalent to the B-like strain","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of influenza infection","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"25/05/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi pasteur; Email: piplan@sanofipasteur.com; Tel. +33 4373 75038","first_published_date":"27/11/2018","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002353-pip01-18"},{"decision_number":"P/0145/2018","pip_number":"EMEA-002192-PIP02-17","active_substance":"amlodipine;irbesartan","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/05/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Win Medica S.A.; E-mail: info@winmedica.gr; Tel. +30 2107488821","first_published_date":"27/11/2018","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002192-pip02-17"},{"decision_number":"P/0135/2018","pip_number":"EMEA-002002-PIP02-17","active_substance":"Ibuprofen;paracetamol","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Oral suspension","condition_indication":"Treatment of febrile disorders;Treatment of pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/05/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Farmalider, S.A; E-mail: carloscalandria@farmalider.com; Tel. +34 9166 12335","first_published_date":"27/11/2018","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002002-pip02-17"},{"decision_number":"P/0178/2018","pip_number":"EMEA-001469-PIP02-17","active_substance":"somapacitan","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of short stature","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/06/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; E-mail: paediatrics@novonordisk.com; Tel. +45 4444 8888","first_published_date":"27/11/2018","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001469-pip02-17"},{"decision_number":"P/0187/2018","pip_number":"EMEA-001741-PIP05-17","active_substance":"upadacitinib","invented_name":"","therapeutic_area":"","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of vasculitides","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/07/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628925033","first_published_date":"27/11/2018","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001741-pip05-17"},{"decision_number":"P/0202/2018","pip_number":"EMEA-000694-PIP03-17","active_substance":"dapagliflozin","invented_name":"Forxiga; Forxiga","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events in patients with chronic heart failure","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/07/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB (UK); Tel. +44 2037496236; E-mail: paediatrics@astrazeneca.com","first_published_date":"27/11/2018","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000694-pip03-17"},{"decision_number":"P/0148/2018","pip_number":"EMEA-001080-PIP01-10","active_substance":"Delafloxacin","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for solution for infusion;Capsule, hard;Tablet","condition_indication":"Treatment of local infections of skin and subcutaneous tissues","routes_of_administration":"Intravenous use;Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/05/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"A.Menarini - IndustrieFarmaceutiche Riunite - s.r.I.; E-mail: prijli@menarini.it; Tel. +39 0555 680633","first_published_date":"27/11/2018","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001080-pip01-10-0"},{"decision_number":"P/0195/2018","pip_number":"EMEA-001196-PIP02-17","active_substance":"Fostamatinib","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of idiopathic thrombocytopenic purpura as a model for immunomodulation","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Rigel Pharmaceuticals Ltd; E-mail: dvance@rigel.com; Tel. +44 (0)1603 693204","first_published_date":"27/11/2018","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001196-pip02-17"},{"decision_number":"P/0147/2018","pip_number":"EMEA-000342-PIP01-08-M07","active_substance":"sunitinib","invented_name":"Sutent; Sutent","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of gastro-intestinal stromal tumours","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/05/2018","compliance_outcome":"Positive","compliance_opinion_date":"29/06/2018","compliance_procedure_number":"EMEA-C-000342-PIP01-08-M07","contact_for_public_enquiries":"Pfizer Limited; Tel. + 44 1304646607; E-mail: pip_enquiries@pfizer.com","first_published_date":"23/04/2009","last_updated_date":"27/11/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000342-pip01-08-m07"},{"decision_number":"P/0226/2018","pip_number":"EMEA-001417-PIP01-12-M04","active_substance":"febuxostat","invented_name":"Adenuric; Adenuric","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of hyperuricaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/07/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Menarini International Operations Luxembourg S.A.; E-mail: prijli@menarini.it; Tel. +39 0555 680633","first_published_date":"05/06/2014","last_updated_date":"22/11/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001417-pip01-12-m04"},{"decision_number":"P/0142/2018","pip_number":"EMEA-000527-PIP05-17","active_substance":"ranibizumab","invented_name":"Lucentis; Lucentis","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection","condition_indication":"Diabetic retinopathy","routes_of_administration":"Intravitreal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/05/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"22/11/2018","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000527-pip05-17"},{"decision_number":"P/0206/2018","pip_number":"EMEA-000347-PIP03-18","active_substance":"bilastine","invented_name":"Bilaxten and associated names","therapeutic_area":"Dermatology","pharmaceutical_forms":"Orodispersible film","condition_indication":"Treatment of allergic rhinoconjunctivitis;Treatment of urticaria","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/07/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Faes Farma S.A.; E-mail: ieguidazu@faes.es, mjarenal@faes.es; Tel. +34 944818300","first_published_date":"22/11/2018","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000347-pip03-18"},{"decision_number":"P/0183/2018","pip_number":"EMEA-000118-PIP04-17","active_substance":"abatacept","invented_name":"Orencia; Orencia","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder for concentrate for solution for infusion;Solution for injection","condition_indication":"","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/06/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"22/11/2018","last_updated_date":"","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000118-pip04-17"},{"decision_number":"P/245/2011","pip_number":"EMEA-000982-PIP01-10","active_substance":"Furosemide","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Orodispersible tablet","condition_indication":"Treatment of fluid retention","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"21/10/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"KidzPharma Inc.; United Kingdom; george.overend@orsoxford.co.uk; +44 1844279600; +44 1844279602","first_published_date":"28/11/2011","last_updated_date":"02/10/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000982-pip01-10"},{"decision_number":"P/0148/2014","pip_number":"EMEA-001487-PIP01-13","active_substance":"Gevokizumab","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic non-infectious uveitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/06/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierE-mail: cafaro@xoma.comTel. +1 5105415034","first_published_date":"18/07/2014","last_updated_date":"02/10/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001487-pip01-13"},{"decision_number":"P/0131/2018","pip_number":"EMEA-001039-PIP03-17","active_substance":"Clostridium Botulinum neurotoxin type A (150 kD), free from complexing proteins","invented_name":"Xeomin; Bocouture","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of hemifacial spasm","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/04/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merz Pharmaceuticals GmbH; Tel.: +49 6915031; E-mail: contact@merz.de","first_published_date":"26/07/2018","last_updated_date":"26/07/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001039-pip03-17"},{"decision_number":"P/0126/2018","pip_number":"EMEA-001344-PIP02-17","active_substance":"ezetimibe;rosuvastatin","invented_name":"Zenon; Suvezen","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Prevention of cardiovascular events","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/04/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Zentiva, k.s.; Czech Republic; blanka.zoubkova@zentiva.com; Tel. +42 0267243574","first_published_date":"26/07/2018","last_updated_date":"26/07/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001344-pip02-17"},{"decision_number":"P/0118/2018","pip_number":"EMEA-002220-PIP01-17","active_substance":"Influenza virus H1 haemagglutinin;influenza virus haemagglutinin from strain B Yamagata lineage (expressed as virus-like particle [VLP]);influenza virus H3 haemagglutinin;influenza virus haemagglutinin from strain B Victoria lineage","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of influenza","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/04/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Medicago Inc.; Tel.: +418 6589393 ext 156; E-mail: martrejl@medicago.com","first_published_date":"26/07/2018","last_updated_date":"26/07/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002220-pip01-17"},{"decision_number":"P/0117/2018","pip_number":"EMEA-002255-PIP01-17","active_substance":"polatuzumab vedotin","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of mature B-cell neoplasms","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/04/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration Limited; Tel. +41 616879411; E-mail: global.paediatrics@roche.com","first_published_date":"25/07/2018","last_updated_date":"25/07/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002255-pip01-17"},{"decision_number":"P/0116/2018","pip_number":"EMEA-002292-PIP01-17","active_substance":"rovalpituzumab tesirine","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder and solvent for concentrate for solution for infusion","condition_indication":"Treatment of lung carcinoma (small cell and non-small cell carcinoma)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/04/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628925033","first_published_date":"25/07/2018","last_updated_date":"25/07/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002292-pip01-17"},{"decision_number":"P/0115/2018","pip_number":"EMEA-002293-PIP01-17","active_substance":"Calcium, N,N'-1,2-ethanediylbis[N-[[3-(hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinyl]methyl]glycine] manganese complexes","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Prevention of oxaliplatin induced peripheral neuropathy","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/04/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"PledPharma AB; Tel.: +46 708368702; E-mail: malin.nittve@pledpharma.se","first_published_date":"25/07/2018","last_updated_date":"25/07/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002293-pip01-17"},{"decision_number":"P/0114/2018","pip_number":"EMEA-002299-PIP01-17","active_substance":"Enfortumab vedotin","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder and solvent for solution for infusion","condition_indication":"Treatment of urothelial carcinoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/04/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Astellas Pharma Europe B.V.Tel. +31 7154 55878E-mail: contact.nl@astellas.com&nbsp","first_published_date":"25/07/2018","last_updated_date":"25/07/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002299-pip01-17"},{"decision_number":"P/0104/2018","pip_number":"EMEA-001304-PIP03-17","active_substance":"obeticholic acid","invented_name":"Ocaliva; Ocaliva","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Age appropriate oral solid dosage form;Tablet","condition_indication":"Treatment of non-alcoholic steatohepatitis (NASH)","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/04/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Intercept Pharma Ltd.; Tel.: +1 6195417227; E-mail: reginfo@interceptpharma.com","first_published_date":"25/07/2018","last_updated_date":"25/07/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001304-pip03-17"},{"decision_number":"P/0346/2023","pip_number":"EMEA-001523-PIP02-14-M03","active_substance":"Guselkumab","invented_name":"Tremfya; Tremfya","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of psoriasis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/09/2023","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen Cilag International NV; Tel. +3214602111; E-mail: contact@Janssen-emea.com","first_published_date":"25/04/2016","last_updated_date":"25/07/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001523-pip02-14-m03"},{"decision_number":"P/023/2018","pip_number":"EMEA-001448-PIP01-13-M03","active_substance":"nusinersen","invented_name":"Spinraza; Spinraza","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of spinal muscular atrophy","routes_of_administration":"Intrathecal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/04/2018","compliance_outcome":"Positive","compliance_opinion_date":"29/06/2018","compliance_procedure_number":"EMEA-C-001448-PIP01-13-M03","contact_for_public_enquiries":"Biogen Idec Ltd; Tel. +44 1628501014; E-mail: pip.enquiries@biogenidec.com","first_published_date":"13/05/2014","last_updated_date":"25/07/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001448-pip01-13-m03"},{"decision_number":"P/0227/2014","pip_number":"EMEA-000362-PIP01-08-M04","active_substance":"aliskiren","invented_name":"Rasilez; Rasilez","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet;Granules","condition_indication":"Heart Failure;Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/09/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm Ltd; E-mail: marine.lafargue@iqvia.com; Tel. +33 1748 82008","first_published_date":"17/10/2011","last_updated_date":"16/07/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000362-pip01-08-m04"},{"decision_number":"P/62/2008","pip_number":"Thrombin alfa","active_substance":"thrombin alfa","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for reconstitution","condition_indication":"Haemorrhage complicating a surgical procedure","routes_of_administration":"Epilesional use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/08/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer HealthCare AG; Tel. +49 30346815333; Fax +49 3046895333; E-mail: pediatrics.medical-affairs-europe@bayerhealthcare.com","first_published_date":"18/09/2008","last_updated_date":"06/07/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/thrombin-alfa"},{"decision_number":"P/0112/2017","pip_number":"EMEA-001965-PIP01-16","active_substance":"olodaterol (hydrochloride)","invented_name":"Striverdi; Respimat","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Inhalation solution","condition_indication":"Treatment of cystic fibrosis","routes_of_administration":"Inhalation use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/04/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"29/05/2017","last_updated_date":"05/07/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001965-pip01-16"},{"decision_number":"P/0089/2018","pip_number":"EMEA-002263-PIP01-17","active_substance":"trazodone (hydrochloride);gabapentin","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of painful diabetic neuropathy","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/03/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - S.p.A.; Tel. +39 0691045249; E-mail: m.gatto@angelini.it;  ","first_published_date":"19/06/2018","last_updated_date":"19/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002263-pip01-17"},{"decision_number":"P/0063/2018","pip_number":"EMEA-000499-PIP04-17","active_substance":"veliparib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard;Age appropriate oral liquid dosage formulation;Tablet","condition_indication":"Treatment of lung carcinoma (small cell and non-small cell carcinoma)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/03/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628925033","first_published_date":"19/06/2018","last_updated_date":"19/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000499-pip04-17"},{"decision_number":"P/0059/2018","pip_number":"EMEA-001151-PIP02-17","active_substance":"dapagliflozin;metformin hydrochloride","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Modified-release tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/03/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB (UK); Tel. +44 1625230700; E-mail: paediatrics@astrazeneca.com;  ","first_published_date":"19/06/2018","last_updated_date":"19/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001151-pip02-17"},{"decision_number":"P/0086/2018","pip_number":"EMEA-002302-PIP01-17","active_substance":"Ibuprofen","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of febrile disorders;Treatment of pain","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/03/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Farmalíder, S.A.; Tel. +34 916612335; E-mail: carloscalandria@farmalider.com","first_published_date":"19/06/2018","last_updated_date":"19/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002302-pip01-17"},{"decision_number":"P/0093/2018","pip_number":"EMEA-002248-PIP01-17","active_substance":"Candesartan cilexetil;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/03/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Midas Pharma GmbH; E-mail: info@midas-pharma.com; Tel. +49 6132 9900","first_published_date":"19/06/2018","last_updated_date":"19/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002248-pip01-17"},{"decision_number":"P/0087/2018","pip_number":"EMEA-002272-PIP01-17","active_substance":"Entinostat Polymorph B","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of breast malignant neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/03/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Syndax Pharmaceuticals, Inc.; Tel. +44(0) 7723045990","first_published_date":"19/06/2018","last_updated_date":"19/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002272-pip01-17"},{"decision_number":"P/0066/2018","pip_number":"EMEA-001716-PIP02-17","active_substance":"venglustat","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of Parkinson's disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/03/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Genzyme Europe B.V.; Tel. +31 356991499; E-mail: eumedinfo.gz@sanofi.com","first_published_date":"19/06/2018","last_updated_date":"19/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001716-pip02-17"},{"decision_number":"P/0091/2018","pip_number":"EMEA-002252-PIP01-17","active_substance":"T-cell bispecific antibody targeting carcinoembryonic antigen expressed on tumor cells and CD3 epsilon chain present on T-cells","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/03/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration Limited; Tel. +41 616879411; E-mail: global.paediatrics@roche.com","first_published_date":"19/06/2018","last_updated_date":"19/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002252-pip01-17"},{"decision_number":"P/0094/2018","pip_number":"EMEA-002254-PIP01-17","active_substance":"treprostinil sodium","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of chronic thromboembolic pulmonary hypertension","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/03/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"SciPharm Sàrl; Tel. +352 271127017; E-mail: office@scipharm.eu","first_published_date":"19/06/2018","last_updated_date":"19/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002254-pip01-17"},{"decision_number":"P/0088/2018","pip_number":"EMEA-002268-PIP01-17","active_substance":"niraparib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of prostate malignant neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/03/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen Research & Development; Tel. +353 857446696; E-mail: nbuhl@its.jnj.com","first_published_date":"19/06/2018","last_updated_date":"19/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002268-pip01-17"},{"decision_number":"P/0090/2018","pip_number":"EMEA-002257-PIP01-17","active_substance":"rosuvastatin;ezetimibe","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/03/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ELPEN Pharmaceutical Co. Inc; E-mail: regulatoryaffairs@elpen.gr; Tel. +30 2106039326; &nbsp","first_published_date":"19/06/2018","last_updated_date":"19/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002257-pip01-17"},{"decision_number":"P/0073/2018","pip_number":"EMEA-001573-PIP02-17","active_substance":"pemafibrate","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events in patients with elevated triglycerides levels;Treatment of hypertriglyceridaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/03/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kowa Research Europe Ltd; Tel. +44 01189229000; E-mail: regulatory@kowa.co.uk","first_published_date":"19/06/2018","last_updated_date":"19/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001573-pip02-17"},{"decision_number":"P/0103/2018","pip_number":"EMEA-001639-PIP02-17","active_substance":"Plazomicin (sulfate)","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of infections due to Enterobacteriaceae;Treatment of complicated urinary tract infections","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"19/03/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Achaogen, Inc.; Tel. +1 6502661120; E-mail: info@achaogen.com","first_published_date":"19/06/2018","last_updated_date":"19/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001639-pip02-17"},{"decision_number":"P/0095/2018","pip_number":"EMEA-002155-PIP01-17","active_substance":"non-pathogenic bacterial lysate of Escherichia coli and Enterococcus faecalis","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of irritable bowel syndrome (IBS)","routes_of_administration":"Oral use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"16/03/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"SymbioPharm GmbH; Tel. +41 613120510; E-mail: klaus.rose@klausrose.net","first_published_date":"19/06/2018","last_updated_date":"19/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002155-pip01-17"},{"decision_number":"P/0092/2018","pip_number":"EMEA-002249-PIP01-17","active_substance":"dapagliflozin;saxagliptin;metformin hydrochloride","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Modified-release tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/03/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB (Sweden); Tel. +46 8 5532791; E-mail: paediatrics@astrazeneca.com","first_published_date":"19/06/2018","last_updated_date":"19/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002249-pip01-17"},{"decision_number":"P/0100/2018","pip_number":"EMEA-002226-PIP02-17","active_substance":"Humanized recombinant IgG4 anti-human tau antibody","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Concentrate and solvent for concentrate for solution for infusion","condition_indication":"Treatment of progressive supranuclear palsy","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/03/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 07818428129","first_published_date":"19/06/2018","last_updated_date":"19/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002226-pip02-17"},{"decision_number":"P/0186/2016","pip_number":"EMEA-001108-PIP02-15","active_substance":"cadazolid","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Granules for oral suspension","condition_indication":"Treatment of Clostridium difficile infection","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/07/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Actelion Registration LtdTel. +41 6156 56565E-mail: medinfo@actelion.com","first_published_date":"19/09/2016","last_updated_date":"08/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001108-pip02-15"},{"decision_number":"P/0275/2015","pip_number":"EMEA-000848-PIP01-10-M02","active_substance":"Pollen from Phleum pratense","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of rhino-conjuctivitis;Treatment of allergic rhinitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/11/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ALK-Abelló A/S; Denmark; Tel +45 4574 7976; E-mail: alkmrp@alk.net","first_published_date":"24/01/2011","last_updated_date":"06/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000848-pip01-10-m02"},{"decision_number":"P/0272/2015","pip_number":"EMEA-000845-PIP01-10-M02","active_substance":"Pollen from Dactylis glomerata, Lolium perenne, Phleum pratense, Festuca pratensis, Secale cereale","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of rhino-conjuctivitis;Treatment of allergic rhinitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/11/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ALK-Abelló A/S; Denmark; Tel +45 4574 7976; E-mail: alkmrp@alk.net","first_published_date":"24/01/2011","last_updated_date":"06/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000845-pip01-10-m02"},{"decision_number":"P/273/2015","pip_number":"EMEA-000846-PIP01-10-M01","active_substance":"Betula verrucosa","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/11/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ALK-Abelló A/S; Denmark; Tel +45 4574 7976; E-mail: alkmrp@alk.net","first_published_date":"24/01/2011","last_updated_date":"06/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000846-pip01-10-m01"},{"decision_number":"P/0274/2015","pip_number":"EMEA-000847-PIP01-10-M01","active_substance":"Dermatophagoides pteronyssinus;Dermatophagoides farinae","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/11/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ALK-Abelló A/S; Denmark; Tel +45 4574 7976; E-mail: alkmrp@alk.net","first_published_date":"07/02/2011","last_updated_date":"06/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000847-pip01-10-m01"},{"decision_number":"P/0276/2015","pip_number":"EMEA-000849-PIP01-10-M01","active_substance":"pollen from Alnus glutinosa, Betula verrucosa and Corylus avellana","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of rhino-conjuctivitis;Treatment of allergic rhinitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/11/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ALK-Abelló A/S; Denmark; Tel +45 4574 7976; E-mail: alkmrp@alk.net","first_published_date":"07/02/2011","last_updated_date":"06/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000849-pip01-10-m01"},{"decision_number":"P/0128/2014","pip_number":"EMEA-000118-PIP02-10-M03","active_substance":"abatacept","invented_name":"Orencia; Orencia","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis)","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/03/2018","compliance_outcome":"Positive","compliance_opinion_date":"23/03/2018","compliance_procedure_number":"EMEA-C-000118-PIP02-10-M03","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"08/04/2011","last_updated_date":"06/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000118-pip02-10-m03"},{"decision_number":"P/0062/2018","pip_number":"EMEA-000636-PIP01-09-M07","active_substance":"fidaxomicin","invented_name":"Dificlir; Dificlir","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Granules for oral suspension","condition_indication":"Treatment of enterocolitis caused by Clostridium  difficile","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/03/2018","compliance_outcome":"Positive","compliance_opinion_date":"16/11/2018","compliance_procedure_number":"EMEA-C-000636-PIP01-09-M07","contact_for_public_enquiries":"Astellas Pharma Europe B.V.Tel. +31 7154 55878E-mail: contact.nl@astellas.com&nbsp","first_published_date":"22/07/2010","last_updated_date":"06/06/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000636-pip01-09-m07"},{"decision_number":"P/0201/2016","pip_number":"EMEA-000876-PIP06-15","active_substance":"Eculizumab","invented_name":"Soliris","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Prevention of graft rejection following solid organ transplantation","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"28/07/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alexion Europe SAS; France; E-mail: pip.enquiries.eu@alxn.com ; Tel. +33 1 47 10 06 06; Fax +33 1 47 10 06 11","first_published_date":"22/09/2016","last_updated_date":"20/04/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000876-pip06-15"},{"decision_number":"P/0173/2012","pip_number":"EMEA-001133-PIP01-11","active_substance":"trivalent, seasonal, recombinant influenza hemagglutinin vaccine","invented_name":"Flublok","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of influenza infection","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/07/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Protein Sciences Europa; manon.cox@proteinsciences.com; ldunkle@proteinsciences.com; dadams@proteinsciences.com; The Netherlands; +31 2036860800; +31 2036860268","first_published_date":"23/08/2012","last_updated_date":"20/04/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001133-pip01-11"},{"decision_number":"P/0180/2016","pip_number":"EMEA-001581-PIP01-13-M03","active_substance":"solithromycin","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Capsule, hard;Powder for concentrate for solution for infusion;Powder for oral suspension","condition_indication":"Treatment of anthrax;Treatment of tularaemia;Treatment of bacterial pneumonia","routes_of_administration":"Oral use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/07/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Triskel EU Services, Ltd; United States; Tel. +1 9195762306; E-mail: ghorwith@cempra.com","first_published_date":"05/11/2014","last_updated_date":"20/04/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001581-pip01-13-m03"},{"decision_number":"P/0120/2016","pip_number":"EMEA-001581-PIP02-16","active_substance":"solithromycin","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Capsule, hard;Powder for concentrate for solution for infusion;Powder for oral suspension","condition_indication":"Treatment of gonococcal infection","routes_of_administration":"Oral use;Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"28/04/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Triskel EU Services; United Kingdom; Tel. +1 9195762306; E-mail: ghorwith@cempra.com;  ","first_published_date":"02/06/2016","last_updated_date":"20/04/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001581-pip02-16"},{"decision_number":"P/0021/2018","pip_number":"EMEA-001797-PIP01-15-M01","active_substance":"human normal immunoglobulin","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Primary Immunodeficiency (PID)","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/01/2018","compliance_outcome":"Positive","compliance_opinion_date":"21/09/2018","compliance_procedure_number":"EMEA-C-001797-PIP01-15-M01","contact_for_public_enquiries":"Octapharma Pharmazeutika Produktionsges.m.b.H; Tel. +43 1610 321201; E-mail: wolfgang.frenzel@octapharma.com","first_published_date":"25/04/2016","last_updated_date":"19/04/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001797-pip01-15-m01"},{"decision_number":"P/0534/2021","pip_number":"EMEA-001474-PIP02-16-M02","active_substance":"pembrolizumab","invented_name":"Keytruda","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion;Powder for concentrate for solution for infusion","condition_indication":"Treatment of Hodgkin lymphoma","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/01/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"28/10/2016","last_updated_date":"19/04/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001474-pip02-16-m02"},{"decision_number":"P/0039/2018","pip_number":"EMEA-002239-PIP01-17","active_substance":"rosuvastatin calcium;acetylsalicylic acid","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Prevention of cardiovascular events","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/02/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Adamed Sp. z o.o.; Tel. +48227327736; E-mail: joanna.pawlak@adamed.com.pl","first_published_date":"18/04/2018","last_updated_date":"18/04/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002239-pip01-17"},{"decision_number":"P/0036/2018","pip_number":"EMEA-002242-PIP01-17","active_substance":"tucatinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of breast malignant neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cascadian Therapeutics Luxembourg S.A.R.L.; Tel. +1 2068012100; E-mail: HER2CLIMBinquiries@cascadianrx.com","first_published_date":"18/04/2018","last_updated_date":"18/04/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002242-pip01-17"},{"decision_number":"P/0038/2018","pip_number":"EMEA-002258-PIP01-17","active_substance":"recombinant human epidermal growth factor","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of diabetic foot ulcer","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Praxis Pharmaceuticals S.A; Tel. +436643564874; E-mail: j.rogan@inphares.net","first_published_date":"18/04/2018","last_updated_date":"18/04/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002258-pip01-17"},{"decision_number":"P/0029/2018","pip_number":"EMEA-002129-PIP02-17","active_substance":"Fluorocholine (18F)","invented_name":"","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Solution for injection","condition_indication":"Visualisation of choline metabolism in malignant neoplasms","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"UJV Rez, a. s.; Tel. +420266172269; E-mail: lukas.pech@ujv.cz","first_published_date":"18/04/2018","last_updated_date":"18/04/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002129-pip02-17"},{"decision_number":"P/0023/2018","pip_number":"EMEA-002109-PIP01-16","active_substance":"1,4-dihydro-1-[(2R)-2-(2-methoxyphenyl)-2-[(tetrahydro-2H-pyran-4-yl)oxy]ethyl]-α,α,5-trimethyl-6-(2-oxazolyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-3(2H)-acetic acid (GS-0976)","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of non-alcoholic steatohepatitis (NASH)","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/01/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd.; Tel. +44 1223897300; E-mail: regulatory.pip@gilead.com","first_published_date":"18/04/2018","last_updated_date":"18/04/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002109-pip01-16"},{"decision_number":"P/0012/2018","pip_number":"EMEA-000979-PIP01-10-M02","active_substance":"Matrix applied characterised autologous cultured chondrocytes","invented_name":"Maci; Maci","therapeutic_area":"Other","pharmaceutical_forms":"Implant","condition_indication":"Treatment of cartilage disorders","routes_of_administration":"Implant use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/01/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vericel Denmark ApS; Tel. +1 6175885661; E-mail: maguilera@vcel.com","first_published_date":"09/06/2011","last_updated_date":"18/04/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000979-pip01-10-m02"},{"decision_number":"P/0001/2018","pip_number":"EMEA-000402-PIP02-11-M05","active_substance":"lacosamide","invented_name":"Vimpat; Vimpat","therapeutic_area":"Neurology","pharmaceutical_forms":"Film-coated tablet;Syrup;Solution for infusion","condition_indication":"Treatment of epilepsy with partial-onset seizures","routes_of_administration":"Oral use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/01/2018","compliance_outcome":"Positive","compliance_opinion_date":"27/07/2018","compliance_procedure_number":"EMEA-C-000402-PIP02-11-M05","contact_for_public_enquiries":"UCB Pharma S.A.; Tel. +44 1753677251; E-mail: kenneth.johnson@ucb.com","first_published_date":"25/07/2017","last_updated_date":"17/04/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000402-pip02-11-m05"},{"decision_number":"P/0004/2018","pip_number":"EMEA-000341-PIP02-09-M05","active_substance":"L-asparaginase encapsulated in erythrocytes","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Dispersion for injection","condition_indication":"Treatment of acute lymphoblastic leukaemia","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/01/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Erytech pharma S.A.; Tel. +33 4787 44438; E-mail: vsemareg@erytech.com","first_published_date":"25/11/2010","last_updated_date":"17/04/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000341-pip02-09-m05"},{"decision_number":"P/0002/2018","pip_number":"EMEA-000153-PIP01-07-M05","active_substance":"artenimol;piperaquine phosphate anhydride","invented_name":"Eurartesim; Eurartesim","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Dispersible tablet","condition_indication":"Treatment of uncomplicated malaria caused by Plasmodium falciparum","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/01/2018","compliance_outcome":"Positive","compliance_opinion_date":"26/01/2018","compliance_procedure_number":"EMEA-C-000153-PIP01-07-M05","contact_for_public_enquiries":"Alfasigma SpA; Tel. +39 0691393657; E-mail: giulia.bruno@alfasigma.com","first_published_date":"17/10/2011","last_updated_date":"17/04/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000153-pip01-07-m05"},{"decision_number":"P/0018/2018","pip_number":"EMEA-002144-PIP01-17","active_substance":"obiltoxaximab","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Intravenous drip use","condition_indication":"Prevention of bacillary infection;Treatment of bacillary infection","routes_of_administration":"Solution for infusion","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"30/01/2018","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"SFL Pharmaceuticals Deutschland GmbH; Tel. +49 7621 5500 250; E-mail: RA@sfl-services.com","first_published_date":"17/04/2018","last_updated_date":"17/04/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002144-pip01-17"},{"decision_number":"P/0271/2013","pip_number":"EMEA-001395-PIP01-12","active_substance":"quilizumab","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of asthma","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"30/10/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration Limited; United Kingdom; Tel. +41 6168 79411; E-mail: info.paediatrics@roche.com","first_published_date":"15/11/2013","last_updated_date":"13/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001395-pip01-12"},{"decision_number":"P/0394/2017","pip_number":"EMEA-002224-PIP01-17","active_substance":"synthetic double-stranded small interfering RNA (siRNA) oligonucleotide specific to the mRNA of the caspase 2 gene","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of optic ischaemic neuropathy","routes_of_administration":"Intravitreal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/12/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Quark Pharmaceuticals, Inc.; Tel. +1 5103645121; E-mail: DCafaro@quarkpharma.com","first_published_date":"07/03/2018","last_updated_date":"07/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002224-pip01-17"},{"decision_number":"P/0395/2017","pip_number":"EMEA-002213-PIP01-17","active_substance":"sirolimus","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Implant","condition_indication":"Prevention of arteriovenous access dysfunction","routes_of_administration":"Implantation","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/12/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vascular Therapies, Inc.; Tel. +1 2012668310; E-mail: david@vasculartx.com","first_published_date":"07/03/2018","last_updated_date":"07/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002213-pip01-17"},{"decision_number":"P/0376/2017","pip_number":"EMEA-002211-PIP01-17","active_substance":"resminostat","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Coated tablet","condition_indication":"Treatment of Cutaneous T-Cell Lymphoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"4SC AGTel. +49 897007630E-mail: public@4sc.com","first_published_date":"07/03/2018","last_updated_date":"07/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002211-pip01-17"},{"decision_number":"EMEA-002207-PIP01-17","pip_number":"EMEA-002207-PIP01-17","active_substance":"atorvastatin;ezetimibe","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"07/03/2018","last_updated_date":"07/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002207-pip01-17"},{"decision_number":"EMEA-002197-PIP01-17","pip_number":"EMEA-002197-PIP01-17","active_substance":"soluble human T cell receptor (TCR) directed against the glycoprotein 100 (gp100) melanoma antigen, linked to the single-chain variable fragment (ScFv) domain of the anti-cluster of differentiation 3 (CD3) antibody","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of ocular melanoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Immunocore Ltd; Tel. +1 2153139618; E-mail: Chris.Coughlin@immunocore.com","first_published_date":"07/03/2018","last_updated_date":"07/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002197-pip01-17"},{"decision_number":"P/0368/2017","pip_number":"EMEA-002195-PIP01-17","active_substance":"vonapanitase","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Irrigation solution","condition_indication":"Prevention of arteriovenous access dysfunction","routes_of_administration":"Epilesional use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Proteon Therapeutics Limited; Tel. +44 1635576298; E-mail: info@proteontx.com","first_published_date":"07/03/2018","last_updated_date":"07/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002195-pip01-17"},{"decision_number":"P/0367/2017","pip_number":"EMEA-002196-PIP01-17","active_substance":"human Neutrophil Elastase Inhibitor (CHF6333)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Pressurised inhalation (suspension)","condition_indication":"Treatment of bronchiectasis","routes_of_administration":"Inhalation use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"01/12/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Chiesi Farmaceutici S.p.A; Tel. +39 05212791; E-mail: info@chiesi.com","first_published_date":"07/03/2018","last_updated_date":"07/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002196-pip01-17"},{"decision_number":"P/0300/2016","pip_number":"EMEA-001831-PIP01-15","active_substance":"monoclonal IgG1 anti-influenza A antibody","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of influenza","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/11/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Products Limited; Switzerland; Tel. +41 6168 79411; E-mail: info.paediatrics@roche.com","first_published_date":"06/01/2017","last_updated_date":"06/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001831-pip01-15"},{"decision_number":"P/0276/2017","pip_number":"EMEA-001340-PIP01-12-M03","active_substance":"human fibrinogen;human thrombin","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder for sealant","condition_indication":"Treatment of haemorrhage resulting from a surgical procedure","routes_of_administration":"Epilesional use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/10/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mallinckrodt Pharmaceuticals Ireland Ltd; Tel. +49 173 2393159; E-mail: markus.rothenburger@mallinckrodt.com","first_published_date":"13/08/2013","last_updated_date":"06/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001340-pip01-12-m03"},{"decision_number":"P/0355/2017","pip_number":"EMEA-000018-PIP01-07-M14","active_substance":"tapentadol hydrochloride","invented_name":"Palexia and associated names; Yantil and associated names; Tapentadol and associated names","therapeutic_area":"Pain","pharmaceutical_forms":"Film-coated tablet;Oral solution;Solution for injection/infusion","condition_indication":"Treatment of acute pain","routes_of_administration":"Oral use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Grünenthal GmbH; Tel.: +49 2415690; E-mail: pediatrics@grunenthal.com ","first_published_date":"03/07/2017","last_updated_date":"05/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000018-pip01-07-m14"},{"decision_number":"P/0389/2017","pip_number":"EMEA-000971-PIP01-10-M03","active_substance":"human coagulation factor X","invented_name":"Coagadex; Coagadex","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder for solution for injection or infusion","condition_indication":"Treatment of hereditary factor X deficiency","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/12/2017","compliance_outcome":"Positive","compliance_opinion_date":"26/01/2018","compliance_procedure_number":"EMEA-C-000971-PIP01-10-M03","contact_for_public_enquiries":"Bio Products Laboratory Limited; Tel. +44 2089572200; E-mail: medinfo@bpl.co.uk","first_published_date":"08/04/2011","last_updated_date":"05/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000971-pip01-10-m03"},{"decision_number":"P/0391/2017","pip_number":"EMEA-000794-PIP01-09-M01","active_substance":"aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergic extract of equal amounts of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis pollen (Grasses-Mix) (1/5) each","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/12/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LETI Pharma GmbH; Tel. +49 89121400290; E-mail: paediatrics@leti.de","first_published_date":"21/12/2010","last_updated_date":"05/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000794-pip01-09-m01"},{"decision_number":"P/0392/2017","pip_number":"EMEA-000792-PIP01-09-M01","active_substance":"aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergic extract of equal amounts of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis pollen (Grasses-Mix) and Secale cereale (cultivated rye) pollen (50/50)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/12/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LETI Pharma GmbH; Tel. +49 89121400290; E-mail: paediatrics@leti.de","first_published_date":"21/12/2010","last_updated_date":"05/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000792-pip01-09-m01"},{"decision_number":"P/0390/2017","pip_number":"EMEA-000795-PIP01-09-M01","active_substance":"aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergic extract of Phleum pratense pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/12/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LETI Pharma GmbH; Tel. +49 89121400290; E-mail: paediatrics@leti.de","first_published_date":"21/12/2010","last_updated_date":"05/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000795-pip01-09-m01"},{"decision_number":"P/0354/2017","pip_number":"EMEA-000239-PIP01-08-M03","active_substance":"telavancin hydrochloride","invented_name":"Vibativ; Vibativ","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of nosocomial pneumonia;Treatment of complicated skin and soft tissue infections (cSSTI)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Theravance Biopharma Ireland Ltd.; Tel. +33 174882008; E-mail: marine.lafargue@quintilesims.com","first_published_date":"16/09/2009","last_updated_date":"05/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000239-pip01-08-m03"},{"decision_number":"P/0369/2017","pip_number":"EMEA-002194-PIP01-17","active_substance":"opicinumab","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of multiple sclerosis","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biogen Idec LimitedTel. +44 1628512586E-mail: pip.enquiries@biogen.com","first_published_date":"05/03/2018","last_updated_date":"05/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002194-pip01-17"},{"decision_number":"P/0370/2017","pip_number":"EMEA-002170-PIP01-17","active_substance":"tolonium chloride","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Oromucosal gel","condition_indication":"Treatment of dental and oral soft tissue infections","routes_of_administration":"Dental use;Oromucosal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cumdente GmbH; Tel. +49 70719755721; E-mail: info@cumdente.de","first_published_date":"05/03/2018","last_updated_date":"05/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002170-pip01-17"},{"decision_number":"P/0396/2017","pip_number":"EMEA-002142-PIP01-17","active_substance":"trazodone (hydrochloride)","invented_name":"Trittico and associated names","therapeutic_area":"Neurology","pharmaceutical_forms":"Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of insomnia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"19/12/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F - S.p.A; Tel. +39 0691045249; E-mail: m.gatto@angelini.it","first_published_date":"05/03/2018","last_updated_date":"05/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002142-pip01-17"},{"decision_number":"P/0372/2017","pip_number":"EMEA-002094-PIP01-16","active_substance":"Iron hydroxyethyl amylopectin heptonate","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of iron deficiency or iron deficiency anaemia","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/12/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"iron4u; Tel. +45 45475040; E-mail: ovn@iron4u.com","first_published_date":"05/03/2018","last_updated_date":"05/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002094-pip01-16"},{"decision_number":"P/0357/2017","pip_number":"EMEA-002051-PIP02-16","active_substance":"allopregnanolone","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Intravenous use","condition_indication":"Treatment of postpartum depression","routes_of_administration":"Solution for infusion","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/12/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sage Therapeutics Inc; Tel. +1 6172998380; E-mail: contact@sagerx.com","first_published_date":"05/03/2018","last_updated_date":"05/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002051-pip02-16"},{"decision_number":"P/0278/2017","pip_number":"EMEA-000559-PIP01-09-M04","active_substance":"Japanese encephalitis virus, inactivated (attenuated strain SA14-14-2 grown in vero cells)","invented_name":"Ixiaro; Ixiaro","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of Japanese encephalitis","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/10/2017","compliance_outcome":"Positive","compliance_opinion_date":"10/11/2017","compliance_procedure_number":"EMEA-C-000559-PIP01-09-M04","contact_for_public_enquiries":"Valneva Austria GmbH; Tel. +43 1206201286; E-mail: Christian.TAUCHER@valneva.com","first_published_date":"12/05/2011","last_updated_date":"02/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000559-pip01-09-m04"},{"decision_number":"P/0128/2017","pip_number":"EMEA-000078-PIP01-07-M08","active_substance":"cinacalcet hydrochloride","invented_name":"Mimpara; Mimpara","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Film-coated tablet;Capsule, hard;Age appropriate dosage form, other","condition_indication":"Treatment of parathyroid carcinoma;Treatment of primary hyperparathyroidism;Treatment of secondary hyperparathyroidism in patients with end-stage renal disease","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/05/2017","compliance_outcome":"Positive","compliance_opinion_date":"19/05/2017","compliance_procedure_number":"EMEA-C-000078-PIP01-07-M08","contact_for_public_enquiries":"Amgen Europe B.V; Tel.: +44 (0)1223 420305; E-mail: medinfointernational@amgen.com","first_published_date":"29/10/2010","last_updated_date":"02/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000078-pip01-07-m08"},{"decision_number":"P/0298/2013","pip_number":"EMEA-001271-PIP01-12-M01","active_substance":"travoprost","invented_name":"Travatan; Travatan","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution","condition_indication":"Treatment of glaucoma","routes_of_administration":"Ocular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/11/2013","compliance_outcome":"Positive","compliance_opinion_date":"23/05/2014","compliance_procedure_number":"EMEA-001271-PIP01-12-M01","contact_for_public_enquiries":"Alcon Laboratories (UK) Ltd.; United Kingdom; bettina.maunz@alconlabs.com; Tel. +1 8175514858","first_published_date":"11/01/2013","last_updated_date":"02/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001271-pip01-12-m01"},{"decision_number":"P/0155/2016","pip_number":"EMEA-000279-PIP01-08-M05","active_substance":"raltegravir","invented_name":"Isentress; Isentress","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Chewable tablet;Granules for oral suspension","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/06/2016","compliance_outcome":"Positive","compliance_opinion_date":"19/06/2017","compliance_procedure_number":"EMEA-C-000279-PIP01-08-M05","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"09/07/2009","last_updated_date":"02/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000279-pip01-08-m05"},{"decision_number":"P/0299/2014","pip_number":"EMEA-000228-PIP01-08-M04","active_substance":"asenapine maleate","invented_name":"Sycrest; Sycrest","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Sublingual tablet","condition_indication":"Treatment of bipolar I disorder","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"24/11/2014","compliance_outcome":"Positive","compliance_opinion_date":"18/08/2017","compliance_procedure_number":"EMEA-C-000228-PIP01-08-M04","contact_for_public_enquiries":"N.V. Organon; E-mail: regaffairseurope@organon.com; Tel: +31 412770000","first_published_date":"03/10/2011","last_updated_date":"02/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000228-pip01-08-m04"},{"decision_number":"P/0050/2017","pip_number":"EMEA-000087-PIP01-07-M05","active_substance":"fingolimod hydrochloride ","invented_name":"Gilenya; Gilenya","therapeutic_area":"Neurology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of multiple sclerosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/04/2017","compliance_outcome":"Positive","compliance_opinion_date":"10/11/2017","compliance_procedure_number":"EMEA-C-000087-PIP01-07-M05","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"04/01/2013","last_updated_date":"02/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000087-pip01-07-m05"},{"decision_number":"P/0129/2017","pip_number":"EMEA-001254-PIP01-11-M02","active_substance":"split influenza virus, inactivated containing antigens equivalent to the B-like strain (B/Yamagata lineage);split influenza virus, inactivated containing antigens equivalent to the B-like strain (B/Victoria lineage);split influenza virus, inactivated (B/Victoria lineage);split influenza virus, inactivated containing antigens equivalent to the A/H1N1-like strain;split influenza virus, inactivated containing antigens equivalent to the A/H3N2-like strain","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of influenza infection","routes_of_administration":"Subcutaneous use;Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/05/2017","compliance_outcome":"Positive","compliance_opinion_date":"23/06/2017","compliance_procedure_number":"EMEA-C-001254-PIP01-11-M02","contact_for_public_enquiries":"Sanofi Pasteur SP; France; Tel. +33 4373 75038; E-mail: piplan@sanofipasteur.com","first_published_date":"18/09/2012","last_updated_date":"02/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001254-pip01-11-m02"},{"decision_number":"P/0306/2012","pip_number":"EMEA-000876-PIP02-11-M01","active_substance":"Eculizumab","invented_name":"Soliris; Soliris","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Shiga-toxin-producing Escherichia coli haemolytic uraemic syndrome","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"21/12/2012","compliance_outcome":"Positive","compliance_opinion_date":"02/06/2015","compliance_procedure_number":"EMEA-000876-PIP01-10-M01","contact_for_public_enquiries":"Alexion Europe SAS; France; E-mail: pip.enquiries.eu@alxn.com ; Tel. +33 1 47 10 06 06; Fax +33 1 47 10 06 11","first_published_date":"23/08/2012","last_updated_date":"02/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000876-pip02-11-m01"},{"decision_number":"P/0083/2017","pip_number":"EMEA-000717-PIP02-13-M02","active_substance":"vigabatrin","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Soluble tablet","condition_indication":"Treatment of epilepsy","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/03/2017","compliance_outcome":"Positive","compliance_opinion_date":"21/07/2017","compliance_procedure_number":"EMEA-C-000717-PIP02-13-M02","contact_for_public_enquiries":"Orphelia Pharma SA; France; E-mail: contact@orphelia-pharma.eu; Tel. +33 1427 70818","first_published_date":"31/07/2014","last_updated_date":"02/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000717-pip02-13-m02"},{"decision_number":"P/0280/2016","pip_number":"EMEA-001729-PIP01-14-M01","active_substance":"recombinant human nerve growth factor","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution","condition_indication":"Treatment of neurotrophic keratitis","routes_of_administration":"Ocular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/10/2016","compliance_outcome":"Positive","compliance_opinion_date":"10/11/2017","compliance_procedure_number":"EMEA-C-001729-PIP01-14-M01","contact_for_public_enquiries":"Dompé farmaceutici SpA; Italy; Tel.: +39 3669018586; Email: lamberto.dionigi@dompe.com","first_published_date":"22/09/2015","last_updated_date":"02/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001729-pip01-14-m01"},{"decision_number":"P/0157/2016","pip_number":"EMEA-001039-PIP01-10-M02","active_substance":"Clostridium Botulinum neurotoxin type A (150 kD), free from complexing proteins","invented_name":"Xeomin; Bocouture","therapeutic_area":"Neurology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of dystonia;Treatment of muscle spasticity;Treatment of muscle-induced wrinkles","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/06/2016","compliance_outcome":"Positive","compliance_opinion_date":"15/12/2017","compliance_procedure_number":"EMEA-C-001039-PIP01-10-M02","contact_for_public_enquiries":"Merz Pharmaceuticals GmbH ; Germany; Tel. +49 6915031 ; Fax +49 691503200; E-mail: contact@merz.de","first_published_date":"06/05/2015","last_updated_date":"02/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001039-pip01-10-m02"},{"decision_number":"P/0346/2017","pip_number":"EMEA-001363-PIP01-12-M01","active_substance":"thrombomodulin alfa","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of sepsis","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/12/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Asahi Kasei Pharma America Corporation; Tel. +1 7814191940; E-mail: RegInquiry@akpamerica.com","first_published_date":"08/10/2013","last_updated_date":"02/03/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001363-pip01-12-m01"},{"decision_number":"P/0270/2013","pip_number":"EMEA-001382-PIP01-12","active_substance":"eptacog alfa (activated)","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of congenital coagulation disorders","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"30/10/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Baxalta Innovations GmbH; Austria; E-mail: johannes.braun@baxalta.com; Tel. +43 1201002472542","first_published_date":"15/11/2013","last_updated_date":"26/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001382-pip01-12"},{"decision_number":"P/0246/2015","pip_number":"EMEA-000674-PIP02-11-M01","active_substance":"volasertib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of acute myeloid leukaemia","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/10/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"30/04/2013","last_updated_date":"23/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000674-pip02-11-m01"},{"decision_number":"P/257/2011","pip_number":"EMEA-001078-PIP01-10","active_substance":"Lixivaptan","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hyponatraemia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/10/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cardiokine Biopharma, LLC ; USA; struocchio@cardiokine.com; +1 2153991219; +1 2153991230","first_published_date":"29/11/2011","last_updated_date":"23/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001078-pip01-10"},{"decision_number":"P/0321/2017","pip_number":"EMEA-000782-PIP01-09-M04","active_substance":"tralokinumab","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of asthma","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/10/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"MedImmune Ltd; Tel. +44 (0)1582836181; E-mail: paediatrics@medimmune.com","first_published_date":"21/12/2011","last_updated_date":"23/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000782-pip01-09-m04"},{"decision_number":"P/0021/2014","pip_number":"EMEA-001406-PIP01-12","active_substance":"Mesalazine;prednisolone metasulphobenzoate","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Rectal suspension","condition_indication":"Treatment of ulcerative colitis","routes_of_administration":"Rectal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/01/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Disphar International B.V.; The Netherlands; E-mail: mcguinness@disphar.com; Tel. +31 3552 80400; Fax +31 3554 80585","first_published_date":"20/02/2014","last_updated_date":"23/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001406-pip01-12"},{"decision_number":"P/0042/2018","pip_number":"EMEA-000567-PIP01-09-M05","active_substance":"dasatinib","invented_name":"Sprycel; Sprycel","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral formulation","condition_indication":"Treatment of Philadelphia-chromosome (BCR-ABL translocation)-positive acute lymphoblastic leukaemia;Treatment of Philadelphia-chromosome (BCR-ABL translocation)-positive chronic myeloid leukaemia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/02/2018","compliance_outcome":"Positive","compliance_opinion_date":"23/02/2018","compliance_procedure_number":"EMEA-C-000567-PIP01-09-M05","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"15/09/2011","last_updated_date":"16/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000567-pip01-09-m05"},{"decision_number":"P/0321/2017","pip_number":"EMEA-001418-PIP01-15-M01","active_substance":"cabotegravir","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Suspension for injection;Tablet;Age appropriate oral dosage formulation","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use;Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/10/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ViiV Healthcare UK Limited; E-mail: eu.paediatric-plans@gsk.com; Tel. +44 (0)208 990 3650","first_published_date":"28/10/2016","last_updated_date":"15/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001418-pip01-15-m01"},{"decision_number":"P/0316/2017","pip_number":"EMEA-000019-PIP08-12-M03","active_substance":"everolimus","invented_name":"Votubia","therapeutic_area":"Neurology","pharmaceutical_forms":"Tablet;Dispersible tablet","condition_indication":"Treatment of tuberous sclerosis complex","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/10/2017","compliance_outcome":"Positive","compliance_opinion_date":"01/06/2018","compliance_procedure_number":"EMEA-C-000019-PIP08-12-M03","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"03/04/2013","last_updated_date":"13/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000019-pip08-12-m03"},{"decision_number":"P/0303/2017","pip_number":"EMEA-002222-PIP01-17","active_substance":"1H-Isoindol-1-one,2-[[1-[2-(4-fluorophenyl)-2-oxoethyl]-4-piperidinyl]methyl]-2,3-dihydro-,hydrochloride, hydrate (1:1:2) (MIN-101)","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Gastro-resistant tablet","condition_indication":"Treatment of schizophrenia","routes_of_administration":"Oral use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"08/11/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Minerva Neurosciences, Inc.; Tel. +1 6176007373; E-mail: info@minervaneurosciences.com","first_published_date":"12/02/2018","last_updated_date":"12/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002222-pip01-17"},{"decision_number":"P/0335/2017","pip_number":"EMEA-002202-PIP01-17","active_substance":"rosuvastatin;ezetimibe","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/10/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Krka, d.d., Novo mesto; Tel. +38 67331 2055; E-mail: tomaz.kralj@krka.biz","first_published_date":"12/02/2018","last_updated_date":"12/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002202-pip01-17"},{"decision_number":"P/0281/2017","pip_number":"EMEA-002175-PIP01-17","active_substance":"netarsudil;Latanoprost","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution;Solution","condition_indication":"Treatment of glaucoma","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/10/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aerie Pharmaceuticals Ireland Ltd; Tel. +1 9495268700; E-mail: info@aeriepharma.com","first_published_date":"12/02/2018","last_updated_date":"12/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002175-pip01-17"},{"decision_number":"P/0305/2017","pip_number":"EMEA-002203-PIP01-17","active_substance":"Capmatinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of lung malignant neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/10/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"12/02/2018","last_updated_date":"12/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002203-pip01-17"},{"decision_number":"P/0334/2017","pip_number":"EMEA-002200-PIP01-17","active_substance":"bempedoic acid;ezetimibe","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Coated tablet","condition_indication":"Treatment of elevated cholesterol","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/10/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Esperion Therapeutics, Inc.; Tel. +1 7346346816; E-mail: ahall@esperion.com","first_published_date":"12/02/2018","last_updated_date":"12/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002200-pip01-17"},{"decision_number":"P/0333/2017","pip_number":"EMEA-002181-PIP01-17","active_substance":"Pilocarpine (hydrochloride);Oxymetazoline hydrochloride","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution;Solution","condition_indication":"Treatment of presbyopia","routes_of_administration":"Ophthalmic use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/10/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628925033","first_published_date":"12/02/2018","last_updated_date":"12/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002181-pip01-17"},{"decision_number":"P/0304/2017","pip_number":"EMEA-002212-PIP01-17","active_substance":"Meldonium dihydrate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of angina pectoris","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/10/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ELC GROUP s.r.o., Karolinská; Tel. +42 773 653633; E-mail: parvinderpunia@pharmexon.com","first_published_date":"12/02/2018","last_updated_date":"12/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002212-pip01-17"},{"decision_number":"P/0297/2017","pip_number":"EMEA-001397-PIP06-17","active_substance":"Ibrutinib","invented_name":"Imbruvica; Imbruvica","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of lymphoplasmacytic lymphoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/10/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International N.V.; Tel. +32 1 464 1125; E-mail: JWeemer1@its.jnj.com","first_published_date":"12/02/2018","last_updated_date":"12/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001397-pip06-17"},{"decision_number":"P/0298/2017","pip_number":"EMEA-001397-PIP05-17","active_substance":"Ibrutinib","invented_name":"Imbruvica; Imbruvica","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of mantle cell lymphoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/10/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International N.V.; Tel. +32 1 464 1125; E-mail: JWeemer1@its.jnj.com","first_published_date":"12/02/2018","last_updated_date":"12/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001397-pip05-17"},{"decision_number":"P/0288/2017","pip_number":"EMEA-001214-PIP02-17","active_substance":"Benralizumab","invented_name":"","therapeutic_area":"Oto-rhino-laryngology","pharmaceutical_forms":"Solution for injection in pre-filled syringe","condition_indication":"Treatment of nasal polyposis","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/10/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB (Sweden); Tel. +46 8 5532791; E-mail: paediatrics@astrazeneca.com","first_published_date":"12/02/2018","last_updated_date":"12/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001214-pip02-17"},{"decision_number":"P/0290/2017","pip_number":"EMEA-002173-PIP01-17","active_substance":"perindopril arginine;amlodipine;Bisoprolol fumarate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypertension;Treatment of ischaemic coronary artery disorders","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/10/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierTel. +33 1 55 72 60 00E-mail: mail.pip.enquiries@fr.netgrs.com","first_published_date":"12/02/2018","last_updated_date":"12/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002173-pip01-17"},{"decision_number":"P/0282/2017","pip_number":"EMEA-002074-PIP01-16","active_substance":"ramucirumab","invented_name":"Cyramza; Cyramza","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of gastric cancer and gastro-oesophageal junction adenocarcinoma;Treatment of intestinal malignant neoplasms;Treatment of liver cancer;Treatment of lung malignant neoplasms;Treatment of urinary tract malignant neoplasm","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/10/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"12/02/2018","last_updated_date":"12/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002074-pip01-16"},{"decision_number":"P/0332/2017","pip_number":"EMEA-002167-PIP01-17","active_substance":"amlodipine;irbesartan;hydrochlorothiazide","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/10/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Win Medica S.A.; E-mail: info@winmedica.gr; Tel. +30 2107488821","first_published_date":"12/02/2018","last_updated_date":"12/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002167-pip01-17"},{"decision_number":"EMEA-000499-PIP03-17","pip_number":"EMEA-000499-PIP03-17","active_substance":"veliparib","invented_name":"","therapeutic_area":"","pharmaceutical_forms":"Tablet;Capsule, hard;Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of breast cancer","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/10/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628925033","first_published_date":"12/02/2018","last_updated_date":"12/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000499-pip03-17"},{"decision_number":"EMEA-000371-PIP04-16","pip_number":"EMEA-000371-PIP04-16","active_substance":"lenalidomide","invented_name":"Revlimid; Revlimid","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of mature B-cell neoplasms","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/10/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Celgene Europe LimitedTel.  +41 327298500E-mail: medinfo.intl@celgene.com","first_published_date":"12/02/2018","last_updated_date":"12/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000371-pip04-16"},{"decision_number":"P/0291/2017","pip_number":"EMEA-002174-PIP01-17","active_substance":"hydrochlorothiazide;Candesartan cilexetil;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/10/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Zentiva, k.s.; Tel. +42 267242361; E-mail: dana.petrikova@sanofi.com","first_published_date":"12/02/2018","last_updated_date":"12/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002174-pip01-17"},{"decision_number":"P/0289/2017","pip_number":"EMEA-002082-PIP01-16","active_substance":"Phenyl- and piperidin-containing derivative of amiloride (BI 443651)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Inhalation solution","condition_indication":"Treatment of cystic fibrosis","routes_of_administration":"Inhalation use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/10/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"12/02/2018","last_updated_date":"12/02/2018","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002082-pip01-16"},{"decision_number":"P/0263/2016","pip_number":"EMEA-001979-PIP01-16","active_substance":"Lifitegrast","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution;Solution","condition_indication":"Treatment of dry eye disease","routes_of_administration":"Ophthalmic use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"05/10/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Shire Pharmaceuticals Ireland Limited; United Kingdom; Tel. +800 6683 8470; E-mail: medinfoemea@shire.com","first_published_date":"23/11/2016","last_updated_date":"18/12/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001979-pip01-16"},{"decision_number":"P/0295/2017","pip_number":"EMEA-002020-PIP01-16-M01","active_substance":"Entolimod","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of acute radiation syndrome","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/09/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cleveland BioLabs Inc; Tel. +1 9705 350201; E-mail: ahards@cbiolabs.com","first_published_date":"29/05/2017","last_updated_date":"26/10/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002020-pip01-16-m01"},{"decision_number":"P/0249/2017","pip_number":"EMEA-002004-PIP01-16","active_substance":"atacicept","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Systemic Lupus Erythematosus (SLE)","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"05/09/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck KGaA; Tel. +49 6151 725200; E-mail: service@merckgroup.com","first_published_date":"24/10/2017","last_updated_date":"24/10/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002004-pip01-16"},{"decision_number":"P/0246/2017","pip_number":"EMEA-002163-PIP01-17","active_substance":"human normal immunoglobulin","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of Primary Immunodeficiency (PID)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/09/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kedrion S.p.A.; Tel. +39 0583 1969697; E-mail: info@kedrion.com","first_published_date":"24/10/2017","last_updated_date":"24/10/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002163-pip01-17"},{"decision_number":"P/0265/2017","pip_number":"EMEA-002140-PIP01-17","active_substance":"fluticasone propionate","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Inhalation powder","condition_indication":"Treatment of asthma","routes_of_administration":"Inhalation use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/09/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Teva Pharmaceuticals Europe B.V.; Tel. +44 (0)20 7540 7117; E-mail: medinfo@tevauk.com","first_published_date":"24/10/2017","last_updated_date":"24/10/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002140-pip01-17"},{"decision_number":"P/0247/2017","pip_number":"EMEA-002151-PIP01-17","active_substance":"Litoxetine (benzoate)","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Bladder and urethral symptoms (including incontinence)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/09/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ixaltis SA; Tel. +33 6294 74669; E-mail: info@kedrion.com","first_published_date":"24/10/2017","last_updated_date":"24/10/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002151-pip01-17"},{"decision_number":"P/0245/2017","pip_number":"EMEA-002177-PIP01-17","active_substance":"fluticasone propionate;salmeterol xinafoate","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Inhalation powder","condition_indication":"Treatment of asthma","routes_of_administration":"Inhalation use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/09/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Teva Pharmaceuticals Europe B.V.; Tel. +44 (0)20 7540 7117; E-mail: medinfo@tevauk.com","first_published_date":"24/10/2017","last_updated_date":"24/10/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002177-pip01-17"},{"decision_number":"P/0250/2017","pip_number":"EMEA-002084-PIP01-16","active_substance":"human normal immunoglobulin","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of Primary Immunodeficiency (PID)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/09/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ProMetic BioTherapeutics Ltd; Tel. +1 4507 810115; E-mail: j.booth@prometic.com, regaffairsuk@prometic.com","first_published_date":"24/10/2017","last_updated_date":"24/10/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002084-pip01-16"},{"decision_number":"P/0248/2017","pip_number":"EMEA-002092-PIP01-16","active_substance":"human normal immunoglobulin","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of Idiopathic Thrombocytopenia Purpura (ITP);Treatment of Primary Immunodeficiency (PID)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/09/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biotest AG; Tel. + 49 6103 801497E-mail: clinical.trials@biotest.com","first_published_date":"24/10/2017","last_updated_date":"24/10/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002092-pip01-16"},{"decision_number":"P/0223/2017","pip_number":"EMEA-001886-PIP02-15-M01","active_substance":"recombinant rusion protein linking coagulation Factor VIIa with Albumin (rVIIa-FP; CSL689)","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of congenital Factor VII Deficiency","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/08/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CSL Behring GmbH; Tel.: +49 6421393304; E-mail: rix-fp@cslbehring.com","first_published_date":"27/01/2017","last_updated_date":"02/10/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001886-pip02-15-m01"},{"decision_number":"P/0207/2017","pip_number":"EMEA-001886-PIP01-15-M01","active_substance":"recombinant rusion protein linking coagulation Factor VIIa with Albumin (rVIIa-FP; CSL689)","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of Haemophilia A;Treatment of Haemophilia B","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/08/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CSL Behring GmbH; Tel.: +49 6421393304; E-mail: rix-fp@cslbehring.com","first_published_date":"27/01/2017","last_updated_date":"02/10/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001886-pip01-15-m01"},{"decision_number":"P/0225/2017","pip_number":"EMEA-001590-PIP01-13-M04","active_substance":"allantoin","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Cream","condition_indication":"Treatment of epidermolysis bullosa","routes_of_administration":"Topical use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/08/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Scioderm, Inc. ; United States; Tel. +1 9193 282020; E-mail: info@sdermebtrials.com","first_published_date":"05/11/2014","last_updated_date":"02/10/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001590-pip01-13-m04"},{"decision_number":"P/0210/2017","pip_number":"EMEA-001517-PIP01-13-M01","active_substance":"sotagliflozin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/08/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"sanofi-aventis R&D; France; Tel. +33 1 60 49 66 82; E-mail: contact-us@sanofi.com","first_published_date":"04/12/2014","last_updated_date":"02/10/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001517-pip01-13-m01"},{"decision_number":"P/0231/2017","pip_number":"EMEA-000989-PIP01-10-M02","active_substance":"chlorhexidine gluconate;isopropyl alcohol","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Solution","condition_indication":"Prevention of infection prior to invasive procedures","routes_of_administration":"Cutaneous use","decision_type":"RPM: decision refers to a refusal on the application for modification of an agreed PIP","decision_date":"11/08/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"3M Health Care LimitedTel: +44 1509613275E-mail: bdavidson@mmm.com","first_published_date":"08/08/2011","last_updated_date":"02/10/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000989-pip01-10-m02"},{"decision_number":"P/0218/2017","pip_number":"EMEA-000128-PIP01-07-M08","active_substance":"liraglutide","invented_name":"Victoza; Victoza","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection in pre-filled pen","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/08/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; Denmark; Tel. +45 44448888; E-mail: paediatrics@novonordisk.com","first_published_date":"07/06/2011","last_updated_date":"29/09/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000128-pip01-07-m08"},{"decision_number":"P/0222/2017","pip_number":"EMEA-002125-PIP01-17","active_substance":"osimertinib (as mesilate)","invented_name":"Tagrisso; Tagrisso","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of lung carcinoma (small cell and non-small cell carcinoma)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/08/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB (Sweden); Tel. +46 8 5532791; E-mail: paediatrics@astrazeneca.com","first_published_date":"28/09/2017","last_updated_date":"28/09/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002125-pip01-17"},{"decision_number":"P/0215/2017","pip_number":"EMEA-001032-PIP02-17","active_substance":"macitentan","invented_name":"Opsumit; Opsumit","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Dispersible tablet;Film-coated tablet","condition_indication":"Treatment of chronic thromboembolic pulmonary hypertension (CTEPH)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/08/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Actelion Registration LtdTel. +41 615656565E-mail: clinical-trials-disclosure@its.jnj.com","first_published_date":"28/09/2017","last_updated_date":"28/09/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001032-pip02-17"},{"decision_number":"P/0202/2017","pip_number":"EMEA-002120-PIP01-17","active_substance":"Methacholine chloride","invented_name":"Provocholine","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Powder for nebuliser solution","condition_indication":"Diagnosis of asthma","routes_of_administration":"Inhalation use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/08/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"MWK Healthcare Ltd; United Kingdom; Tel. +44 1691664243; E-mail: mark@mwkhealthcare.co.uk ","first_published_date":"28/09/2017","last_updated_date":"28/09/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002120-pip01-17"},{"decision_number":"P/0199/2017","pip_number":"EMEA-002077-PIP01-16","active_substance":"Fc- and CDR-modified humanised monoclonal antibody against C5 (ravulizumab)","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of paroxysmal nocturnal haemoglobinuria","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/07/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alexion Europe SAS; France; Tel. +33 14100606; E-mail: pip.enquiries@alexion.com ","first_published_date":"28/09/2017","last_updated_date":"28/09/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002077-pip01-16"},{"decision_number":"P/0201/2017","pip_number":"EMEA-002124-PIP01-17","active_substance":"pexastimogene devacirepvec","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of hepatocellular carcinoma","routes_of_administration":"Intratumoral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/07/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Transgene S.A.; France; Tel. +33 388279155; E-mail: clinical.trials@transgene.fr","first_published_date":"28/09/2017","last_updated_date":"28/09/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002124-pip01-17"},{"decision_number":"P/0203/2017","pip_number":"EMEA-002132-PIP01-17","active_substance":"diclofenac (sodium)","invented_name":"Pennsaid","therapeutic_area":"Pain","pharmaceutical_forms":"Cutaneous solution","condition_indication":"Treatment of inflammation;Treatment of pain","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/08/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dimethaid (UK) Limited; Tel. +1 9056 733623; E-mail: bchiasson@nuvopharm.com","first_published_date":"28/09/2017","last_updated_date":"28/09/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002132-pip01-17"},{"decision_number":"P/0220/2017","pip_number":"EMEA-002149-PIP01-17","active_substance":"DaxibotulinumtoxinA","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of glabellar lines","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/08/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Revance Therapeutics Inc; United States; Tel. +1 5107423559; E-mail: lmcbride@revance.com","first_published_date":"28/09/2017","last_updated_date":"28/09/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002149-pip01-17"},{"decision_number":"P/0208/2017","pip_number":"EMEA-002108-PIP01-16","active_substance":"H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val-OH(YGRKKRRQRRRKLSSIESDV)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of acute ischaemic stroke","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/08/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"NoNO Inc.; Canada; Tel. +1 4166035188; E-mail: mtymianski@nonoinc.ca; sok@nonoinc.ca","first_published_date":"28/09/2017","last_updated_date":"28/09/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002108-pip01-16"},{"decision_number":"P/0221/2017","pip_number":"EMEA-002148-PIP01-17","active_substance":"5, 7-dihydroxy-2-[3-hydroxy-4-methoxy-2-(2-methyl-2-propenyl) phenyl]-6, 8-bis (2-methyl-2-propenyl)-4H-chromen-4-one","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of venous and mixed (venous/arterial) leg ulcers","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/08/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ilkos Therapeutic Inc; France; Tel. +33 155726000; E-mail: mail.pip.enquiries@servier.com","first_published_date":"28/09/2017","last_updated_date":"28/09/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002148-pip01-17"},{"decision_number":"P/0216/2017","pip_number":"EMEA-000828-PIP05-17","active_substance":"empagliflozin","invented_name":"Jardiance; Jardiance","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events in patients with chronic heart failure","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/08/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"28/09/2017","last_updated_date":"28/09/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000828-pip05-17"},{"decision_number":"P/0236/2017","pip_number":"EMEA-002137-PIP01-17","active_substance":"recombinant humanized anti-alpha-synuclein IgG1 monoclonal antibody","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Parkinson's disease","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/08/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration Limited; Switzerland; Tel. +41 616879411; E-mail: global.paediatrics@roche.com;  ","first_published_date":"28/09/2017","last_updated_date":"28/09/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002137-pip01-17"},{"decision_number":"P/0182/2017","pip_number":"EMEA-001262-PIP01-12-M03","active_substance":"Dobutamine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of neonatal circulatory failure","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/07/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Proveca LimitedTel. +44 7913048665E-mail: simon@proveca.co.uk","first_published_date":"26/07/2017","last_updated_date":"26/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001262-pip01-12-m03"},{"decision_number":"P/0195/2017","pip_number":"EMEA-001229-PIP01-11-M03","active_substance":"Damoctocog alfa pegol","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of hereditary factor VIII deficiency","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/07/2017","compliance_outcome":"Positive","compliance_opinion_date":"18/08/2017","compliance_procedure_number":"EMEA-C-001229-PIP01-11-M03","contact_for_public_enquiries":"Bayer AG; Tel. +49 30300139003; E-mail: clinical-trials-contact@bayer.com","first_published_date":"26/07/2017","last_updated_date":"26/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001229-pip01-11-m03"},{"decision_number":"P/0143/2017","pip_number":"EMEA-000972-PIP01-10-M05","active_substance":"Laquinimod (sodium)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of relapsing remitting multiple sclerosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/06/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Teva GmbH; Tel. +41 552201546; E-mail: info-era-clinical@teva.de","first_published_date":"26/07/2017","last_updated_date":"26/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000972-pip01-10-m05"},{"decision_number":"P/0192/2017","pip_number":"EMEA-001071-PIP02-12-M02","active_substance":"certolizumab pegol","invented_name":"Cimzia; Cimzia","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis)","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/07/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"UCB Pharma S.A.; E-mail: ucbcares.uk@ucb.com; Tel.  +44 175777100","first_published_date":"26/07/2017","last_updated_date":"26/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001071-pip02-12-m02"},{"decision_number":"P/0173/2017","pip_number":"EMEA-000176-PIP01-07-M05","active_substance":"Colistimethate sodium","invented_name":"Colobreathe; Colobreathe","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of Pseudomonas aeruginosa pulmonary infection / colonisation in patients with cystic fibrosis","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/07/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"TEVA B.V.; United Kingdom; Tel. +44 2075407058; E-mail: rina.joshi@tevaeu.com;  ","first_published_date":"25/07/2017","last_updated_date":"25/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000176-pip01-07-m05"},{"decision_number":"P/0185/2017","pip_number":"EMEA-002135-PIP01-17","active_substance":"ezetimibe;rosuvastatin calcium","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of elevated cholesterol","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/06/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BENEDETTI & Co. S.r.l.; Italy; Tel. +39 0573474007; Fax +39 0573474963; Email: g.delorenzo@bencospa.it","first_published_date":"25/07/2017","last_updated_date":"25/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002135-pip01-17"},{"decision_number":"P/0186/2017","pip_number":"EMEA-002131-PIP01-17","active_substance":"ezetimibe;rosuvastatin calcium","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of elevated cholesterol","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/06/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Errekappa Euroterapici S.p.A.; Italy; Tel. +39 057320877; Fax +39 0573475188; E-mail: regolatorio1@errekappa.it;  ","first_published_date":"25/07/2017","last_updated_date":"25/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002131-pip01-17"},{"decision_number":"P/0174/2017","pip_number":"EMEA-002111-PIP01-17","active_substance":"Miridesap","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of systemic light chain amyloidosis","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/07/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Tel.: +1 4388998201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"25/07/2017","last_updated_date":"25/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002111-pip01-17"},{"decision_number":"P/0184/2017","pip_number":"EMEA-002143-PIP01-17","active_substance":"benzydamine (hydrochloride);econazole nitrate","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Pessary","condition_indication":"Treatment of vulvovaginal candidiasis","routes_of_administration":"Vaginal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/06/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.; Italy; Tel. +39 0691045249; E-mail: ma.gatto@angelini.it; m.gatto@angelini.it","first_published_date":"25/07/2017","last_updated_date":"25/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002143-pip01-17"},{"decision_number":"P/0188/2017","pip_number":"EMEA-002136-PIP01-17","active_substance":"rosuvastatin;amlodipine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Prevention of cardiovascular events;Treatment of dyslipidaemia;Treatment of hypertension;Treatment of ischemic coronary artery disorders","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/07/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Errekappa Euroterapici S.p.A.; Italy; Tel. +39 057320877; Fax +39 0573475188; E-mail: regolatorio1@errekappa.it;  ","first_published_date":"25/07/2017","last_updated_date":"25/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002136-pip01-17"},{"decision_number":"P/0187/2017","pip_number":"EMEA-002111-PIP02-17","active_substance":"Miridesap","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of transthyretin amyloidosis (ATTR)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/07/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Tel. +1 4388998201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"25/07/2017","last_updated_date":"25/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002111-pip02-17"},{"decision_number":"P/0189/2017","pip_number":"EMEA-002130-PIP01-17","active_substance":"rosuvastatin;amlodipine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Prevention of cardiovascular events;Treatment of dyslipidaemia;Treatment of hypertension;Treatment of ischemic coronary artery disorders","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/07/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CIPROS S.R.L.; Italy; Tel. +39 0573474010; Fax +39 0573475188; E- mail: regolatorio@ciprossrl.it;  ","first_published_date":"25/07/2017","last_updated_date":"25/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002130-pip01-17"},{"decision_number":"P/0152/2017","pip_number":"EMEA-000065-PIP01-07-M05","active_substance":"telbivudine","invented_name":"Sebivo; Sebivo","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Film-coated tablet;Oral solution","condition_indication":"Treatment of chronic hepatitis B","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/06/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"25/07/2017","last_updated_date":"25/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000065-pip01-07-m05"},{"decision_number":"P/0130/2017","pip_number":"EMEA-002118-PIP01-17","active_substance":"ezetimibe;rosuvastatin calcium","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/06/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Neopharmed Gentili S.r.l; Tel. +39 06 77209020; E-mail: direnzo@direnzo.biz","first_published_date":"25/07/2017","last_updated_date":"25/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002118-pip01-17"},{"decision_number":"P/0191/2017","pip_number":"EMEA-002114-PIP01-16","active_substance":"abacavir;lamivudine;efavirenz","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/06/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Lek Pharmaceuticals d.d.; Tel.  +41 613241111; E-mail: enquiries.paediatrics@sandoz.com; &nbsp","first_published_date":"25/07/2017","last_updated_date":"25/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002114-pip01-16"},{"decision_number":"P/0177/2017","pip_number":"EMEA-002104-PIP01-16","active_substance":"olmesartan medoxomil;hydrochlorothiazide;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/07/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Accord Healthcare S.L.U.; E-mail: regulatory_EU@accord-healthcare.com; Tel. +34 933010064","first_published_date":"24/07/2017","last_updated_date":"24/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002104-pip01-16"},{"decision_number":"P/0131/2017","pip_number":"EMEA-002099-PIP01-16","active_substance":"buprenorphine hydrochloride","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Implant","condition_indication":"Treatment of opioid dependence","routes_of_administration":"Subdermal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/06/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Titan Pharmaceuticals Inc; United States; Tel. +1 6502444990; E-mail: paediatrics@titanpharm.com","first_published_date":"24/07/2017","last_updated_date":"24/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002099-pip01-16"},{"decision_number":"P/0159/2017","pip_number":"EMEA-002102-PIP01-16","active_substance":"Ibuprofen;pseudoephedrine","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Oral suspension","condition_indication":"Treatment of nasal congestion and inflammations;Treatment of febrile disorders;Treatment of pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/06/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Farmalider, S.A.; Spain; Tel. +34 916612335; Fax +34 916610442; E-mail: carloscalandria@farmalider.com","first_published_date":"24/07/2017","last_updated_date":"24/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002102-pip01-16"},{"decision_number":"P/0169/2017","pip_number":"EMEA-000560-PIP02-15","active_substance":"omadacycline","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for concentrate for solution for infusion;Film-coated tablet;Granules","condition_indication":"Treatment of acute bacterial skin and skin structure infections","routes_of_administration":"Intravenous use;Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/07/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Paratek UK Limited; E-mail: info@paratekpharma.com; Tel. +1 6178 076600","first_published_date":"24/07/2017","last_updated_date":"24/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000560-pip02-15"},{"decision_number":"P/0175/2017","pip_number":"EMEA-002110-PIP02-17","active_substance":"Dezamizumab","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of systemic light chain amyloidosis","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/07/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Tel. +1 4388998201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"24/07/2017","last_updated_date":"24/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002110-pip02-17"},{"decision_number":"P/0134/2017","pip_number":"EMEA-002053-PIP01-16","active_substance":"Polihexanide","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution;Solution","condition_indication":"Treatment of Acanthamoeba keratitis","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/06/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Società Industria Farmaceutica Italiana (S.I.F.I.) SpA; Italy; Tel. +39 0957922111; E-mail: antonino.asero@sifigroup.com","first_published_date":"24/07/2017","last_updated_date":"24/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002053-pip01-16"},{"decision_number":"P/0133/2017","pip_number":"EMEA-002067-PIP02-17","active_substance":"Medium-chain triglycerides;olive oil;Fish oil;acetyl-cysteine;alanine;histidine;Isoleucin;leucine;Lysine acetate;methionine;phenylalanine;proline;tryptophan;tyrosine;valine;glucose;calcium chloride;potassium chloride;sodium acetate;zinc sulfate;Malic acid;arginine;glycine;serine;threonine;sodium glycerophosphate;soya bean oil;magnesium sulfate","invented_name":"","therapeutic_area":"Nutrition","pharmaceutical_forms":"Emulsion for infusion","condition_indication":"Parenteral nutrition","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/06/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Fresenius Kabi Deutschland GmbH; Germany; Tel. +49 61726080; Fax +49 61726082294; E-mail: pr-fe@fresenius.com;  ","first_published_date":"24/07/2017","last_updated_date":"24/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002067-pip02-17"},{"decision_number":"P/0132/2017","pip_number":"EMEA-002097-PIP01-16","active_substance":"nimodipine","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Powder and solvent for prolonged-release suspension for injection","condition_indication":"Treatment of aneurysmal subarchnoidal haemorrhage","routes_of_administration":"Intraventricular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/06/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Edge Therapeutics, Inc; United States; Tel. +1 9083245257; E-mail: afaulkner@edgetherapeutics.com","first_published_date":"24/07/2017","last_updated_date":"24/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002097-pip01-16"},{"decision_number":"P/0178/2017","pip_number":"EMEA-001986-PIP01-16","active_substance":"radium (223Ra) dichloride","invented_name":"Xofigo; Xofigo","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Multiple Myeloma;Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/07/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer AG; Tel. +49 30300139003; E-mail: clinical-trials-contact@bayer.com","first_published_date":"24/07/2017","last_updated_date":"24/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001986-pip01-16"},{"decision_number":"P/0176/2017","pip_number":"EMEA-002110-PIP01-17","active_substance":"Dezamizumab","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of transthyretin amyloidosis (ATTR)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/07/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Tel.: +1 4388998201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"24/07/2017","last_updated_date":"24/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002110-pip01-17"},{"decision_number":"P/0125/2017","pip_number":"EMEA-002081-PIP01-16","active_substance":"ramipril;Indapamide","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Modified-release tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"05/05/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pharmaceutical Works Polpharma SA; Poland; Tel.: +48 58 563 89 44; E-mail: iwona.nowak@polpharma.com","first_published_date":"04/07/2017","last_updated_date":"04/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002081-pip01-16"},{"decision_number":"P/0126/2017","pip_number":"EMEA-002042-PIP01-16","active_substance":"Erdafitinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of urothelial carcinoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"05/05/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International N.V; Tel.: +353 857446696; E-mail: nbuhl@ITS.JNJ.com","first_published_date":"03/07/2017","last_updated_date":"03/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002042-pip01-16"},{"decision_number":"P/0124/2017","pip_number":"EMEA-001006-PIP03-16","active_substance":"nintedanib","invented_name":"Vargatef; Ofev; Vargatef; Ofev","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, soft","condition_indication":"Treatment of lung carcinoma (small cell and non-small cell carcinoma);Treatment of mesothelioma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"05/05/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"03/07/2017","last_updated_date":"03/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001006-pip03-16"},{"decision_number":"P/0122/2017","pip_number":"EMEA-002061-PIP01-16","active_substance":"small interfering RNA targeting human TRPV1 mRNA","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution;Solution","condition_indication":"Treatment of dry eye disease","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"05/05/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sylentis SAU; United Kingdom; Tel.: +44 1844210690; E-mail: steve.pinder@envestia.com, vruz@sylentis.com","first_published_date":"03/07/2017","last_updated_date":"03/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002061-pip01-16"},{"decision_number":"P/0121/2017","pip_number":"EMEA-001152-PIP02-16","active_substance":"recombinant modified human growth hormone","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of growth hormone deficiency","routes_of_administration":"Subcutaneous use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"05/05/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Richardson Associates Regulatory Affairs Ltd; Israel; Tel.: +972 89300051; Fax: +972 89300091; E-mail: contact_opkobiologics@opko.com","first_published_date":"03/07/2017","last_updated_date":"03/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001152-pip02-16"},{"decision_number":"P/0119/2017","pip_number":"EMEA-000069-PIP05-16","active_substance":"Mepolizumab","invented_name":"Nucala; Nucala","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Solution for injection;Powder for solution for injection","condition_indication":"Treatment of nasal polyposis","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"05/05/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GSK Trading Services Limited; United Kingdom; Tel.: +44 2089904891; Fax: +44 2089903501; E-mail: eu.paediatric-plans.gsk.com","first_published_date":"03/07/2017","last_updated_date":"03/07/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000069-pip05-16"},{"decision_number":"P/0170/2015","pip_number":"EMEA-001054-PIP01-10-M03","active_substance":"L-Cysteinyl-L-prolyl-L-alanyl-L-valyl-L-lysyl-L-arginyl-L-aspartyl-L-valyl-L-aspartyl-L-leucyl-L-phenylalanyl-L-leucyl-L-threonine, acetate salt;L-glutamyl-L-glutaminyl-L-valyl-L-alanyl-Lglutaminyl-L-tyrosyl-L-lysyl-L-alanyl-L-leucyl-L-prolyl-L-valyl-L-valyl-L-leucyl-L-glutamyl-L-asparaginyl-L-alanine, acetate salt;L-lysyl-L-alanyl-L-leucyl-L-prolyl-L-valyl-L-valyl-L-leucyl-L-glutamyl-L-asparaginyl-L-alanyl-L-arginyl-L-isoleucyl-L-leucyl-L-lysyl-L-asparaginyl-L-cysteinyl-L-valine, acetate salt...","invented_name":"Katclari","therapeutic_area":"Oto-rhino-laryngology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of perennial allergic rhinitis","routes_of_administration":"Intradermal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/08/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Circassia Limited ; United Kingdom; Email: rodhafner@circassia.co.uk; Tel. +44 (0)1865 598078; Fax +44 (0)7092 987560","first_published_date":"28/11/2011","last_updated_date":"19/06/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001054-pip01-10-m03"},{"decision_number":"P/0099/2017","pip_number":"EMEA-001492-PIP01-13-M01","active_substance":"trifarotene","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Cream","condition_indication":"Treatment of acne","routes_of_administration":"Cutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/04/2017","compliance_outcome":"Positive","compliance_opinion_date":"29/06/2018","compliance_procedure_number":"EMEA-C-001492-PIP01-13-M01","contact_for_public_enquiries":"Galderma International S.A.S; E-mail: Morgan.DANVEL@galderma.com; Tel.: +41 21924 9886","first_published_date":"30/09/2014","last_updated_date":"29/05/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001492-pip01-13-m01"},{"decision_number":"P/0097/2017","pip_number":"EMEA-001653-PIP01-14-M02","active_substance":"recombinant human N-acetylglucosaminidase","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of mucopolysaccharidosis IIIB (Sanfilippo B)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/04/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alexion Europe SAS; France; E-mail: clinicaltrials@alexion.com; Tel.: +33 147100606; Fax: +33 1 47100611","first_published_date":"19/05/2015","last_updated_date":"29/05/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001653-pip01-14-m02"},{"decision_number":"P/0093/2017","pip_number":"EMEA-000196-PIP01-08-M04","active_substance":"telaprevir","invented_name":"Incivo; Incivo","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Chewable tablet","condition_indication":"Treatment of chronic hepatitis C","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/04/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; E-mail: contact@janssen-emea.com; Tel.: +32 14602111","first_published_date":"29/01/2009","last_updated_date":"29/05/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000196-pip01-08-m04"},{"decision_number":"P/0089/2017","pip_number":"EMEA-000440-PIP02-11-M05","active_substance":"melatonin","invented_name":"Circadin; Circadin","therapeutic_area":"Neurology","pharmaceutical_forms":"Prolonged-release tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of insomnia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/04/2017","compliance_outcome":"Positive","compliance_opinion_date":"21/04/2017","compliance_procedure_number":"EMEA-000440-PIP02-11-M05","contact_for_public_enquiries":"RAD Neurim Pharmaceuticals EEC Ltd; United Kingdom; E-mail: talin@neurim.com; Tel. +972 37684902; Fax +972 36494568","first_published_date":"08/08/2012","last_updated_date":"29/05/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000440-pip02-11-m05"},{"decision_number":"P/0114/2017","pip_number":"EMEA-000184-PIP03-16","active_substance":"tobramycin","invented_name":"Tobi Podhaler; Tobi Podhaler","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Inhalation powder;Capsule, hard","condition_indication":"Treatment of Pseudomonas aeruginosa pulmonary colonisation in patients with bronchiectasis","routes_of_administration":"Inhalation use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/04/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mylan IRE Healthcare Limited; E-mail: info.uk@viatris.com; Tel. + 44 (0)1707853000","first_published_date":"29/05/2017","last_updated_date":"29/05/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000184-pip03-16"},{"decision_number":"P/0111/2017","pip_number":"EMEA-002071-PIP01-16","active_substance":"prasugrel (hydrochloride);acetylsalicylic acid","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Prevention of thromboembolic events","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/04/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Daiichi Sankyo Europe GmbH; E-mail: service@daiichi-sankyo.eu; Tel.: +49 8978080","first_published_date":"29/05/2017","last_updated_date":"29/05/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002071-pip01-16"},{"decision_number":"P/0110/2017","pip_number":"EMEA-002091-PIP01-16","active_substance":"amlodipine;perindopril","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/04/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CIPROS S.r.l.; E-mail: regolatorio@ciprossrl.it; Tel.: +39 573474010; Fax: +39 573475188","first_published_date":"29/05/2017","last_updated_date":"29/05/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002091-pip01-16"},{"decision_number":"P/0103/2017","pip_number":"EMEA-002090-PIP01-16","active_substance":"Candesartan;amlodipine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/04/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ERREKAPPA EUROTERAPICI S.p.A.; Italy; E-mail: regolatorio1@errekappa.it; Tel.: +39 57320877; Fax: ++39 573475188","first_published_date":"29/05/2017","last_updated_date":"29/05/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002090-pip01-16"},{"decision_number":"P/0085/2017","pip_number":"EMEA-001549-PIP02-14","active_substance":"baclofen","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of alcohol dependence","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/03/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ethypharm; France; E-mail: Carpentier.Helene@ethypharm.com; Tel.: +33 (0)141121740","first_published_date":"21/04/2017","last_updated_date":"21/04/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001549-pip02-14"},{"decision_number":"P/0081/2017","pip_number":"EMEA-002047-PIP01-16","active_substance":"ezetimibe;atorvastatin calcium","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of elevated cholesterol","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/03/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Midas Pharma GmbH; E-mail: pv@midas-pharma.com; Tel. +49 6132 990583","first_published_date":"21/04/2017","last_updated_date":"21/04/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002047-pip01-16"},{"decision_number":"P/0080/2017","pip_number":"EMEA-002034-PIP01-16","active_substance":"Methylphenidate (hydrochloride)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Prolonged-release capsule;Capsule, hard","condition_indication":"Treatment of Attention Deficit Hyperactivity Disorder (ADHD)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/03/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mundipharma Research Limited; United Kingdom; E-mail: paediatric@mundipharma-rd.eu; Tel.: +44 (0)1223424900","first_published_date":"21/04/2017","last_updated_date":"21/04/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002034-pip01-16"},{"decision_number":"P/0079/2017","pip_number":"EMEA-002016-PIP02-16","active_substance":"alpelisib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of breast cancer","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/03/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"21/04/2017","last_updated_date":"21/04/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002016-pip02-16"},{"decision_number":"P/0078/2017","pip_number":"EMEA-001980-PIP01-16","active_substance":"T-lymphocytes enriched leukocyte preparation depleted ex vivo of host host-alloreactive T cells using photodynamic treatment (ATIR101)","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Cell suspension for infusion","condition_indication":"Adjunctive treatment in haematopoietic stem cell transplantation for a malignant disease","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"16/03/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kiadis Pharma Netherlands B.V.; The Netherlands; E-mail: clinicaltrials@kiadis.com; Tel.: +31 203140250; Fax: +31 203140251","first_published_date":"21/04/2017","last_updated_date":"21/04/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001980-pip01-16"},{"decision_number":"P/0072/2017","pip_number":"EMEA-001868-PIP02-16","active_substance":"5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridi-2-yl)-4-methylbenzamide","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of alcoholic hepatitis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/03/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd.; United Kingdom; E-mail: regulatory.pip@gilead.com; Tel.: +44 1223897300; Fax: +44 (0)1223897284","first_published_date":"21/04/2017","last_updated_date":"21/04/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001868-pip02-16"},{"decision_number":"P/0068/2017","pip_number":"EMEA-001469-PIP01-13","active_substance":"somapacitan","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of growth hormone deficiency","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/03/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; E-mail: paediatrics@novonordisk.com; Tel. +45 4444 8888","first_published_date":"21/04/2017","last_updated_date":"21/04/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001469-pip01-13"},{"decision_number":"P/0010/2017","pip_number":"EMEA-000527-PIP04-13-M01","active_substance":"ranibizumab","invented_name":"Lucentis; Lucentis","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of retinopathy of prematurity","routes_of_administration":"Intravitreal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/01/2017","compliance_outcome":"Positive","compliance_opinion_date":"19/10/2018","compliance_procedure_number":"EMEA-C-000527-PIP04-13-M01","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"22/08/2014","last_updated_date":"20/03/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000527-pip04-13-m01"},{"decision_number":"P/0014/2017","pip_number":"EMEA-001087-PIP02-12-M03","active_substance":"Budesonide","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Nebuliser suspension","condition_indication":"Treatment of asthma","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/01/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vectura Limited; United Kingdom                        ; Tel. +44 1249667538; E-mail: vecturapip@vectura.com","first_published_date":"08/10/2013","last_updated_date":"20/03/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001087-pip02-12-m03"},{"decision_number":"P/0003/2017","pip_number":"EMEA-000117-PIP02-10-M07","active_substance":"Ipilimumab","invented_name":"Yervoy; Yervoy","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of melanoma","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/01/2017","compliance_outcome":"Positive","compliance_opinion_date":"24/02/2017","compliance_procedure_number":"EMEA-000117-PIP02-10-M07","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"13/07/2011","last_updated_date":"20/03/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000117-pip02-10-m07"},{"decision_number":"P/0037/2017","pip_number":"EMEA-002024-PIP01-16","active_substance":"hydrochlorothiazide;Candesartan cilexetil;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Midas Pharma GmbH; Germany; Tel. +49 61329900; E-mail: ra@midas-pharma.com","first_published_date":"17/03/2017","last_updated_date":"17/03/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002024-pip01-16"},{"decision_number":"P/0042/2017","pip_number":"EMEA-002062-PIP01-16","active_substance":"(1S, 3S, 4R)-4-[(3aS, 4R, 5S,7aS)-4-(aminomethyl)-7a-methyl-1-methylidene-octahydro-1H-inden-5-yl]-3-(hydroxymethyl)-4-methylcyclohexan-1-ol (acetic acid salt)","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of interstitial cystitis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/01/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aquinox Pharmaceuticals (Canada) Inc.; United Kingdom; Tel. +44 1372860610; E-mail: tim.walford@ndareg.com","first_published_date":"17/03/2017","last_updated_date":"17/03/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002062-pip01-16"},{"decision_number":"P/0039/2017","pip_number":"EMEA-002039-PIP01-16","active_substance":"(2-hydroxyethyl)trimethylammonium 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4- methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylate","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of leiomyoma of uterus;Treatment of endometriosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ObsEva Ireland Limited; Switzerland; Tel. +41 225521550; Fax +41 22743 2921; E-mail: delphine.renaud@obseva.ch","first_published_date":"17/03/2017","last_updated_date":"17/03/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002039-pip01-16"},{"decision_number":"P/0040/2017","pip_number":"EMEA-002040-PIP01-16","active_substance":"Apolipoprotein A-1","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of acute myocardial infarction","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CSL Behring GmbH; Germany; Tel. +49 64213912; Fax +49 642139 39 85; E-mail: eu-cslbehring@cslbehring.com","first_published_date":"17/03/2017","last_updated_date":"17/03/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002040-pip01-16"},{"decision_number":"P/0005/2017","pip_number":"EMEA-000118-PIP03-15","active_substance":"abatacept","invented_name":"Orencia","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder for concentrate for solution for infusion;Solution for injection","condition_indication":"Treatment of Systemic Lupus Erythematosus (SLE)","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"16/01/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG; Email: medical.information@bms.com; Tel. +44 1895523740","first_published_date":"17/03/2017","last_updated_date":"17/03/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000118-pip03-15"},{"decision_number":"P/0041/2017","pip_number":"EMEA-002043-PIP01-16","active_substance":"doxorubicin hydrochloride","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for suspension for infusion","condition_indication":"Treatment of hepatocellular carcinoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"17/03/2017","last_updated_date":"17/03/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002043-pip01-16"},{"decision_number":"P/0032/2017","pip_number":"EMEA-001921-PIP01-16","active_substance":"mirvetuximab soravtansine","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of fallopian tube cancer;Treatment of ovarian carcinoma;Treatment of peritoneal carcinoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/01/2017","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ImmunoGen Biopharma (Ireland) Limited; E-mail: Regulatory.affairs@immunogen.com; Tel : +1 781 895 0182","first_published_date":"17/03/2017","last_updated_date":"17/03/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001921-pip01-16"},{"decision_number":"P/0290/2014","pip_number":"EMEA-000876-PIP01-10-M01","active_substance":"Eculizumab","invented_name":"Soliris; Soliris","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Atypical Haemolytic Uraemic Syndrome;Treatment of paroxysmal nocturnal haemoglobinuria","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"24/10/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alexion Europe SAS; Tel. +33 153643800; E-mail: pip.enquiries.eu@alexion.com","first_published_date":"25/11/2010","last_updated_date":"02/03/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000876-pip01-10-m01"},{"decision_number":"P/0129/2016","pip_number":"Sitagliptin (phosphate monohydrate)","active_substance":"sitagliptin phosphate monohydrate","invented_name":"Tesavel; Tesavel","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"21/05/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp and Dohme (Europe), Inc.; Belgium; E-mail: paul.robinson@merck.com; Tel. +44 1992452396; Fax +44 1992468175","first_published_date":"01/03/2017","last_updated_date":"28/02/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/sitagliptin-phosphate-monohydrate"},{"decision_number":"P/0358/2016","pip_number":"EMEA-001198-PIP02-16","active_substance":"Fosnetupitant;palonosetron","invented_name":"Akynzeo; Akynzeo","therapeutic_area":"Other","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Prevention of chemotherapy-induced nausea and vomiting","routes_of_administration":"Intravenous use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"21/12/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Helsinn Birex Pharmaceuticals Limited; Switzerland; E-mail: paediatrics-netu@helsinn.com; Tel.: +41 919851950; Fax: +41 919852195","first_published_date":"31/01/2017","last_updated_date":"31/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001198-pip02-16"},{"decision_number":"P/0369/2016","pip_number":"EMEA-002038-PIP01-16","active_substance":"Botulinum toxin, Type A","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of glabellar lines","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/12/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Evolus Inc.; United States; E-mail: Medical-Information@evolusinc.com; Tel.: +1 8055902340; Fax: +1 8055902342","first_published_date":"30/01/2017","last_updated_date":"30/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002038-pip01-16"},{"decision_number":"P/0368/2016","pip_number":"EMEA-002037-PIP01-16","active_substance":"netarsudil","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution;Solution","condition_indication":"Treatment of glaucoma","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/12/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aerie Pharmaceuticals Ireland Ltd; Tel. +1 9495268700; E-mail: info@aeriepharma.com","first_published_date":"30/01/2017","last_updated_date":"30/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002037-pip01-16"},{"decision_number":"P/0367/2016","pip_number":"EMEA-002022-PIP01-16","active_substance":"DNA plasmid encoding HPV type 16 consensus E6 and E7 proteins (pGX3001);DNA plasmid encoding HPV type 18 consensus E6 and E7 proteins (pGX3002)","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Intramuscular use","condition_indication":"Treatment of squamous intraepithelial lesions of the cervix caused by HPV types 16 and 18","routes_of_administration":"Solution for injection (in cartridge)","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/12/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Inovio Pharmaceuticals Inc.E-mail: jrichardson@inovio.comTel.: +1 2674404211","first_published_date":"30/01/2017","last_updated_date":"30/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002022-pip01-16"},{"decision_number":"P/0366/2016","pip_number":"EMEA-002017-PIP01-16","active_substance":"Ibuprofen","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Prolonged-release tablet","condition_indication":"Treatment of febrile disorders;Treatment of pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/12/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Strides Shasun Limited (Formulation Division); India; E-mail: Mohanlal.S@stridesshasun.com; Tel.: +91 8067840217 / +91 9900590513; Fax: +91 8067840700","first_published_date":"30/01/2017","last_updated_date":"30/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002017-pip01-16"},{"decision_number":"P/0365/2016","pip_number":"EMEA-001860-PIP04-16","active_substance":"Galcanezumab","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of cluster headaches","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"21/12/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"30/01/2017","last_updated_date":"30/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001860-pip04-16"},{"decision_number":"P/0351/2016","pip_number":"EMEA-001688-PIP03-16","active_substance":"Pimavanserin","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of schizophrenia and other psychotic disorders","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"02/12/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ACADIA Pharmaceuticals Inc.; United States; E-mail: info@acadia-pharm.com; Tel.: +1 8585582871; Fax: +1 8585582872","first_published_date":"30/01/2017","last_updated_date":"30/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001688-pip03-16"},{"decision_number":"P/0350/2016","pip_number":"EMEA-001154-PIP02-15","active_substance":"antithrombin alfa","invented_name":"Recombinant human antithrombin","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of antithrombin deficiency","routes_of_administration":"Intravenous use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"02/12/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GTC Biotherapeutics UK Limited; France; E-mail: metenanizi@lfb.fr; Tel.: +33 169821029; Fax: +33 183711978","first_published_date":"30/01/2017","last_updated_date":"30/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001154-pip02-15"},{"decision_number":"P/0349/2016","pip_number":"EMEA-002015-PIP01-16","active_substance":"terguride (hydrogenmaleate)","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of systemic sclerosis","routes_of_administration":"Oral use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"02/12/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"medac Gesellschaft für klinische Spezialpräparate mbH; Germany; E-mail: dra@medac.de; Tel.: +49 401380060; Fax: +49 401380068255","first_published_date":"30/01/2017","last_updated_date":"30/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002015-pip01-16"},{"decision_number":"P/0348/2016","pip_number":"EMEA-002011-PIP01-16","active_substance":"chlorhexidine gluconate;isopropyl alcohol","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Cutaneous solution","condition_indication":"Prevention of infections prior to invasive procedures","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/12/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GAMA Healthcare Ltd; United Kingdom; E-mail: pb@gamahealthcare.com; Tel.: +44 20 79930030; Fax: +44 2082028097","first_published_date":"30/01/2017","last_updated_date":"30/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002011-pip01-16"},{"decision_number":"P/0347/2016","pip_number":"EMEA-001993-PIP01-16","active_substance":"synthetic double-stranded siRNA oligonucleotide directed against p53 mRNA (QPI-1002)","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of delayed graft function (DGF) after kidney transplantation","routes_of_administration":"Solution for injection","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"05/12/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Quark Pharmaceuticals Inc.; United States; Email: lgryziewicz@quarkpharma.com; Tel.: +1 5104024003; Fax: +1 5103645121","first_published_date":"30/01/2017","last_updated_date":"30/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001993-pip01-16"},{"decision_number":"P/0346/2016","pip_number":"EMEA-001978-PIP01-16","active_substance":"N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-sulfamide","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/12/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"30/01/2017","last_updated_date":"30/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001978-pip01-16"},{"decision_number":"P/0345/2016","pip_number":"EMEA-001973-PIP01-16","active_substance":"teprotumumab","invented_name":"","therapeutic_area":"","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of active thyroid eye disease","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/12/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"River Vision Development Corporation; United States; E-mail: rivervision@narrowrivermgmt.com ; Tel.: +212 5828400; Fax: +212 5828404","first_published_date":"30/01/2017","last_updated_date":"30/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001973-pip01-16"},{"decision_number":"P/0315/2016","pip_number":"EMEA-000018-PIP01-07-M12","active_substance":"tapentadol hydrochloride","invented_name":"Yantil and associated names; Palexia and associated names; Tapentadol and associated names","therapeutic_area":"Pain","pharmaceutical_forms":"Film-coated tablet;Oral solution","condition_indication":"Treatment of acute pain","routes_of_administration":"Oral use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"02/12/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Grünenthal GmbH; Tel. +49 241 5690E-mail: pediatrics@grunenthal.com","first_published_date":"13/09/2011","last_updated_date":"27/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000018-pip01-07-m12"},{"decision_number":"P/0338/2016","pip_number":"EMEA-001742-PIP02-16","active_substance":"derivative of 4H-pyrazolo[3,4-d]pyrimidin-4-one","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of psychosis","routes_of_administration":"Oral use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"02/12/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"27/01/2017","last_updated_date":"27/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001742-pip02-16"},{"decision_number":"P/0284/2016","pip_number":"EMEA-000115-PIP02-09-M03","active_substance":"ataluren","invented_name":"Translarna; Translarna","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Granules for oral suspension","condition_indication":"Treatment of cystic fibrosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/11/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"PTC Therapeutics International, Limited; France; Tel. +33 141318300; Fax +33 146318309; E-mail: vcparis@voisinconsulting.com","first_published_date":"09/06/2011","last_updated_date":"23/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000115-pip02-09-m03"},{"decision_number":"P/0285/2016","pip_number":"EMEA-000292-PIP01-08-M03","active_substance":"alipogene tiparvovec","invented_name":"Glybera; Glybera","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of hyperchylomicronaemia","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/11/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"uniQure biopharma B.V.; United States; E-mail: m.agarwal@uniqure.com ; Tel.  +1 3399 707027","first_published_date":"29/01/2009","last_updated_date":"23/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000292-pip01-08-m03"},{"decision_number":"P/0286/2016","pip_number":"EMEA-000454-PIP01-08-M07","active_substance":"human normal immunoglobulin","invented_name":"NAXIGLO and associated names","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Primary Immunodeficiency (PID)","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/11/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kedrion S.p.A.; Italy; E-mail: info@kedrion.com; Tel. + 39 0583 1969697","first_published_date":"04/01/2013","last_updated_date":"23/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000454-pip01-08-m07"},{"decision_number":"P/0292/2016","pip_number":"EMEA-001168-PIP01-11-M03","active_substance":"serelaxin","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of acute heart failure","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/11/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm Ltd; United Kingdom; E-mail: clinicaltrial.enquiries@novartis.com; Tel. +41 613241111; Fax +41 613248001","first_published_date":"04/01/2013","last_updated_date":"19/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001168-pip01-11-m03"},{"decision_number":"P/0309/2016","pip_number":"EMEA-000970-PIP01-10-M01","active_substance":"elvitegravir;emtricitabine;cobicistat;tenofovir disoproxil fumarate","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/11/2016","compliance_outcome":"Positive","compliance_opinion_date":"16/12/2016","compliance_procedure_number":"EMEA-C-000970-PIP01-10-M01","contact_for_public_enquiries":"Gilead Sciences International Ltd.; Tel. +44 (0)1223 897 300; E-mail: regulatory.pip@gilead.com","first_published_date":"14/07/2011","last_updated_date":"19/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000970-pip01-10-m01"},{"decision_number":"P/0308/2016","pip_number":"EMEA-002014-PIP01-16","active_substance":"Candesartan;amlodipine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/11/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CIPROS S.r.l.; Italy; Tel. +39 5732 0877; Fax +39 5734 75188; E-mail: regolatorio@ciprossrl.it;  ","first_published_date":"10/01/2017","last_updated_date":"10/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002014-pip01-16"},{"decision_number":"P/0307/2016","pip_number":"EMEA-002006-PIP01-16","active_substance":"amlodipine;valsartan;hydrochlorothiazide","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/11/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ELPEN Pharmaceutical Co. Inc; Tel. +30 2106 039326; E-mail: info@elpen.gr","first_published_date":"10/01/2017","last_updated_date":"10/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002006-pip01-16"},{"decision_number":"P/0306/2016","pip_number":"EMEA-002005-PIP01-16","active_substance":"amlodipine;atorvastatin","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of concomitant hypertension and dyslipidaemia;Treatment of concomitant angina and dyslipidaemia;Prevention of cardiovascular events in hypertension and diabetes mellitus type II","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/11/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ELPEN Pharmaceutical Co. Inc; Greece; Tel. +30 2106 039326; Fax +30 2106 039300; E-mail: info@elpen.gr","first_published_date":"10/01/2017","last_updated_date":"10/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002005-pip01-16"},{"decision_number":"P/0305/2016","pip_number":"EMEA-001998-PIP01-16","active_substance":"ciclosporin","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, emulsion","condition_indication":"Treatment of dry eye disease","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/11/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Drug Delivery Solutions ApS; Denmark; Tel. +45 2018 1111; E-mail: info@mc2biotek.com","first_published_date":"10/01/2017","last_updated_date":"10/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001998-pip01-16"},{"decision_number":"P/0304/2016","pip_number":"EMEA-001968-PIP01-16","active_substance":"perindopril;amlodipine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/11/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Errekappa Euroterapici S.p.A.; Italy; Tel. +39 5734 74010; Fax +39 5734 75188; E-mail: regolatorio1@errekappa.it","first_published_date":"10/01/2017","last_updated_date":"10/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001968-pip01-16"},{"decision_number":"P/0291/2016","pip_number":"EMEA-001043-PIP02-16","active_substance":"sirukumab","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection;Solution for injection/infusion","condition_indication":"Treatment of vasculitides","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/11/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International N.V.; United Kingdom; Tel. +44 (0)1494 567567; Fax +44 (0)1494 658084; E-mail: ldobell@its.jnj.com","first_published_date":"06/01/2017","last_updated_date":"06/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001043-pip02-16"},{"decision_number":"P/0290/2016","pip_number":"EMEA-001140-PIP02-15","active_substance":"allogeneic Mesenchymal Precursor Cells (rexlemestrocel-L)","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of intervertebral disc disorder","routes_of_administration":"Intradiscal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/11/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mesoblast UK Limited; Australia; Tel. +61 3963 96036; Fax +61 3963 96030; E-mail: michelle.coffey@mesoblast.com","first_published_date":"06/01/2017","last_updated_date":"06/01/2017","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001140-pip02-15"},{"decision_number":"P/0096/2016","pip_number":"EMEA-000300-PIP01-08-M04","active_substance":"pitavastatin (calcium)","invented_name":"Alipza and associated names","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of disorders of lipoprotein metabolism and other lipidaemias","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/04/2016","compliance_outcome":"Positive","compliance_opinion_date":"19/08/2016","compliance_procedure_number":"EMEA-C-000300-PIP01-08-M04","contact_for_public_enquiries":"Kowa Pharmaceutical Europe Company Ltd; United Kingdom; Tel. +44 (0)1189229000; E-mail: regulatory@kowa.co.uk","first_published_date":"21/07/2008","last_updated_date":"21/12/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000300-pip01-08-m04"},{"decision_number":"P/0243/2015","pip_number":"EMEA-000408-PIP01-08-M05","active_substance":"icatibant acetate","invented_name":"Firazyr; Firazyr","therapeutic_area":"Other","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of hereditary angioedema","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/10/2015","compliance_outcome":"Positive","compliance_opinion_date":"19/08/2016","compliance_procedure_number":"EMEA-C-000408-PIP01-08-M05","contact_for_public_enquiries":"Shire Orphan Therapies GmbH; Switzerland; Tel. +43 1 20100 2471359; E-mail: magdalena.toro-cortes@shire.com","first_published_date":"17/10/2011","last_updated_date":"21/12/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000408-pip01-08-m05"},{"decision_number":"P/0297/2015","pip_number":"EMEA-000290-PIP01-08-M04","active_substance":"nilotinib","invented_name":"Tasigna; Tasigna","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of chronic myeloid leukaemia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"21/12/2015","compliance_outcome":"Positive","compliance_opinion_date":"11/11/2016","compliance_procedure_number":"EMEA-C-000290-PIP01-08-M04","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"04/01/2013","last_updated_date":"21/12/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000290-pip01-08-m04"},{"decision_number":"P/0200/2016","pip_number":"EMEA-000366-PIP05-12-M02","active_substance":"adalimumab","invented_name":"Humira; Humira","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of non-infectious uveitis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"22/07/2016","compliance_outcome":"Positive","compliance_opinion_date":"14/10/2016","compliance_procedure_number":"EMEA-C-000366-PIP05-12-M02","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628925033","first_published_date":"16/04/2014","last_updated_date":"21/12/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000366-pip05-12-m02"},{"decision_number":"P/0116/2016","pip_number":"EMEA-000709-PIP01-09-M05","active_substance":"rufinamide","invented_name":"Inovelon; Inovelon","therapeutic_area":"Neurology","pharmaceutical_forms":"Tablet;Oral suspension","condition_indication":"Treatment of Lennox-Gastaut syndrome","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/04/2016","compliance_outcome":"Positive","compliance_opinion_date":"16/09/2016","compliance_procedure_number":"EMEA-C-000709-PIP01-09-M05","contact_for_public_enquiries":"Eisai Limited; United Kingdom; Tel. +44 (0)8456 761400; E-mail: eumedinfo@eisai.net","first_published_date":"06/10/2010","last_updated_date":"21/12/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000709-pip01-09-m05"},{"decision_number":"P/0179/2016","pip_number":"EMEA-001885-PIP01-15-M01","active_substance":"levamisole hydrochloride","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of glomerulonephritis and nephrotic syndrome","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/07/2016","compliance_outcome":"Positive","compliance_opinion_date":"22/07/2016","compliance_procedure_number":"EMEA-C-001885-PIP01-15-M01","contact_for_public_enquiries":"ACE Pharmaceuticals B.V.; Tel. +31 365227201; E-mail: ace@ace-pharm.nl","first_published_date":"25/04/2016","last_updated_date":"21/12/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001885-pip01-15-m01"},{"decision_number":"P/0031/2013","pip_number":"EMEA-001283-PIP01-12","active_substance":"hydrocortisone","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Granules","condition_indication":"Treatment of adrenocortical insufficiency","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"26/02/2013","compliance_outcome":"Positive","compliance_opinion_date":"14/10/2016","compliance_procedure_number":"EMEA-C-001283-PIP01-12","contact_for_public_enquiries":"Diurnal Limited; E-mail: martinwhitaker@diurnal.co.uk; Country: United Kingdom; Tel. + 44 (0) 8717168848","first_published_date":"23/04/2013","last_updated_date":"21/12/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001283-pip01-12"},{"decision_number":"P/0095/2016","pip_number":"EMEA-000054-PIP01-07-M04","active_substance":"pitavastatin (calcium)","invented_name":"Livazo and associated names","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of disorders of lipoprotein metabolism and other lipidaemias","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/04/2016","compliance_outcome":"Positive","compliance_opinion_date":"19/08/2016","compliance_procedure_number":"EMEA-C-000054-PIP01-07-M04","contact_for_public_enquiries":"Kowa Pharmaceutical Europe Co. Ltd; Tel. +44 (0)1189229000; E-mail: regulatory@kowa.co.uk","first_published_date":"21/07/2008","last_updated_date":"21/12/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000054-pip01-07-m04"},{"decision_number":"P/0175/2016","pip_number":"EMEA-001103-PIP01-10-M03","active_substance":"deferasirox","invented_name":"Exjade; Exjade","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Dispersible tablet;Film-coated tablet;Granules","condition_indication":"Treatment of chronic iron overload requiring chelation therapy","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/06/2016","compliance_outcome":"Positive","compliance_opinion_date":"14/10/2016","compliance_procedure_number":"EMEA-C-001103-PIP01-10-M03","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"18/10/2011","last_updated_date":"21/12/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001103-pip01-10-m03"},{"decision_number":"P/0281/2015","pip_number":"EMEA-001053-PIP01-10-M03","active_substance":"Lebrikizumab","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of asthma","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/11/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Products Limited; United Kingdom; Tel. +41 6168 79411; Fax +41 6168 79411; E-mail: info.paediatrics@roche.com","first_published_date":"04/01/2013","last_updated_date":"08/12/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001053-pip01-10-m03"},{"decision_number":"P/0080/2014","pip_number":"EMEA-001430-PIP01-13","active_substance":"anti proprotein convertase subtilisin kexin type 9 humanized monoclonal antibody (PF-04950615)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of cardiovascular events in patients with cardiovascular disease or cardiovascular disease risk equivalent;Treatment of elevated cholesterol;Treatment of mixed dyslipidaemia","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"02/04/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Limited; Tel. + 44 1304646607; E-mail: pip_enquiries@pfizer.com","first_published_date":"13/05/2014","last_updated_date":"07/12/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001430-pip01-13"},{"decision_number":"P/0146/2016","pip_number":"EMEA-001813-PIP01-15","active_substance":"recombinant humanized anti-MMP9 monoclonal antibody IgG4 (GS-5745)","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Crohn's disease;Treatment of ulcerative colitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/05/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd; E-mail: regulatory.pip@gilead.com; Tel. +44 (0)1223 897300","first_published_date":"18/07/2016","last_updated_date":"24/11/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001813-pip01-15"},{"decision_number":"P/0259/2016","pip_number":"EMEA-000506-PIP01-08-M02","active_substance":"selepressin","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of septic shock","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/10/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ferring Pharmaceuticals A/S; Tel.: +1 8622865200; E-mail: Dk0-Disclosure@ferring.com","first_published_date":"29/10/2010","last_updated_date":"24/11/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000506-pip01-08-m02"},{"decision_number":"P/0257/2016","pip_number":"EMEA-001453-PIP01-13-M01","active_substance":"zuretinol (acetate)","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of Leber's Congenital Amaurosis;Treatment of Retinitis Pigmentosa","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/10/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"QLT Ophthalmics (UK) Ltd; E-mail: marco@retinagenix.com; Tel. +1 7863 5214 99","first_published_date":"20/02/2014","last_updated_date":"24/11/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001453-pip01-13-m01"},{"decision_number":"P/0274/2016","pip_number":"EMEA-000968-PIP02-11-M05","active_substance":"elvitegravir","invented_name":"Vitekta; Vitekta","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Dispersible tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/10/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd; E-mail: regulatory.pip@gilead.com; Tel. +44 (0)1223 897300","first_published_date":"24/02/2012","last_updated_date":"24/11/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000968-pip02-11-m05"},{"decision_number":"P/0271/2016","pip_number":"EMEA-001982-PIP01-16","active_substance":"gentamicin sulfate","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Medicated sponge","condition_indication":"Treatment of infected diabetic foot ulcers","routes_of_administration":"Topical use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/10/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Innocoll; Ireland; Tel. +353 906486834; E-mail: info@innocoll.com","first_published_date":"23/11/2016","last_updated_date":"23/11/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001982-pip01-16"},{"decision_number":"P/0267/2016","pip_number":"EMEA-002002-PIP01-16","active_substance":"Ibuprofen;paracetamol","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Granules;Tablet","condition_indication":"Treatment of pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"05/10/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Farmalider, S.A; E-mail: carloscalandria@farmalider.com; Tel. +34 9166 12335","first_published_date":"23/11/2016","last_updated_date":"23/11/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002002-pip01-16"},{"decision_number":"P/0258/2016","pip_number":"EMEA-001966-PIP01-16","active_substance":"recombinant respiratory syncytial virus vaccine","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Prevention of lower respiratory tract disease caused by respiratory syncytial virus","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"05/10/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"MedImmune Limited; United Kingdom; Tel. +44 1582836181; E-mail: paediatrics@medimmune.com","first_published_date":"23/11/2016","last_updated_date":"23/11/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001966-pip01-16"},{"decision_number":"P/0266/2016","pip_number":"EMEA-001881-PIP01-15","active_substance":"Ragweed pollen extract (Ambrosia artemisiifolia)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oral lyophilisate","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"05/10/2016","compliance_outcome":"Positive","compliance_opinion_date":"15/11/2019","compliance_procedure_number":"EMEA-C-001881-PIP01-15","contact_for_public_enquiries":"ALK Abelló A/S; Tel. +45 4574 7576; E-mail: alkmrp@alk.net","first_published_date":"23/11/2016","last_updated_date":"23/11/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001881-pip01-15"},{"decision_number":"P/0277/2016","pip_number":"EMEA-001977-PIP02-16","active_substance":"fluoromisonidazole (18F)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Imaging of hypoxic tissue in gliomas for diagnostic purposes;Imaging of hypoxic tissue in head and neck squamous cell carcinoma for diagnostic purposes;Imaging of hypoxic tissue in non-small cell lung cancer for diagnostic purposes;Imaging of hypoxic tissue in renal cell carcinoma for diagnostic purposes","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"05/10/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"RadioMedic s.r.o.; Czech Republic; Tel. +42 0266173253; Fax +42 0220940151; E-mail: info@radiomedic.cz;  ","first_published_date":"23/11/2016","last_updated_date":"23/11/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001977-pip02-16"},{"decision_number":"P/0268/2016","pip_number":"EMEA-001730-PIP02-15","active_substance":"Guadecitabine","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of acute myeloid leukaemia","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"07/10/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Otsuka Europe Development and Commercialisation Ltd.; United Kingdom; Tel. +44 2037475000; Fax +44 1895207115; E-mail: info@otsuka-europe.com","first_published_date":"23/11/2016","last_updated_date":"23/11/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001730-pip02-15"},{"decision_number":"P/0226/2016","pip_number":"EMEA-001942-PIP01-16","active_substance":"ramipril;amlodipine;hydrochlorothiazide","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/08/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Adamed Sp. z o.o.; Tel. +48227327736; E-mail: joanna.pawlak@adamed.com.pl","first_published_date":"28/10/2016","last_updated_date":"28/10/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001942-pip01-16"},{"decision_number":"P/0228/2016","pip_number":"EMEA-001909-PIP01-15","active_substance":"cathine (hydrochloride)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Oral drops (solution)","condition_indication":"Treatment of obesity","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/08/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Schuck GmbH; Germany; Tel. +49 30338427532; Fax +49 383517688121; E-mail: schroederd@riemser.com","first_published_date":"28/10/2016","last_updated_date":"28/10/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001909-pip01-15"},{"decision_number":"P/0225/2016","pip_number":"EMEA-001935-PIP01-16","active_substance":"amlodipine;rosuvastatin","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of cardiovascular disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/08/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Adamed Sp. z o.o.; Tel. +48227327736; E-mail: joanna.pawlak@adamed.com.pl","first_published_date":"28/10/2016","last_updated_date":"28/10/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001935-pip01-16"},{"decision_number":"P/0224/2016","pip_number":"EMEA-001905-PIP01-15","active_substance":"Lusutrombopag","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of thrombocytopenia secondary to liver disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/08/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Shionogi Limited; United Kingdom; Tel. +44 (0)203 053 4200; E-mail: shionogiclintrials-admin@shionogi.co.jp","first_published_date":"28/10/2016","last_updated_date":"28/10/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001905-pip01-15"},{"decision_number":"P/0164/2016","pip_number":"EMEA-001841-PIP01-15","active_substance":"bexagliflozin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/06/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Theracos Sub, LLC; United States; Tel. +1 6177264236; Fax +1 6176438203;  ","first_published_date":"28/10/2016","last_updated_date":"28/10/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001841-pip01-15"},{"decision_number":"P/0249/2016","pip_number":"EMEA-001476-PIP01-13-M01","active_substance":"sapropterin dihydrochloride","invented_name":"Kuvan; Kuvan","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Soluble tablet;Powder for oral solution","condition_indication":"Treatment of hyperphenylalaninemia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/09/2016","compliance_outcome":"Positive","compliance_opinion_date":"10/10/2014","compliance_procedure_number":"EMEA-C-001476-PIP01-13","contact_for_public_enquiries":"BioMarin International Limited; Tel. +44 (0)20 7420 0800; E-mail: biomarin-europe@bmrn.com","first_published_date":"15/11/2013","last_updated_date":"27/10/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001476-pip01-13-m01"},{"decision_number":"P/0208/2013","pip_number":"EMEA-001285-PIP01-12-M02","active_substance":"Dinutuximab","invented_name":"Unituxin; Unituxin","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of neuroblastoma","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/08/2016","compliance_outcome":"Positive","compliance_opinion_date":"16/12/2016","compliance_procedure_number":"EMEA-C-001285-PIP01-12-M02","contact_for_public_enquiries":"United Therapeutics Europe Limited; United Kingdom; Tel. +44 (0)1932 573800; Fax +44 (0)1932 571110; E-mail: info1@unither.com","first_published_date":"08/02/2013","last_updated_date":"27/10/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001285-pip01-12-m02"},{"decision_number":"P/0218/2016","pip_number":"EMEA-001484-PIP01-13-M01","active_substance":"Elobixibat","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Film-coated tablet;Age appropriate dosage form, other","condition_indication":"Treatment of chronic constipation","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/08/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Elobix AB; Sweden; Tel. +46 317411480; E-mail: info@albireopharma.com","first_published_date":"16/04/2014","last_updated_date":"27/10/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001484-pip01-13-m01"},{"decision_number":"P/0210/2016","pip_number":"EMEA-000978-PIP01-10-M01","active_substance":"vemurafenib","invented_name":"Zelboraf; Zelboraf","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of melanoma","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/08/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration Limited; Switzerland; Tel. +41 6168794 11; Fax +41 616879411; E-mail: info.paediatrics@roche.com","first_published_date":"12/05/2011","last_updated_date":"27/10/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000978-pip01-10-m01"},{"decision_number":"P/0244/2016","pip_number":"EMEA-001962-PIP01-16","active_substance":"Humanized IgG1, kappa anti-serum amyloid A and anti-AL amyloid antibody","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of systemic light chain amyloidosis","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Prothena Therapeutics Limited; Ireland; Tel. +353 12362505; Fax +353 1 6865675; E-mail: patrick.murphy@prothena.com","first_published_date":"27/10/2016","last_updated_date":"27/10/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001962-pip01-16"},{"decision_number":"P/0209/2016","pip_number":"EMEA-000673-PIP01-09-M09","active_substance":"Pneumococcal polysaccharide serotype 1 conjugated to protein D (derived from non-typeable Haemophilus influenzae) carrier protein;pneumococcal polysaccharide serotype 4 conjugated to protein D (derived from non-typeable Haemophilus influenzae) carrier protein;pneumococcal polysaccharide serotype 5 conjugated to protein D (derived from non-typeable Haemophilus influenzae) carrier protein...","invented_name":"Synflorix; Synflorix","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of acute otitis media caused by non-typeable Haemophilus influenzae","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/08/2016","compliance_outcome":"Positive","compliance_opinion_date":"27/01/2017","compliance_procedure_number":"EMEA-000673-PIP01-09-M09","contact_for_public_enquiries":"GlaxoSmithKline Biologicals S.A. (UK); E-mail: eu.paediatric-plans@gsk.com; Tel.: +1 438 899 8201","first_published_date":"04/01/2013","last_updated_date":"27/10/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000673-pip01-09-m09"},{"decision_number":"P/0243/2016","pip_number":"EMEA-001961-PIP01-16","active_substance":"macitentan;tadalafil","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of pulmonary arterial hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"27/10/2016","last_updated_date":"27/10/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001961-pip01-16"},{"decision_number":"P/0240/2016","pip_number":"EMEA-001953-PIP01-16","active_substance":"(S)-lactic acid","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Vaginal gel","condition_indication":"Prevention of pregnancy","routes_of_administration":"Vaginal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"YES Pharmaceutical Development Services GmbH; United States; Tel. +1 8585501900 ext 244; Email: smatsumoto@evofem.com","first_published_date":"27/10/2016","last_updated_date":"27/10/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001953-pip01-16"},{"decision_number":"P/0239/2016","pip_number":"EMEA-001952-PIP01-16","active_substance":"lesinurad;allopurinol","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hyperuricaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB (Germany); Tel. +49 6132778271","first_published_date":"27/10/2016","last_updated_date":"27/10/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001952-pip01-16"},{"decision_number":"P/0245/2016","pip_number":"EMEA-001948-PIP01-16","active_substance":"Indapamide;perindopril erbumine;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Zentiva, k.s.; Czech Republic; blanka.zoubkova@zentiva.com; Tel. +42 0267243574","first_published_date":"27/10/2016","last_updated_date":"27/10/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001948-pip01-16"},{"decision_number":"P/0238/2016","pip_number":"EMEA-001941-PIP01-16","active_substance":"ezetimibe;rosuvastatin calcium","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/09/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Adamed Sp. z o.o.; Tel. +48227327736; E-mail: joanna.pawlak@adamed.com.pl","first_published_date":"27/10/2016","last_updated_date":"27/10/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001941-pip01-16"},{"decision_number":"P/0246/2016","pip_number":"EMEA-001969-PIP01-16","active_substance":"allogeneic human neural stem cells genetically modified to express c-MycERTAM, a c-Myc and modified oestrogen receptor fusion protein (CTX0E03)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of cerebral infarction","routes_of_administration":"Intracerebral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/09/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ReNeuron Ltd; United Kingdom; Tel. +44 2038198400; Email: info@reneuron.com","first_published_date":"27/10/2016","last_updated_date":"27/10/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001969-pip01-16"},{"decision_number":"P/0253/2016","pip_number":"EMEA-001912-PIP01-15","active_substance":"angiotensin II (LJPC-501)","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of catecholamine-resistant hypotension associated with distributive shock","routes_of_administration":"Intravenous use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"26/09/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"La Jolla Pharmaceutical Company, Inc.; United States; Tel. +1 8584336908","first_published_date":"27/10/2016","last_updated_date":"27/10/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001912-pip01-15"},{"decision_number":"P/0229/2016","pip_number":"EMEA-000876-PIP07-15","active_substance":"Eculizumab","invented_name":"Soliris; Soliris","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Prevention of delayed graft function after solid organ transplantation","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/09/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alexion Europe SAS; France; E-mail: pip.enquiries.eu@alxn.com ; Tel. +33 1 47 10 06 06; Fax +33 1 47 10 06 11","first_published_date":"27/10/2016","last_updated_date":"27/10/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000876-pip07-15"},{"decision_number":"P/0183/2016","pip_number":"EMEA-000520-PIP01-08-M05","active_substance":"belimumab","invented_name":"Benlysta; Benlysta","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of Systemic Lupus Erythematosus (SLE)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/07/2016","compliance_outcome":"Positive","compliance_opinion_date":"16/11/2018","compliance_procedure_number":"EMEA-C-000520-PIP01-08-M05","contact_for_public_enquiries":"Glaxo Group Limited; E-mail: eu.paediatrics-plans@gsk.com; Tel. +44 (0)20 8990 2458","first_published_date":"25/01/2010","last_updated_date":"23/09/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000520-pip01-08-m05"},{"decision_number":"P/0178/2016","pip_number":"EMEA-001697-PIP02-14","active_substance":"Eleclazine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet;Tablet;Age appropriate oral dosage formulation","condition_indication":"Treatment of hypertrophic cardiomyopathy","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/07/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd; E-mail: regulatory.pip@gilead.com; Tel. +44 (0)1223 897300","first_published_date":"19/09/2016","last_updated_date":"19/09/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001697-pip02-14"},{"decision_number":"P/0177/2016","pip_number":"EMEA-001697-PIP01-14","active_substance":"Eleclazine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Age appropriate oral solid dosage form;Film-coated tablet;Tablet","condition_indication":"Treatment of congenital long QT syndromes","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/07/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd; E-mail: regulatory.pip@gilead.com; Tel. +44 (0)1223 897300","first_published_date":"19/09/2016","last_updated_date":"19/09/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001697-pip01-14"},{"decision_number":"P/0167/2016","pip_number":"EMEA-000170-PIP01-07-M04","active_substance":"eltrombopag","invented_name":"Revolade","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder for oral suspension;Film-coated tablet","condition_indication":"Treatment of Idiopathic Thrombocytopenia Purpura (ITP)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/06/2016","compliance_outcome":"Positive","compliance_opinion_date":"14/11/2014","compliance_procedure_number":"EMEA-C-000170-PIP01-07-M03","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"07/12/2009","last_updated_date":"26/08/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000170-pip01-07-m04"},{"decision_number":"P/0147/2016","pip_number":"EMEA-000329-PIP02-09-M05","active_substance":"darbepoetin alfa","invented_name":"Aranesp; Aranesp","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of anaemia due to chronic disorders","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"14/06/2016","compliance_outcome":"","compliance_opinion_date":"24/03/2017","compliance_procedure_number":"EMEA-000329-PIP02-09-M05","contact_for_public_enquiries":"Amgen Europe B.V; United Kingdom; Tel. +44 (0)1223 420305; E-mail: medinfointernational@amgen.com","first_published_date":"12/05/2011","last_updated_date":"26/08/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000329-pip02-09-m05"},{"decision_number":"P/0173/2016","pip_number":"EMEA-001916-PIP01-15","active_substance":"ciclosporin","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution;Solution","condition_indication":"Treatment of keratoconjunctivitis sicca","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"17/06/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Laboratoires Théa; Email: s.momege@laboratoires-thea.fr; Tel. +33 473981436","first_published_date":"26/08/2016","last_updated_date":"26/08/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001916-pip01-15"},{"decision_number":"P/0166/2016","pip_number":"EMEA-001914-PIP01-15","active_substance":"olmesartan medoxomil;rosuvastatin calcium","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events;Treatment of dyslipidaemia;Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/06/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Daewoong Pharmaceutical Co., Ltd.; Republic of Korea; Tel. +82 221906470 / +82 221906774; Fax +82 25508660; Email: gmkang294@daewoong.co.kr / oscar23@daewoong.co.kr","first_published_date":"26/08/2016","last_updated_date":"26/08/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001914-pip01-15"},{"decision_number":"P/0165/2016","pip_number":"EMEA-001910-PIP01-15","active_substance":"imetelstat","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of myelofibrosis","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/06/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International N.V.; E-mail: ivan.tommasini@parexel.com; Tel. + 44 (0)1895 614784","first_published_date":"26/08/2016","last_updated_date":"26/08/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001910-pip01-15"},{"decision_number":"P/0153/2016","pip_number":"EMEA-001887-PIP01-15","active_substance":"Ibuprofen;tramadol","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Solution for infusion;Granules for oral solution;Concentrate for solution for infusion","condition_indication":"Treatment of pain","routes_of_administration":"Oral use;Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/06/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Farmalider, S.A.; Spain; Tel. +34 916612335; Fax +34 916610442; E-mail: carloscalandria@farmalider.com","first_published_date":"26/08/2016","last_updated_date":"26/08/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001887-pip01-15"},{"decision_number":"P/0151/2016","pip_number":"EMEA-001753-PIP02-15","active_substance":"peanut flour","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of peanut allergy","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/06/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cambridge Allergy Ltd; United Kingdom; Tel. +44 1223245151; Email: andrew.clark@addenbrookes.nhs.uk","first_published_date":"26/08/2016","last_updated_date":"26/08/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001753-pip02-15"},{"decision_number":"P/0136/2016","pip_number":"EMEA-001495-PIP01-13-M01","active_substance":"drospirenone","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of pregnancy","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"20/05/2016","compliance_outcome":"Positive","compliance_opinion_date":"23/03/2018","compliance_procedure_number":"EMEA-C-001495-PIP01-13-M01","contact_for_public_enquiries":"Laboratorios León Farma S.A.; Spain; Tel. +34 9177 11500; E-mail: enrico.colli@exeltis.com; ana.orozco@exeltis.com","first_published_date":"05/06/2014","last_updated_date":"27/07/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001495-pip01-13-m01"},{"decision_number":"P/0131/2016","pip_number":"EMEA-000778-PIP02-12-M01","active_substance":"vorapaxar","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Prevention of arterial thromboembolism","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"20/05/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"14/11/2013","last_updated_date":"22/07/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000778-pip02-12-m01"},{"decision_number":"P/0128/2016","pip_number":"EMEA-000471-PIP01-08-M02","active_substance":"sitagliptin phosphate monohydrate","invented_name":"Xelevia; Xelevia","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"21/05/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp and Dohme (Europe), Inc.; Belgium; Tel. +44 (0)1992 452396; Fax +44 (0)1992 468175; E-mail: paul.robinson@merck.com","first_published_date":"07/12/2009","last_updated_date":"22/07/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000471-pip01-08-m02"},{"decision_number":"P/0142/2016","pip_number":"EMEA-001861-PIP01-15","active_substance":"diclofenac (sodium);capsaicin","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Gel","condition_indication":"Treatment of musculoskeletal and connective tissue pain and discomfort","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/05/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"18/07/2016","last_updated_date":"18/07/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001861-pip01-15"},{"decision_number":"P/0143/2016","pip_number":"EMEA-001884-PIP02-15","active_substance":"Hydrogen peroxide","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Cutaneous solution","condition_indication":"Treatment of seborrhoeic keratosis","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/05/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aclaris Therapeutics, Inc.; Tel. +1 484 540 6264; E-mail: cmatkowski@aclaristx.com ","first_published_date":"18/07/2016","last_updated_date":"18/07/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001884-pip02-15"},{"decision_number":"P/0233/2015","pip_number":"EMEA-001006-PIP02-15","active_substance":"nintedanib","invented_name":"Ofev; Ofev","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Capsule, soft","condition_indication":"Treatment of systemic sclerosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/10/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"17/12/2015","last_updated_date":"11/07/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001006-pip02-15"},{"decision_number":"P/0112/2016","pip_number":"EMEA-001876-PIP01-15","active_substance":"atorvastatin;perindopril arginine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of cardiovascular disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/04/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierE-mail: mail.pip.enquiries@servier.comTel.: +33 155726000","first_published_date":"02/06/2016","last_updated_date":"02/06/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001876-pip01-15"},{"decision_number":"P/0110/2016","pip_number":"EMEA-001842-PIP02-15","active_substance":"Gallium (68Ga)","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Radiopharmaceutical precursor;Solution","condition_indication":"Radiolabelling agent","routes_of_administration":"Parenteral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/04/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"IRE-Elit SA; Belgium; Tel. +3 2498178381; E-mail: philippe.vanwolleghem@ire.eu","first_published_date":"02/06/2016","last_updated_date":"02/06/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001842-pip02-15"},{"decision_number":"P/0114/2016","pip_number":"EMEA-001908-PIP01-15","active_substance":"levocetirizine (dihydrochloride);montelukast sodium","invented_name":"P/0114/2016","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of asthma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/04/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Invest Bielany Sp. z o.o.; Poland; Tel. +48 734666650; Fax +48 228411671; E-mail: katarzyna.rawa@investbielany.pl","first_published_date":"02/06/2016","last_updated_date":"02/06/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001908-pip01-15"},{"decision_number":"P/0117/2016","pip_number":"EMEA-001874-PIP01-15","active_substance":"levodopa","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Inhalation powder","condition_indication":"Treatment of Parkinson's disease","routes_of_administration":"Inhalation use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/04/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Acorda Therapeutics, Inc.; United States; Tel. +1 9143474300; Fax +1 9143474560 ; E-mail: info@acorda.com;  ","first_published_date":"02/06/2016","last_updated_date":"02/06/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001874-pip01-15"},{"decision_number":"P/0113/2016","pip_number":"EMEA-001878-PIP01-15","active_substance":"Finasteride","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Cutaneous spray;Solution","condition_indication":"Treatment of androgenetic alopecia","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/04/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Polichem S.A.; Tel. + 34 93 291 35 06 / + 34 609 907 326; E-mail: xavier.llaurado@almirall.com","first_published_date":"02/06/2016","last_updated_date":"02/06/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001878-pip01-15"},{"decision_number":"P/0123/2016","pip_number":"EMEA-001825-PIP01-15","active_substance":"darunavir;cobicistat;emtricitabine;tenofovir alafenamide","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"12/05/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; Belgium; Tel. +32 14602111; E-mail: contact@janssen-emea.com ","first_published_date":"02/06/2016","last_updated_date":"02/06/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001825-pip01-15"},{"decision_number":"P/0107/2016","pip_number":"EMEA-001414-PIP01-12-M01","active_substance":"olesoxime","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Age appropriate oral liquid dosage formulation","condition_indication":"Treatment of spinal muscular atrophy","routes_of_administration":"Oral use;Gastric use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/04/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration Limited; United Kingdom; Tel. +41 (0)61 6879411; E-mail: global.paediatrics@roche.com","first_published_date":"23/03/2015","last_updated_date":"02/06/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001414-pip01-12-m01"},{"decision_number":"P/0115/2016","pip_number":"EMEA-001155-PIP01-11-M03","active_substance":"heterologous human adult liver-derived progenitor cells","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Cell suspension for infusion","condition_indication":"Treatment of urea cycle disorders","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/04/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Promethera Biosciences; Belgium; Tel. +32 10394300; Fax +32 10394301; E-mail: contact@promethera.com","first_published_date":"05/02/2014","last_updated_date":"02/06/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001155-pip01-11-m03"},{"decision_number":"P/0288/2014","pip_number":"EMEA-001519-PIP01-13","active_substance":"(R)-7-Chloro-benzo[b]thiophene-2-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide hydrochloride hydrate (EVP-6124)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of schizophrenia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"12/12/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"FORUM Pharmaceuticals, Inc. ; United States ; E-mail: cboislcair@forumpharma.com ; Tel. +1 6172525350 ; Fax +1 6172254208","first_published_date":"22/01/2015","last_updated_date":"25/05/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001519-pip01-13"},{"decision_number":"P/0027/2016","pip_number":"EMEA-001671-PIP01-14","active_substance":"abrilumab","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of ulcerative colitis;Treatment of Crohn's disease","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/01/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"MedImmune Ltd.; United Kingdom; E- mail: paediatrics@astrazeneca.com; Tel.: +46 855259283; Fax: +46 855326904","first_published_date":"29/03/2016","last_updated_date":"25/05/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001671-pip01-14"},{"decision_number":"P/0179/2015","pip_number":"EMEA-001752-PIP01-15","active_substance":"(S)-1-{5-Phenyl-4-[(pyridin-2-ylmethyl)-amino]-thieno[2,3-d]pyrimidin-2-yl}-piperidine-3-carboxylic acid (2-hydroxy-ethyl)-amide","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of supraventricular arrhythmias","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/08/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Xention Limited; United Kingdom; Email: info@xention.com; Tel.: +44 (0)1223 493900; Fax: +44 (0)1223 493901","first_published_date":"22/09/2015","last_updated_date":"25/05/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001752-pip01-15"},{"decision_number":"P/0091/2016","pip_number":"EMEA-000495-PIP01-08-M09","active_substance":"tapentadol hydrochloride","invented_name":"Palexia and associated names; Yantil and associated names; Tapentadol and associated names","therapeutic_area":"Pain","pharmaceutical_forms":"Film-coated tablet;Oral solution;Solution for injection/infusion","condition_indication":"Treatment of acute pain","routes_of_administration":"Oral use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/03/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Grünenthal GmbH; Tel. +49 241 5690E-mail: pediatrics@grunenthal.com","first_published_date":"15/09/2011","last_updated_date":"26/04/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000495-pip01-08-m09"},{"decision_number":"P/0065/2016","pip_number":"EMEA-000898-PIP01-10-M02","active_substance":"Meropenem","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for solution for injection or infusion","condition_indication":"Treatment of bacterial meningitis;Treatment of bacterial sepsis","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/03/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"NeoMero Consortium; Italy; Tel. +39 0498215447; Fax +39 0499640123; E-mail: management@neomero.org","first_published_date":"24/02/2011","last_updated_date":"26/04/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000898-pip01-10-m02"},{"decision_number":"P/0062/2016","pip_number":"EMEA-000661-PIP01-09-M07","active_substance":"trenonacog alfa","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder for solution for injection;Powder and solvent for solution for infusion","condition_indication":"Treatment of hereditary factor IX deficiency (Haemophilia B)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/03/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cangene Europe Ltd; United Kingdom; Tel. +44 (0)20 8654 0555; E-mail: jwhitehead@apvo.com","first_published_date":"24/05/2012","last_updated_date":"26/04/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000661-pip01-09-m07"},{"decision_number":"P/0052/2016","pip_number":"EMEA-001506-PIP02-14-M01","active_substance":"basmisanil","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Granules","condition_indication":"Treatment of down syndrome","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/03/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration Ltd; Switzerland; Tel. +41 616879411; E-mail: info.paediatrics@roche.com","first_published_date":"07/05/2015","last_updated_date":"26/04/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001506-pip02-14-m01"},{"decision_number":"P/0092/2016","pip_number":"EMEA-000494-PIP01-08-M09","active_substance":"tapentadol hydrochloride","invented_name":"Palexia and associated names; Yantil and associated names; Tapentadol and associated names","therapeutic_area":"Pain","pharmaceutical_forms":"Film-coated tablet;Oral solution;Solution for injection/infusion","condition_indication":"Treatment of acute pain","routes_of_administration":"Oral use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/03/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Grünenthal GmbH; Tel. +49 241 5690E-mail: pediatrics@grunenthal.com","first_published_date":"15/09/2011","last_updated_date":"25/04/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000494-pip01-08-m09"},{"decision_number":"P/0044/2016","pip_number":"EMEA-000486-PIP01-08-M04","active_substance":"tapentadol hydrochloride","invented_name":"Palexia and associated names","therapeutic_area":"Pain","pharmaceutical_forms":"Prolonged-release tablet;Prolonged-release granules","condition_indication":"Treatment of chronic pain","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/02/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Grünenthal GmbH; Tel. +49 241 5690E-mail: pediatrics@grunenthal.com","first_published_date":"18/05/2009","last_updated_date":"25/04/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000486-pip01-08-m04"},{"decision_number":"P/0043/2016","pip_number":"EMEA-000485-PIP01-08-M04","active_substance":"tapentadol hydrochloride","invented_name":"Palexia and associated names; Yantil and associated names; Tapentadol and associated names","therapeutic_area":"Pain","pharmaceutical_forms":"Prolonged-release tablet;Prolonged-release granules","condition_indication":"Treatment of chronic pain","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/02/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Grünenthal GmbH; Tel. +49 241 5690E-mail: pediatrics@grunenthal.com","first_published_date":"18/05/2009","last_updated_date":"25/04/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000485-pip01-08-m04"},{"decision_number":"P/0089/2016","pip_number":"EMEA-001769-PIP01-15","active_substance":"azithromycin;Miconazole;sulfamethoxazole","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Ointment","condition_indication":"Treatment of burns","routes_of_administration":"Topical use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/03/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Lukács és Társa Gyógyszerkereskedelmi Bt.; Hungary; Tel. +36 87789073; Fax +36 87789074; E-mail: info@adwareresearch.com","first_published_date":"25/04/2016","last_updated_date":"25/04/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001769-pip01-15"},{"decision_number":"P/0087/2016","pip_number":"EMEA-001873-PIP01-15","active_substance":"testosterone","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution","condition_indication":"Treatment of dry eye disease","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/03/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628925033","first_published_date":"25/04/2016","last_updated_date":"25/04/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001873-pip01-15"},{"decision_number":"P/0086/2016","pip_number":"EMEA-001859-PIP02-15","active_substance":"recombinant human monoclonal antibody against growth differentiation factor 8 (REGN1033)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of sporadic inclusion body myositis","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/03/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Regeneron Pharmaceuticals, Inc; USA; Tel. +1 9148475385; E-mail: clinicaltrials@regeneron.com","first_published_date":"25/04/2016","last_updated_date":"25/04/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001859-pip02-15"},{"decision_number":"P/0083/2016","pip_number":"EMEA-001792-PIP01-15","active_substance":"autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human Wiskott Aldrich Syndrome (WAS) cDNA sequence","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of Wiskott Aldrich Syndrome","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"18/03/2016","compliance_outcome":"Positive","compliance_opinion_date":"24/03/2017","compliance_procedure_number":"EMEA-001792-PIP01-15","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Tel. +1 4388998201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"25/04/2016","last_updated_date":"25/04/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001792-pip01-15"},{"decision_number":"P/0082/2016","pip_number":"EMEA-001764-PIP03-15","active_substance":"tetracaine hydrochloride;Oxymetazoline hydrochloride","invented_name":"","therapeutic_area":"Anaesthesiology","pharmaceutical_forms":"Nasal spray (solution)","condition_indication":"Local anaesthesia","routes_of_administration":"Nasal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"18/03/2016","compliance_outcome":"Positive","compliance_opinion_date":"21/04/2017","compliance_procedure_number":"EMEA-001764-PIP03-15","contact_for_public_enquiries":"St. Renatus, LLC; USA; Tel. +1 9704494455; Fax +1 9704494456; E-mail: ndiel@st-renatus.com","first_published_date":"25/04/2016","last_updated_date":"25/04/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001764-pip03-15"},{"decision_number":"P/0080/2016","pip_number":"EMEA-001755-PIP01-15","active_substance":"exenatide","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Implant","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"18/03/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierE-mail: christine.bouillant@fr.netgrs.comTel. +33 155723785","first_published_date":"25/04/2016","last_updated_date":"25/04/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001755-pip01-15-0"},{"decision_number":"P/0077/2016","pip_number":"EMEA-001712-PIP02-15","active_substance":"biotin","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of multiple sclerosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/03/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"MEDDAY SAS; France; Tel. +33 157274604; Fax +33 184177604; E-mail: contact@medday-pharma.com","first_published_date":"25/04/2016","last_updated_date":"25/04/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001712-pip02-15"},{"decision_number":"P/0080/2016","pip_number":"EMEA-001755-PIP01-15","active_substance":"exenatide","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Implant","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"18/03/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierE-mail: christine.bouillant@fr.netgrs.comTel. +33 155723785","first_published_date":"25/04/2016","last_updated_date":"25/04/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001755-pip01-15"},{"decision_number":"P/0041/2016","pip_number":"EMEA-001867-PIP01-15","active_substance":"Humanised IgG4 monoclonal antibody against extracellular tau (BMS-986168)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of progressive supranuclear palsy","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/02/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biogen Idec Ltd; Tel. +44 (0)1628 512749; E-mail: pip.enquiries@biogenidec.com","first_published_date":"25/04/2016","last_updated_date":"25/04/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001867-pip01-15"},{"decision_number":"P/0055/2016","pip_number":"EMEA-001892-PIP01-15","active_substance":"Fluoroestradiol (18F)","invented_name":"","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Solution for injection","condition_indication":"Detection of increased expression of oestrogen receptors in tissues and organs for diagnostic purposes","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/03/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Florentin Artner; France; Tel. +33 685924389; E-mail: didier.garonnat@iason.eu","first_published_date":"22/04/2016","last_updated_date":"22/04/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001892-pip01-15"},{"decision_number":"P/0048/2016","pip_number":"EMEA-001871-PIP01-15","active_substance":"ramipril;amlodipine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/02/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Krka, d.d., Novo mesto; Slovenia; Tel. +386 73319037; Fax +386 73322742; E-mail: dragan.priselac@krka.biz","first_published_date":"22/04/2016","last_updated_date":"22/04/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001871-pip01-15"},{"decision_number":"P/0037/2016","pip_number":"EMEA-001747-PIP01-15","active_substance":"recombinant human antibody against the respiratory syncytial virus fusion protein (REGN2222)","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of lower respiratory tract disease caused by respiratory syncytial virus","routes_of_administration":"Intramuscular use;Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"12/02/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Regeneron Ireland DAC; Tel. +1 9148 475385; E-mail: clinicaltrials@regeneron.com","first_published_date":"22/04/2016","last_updated_date":"22/04/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001747-pip01-15"},{"decision_number":"P/0036/2016","pip_number":"EMEA-001807-PIP02-15","active_substance":"processed nerve allograft (human)","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Implant","condition_indication":"Treatment of nerve injuries","routes_of_administration":"Implantation","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"05/02/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AxoGen Corporation; USA; Tel. +1 3864626820; Fax +1 3864626801; E-mail: mfriedman@axogeninc.com","first_published_date":"22/04/2016","last_updated_date":"22/04/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001807-pip02-15"},{"decision_number":"P/0035/2016","pip_number":"EMEA-001844-PIP01-15","active_substance":"methacetin (13C)","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Diagnosis of liver disease","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/02/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Humedics GmbH; Germany; Tel. +49 30590083249 ; Fax +49 30590083230; Email: brigitte.hoch@humedics.de","first_published_date":"22/04/2016","last_updated_date":"22/04/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001844-pip01-15"},{"decision_number":"P/0006/2016","pip_number":"EMEA-000067-PIP02-11-M02","active_substance":"human heterologous liver cells","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Suspension for infusion","condition_indication":"Treatment of urea cycle disorders","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"21/01/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cytonet GmbH & Co KG; Germany; E-mail: info@cytonet.de; Tel. +49 6201 25980; Fax +49 6201 259828","first_published_date":"27/11/2012","last_updated_date":"29/03/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000067-pip02-11-m02"},{"decision_number":"P/0034/2016","pip_number":"EMEA-001854-PIP01-15","active_substance":"(3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)-carbonyl]-3-pyrrolidinone-O-methyloxime","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Dispersible tablet","condition_indication":"Treatment of female infertility","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ObsEva Ireland Limited; Ireland; E-mail: delphine.renaud@obseva.ch; Tel.: +41 225521550","first_published_date":"29/03/2016","last_updated_date":"29/03/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001854-pip01-15"},{"decision_number":"P/0033/2016","pip_number":"EMEA-001851-PIP01-15","active_substance":"tiprelestat","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of oesophageal carcinoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Proteo Biotech AG; Germany; E-mail: info@proteo.de; Tel.: +49 4318888462; Fax: +49 4318888463","first_published_date":"29/03/2016","last_updated_date":"29/03/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001851-pip01-15"},{"decision_number":"P/0032/2016","pip_number":"EMEA-001847-PIP01-15","active_substance":"pexiganan (acetate)","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Cream","condition_indication":"Treatment of diabetic foot ulcer","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dipexium Pharmaceuticals, Inc.; United States; E-mail: www.dipexiumpharmaceuticals.com; Tel.: +1 2122692724","first_published_date":"29/03/2016","last_updated_date":"29/03/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001847-pip01-15"},{"decision_number":"P/0031/2016","pip_number":"EMEA-001836-PIP01-15","active_substance":"revusiran","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of transthyretin-related amyloidosis (ATTR amyloidosis)","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/01/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alnylam Pharmaceuticals, Inc.; United States; E-mail: clinicaltrials@alnylam.com; Tel.: +1 8663300326","first_published_date":"29/03/2016","last_updated_date":"29/03/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001836-pip01-15"},{"decision_number":"P/0028/2016","pip_number":"EMEA-001718-PIP01-14","active_substance":"17 beta-estradiol;etonogestrel","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Vaginal delivery system","condition_indication":"Treatment of dysmenorrhea;Prevention of pregnancy","routes_of_administration":"Vaginal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/01/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe), Inc.; Belgium; E- mail: pip.information@merck.com; Tel.: +31 412663179; Fax: +31 412662517","first_published_date":"29/03/2016","last_updated_date":"29/03/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001718-pip01-14"},{"decision_number":"P/0026/2016","pip_number":"EMEA-001311-PIP01-12-M01","active_substance":"vancomycin","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of bacterial sepsis","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"26/01/2016","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Fondazione PENTA Onlus; Italy; Tel. +39 0498215447; Fax +39 0499640123; E-mail: pmo@neovanc.org","first_published_date":"04/10/2013","last_updated_date":"26/03/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001311-pip01-12-m01"},{"decision_number":"P/0307/2015","pip_number":"EMEA-001123-PIP01-11-M03","active_substance":"odanacatib","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of osteoporosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"21/12/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"09/08/2012","last_updated_date":"04/02/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001123-pip01-11-m03"},{"decision_number":"P/305/2015","pip_number":"EMEA-001098-PIP01-10-M01","active_substance":"Lorcaserin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet;Age appropriate dosage form, other","condition_indication":"Treatment of obesity","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"21/12/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eisai Limited; United Kingdom; Tel. +44 (0)20 8600 1400; Fax +44 (0)20 8676 1504; E-mail: LMedinfo@eisai.net","first_published_date":"18/10/2011","last_updated_date":"04/02/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001098-pip01-10-m01"},{"decision_number":"P/0299/2015","pip_number":"EMEA-000568-PIP01-09-M06","active_substance":"C1 inhibitor (human)","invented_name":"Cinryze; Cinryze","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of C1 inhibitor deficiency","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"21/12/2015","compliance_outcome":"Positive","compliance_opinion_date":"26/02/2016","compliance_procedure_number":"EMEA-C-000568-PIP01-09-M06","contact_for_public_enquiries":"NPS Pharma Holdings Limited; United Kingdom; Tel. +80066838470; E-mail: medinfoeuceemea@shire.com","first_published_date":"23/02/2011","last_updated_date":"02/02/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000568-pip01-09-m06"},{"decision_number":"P/0296/2015","pip_number":"EMEA-001450-PIP01-13-M01","active_substance":"vosaroxin","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of acute myeloid leukaemia","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/12/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sunesis Europe Ltd ; Belgium; Tel. +1 6502663728 ; Fax +1 6502663528; E-mail: dthomas@sunesis.com","first_published_date":"22/08/2014","last_updated_date":"02/02/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001450-pip01-13-m01"},{"decision_number":"P/0295/2015","pip_number":"EMEA-000830-PIP02-10-M02","active_substance":"human normal immunoglobulin","invented_name":"Gammaplex","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of idiopathic thrombocytopenic purpura as a model for immunomodulation;Treatment of primary immunodeficiency (PID) as model for replacement therapy","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/12/2015","compliance_outcome":"Positive","compliance_opinion_date":"29/01/2016","compliance_procedure_number":"EMEA-C-000830-PIP02-10-M02","contact_for_public_enquiries":"Bio Products Laboratory Limited; United Kingdom; Tel. +44 (0)20 8957 2622; Fax +44 (0)20 8957 2608; E-mail: Omotayo.Onabaworin@bpl.co.uk;  ","first_published_date":"14/07/2011","last_updated_date":"02/02/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000830-pip02-10-m02"},{"decision_number":"P/0311/2015","pip_number":"EMEA-001501-PIP03-15","active_substance":"dupilumab","invented_name":"","therapeutic_area":"Oto-rhino-laryngology","pharmaceutical_forms":"Solution for injection in pre-filled pen","condition_indication":"Treatment of nasal polyposis","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/12/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"sanofi-aventis recherche & développement; Tel. +33 1697 45695; E-mail: contact-us@sanofi.com","first_published_date":"02/02/2016","last_updated_date":"02/02/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001501-pip03-15"},{"decision_number":"P/0320/2015","pip_number":"EMEA-001850-PIP01-15","active_substance":"Inactivated Type 1 poliovirus (Brunhilde);Inactivated Type 3 Poliovirus (Saukett);Inactivated Type 2 Poliovirus (MEF-1)","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of poliomyelitis","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/12/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Statens Serum Institut; Denmark; Tel. +4541714897; E-mail: regaffairs@ajvaccines.com","first_published_date":"02/02/2016","last_updated_date":"02/02/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001850-pip01-15"},{"decision_number":"P/0319/2015","pip_number":"EMEA-001849-PIP01-15","active_substance":"recombinant human monoclonal IgG1 antibody directed against Programmed Death Ligand-1 (anti-PD-L1) (MSB0010718C)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Merkel cell carcinoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/12/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck KGaA; Germany; E-mail: service@merck.de; Tel. +49 6151725200; Fax +49 615172200","first_published_date":"02/02/2016","last_updated_date":"02/02/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001849-pip01-15"},{"decision_number":"P/0318/2015","pip_number":"EMEA-001840-PIP01-15","active_substance":"telotristat etiprate","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Coated tablet","condition_indication":"Treatment of carcinoid syndrome","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/12/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ipsen Pharma; E-mail: paediatrics.plans@ipsen.com; Tel. +33 158335000","first_published_date":"02/02/2016","last_updated_date":"02/02/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001840-pip01-15"},{"decision_number":"P/0317/2015","pip_number":"EMEA-001783-PIP02-15","active_substance":"ketoprofen","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Medicated plaster","condition_indication":"Treatment of musculoskeletal and connective tissue pain","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/12/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Promo International S.r.l.; Italy; Tel. +39 382530059; E-mail: regulatory@gbpharma.it","first_published_date":"02/02/2016","last_updated_date":"02/02/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001783-pip02-15"},{"decision_number":"P/0315/2015","pip_number":"EMEA-001617-PIP01-14","active_substance":"ethosuximide","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Age appropriate oral solid dosage form","condition_indication":"Treatment of childhood absence epilepsy","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"21/12/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"02/02/2016","last_updated_date":"02/02/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001617-pip01-14"},{"decision_number":"P/0294/2015","pip_number":"EMEA-001091-PIP02-15","active_substance":"emtricitabine;tenofovir disoproxil fumarate","invented_name":"Truvada; Truvada","therapeutic_area":"","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/12/2015","compliance_outcome":"Positive","compliance_opinion_date":"16/12/2016","compliance_procedure_number":"EMEA-C-001091-PIP02-15","contact_for_public_enquiries":"Gilead Sciences International Ltd; United Kingdom; Tel. +44 1223 897342; E-mail: regulatory.pip@gilead.com","first_published_date":"02/02/2016","last_updated_date":"02/02/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001091-pip02-15"},{"decision_number":"P/0266/2015","pip_number":"EMEA-000309-PIP01-08-M07","active_substance":"tocilizumab","invented_name":"RoActemra; RoActemra","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis)","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/11/2015","compliance_outcome":"Positive","compliance_opinion_date":"23/02/2018","compliance_procedure_number":"EMEA-C-000309-PIP01-08-M07","contact_for_public_enquiries":"Roche Registration Limited; United Kingdom; Tel. +41 6168 79411; Fax +41 6168 79233; E-mail: info.paediatrics@roche.com","first_published_date":"21/12/2011","last_updated_date":"07/01/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000309-pip01-08-m07"},{"decision_number":"P/0293/2015","pip_number":"EMEA-001852-PIP01-15","active_substance":"olmesartan medoxomil;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/11/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Krka, d.d., Novo mesto; Slovenia; Tel. +386 7331 2055; Fax +386 7332 2742; E-mail: tomaz.kralj@krka.biz","first_published_date":"07/01/2016","last_updated_date":"07/01/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001852-pip01-15"},{"decision_number":"P/0292/2015","pip_number":"EMEA-001824-PIP01-15","active_substance":"(R)-N-({5-[3-(2,5-Difluorophenyl)-2-(2,3-dihydro-1H-benzimidazol-2-ylidene)-3- oxopropanoyl]-2-fluorophenyl}sulfonyl)-2-hydroxypropanimidamide","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of endometriosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/11/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Astellas Pharma Europe B.V.Tel. +31 7154 55878E-mail: contact.nl@astellas.com&nbsp","first_published_date":"07/01/2016","last_updated_date":"07/01/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001824-pip01-15"},{"decision_number":"P/0291/2015","pip_number":"EMEA-001820-PIP01-15","active_substance":"recombinant human growth hormone fused to hybrid Fc composed of the hinge region and N-terminal of CH2 domain of IgD and C-terminal of CH2 and full CH3 domain of IgG4","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of growth hormone deficiency","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/11/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Genexine, Inc.; Hungary; Tel. +82 31628 3278; Fax +82 31628 3229; E-mail: yjlee@genexine.com","first_published_date":"07/01/2016","last_updated_date":"07/01/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001820-pip01-15"},{"decision_number":"P/0289/2015","pip_number":"EMEA-001745-PIP01-14","active_substance":"4-Amino-2-butoxy-8-[3-(pyrrolidin-1-ylmethyl)benzyl]-7,8-dihydropteridin-6(5H)-one (GS-9620)","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Tablet;Age appropriate oral formulation","condition_indication":"Treatment of chronic viral hepatitis B","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/11/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd.; United Kingdom; Email: regulatory.pip@gilead.com; Tel.: +44 1223897300; Fax:  +44 1223897284","first_published_date":"07/01/2016","last_updated_date":"07/01/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001745-pip01-14"},{"decision_number":"P/0231/2015","pip_number":"EMEA-000639-PIP02-09-M02","active_substance":"chloroprocaine hydrochloride","invented_name":"","therapeutic_area":"Anaesthesiology","pharmaceutical_forms":"Solution for injection","condition_indication":"Intrathecal anaesthesia","routes_of_administration":"Intrathecal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/10/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sintetica Italia S.r.l.; Switzerland; Tel. +39 3466 632572; Fax +41 9164 68561; E-mail: italia@sintetica.com, edonati@sintetica.com","first_published_date":"26/08/2010","last_updated_date":"06/01/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000639-pip02-09-m02"},{"decision_number":"P/0057/2015","pip_number":"EMEA-000060-PIP04-14-M01","active_substance":"Canakinumab","invented_name":"Ilaris; Ilaris","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection;Powder for solution for injection;Powder and solvent for solution for injection","condition_indication":"Treatment of familial Mediterranean fever;Treatment of hyperimmunoglobulin D syndrome","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/10/2015","compliance_outcome":"Positive","compliance_opinion_date":"26/02/2016","compliance_procedure_number":"EMEA-C-000060-PIP04-14-M01","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"07/05/2015","last_updated_date":"06/01/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000060-pip04-14-m01"},{"decision_number":"P/0239/2015","pip_number":"EMEA-000060-PIP05-14-M01","active_substance":"Canakinumab","invented_name":"Ilaris","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection;Powder for solution for injection;Powder and solvent for solution for injection","condition_indication":"Treatment of tumour necrosis factor receptor associated periodic syndrome","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/10/2015","compliance_outcome":"Positive","compliance_opinion_date":"26/02/2016","compliance_procedure_number":"EMEA-C-000060-PIP05-14-M01","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"07/05/2015","last_updated_date":"06/01/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000060-pip05-14-m01"},{"decision_number":"P/0237/2015","pip_number":"EMEA-000020-PIP01-07-M05","active_substance":"maraviroc","invented_name":"Celsentri; Celsentri","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Oral solution","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/10/2015","compliance_outcome":"Positive","compliance_opinion_date":"29/04/2016","compliance_procedure_number":"EMEA-C-000020-PIP01-07-M05","contact_for_public_enquiries":"ViiV Healthcare UK Ltd; United Kingdom; Tel. +44 (0)20 8380 6215; E-mail: neil.p.shortman@viivhealthcare.com","first_published_date":"29/01/2009","last_updated_date":"06/01/2016","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000020-pip01-07-m05"},{"decision_number":"P/0287/2015","pip_number":"EMEA-001721-PIP01-14","active_substance":"dimethyl fumarate","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Gastro-resistant tablet","condition_indication":"Treatment of psoriasis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"26/11/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Almirall S.A.Tel. +34 9329 13190Fax +34 9329 13531E-mail: paediatrics@almirall.com","first_published_date":"22/12/2015","last_updated_date":"22/12/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001721-pip01-14"},{"decision_number":"P/0259/2015","pip_number":"EMEA-001810-PIP01-15","active_substance":"L-Cysteine, L-leucyl-L-α-glutamyl-L-α-glutamyl-L-lysyl-L-lysylglycyl-L-asparaginyl-L-tyrosyl-L-valyl-L-valyl-L-threonyl-L-α -aspartyl-L-histidyl-S-[1-[(4-carboxycyclohexyl)methyl]-2,5-dioxo-3-pyrrolidinyl]-, complex with keyhole limpet haemocyanin","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of high-grade glioma","routes_of_administration":"Intradermal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/10/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Celldex Therapeutics, Inc.; Germany; Tel. +1 7814 333111; Fax +1 7814 333133; E-mail: aelnatan@celldex.com","first_published_date":"22/12/2015","last_updated_date":"22/12/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001810-pip01-15"},{"decision_number":"P/0262/2015","pip_number":"EMEA-001817-PIP01-15","active_substance":"Fluoroestradiol (18F)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Detection of pathological expression of estrogen receptors in organs and tissues","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/10/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Laboratoires Cyclopharma; France; Tel. +33 4736 32700; E-mail: jmdecomps@cyclopharma.fr","first_published_date":"22/12/2015","last_updated_date":"22/12/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001817-pip01-15"},{"decision_number":"P/0261/2015","pip_number":"EMEA-001816-PIP02-15","active_substance":"mogamulizumab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Cutaneous T-Cell Lymphoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/10/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ProStrakan Ltd; United Kingdom; Tel. +1 6099 191100; Fax +1 6099 191111; E-mail: kw-0761@kyowa-kirin-pharma.com","first_published_date":"22/12/2015","last_updated_date":"22/12/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001816-pip02-15"},{"decision_number":"P/0264/2015","pip_number":"EMEA-001845-PIP01-15","active_substance":"telmisartan;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/10/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Krka, d.d. Novo mesto; Croatia; Tel. +385 9931 10291; Fax +385 1631 2153; E-mail: helen.lukin@krka.biz","first_published_date":"22/12/2015","last_updated_date":"22/12/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001845-pip01-15"},{"decision_number":"P/0260/2015","pip_number":"EMEA-001816-PIP01-15","active_substance":"mogamulizumab","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of adult T-cell leukaemia / lymphoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/10/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ProStrakan Ltd; United Kingdom; Tel. +1 6099 191100; Fax +1 6099 191111; E-mail: kw-0761@kyowa-kirin-pharma.com","first_published_date":"22/12/2015","last_updated_date":"22/12/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001816-pip01-15"},{"decision_number":"P/0254/2015","pip_number":"EMEA-001511-PIP03-14","active_substance":"simtuzumab","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of interstitial pulmonary diseases with fibrosis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"30/10/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd; E-mail: regulatory.pip@gilead.com; Tel. +44 (0)1223 897300","first_published_date":"21/12/2015","last_updated_date":"21/12/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001511-pip03-14"},{"decision_number":"P/0253/2015","pip_number":"EMEA-001487-PIP02-15","active_substance":"Gevokizumab","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Schnitzler Syndrome","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/10/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"18/12/2015","last_updated_date":"18/12/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001487-pip02-15"},{"decision_number":"P/0234/2015","pip_number":"EMEA-001007-PIP02-15","active_substance":"ciclosporin","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution","condition_indication":"Treatment of dry eye disease","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/10/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628925033","first_published_date":"17/12/2015","last_updated_date":"17/12/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001007-pip02-15"},{"decision_number":"P/0223/2015","pip_number":"EMEA-001762-PIP01-15","active_substance":"hydromorphone (hydrochloride);naloxone (hydrochloride)","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Prolonged-release capsule;Capsule, hard","condition_indication":"Treatment of opioid-induced constipation;Treatment of pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/10/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mundipharma Research GmbH & Co. KG; Germany; Tel. +49 6431 701453; Fax +49 6431 7018453; E-mail: barbara.riechert@mundipharma-rd.eu","first_published_date":"19/11/2015","last_updated_date":"17/12/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001762-pip01-15"},{"decision_number":"P/0225/2015","pip_number":"EMEA-001790-PIP01-15","active_substance":"alpha Connexin C-terminal 1 peptide","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Gel","condition_indication":"Treatment of diabetic foot ulcer;Treatment of venous leg ulcer","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/10/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"FirstString Research Inc; United States; Tel. +1 8438 608372; E-mail: info@firststring.com","first_published_date":"19/11/2015","last_updated_date":"17/12/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001790-pip01-15"},{"decision_number":"P/0200/2015","pip_number":"EMEA-001761-PIP01-15","active_substance":"hydrochlorothiazide;nebivolol (hydrochloride)","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/09/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Actavis Group PTC ehf; Iceland; Tel. +354 5503482; E-mail: hrefna.haraldsdottir@actavis.com","first_published_date":"20/10/2015","last_updated_date":"17/12/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001761-pip01-15"},{"decision_number":"P/0168/2015","pip_number":"EMEA-000980-PIP02-15","active_substance":"Brentuximab vedotin","invented_name":"Adcetris; Adcetris","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of Cutaneous T-Cell Lymphoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/08/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Pharma A/S; United Kingdom; Email: bharti.navsariwala@takeda.com; Tel.: +44 (0) 2031 168000","first_published_date":"22/09/2015","last_updated_date":"17/12/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000980-pip02-15"},{"decision_number":"P/0180/2015","pip_number":"EMEA-001754-PIP01-15","active_substance":"rifamycin","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Prolonged-release tablet","condition_indication":"Treatment of acute infectious diarrhoea","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/08/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dr. Falk Pharma GmbH; Email: zentrale@drfalkpharma.de; Tel.: +49 76115140","first_published_date":"24/09/2015","last_updated_date":"17/12/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001754-pip01-15"},{"decision_number":"P/0199/2015","pip_number":"EMEA-001759-PIP01-15","active_substance":"torasemide;lisinopril","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of heart failure;Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/09/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Accupharma spółka z ograniczoną odpowiedzialnością; Poland; E-mail: biuro@accupharma.pl; Tel. +48 224905162; Fax +48 224905153","first_published_date":"20/10/2015","last_updated_date":"17/12/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001759-pip01-15"},{"decision_number":"P/0218/2015","pip_number":"EMEA-001461-PIP02-14","active_substance":"acotiamide","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Coated tablet","condition_indication":"Treatment of functional dyspepsia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"02/10/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Zeria Pharmaceutical Co Ltd; tomoharu-miyagawa@zeria.co.jp; Tel. +44 (0)7528 697428","first_published_date":"19/11/2015","last_updated_date":"17/12/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001461-pip02-14"},{"decision_number":"P/0204/2015","pip_number":"EMEA-001779-PIP01-15","active_substance":"enclomifene citrate","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypogonadotrophic hypogonadism","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/09/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Renable Pharma Limited; United Kingdom; E-mail: carole.pugh@eudrac.com; Tel. +44 1865893274; Fax +44 1865893333","first_published_date":"20/10/2015","last_updated_date":"17/12/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001779-pip01-15"},{"decision_number":"P/0224/2015","pip_number":"EMEA-001788-PIP01-15","active_substance":"Botulinum Neurotoxin Type A","invented_name":"","therapeutic_area":"","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of muscle induced wrinkles","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/10/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Croma Pharma GmbH; Austria; Tel. +43 2262 684680; Fax +43 2262 68468165; E-mail: office@croma.at","first_published_date":"19/11/2015","last_updated_date":"17/12/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001788-pip01-15"},{"decision_number":"P/0228/2015","pip_number":"EMEA-001805-PIP01-15","active_substance":"Dasabuvir;ombitasvir;paritaprevir;ritonavir","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of chronic hepatitis C","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/10/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: ukpaediatricteam@abbvie.comTel. +44 1628 644474","first_published_date":"19/11/2015","last_updated_date":"17/12/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001805-pip01-15"},{"decision_number":"P/0203/2015","pip_number":"EMEA-001777-PIP01-15","active_substance":"azithromycin","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution;Solution","condition_indication":"Treatment of bacterial conjunctivitis","routes_of_administration":"Topical use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/09/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Laboratoires Doliage (Groupe Nicox); France; E-mail: communications@nicox.com; Tel. +33 497245300","first_published_date":"20/10/2015","last_updated_date":"17/12/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001777-pip01-15"},{"decision_number":"P/0181/2015","pip_number":"EMEA-001773-PIP01-15","active_substance":"DNA, d(P-thio)([2'-0-(2-methoxyethyl)]m5rU-[2'-0-(2-methoxyethyl)]m5rC-[2'-0-(2-methoxyethyl)]m5rU-[2'-0-(2-methoxyethyl)]m5rU-[2'-0-(2-methoxyethyl)]rG-G-T-T-A-m5C-A-T-G-A-A-[2'-0-(2-methoxyethyl)]rA-[2'-0-(2-methoxyethyl)]m5rU-[2'-0-(2-methoxyethyl)]m5rC-[2'-0-(2-methoxyethy l)]m5rC-[2'-0-(2-methoxyethyl)]m5rC), sodium salt","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of transthyretin-related amyloidosis (ATTR amyloidosis)","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/08/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Isis Pharmaceuticals, Inc.; Email: info@akceatx.com; Tel. + 353 (0) 1 477 3197","first_published_date":"24/09/2015","last_updated_date":"17/12/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001773-pip01-15"},{"decision_number":"P/0217/2015","pip_number":"EMEA-001272-PIP02-13-M01","active_substance":"azacitidine","invented_name":"Vidaza; Vidaza","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder for suspension for injection;Powder for solution for infusion","condition_indication":"Treatment of acute myeloid leukaemia;Treatment of myelodysplastic syndrome (including juvenile myelomonocytic leukaemia)","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"02/10/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Celgene Europe LimitedTel.  +41 327298500E-mail: medinfo.intl@celgene.com","first_published_date":"20/03/2014","last_updated_date":"23/11/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001272-pip02-13-m01"},{"decision_number":"P/0186/2015","pip_number":"EMEA-000872-PIP01-10-M03","active_substance":"human normal immunoglobulin","invented_name":"HyQvia; HyQvia","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of primary immunodeficiency (PID) as model for replacement therapy","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/08/2015","compliance_outcome":"Positive","compliance_opinion_date":"30/10/2015","compliance_procedure_number":"EMEA-C-000872-PIP01-10-M03","contact_for_public_enquiries":"Baxalta Innovations GmbH; Austria; Tel. +43 1201 000; Fax +43 1201 002 475990; E-mail: europa_biosci_globalra@baxter.com","first_published_date":"22/08/2012","last_updated_date":"13/11/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000872-pip01-10-m03"},{"decision_number":"P/0141/2013","pip_number":"EMEA-000060-PIP02-08-M06","active_substance":"Canakinumab","invented_name":"Ilaris; Ilaris","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder for solution for injection;Powder and solvent for solution for injection;Solution for injection in pre-filled syringe","condition_indication":"Treatment of juvenile idiopathic arthritis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/07/2013","compliance_outcome":"Positive","compliance_opinion_date":"09/10/2015","compliance_procedure_number":"EMEA-C-000060-PIP02-08-M06","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"17/10/2011","last_updated_date":"13/11/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000060-pip02-08-m06"},{"decision_number":"P/0118/2015","pip_number":"EMEA-000777-PIP01-09-M05","active_substance":"artemether;lumefantrine","invented_name":"Riamet","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Tablet;Dispersible tablet","condition_indication":"Treatment of Plasmodium falciparum malaria","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/06/2015","compliance_outcome":"Positive","compliance_opinion_date":"09/10/2015","compliance_procedure_number":"EMEA-C-000777-PIP01-09-M05","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"04/01/2013","last_updated_date":"13/11/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000777-pip01-09-m05"},{"decision_number":"P/0034/2015","pip_number":"EMEA-000479-PIP01-08-M03","active_substance":"insulin degludec;insulin aspart","invented_name":"Ryzodeg; Ryzodeg","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of type I diabetes mellitus;Treatment of type II diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/03/2015","compliance_outcome":"Positive","compliance_opinion_date":"11/09/2015","compliance_procedure_number":"EMEA-C-000479-PIP01-08-M03","contact_for_public_enquiries":"Novo Nordisk A/S; Denmark; Tel. +45 3075 8242; Fax +45 3969 9173; E-mail: de@novonordisk.com","first_published_date":"18/05/2010","last_updated_date":"13/11/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000479-pip01-08-m03"},{"decision_number":"P/0189/2015","pip_number":"EMEA-000347-PIP01-08-M06","active_substance":"bilastine","invented_name":"Bilaxten and associated names","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Tablet;Orodispersible tablet;Oral liquid","condition_indication":"Treatment of urticaria;Treatment of allergic rhinoconjunctivitis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/09/2015","compliance_outcome":"Positive","compliance_opinion_date":"13/11/2015","compliance_procedure_number":"EMEA-C-000347-PIP01-08-M06","contact_for_public_enquiries":"Faes Farma S.A.; E-mail: ieguidazu@faes.es, mjarenal@faes.es; Tel. +34 944818300","first_published_date":"23/10/2015","last_updated_date":"15/06/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000347-pip01-08-m06"},{"decision_number":"P/0202/2015","pip_number":"EMEA-001772-PIP01-15","active_substance":"amlodipine;rosuvastatin;perindopril tert-butylamine","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events;Treatment of hypertension;Treatment of lipid metabolism disorders","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/09/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Krka, d.d., Novo mesto ; Slovenia ; E-mail: dragan.priselac@krka.biz ; Tel. +386 73319037 ; Fax +386 73322742","first_published_date":"23/10/2015","last_updated_date":"23/10/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001772-pip01-15"},{"decision_number":"P/0155/2013","pip_number":"EMEA-001180-PIP01-11","active_substance":"Evacetrapib","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of hypercholesterolaemia;Treatment of hypo-high-density-lipoprotein-cholesterolaemia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"05/07/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"09/08/2013","last_updated_date":"22/10/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001180-pip01-11"},{"decision_number":"P/0196/2015","pip_number":"EMEA-001569-PIP01-13","active_substance":"raxibacumab","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of bacillary infection","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/09/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Tel. +1 4388998201; E-mail: eu.paediatric-plans@gsk.com","first_published_date":"20/10/2015","last_updated_date":"20/10/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001569-pip01-13"},{"decision_number":"P/0158/2015","pip_number":"EMEA-001746-PIP01-15","active_substance":"clonidine","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Gel","condition_indication":"Treatment of painful diabetic neuropathy","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/07/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BioDelivery Sciences International, Inc. Tel. +1 9195829050E-mail: cprue@bdsi.com, swhight@bdsi.com","first_published_date":"25/08/2015","last_updated_date":"19/10/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001746-pip01-15"},{"decision_number":"P/0172/2015","pip_number":"EMEA-001316-PIP01-12-M01","active_substance":"clonidine hydrochloride","invented_name":"","therapeutic_area":"Anaesthesiology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Sedation","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/08/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Therakind Limited; United Kingdom; E-mail: admin@therakind.com; Tel. + 44 (0)20 8346 6035; Fax + 44 (0)20 8346 7305","first_published_date":"03/05/2013","last_updated_date":"25/09/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001316-pip01-12-m01"},{"decision_number":"P/0178/2015","pip_number":"EMEA-001743-PIP01-14","active_substance":"carvedilol;ivabradine hydrochloride","invented_name":"","therapeutic_area":"","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of heart failure;Treatment of ischaemic coronary artery disorders","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/08/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierE-mail: mail.pip.enquiries@servier.comTel.: +33 155726000","first_published_date":"22/09/2015","last_updated_date":"22/09/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001743-pip01-14"},{"decision_number":"P/0124/2015","pip_number":"EMEA-001601-PIP01-13","active_substance":"misoprostol","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Induction of labour","routes_of_administration":"Oral use;Sublingual use;Vaginal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"05/06/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Azanta Danmark A/S; Denmark; Tel. +45 70259545; Fax +45 70259546; E-mail: cm@azanta.com","first_published_date":"03/07/2015","last_updated_date":"02/09/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001601-pip01-13"},{"decision_number":"P/0135/2015","pip_number":"EMEA-000309-PIP02-14","active_substance":"tocilizumab","invented_name":"RoActemra; RoActemra","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection in pre-filled syringe","condition_indication":"Treatment of vasculitides","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/06/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration Limited; United Kingdom; Tel. +41 6168 79411; Fax +41 6168 79233; E-mail: info.paediatrics@roche.com","first_published_date":"03/07/2015","last_updated_date":"02/09/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000309-pip02-14"},{"decision_number":"P/0128/2015","pip_number":"EMEA-001724-PIP01-14","active_substance":"levomilnacipran","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Prolonged-release capsule;Capsule, hard","condition_indication":"Treatment of stroke","routes_of_administration":"Oral use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"05/06/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pierre Fabre Medicament; France; Tel. +33 149108081","first_published_date":"06/07/2015","last_updated_date":"02/09/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001724-pip01-14"},{"decision_number":"P/0151/2015","pip_number":"EMEA-001547-PIP01-13","active_substance":"atorvastatin;perindopril;acetylsalicylic acid","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of elevated cholesterol;Treatment of ischemic coronary artery disorders","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/07/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierE-mail: mail.pip.enquiries@servier.comTel.: +33 155726000","first_published_date":"25/08/2015","last_updated_date":"25/08/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001547-pip01-13"},{"decision_number":"P/0142/2015","pip_number":"EMEA-000575-PIP01-09-M03","active_substance":"ciclosporin","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, emulsion","condition_indication":"Treatment of keratoconjunctivitis sicca;Treatment of vernal keratoconjunctivitis","routes_of_administration":"Ocular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/07/2015","compliance_outcome":"Positive","compliance_opinion_date":"29/04/2016","compliance_procedure_number":"EMEA-C-000575-PIP01-09-M03","contact_for_public_enquiries":"Santen SAS; France; Tel. +33 169874020; E-mail: mohamed.ibrahiem@santen.fr","first_published_date":"11/08/2011","last_updated_date":"24/08/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000575-pip01-09-m03"},{"decision_number":"P/0143/2015","pip_number":"EMEA-000775-PIP01-09-M02","active_substance":"human normal immunoglobulin","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of Idiopathic Thrombocytopenia Purpura (ITP);Treatment of Primary Immunodeficiency (PID)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/07/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kedrion S.p.A.; Italy; E-mail: info@kedrion.com; Tel. + 39 0583 1969697","first_published_date":"29/07/2010","last_updated_date":"24/08/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000775-pip01-09-m02"},{"decision_number":"P/0002/2015","pip_number":"EMEA-001485-PIP01-13-M01","active_substance":"asunaprevir;(1aR,12bS)-8-cyclohexyl-N-(dimethylsulfamoyl)-11-methoxy-1a-(((1R,5S)-3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide hydrochloride (BMS-791325);daclatasvir dihydrochloride","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Age appropriate oral solid dosage form;Film-coated tablet","condition_indication":"Treatment of chronic hepatitis C","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"15/01/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb International Corporation; Tel. +44 (0)1895 523740; E-mail: medical.information@bms.com","first_published_date":"22/08/2014","last_updated_date":"20/08/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001485-pip01-13-m01"},{"decision_number":"P/0100/2015","pip_number":"EMEA-001693-PIP01-14","active_substance":"reparixin","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Prevention of graft rejection","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/05/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dompé farmaceutici SpA ; Italy; Tel. +39 0258383559; E-mail: lamberto.dionigi@dompe.com","first_published_date":"16/06/2015","last_updated_date":"20/08/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001693-pip01-14"},{"decision_number":"P/0101/2015","pip_number":"EMEA-001719-PIP01-14","active_substance":"L-Pyr-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-L-Ser-L-Ser","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of sarcoidosis","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/05/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Araim Pharna Europe Ltd; United Kingdom; Tel. +1 9147627586201 ; Fax +1 9142944170; E-mail: rkirk@araimpharma.com","first_published_date":"16/06/2015","last_updated_date":"20/08/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001719-pip01-14"},{"decision_number":"P/0104/2015","pip_number":"EMEA-001663-PIP01-14","active_substance":"Ibodutant","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Tablet;Film-coated tablet","condition_indication":"Treatment of diarrhoea-predominant irritable bowel Syndrome","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/05/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Menarini Ricerche S.p.A. ; Italy; Tel. +39 0555680633; E-mail: prijli@menarini.it","first_published_date":"16/06/2015","last_updated_date":"20/08/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001663-pip01-14"},{"decision_number":"P/0097/2015","pip_number":"EMEA-001556-PIP01-13","active_substance":"Human recombinant interleukin-2","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of type I diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/05/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Iltoo Pharma ; France ; Tel. +33 664233213; E-mail: j.mariau@iltoopharma.fr","first_published_date":"16/06/2015","last_updated_date":"20/08/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001556-pip01-13"},{"decision_number":"P/0093/2015","pip_number":"EMEA-001266-PIP02-14","active_substance":"Masitinib mesilate","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of mastocytosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/05/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AB Science; France; a.moussy@ab-science.com ; +33 147200014; +33 147202411","first_published_date":"16/06/2015","last_updated_date":"20/08/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001266-pip02-14"},{"decision_number":"P/0096/2015","pip_number":"EMEA-001511-PIP02-13","active_substance":"simtuzumab","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of hepatic cirrhosis;Treatment of hepatic fibrosis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/05/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd ; United Kingdom; Tel. +44 (0)1223 897300 ; Fax +44 (0)1223 897284; E-mail: regulatory.pip@gilead.com","first_published_date":"16/06/2015","last_updated_date":"20/08/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001511-pip02-13"},{"decision_number":"P/0098/2014","pip_number":"EMEA-000804-PIP01-09-M02","active_substance":"atazanavir (as sulfate)","invented_name":"Reyataz; Reyataz","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Capsule;Hard oral powder","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/04/2014","compliance_outcome":"Positive","compliance_opinion_date":"13/02/2015","compliance_procedure_number":"EMEA-C-000804-PIP01-09-M02","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"20/12/2010","last_updated_date":"27/07/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000804-pip01-09-m02"},{"decision_number":"P/0260/2014","pip_number":"EMEA-000573-PIP01-09-M05","active_substance":"solifenacin (succinate)","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Oral suspension;Film-coated tablet","condition_indication":"Treatment of idiopathic overactive bladder","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/09/2014","compliance_outcome":"Positive","compliance_opinion_date":"22/05/2015","compliance_procedure_number":"EMEA-C-000573-PIP01-09-M05","contact_for_public_enquiries":"Astellas Pharma Europe B.V.Tel. +31 7154 55878E-mail: contact.nl@astellas.com&nbsp","first_published_date":"27/07/2010","last_updated_date":"27/07/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000573-pip01-09-m05"},{"decision_number":"P/208/2011","pip_number":"EMEA-000060-PIP01-07-M03","active_substance":"Canakinumab","invented_name":"Ilaris","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder for solution for injection;Powder and solvent for solution for injection;Solution for injection","condition_indication":"Cryopyrin Associated Periodic Syndromes (CAPS);Familial Cold Autoinflammatory Syndrome (FCAS) / Familial Cold Urticaria (FCU);Muckle-Wells Syndrome (MWS);Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA)","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/09/2011","compliance_outcome":"Positive","compliance_opinion_date":"19/06/2015","compliance_procedure_number":"EMEA-C-000060-PIP01-07-M03","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"17/10/2011","last_updated_date":"27/07/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000060-pip01-07-m03"},{"decision_number":"P/0144/2012","pip_number":"EMEA-001005-PIP01-10-M01","active_substance":"lopinavir;ritonavir","invented_name":"Kaletra; Kaletra","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Oral solution;Capsule, soft;Film-coated tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"23/07/2012","compliance_outcome":"Positive","compliance_opinion_date":"17/07/2015","compliance_procedure_number":"EMEA-C-001005-PIP01-10-M01","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"13/09/2011","last_updated_date":"27/07/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001005-pip01-10-m01"},{"decision_number":"P/0033/2015","pip_number":"EMEA-000319-PIP01-08-M03","active_substance":"House dust mites allergen extracts","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Sublingual tablet","condition_indication":"Treatment of allergic rhinitis;Treatment of asthma","routes_of_administration":"Sublingual use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/03/2015","compliance_outcome":"Positive","compliance_opinion_date":"19/06/2015","compliance_procedure_number":"EMEA-C-000319-PIP01-08-M03","contact_for_public_enquiries":"Stallergenes; France; E-mail: mites.development@stallergenes.fr; Tel. +33 155592633; Fax +33 155592068","first_published_date":"11/08/2011","last_updated_date":"27/07/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000319-pip01-08-m03"},{"decision_number":"P/0274/2014","pip_number":"EMEA-000312-PIP01-08-M07","active_substance":"human coagulation factor VIII;von Willebrand factor","invented_name":"Voncento; Voncento","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection;Powder and solvent for solution for infusion","condition_indication":"Treatment of hereditary factor-VIII deficiency  (Haemophilia A);Treatment of von Willebrand disease","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"28/10/2014","compliance_outcome":"Positive","compliance_opinion_date":"22/05/2015","compliance_procedure_number":"EMEA-C-000312-PIP01-08-M07","contact_for_public_enquiries":"CSL Behring; Germany; E-mail: eu-cslbehring@cslbehring.com; Tel. +49 642 1395212; Fax +49 642 1394196","first_published_date":"25/05/2012","last_updated_date":"27/07/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000312-pip01-08-m07"},{"decision_number":"P/0297/2014","pip_number":"EMEA-000127-PIP01-07-M03","active_substance":"fluticasone propionate;Formoterol (fumarate)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Pressurised inhalation;Suspension","condition_indication":"Asthma","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"24/11/2014","compliance_outcome":"Positive","compliance_opinion_date":"13/02/2015","compliance_procedure_number":"EMEA-C-000127-PIP01-07-M03","contact_for_public_enquiries":"Mundipharma Research Ltd; United Kingdom; E-mail: paediatric@mundipharma-rd.eu; Tel. +44 (0)1223 424444; Fax +44 (0)1223 426054","first_published_date":"11/08/2011","last_updated_date":"27/07/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000127-pip01-07-m03"},{"decision_number":"P/0130/2015","pip_number":"EMEA-000746-PIP01-09-M04","active_substance":"Drisapersen","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Duchenne muscular dystrophy","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"10/06/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BioMarin International Limited; Ireland; Email: shanbally@bmrn.com; Tel. +35 3215007990","first_published_date":"08/04/2011","last_updated_date":"06/07/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000746-pip01-09-m04"},{"decision_number":"P/0120/2015","pip_number":"EMEA-001295-PIP01-12-M01","active_substance":"Epratuzumab","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of Systemic Lupus Erythematosus (SLE)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/06/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"UCB Pharma S.A.; E-mail: catrinel.galateanu@ucb.com; Tel. +32 25599762;  ","first_published_date":"31/05/2013","last_updated_date":"06/07/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001295-pip01-12-m01"},{"decision_number":"P/0115/2015","pip_number":"EMEA-000573-PIP02-13-M03","active_substance":"solifenacin (succinate)","invented_name":"Vesicare and associated names","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Oral suspension;Film-coated tablet","condition_indication":"Treatment of neurogenic detrusor overactivity","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/06/2015","compliance_outcome":"Positive","compliance_opinion_date":"16/12/2016","compliance_procedure_number":"EMEA-C-000573-PIP02-13-M03","contact_for_public_enquiries":"Astellas Pharma Europe B.V.Tel. +31 7154 55878E-mail: contact.nl@astellas.com&nbsp","first_published_date":"31/05/2013","last_updated_date":"06/07/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000573-pip02-13-m03"},{"decision_number":"P/0079/2015","pip_number":"EMEA-001204-PIP02-14","active_substance":"ezetimibe;atorvastatin (calcium trihydrate)","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of coronary artery disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/04/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"19/05/2015","last_updated_date":"06/07/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001204-pip02-14"},{"decision_number":"P/0078/2015","pip_number":"EMEA-001713-PIP02-14","active_substance":"Ibuprofen;Codeine","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/04/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Laboratórios Vitória, S.A.; Portugal; E-mail: dina.c@labvitoria.pt; Tel. +351 214758300 ext. 357; Fax +351 214747070;  ","first_published_date":"07/05/2015","last_updated_date":"06/07/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001713-pip02-14"},{"decision_number":"P/0077/2015","pip_number":"EMEA-001694-PIP01-14","active_substance":"autologous bone marrow-derived cardiopoietic stem cells","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of ischemic heart disease","routes_of_administration":"Intracardiac use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/04/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cardio3 BioSciences SA; Belgium; E-mail: info@c3bs.com / regulatory@c3bs.com; Tel. +32 10394100; Fax: +32 10394141; ; ;  ","first_published_date":"07/05/2015","last_updated_date":"06/07/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001694-pip01-14"},{"decision_number":"EMEA-001726-PIP01-14","pip_number":"EMEA-001726-PIP01-14","active_substance":"ranolazine;dronedarone","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of supraventricular arrhythmias","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"05/06/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd; United Kingdom; Email: nick.clark@gilead.com; Tel. +44 1223897356","first_published_date":"06/07/2015","last_updated_date":"06/07/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001726-pip01-14"},{"decision_number":"P/0049/2015","pip_number":"EMEA-001700-PIP01-14","active_substance":"Oxycodone (hydrochloride);naloxone (hydrochloride)","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Prolonged-release tablet","condition_indication":"Treatment of opioid-induced constipation;Treatment of pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/03/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Develco Pharma GmbH; Germany; E-mail: n.burger@develco.ch, k.schmid@develco.ch; Tel. +41 614255020; Fax +41 614255029","first_published_date":"24/03/2015","last_updated_date":"06/07/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001700-pip01-14"},{"decision_number":"P/0051/2015","pip_number":"EMEA-001711-PIP01-14","active_substance":"Candesartan;amlodipine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard;Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/03/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Adamed Sp. z o.o.; Tel. +48227327736; E-mail: joanna.pawlak@adamed.com.pl","first_published_date":"24/03/2015","last_updated_date":"06/07/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001711-pip01-14"},{"decision_number":"P/0048/2015","pip_number":"EMEA-001699-PIP01-14","active_substance":"hydromorphone (hydrochloride);naloxone (hydrochloride)","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Prolonged-release tablet","condition_indication":"Treatment of opioid-induced constipation;Treatment of pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/03/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Develco Pharma GmbH; Germany; E-mail: n.burger@develco.ch, k.schmid@develco.ch; Tel. +41 614255020; Fax +41 614255029","first_published_date":"24/03/2015","last_updated_date":"06/07/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001699-pip01-14"},{"decision_number":"P/0088/2015","pip_number":"EMEA-000178-PIP01-07-M04","active_substance":"","invented_name":"Pumarix; Pumarix","therapeutic_area":"Vaccines","pharmaceutical_forms":"Emulsion and suspension for emulsion for injection","condition_indication":"Prevention of influenza infection","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/05/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Biologicals S.A. (Belgium); Tel. +1 438 899 8201; Email: eu.paediatric-plans@gsk.com","first_published_date":"10/06/2009","last_updated_date":"15/06/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000178-pip01-07-m04"},{"decision_number":"P/0085/2015","pip_number":"EMEA-000117-PIP01-07-M07","active_substance":"Ipilimumab","invented_name":"Yervoy; Yervoy","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of all conditions included in the category of malignant neoplasms (except melanoma, nervous system, haematopoietic and lymphoid tissue)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/05/2015","compliance_outcome":"Positive","compliance_opinion_date":"11/12/2015","compliance_procedure_number":"EMEA-C-000117-PIP01-07-M07","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"13/07/2011","last_updated_date":"15/06/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000117-pip01-07-m07"},{"decision_number":"P/0074/2015","pip_number":"EMEA-001404-PIP01-12","active_substance":"tetrabenazine (ADV6979)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Oral suspension","condition_indication":"Treatment of dystonia","routes_of_administration":"Oral use;Gastric use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/04/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Advicenne Pharma ; E-mail: contact@advicenne.com; Tel. +33 4660 55420","first_published_date":"07/05/2015","last_updated_date":"07/05/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001404-pip01-12"},{"decision_number":"P/0072/2015","pip_number":"EMEA-001324-PIP01-12-M01","active_substance":"glibenclamide","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Oral suspension","condition_indication":"Treatment of neonatal diabetes mellitus","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/04/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AMMTeK; France; E-mail: a.ulmann@ammtek.eu; Tel. +33 182731319; Fax +33 140331231","first_published_date":"07/10/2013","last_updated_date":"06/05/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001324-pip01-12-m01"},{"decision_number":"P/0035/2015","pip_number":"EMEA-000500-PIP01-08-M03","active_substance":"Diphtheria toxoid;tetanus toxoid;Bordetella pertussis antigen: Pertussis toxoid;Bordetella pertussis antigen: Filamentous Haemagglutinin;Bordetella pertussis antigen: Pertactin;Inactivated Type 2 Poliovirus (MEF-1);Inactivated Type 3 Poliovirus (Saukett);Inactivated Type 1 Poliovirus (Mahoney)","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection;Suspension for injection in pre-filled syringe","condition_indication":"Prevention of infectious diseases caused by Corynebacterium diphtheriae / Clostridium tetani / Bordetella pertussis / Poliovirus types 1, 2 and 3","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"07/03/2015","compliance_outcome":"Positive","compliance_opinion_date":"27/05/2016","compliance_procedure_number":"EMEA-C-000500-PIP01-08-M03","contact_for_public_enquiries":"GSK Vaccines S.r.l.; Tel. +1 438 899 8201; Email: eu.paediatric-plans@gsk.com","first_published_date":"30/10/2010","last_updated_date":"25/03/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000500-pip01-08-m03"},{"decision_number":"P/0050/2015","pip_number":"EMEA-001702-PIP01-14","active_substance":"perindopril;amlodipine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/03/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Adamed Sp. z o.o.; Tel. +48227327736; E-mail: joanna.pawlak@adamed.com.pl","first_published_date":"24/03/2015","last_updated_date":"24/03/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001702-pip01-14"},{"decision_number":"P/0054/2015","pip_number":"EMEA-001568-PIP03-14","active_substance":"ceftriaxone;sulbactam","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for solution for injection or infusion","condition_indication":"Treatment of bacterial infections","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/03/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Venus Pharma GmbH; India; E-mail: katja.petrovic@rega.si; Tel. +91 1795 302017, +91 1795 302018; Fax +91 1795 271272","first_published_date":"24/03/2015","last_updated_date":"24/03/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001568-pip03-14"},{"decision_number":"P/0045/2015","pip_number":"EMEA-001483-PIP01-13","active_substance":"(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) phosphorodiamidate [TH-302]","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Ewing sarcoma;Treatment of soft tissue sarcoma","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/03/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck KGaA; Germany; Tel. +49 6151 725200; Fax +49 6151 722000; E-mail: service@merck.de","first_published_date":"23/03/2015","last_updated_date":"23/03/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001483-pip01-13"},{"decision_number":"P/0008/2015","pip_number":"EMEA-000234-PIP02-14","active_substance":"human papillomavirus type 18 L1 protein;human papillomavirus type 16 L1 protein","invented_name":"Cervarix; Cervarix","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of infection by human papillomavirus","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/01/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Biologicals S.A. (Belgium); Tel. +1 438 899 8201; Email: eu.paediatric-plans@gsk.com","first_published_date":"05/03/2015","last_updated_date":"10/03/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000234-pip02-14"},{"decision_number":"P/0026/2015","pip_number":"EMEA-001633-PIP01-14","active_substance":"Candesartan cilexetil;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/01/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Krka, d.d., Novo mesto; Slovenia; E-mail: tomaz.kralj@krka.biz; Tel. +386 73312055; Fax +386 73322742 ","first_published_date":"05/03/2015","last_updated_date":"10/03/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001633-pip01-14"},{"decision_number":"P/0322/2014","pip_number":"EMEA-001677-PIP01-14","active_substance":"saxagliptin;dapagliflozin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/12/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB ; Sweden ; E-mail: paediatrics@astrazeneca.com ; Tel. +46 8 5532 7709","first_published_date":"23/02/2015","last_updated_date":"10/03/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001677-pip01-14"},{"decision_number":"P/0028/2015","pip_number":"EMEA-001669-PIP01-14","active_substance":"amlodipine;perindopril erbumine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension;Treatment of stable coronary artery disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/01/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Actavis Group PTC ehf; Iceland; Tel. +354 5503482; E-mail: hrefna.haraldsdottir@actavis.com","first_published_date":"05/03/2015","last_updated_date":"10/03/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001669-pip01-14"},{"decision_number":"P/0019/2015","pip_number":"EMEA-001226-PIP01-11-M01","active_substance":"surotomycin","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of clostridia infections","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/01/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cubist (UK) Ltd; United Kingdom; E-mail: deepak.jain@cubist.com; Tel. +1 7818601244","first_published_date":"31/05/2013","last_updated_date":"05/03/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001226-pip01-11-m01"},{"decision_number":"P/0005/2015","pip_number":"EMEA-000035-PIP02-09-M02","active_substance":"tiotropium bromide (monohydrate)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Inhalation solution;Inhalation powder;Capsule, hard","condition_indication":"Treatment of asthma","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/01/2015","compliance_outcome":"Positive","compliance_opinion_date":"27/05/2016","compliance_procedure_number":"EMEA-C-000035-PIP02-09-M02","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"23/04/2013","last_updated_date":"05/03/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000035-pip02-09-m02"},{"decision_number":"P/0029/2015","pip_number":"EMEA-001674-PIP01-14","active_substance":"lutetium (177Lu) chloride","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Radiopharmaceutical precursor;Solution","condition_indication":"Radiolabelling agent","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/01/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ITG Isotope Technologies Garching GmbH; Germany; E-mail: regulatory@brinkerpharma.de; Tel. +49 308100980","first_published_date":"05/03/2015","last_updated_date":"05/03/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001674-pip01-14"},{"decision_number":"P/0004/2015","pip_number":"EMEA-000019-PIP11-14","active_substance":"everolimus","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet;Dispersible tablet","condition_indication":"Treatment of thoracic neuroendocrine tumour","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/01/2015","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm Ltd; United Kingdom; E-mail: paediatric.enquiries@novartis.com; Tel. +41 613241111; Fax +41 613248001;  ","first_published_date":"05/03/2015","last_updated_date":"05/03/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000019-pip11-14"},{"decision_number":"P/0324/2014","pip_number":"EMEA-001689-PIP01-14","active_substance":"zoledronic acid monohydrate","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Prevention of skeletal related events in patients with advanced malignancies involving bone","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/12/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gedeon Richter Plc. ; Hungary ; E-mail: mrpRichter@richter.hu ; Tel. +36 14314040 ; Fax +36 14315415","first_published_date":"23/02/2015","last_updated_date":"23/02/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001689-pip01-14"},{"decision_number":"P/0339/2014","pip_number":"EMEA-001630-PIP01-14","active_substance":"ibandronic acid","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Solution for injection","condition_indication":"Combination treatment of osteoporosis","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/12/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gedeon Richter Plc. ; Hungary ; E-mail: mrpRichter@richter.hu ; Tel. +36 14314040 ; Fax +36 14315415","first_published_date":"23/02/2015","last_updated_date":"23/02/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001630-pip01-14"},{"decision_number":"P/0341/2014","pip_number":"EMEA-001670-PIP01-14","active_substance":"cholecalciferol;calcium carbonate","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Combination treatment of osteoporosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/12/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gedeon Richter Plc. ; Hungary ; E-mail: mrpRichter@richter.hu ; Tel. +36 14314040 ; Fax +36 14315415","first_published_date":"23/02/2015","last_updated_date":"23/02/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001670-pip01-14"},{"decision_number":"P/0343/2014","pip_number":"EMEA-001591-PIP01-14","active_substance":"glycopyrronium bromide","invented_name":"","therapeutic_area":"Oto-rhino-laryngology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of sialorrhoea","routes_of_administration":"Oral use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"22/12/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Desitin Arzneimittel GmbH ; Germany ; E-mail: info@desitin.de ; Tel. +49 4059101525","first_published_date":"23/02/2015","last_updated_date":"23/02/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001591-pip01-14"},{"decision_number":"P/0321/2014","pip_number":"EMEA-001655-PIP01-14","active_substance":"urofollitropin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"","condition_indication":"Treatment of female infertility;Treatment of hypogonadotrophic hypogonadism","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/12/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Regiomedica GmbH ; Germany ; E-mail: info@regiomedica.de ; Tel. +49 7621166444","first_published_date":"23/02/2015","last_updated_date":"23/02/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001655-pip01-14"},{"decision_number":"P/0323/2014","pip_number":"EMEA-001685-PIP01-14","active_substance":"amlodipine;ramipril","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/12/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Helm Portugal, LDA. ; Portugal ; E-mail: i.botelheiro@helmportugal.com ; Tel. +35 1219948300 ; Fax +35 1219552475","first_published_date":"23/02/2015","last_updated_date":"23/02/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001685-pip01-14"},{"decision_number":"P/0325/2014","pip_number":"EMEA-001690-PIP01-14","active_substance":"calcium carbonate;cholecalciferol","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of skeletal related events in patients with advanced malignancies involving bone","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/12/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gedeon Richter Plc. ; Hungary ; E-mail: mrpRichter@richter.hu ; Tel. +36 14314040 ; Fax +36 14315415","first_published_date":"23/02/2015","last_updated_date":"23/02/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001690-pip01-14"},{"decision_number":"P/0315/2014","pip_number":"EMEA-001680-PIP01-14","active_substance":"valsartan;amlodipine besilate","invented_name":"Exforge","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet;Orodispersible tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"05/12/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"22/01/2015","last_updated_date":"17/02/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001680-pip01-14"},{"decision_number":"P/0307/2014","pip_number":"EMEA-001667-PIP01-14","active_substance":"abaloparatide","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection;Transdermal system","condition_indication":"Treatment of osteoporosis","routes_of_administration":"Subcutaneous use;Transdermal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/11/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Triskel EU Services, Ltd (Jean-Yves le Cotonnec) ; United Kingdom ; E-mail: gwilliams@radiuspharm.com ; Tel. +1 6175514700","first_published_date":"12/12/2014","last_updated_date":"17/02/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001667-pip01-14"},{"decision_number":"P/0207/2014","pip_number":"EMEA-001548-PIP01-13","active_substance":"valaciclovir (hydrochloride)","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for oral suspension","condition_indication":"Treatment and prevention of Herpes simplex virus disease;Treatment and prevention of Varicella Zoster virus disease","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/08/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pharmathen S.A. ; Greece ; E-mail: mkalovidouri@pharmathen.com ; Tel. +30 2106604354","first_published_date":"22/08/2014","last_updated_date":"17/02/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001548-pip01-13"},{"decision_number":"P/253/2011","pip_number":"EMEA-000150-PIP02-10","active_substance":"(1R, 4S, 5S, 6S)-4-[[(2s)-2-amino-4-(methylthio)-1-oxobutyl]amino]-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid,2,2-dioxide, monohydrate (LY2140023)","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Coated tablet","condition_indication":"Treatment of schizophrenia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/10/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"29/11/2011","last_updated_date":"16/02/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000150-pip02-10"},{"decision_number":"P/271/2010","pip_number":"EMEA-000888-PIP01-10","active_substance":"Betula alba;Betula pendula;Betula verrucosa","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal solution","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergopharma Joachim Ganzer KG; Germany; E-mail: info@allergopharma.de; Tel. +49 40727650; Fax +49 407227713","first_published_date":"10/01/2011","last_updated_date":"16/02/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000888-pip01-10"},{"decision_number":"P/207/2011","pip_number":"EMEA-000878-PIP02-11","active_substance":"colestilan","invented_name":"BindRen; BindRen","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Granules;Film-coated tablet","condition_indication":"Treatment of hyperphosphataemia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/09/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mitsubishi Pharma Europe Ltd ; United Kingdom; E-mail: jvlek@m-pharma.co.uk; +44 (0)20 7065 5000; +44 (0)20 7065 5050","first_published_date":"18/10/2011","last_updated_date":"29/01/2015","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000878-pip02-11"},{"decision_number":"P/0311/2014","pip_number":"EMEA-001558-PIP02-14","active_substance":"thiocolchicoside;diclofenac (sodium)","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Cutaneous patch","condition_indication":"Treatment of musculoskeletal and connective tissue pain","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"25/11/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Epifarma Srl ; Italy ; E-mail: b.trupa@epifarma.it ; Tel. +39 0973 655200 ; Fax +39 0973 655318","first_published_date":"12/12/2014","last_updated_date":"12/12/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001558-pip02-14"},{"decision_number":"P/0313/2014","pip_number":"EMEA-001559-PIP01-13","active_substance":"Pandemic live attenuated influenza virus (H5N1)","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Nasal spray;Suspension","condition_indication":"Prevention of influenza infection","routes_of_administration":"Nasal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/11/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"MedImmune Limited ; United Kingdom ; E-mail: paediatrics@medimmune.com ; Tel. +44 (0)1223 471471","first_published_date":"12/12/2014","last_updated_date":"12/12/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001559-pip01-13"},{"decision_number":"P/0309/2014","pip_number":"EMEA-001672-PIP01-14","active_substance":"varicella-zoster virus (live, attenuated)","invented_name":"Copalia; Zostavax","therapeutic_area":"Vaccines","pharmaceutical_forms":"Powder and solvent for suspension for injection","condition_indication":"","routes_of_administration":"Subcutaneous use;Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/11/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi Pasteur MSD SNC ; France ; E-mail: cbesnard@spmsd.com ; Tel. +33 437284723 ; Fax +1 2673056450 / +1 7325944950","first_published_date":"12/12/2014","last_updated_date":"12/12/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001672-pip01-14"},{"decision_number":"P/0308/2014","pip_number":"EMEA-001668-PIP01-14","active_substance":"Macrogol 3350","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Oral powder","condition_indication":"Treatment of constipation","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/11/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mayoly Spindler ; France ; E-mail: beatrice.raffaillac@mayoly-spindler.fr ; Tel. +1 34805536","first_published_date":"12/12/2014","last_updated_date":"12/12/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001668-pip01-14"},{"decision_number":"P/0306/2014","pip_number":"EMEA-001651-PIP01-14","active_substance":"purified adenylate cyclase recombinant protein carrying subfragments of the early protein E7 antigen from human papillomavirus strain 16 (recombinant CyaA-HPV16E7);purified adenylate cyclase recombinant protein carrying subfragments of the early protein E7 antigen from human papillomavirus strain 18 (recombinant CyaA-HPV18E7)","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of Human Papilloma Virus (HPV) 16 and/or 18 infection","routes_of_administration":"Intradermal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/11/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Genticel S.A. ; France ; E-mail: solivier@genticel.com; Tel. +33 638682337 ; Fax +33 561287069","first_published_date":"12/12/2014","last_updated_date":"12/12/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001651-pip01-14"},{"decision_number":"P/0294/2014","pip_number":"EMEA-001099-PIP02-11-M01","active_substance":"MAGE-A3 recombinant protein","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of melanoma","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/10/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Biologicals S.A. (Belgium); Tel. +1 438 899 8201; Email: eu.paediatric-plans@gsk.com","first_published_date":"23/08/2012","last_updated_date":"09/12/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001099-pip02-11-m01"},{"decision_number":"P/0293/2014","pip_number":"EMEA-000917-PIP01-10-M04","active_substance":"bimatoprost","invented_name":"Lumigan; Lumigan and associated names","therapeutic_area":"Dermatology","pharmaceutical_forms":"Eye drops, solution;Cutaneous solution;Ophthalmic insert","condition_indication":"Treatment of glaucoma;Treatment of non-scarring hair loss","routes_of_administration":"Ocular use;Cutaneous use;Intraocular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/10/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergan Pharmaceuticals International Limited; E-mail: ml-eu_reg_affairs@allergan.com; Tel. +44 (0)1628 4944444","first_published_date":"08/04/2011","last_updated_date":"09/12/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000917-pip01-10-m04"},{"decision_number":"P/0292/2014","pip_number":"EMEA-000120-PIP01-07-M05","active_substance":"tigecycline","invented_name":"Tygacil; Tygacil","therapeutic_area":"Other","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of complicated intra-abdominal infections;Treatment of complicated skin and soft-tissue infections","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"24/10/2014","compliance_outcome":"Positive","compliance_opinion_date":"12/12/2014","compliance_procedure_number":"EMEA-C-000120-PIP01-07-M05","contact_for_public_enquiries":"Pfizer Limited; Tel. + 44 1304646607; E-mail: pip_enquiries@pfizer.com","first_published_date":"07/07/2009","last_updated_date":"05/12/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000120-pip01-07-m05"},{"decision_number":"P/0271/2014","pip_number":"EMEA-001397-PIP02-13","active_substance":"Ibrutinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of lymphoplasmacytic lymphoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/10/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International N.V.; E-mail: sglawe@its.jnj.com; Tel. +49 2638 9479218","first_published_date":"04/12/2014","last_updated_date":"04/12/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001397-pip02-13"},{"decision_number":"P/0213/2014","pip_number":"EMEA-001497-PIP01-13","active_substance":"perindopril;bisoprolol","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of heart failure;Treatment of hypertension;Treatment of ischaemic coronary artery disorders","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/09/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierE-mail: mail.pip.enquiries@servier.comTel.: +33 155726000","first_published_date":"30/09/2014","last_updated_date":"14/11/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001497-pip01-13"},{"decision_number":"P/0233/2014","pip_number":"EMEA-001628-PIP01-14","active_substance":"antisense oligonucleotide (30-mer) with nucleotide sequence 5′-GTAATTGCGGCAAGAAGAATTGTTTCTGTC-3′(CODA001)","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Gel","condition_indication":"Treatment of venous leg ulcer","routes_of_administration":"Epilesional use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"05/09/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CoDa Therapeutics Inc ; USA ; E-mail: tracey@codanz.com ; Tel. +64 93760421 ; Fax +64 93760510","first_published_date":"30/09/2014","last_updated_date":"14/11/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001628-pip01-14"},{"decision_number":"P/0222/2014","pip_number":"EMEA-001573-PIP01-13","active_substance":"(R)-2-[3-({Benzoxazol-2-yl[3-(4-methoxyphenoxy)propyl]amino}methyl)phenoxy]butanoic acid","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Reduction of residual cardiovascular events in patients with diabetes","routes_of_administration":"Oral use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"03/09/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kowa Research Europe Ltd ; United Kingdom ; E-mail: regulatory@kowa.co.uk ; Tel. +44 (0)1189 229 000","first_published_date":"30/09/2014","last_updated_date":"14/11/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001573-pip01-13"},{"decision_number":"P/0232/2014","pip_number":"EMEA-001595-PIP01-13","active_substance":"bromfenac sodium sesquihydrate","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution;Solution","condition_indication":"Prevention of postoperative pain and inflammation associated with cataract surgery;Treatment of postoperative pain and inflammation associated with cataract surgery","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"05/09/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"InSite Vision Incorporated ; USA ; E-mail: khosseini@insite.com; Tel. +510 7471264 ; Fax +510 8655700","first_published_date":"30/09/2014","last_updated_date":"14/11/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001595-pip01-13"},{"decision_number":"P/0211/2014","pip_number":"EMEA-001632-PIP01-14","active_substance":"rosuvastatin;valsartan","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Prevention of cardiovascular events;Treatment of hypertension;Treatment of dyslipidaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/08/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Krka, d.d., Novo mesto ; Slovenia ; E-mail: helen.lukin@krka.biz ; Tel. +385 99 3110 291 ; Fax +385 1 6312 153","first_published_date":"30/09/2014","last_updated_date":"14/11/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001632-pip01-14"},{"decision_number":"P/0255/2014","pip_number":"EMEA-001599-PIP01-13","active_substance":"Ibuprofen (sodium dihydrate)","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of febrile disorders;Treatment of pain","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"30/09/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Proveca LimitedTel. +44 7913048665E-mail: simon@proveca.co.uk","first_published_date":"05/11/2014","last_updated_date":"05/11/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001599-pip01-13"},{"decision_number":"P/0240/2014","pip_number":"EMEA-001366-PIP01-12-M02","active_substance":"glycopyrronium bromide","invented_name":"Sialanar","therapeutic_area":"Neurology","pharmaceutical_forms":"Oral liquid","condition_indication":"Treatment of sialorrhoea","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"26/09/2014","compliance_outcome":"Positive","compliance_opinion_date":"14/11/2014","compliance_procedure_number":"EMEA-C-001366-PIP01-12-M02","contact_for_public_enquiries":"Proveca LimitedTel. +44 7913048665E-mail: simon@proveca.co.uk","first_published_date":"13/08/2013","last_updated_date":"09/10/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001366-pip01-12-m02"},{"decision_number":"P/0221/2014","pip_number":"EMEA-001530-PIP01-13","active_substance":"4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide (JNJ-54781532-AAD)","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral dosage formulation","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondyloarthritis, psoriatic arthritis and juvenile idiopathic arthritis)","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/09/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen Cilag International NV (Belgium); Belgium ; E-mail: ldobell@its.jnj.com ; Tel. +44 (0)1494 567 567 ; Fax +44 (0)1494 658 084","first_published_date":"30/09/2014","last_updated_date":"30/09/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001530-pip01-13"},{"decision_number":"P/0226/2014","pip_number":"EMEA-000265-PIP01-08-M04","active_substance":"golimumab","invented_name":"Simponi; Simponi","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection;Solution for infusion","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondylarthritis and juvenile idiopathic arthritis)","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/09/2014","compliance_outcome":"Positive","compliance_opinion_date":"10/10/2014","compliance_procedure_number":"EMEA-C-000265-PIP01-08-M04","contact_for_public_enquiries":"Janssen Biologics B.V.; The Netherlands; E-mail: info@janssen.immunology.com; Tel +31 202015009; Fax: +31 713065100","first_published_date":"03/10/2011","last_updated_date":"29/09/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000265-pip01-08-m04"},{"decision_number":"P/0219/2014","pip_number":"EMEA-001241-PIP02-13-M01","active_substance":"Enalapril (maleate)","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of heart failure","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/09/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Proveca LimitedTel. +44 7913048665E-mail: simon@proveca.co.uk","first_published_date":"16/04/2014","last_updated_date":"29/09/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001241-pip02-13-m01"},{"decision_number":"P/0208/2014","pip_number":"EMEA-001594-PIP02-13","active_substance":"tirasemtiv","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of amyotrophic lateral sclerosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/08/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"NDA Group; United States ; E-mail: medicalaffairs@cytokinetics.com; Tel. +1  650 6243000","first_published_date":"22/08/2014","last_updated_date":"22/08/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001594-pip02-13"},{"decision_number":"P/0201/2014","pip_number":"EMEA-001269-PIP02-14","active_substance":"rosuvastatin;acetylsalicylic acid","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of cardiovascular disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/08/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"EGIS Pharmaceuticals PLC ; Tel. +36 18032414; E-mail: registry@registry.hu","first_published_date":"22/08/2014","last_updated_date":"22/08/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001269-pip02-14"},{"decision_number":"P/0193/2014","pip_number":"EMEA-001621-PIP01-14","active_substance":"Pacritinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of post-essential thrombocythaemia myelofibrosis;Treatment of post-polycythaemia vera myelofibrosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/08/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CTI Life Sciences Ltd ; Italy ; E-mail: jbianco@ctiseattle.com ; Tel. +1 2062845774 ; Fax +1 2062846114","first_published_date":"22/08/2014","last_updated_date":"22/08/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001621-pip01-14"},{"decision_number":"P/0200/2014","pip_number":"EMEA-001183-PIP02-13","active_substance":"Human recombinant follicle-stimulating hormone (FE 999049)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Concentrate for solution for injection","condition_indication":"Treatment of female infertility;Treatment of hypogonadotrophic hypogonadism","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/08/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ferring Pharmaceuticals A/S ; Denmark ; E-mail: dk0-disclosure@ferring.com ; Tel. +45 88338834","first_published_date":"22/08/2014","last_updated_date":"22/08/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001183-pip02-13"},{"decision_number":"P/0190/2014","pip_number":"EMEA-001289-PIP01-12-M01","active_substance":"autologous CD34+ cells transduced ex-vivo with retroviral vector (GIADAl) containing human adenosine deaminase gene from cDNA","invented_name":"Strimvelis","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Cell suspension for infusion","condition_indication":"Treatment of severe combined immunodeficiency due to adenosine deaminase deficiency","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/08/2014","compliance_outcome":"Positive","compliance_opinion_date":"14/11/2014","compliance_procedure_number":"EMEA-C-001289-PIP01-12-M01","contact_for_public_enquiries":"Orchard Therapeutics (Netherlands) B.V.; regulatory@orchard-tx.com; Tel. +44 (0) 20 3808 8286","first_published_date":"03/05/2013","last_updated_date":"22/08/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001289-pip01-12-m01"},{"decision_number":"P/0202/2014","pip_number":"EMEA-001292-PIP01-12-M01","active_substance":"mifepristone","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypercortisolism (Cushing's syndrome) of endogenous origin","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/08/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Corcept Therapeutics Incorporated; United States; E-mail: srinne@corcept.com ; Tel. +1 6506888784; Fax +1 6503273218","first_published_date":"09/08/2013","last_updated_date":"22/08/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001292-pip01-12-m01"},{"decision_number":"P/0184/2014","pip_number":"EMEA-000184-PIP02-14","active_substance":"tobramycin","invented_name":"Tobi","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Nebuliser solution","condition_indication":"Treatment of Pseudomonas aeruginosa pulmonary infection / colonisation in patients with cystic fibrosis","routes_of_administration":"Inhalation use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/08/2014","compliance_outcome":"Positive","compliance_opinion_date":"29/04/2016","compliance_procedure_number":"EMEA-C-000184-PIP02-14","contact_for_public_enquiries":"Mylan IRE Healthcare Limited; E-mail: info.uk@viatris.com; Tel. + 44 (0)1707853000","first_published_date":"22/08/2014","last_updated_date":"22/08/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000184-pip02-14"},{"decision_number":"EMA/PE/0000221485","pip_number":"EMA/PE/0000221485","active_substance":"cangrelor (tetrasodium)","invented_name":"Kengrexal","therapeutic_area":"Surgical and medical procedures","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Prevention of non-site-specific embolism and thrombosis","routes_of_administration":"Intravenous use","decision_type":"RPM: decision refers to a refusal on the application for modification of an agreed PIP","decision_date":"06/12/2024","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Chiesi Farmaceutici S.p.A.; Tel. +39 0521 2791; E-mail: info@chiesi.com","first_published_date":"07/10/2013","last_updated_date":"22/08/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000221485"},{"decision_number":"P/0185/2014","pip_number":"EMEA-000527-PIP03-13","active_substance":"ranibizumab","invented_name":"Lucentis","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of choroidal neovascularisation;Treatment of macular oedema","routes_of_administration":"Intravitreal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/08/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"22/08/2014","last_updated_date":"22/08/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000527-pip03-13"},{"decision_number":"P/67/2008","pip_number":"EMEA-000019-PIP03-08","active_substance":"everolimus","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Carcinoid tumours","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/08/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"18/09/2008","last_updated_date":"22/08/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000019-pip03-08"},{"decision_number":"P/0167/2014","pip_number":"EMEA-000981-PIP01-10-M04","active_substance":"Ozenoxacin","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Cream","condition_indication":"Treatment of impetigo","routes_of_administration":"Cutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/07/2014","compliance_outcome":"Positive","compliance_opinion_date":"29/01/2016","compliance_procedure_number":"EMEA-C-000981-PIP01-10-M04","contact_for_public_enquiries":"Ferrer Internacional S.A; Spain; E-mail: silviamartin@ferrergrupo.com, ccasadoc@ferrergrupo.com; Tel. +34 9350 93227, +34 935093289; Fax +34 9350 93270","first_published_date":"17/10/2011","last_updated_date":"05/08/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000981-pip01-10-m04"},{"decision_number":"P/0172/2014","pip_number":"EMEA-000412-PIP01-08-M01","active_substance":"Insulin detemir","invented_name":"Levemir; Levemir","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of type II diabetes mellitus;Treatment of type I diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/07/2014","compliance_outcome":"Positive","compliance_opinion_date":"14/11/2014","compliance_procedure_number":"EMEA-000412-PIP01-08-M01","contact_for_public_enquiries":"Novo Nordisk A/S; Denmark; E-mail: drej@novonordisk.com; Tel. +45 30758086; Fax +45 44436740","first_published_date":"10/01/2011","last_updated_date":"05/08/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000412-pip01-08-m01"},{"decision_number":"P/0177/2014","pip_number":"EMEA-000184-PIP01-08-M02","active_substance":"tobramycin","invented_name":"Tobi Podhaler; Tobi Podhaler","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Inhalation powder;Capsule, hard","condition_indication":"Treatment of Pseudomonas aeruginosa pulmonary infection / colonisation in patients with cystic fibrosis","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"08/07/2014","compliance_outcome":"Positive","compliance_opinion_date":"12/09/2014","compliance_procedure_number":"EMEA-C-000184-PIP01-08-M02","contact_for_public_enquiries":"Mylan IRE Healthcare Limited; E-mail: info.uk@viatris.com; Tel. + 44 (0)1707853000","first_published_date":"18/05/2009","last_updated_date":"05/08/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000184-pip01-08-m02"},{"decision_number":"P/0164/2014","pip_number":"EMEA-001329-PIP02-13","active_substance":"expanded autologous bone marrow-derived osteoblastic cells","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of non-traumatic osteonecrosis","routes_of_administration":"Intraosseous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"25/06/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bone Therapeutics S.A.; Belgium; E-mail: preob.pip@bonetherapeutics.com; Tel. + 32 25295990; Fax +32 25295993","first_published_date":"31/07/2014","last_updated_date":"31/07/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001329-pip02-13"},{"decision_number":"P/0165/2014","pip_number":"EMEA-000236-PIP04-14","active_substance":"aflibercept","invented_name":"Eylea; Eylea","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of choroidal neovascularisation secondary to pathologic myopia;Treatment of branch retinal vein occlusion","routes_of_administration":"Solution for injection","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/06/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer Pharma AG; Tel. +49 3046 815333; E-mail: pediatrics.medical-affairs-europe@bayer.com","first_published_date":"31/07/2014","last_updated_date":"31/07/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000236-pip04-14"},{"decision_number":"P/0155/2014","pip_number":"EMEA-001541-PIP01-13","active_substance":"Freeze-dried culture of Lactobacillus casei subspecies rhamnosus Döderleini (Lcr35)","invented_name":"","therapeutic_area":"","pharmaceutical_forms":"Vaginal capsule;Capsule, hard","condition_indication":"Prevention of bacterial vaginosis;Prevention of vulvo-vaginal candidiasis","routes_of_administration":"Vaginal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/06/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Probionov; France; E-mail: ml.bouyge@probionov.com; Tel. +33 4714 65462; Fax +33 4716 35398","first_published_date":"22/07/2014","last_updated_date":"22/07/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001541-pip01-13"},{"decision_number":"P/0156/2014","pip_number":"EMEA-001574-PIP01-13","active_substance":"amoxicillin","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Orodispersible tablet;Film-coated tablet;Gastro-resistant tablet;Tablet","condition_indication":"Treatment of Helicobacter spp. infections","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/06/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mayoly-Spindler; France; E-mail: beatrice.raffaillac@mayoly-spindler.fr; Tel. +013 4805536","first_published_date":"22/07/2014","last_updated_date":"22/07/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001574-pip01-13"},{"decision_number":"P/0152/2014","pip_number":"EMEA-001576-PIP01-13","active_substance":"(11beta,17beta)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of leiomyoma of uterus;Treatment of endometriosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/06/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer Pharma AG; Germany; E-mail: pediatrics-medical-affairs-europe@bayerhealthcare.com; Tel. +49 30468 15333; Fax +49 30468 95333","first_published_date":"22/07/2014","last_updated_date":"22/07/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001576-pip01-13"},{"decision_number":"P/0153/2014","pip_number":"EMEA-001597-PIP01-13","active_substance":"lesinurad","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Tablet","condition_indication":"Prevention of hyperuricaemia;Treatment of hyperuricaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/06/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB - Astrazeneca European Regulatory Affairs; Sweden; E-mail: solange.rohou@astrazeneca.com; Tel. +33 609050197; Fax +46 855326904","first_published_date":"22/07/2014","last_updated_date":"22/07/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001597-pip01-13"},{"decision_number":"P/0154/2014","pip_number":"EMEA-001607-PIP01-13","active_substance":"amlodipine besilate;ramipril","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"13/06/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pharmaceutical Works Polpharma SA; Poland; E-mail: michal.dembowski@polpharma.com; Tel. +48 2236 46321","first_published_date":"22/07/2014","last_updated_date":"22/07/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001607-pip01-13"},{"decision_number":"P/0140/2014","pip_number":"EMEA-001608-PIP01-13","active_substance":"Doxylamine (succinate);pyridoxine (hydrochloride)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Gastro-resistant tablet","condition_indication":"Treatment of nausea and vomiting in pregnancy","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/06/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Duchesnay Inc.; Canada; E-mail: bmartin@regintel.com; Tel. +353 429376740; Fax +353 429397677","first_published_date":"22/07/2014","last_updated_date":"22/07/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001608-pip01-13"},{"decision_number":"P/0157/2014","pip_number":"EMEA-001614-PIP01-13","active_substance":"clarithromycin","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Orodispersible tablet;Film-coated tablet;Gastro-resistant tablet;Tablet","condition_indication":"Treatment of Helicobacter spp. infections","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/06/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mayoly-Spindler; France; E-mail: beatrice.raffaillac@mayoly-spindler.fr; Tel. +013 4805536","first_published_date":"22/07/2014","last_updated_date":"22/07/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001614-pip01-13"},{"decision_number":"P/0158/2014","pip_number":"EMEA-001615-PIP01-13","active_substance":"Metronidazole","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Orodispersible tablet;Film-coated tablet;Gastro-resistant tablet;Tablet","condition_indication":"Treatment of Helicobacter spp. infections","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/06/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mayoly-Spindler; France; E-mail: beatrice.raffaillac@mayoly-spindler.fr; Tel. +013 4805536","first_published_date":"22/07/2014","last_updated_date":"22/07/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001615-pip01-13"},{"decision_number":"P/0159/2014","pip_number":"EMEA-001616-PIP01-13","active_substance":"pantoprazole","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Orodispersible tablet;Film-coated tablet;Gastro-resistant tablet;Tablet","condition_indication":"Treatment of Helicobacter spp. infections","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/06/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mayoly-Spindler; France; E-mail: beatrice.raffaillac@mayoly-spindler.fr; Tel. +013 4805536","first_published_date":"22/07/2014","last_updated_date":"22/07/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001616-pip01-13"},{"decision_number":"P/0150/2014","pip_number":"EMEA-001504-PIP01-13","active_substance":"5-(4,6-Dimethyl-1H-benzimidazol-2-yl)-4-methyl-N-[3-(1-methyl-4-piperidinyl)propyl]-2-pyrimidinamine 2,3-dihydroxybutanedioate hydrate (1:0.5:4) (JNJ-38518168)","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Coated tablet;Age appropriate dosage form, other","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis)","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/06/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen Cilag International NV (Belgium); Belgium; E-mail: ldobell@its.jnj.com; Tel. + 44 (0)1494 567567; Fax +44 (0)1494 658084","first_published_date":"18/07/2014","last_updated_date":"18/07/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001504-pip01-13"},{"decision_number":"P/0149/2014","pip_number":"EMEA-001502-PIP01-13","active_substance":"adeno-associated viral vector serotype 9 containing human sulfamidase gene","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)","routes_of_administration":"Intracerebroventricular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/06/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Laboratorios Dr. Esteve S.A; Spain; E-mail: evalenti@esteve.es; Tel. +34 934466000; Fax +34 934504899","first_published_date":"18/07/2014","last_updated_date":"18/07/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001502-pip01-13"},{"decision_number":"P/0134/2014","pip_number":"EMEA-001365-PIP01-12","active_substance":"anamorelin hydrochloride","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Tablet;Oral liquid","condition_indication":"Treatment of cancer related cachexia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/06/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Helsinn Therapeutics (U.S.) Inc.; United States; E-mail: jfriend@helsinnthera.com; Tel. +1 9082036545; Fax +1 9082311459","first_published_date":"18/07/2014","last_updated_date":"18/07/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001365-pip01-12"},{"decision_number":"P/0136/2014","pip_number":"EMEA-000457-PIP02-10-M02","active_substance":"fibrinogen (human plasma-derived)","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for infusion","condition_indication":"Treatment of congenital fibrinogen deficiency","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/06/2014","compliance_outcome":"Positive","compliance_opinion_date":"16/12/2016","compliance_procedure_number":"EMEA-C-000457-PIP02-10-M02","contact_for_public_enquiries":"LFB Biotechnologies; France; E-mail: brossela@lfb.fr; Tel. +33 169821786; Fax +33 169827182","first_published_date":"10/05/2011","last_updated_date":"15/07/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000457-pip02-10-m02"},{"decision_number":"P/0129/2014","pip_number":"EMEA-000456-PIP01-08-M02","active_substance":"insulin degludec","invented_name":"Tresiba; Tresiba","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of type I diabetes mellitus;Treatment of type II diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"20/05/2014","compliance_outcome":"Positive","compliance_opinion_date":"23/05/2014","compliance_procedure_number":"EMEA-C-000456-PIP01-08-M02","contact_for_public_enquiries":"Novo Nordisk A/S; Denmark; E-mail: jamp@novonordisk.com; Tel. +45 3075 3759; Fax +45 3969 9173","first_published_date":"18/05/2010","last_updated_date":"25/06/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000456-pip01-08-m02"},{"decision_number":"P/0125/2014","pip_number":"EMEA-000339-PIP02-09-M03","active_substance":"Entecavir","invented_name":"Baraclude; Baraclude","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Oral solution","condition_indication":"Treatment of chronic hepatitis B","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"16/05/2014","compliance_outcome":"Positive","compliance_opinion_date":"20/06/2014","compliance_procedure_number":"EMEA-C-000339-PIP02-09-M03","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG; United Kingdom; E-mail: medinfo.emea@bms.com; Tel. +44 (0)189 552 3686; ax +44 (0)189 552 3788","first_published_date":"24/01/2011","last_updated_date":"25/06/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000339-pip02-09-m03"},{"decision_number":"P/236/2011","pip_number":"EMEA-000328-PIP02-09","active_substance":"vatreptacog alfa (activated)","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of hereditary factor VIII and IX deficiency","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"30/09/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; E-mail: paediatrics@novonordisk.com ; Tel.: +45 44448888","first_published_date":"18/10/2011","last_updated_date":"13/06/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000328-pip02-09"},{"decision_number":"P/0107/2013","pip_number":"EMEA-001003-PIP01-10-M02","active_substance":"(3aR,4S,7aR)-octahydro-4-hydroxy-4-[(3-methylphenyl)ethynyl]-1H-indole-1-carboxylic acid methyl ester","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Capsule, hard;Powder for oral suspension","condition_indication":"Treatment of fragile-X syndrome","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/04/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm Ltd; United Kingdom; E-mail: paediatric.enquiries@novartis.com; Tel. +41 613241111; Fax +41 613248001;  ","first_published_date":"15/07/2011","last_updated_date":"13/06/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001003-pip01-10-m02"},{"decision_number":"P/0105/2014","pip_number":"EMEA-000019-PIP06-09-M05","active_substance":"everolimus","invented_name":"Afinitor; Certican; Afinitor and associated names","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Tablet;Dispersible tablet","condition_indication":"Prevention of rejection of transplanted liver;Prevention of rejection of transplanted heart;Prevention of rejection of transplanted kidney","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/05/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 6132 46715","first_published_date":"07/06/2011","last_updated_date":"11/06/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000019-pip06-09-m05"},{"decision_number":"P/0121/2014","pip_number":"EMEA-001578-PIP01-13","active_substance":"amlodipine;rosuvastatin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events;Treatment of ischemic coronary artery disorders;Treatment of hypertension;Treatment of dyslipidaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/05/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Krka, d.d., Novo mesto; E-mail: dragan.priselac@krka.biz; Tel. +386 7331 9037","first_published_date":"06/06/2014","last_updated_date":"06/06/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001578-pip01-13"},{"decision_number":"P/0104/2014","pip_number":"EMEA-001575-PIP01-13","active_substance":"anastrozole;levonorgestrel","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Vaginal delivery system","condition_indication":"Treatment of endometriosis","routes_of_administration":"Vaginal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/05/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer Pharma AG; Germany; E-mail: pediatrics-medical-affairs-europe@bayerhealthcare.com; Tel. +49 30468 15333; Fax +49 30468 95333","first_published_date":"06/06/2014","last_updated_date":"06/06/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001575-pip01-13"},{"decision_number":"P/0103/2014","pip_number":"EMEA-001571-PIP01-13","active_substance":"N-{2-(2,3-Difluorobenzylthio)-6-[(2R,3S)-3,4-dihydroxybut-2-yloxy]pyrimidin-4-yl}azetidine-1-sulfonamide (AZD5069)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of asthma","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"02/05/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: alison.mcgregor@astrazeneca.com; Tel. +44 (0)7748 761375","first_published_date":"06/06/2014","last_updated_date":"06/06/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001571-pip01-13"},{"decision_number":"P/0112/2014","pip_number":"EMEA-001516-PIP01-13","active_substance":"Enalapril (maleate)","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet for oral suspension;Orodispersible film","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"05/05/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pharmathen S.A.; Greece; E-mail: mkalovidouri@pharmathen.com; Tel. +30 2106 604354;  ","first_published_date":"06/06/2014","last_updated_date":"06/06/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001516-pip01-13"},{"decision_number":"P/0091/2014","pip_number":"EMEA-000558-PIP01-09-M02","active_substance":"human normal immunoglobulin","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of Idiopathic Thrombocytopenia Purpura (ITP);Treatment of Primary Immunodeficiency (PID)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/04/2014","compliance_outcome":"Positive","compliance_opinion_date":"23/05/2014","compliance_procedure_number":"EMEA-C-000558-PIP01-09-M02","contact_for_public_enquiries":"LFB Biotechnologies; France; E-mail: metenanizi@lfb.fr; Tel. +33 1698 21029; Fax +33 1837 11978","first_published_date":"22/10/2009","last_updated_date":"14/05/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000558-pip01-09-m02"},{"decision_number":"P/0089/2014","pip_number":"EMEA-001586-PIP01-13","active_substance":"atropine sulfate;dimethanesulfonate;avizafone (hydrochloride)","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of organophosphorus poisoning","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/04/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Service de Santé des Armées; France; E-mail: isabelle.besse@santarm.fr; Tel. +33 2386 07312;  ","first_published_date":"13/05/2014","last_updated_date":"13/05/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001586-pip01-13"},{"decision_number":"P/0100/2014","pip_number":"EMEA-001169-PIP02-13","active_substance":"alirocumab","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of mixed dyslipidaemia","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/04/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi-Aventis Recherche & Développement; E-mail: contact-us@sanofi-aventis.com; Tel. +33 1 60 49 66 82","first_published_date":"12/05/2014","last_updated_date":"12/05/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001169-pip02-13"},{"decision_number":"P/0065/2014","pip_number":"EMEA-001462-PIP01-13","active_substance":"recombinant human growth hormone modified by fusion with two hydrophilic polypeptide chains (VRS-317)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of growth hormone deficiency","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/03/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Versartis, Inc. ; United States ; E-mail: jcleland@versartis.com ; Tel. +1 6509638580 ; Fax +1 6509638598","first_published_date":"16/04/2014","last_updated_date":"16/04/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001462-pip01-13"},{"decision_number":"P/0067/2014","pip_number":"EMEA-001413-PIP01-13","active_substance":"Phleum pratense","invented_name":"Allergovit Phleum","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinoconjunctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/03/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergopharma GmbH & Co. KG ; Germany ; E-mail: info@allergopharma.com; Tel. +49 4027650 ; Fax +49 407227713","first_published_date":"16/04/2014","last_updated_date":"16/04/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001413-pip01-13"},{"decision_number":"P/0066/2014","pip_number":"EMEA-001560-PIP01-13","active_substance":"ramipril;amlodipine besilate","invented_name":"BR/AM","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/03/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Brunifarma Research s.r.l. ; Italy ; E-mail: info@brunifarmaresearch.com; Tel. +39 091900529 ; Fax +39 091905535","first_published_date":"16/04/2014","last_updated_date":"16/04/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001560-pip01-13"},{"decision_number":"P/0054/2014","pip_number":"EMEA-001532-PIP01-13","active_substance":"Ertugliflozin;Metformin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/03/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe), Inc. ; Belgium ; E-mail: pip.information@merck.com ; Tel. +31 412663179 ; Fax +31 412662571","first_published_date":"16/04/2014","last_updated_date":"16/04/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001532-pip01-13"},{"decision_number":"P/0055/2014","pip_number":"EMEA-001552-PIP01-13","active_substance":"telmisartan;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/03/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Zentiva, k.s.; Czech Republic; blanka.zoubkova@zentiva.com; Tel. +42 0267243574","first_published_date":"16/04/2014","last_updated_date":"16/04/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001552-pip01-13"},{"decision_number":"P/0057/2014","pip_number":"EMEA-001370-PIP02-13","active_substance":"Herpes simplex 1 virus thymidine kinase and truncated low affinity nerve growth factor receptor transfected donor lymphocytes","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Cell suspension for infusion","condition_indication":"Adjunctive treatment in haematopoietic cell transplantation","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/03/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"MolMed S.p.A. ; Italy ; E-mail: info@molmed.com ; Tel. +39 02212771 ; Fax +39 0221277220","first_published_date":"16/04/2014","last_updated_date":"16/04/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001370-pip02-13"},{"decision_number":"P/0056/2014","pip_number":"EMEA-001558-PIP01-13","active_substance":"thiocolchicoside;diclofenac (sodium)","invented_name":"Muscoplus","therapeutic_area":"Pain","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of musculoskeletal and connective tissue pain","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/03/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Epifarma Srl ; Italy ; E-mail: b.trupa@epifarma.it ; Tel. +39 0973 655200 ; Fax +39 0973 655318","first_published_date":"16/04/2014","last_updated_date":"16/04/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001558-pip01-13"},{"decision_number":"P/0049/2014","pip_number":"EMEA-000986-PIP02-13","active_substance":"ocriplasmin","invented_name":"Jetrea; Jetrea","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Concentrate for solution for injection","condition_indication":"Treatment of symptomatic focal vitreomacular adhesion","routes_of_administration":"Intravitreal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/03/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ThromboGenics NV ; Belgium ; E-mail: info@thrombogenics.com; Tel. +32 16751310","first_published_date":"16/04/2014","last_updated_date":"16/04/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000986-pip02-13"},{"decision_number":"P/0047/2014","pip_number":"EMEA-001637-PIP01-13","active_substance":"human normal immunoglobulin","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of Primary Immunodeficiency (PID)","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/03/2014","compliance_outcome":"Positive","compliance_opinion_date":"16/01/2015","compliance_procedure_number":"EMEA-001637-PIP01-13","contact_for_public_enquiries":"Baxter Innovations GmbH; Austria; E-mail: europa_biosci_globalra@baxter.com; Tel. +43 1201000; Fax +43 120100 / 2475990","first_published_date":"16/04/2014","last_updated_date":"16/04/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001637-pip01-13"},{"decision_number":"P/0041/2014","pip_number":"EMEA-001494-PIP01-13","active_substance":"Fluocinolone acetonide","invented_name":"Otoken","therapeutic_area":"Oto-rhino-laryngology","pharmaceutical_forms":"Ear drops, solution","condition_indication":"Treatment of dermatitis and eczema","routes_of_administration":"Auricular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"05/03/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Laboratorios Salvat, S.A.E-mail: regulatory@svt.com Tel. +34 933946400","first_published_date":"16/04/2014","last_updated_date":"16/04/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001494-pip01-13"},{"decision_number":"P/0032/2014","pip_number":"EMEA-001534-PIP01-13","active_substance":"Ertugliflozin;sitagliptin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/03/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe), Inc.; Belgium; E-mail: pip.information@merck.com; Tel. +31 412663179; Fax +31 412662571","first_published_date":"20/03/2014","last_updated_date":"20/03/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001534-pip01-13"},{"decision_number":"P/0043/2014","pip_number":"EMEA-000582-PIP01-09-M03","active_substance":"rupatadine fumarate","invented_name":"Rupafin and associated names","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Tablet;Granules;Oral liquid","condition_indication":"Treatment of allergic rhinitis;Treatment of chronic idiopathic urticaria","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/02/2014","compliance_outcome":"Positive","compliance_opinion_date":"21/03/2014","compliance_procedure_number":"EMEA-C-000582-PIP01-09-M03","contact_for_public_enquiries":"J. Uriach y Compañía, S.A; Spain; E-mail: clin-izquierdo@uriach.com; Tel. +34 938630272; Fax:  +34 938646606","first_published_date":"19/04/2010","last_updated_date":"20/03/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000582-pip01-09-m03"},{"decision_number":"P/0013/2014","pip_number":"EMEA-000630-PIP02-09-M05","active_substance":"Betula alba;aluminium hydroxide adsorbed;depigmented glutaraldehyde polymerised","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Subcutaneous use","decision_type":"RPM: decision refers to a refusal on the application for modification of an agreed PIP","decision_date":"30/12/2022","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Leti Pharma GmbH; Germany; E-mail: paediatrics@leti.de; Tel. +49 230 2202 860; Fax +49 230 2202 8623","first_published_date":"20/12/2010","last_updated_date":"20/02/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000630-pip02-09-m05"},{"decision_number":"P/0027/2014","pip_number":"EMEA-001536-PIP01-13","active_substance":"diclofenac;Levomenthol","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Gel","condition_indication":"Treatment of local pain and inflammation","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/01/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Consumer Trading Services Limited; United Kingdom; E-mail: rd.gskch-paediatric-plans@gsk.com; Tel. +44 (0)19 3282 6987","first_published_date":"20/02/2014","last_updated_date":"20/02/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001536-pip01-13"},{"decision_number":"P/0024/2014","pip_number":"EMEA-001537-PIP01-13","active_substance":"Caffeine;Ibuprofen","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/01/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"20/02/2014","last_updated_date":"20/02/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001537-pip01-13"},{"decision_number":"P/0010/2014","pip_number":"EMEA-000406-PIP01-08-M04","active_substance":"fosaprepitant","invented_name":"Ivemend; Ivemend","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Prevention of nausea and vomiting","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"22/01/2014","compliance_outcome":"Positive","compliance_opinion_date":"10/10/2014","compliance_procedure_number":"EMEA-C-000406-PIP01-08-M04","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"11/08/2011","last_updated_date":"19/02/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000406-pip01-08-m04"},{"decision_number":"P/0008/2014","pip_number":"EMEA-000144-PIP01-07-M05","active_substance":"aprepitant","invented_name":"Emend; Emend","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for suspension;Capsule, hard","condition_indication":"Prevention of nausea and vomiting","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"22/01/2014","compliance_outcome":"Positive","compliance_opinion_date":"10/10/2014","compliance_procedure_number":"EMEA-C-000144-PIP01-07-M05","contact_for_public_enquiries":"Merck Sharp & Dohme Ltd; United Kingdom; E-mail: pip.information@merck.com; Tel. +31 412663179; Fax +31 412662571","first_published_date":"11/08/2011","last_updated_date":"19/02/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000144-pip01-07-m05"},{"decision_number":"P/0009/2014","pip_number":"EMEA-000282-PIP01-08-M02","active_substance":"clevidipine butyrate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Emulsion for infusion","condition_indication":"Treatment of hypertensive disease","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"22/01/2014","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"The Medicines Company UK Ltd; United Kingdom; Tel. +39 0521 2791; Fax +39 0521 774468; E-mail: info@chiesi.com","first_published_date":"23/04/2009","last_updated_date":"19/02/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000282-pip01-08-m02"},{"decision_number":"P/0005/2014","pip_number":"EMEA-000056-PIP03-10-M02","active_substance":"bevacizumab","invented_name":"Avastin; Avastin","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of high-grade glioma","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"22/01/2014","compliance_outcome":"Positive","compliance_opinion_date":"13/11/2015","compliance_procedure_number":"EMEA-C-000056-PIP03-10-M02","contact_for_public_enquiries":"Roche Registration Ltd; United Kingdom; E-mail: info.paediatrics@roche.com; Tel. +41 616879411","first_published_date":"08/04/2011","last_updated_date":"19/02/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000056-pip03-10-m02"},{"decision_number":"P/0003/2014","pip_number":"EMEA-000019-PIP02-07-M05","active_substance":"everolimus","invented_name":"Votubia; Votubia","therapeutic_area":"Neurology","pharmaceutical_forms":"Tablet;Dispersible tablet","condition_indication":"Treatment of angiomyolipoma;Treatment of subependymal giant-cell astrocytoma","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"22/01/2014","compliance_outcome":"Positive","compliance_opinion_date":"29/01/2016","compliance_procedure_number":"EMEA-C-000019-PIP02-07-M05","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"13/07/2011","last_updated_date":"19/02/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000019-pip02-07-m05"},{"decision_number":"P/0004/2014","pip_number":"EMEA-000056-PIP01-07-M02","active_substance":"bevacizumab","invented_name":"Avastin; Avastin","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of non-rhabdomyosarcoma soft tissue sarcoma;Treatment of rhabdomyosarcoma","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"22/01/2014","compliance_outcome":"Positive","compliance_opinion_date":"26/02/2016","compliance_procedure_number":"EMEA-C-000056-PIP01-07-M02","contact_for_public_enquiries":"Roche Registration Ltd; United Kingdom; E-mail: info.paediatrics@roche.com; Tel. +41 616879411","first_published_date":"24/11/2008","last_updated_date":"19/02/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000056-pip01-07-m02"},{"decision_number":"P/0320/2013","pip_number":"EMEA-001538-PIP01-13","active_substance":"olmesartan medoxomil;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/12/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Zentiva, k.s.; Czech Republic; blanka.zoubkova@zentiva.com; Tel. +42 0267243574","first_published_date":"05/02/2014","last_updated_date":"05/02/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001538-pip01-13"},{"decision_number":"P/0001/2014","pip_number":"EMEA-001442-PIP01-13","active_substance":"raltegravir;lamivudine","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/01/2014","compliance_outcome":"Positive","compliance_opinion_date":"21/03/2014","compliance_procedure_number":"EMEA-C-001442-PIP01-13","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"05/02/2014","last_updated_date":"05/02/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001442-pip01-13"},{"decision_number":"P/0319/2013","pip_number":"EMEA-001528-PIP01-13","active_substance":"solifenacin (succinate);Mirabegron","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Modified-release tablet","condition_indication":"Treatment of myoneurogenic bladder disorders","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/12/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Astellas Pharma Europe B.V.Tel. +31 7154 55878E-mail: contact.nl@astellas.com&nbsp","first_published_date":"05/02/2014","last_updated_date":"05/02/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001528-pip01-13"},{"decision_number":"P/0316/2013","pip_number":"EMEA-001473-PIP01-13","active_substance":"acetylsalicylic acid;omeprazole","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Modified-release tablet","condition_indication":"Prevention of cerebrovascular embolism and thrombosis;Prevention of ischaemic coronary artery disorders","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/12/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pozen UK ; Limited United Kingdom ; E-mail: paediatrics@pozen.com ; Tel. +1 9199131030 ; Fax +1 9199131039","first_published_date":"05/02/2014","last_updated_date":"05/02/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001473-pip01-13"},{"decision_number":"P/0317/2013","pip_number":"EMEA-001513-PIP01-13","active_substance":"Estetrol;levonorgestrel","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of pregnancy","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"19/12/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Estetra S.A. ; Belgium ; E-mail: llebon@uteron.com; Tel. +32 496553302 ; Fax +32 42209631","first_published_date":"05/02/2014","last_updated_date":"05/02/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001513-pip01-13"},{"decision_number":"P/0318/2013","pip_number":"EMEA-001525-PIP01-13","active_substance":"alpha-1 antitrypsin","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Nebuliser solution","condition_indication":"Treatment of emphysema secondary to congenital deficiency of alpha-1 antitrypsin","routes_of_administration":"Inhalation use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/12/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Triskel EU Services Ltd; United Kingdom ; E-mail: oritp@kamada.com; Tel. +44 (0)9728 940 64 72 ; Fax +44 (0)9728 940 64 73","first_published_date":"05/02/2014","last_updated_date":"05/02/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001525-pip01-13"},{"decision_number":"P/0311/2013","pip_number":"EMEA-000994-PIP01-10-M01","active_substance":"Gadobutrol","invented_name":"Gadovist","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Solution for injection","condition_indication":"Diagnostic evaluation of tissue pathologies with contrast-enhanced magnetic resonance imaging (MRI)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/12/2012","compliance_outcome":"Positive","compliance_opinion_date":"20/06/2014","compliance_procedure_number":"EMEA-C-000994-PIP01-10-M01","contact_for_public_enquiries":"Bayer harma AG; pediatrics.medical-affairs-europe@bayer.com; Germany; Tel. +49 3046815333; Fax +49 3046895333","first_published_date":"09/08/2011","last_updated_date":"04/02/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000994-pip01-10-m01"},{"decision_number":"P/0268/2013","pip_number":"EMEA-001173-PIP01-11-M01","active_substance":"Lumacaftor","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral formulation","condition_indication":"Treatment of cystic fibrosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/12/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vertex Pharmaceuticals (Europe) Ltd.; Tel. +1 8776348789; E-mail: medicalinfo@vrtx.com","first_published_date":"09/08/2012","last_updated_date":"04/02/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001173-pip01-11-m01"},{"decision_number":"P/0324/2013","pip_number":"EMEA-000366-PIP01-08-M06","active_substance":"adalimumab","invented_name":"Humira; Humira","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of psoriasis;Treatment of Crohn's disease;Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis)","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"19/12/2013","compliance_outcome":"Positive","compliance_opinion_date":"20/06/2014","compliance_procedure_number":"EMEA-C-000366-PIP01-08-M06","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)791 988 1614","first_published_date":"04/01/2013","last_updated_date":"04/02/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000366-pip01-08-m06"},{"decision_number":"P/0302/2013","pip_number":"EMEA-001503-PIP01-13","active_substance":"Lanreotide acetate","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder and solvent for prolonged-release suspension for injection;Solution for injection in pre-filled syringe;Powder for suspension for injection","condition_indication":"Treatment of acromegaly;Treatment of gastrointestinal fistulae;Treatment of metastases to peritoneum;Treatment of pituitary gigantism;Treatment of pituitary neoplasms","routes_of_administration":"Intramuscular use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/11/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ipsen Pharma; Email: paediatrics.plans@ipsen.com; Tel. +33 1 58 33 50 00;  ","first_published_date":"17/01/2014","last_updated_date":"17/01/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001503-pip01-13"},{"decision_number":"P/0285/2013","pip_number":"EMEA-000052-PIP01-07-M03","active_substance":"vandetanib","invented_name":"Caprelsa; Caprelsa","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of medullary thyroid carcinoma","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/11/2013","compliance_outcome":"Positive","compliance_opinion_date":"20/06/2014","compliance_procedure_number":"EMEA-C-000052-PIP01-07-M03","contact_for_public_enquiries":"AstraZeneca AB (Sweden); Tel. +46 8 5532791; E-mail: paediatrics@astrazeneca.com","first_published_date":"07/01/2009","last_updated_date":"06/01/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000052-pip01-07-m03"},{"decision_number":"P/0301/2013","pip_number":"EMEA-001499-PIP01-13","active_substance":"odanacatib;colecalciferol","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of osteoporosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/11/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"06/01/2014","last_updated_date":"06/01/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001499-pip01-13"},{"decision_number":"P/0303/2013","pip_number":"EMEA-001508-PIP01-13","active_substance":"metformin hydrochloride;rosuvastatin calcium","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of type II diabetes mellitus concomitant with hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/11/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Ireland; Email: admin@wainwrightassociates.co.uk; Tel. +44 1628530554","first_published_date":"06/01/2014","last_updated_date":"06/01/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001508-pip01-13"},{"decision_number":"P/0304/2013","pip_number":"EMEA-001520-PIP01-13","active_substance":"synthetic double-stranded siRNA oligonucleotide directed against transthyretin mRNA","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of familial amyloid polyneuropathy","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/11/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alnylam Pharmaceuticals, Inc.; United States; E-mail: snochur@alnylam.com; Tel. +1 6175518393; Fax +1 6175757339","first_published_date":"06/01/2014","last_updated_date":"06/01/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001520-pip01-13"},{"decision_number":"P/0299/2013","pip_number":"EMEA-001398-PIP02-13","active_substance":"sodium benzylpenilloate;benzylpenicilloyl octa- L-lysine","invented_name":"","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Diagnosis of beta-lactam allergy","routes_of_administration":"Skin scarification;Intradermal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/11/2013","compliance_outcome":"Positive","compliance_opinion_date":"12/09/2014","compliance_procedure_number":"EMEA-C-001398-PIP02-13","contact_for_public_enquiries":"Diater Laboratorio de Diagnóstico y Aplicaciones Terapéuticas, S.A.; Spain; E-mail: diater@diater.com ; Tel. +34 9149 660 13; Fax +34 9149 660 12","first_published_date":"06/01/2014","last_updated_date":"06/01/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001398-pip02-13"},{"decision_number":"P/0300/2013","pip_number":"EMEA-001496-PIP01-13","active_substance":"atorvastatin (calcium trihydrate);perindopril arginine;amlodipine besilate","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of elevated cholesterol;Treatment of hypertension;Treatment of ischemic coronary artery disorders","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/11/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierE-mail: mail.pip.enquiries@servier.comTel.: +33 155726000","first_published_date":"06/01/2014","last_updated_date":"06/01/2014","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001496-pip01-13"},{"decision_number":"P/0253/2013","pip_number":"EMEA-000174-PIP01-07-M03","active_substance":"Plerixafor","invented_name":"Mozobil; Mozobil","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Myelosuppression caused by chemotherapy to treat malignant disorders, which requires an autologous haematopoietic stem cell transplant","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/10/2013","compliance_outcome":"Positive","compliance_opinion_date":"26/01/2018","compliance_procedure_number":"EMEA-C-000174-PIP01-07-M03","contact_for_public_enquiries":"Sanofi B.V.E-mail: eumedinfo.GZ@sanofi.com Tel. +31 2024 54000&nbsp","first_published_date":"18/05/2010","last_updated_date":"19/11/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000174-pip01-07-m03"},{"decision_number":"P/0276/2013","pip_number":"EMEA-000784-PIP02-11-M01","active_substance":"nitisinone","invented_name":"Orfadin; Orfadin","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Oral suspension","condition_indication":"Treatment of tyrosinemia type 1","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/10/2013","compliance_outcome":"Positive","compliance_opinion_date":"17/01/2014","compliance_procedure_number":"EMEA-C-000784-PIP02-11-M01","contact_for_public_enquiries":"Swedish Orphan Biovitrum International AB; Sweden; E-mail: maria.sahlberg@sobi.com; Tel. +46 (0)8697 2030","first_published_date":"23/07/2012","last_updated_date":"19/11/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000784-pip02-11-m01"},{"decision_number":"P/0255/2013","pip_number":"EMEA-000293-PIP02-10-M01","active_substance":"pegloticase","invented_name":"Krystexxa; Krystexxa","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Prevention of hyperuricaemia;Treatment of hyperuricaemia","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Savient Pharmaceuticals, Inc.; United States; E-mail: drug.development@savient.com; Tel. +1 7324 189300","first_published_date":"23/02/2011","last_updated_date":"18/11/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000293-pip02-10-m01"},{"decision_number":"P/0261/2013","pip_number":"EMEA-001510-PIP01-13","active_substance":"amlodipine;atorvastatin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of dyslipidaemia;Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pharmaceutical Works Polpharma SA; Poland; E-mail: michal.dembowski@polpharma.com; Tel. +48 2236 46321","first_published_date":"18/11/2013","last_updated_date":"18/11/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001510-pip01-13"},{"decision_number":"P/0274/2013","pip_number":"EMEA-001478-PIP01-13","active_substance":"ezetimibe;rosuvastatin","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of elevated cholesterol","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/10/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Althera Laboratoires LimitedEmail: charmaine.dias@altherainc.comTel. +353 1 906 0479","first_published_date":"18/11/2013","last_updated_date":"18/11/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001478-pip01-13"},{"decision_number":"P/0273/2013","pip_number":"EMEA-001477-PIP01-13","active_substance":"ezetimibe;atorvastatin","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of elevated cholesterol","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/10/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Althera Laboratoires LimitedEmail: charmaine.dias@altherainc.comTel. +353 1 906 0479","first_published_date":"18/11/2013","last_updated_date":"18/11/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001477-pip01-13"},{"decision_number":"P/0272/2013","pip_number":"EMEA-001475-PIP01-13","active_substance":"(4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of primary biliary cirrhosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/10/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mirum PharmaceuticalsE-mail: medinfo@mirumpharma.com Tel.  +1 6506674085","first_published_date":"18/11/2013","last_updated_date":"18/11/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001475-pip01-13"},{"decision_number":"P/0247/2013","pip_number":"EMEA-001374-PIP01-12","active_substance":"exon 53 specific phosphorothioate oligonucleotide","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Concentrate for solution for injection","condition_indication":"Treatment of Duchenne muscular dystrophy","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/10/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BioMarin International Limited; Ireland; Tel. +353 21 500 7990; Fax +31 7133 22088; E-mail: shanbally@bmrn.nl","first_published_date":"15/11/2013","last_updated_date":"15/11/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001374-pip01-12"},{"decision_number":"P/0246/2013","pip_number":"EMEA-001369-PIP01-12","active_substance":"exon 45 specific phosphorothioate oligonucleotide","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Concentrate for solution for injection","condition_indication":"Treatment of Duchenne muscular dystrophy","routes_of_administration":"Subcutaneous use;Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/10/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BioMarin International Limited; Ireland; E-mail: shanbally@bmrn.nl; Tel. +353 21 500 7990; Fax +31 7133 22088","first_published_date":"15/11/2013","last_updated_date":"15/11/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001369-pip01-12"},{"decision_number":"P/0229/2013","pip_number":"EMEA-001201-PIP01-11-M02","active_substance":"purified tetanus toxoid;Inactivated Type 1 Poliovirus (Mahoney);Inactivated Type 2 Poliovirus (MEF-1);Inactivated Type 3 Poliovirus (Saukett);Haemophilus influenzae type b polysaccharide conjugated to tetanus protein;Hepatitis B Surface Antigen, recombinant;purified diphtheria toxoid (DTaP-IPV-HepB-PRP-T);purified filamentous haemagglutinin;purified pertussis toxoid","invented_name":"Hexacima and associated names","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2 and 3, Haemophilus influenzae type b and Hepatitis B virus","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"23/09/2013","compliance_outcome":"Positive","compliance_opinion_date":"27/01/2017","compliance_procedure_number":"EMEA-001201-PIP01-11-M02","contact_for_public_enquiries":"Sanofi pasteur; Email: piplan@sanofipasteur.com; Tel. +33 4373 75038","first_published_date":"24/02/2012","last_updated_date":"15/11/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001201-pip01-11-m02"},{"decision_number":"P/0242/2013","pip_number":"EMEA-001480-PIP01-13","active_substance":"calcium (citrate);colecalciferol","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of calcium and vitamin D3 deficiency;Prevention of calcium and vitamin D3 deficiency","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/09/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pharma Patent Kft.; Hungary; Email: info@pharmapatent.hu; Tel. +36 1630 2560; Fax +36 1630 2560","first_published_date":"15/11/2013","last_updated_date":"15/11/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001480-pip01-13"},{"decision_number":"P/0241/2013","pip_number":"EMEA-001471-PIP01-13","active_substance":"ramipril;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/09/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Email: admin@wainwrightassociates.co.uk; Tel. +44 (0)1628 530554","first_published_date":"15/11/2013","last_updated_date":"15/11/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001471-pip01-13"},{"decision_number":"P/0233/2013","pip_number":"EMEA-001479-PIP01-13","active_substance":"Metformin;rosuvastatin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Modified-release tablet","condition_indication":"Treatment of type II diabetes mellitus concomitant with hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/09/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Althera Laboratories LimitedEmail: regulatory.eu@altherainc.comTel.: +353 1 906 0479","first_published_date":"15/11/2013","last_updated_date":"15/11/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001479-pip01-13"},{"decision_number":"P/0231/2013","pip_number":"EMEA-001472-PIP01-13","active_substance":"valsartan;atorvastatin","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of elevated cholesterol;Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/09/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; Ireland; Email: admin@wainwrightassociates.co.uk; Tel. +44 1628530554","first_published_date":"15/11/2013","last_updated_date":"15/11/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001472-pip01-13"},{"decision_number":"P/0230/2013","pip_number":"EMEA-001467-PIP01-13","active_substance":"perindopril erbumine;amlodipine besilate","invented_name":"","therapeutic_area":"","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/09/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Zentiva, k.s.; Czech Republic; blanka.zoubkova@zentiva.com; Tel. +42 0267243574","first_published_date":"15/11/2013","last_updated_date":"15/11/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001467-pip01-13"},{"decision_number":"P/0243/2013","pip_number":"EMEA-001394-PIP01-12","active_substance":"Clostridium difficile toxin A human monoclonal antibody;Clostridium difficile toxin B human monoclonal antibody","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of Clostridium difficile infection","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"21/09/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"15/11/2013","last_updated_date":"15/11/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001394-pip01-12"},{"decision_number":"P/0220/2013","pip_number":"EMEA-000726-PIP01-09-M02","active_substance":"valganciclovir","invented_name":"Valcyte and associated names","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Powder for oral solution","condition_indication":"Prevention of infection due to cytomegalovirus in solid-organ-transplant recipients;Treatment of infection due to cytomegalovirus in immunocompromised patients","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"06/09/2013","compliance_outcome":"Positive","compliance_opinion_date":"11/10/2013","compliance_procedure_number":"EMEA-C-000726-PIP01-09-M02","contact_for_public_enquiries":"Roche Registration Limited; alexandra.kalb@roche.com; Tel. +41 61687360; Fax +41 61681560","first_published_date":"12/05/2011","last_updated_date":"08/10/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000726-pip01-09-m02"},{"decision_number":"P/0204/2013","pip_number":"EMEA-000284-PIP01-08-M04","active_substance":"grass pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of acute atopic conjunctivitis;Treatment of allergic rhinitis due to pollen","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/09/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergy Therapeutics (UK) Ltd; sue.sulsh@allergytherapeutics.com; Tel. +44 (0)1903 844757; Fax +44 (0)1903 844726","first_published_date":"03/10/2011","last_updated_date":"08/10/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000284-pip01-08-m04"},{"decision_number":"P/0196/2013","pip_number":"EMEA-000654-PIP01-09-M02","active_substance":"Human-papillomavirus-type-6 L1 protein;human-papillomavirus-type-11 L1 protein;human-papillomavirus-type-16 L1 protein;human-papillomavirus-type-18 L1 protein;human-papillomavirus-type-31 L1 protein;human-papillomavirus-type-33 L1 protein;human-papillomavirus-type-45 L1 protein;human-papillomavirus-type-52 L1 protein;human-papillomavirus-type-58 L1 protein","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection;Suspension for injection in pre-filled syringe","condition_indication":"Prevention of infection by human papillomavirus","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"02/09/2013","compliance_outcome":"Positive","compliance_opinion_date":"17/01/2014","compliance_procedure_number":"EMEA-C-000654-PIP01-09-M02","contact_for_public_enquiries":"Sanofi Pasteur MSD SNC; piplan@spmsd.com; Tel. +33 437284000","first_published_date":"27/07/2010","last_updated_date":"08/10/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000654-pip01-09-m02"},{"decision_number":"P/0213/2013","pip_number":"EMEA-001461-PIP01-13","active_substance":"acotiamide","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Coated tablet","condition_indication":"Treatment of functional dyspepsia","routes_of_administration":"Oral use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"05/09/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Zeria Pharmaceutical Co Ltd; tomoharu-miyagawa@zeria.co.jp; Tel. +44 (0)7528 697428","first_published_date":"08/10/2013","last_updated_date":"08/10/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001461-pip01-13"},{"decision_number":"P/0212/2013","pip_number":"EMEA-001421-PIP01-12","active_substance":"risedronate sodium;colecalciferol","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of osteoporosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"05/09/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pharma Patent Kft.; E-mail: info@pharmapatent.hu; Tel. +36 16306182","first_published_date":"08/10/2013","last_updated_date":"08/10/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001421-pip01-12"},{"decision_number":"P/0203/2013","pip_number":"EMEA-001457-PIP01-13","active_substance":"Pomalidomide","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of post-essential thrombocythaemia myelofibrosis;Treatment of post-polycythaemia vera myelofibrosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/09/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Celgene Europe LimitedTel.  +41 327298500E-mail: medinfo.intl@celgene.com","first_published_date":"07/10/2013","last_updated_date":"07/10/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001457-pip01-13"},{"decision_number":"P/0202/2013","pip_number":"EMEA-001437-PIP01-13","active_substance":"mifepristone","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of leiomyoma of uterus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/09/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Laboratories Litaphar, S.A.; litaphar@litaphar.com; Tel. +34 943157299; Fax +34 902999881","first_published_date":"07/10/2013","last_updated_date":"07/10/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001437-pip01-13"},{"decision_number":"P/0184/2013","pip_number":"EMEA-001409-PIP01-12","active_substance":"capsici acris","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Cream","condition_indication":"Treatment of painful peripheral neuropathy","routes_of_administration":"Cutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/07/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Momaja s.r.o. ; Czech Republic ; E-mail: lucie@elc-group.com ; Tel. +420 224910000 ; Fax +420 224910671","first_published_date":"03/09/2013","last_updated_date":"03/09/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001409-pip01-12"},{"decision_number":"P/0180/2013","pip_number":"EMEA-001464-PIP01-13","active_substance":"amlodipine;ramipril","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/07/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Adamed Sp. z o.o. ; Poland ; E-mail: kamila.kawiak@adamed.com.pl ; Tel. +482 22187651 ; Fax +482 27327800","first_published_date":"03/09/2013","last_updated_date":"03/09/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001464-pip01-13"},{"decision_number":"P/0178/213","pip_number":"EMEA-001433-PIP01-13","active_substance":"pegylated proline-interferon alpha-2b","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of polycythaemia vera","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/07/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AOP Orphan Pharmaceuticals AG ; Austria ; E-mail: office@aoporphan.com ; Tel. +43 15037244 ; Fax +43 150372445","first_published_date":"03/09/2013","last_updated_date":"03/09/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001433-pip01-13"},{"decision_number":"P/0179/2013","pip_number":"EMEA-001463-PIP01-13","active_substance":"acetylsalicylic acid;clopidogrel hydrogen sulfate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/07/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Billev Pharma ApS ; Denmark ; E-mail: katja.pecjak@billevpharma.dk ; Tel. +386 12322095 ; Fax +386 12322096","first_published_date":"03/09/2013","last_updated_date":"03/09/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001463-pip01-13"},{"decision_number":"P/0177/2013","pip_number":"EMEA-001428-PIP01-13","active_substance":"Esketamine","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Nasal spray;Solution","condition_indication":"Treatment of major depressive disorder","routes_of_administration":"Intranasal use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"30/07/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International N.V. ; E-mail: mojanen@ITS.JNJ.com; Tel. +34 917228079","first_published_date":"03/09/2013","last_updated_date":"03/09/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001428-pip01-13"},{"decision_number":"P/0175/2013","pip_number":"EMEA-001368-PIP01-12","active_substance":"lopinavir;lamivudine;ritonavir;zidovudine","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/07/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel: +441628644475","first_published_date":"03/09/2013","last_updated_date":"03/09/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001368-pip01-12"},{"decision_number":"P/0173/2013","pip_number":"EMEA-001237-PIP01-11","active_substance":"3-[[4-[(1S)-1-[4-(4-tert-butylphenyl)-3,5-dimethyl-phenoxy]-4,4,4-trifluorobutyl]benzoyl]amino]propanoic acid","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"30/07/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"03/09/2013","last_updated_date":"03/09/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001237-pip01-11"},{"decision_number":"P/0171/2013","pip_number":"EMEA-000817-PIP02-11-M01","active_substance":"purified antigen fractions of inactivated split virion influenza virus type A, H1N1;influenza virus type A, H3N2;influenza virus type B, Victoria lineage;influenza virus type B, Yamagata lineage","invented_name":"Influsplit Tetra and associated names","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Prevention of influenza infection","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/07/2013","compliance_outcome":"Positive","compliance_opinion_date":"21/04/2017","compliance_procedure_number":"EMEA-000817-PIP02-11-M01","contact_for_public_enquiries":"GSK Vaccines S.r.l.; Tel. +1 438 899 8201; Email: eu.paediatric-plans@gsk.com","first_published_date":"02/09/2013","last_updated_date":"19/01/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000817-pip02-11-m01"},{"decision_number":"P/0159/2013","pip_number":"EMEA-001410-PIP01-12","active_substance":"ixazomib citrate","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of systemic light chain amyloidosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"05/07/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Global Research & Development Centre (Europe) Ltd; United Kingdom; E-mail: paediatrics@tgrd.com; Tel. +44 (0)20 3116 8250","first_published_date":"13/08/2013","last_updated_date":"13/08/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001410-pip01-12"},{"decision_number":"P/0148/2013","pip_number":"EMEA-001361-PIP01-12","active_substance":"ketoprofen;omeprazole","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Capsule, hard;Modified release capsule","condition_indication":"Treatment of pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/07/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Conventia Healthcare LLP; United Kingdom; E-mail: kim@conventia.com ; Tel. +44 (0)1442 890903","first_published_date":"13/08/2013","last_updated_date":"13/08/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001361-pip01-12"},{"decision_number":"P/0149/2013","pip_number":"EMEA-001397-PIP01-12","active_substance":"Ibrutinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of mantle cell lymphoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/07/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International N.V.; E-mail: sglawe@its.jnj.com ; Tel. +49 9479218","first_published_date":"13/08/2013","last_updated_date":"13/08/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001397-pip01-12"},{"decision_number":"P/0150/2013","pip_number":"EMEA-001444-PIP01-13","active_substance":"zolpidem (tartrate)","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Sublingual tablet","condition_indication":"Treatment of insomnia","routes_of_administration":"Sublingual use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/07/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Transcept Pharmaceuticals, Inc; United States; E-mail: ssakai@transcept.com ; Tel. +1 5102153515","first_published_date":"13/08/2013","last_updated_date":"13/08/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001444-pip01-13"},{"decision_number":"P/0156/2013","pip_number":"EMEA-001299-PIP01-12","active_substance":"Betulae cortex","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Ointment","condition_indication":"Treatment of skin injuries","routes_of_administration":"Cutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"05/07/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Birken AG; Germany; E-mail: info@birken.eu ; Tel. +49 72339749; Fax +49 7233974922","first_published_date":"09/08/2013","last_updated_date":"09/08/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001299-pip01-12"},{"decision_number":"P/0145/2013","pip_number":"EMEA-001305-PIP01-12","active_substance":"cebranopadol","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Film-coated tablet;Granules","condition_indication":"Treatment of chronic pain","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/07/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Grünenthal GmbH; Tel. +49 2415690E-mail: pediatrics@grunenthal.com","first_published_date":"09/08/2013","last_updated_date":"09/08/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001305-pip01-12"},{"decision_number":"P/0151/2013","pip_number":"EMEA-000191-PIP01-08-M05","active_substance":"voriconazole","invented_name":"Vfend; Vfend","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Powder for oral suspension;Powder for solution for infusion","condition_indication":"Treatment of candidaemia in non-neutropenic patients;Treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei);Treatment of invasive aspergillosis;Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.","routes_of_administration":"Oral use;Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"05/07/2013","compliance_outcome":"Positive","compliance_opinion_date":"09/08/2013","compliance_procedure_number":"EMEA-C-000191-PIP01-08-M05","contact_for_public_enquiries":"Pfizer Limited; Tel. + 44 1304646607; E-mail: pip_enquiries@pfizer.com","first_published_date":"10/05/2011","last_updated_date":"08/08/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000191-pip01-08-m05"},{"decision_number":"P/0120/2013","pip_number":"EMEA-001396-PIP01-12","active_substance":"Clostridium botulinum toxin type A, purified neurotoxin","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of skin dystrophies","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/05/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen Biologics B.V.; The Netherlands; ssilk@its.jnj.com ; Tel. +44 (0) 1494 55 39 55; Fax +44 (0) 1494 65 80 14","first_published_date":"24/06/2013","last_updated_date":"24/06/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001396-pip01-12"},{"decision_number":"P/0129/2013","pip_number":"EMEA-001405-PIP01-12","active_substance":"metoprolol (tartrate);ivabradine hydrochloride","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of ischaemic coronary artery disorders","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/05/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierE-mail: mail.pip.enquiries@servier.comTel.: +33 155726000","first_published_date":"24/06/2013","last_updated_date":"24/06/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001405-pip01-12"},{"decision_number":"P/0130/2013","pip_number":"EMEA-001408-PIP01-12","active_substance":"valsartan;hydrochlorothiazide;rosuvastatin","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of thromboembolic events;Treatment of dyslipidaemia;Treatment of elevated cholesterol;Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/05/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Krka, d.d., Novo mesto; Slovenia; dragan.priselac@krka.biz ; Tel. +386 73322741; Fax +386 73322742","first_published_date":"24/06/2013","last_updated_date":"24/06/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001408-pip01-12"},{"decision_number":"P/0128/2013","pip_number":"EMEA-001403-PIP01-12","active_substance":"menotrophin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of female infertility","routes_of_administration":"Subcutaneous use;Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/05/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Laboratoires Genevrier; France; amy.whyte@regulis.com ; Tel. 44 (0) 1442 890903","first_published_date":"24/06/2013","last_updated_date":"24/06/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001403-pip01-12"},{"decision_number":"P/0131/2013","pip_number":"EMEA-001447-PIP01-12","active_substance":"rosuvastatin;ezetimibe","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of elevated cholesterol","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/05/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"EGIS Pharmaceuticals PLC; Hungary; registry@egis.hu ; Tel. +361 18032414","first_published_date":"24/06/2013","last_updated_date":"24/06/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001447-pip01-12"},{"decision_number":"P/0121/2013","pip_number":"EMEA-000366-PIP04-12","active_substance":"adalimumab","invented_name":"Humira; Humira","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of hidradenitis suppurativa","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/05/2013","compliance_outcome":"Positive","compliance_opinion_date":"01/04/2016","compliance_procedure_number":"EMEA-C-000366-PIP04-12","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)791 988 1614","first_published_date":"21/06/2013","last_updated_date":"21/06/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000366-pip04-12"},{"decision_number":"P/0090/2013","pip_number":"EMEA-000425-PIP02-10-M04","active_substance":"Bosentan","invented_name":"Tracleer; Tracleer","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Film-coated tablet;Dispersible tablet","condition_indication":"Treatment of interstitial pulmonary fibrosis;Treatment of pulmonary arterial hypertension;Treatment of systemic sclerosis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/04/2013","compliance_outcome":"Positive","compliance_opinion_date":"21/03/2014","compliance_procedure_number":"EMEA-C-000425-PIP02-10-M04","contact_for_public_enquiries":"Actelion Registration LtdTel. +41 615656565E-mail: clinical-trials-disclosure@its.jnj.com","first_published_date":"04/01/2013","last_updated_date":"31/05/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000425-pip02-10-m04"},{"decision_number":"P/0092/2013","pip_number":"EMEA-000822-PIP01-09-M01","active_substance":"bucelipase alfa","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Powder for oral solution","condition_indication":"Prevention of growth retardation due to lack of bile-salt-stimulated lipase in enteral nutrition","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/04/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Swedish Orphan Biovitrum AB; E-mail: communication@sobi.com; Country: Sweden; Tel. +46 86972000","first_published_date":"08/04/2011","last_updated_date":"31/05/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000822-pip01-09-m01"},{"decision_number":"P/0084/2013","pip_number":"EMEA-000013-PIP01-07-M03","active_substance":"recombinant L-asparaginase","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution for injection or infusion","condition_indication":"Treatment of acute lymphoblastic leukaemia;Treatment of lymphoblastic lymphoma","routes_of_administration":"Intravenous use;Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/04/2013","compliance_outcome":"Positive","compliance_opinion_date":"14/06/2013","compliance_procedure_number":"EMEA-C-000013-PIP01-07-M03","contact_for_public_enquiries":"Medac Gesellschaft für klinische Spezialpräparate mbH; E-mail: j.kuehnel@medac.de; Country: Germany; Tel. +49 41038006413; Fax: +49 41038009130","first_published_date":"06/03/2009","last_updated_date":"31/05/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000013-pip01-07-m03"},{"decision_number":"P/0101/2013","pip_number":"EMEA-000627-PIP01-09-M04","active_substance":"ivabradine hydrochloride","invented_name":"Corlentor; Corlentor","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet;Solution for injection;Oral solution","condition_indication":"Treatment of angina pectoris;Treatment of chronic heart failure;Treatment of coronary artery disease","routes_of_administration":"Intravenous use;Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/04/2013","compliance_outcome":"Positive","compliance_opinion_date":"10/10/2014","compliance_procedure_number":"EMEA-C-000627-PIP01-09-M04","contact_for_public_enquiries":"Les Laboratoires ServierTel. +33 1 55 72 60 00E-mail: mail.pip.enquiries@fr.netgrs.com","first_published_date":"12/05/2011","last_updated_date":"31/05/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000627-pip01-09-m04"},{"decision_number":"P/0098/2013","pip_number":"EMEA-001392-PIP01-12","active_substance":"chlormethine","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Gel","condition_indication":"Treatment of Cutaneous T-Cell Lymphoma","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/04/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Actelion Registration LtdTel. +41 919851950E-mail: paediatrics-info@helsinn.com","first_published_date":"31/05/2013","last_updated_date":"31/05/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001392-pip01-12"},{"decision_number":"P/0111/2013","pip_number":"EMEA-001309-PIP01-12","active_substance":"palivizumab","invented_name":"Synagis; Synagis","therapeutic_area":"Neonatology-Paediatric Intensive Care","pharmaceutical_forms":"Solution for injection;Powder and solvent for solution for injection","condition_indication":"Prevention of lower respiratory tract disease caused by respiratory syncytial virus","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"30/04/2013","compliance_outcome":"Positive","compliance_opinion_date":"09/08/2013","compliance_procedure_number":"EMEA-C-001309-PIP01-12","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. : +44 1628644475","first_published_date":"31/05/2013","last_updated_date":"31/05/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001309-pip01-12"},{"decision_number":"P/0102/2013","pip_number":"EMEA-000628-PIP01-09-M04","active_substance":"ivabradine hydrochloride","invented_name":"Procoralan; Procoralan","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet;Solution for injection;Oral solution","condition_indication":"Treatment of angina pectoris;Treatment of chronic heart failure;Treatment of coronary artery disease","routes_of_administration":"Intravenous use;Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/04/2013","compliance_outcome":"Positive","compliance_opinion_date":"10/10/2014","compliance_procedure_number":"EMEA-C-000628-PIP01-09-M04","contact_for_public_enquiries":"Les Laboratoires ServierTel. +33 1 55 72 60 00E-mail: mail.pip.enquiries@fr.netgrs.com","first_published_date":"12/05/2011","last_updated_date":"31/05/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000628-pip01-09-m04"},{"decision_number":"P/0095/2013","pip_number":"EMEA-001167-PIP02-11-M01","active_substance":"atomoxetine (hydrochloride)","invented_name":"Strattera","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of Attention Deficit Hyperactivity Disorder (ADHD)","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/04/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"19/01/2012","last_updated_date":"31/05/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001167-pip02-11-m01"},{"decision_number":"P/0085/2013","pip_number":"EMEA-000132-PIP01-07-M04","active_substance":"voclosporin","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Oral liquid;Capsule, soft","condition_indication":"Treatment of non-infectious uveitis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/04/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Lux Biosciences GmbH; E-mail: info@luxbio.com; Country: Germany; Tel. +49 8924213109","first_published_date":"26/08/2010","last_updated_date":"31/05/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000132-pip01-07-m04"},{"decision_number":"P/0113/2013","pip_number":"EMEA-001390-PIP01-12","active_substance":"Losartan potassium;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/04/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; E-mail: admin@wainwrightassociates.co.uk; Country: Ireland; Tel. +44 (0)1628 530554","first_published_date":"31/05/2013","last_updated_date":"31/05/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001390-pip01-12"},{"decision_number":"P/0087/2013","pip_number":"EMEA-000205-PIP01-08-M02","active_substance":"ceftobiprole medocaril (sodium)","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of complicated skin and soft-tissue infections","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/04/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Basilea Pharmaceutica International Ltd.; Tel. +41 616061400; E-mail: medical.information@basilea.com","first_published_date":"06/03/2009","last_updated_date":"31/05/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000205-pip01-08-m02"},{"decision_number":"P/0082/2013","pip_number":"EMEA-001288-PIP01-12","active_substance":"1-(2R,5R)-5-ethynyl-5-(hydroxymethyl)-2,5-dihydro-2-furanyl)-5-methyl-2,4(1H,3H)-pyrimidinedione (BMS-986001)","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral solid dosage form","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/03/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb International Corporation; E-mail: yoshida@oncolys.com; Tel. +81354721578;  ","first_published_date":"03/05/2013","last_updated_date":"03/05/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001288-pip01-12"},{"decision_number":"P/0080/2013","pip_number":"EMEA-001400-PIP01-12","active_substance":"sialic acid","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Modified-release tablet","condition_indication":"Treatment of distal myopathy, Nonaka type (hereditary inclusion-body myopathy)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/03/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ultragenyx UK Limited c/o Regus; Tel. +1 (415) 4838148; Fax +1 (415) 4838920; E-mail: rhostutler@ultragenyx.com","first_published_date":"03/05/2013","last_updated_date":"03/05/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001400-pip01-12"},{"decision_number":"P/0077/2013","pip_number":"EMEA-001385-PIP01-12","active_substance":"bisoprolol;amlodipine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of ischaemic coronary artery disorders;Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"26/03/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Krka d.d. Novo Mesto; E-mail: bernarda.bevc@krka.biz; Country: Slovenia; Tel. + 386 73312730; Fax + 386 73322742","first_published_date":"03/05/2013","last_updated_date":"03/05/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001385-pip01-12"},{"decision_number":"P/0076/2013","pip_number":"EMEA-001381-PIP01-12","active_substance":"lutetium (177Lu)","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Radiopharmaceutical precursor;Solution","condition_indication":"Radiolabelling agent","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"26/03/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"I.D.B. Radiopharmacy B.V.; E-mail: je.vaessen@bfc.nl; Country: The Netherlands; Tel. + 31 402453611; Fax + 31 402374460","first_published_date":"03/05/2013","last_updated_date":"03/05/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001381-pip01-12"},{"decision_number":"P/0075/2013","pip_number":"EMEA-001327-PIP01-12","active_substance":"alendronic acid;colecalciferol","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of osteoporosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"26/03/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Teva Pharma B.V.; E-mail: lidija.brnic@tevapharm.com; Country: The Netherlands; Tel. +38 53722150","first_published_date":"03/05/2013","last_updated_date":"03/05/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001327-pip01-12"},{"decision_number":"P/0070/2013","pip_number":"EMEA-001245-PIP01-11","active_substance":"hexaminolevulinate","invented_name":"Hexvix","therapeutic_area":"Oncology","pharmaceutical_forms":"Vaginal ointment;Powder and solvent for intravesical solution","condition_indication":"Diagnosis of bladder cancer;Treatment of cervical dysplasia","routes_of_administration":"Vaginal use;Intravesical use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"26/03/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Photocure ASA; E-mail: info@photocure.no; Country: Norway; Tel. + 47 22062216; Fax + 47 22062218","first_published_date":"03/05/2013","last_updated_date":"03/05/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001245-pip01-11"},{"decision_number":"P/0042/2013","pip_number":"EMEA-000550-PIP02-10-M01","active_substance":"cilengitide","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of high-grade glioma","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/03/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck KGaA; E-mail: service@merck.de; Country: Germany; Tel. +49 6151720","first_published_date":"03/10/2011","last_updated_date":"03/05/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000550-pip02-10-m01"},{"decision_number":"P/0068/2013","pip_number":"EMEA-001100-PIP01-10","active_substance":"anacetrapib","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet;Age appropriate oral solid dosage form","condition_indication":"Prevention of cardiovascular events in patients with hypercholesterolaemia;Treatment of hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"26/03/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"03/05/2013","last_updated_date":"03/05/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001100-pip01-10"},{"decision_number":"P/0055/2013","pip_number":"EMEA-000764-PIP02-11","active_substance":"etoxybamide","invented_name":"","therapeutic_area":"Anaesthesiology","pharmaceutical_forms":"Solution for injection/infusion","condition_indication":"Sedation","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"25/03/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dr. Franz Köhler Chemie GmbH; E-mail: info@koehler-chemie.de; Country: Germany; Tel. + 49 625110830; Fax + 49 62511083246","first_published_date":"02/05/2013","last_updated_date":"02/05/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000764-pip02-11"},{"decision_number":"P/0048/2013","pip_number":"EMEA-001267-PIP01-12","active_substance":"N-{4-chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl}-4-(1,1-dimethylethyl) benzenesulfonamide, sodium salt","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Capsule, hard;Age appropriate dosage form, other","condition_indication":"Treatment of Crohn's disease","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/03/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Glaxo Group Limited; E-mail: eu.paediatric-plans@gsk.com; Country: United Kingdom; Tel. + +44 (0)20 8990 3650; Fax + +44 (0)20 8990 3511","first_published_date":"30/04/2013","last_updated_date":"30/04/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001267-pip01-12"},{"decision_number":"P/0045/2013","pip_number":"EMEA-001033-PIP02-11","active_substance":"enzastaurin hydrochloride","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of diffuse large B-cell lymphoma","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/03/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"30/04/2013","last_updated_date":"30/04/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001033-pip02-11"},{"decision_number":"P/0040/2013","pip_number":"EMEA-001380-PIP01-12","active_substance":"amlodipine;losartan","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/02/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Krka, d.d., Novo mesto; E-mail: tomaz.kralj@krka.biz; Country: Slovenia; Tel. + 386 73312055; Fax + 386 73322742","first_published_date":"23/04/2013","last_updated_date":"23/04/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001380-pip01-12"},{"decision_number":"P/0039/2013","pip_number":"EMEA-001377-PIP01-12","active_substance":"valsartan;Indapamide","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet;Prolonged-release tablet","condition_indication":"Treatment of heart failure;Treatment of acute myocardial infarction;Treatment of essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/02/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gedeon Richter Plc.; E-mail: mrprichter@richter.hu; Country: Hungary; Tel. + 36 14314040; Fax + 36 14315415","first_published_date":"23/04/2013","last_updated_date":"23/04/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001377-pip01-12"},{"decision_number":"P/0038/2013","pip_number":"EMEA-001355-PIP01-12","active_substance":"perindopril;Indapamide;amlodipine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/02/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pharma-Regist Kft.; E-mail: vera.ruda@pharmaregist.hu; Country: Hungary; Tel. + 36 13187160; Fax + 36 13188546","first_published_date":"23/04/2013","last_updated_date":"23/04/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001355-pip01-12"},{"decision_number":"P/0037/2013","pip_number":"EMEA-001298-PIP01-12","active_substance":"azithromycin","invented_name":"","therapeutic_area":"Neonatology-Paediatric Intensive Care","pharmaceutical_forms":"Age appropriate dosage form for parenteral use","condition_indication":"Prevention of bronchopulmonary dysplasia","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/02/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Only For Children Pharmaceuticals; E-mail: evelyne.jacqzaigrain@gmail.com; Country: France; Tel. + 33 140034099","first_published_date":"23/04/2013","last_updated_date":"23/04/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001298-pip01-12"},{"decision_number":"P/0034/2013","pip_number":"EMEA-001364-PIP01-12","active_substance":"atorvastatin calcium;amlodipine besilate","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events in hypertensive patients and diabetes mellitus type II patients with multiple risk factors for cardiovascular disease;Treatment of concomitant angina and dyslipidaemia;Treatment of concomitant hypertension and dyslipidaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"26/02/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"HCS bvba; E-mail: info@hcsbvba.be; Country: Belgium; Tel. + 32 475591545; Fax + 32 33215069","first_published_date":"23/04/2013","last_updated_date":"23/04/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001364-pip01-12"},{"decision_number":"P/0032/2013","pip_number":"EMEA-001317-PIP01-12","active_substance":"Frovatriptan (succinate monohydrate);Dexketoprofen (trometamol)","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of migraine","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"26/02/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Menarini Ricerche S.p.A.; E-mail: prijli@menarini.it; Tel. + 39 0555680633","first_published_date":"23/04/2013","last_updated_date":"23/04/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001317-pip01-12"},{"decision_number":"P/0030/2013","pip_number":"EMEA-001200-PIP01-11","active_substance":"proteinase, metallo- (synthetic nociceptin receptor-binding) 1290102-81-6 (AGN214868)","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of overactive bladder;Treatment of postherpetic neuralgia","routes_of_administration":"Intradermal use;Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/02/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergan Pharmaceuticals Ireland; Ireland; Tel. +44 (0)1628 494026; Fax +44 (0)1628 494058; E-mail: uk_medinfo@allergan.com","first_published_date":"23/04/2013","last_updated_date":"23/04/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001200-pip01-11"},{"decision_number":"P/0029/2013","pip_number":"EMEA-001131-PIP02-12","active_substance":"strontium succinate;vitamin D3","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of osteoporosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"26/02/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierE-mail: mail.pip.enquiries@servier.comTel.: +33 155726000","first_published_date":"23/04/2013","last_updated_date":"23/04/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001131-pip02-12"},{"decision_number":"P/0022/2013","pip_number":"EMEA-000733-PIP02-12","active_substance":"strontium succinate","invented_name":"Osseor; Protelos; Protelos; Osseor","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Granules for oral suspension;Tablet","condition_indication":"Treatment of osteoporosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"25/02/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierTel. +33 1 55 72 60 00E-mail: mail.pip.enquiries@fr.netgrs.com","first_published_date":"23/04/2013","last_updated_date":"23/04/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000733-pip02-12"},{"decision_number":"P/0026/2013","pip_number":"EMEA-000827-PIP03-11","active_substance":"aztreonam","invented_name":"Cayston; Cayston","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder and solvent for nebuliser solution","condition_indication":"Treatment of Gram-negative endobronchial infection in bronchiectasis patients","routes_of_administration":"Inhalation use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"26/02/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gilead Sciences International Ltd; E-mail: regulatory.pip@gilead.com; Country: United Kingdom; Tel. +44 (0)1223 897300; Fax +44 (0)1223 897284","first_published_date":"23/04/2013","last_updated_date":"23/04/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000827-pip03-11"},{"decision_number":"P/0001/2013","pip_number":"EMEA-000185-PIP01-08-M05","active_substance":"catridecacog","invented_name":"NovoThirteen; NovoThirteen","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of congenital factor-XIII A-subunit deficiency","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/01/2013","compliance_outcome":"Positive","compliance_opinion_date":"16/12/2016","compliance_procedure_number":"EMEA-C-000185-PIP01-08-M05","contact_for_public_enquiries":"Novo Nordisk A/S; E-mail: paediatrics@novonordisk.com; Tel. +45 4444 8888","first_published_date":"10/01/2011","last_updated_date":"05/04/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000185-pip01-08-m05"},{"decision_number":"P/0004/2013","pip_number":"EMEA-000511-PIP01-08-M04","active_substance":"propranolol hydrochloride","invented_name":"Hemangiol; Hemangiol","therapeutic_area":"Dermatology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of haemangioma","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"21/01/2013","compliance_outcome":"Positive","compliance_opinion_date":"14/02/2013","compliance_procedure_number":"EMEA-C-000511-PIP01-08-M04","contact_for_public_enquiries":"Pierre Fabre Dermatologie; E-mail: peggy.michel@pierre-fabre.com; Country: France; Tel. +33 534506450; Fax +33 149100216","first_published_date":"24/11/2010","last_updated_date":"05/04/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000511-pip01-08-m04"},{"decision_number":"P/0007/2013","pip_number":"EMEA-001281-PIP01-12","active_substance":"morphine;oxycodone","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Capsule, hard","condition_indication":"","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/01/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"QRxPharma Inc.; E-mail: michael.schroeder@qrxpharma.com; Country: United States; Tel. +1 (908)5062900; Fax +1 (908)5062918","first_published_date":"03/04/2013","last_updated_date":"03/04/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001281-pip01-12"},{"decision_number":"P/0011/2013","pip_number":"EMEA-001358-PIP01-12","active_substance":"perindopril;Indapamide;amlodipine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/01/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Billev Pharma Aps; E-mail: katja.pecjak@billevpharma.dk; Country: Denmark; Tel. +386 12322095; Fax +386 12322096","first_published_date":"03/04/2013","last_updated_date":"03/04/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001358-pip01-12"},{"decision_number":"P/0010/2013","pip_number":"EMEA-001353-PIP01-12","active_substance":"atorvastatin calcium;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events in hypertensive patients and diabetes mellitus type II patients with multiple risk factors for cardiovascular disease;Treatment of concomitant angina and dyslipidaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/01/2013","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Billev Pharma Aps; E-mail: katja.pecjak@billevpharma.dk; Country: Denmark; Tel. +386 12322095; Fax +386 12322096","first_published_date":"03/04/2013","last_updated_date":"03/04/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001353-pip01-12"},{"decision_number":"P/0297/2012","pip_number":"EMEA-001323-PIP02-12","active_substance":"Elagolix","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of endometriosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/12/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel: +441628644475","first_published_date":"11/03/2013","last_updated_date":"11/03/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001323-pip02-12"},{"decision_number":"P/0298/2012","pip_number":"EMEA-001334-PIP01-12","active_substance":"ivermectin","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Cream","condition_indication":"Treatment of rosacea","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/12/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Galderma R&D; France; E-mail: martine.ortega@galderma.com ; Tel. +33 492952906; Fax +33 493957071","first_published_date":"11/02/2013","last_updated_date":"11/02/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001334-pip01-12"},{"decision_number":"P/0299/2012","pip_number":"EMEA-001345-PIP01-12","active_substance":"skeletal-muscle-derived cells","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Cell suspension for infusion","condition_indication":"Treatment of stress urinary incontinence","routes_of_administration":"Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/12/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Innovacell Biotechnologie AG; Austria; E-mail: paediatrics@innovacell.com; Tel. +43 512573680; Fax +43 5125736805","first_published_date":"11/02/2013","last_updated_date":"11/02/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001345-pip01-12"},{"decision_number":"P/0296/2012","pip_number":"EMEA-001323-PIP01-12","active_substance":"Elagolix","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of uterine leiomyoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/12/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. : +44 1628644475","first_published_date":"08/02/2013","last_updated_date":"08/02/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001323-pip01-12"},{"decision_number":"P/0310/2012","pip_number":"EMEA-001326-PIP01-12","active_substance":"human dermal fibroblasts cultured on bioresorbable polyglactin mesh (ABH001)","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Living tissue equivalent","condition_indication":"Treatment of epidermolysis bullosa","routes_of_administration":"Topical use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"21/12/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"TMC Pharma; United States; E-mail: paediatrics@abh.com ; Tel. +1 8662891915; Fax +1 8587545371","first_published_date":"08/02/2013","last_updated_date":"08/02/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001326-pip01-12"},{"decision_number":"P/0311/2012","pip_number":"EMEA-001329-PIP01-12","active_substance":"expanded autologous bone marrow-derived osteoblastic cells","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of non-union fracture;Treatment of osteonecrosis","routes_of_administration":"Intraosseous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/12/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bone Therapeutics S.A.; Belgium; E-mail: preob.on3@bonetherapeutics.com, preob.nu3@bonetherapeutics.com ; Tel. +32 25295990; Fax +32 25295993","first_published_date":"08/02/2013","last_updated_date":"08/02/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001329-pip01-12"},{"decision_number":"P/0301/2012","pip_number":"EMEA-000602-PIP02-12","active_substance":"faldaprevir","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Capsule, soft;Oral solution","condition_indication":"Treatment of chronic viral hepatitis C","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"20/12/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"08/02/2013","last_updated_date":"08/02/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000602-pip02-12"},{"decision_number":"P/0293/2012","pip_number":"EMEA-000459-PIP01-08-M02","active_substance":"prucalopride succinate","invented_name":"Resolor","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Film-coated tablet;Oral solution","condition_indication":"Treatment of chronic constipation;Treatment of opioid-induced constipation","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"18/12/2012","compliance_outcome":"Positive","compliance_opinion_date":"06/12/2013","compliance_procedure_number":"EMEA-C-000459-PIP01-08-M02","contact_for_public_enquiries":"Takeda Pharmaceuticals International AG Ireland Branch; E-mail: medinfoemea@takeda.com; Tel. +80066838470","first_published_date":"26/04/2012","last_updated_date":"07/02/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000459-pip01-08-m02"},{"decision_number":"P/0261/2012","pip_number":"EMEA-001325-PIP01-12","active_substance":"N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino]benzenesulfonamide dihydrochloride monohydrate (SAR302503A)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of essential thrombocythaemia;Treatment of polycythaemia vera;Treatment of primary myelofibrosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/11/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme Ltd; France; sylvie.gabriel@sanofi.com; Tel. +33 153774152; Fax +33 153774133","first_published_date":"11/01/2013","last_updated_date":"11/01/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001325-pip01-12"},{"decision_number":"P/0260/2012","pip_number":"EMEA-001312-PIP01-12","active_substance":"alpha-1 proteinase inhibitor","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Powder and solvent for solution for infusion","condition_indication":"Treatment of chronic obstructive pulmonary disease due to alpha1-antitrypsin deficiency;Treatment of liver disease due to alpha1-antitrypsin deficiency","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/11/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CSL Behring GmbH; Tel. 41 313445118E-mail: PIP-CSLBehring@cslbehring.com; &nbsp","first_published_date":"11/01/2013","last_updated_date":"11/01/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001312-pip01-12"},{"decision_number":"P/0268/2012","pip_number":"EMEA-001307-PIP01-12","active_substance":"lopinavir;ritonavir;lamivudine","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/11/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. : +44 1628644475","first_published_date":"11/01/2013","last_updated_date":"11/01/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001307-pip01-12"},{"decision_number":"P/0282/2012","pip_number":"EMEA-000408-PIP02-12","active_substance":"icatibant","invented_name":"Firazyr","therapeutic_area":"Other","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of ACE inhibitor-induced angioedema","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/11/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Shire Orphan Therapies GmbH; United States; E-mail: medinfoeu-ceemea@shire.com; Tel. +44 (0)2196 65520; Fax +1 7814822954","first_published_date":"07/01/2013","last_updated_date":"07/01/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000408-pip02-12"},{"decision_number":"P/0281/2012","pip_number":"EMEA-001239-PIP01-11","active_substance":"brimonidine tartrate","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Gel","condition_indication":"Treatment of rosacea","routes_of_administration":"Topical use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/11/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Galderma International; France; regulatory.affairs@galderma.com; Tel. +33 493957105; Fax +33 492952101","first_published_date":"07/01/2013","last_updated_date":"07/01/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001239-pip01-11"},{"decision_number":"P/0271/2012","pip_number":"EMEA-001344-PIP01-12","active_substance":"ezetimibe;rosuvastatin","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/11/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Zentiva, k.s.; Czech Republic; blanka.zoubkova@zentiva.com; Tel. +42 0267243574","first_published_date":"04/01/2013","last_updated_date":"04/01/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001344-pip01-12"},{"decision_number":"P/0266/2012","pip_number":"EMEA-001234-PIP01-11","active_substance":"(2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2,6-dihydro-2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine (MK-3102)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Capsule;Capsule, hard","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"20/11/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe), Inc.; Belgium; E-mail: pip.information@merck.com; Tel. +31 412663179; Fax +31 412662571","first_published_date":"04/01/2013","last_updated_date":"04/01/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001234-pip01-11"},{"decision_number":"P/0270/2012","pip_number":"EMEA-001343-PIP01-12","active_substance":"valsartan;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/11/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Zentiva, k.s.; Czech Republic; blanka.zoubkova@zentiva.com; Tel. +42 0267243574","first_published_date":"04/01/2013","last_updated_date":"04/01/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001343-pip01-12"},{"decision_number":"P/0269/2012","pip_number":"EMEA-001337-PIP01-12","active_substance":"perindopril;Indapamide;amlodipine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/11/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Krka, d.d., Novo mesto; Slovenia; martina.crevar@krka.biz; Tel. +38 516312155; Fax +38 516312153","first_published_date":"04/01/2013","last_updated_date":"04/01/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001337-pip01-12"},{"decision_number":"P/0262/2012","pip_number":"EMEA-000063-PIP01-07-M01","active_substance":"nicotinic acid;laropiprant","invented_name":"Tredaptive; Tredaptive","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Age appropriate oral solid dosage form;Modified-release tablet","condition_indication":"Prevention of major vascular and major coronary events;Treatment of dyslipidaemia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"20/11/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp and Dohme (Europe), Inc.; Belgium; Tel. +33 180464738; E-mail: pip.information@merck.com","first_published_date":"04/01/2013","last_updated_date":"04/01/2013","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000063-pip01-07-m01"},{"decision_number":"P/0252/2012","pip_number":"EMEA-001095-PIP02-12","active_substance":"natalizumab","invented_name":"Tysabri; Tysabri","therapeutic_area":"Neurology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of multiple sclerosis","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"19/10/2012","compliance_outcome":"Positive","compliance_opinion_date":"16/12/2016","compliance_procedure_number":"EMEA-C-001095-PIP02-12","contact_for_public_enquiries":"Biogen Idec Limited E-mail: Hema.borde@biogenidec.com Tel. +44 1628 512674","first_published_date":"27/11/2012","last_updated_date":"27/11/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001095-pip02-12"},{"decision_number":"P/0249/2012","pip_number":"EMEA-001322-PIP01-12","active_substance":"Etarfolatide","invented_name":"","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Kit for radiopharmaceutical preparation","condition_indication":"Diagnosis of folate-receptor status in malignant tissues","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/10/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Endocyte Europe B.V.; United States; kcarlson@endocyte.com; Phone: +1 7658070658","first_published_date":"27/11/2012","last_updated_date":"27/11/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001322-pip01-12"},{"decision_number":"P/0248/2012","pip_number":"EMEA-001321-PIP01-12","active_substance":"folic acid","invented_name":"","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Solution for injection;Solution for infusion","condition_indication":"Diagnosis of folate-receptor status in malignant tissues","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/10/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Endocyte Europe B.V.; United States; kcarlson@endocyte.com; Phone: +1 7658070658","first_published_date":"27/11/2012","last_updated_date":"27/11/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001321-pip01-12"},{"decision_number":"P/0247/2012","pip_number":"EMEA-001342-PIP01-12","active_substance":"atorvastatin;ramipril;acetyl salicylic acid","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of cardiovascular disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/10/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ferrer Internacional, S.A.; E-mail: smartin@ferrer.com​; Tel. +34 9350 93227","first_published_date":"27/11/2012","last_updated_date":"27/11/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001342-pip01-12"},{"decision_number":"P/0246/2012","pip_number":"EMEA-001320-PIP01-12","active_substance":"perindopril (tosilate);amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/10/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Teva Pharma B.V.; Croatia; lidija.brnic@pliva.com; Phone: +38 513722150","first_published_date":"27/11/2012","last_updated_date":"27/11/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001320-pip01-12"},{"decision_number":"P/0245/2012","pip_number":"EMEA-001319-PIP01-12","active_substance":"Candesartan cilexetil;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/10/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Zentiva, k.s.; Czech Republic; blanka.zoubkova@zentiva.com; Tel. +42 0267243574","first_published_date":"27/11/2012","last_updated_date":"27/11/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001319-pip01-12"},{"decision_number":"P/0244/2012","pip_number":"EMEA-001302-PIP01-12","active_substance":"Dexketoprofen (trometamol);tramadol hydrochloride","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of acute pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/10/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Menarini Ricerche SpA; Italy; prijli@menarini.it; Phone: +39 0555680 633; Fax: +39 0555680689","first_published_date":"27/11/2012","last_updated_date":"27/11/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001302-pip01-12"},{"decision_number":"P/0242/2012","pip_number":"EMEA-001196-PIP01-11","active_substance":"Fostamatinib","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis and juvenile idiopathic arthritis)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/10/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Astrazeneca AB (France); Tel. +33 609050197; E-mail: solange.rohou@astrazeneca.com","first_published_date":"27/11/2012","last_updated_date":"27/11/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001196-pip01-11"},{"decision_number":"P/0229/2012","pip_number":"EMEA-000439-PIP02-11","active_substance":"bitopertin","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of schizophrenia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/10/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration Limited; Switzerland; E-mail: info.paediatrics@roche.com; Tel. +41 616879411; Fax +41 616879233","first_published_date":"27/11/2012","last_updated_date":"27/11/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000439-pip02-11"},{"decision_number":"P/0224/2012","pip_number":"EMEA-001294-PIP01-12","active_substance":"azilsartan medoxomil;chlortalidone","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/10/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Pharma A/S; Lars.olsen@takeda.com; Tel. : +45 46771111; Fax: +45 46756560","first_published_date":"27/11/2012","last_updated_date":"27/11/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001294-pip01-12"},{"decision_number":"P/0223/2012","pip_number":"EMEA-001269-PIP01-12","active_substance":"rosuvastatin;acetylsalicylic acid","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet;Gastro-resistant tablet","condition_indication":"Treatment of cardiovascular disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/10/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"EGIS Pharmaceuticals PLC; Hungary; registry@egis.hu; Phone: +36 18032414; Fax: +36 18032415","first_published_date":"27/11/2012","last_updated_date":"27/11/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001269-pip01-12"},{"decision_number":"P/0256/2012","pip_number":"EMEA-000235-PIP02-10-M02","active_substance":"aripiprazole","invented_name":"Abilify","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Tablet;Orodispersible tablet;Oral solution;Solution for injection","condition_indication":"Treatment of bipolar affective disorder;Treatment of schizophrenia","routes_of_administration":"Oral use;Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"26/10/2012","compliance_outcome":"Positive","compliance_opinion_date":"24/06/2016","compliance_procedure_number":"EMEA-C-000235-PIP02-10-M02","contact_for_public_enquiries":"Otsuka Pharmaceutical Europe Ltd.; E-mail: medinfo.emea@bms.com; Country: United Kingdom; Tel. +44 1895 523686; Fax +44 1895 52378","first_published_date":"13/05/2011","last_updated_date":"26/11/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000235-pip02-10-m02"},{"decision_number":"P/0250/2012","pip_number":"EMEA-000510-PIP02-10-M02","active_substance":"tazarotene","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Cream","condition_indication":"Treatment of lamellar ichthyosis","routes_of_administration":"Cutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"24/10/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Orfagen; France; E-mail: info@orfagen.com; Tel. +33 5345 06457; Fax +33 5345 03457","first_published_date":"07/06/2011","last_updated_date":"26/11/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000510-pip02-10-m02"},{"decision_number":"P/0234/2012","pip_number":"EMEA-001051-PIP01-10-M03","active_substance":"Influenza virus type A, H1N1;influenza virus type A, H3N2;influenza virus type B, Yamagata lineage;influenza virus type B, Victoria lineage","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Nasal spray","condition_indication":"Prevention of influenza infection","routes_of_administration":"Nasal use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"12/10/2012","compliance_outcome":"Positive","compliance_opinion_date":"14/06/2013","compliance_procedure_number":"EMEA-001051-PIP01-10-M03","contact_for_public_enquiries":"MedImmune Limited; United Kingdom; paediatrics@medimmune.com; Phone: +44 1223 471471; Fax: +44 1223 890339","first_published_date":"30/11/2011","last_updated_date":"26/11/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001051-pip01-10-m03"},{"decision_number":"P/0233/2012","pip_number":"EMEA-000302-PIP01-08-M03","active_substance":"pitavastatin (calcium)","invented_name":"Pitavastatin and associated names","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of disorders of lipoprotein metabolism and other lipidaemias","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/10/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kowa Pharmaceutical Europe Company Ltd; E-mail: nhounslow@kowa.co.uk; Country: United Kingdom; Phone: +44 1189229000","first_published_date":"21/07/2008","last_updated_date":"26/11/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000302-pip01-08-m03"},{"decision_number":"P/0232/2012","pip_number":"EMEA-000301-PIP01-08-M03","active_substance":"pitavastatin (calcium)","invented_name":"Vezepra and associated names","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of disorders of lipoprotein metabolism and other lipidaemias","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/10/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kowa Pharmaceutical Europe Company Ltd; E-mail: nhounslow@kowa.co.uk; Country: United Kingdom; Phone: +44 118922900","first_published_date":"21/07/2008","last_updated_date":"23/11/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000301-pip01-08-m03"},{"decision_number":"P/0213/2012","pip_number":"EMEA-000404-PIP02-12","active_substance":"Lapatinib ditosilate monohydrate","invented_name":"Tyverb; Tyverb","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet;Powder for oral suspension","condition_indication":"Treatment of gastro oesophageal junction adenocarcinoma;Treatment of oesophageal adenocarcinoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/09/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Glaxo Group Ltd; Tel. +41 613241111; E-mail: paediatric.enquiries@novartis.com","first_published_date":"17/10/2012","last_updated_date":"17/10/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000404-pip02-12"},{"decision_number":"P/0217/2012","pip_number":"EMEA-001300-PIP01-12","active_substance":"Icosapent ethyl","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, soft","condition_indication":"Treatment of hypertriglyceridaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/09/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amarin Pharmaceuticals Ireland Limited; United States; libette.luce@amarincorp.com ; +1 9083261233","first_published_date":"17/10/2012","last_updated_date":"17/10/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001300-pip01-12"},{"decision_number":"P/0201/2012","pip_number":"EMEA-001286-PIP01-12","active_substance":"recombinant human antibody against activin type IIB receptors","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Concentrate for solution for injection","condition_indication":"Treatment of sporadic inclusion body myositis","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/08/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"18/09/2012","last_updated_date":"18/09/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001286-pip01-12"},{"decision_number":"P/0195/2012","pip_number":"EMEA-001279-PIP01-12","active_substance":"co-crystal of tramadol (hydrochloride);celecoxib","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/08/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Laboratorios del Dr. Esteve S.A.; Spain; evalenti@esteve.es; +34 934466000","first_published_date":"18/09/2012","last_updated_date":"18/09/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001279-pip01-12"},{"decision_number":"P/0188/2012","pip_number":"EMEA-001291-PIP01-12","active_substance":"lisinopril (dihydrate);amlodipine besilate;rosuvastatin calcium","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Cardiovascular-event prophylaxis;Treatment of dyslipidaemia;Treatment of elevated cholesterol;Treatment of heart failure;Treatment of ischaemic coronary artery disorders;Treatment of vascular hypertensive disorders","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/08/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gedeon Richter Plc.; Hungary; mrprichter@richter.hu; Phone: +36 14314040; Fax: +36 14315415","first_published_date":"18/09/2012","last_updated_date":"18/09/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001291-pip01-12"},{"decision_number":"P/0187/2012","pip_number":"EMEA-001277-PIP01-12","active_substance":"[N-((2S,3R,3aS,3´R,4a´R,6S,6a´R,6b´S,7aR,12a´S,12b´S,Z)-3,6,11´,12b´-tetramethyl-2´,3a,3´,4,4´,4a´,5,5´,6,6´,6a´,6b´,7,7a,7´,8´,10´,12´,12a´,12b´-icosahydro-1´H,3Hspiro[furo[3,2-b]pyridine-2,9´-naphtho[2,1-a]azulene]-3´-yl)methanesulfonamide hydrochloride]","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of chondrosarcoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/08/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Voisin Consulting; United States; irpr_info@info.com; Phone: +1 6174531336; Fax: +1 6174531001","first_published_date":"18/09/2012","last_updated_date":"18/09/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001277-pip01-12"},{"decision_number":"P/0186/2012","pip_number":"EMEA-001275-PIP01-12","active_substance":"sitagliptin;atorvastatin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus concomitant with hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/08/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe), Inc.; Belgium; E-mail: pip.information@merck.com; Tel. +31 412663179; Fax +31 412662571","first_published_date":"18/09/2012","last_updated_date":"18/09/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001275-pip01-12"},{"decision_number":"P/0181/2012","pip_number":"EMEA-001278-PIP01-12","active_substance":"rosuvastatin;ezetimibe","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet;Tablet","condition_indication":"Treatment of hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/08/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"EGIS Pharmaceuticals PLC; Country: Hungary; E-mail: registry@egis.hu; Tel. +36 1803 2414; Fax +36 18032415","first_published_date":"17/09/2012","last_updated_date":"17/09/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001278-pip01-12"},{"decision_number":"P/0180/2012","pip_number":"EMEA-001274-PIP01-12","active_substance":"autologous tumour-derived immunoglobulin idiotype coupled to keyhole limpet hemocyanin","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of mantle cell lymphoma","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/08/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biovest Europe Ltd.; Country: United States; dwcalder@accentia.net; Phone: +1 8138642558; Fax: +1 8132586912","first_published_date":"17/09/2012","last_updated_date":"17/09/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001274-pip01-12"},{"decision_number":"P/0175/2012","pip_number":"EMEA-001216-PIP01-12","active_substance":"tafluprost;timolol","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution;Solution","condition_indication":"Treatment of ocular hypertension;Treatment of glaucoma","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/07/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Santen Oy; mail@santen.de; Finland; +49 8984807822; +49 8984807860","first_published_date":"23/08/2012","last_updated_date":"23/08/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001216-pip01-12"},{"decision_number":"P/0167/2012","pip_number":"EMEA-001192-PIP01-11","active_substance":"peginterferon lambda-1a","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic hepatitis C","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/07/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb International Corporation; Tel. +44 1895523740; E-mail: medical.information@bms.com","first_published_date":"23/08/2012","last_updated_date":"23/08/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001192-pip01-11"},{"decision_number":"P/0165/2012","pip_number":"EMEA-001190-PIP01-11","active_substance":"asunaprevir","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Capsule, soft;Chewable tablet","condition_indication":"Treatment of chronic hepatitis C","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/08/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb International Corporation; Tel. +44 1895523740; E-mail: medical.information@bms.com","first_published_date":"23/08/2012","last_updated_date":"23/08/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001190-pip01-11"},{"decision_number":"P/0163/2012","pip_number":"EMEA-001159-PIP02-12","active_substance":"misoprostol","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Vaginal delivery system","condition_indication":"Induction of labour","routes_of_administration":"Vaginal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"23/07/2012","compliance_outcome":"Positive","compliance_opinion_date":"11/10/2012","compliance_procedure_number":"EMEA-C-001159-PIP02-12","contact_for_public_enquiries":"Ferring pharmaceuticals A/S; gb3-info@ferring.com ; United Kingdom; +44 1355293166; +44 1355269661","first_published_date":"23/08/2012","last_updated_date":"23/08/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001159-pip02-12"},{"decision_number":"P/0149/2012","pip_number":"EMEA-001284-PIP01-12","active_substance":"tivantinib","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hepatoblastoma","routes_of_administration":"Oral use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"24/07/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Daiichi Sankyo Development Limited; kourumova@dsd-eu.com ; United Kingdom; +44 1753482813; +44 1753899107","first_published_date":"22/08/2012","last_updated_date":"22/08/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001284-pip01-12"},{"decision_number":"P/0141/2012","pip_number":"EMEA-000006-PIP03-12","active_substance":"ezetimibe;simvastatin","invented_name":"Inegy and associated names","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Prevention of coronary heart disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/07/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme Limited; E-mail: regaffairseurope@organon.com; Tel: +31 412770000","first_published_date":"22/08/2012","last_updated_date":"22/08/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000006-pip03-12"},{"decision_number":"P/0135/2012","pip_number":"EMEA-000007-PIP04-12","active_substance":"ezetimibe","invented_name":"Ezetrol and associated names","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Prevention of coronary heart disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/07/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme Limited; E-mail: regaffairseurope@organon.com; Tel: +31 412770000","first_published_date":"22/08/2012","last_updated_date":"22/08/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000007-pip04-12"},{"decision_number":"P/0142/2012","pip_number":"EMEA-000414-PIP02-11","active_substance":"Ethanol","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Gel for injection","condition_indication":"Treatment of congenital venous malformations","routes_of_administration":"Intralesional use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"23/07/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Orphagen; info@orfagen.com; France; +33 534506458; +33 534503458","first_published_date":"22/08/2012","last_updated_date":"22/08/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000414-pip02-11"},{"decision_number":"P/0138/2012","pip_number":"EMEA-001110-PIP01-10-M01","active_substance":"human normal immunoglobulin","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of chronic inflammatory demyelinating polyradiculo-neuropathy;Treatment of idiopathic thrombocytopenic purpura as a model for immunomodulation;Treatment of primary immunodeficiency (PID) as model for replacement therapy","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"20/07/2012","compliance_outcome":"Positive","compliance_opinion_date":"11/10/2013","compliance_procedure_number":"EMEA-C-001110-PIP01-10-M01","contact_for_public_enquiries":"Octapharma Pharmazeutika Produktionsges.m.b.H; wolfgang.frenzel@octapharma.com; Austria; + 43 1610321201 ; + 43 1610329249","first_published_date":"21/12/2011","last_updated_date":"22/08/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001110-pip01-10-m01"},{"decision_number":"P/0157/2012","pip_number":"EMEA-000556-PIP01-09-M02","active_substance":"velaglucerase alfa","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Lyophilisate for solution for infusion","condition_indication":"Treatment of Gaucher disease, type 2;Gaucher disease, types 1 and 3","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"26/07/2012","compliance_outcome":"Positive","compliance_opinion_date":"29/01/2016","compliance_procedure_number":"EMEA-C-000556-PIP01-09-M02","contact_for_public_enquiries":"Shire Pharmaceuticals Ireland Limited; medinfouk@shire.com; United Kingdom; Phone +44 1256894000","first_published_date":"13/05/2011","last_updated_date":"22/08/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000556-pip01-09-m02"},{"decision_number":"P/0161/2012","pip_number":"EMEA-000036-PIP01-07-M06","active_substance":"13-valent pneumococcal polysaccharide conjugate vaccine: pneumococcal polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F; diphtheria CRM197 conjugate","invented_name":"Prevenar 13; Prevenar 13","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Disease caused by Streptococcus pneumoniae","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/04/2011","compliance_outcome":"Positive","compliance_opinion_date":"10/10/2014","compliance_procedure_number":"EMEA-C-000036-PIP01-07-M06","contact_for_public_enquiries":"Pfizer Limited; Tel. + 44 1304646607; E-mail: pip_enquiries@pfizer.com","first_published_date":"10/05/2011","last_updated_date":"21/08/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000036-pip01-07-m06"},{"decision_number":"P/0129/2012","pip_number":"EMEA-001144-PIP01-11","active_substance":"ulimorelin","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Prevention of post-operative ileus","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/07/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Norgine Ltd; United Kingdom; enquiries@norgine.com ; +44 1895 826600","first_published_date":"09/08/2012","last_updated_date":"09/08/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001144-pip01-11"},{"decision_number":"P/0124/2012","pip_number":"EMEA-000724-PIP02-11","active_substance":"alisporivir","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Capsule, soft","condition_indication":"Treatment of chronic hepatitis C","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/07/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Debiopharm International SA; E-mail: regulatory.affairs@debiopharm.com; Tel. +41 2131 10111","first_published_date":"09/08/2012","last_updated_date":"09/08/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000724-pip02-11"},{"decision_number":"P/0119/2012","pip_number":"EMEA-001145-PIP01-10","active_substance":"azithromycin (monohydrate)","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Gel","condition_indication":"Prevention of borrelial infections","routes_of_administration":"Cutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"02/07/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ixodes AG, Zürih; Switzerland; ixodesag@bluewin.ch ; +41 432680565; +41 432680864","first_published_date":"09/08/2012","last_updated_date":"09/08/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001145-pip01-10"},{"decision_number":"P/0105/2012","pip_number":"EMEA-000035-PIP01-07-M05","active_substance":"tiotropium bromide (monohydrate)","invented_name":"Spiriva Respimat and associated names","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Solution for inhalation via the Respimat inhaler","condition_indication":"Treatment of cystic fibrosis","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"04/06/2012","compliance_outcome":"Positive","compliance_opinion_date":"21/08/2012","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"24/11/2010","last_updated_date":"23/07/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000035-pip01-07-m05"},{"decision_number":"P/0110/2012","pip_number":"EMEA-001065-PIP01-10","active_substance":"Bivalirudin","invented_name":"Angiox; Angiox","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Treatment of atherosclerosis;Treatment of thrombosis","routes_of_administration":"Intravenous use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"18/06/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"The Medicines Company UK Limited; United Kingdom; camille.debray@themedco.com ; +44 1235 448500; +44 1235 835561","first_published_date":"19/07/2012","last_updated_date":"19/07/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001065-pip01-10"},{"decision_number":"P/0104/2012","pip_number":"EMEA-001266-PIP01-12","active_substance":"Masitinib mesilate","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of gastro-intestinal stromal tumours","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/06/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AB Science; France; a.moussy@ab-science.com ; +33 147200014; +33 147202411","first_published_date":"19/07/2012","last_updated_date":"19/07/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001266-pip01-12"},{"decision_number":"P/0114/2012","pip_number":"EMEA-001247-PIP01-11","active_substance":"valsartan;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/06/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Synthon B.V.; Germany; avril.mankel@ndareg.com ; +49 89 35854009; +49 89 35854010","first_published_date":"19/07/2012","last_updated_date":"19/07/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001247-pip01-11"},{"decision_number":"P/0103/2012","pip_number":"EMEA-001232-PIP01-11","active_substance":"glimepiride;atorvastatin calcium","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hyperlipidaemia;Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/05/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Trading Services Limited; United Kingdom; admin@wainwrightassociates.co.uk; +44 1628530554","first_published_date":"25/06/2012","last_updated_date":"25/06/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001232-pip01-11"},{"decision_number":"P/0089/2012","pip_number":"EMEA-000917-PIP02-11","active_substance":"bimatoprost","invented_name":"Lumigan; Lumigan","therapeutic_area":"Dermatology","pharmaceutical_forms":"Cutaneous solution","condition_indication":"Treatment of androgenic alopecia","routes_of_administration":"Cutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/05/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergan Pharmaceuticals International Limited; E-mail: ml-eu_reg_affairs@allergan.com; Tel. +44 (0)1628 4944444","first_published_date":"25/06/2012","last_updated_date":"25/06/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000917-pip02-11"},{"decision_number":"P/0092/2012","pip_number":"EMEA-001252-PIP01-11","active_substance":"nifedipine;Candesartan cilexetil","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Coated tablet","condition_indication":"Treatment of essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/05/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer Pharma AG; Germany; pediatrics.medical-affairs-europe@bayerhealthcare.com ; +49 3046815333; +49 3046895333","first_published_date":"25/06/2012","last_updated_date":"25/06/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001252-pip01-11"},{"decision_number":"P/0094/2012","pip_number":"EMEA-000266-PIP01-08-M01","active_substance":"nalfurafine hydrochloride","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Severe uraemic pruritus","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/05/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Toray International U.K. Limited; E-mail: nalfurafine_pip@toray-intl.co.uk; Country: United Kingdom; Phone: +44 2076637760; Fax: +44 2076637770","first_published_date":"24/11/2008","last_updated_date":"22/06/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000266-pip01-08-m01"},{"decision_number":"P/0079/2012","pip_number":"Human normal immunoglobulin","active_substance":"human normal immunoglobulin","invented_name":"Gammagen","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of dermatopolymyositis","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/04/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Orfagen; E-mail: info@orfagen.com; Country: France; Phone: + 33 5354506457; Fax: +33 534503457","first_published_date":"25/05/2012","last_updated_date":"25/05/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/human-normal-immunoglobulin-0"},{"decision_number":"P/0071/2012","pip_number":"EMEA-000015-PIP01-07-M04","active_substance":"Doripenem monohydrate","invented_name":"Doribax; Doribax","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Intravenous use","condition_indication":"Treatment of bacterial infections","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"21/04/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Shionogi Limited; E-mail: joe.gaugas@shionogi.co.uk; Tel. +44 (0)20 3609 8660","first_published_date":"24/05/2012","last_updated_date":"24/05/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000015-pip01-07-m04"},{"decision_number":"P/0077/2012","pip_number":"EMEA-001257-PIP01-11","active_substance":"clopidogrel hydrogen sulfate;acetylsalicylic acid","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of arterial thromboembolism","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"25/04/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sandoz BV; The Netherlands; Phone: +31 365241700; caroline.kleinjan@sandoz.com","first_published_date":"24/05/2012","last_updated_date":"24/05/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001257-pip01-11"},{"decision_number":"P/0061/2012","pip_number":"EMEA-000007-PIP01-07-M02","active_substance":"ezetimibe","invented_name":"Ezetrol and associated names","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypercholesterolaemia;Treatment of sitosterolaemia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"28/03/2012","compliance_outcome":"Positive","compliance_opinion_date":"17/01/2013","compliance_procedure_number":"EMEA-C-000007-PIP01-07-M02","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"20/04/2012","last_updated_date":"20/04/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000007-pip01-07-m02"},{"decision_number":"P/0066/2012","pip_number":"EMEA-001212-PIP01-11","active_substance":"anakinra","invented_name":"Kineret; Kineret","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing;Treatment of cryopyrin-associated periodic syndromes (CAPS)","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"28/03/2012","compliance_outcome":"Positive","compliance_opinion_date":"12/12/2014","compliance_procedure_number":"EMEA-C-001212-PIP01-11","contact_for_public_enquiries":"Swedish Orphan Biovitrum AB; christina.rickhammar@sobi.com; Country: Sweden; Phone: +46 86972000","first_published_date":"19/04/2012","last_updated_date":"19/04/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001212-pip01-11"},{"decision_number":"-","pip_number":"EMEA-001218-PIP01-11","active_substance":"Deoxycholic acid","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of localised fat deposits","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/03/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kythera Biopharmaceuticals (Europe) Limited; United Kingdom; Email: dstroehmann@kytherabiopharma.com ; Tel. +1 818 587 4521; Fax +1 818 587 4591","first_published_date":"19/04/2012","last_updated_date":"19/04/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001218-pip01-11"},{"decision_number":"P/0052/2012","pip_number":"EMEA-000488-PIP02-11","active_substance":"rubidium (82Rb) chloride","invented_name":"","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Radionuclide generator","condition_indication":"Visualisation of myocardial perfusion for diagnostic purposes","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"23/03/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Advanced Accelerator Applications; Email: infomed@adacap.com    ; Tel. +33 (0)450993070","first_published_date":"19/04/2012","last_updated_date":"19/04/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000488-pip02-11"},{"decision_number":"P/0043/2012","pip_number":"EMEA-001121-PIP01-10","active_substance":"Elacytarabine","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Dispersion for infusion","condition_indication":"Treatment of acute myeloid leukaemia","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"28/02/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Clavis Pharma ASA ; Norway ; mail@clavispharma.com ; +47 24110850 ; +47 24110951","first_published_date":"26/03/2012","last_updated_date":"26/03/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001121-pip01-10"},{"decision_number":"P/0034/2012","pip_number":"EMEA-000394-PIP01-08-M01","active_substance":"purified tetanus toxoid;Inactivated Type 1 Poliovirus (Mahoney);Inactivated Type 2 Poliovirus (MEF-1);Inactivated Type 3 Poliovirus (Saukett);polyribosylribitol phosphate (PRP) from Haemophilus influenzae type b as prp-ompc;hepatitis B surface antigen recombinant;purified filamentous haemagglutinin;purified pertussis toxoid;purified fimbriae types 2 and 3;purified pertactin;purified diphtheria toxoid","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection;Suspension for injection in pre-filled syringe","condition_indication":"Active immunisation against infectious diseases caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis and poliovirus types 1, 2 and 3, against invasive disease caused by...","routes_of_administration":"Intramuscular route","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/02/2012","compliance_outcome":"Positive","compliance_opinion_date":"10/10/2014","compliance_procedure_number":"EMEA-C-000394-PIP01-08-M01","contact_for_public_enquiries":"Sanofi Pasteur MSD SNC; E-mail: piplan@spmsd.com; Country: France; Phone: + 33 437284000","first_published_date":"22/10/2009","last_updated_date":"15/03/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000394-pip01-08-m01"},{"decision_number":"P/0022/2012","pip_number":"EMEA-000736-PIP01-09","active_substance":"culture expanded autologous chondrocytes","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Implant","condition_indication":"Treatment of cartilage disorders","routes_of_administration":"Implant use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/01/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Fidia Advanced Biopolymers S.r.l.; info@fidiapharma.it; Italy; +39 0498232111","first_published_date":"24/02/2012","last_updated_date":"24/02/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000736-pip01-09"},{"decision_number":"P/0018/2012","pip_number":"EMEA-001204-PIP01-11","active_substance":"ezetimibe;atorvastatin calcium","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypercholesterolaemia;Treatment of mixed hyperlipidaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"25/01/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"24/02/2012","last_updated_date":"24/02/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001204-pip01-11"},{"decision_number":"P/0026/2012","pip_number":"EMEA-001223-PIP01-11","active_substance":"Diltiazem (hydrochloride)","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Cream","condition_indication":"Treatment of chronic anal fissure","routes_of_administration":"Cutaneous use;Epilesional use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/01/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"S.L.A. Pharma (UK) Limited; United Kingdom; info@slapharma.com; +44 1923 681001; +44 1923 681221","first_published_date":"24/02/2012","last_updated_date":"24/02/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001223-pip01-11"},{"decision_number":"P/0021/2012","pip_number":"EMEA-000530-PIP02-11","active_substance":"cyclophosphamide","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Soluble tablet","condition_indication":"Treatment of malignant diseases","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/01/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Keocyt SAS; catherine.lallier@keocyt.com; France; +33 1423107; +33 142312379","first_published_date":"24/02/2012","last_updated_date":"24/02/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000530-pip02-11"},{"decision_number":"P/0014/2012","pip_number":"EMEA-001198-PIP01-11","active_substance":"netupitant;palonosetron","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Capsule, hard","condition_indication":"Prevention of chemotherapy-induced nausea and vomiting","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/01/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Helsinn Birex Pharmaceuticals Limited; E-mail: paediatrics-netu@helsinn.com; Tel. +41 9198 51950","first_published_date":"24/02/2012","last_updated_date":"24/02/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001198-pip01-11"},{"decision_number":"P/0001/2012","pip_number":"EMEA-000711-PIP01-09","active_substance":"morphine (hydrochloride)","invented_name":"","therapeutic_area":"Neonatology-Paediatric Intensive Care","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of acute pain","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"20/01/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"EPMC Pharma SPRL; hugo.lagercrantz@ki.se; Sweden; +46 8 7098 45273; +46 8 5177 7353","first_published_date":"24/02/2012","last_updated_date":"24/02/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000711-pip01-09"},{"decision_number":"P/0013/2012","pip_number":"EMEA-001165-PIP01-11","active_substance":"treprostinil diethanolamine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Prolonged-release tablet;Prolonged-release oral liquid formulation","condition_indication":"Treatment of pulmonary hypertension","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"24/01/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"United Therapeutics Europe Ltd; info1@unither.com; United Kingdom; +44 1932573800; +44 1932571110","first_published_date":"24/02/2012","last_updated_date":"24/02/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001165-pip01-11"},{"decision_number":"P/0028/2012","pip_number":"EMEA-000463-PIP01-08-M03","active_substance":"imatinib mesilate","invented_name":"Glivec; Glivec","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard;Film-coated tablet","condition_indication":"Dermatofibrosarcoma protuberans;Hypereosinophilic syndrome and/or chronic eosinophilic leukaemia with FIP1L1-platelet-derived growth factor receptor alpha gene re-arrangement;Kit (CD 117)-positive gastrointestinal stromal tumours;Myelodysplastic / myeloproliferative diseases associated with platelet-derived growth factor receptor gene re-arrangements;Philadelphia chromosome (BCR-ABL translocation)-positive acute lymphoblastic leukaemia;Philadelphia chromosome (BCR-ABL translocation)-positive chronic myeloid leukaemia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"28/01/2012","compliance_outcome":"Positive","compliance_opinion_date":"09/03/2012","compliance_procedure_number":"EMEA-C-000463-PIP01-08-M03","contact_for_public_enquiries":"Novartis Europharm Limited; paediatric.enquiries@novartis.com; Country: Switzerland; Phone: +41 61 324 6715; Fax: +41 61 324 2224","first_published_date":"14/07/2011","last_updated_date":"23/02/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000463-pip01-08-m03"},{"decision_number":"P/0029/2012","pip_number":"EMEA-000562-PIP01-09-M01","active_substance":"semuloparin sodium","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for injection","condition_indication":"Thromboembolic events","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/01/2012","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi-aventis Recherche & Développement; France; frederique.maneval@sanofi-aventis.com; +33 169495011","first_published_date":"18/05/2010","last_updated_date":"23/02/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000562-pip01-09-m01"},{"decision_number":"P/304/2011","pip_number":"EMEA-001042-PIP02-11","active_substance":"recombinant human granulocyte colony stimulating factor coupled with recombinant human albumin fusion protein","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of chemotherapy-induced neutropenia;Prevention of chemotherapy-induced febrile neutropenia","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"20/12/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Teva Pharma B.V.; E-mail: info@ratiopharm.de; Tel. : +49 73140202; Fax: +49 7314027832","first_published_date":"19/01/2012","last_updated_date":"19/01/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001042-pip02-11"},{"decision_number":"P/308/2011","pip_number":"EMEA-001134-PIP01-11","active_substance":"chimeric monoclonal anti-Shiga toxin antibodies cαStx1 and cαStx2","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of Shiga toxin-mediated complications","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"20/12/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LFB Biotechnologies ; France ; roussariec@lfb.fr; +33 169828842 ; +33 169827182","first_published_date":"19/01/2012","last_updated_date":"19/01/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001134-pip01-11"},{"decision_number":"P/310/2011","pip_number":"EMEA-001193-PIP01-11","active_substance":"insulin degludec;liraglutide","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/12/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S ; Denmark ; mbse@novonordisk.com ; +45 30796941 ; +45 39699173","first_published_date":"19/01/2012","last_updated_date":"19/01/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001193-pip01-11"},{"decision_number":"P/313/2011","pip_number":"EMEA-001075-PIP01-10","active_substance":"anti-sclerostin human monoclonal antibody (AMG785)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of fractures and fracture associated complications","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/12/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Amgen Europe B.V ; United Kingdom ; pipenquiry@amgen.com ; + 44 1223420305 ; + 44 1223426814","first_published_date":"19/01/2012","last_updated_date":"19/01/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001075-pip01-10"},{"decision_number":"P/302/2011","pip_number":"EMEA-000770-PIP02-11","active_substance":"esketamine hydrochloride","invented_name":"","therapeutic_area":"Oto-rhino-laryngology","pharmaceutical_forms":"Gel for injection","condition_indication":"Treatment of acute inner ear tinnitus","routes_of_administration":"Intratympanic use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/12/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Auris Medical Limited ; Ireland ; ear@aurismedical.com ; +353 766154675 ; +353 16853040","first_published_date":"19/01/2012","last_updated_date":"19/01/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000770-pip02-11"},{"decision_number":"P/290/2011","pip_number":"EMEA-000389-PIP01-08-M01","active_substance":"N-[4-(3-amino-1H-indazol-4 yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea (ABT-869)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Liquid formulation;Age appropriate oral formulation","condition_indication":"Treatment of solid malignant tumours","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"02/12/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. : +44 1628644475","first_published_date":"16/09/2009","last_updated_date":"18/01/2012","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000389-pip01-08-m01"},{"decision_number":"P/285/2011","pip_number":"EMEA-001120-PIP01-10","active_substance":"Budesonide","invented_name":"Budiair and associated names","therapeutic_area":"Neonatology-Paediatric Intensive Care","pharmaceutical_forms":"Pressurised inhalation (solution)","condition_indication":"Prevention of bronchopulmonary dysplasia","routes_of_administration":"Inhalation use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"30/11/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Neurosis Consortium ; dirk.bassler@med.uni-tuebingen.de; German; +49 7071 29 80898 ; +49 7071 29 4471","first_published_date":"21/12/2011","last_updated_date":"21/12/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001120-pip01-10"},{"decision_number":"P/281/2011","pip_number":"EMEA-001117-PIP01-10","active_substance":"Icosapent","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Gastro-resistant capsule;Capsule, soft","condition_indication":"Treatment of Familial Adenomatous Polyposis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/11/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"S.L.A. Pharma (UK) Limited ; info@slapharma.com ; United Kingdom; +44 1923681001 ; +44 1923681 221","first_published_date":"21/12/2011","last_updated_date":"21/12/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001117-pip01-10"},{"decision_number":"P/269/2011","pip_number":"EMEA-000800-PIP01-09-M01","active_substance":"ombrabulin","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Treatment of non-rhabdomyosarcoma soft tissue sarcoma;Treatment of rhabdomyosarcoma","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"28/10/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi-aventis recherche & developpement; France; E-mail: sylvie.gabriel@sanofi-aventis.com; Tel. +33 1537 74152; Fax +33 1537 74133","first_published_date":"14/07/2011","last_updated_date":"30/11/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000800-pip01-09-m01"},{"decision_number":"P/271/2011","pip_number":"EMEA-001182-PIP01-11","active_substance":"(2S,3R,4R,5S,6R)-2-(4-chloro-3-{3-[(S)-(tetrahydrofuran-3-yl)oxy]-benzyl}-phenyl)-6-hydroxymethyltetrahydro-pyran-3,4,5-triol;Metformin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/10/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"29/11/2011","last_updated_date":"29/11/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001182-pip01-11"},{"decision_number":"P/270/2011","pip_number":"EMEA-001163-PIP01-11","active_substance":"clopidogrel (bisulfate);acetylsalicylic acid","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Prevention of cardiovascular disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/10/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"TEVA Pharma B.V.; Croatia; lidija.brnic@tevapharm.com ; +38 53722150","first_published_date":"29/11/2011","last_updated_date":"29/11/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001163-pip01-11"},{"decision_number":"P/262/2011","pip_number":"EMEA-000026-PIP02-11","active_substance":"temsirolimus","invented_name":"Torisel; Torisel","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate and diluent for solution for infusion","condition_indication":"Treatment of mantle cell lymphoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/10/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Limited; Tel. + 44 1304646607; E-mail: pip_enquiries@pfizer.com","first_published_date":"29/11/2011","last_updated_date":"29/11/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000026-pip02-11"},{"decision_number":"P/260/2011","pip_number":"EMEA-001069-PIP01-10","active_substance":"secretin","invented_name":"","therapeutic_area":"","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Diagnosis of pancreatic diseases","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"28/10/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Repligen Europe Limited; USA; kjauregui@repligen.com; +1 7814191821","first_published_date":"29/11/2011","last_updated_date":"29/11/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001069-pip01-10"},{"decision_number":"P/259/2011","pip_number":"EMEA-001172-PIP01-11","active_substance":"brinzolamide;brimonidine tartrate","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution;Suspension","condition_indication":"Treatment of glaucoma","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"26/10/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alcon Laboratories (UK) Ltd.; Doug.MacHatton@AlconLabs.com; United States; Phone: +1 8175518974; Fax: +1 8176154607","first_published_date":"29/11/2011","last_updated_date":"29/11/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001172-pip01-11"},{"decision_number":"P/258/2011","pip_number":"EMEA-001170-PIP01-11","active_substance":"4-[[9-[(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-transcyclohexanol (CC-930)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of idiopathic pulmonary fibrosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"26/10/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Celgene Europe LimitedTel.  +41 327298500E-mail: medinfo.intl@celgene.com","first_published_date":"29/11/2011","last_updated_date":"29/11/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001170-pip01-11"},{"decision_number":"P/254/2011","pip_number":"EMEA-000287-PIP02-10","active_substance":"pancreas powder","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Gastro-resistant capsule;Capsule, hard","condition_indication":"Treatment of exocrine pancreatic insufficiency","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"26/11/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eurand Pharmaceuticals Limited; Italy; pamela.ventura@eurand.com; +39 0295428347; +39 0295745018","first_published_date":"29/11/2011","last_updated_date":"29/11/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000287-pip02-10"},{"decision_number":"P/247/2011","pip_number":"EMEA-001184-PIP01-11","active_substance":"(2S,3R,4R,5S,6R)-2-(4-chloro-3-{3-[(S)-(tetrahydrofuran-3-yl)oxy]-benzyl}-phenyl)-6-hydroxymethyltetrahydro-pyran-3,4,5-triol;linagliptin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/10/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"28/11/2011","last_updated_date":"28/11/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001184-pip01-11"},{"decision_number":"P/22/2010","pip_number":"EMEA-000637-PIP01-09-M01","active_substance":"Lanthanum carbonate hydrate","invented_name":"Fosrenol and associated name Foznol","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Chewable tablet;Granules","condition_indication":"Hyperphosphataemia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"28/11/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Shire Pharmaceutical Contracts Ltd; United Kingdom; Tel. +44 (0)1423 850717; E-mail: medinfoemea@shire.com ","first_published_date":"28/11/2011","last_updated_date":"28/11/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000637-pip01-09-m01"},{"decision_number":"P/240/2011","pip_number":"EMEA-001148-PIP01-11","active_substance":"Dextromethorphan (hydrobromide);quinidine sulfate","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of pseudobulbar affect (uncontrollable laughing and/or crying)","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"30/09/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Avanir Pharmaceuticals, Incorporated; E-mail: arosenthal@avanir.com; Tel.: +1 9493896748","first_published_date":"18/10/2011","last_updated_date":"18/10/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001148-pip01-11"},{"decision_number":"P/230/2011","pip_number":"EMEA-001109-PIP01-10","active_substance":"progesterone","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Vaginal delivery system","condition_indication":"Treatment of female infertility","routes_of_administration":"Vaginal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"28/09/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Teva Pharmaceuticals Europe B.V.; Country: Croatia; E-mail: ana.lebo@pliva.com, lidija.brnic@pliva.com; Phone: +385 13722875, +385 13722150; Fax: +385 13723157","first_published_date":"18/10/2011","last_updated_date":"18/10/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001109-pip01-10"},{"decision_number":"P/226/2011","pip_number":"EMEA-001154-PIP01-11","active_substance":"antithrombin alfa","invented_name":"ATryn; ATryn","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of antithrombin deficiency","routes_of_administration":"Intravenous use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"27/09/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GTC Biotherapeutics UK Limited; E-mail: Dick.Scotland@gtc-bio.com; Tel.: +1 5083705164","first_published_date":"18/10/2011","last_updated_date":"18/10/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001154-pip01-11"},{"decision_number":"P/221/2011","pip_number":"EMEA-001151-PIP01-11","active_substance":"dapagliflozin;metformin hydrochloride","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"26/09/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb / AstraZeneca EEIG; Email: medical.information@bms.com; Tel.: +44 1895523740","first_published_date":"18/10/2011","last_updated_date":"18/10/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001151-pip01-11"},{"decision_number":"P/217/2011","pip_number":"EMEA-000993-PIP01-10","active_substance":"prednicarbate;octenidine dihydrochloride","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Cream","condition_indication":"Treatment of atopic dermatitis;Treatment of dermatomycosis","routes_of_administration":"Cutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"16/09/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Almirall Hermal GmbH; Country: Germany; E-mail: info@almirall.de; Phone: +49 40727040; Fax: +49 407229296","first_published_date":"18/10/2011","last_updated_date":"18/10/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000993-pip01-10"},{"decision_number":"P/241/2011","pip_number":"Etanercept","active_substance":"etanercept","invented_name":"Enbrel; Enbrel","therapeutic_area":"Dermatology","pharmaceutical_forms":"Powder and solvent for solution for injection;Powder for solution for injection;Solution for injection;Powder and solvent for solution for injection","condition_indication":"Juvenile idiopathic arthritis;Plaque psoriasis","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/09/2011","compliance_outcome":"Positive","compliance_opinion_date":"13/12/2011","compliance_procedure_number":"EMEA-C-000299-PIP01-08-M03","contact_for_public_enquiries":"Wyeth Europa Limited; julian.britton@pfizer.com; United Kingdom; Phone: +44 1628692245","first_published_date":"17/10/2011","last_updated_date":"17/10/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/etanercept"},{"decision_number":"P228/2011","pip_number":"EMEA-000725-PIP01-09-M03","active_substance":"split influenza virus, inactivated, containing antigen: A/California/7/2009 (H1N1)v like strain (X-179A)","invented_name":"Pandemrix; Pandemrix","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension and emulsion for injection","condition_indication":"Influenza","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/09/2011","compliance_outcome":"Positive","compliance_opinion_date":"12/12/2014","compliance_procedure_number":"EMEA-000725-PIP01-09-M03","contact_for_public_enquiries":"GlaxoSmithKline Biologicals S.A. (Belgium); Tel. +1 438 899 8201; Email: eu.paediatric-plans@gsk.com","first_published_date":"17/10/2011","last_updated_date":"17/10/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000725-pip01-09-m03"},{"decision_number":"P/215/2011","pip_number":"EMEA-000670-PIP01-09-M02","active_substance":"split influenza virus, inactivated containing antigen equivalent to A/California/7/2009 (H1N1)-like strain (A/California/7/2009 (NYMC X-179A)), non-adjuvanted","invented_name":"Panenza","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Influenza","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/09/2011","compliance_outcome":"Positive","compliance_opinion_date":"13/09/2013","compliance_procedure_number":"EMEA-C-000670-PIP01-09-M02","contact_for_public_enquiries":"Sanofi Pasteur SA; E-mail: Piplan@sanofipasteur.com; Country: France; Phone: +33 437375038","first_published_date":"17/10/2011","last_updated_date":"17/10/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000670-pip01-09-m02"},{"decision_number":"P/206/2011","pip_number":"Cholic acid","active_substance":"cholic acid","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Capsule, hard;Age appropriate oral formulation","condition_indication":"Treatment of other inborn errors of bile acid synthesis;Treatment of oxysterol 7a-hydrolylase deficiency and defective amida","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/08/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"FGK Representative Service GmbH; E-mail: info@nymox.com; Tel. +1 8009369669","first_published_date":"03/10/2011","last_updated_date":"03/10/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/cholic-acid"},{"decision_number":"P/198/2011","pip_number":"EMEA-000305-PIP01-08-M02","active_substance":"ulipristal acetate","invented_name":"ellaOne; ellaOne","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Contraception","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/08/2011","compliance_outcome":"Positive","compliance_opinion_date":"08/11/2013","compliance_procedure_number":"EMEA-C-000305-PIP01-08-M02","contact_for_public_enquiries":"Laboratoire HRA Pharma; regulatory@hra-pharma.com; France; Phone: +33 140331130; Fax: +33 142771060","first_published_date":"03/10/2011","last_updated_date":"03/10/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000305-pip01-08-m02"},{"decision_number":"P/177/2011","pip_number":"EMEA-000700-PIP02-10","active_substance":"vildagliptin","invented_name":"Galvus; Galvus","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"26/08/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"03/10/2011","last_updated_date":"03/10/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000700-pip02-10"},{"decision_number":"P/195/2011","pip_number":"Human normal immunoglobulin","active_substance":"human normal immunoglobulin","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for infusion","condition_indication":"Idiopathic thrombocytopenic purpura (ITP);Neonatal haemolytic disease (ABO - Rh-incompatability);Primary immunodeficiency (PID)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/07/2011","compliance_outcome":"Positive","compliance_opinion_date":"15/10/2012","compliance_procedure_number":"EMEA-C-000167-PIP01-07-M02","contact_for_public_enquiries":"LFB Biotechnologies; micardt@lfb.fr; France; Phone: +33 169828842; Fax: +33 169827182","first_published_date":"15/09/2011","last_updated_date":"15/09/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/human-normal-immunoglobulin"},{"decision_number":"P/190/2011","pip_number":"EMEA-001138-PIP02-11","active_substance":"valsartan;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of acute myocardial infarction;Prevention of atherosclerotic heart disease;Prevention of stroke;Treatment of essential hypertension;Treatment of heart failure;Treatment of Prinzmetal's angina","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/08/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gedeon Richter Plc.; mrpRichter@richter.hu; Hungary; Phone +36 1 431 4040; Fax +36 1 431 5415","first_published_date":"13/09/2011","last_updated_date":"13/09/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001138-pip02-11"},{"decision_number":"P/189/2011","pip_number":"EMEA-001135-PIP01-11","active_substance":"teriparatide","invented_name":"Forsteo; Forsteo","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection in pre-filled pen;Transdermal system","condition_indication":"Treatment of fractures;Treatment of osteoporosis","routes_of_administration":"Subcutaneous use;Transdermal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/08/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"13/09/2011","last_updated_date":"13/09/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001135-pip01-11"},{"decision_number":"P/188/2011","pip_number":"EMEA-001131-PIP01-11","active_substance":"colecalciferol;strontium ranelate","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Granules for oral suspension","condition_indication":"Treatment of osteoporosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/08/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierTel. +33 1 55 72 60 00E-mail: mail.pip.enquiries@fr.netgrs.com","first_published_date":"13/09/2011","last_updated_date":"13/09/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001131-pip01-11"},{"decision_number":"P/193/2011","pip_number":"EMEA-001090-PIP01-11","active_substance":"Florbetaben","invented_name":"","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Solution for injection","condition_indication":"Diagnosis of Alzheimer's disease","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/08/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer Schering Pharma AG; ulrike.bodesheim@bayer.com; Germany; Phone +49 3046818208","first_published_date":"13/09/2011","last_updated_date":"13/09/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001090-pip01-11"},{"decision_number":"P/186/2011","pip_number":"EMEA-000236-PIP03-11","active_substance":"aflibercept","invented_name":"Eylea","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of central retinal vein occlusion","routes_of_administration":"Intravitreal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/08/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer Schering Pharma AG; pediatrics.medical-affairs-europe@bayerhealthcare.com; Germany; Phone: +49 3046815333; Fax: +49 3046895333","first_published_date":"13/09/2011","last_updated_date":"13/09/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000236-pip03-11"},{"decision_number":"P/194/2011","pip_number":"EMEA-000092-PIP02-11","active_substance":"recombinant salmon calcitonin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of bone metabolism disorders","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/08/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"13/09/2011","last_updated_date":"13/09/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000092-pip02-11"},{"decision_number":"P/135/2011","pip_number":"EMEA-000478-PIP01-08-M01","active_substance":"Benzamide, 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl] propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl] sulfonyl] (ABT-263)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution;Capsule;Capsule, soft;Liquid formulation","condition_indication":"Treatment of acute lymphoblastic leukaemia;Treatment of non-Hodgkin lymphoma","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/06/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"12/08/2011","last_updated_date":"12/08/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000478-pip01-08-m01"},{"decision_number":"P/154/2011","pip_number":"EMEA-000014-PIP01-07-M06","active_substance":"paliperidone;paliperidone palmitate","invented_name":"Invega; Invega","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Prolonged-release tablet;Suspension for injection","condition_indication":"Schizoaffective disorder;Schizophrenia","routes_of_administration":"Oral use;Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/07/2011","compliance_outcome":"Positive","compliance_opinion_date":"14/02/2013","compliance_procedure_number":"EMEA-C-000014-PIP01-07-M06","contact_for_public_enquiries":"Janssen-Cilag International NV; bbyl@gcpbe.jnj.com; Belgium; Phone: +32 14607172; Fax: +32 473839426","first_published_date":"10/08/2011","last_updated_date":"10/08/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000014-pip01-07-m06"},{"decision_number":"P/167/2011","pip_number":"EMEA-001034-PIP01-10","active_substance":"risperidone","invented_name":"Risperdal and associated names","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of conduct disorder","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/07/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Wockhardt UK Ltd; gordon.urquhart@wockhardt.co.uk; United Kingdom; Phone: +44 1961773934","first_published_date":"09/08/2011","last_updated_date":"09/08/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001034-pip01-10"},{"decision_number":"P/165/2011","pip_number":"EMEA-001128-PIP01-10","active_substance":"alogliptin benzoate;metformin hydrochloride","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/07/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Global Research and Development Centre (Europe) Ltd; paediatrics@tgrd.com; United Kingdom; Phone: +44 2031168237; Fax: +44 2031168250","first_published_date":"09/08/2011","last_updated_date":"09/08/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001128-pip01-10"},{"decision_number":"P/166/2011","pip_number":"EMEA-001007-PIP01-10","active_substance":"ciclosporin","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution;Solution","condition_indication":"Treatment of atopic keratoconjunctivitis","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/07/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergan Pharmaceuticals International Limited; E-mail: ml-eu_reg_affairs@allergan.com; Tel. +44 (0)1628 4944444","first_published_date":"09/08/2011","last_updated_date":"09/08/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001007-pip01-10"},{"decision_number":"P/174/2011","pip_number":"EMEA-001118-PIP01-10","active_substance":"acetylsalicylic acid;Pravastatin sodium","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of cardiovascular disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/07/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"TEVA Pharma B.V.; Lidija.Brnic@tevapharm.com; Croatia; Phone: +385 3722150","first_published_date":"09/08/2011","last_updated_date":"09/08/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001118-pip01-10"},{"decision_number":"P/187/2011","pip_number":"EMEA-001141-PIP01-11","active_substance":"perindopril erbumine;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/07/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"KBM Pharma OÜ; tiina.must@kbmpharma.eu; Estonia; Phone: +372 7338080; Fax: +372 7338081","first_published_date":"09/08/2011","last_updated_date":"09/08/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001141-pip01-11"},{"decision_number":"P/150/2011","pip_number":"EMEA-001137-PIP01-11","active_substance":"progesterone","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection;Powder for solution for injection","condition_indication":"Treatment of female infertility;Prevention of recurrent spontaneous abortion","routes_of_administration":"Subcutaneous use;Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/06/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"IBSA Farmaceutici Italia Srl; Julie.cook@regulis.com; United Kingdom; +44 1442890909; +44 1442890903","first_published_date":"14/07/2011","last_updated_date":"14/07/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001137-pip01-11"},{"decision_number":"P/133/2011","pip_number":"EMEA-001102-PIP01-10","active_substance":"gallium (68Ga) chloride;germanium (68Ge) chloride","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Radionuclide generator","condition_indication":"Radiolabelling agent","routes_of_administration":"Other use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/06/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eckert & Ziegler Radiopharma GmbH; regaffairs.radiopharma@ezag.de; Germany; +49 30941084282; +49 30941084160","first_published_date":"14/07/2011","last_updated_date":"14/07/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001102-pip01-10"},{"decision_number":"P/138/2011","pip_number":"EMEA-001111-PIP01-10","active_substance":"canagliflozin;Metformin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"10/06/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International; E-mail: lpeeter8@its.jnj.com; Tel. +32 14 603 876;  ","first_published_date":"14/07/2011","last_updated_date":"14/07/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001111-pip01-10"},{"decision_number":"P/139/2011","pip_number":"EMEA-000928-PIP01-10-M01","active_substance":"mipomersen sodium","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of heterozygous and homozygous familial hypercholesterolaemia","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/06/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Genzyme Europe B.V.; Tel. +31 (0) 20 245 3917; E-mail: EUmedinfo@genzyme.com;  ","first_published_date":"13/07/2011","last_updated_date":"13/07/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000928-pip01-10-m01"},{"decision_number":"P/149/2011","pip_number":"EMEA000967-PIP01-10-M01","active_substance":"rotavirus serotype G1;rotavirus serotype G2;rotavirus serotype G3;rotavirus serotype G4;rotavirus serotype P1A[8]","invented_name":"RotaTeq; RotaTeq","therapeutic_area":"Vaccines","pharmaceutical_forms":"Oral solution","condition_indication":"Prevention of rotaviral enteritis","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/06/2011","compliance_outcome":"Positive","compliance_opinion_date":"21/07/2011","compliance_procedure_number":"EMEA-C-000967-PIP01-10-M01","contact_for_public_enquiries":"Sanofi Pasteur MSD SNC; piplan@spmsd.com; France; Phone: +33 437284000","first_published_date":"13/07/2011","last_updated_date":"13/07/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea000967-pip01-10-m01"},{"decision_number":"P/116/2011","pip_number":"EMEA-000194-PIP03-10","active_substance":"perflubutane","invented_name":"","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Powder for suspension for injection","condition_indication":"Visualisation of myocardial perfusion for diagnostic purposes","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"18/05/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Granzer Regulatory Consulting & Services; office@granzer.biz; Germany; Phone +49 8978068980; Fax +49 89780689815","first_published_date":"09/06/2011","last_updated_date":"09/06/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000194-pip03-10"},{"decision_number":"P/118/2011","pip_number":"EMEA-001004-PIP01-10","active_substance":"autologous oral mucosal epithelial cells","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Living tissue equivalent","condition_indication":"Treatment of limbal stem cell deficiency","routes_of_administration":"Ocular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"23/05/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CellSeed Europe S.A.R.L.; aokamoto@cellseed.com; Japan; Phone +81 3 5286 6231; Fax +81 3 5286 6233","first_published_date":"09/06/2011","last_updated_date":"09/06/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001004-pip01-10"},{"decision_number":"P/77/2011","pip_number":"EMEA-000988-PIP01-10","active_substance":"ciclosporin","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Nebuliser solution","condition_indication":"Prevention of rejection following lung transplantation","routes_of_administration":"Inhalation use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"05/04/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"APT Pharmaceuticals Limited; info@aptbio.com; United States; Phone +1 6509311666; Fax +1 6509311667","first_published_date":"13/05/2011","last_updated_date":"13/05/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000988-pip01-10"},{"decision_number":"P/98/2011","pip_number":"EMEA-001080-PIP01-10","active_substance":"Delafloxacin","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Treatment of local infections of skin and subcutaneous tissues","routes_of_administration":"Intravenous use;Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"08/04/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Rib-X Therapeutics Ltd; Tel: +39 055 5680 633; E-mail: prijli@menarini.it","first_published_date":"12/05/2011","last_updated_date":"12/05/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001080-pip01-10"},{"decision_number":"P/95/2011","pip_number":"EMEA-000006-PIP02-10","active_substance":"ezetimibe;simvastatin","invented_name":"Inegy and associated names","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Prevention of cardiovascular events in chronic kidney disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/04/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme Limited; E-mail: regaffairseurope@organon.com; Tel: +31 412770000","first_published_date":"12/05/2011","last_updated_date":"12/05/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000006-pip02-10"},{"decision_number":"P/85/2011","pip_number":"EMEA-000463-PIP02-10","active_substance":"imatinib mesilate","invented_name":"Glivec","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet;Capsule, hard;Age appropriate oral solid dosage form","condition_indication":"Treatment of pulmonary arterial hypertension","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"08/04/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"12/05/2011","last_updated_date":"12/05/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000463-pip02-10"},{"decision_number":"P/82/2011","pip_number":"EMEA-000990-PIP02-10","active_substance":"azelastine (hydrochloride);fluticasone propionate","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Nasal spray;Suspension","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Nasal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/04/2011","compliance_outcome":"Positive","compliance_opinion_date":"24/06/2011","compliance_procedure_number":"EMEA-C-000990-PIP02-10","contact_for_public_enquiries":"MEDA Pharma GmbH & Co. KG; info@medapharma.de; Germany; Phone +49 617288801; Fax +49 61728881112","first_published_date":"12/05/2011","last_updated_date":"12/05/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000990-pip02-10"},{"decision_number":"P/83/2011","pip_number":"EMEA-001066-PIP01-10","active_substance":"aciclovir","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Muco-adhesive buccal tablet","condition_indication":"Prevention of recurrences of herpes simplex labialis;Treatment of recurrent herpes simplex labialis","routes_of_administration":"Gingival use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"06/04/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Onxeo; France; E-mail: a.dembri@onxeo.com; Tel. +33 1455 86000; Fax +33 1455 80881","first_published_date":"12/05/2011","last_updated_date":"12/05/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001066-pip01-10"},{"decision_number":"P/93/2011","pip_number":"EMEA-000032-PIP01-07-M04","active_substance":"Meningococcal group A oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenA-CRM) Meningococcal group C oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenC-CRM) Meningococcal group W-135 oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenW-CRM) Meningococcal group Y oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenY-CRM)","invented_name":"Menveo; Menveo","therapeutic_area":"Vaccines","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Meningococcal meningitis","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/04/2011","compliance_outcome":"Positive","compliance_opinion_date":"25/05/2011","compliance_procedure_number":"EMEA-C-000032-PIP01-07-M04","contact_for_public_enquiries":"GSK Vaccines S.r.l.; Tel. +1 438 899 8201; Email: eu.paediatric-plans@gsk.com","first_published_date":"12/05/2011","last_updated_date":"12/05/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000032-pip01-07-m04"},{"decision_number":"P/113/2011","pip_number":"EMEA-001084-PIP02-11","active_substance":"rivastigmine","invented_name":"Exelon; Prometax","therapeutic_area":"Neurology","pharmaceutical_forms":"Capsule, hard;Oral solution;Transdermal patch","condition_indication":"Treatment of dementia","routes_of_administration":"Oral use;Transdermal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/04/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"12/05/2011","last_updated_date":"12/05/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001084-pip02-11"},{"decision_number":"P/94/2011","pip_number":"EMEA-001085-PIP01-10","active_substance":"atorvastatin calcium;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of cardiovascular events in hypertensive patients and diabetes mellitus type II patients with multiple risk factors for cardiovascular disease;Treatment of concomitant angina and dyslipidemia;Treatment of concomitant hypertension and dyslipidemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/04/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Miklich Laboratorios, S.L.; borut@miklich.eu; Spain; Phone +34 9520+8822; Fax +34 952067709","first_published_date":"12/05/2011","last_updated_date":"12/05/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001085-pip01-10"},{"decision_number":"P/79/2011","pip_number":"EMEA-000558-PIP02-10","active_substance":"human normal immunoglobulin","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of multifocal motor neuropathy (MMN)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/04/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LFB Biotechnologies; micardt@lfb.fr; France; Phone +33 169821749; Fax +33 169827182","first_published_date":"12/05/2011","last_updated_date":"12/05/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000558-pip02-10"},{"decision_number":"P/70/2011","pip_number":"EMEA-000823-PIP02-10","active_substance":"amlodipine besilate;perindopril tert-butylamine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Prevention of heart failure;Prevention of stroke;Treatment of acute myocardial infarction;Treatment of atherosclerotic heart disease;Treatment of heart failure;Treatment of Prinzmetal's angina","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/04/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gedeon Richter Plc.; mrpRichter@richter.hu; Hungary; Tel. +36 14314040; Fax. +36 14315415","first_published_date":"10/05/2011","last_updated_date":"10/05/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000823-pip02-10"},{"decision_number":"P/72/2011","pip_number":"EMEA-001028-PIP01-10","active_substance":"flutemetamol (18F)","invented_name":"","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Solution for injection","condition_indication":"Diagnosis of Alzheimer's disease","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/04/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GE Healthcare Inc.; Tel. +44 1494543483; E-mail: Gabriel.Brooks@ge.com","first_published_date":"10/05/2011","last_updated_date":"10/05/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001028-pip01-10"},{"decision_number":"P/71/2011","pip_number":"EMEA-000995-PIP01-10","active_substance":"iloperidone","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Suspension for injection;Tablet","condition_indication":"Treatment of schizophrenia","routes_of_administration":"Intramuscular use;Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/04/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vanda Pharmaceuticals Ltd; United States; E-mail: gunther.birznieks@vandapharma.com; Tel. +1 202 7343416; Fax +1 202 2961450","first_published_date":"10/05/2011","last_updated_date":"10/05/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000995-pip01-10"},{"decision_number":"P/266/2010","pip_number":"EMEA-000926-PIP01-10","active_substance":"Dermatophagoides pteronyssinus;Dermatophagoides farinae","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal solution","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LETI Pharma GmbH; paediatrics@leti.de; Germany; Phone: +49 2302202860; Fax: +49 23022028620","first_published_date":"05/05/2011","last_updated_date":"05/05/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000926-pip01-10"},{"decision_number":"P/81/2010","pip_number":"EMEA-000665-PIP01-09","active_substance":"taspoglutide","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"07/05/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ipsen Pharma; E-mail: paediatrics.plans@ispen.com; Tel. +33 1 5833 5000","first_published_date":"27/07/2010","last_updated_date":"20/04/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000665-pip01-09"},{"decision_number":"P/80/2010","pip_number":"EMEA-000649-PIP01-09","active_substance":"taspoglutide","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"07/05/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ipsen Pharma; E-mail: paediatrics.plans@ispen.com; Tel. +33 1 5833 5000","first_published_date":"27/07/2010","last_updated_date":"20/04/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000649-pip01-09"},{"decision_number":"P/67/2011","pip_number":"EMEA-000156-PIP01-07-M02","active_substance":"antigen of pre-pandemic strain A/Vietnam/1203/2004 propagated in Vero cells","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Influenza infection caused by an influenza strain contained in the vaccine or related to a strain contained in the vaccine","routes_of_administration":"Intramuscular injection","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/03/2011","compliance_outcome":"Positive","compliance_opinion_date":"17/01/2013","compliance_procedure_number":"EMEA-C-000156-PIP01-07-M02","contact_for_public_enquiries":"Baxter Innovations GmbH; E-mail: johannes_braun@baxter.com; Tel.: +43 1201002542","first_published_date":"26/08/2010","last_updated_date":"08/04/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000156-pip01-07-m02"},{"decision_number":"P/61/2011","pip_number":"EMEA-001055-PIP01-10","active_substance":"human papilloma virus type 16 E6 071-095;human papilloma virus type 16 E7 064-098;human papilloma virus type 16 E6 055-080;human papilloma virus type 16 E6 001-032;human papilloma virus type 16 E6 091-122","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for suspension for injection","condition_indication":"Treatment of vulvar intraepithelial neoplasia","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/03/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ISA Therapeutics BV; info@isa-pharma.com; The Netherlands; +31 713322310","first_published_date":"08/04/2011","last_updated_date":"08/04/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001055-pip01-10"},{"decision_number":"P/50/2011","pip_number":"EMEA-000371-PIP02-09","active_substance":"lenalidomide","invented_name":"Revlimid; Revlimid","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of diffuse large B-cell lymphoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/03/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Celgene Europe LimitedTel.  +41 327298500E-mail: medinfo.intl@celgene.com","first_published_date":"08/04/2011","last_updated_date":"08/04/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000371-pip02-09"},{"decision_number":"P/60/2011","pip_number":"EMEA-001026-PIP01-10","active_substance":"testosterone","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Cutaneous solution","condition_indication":"Treatment of male hypogonadism","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/03/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"08/04/2011","last_updated_date":"08/04/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001026-pip01-10"},{"decision_number":"P/65/2011","pip_number":"EMEA-001084-PIP01-10","active_substance":"rivastigmine","invented_name":"Exelon; Exelon","therapeutic_area":"Neurology","pharmaceutical_forms":"Transdermal patch","condition_indication":"Treatment of dementia","routes_of_administration":"Transdermal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/03/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"08/04/2011","last_updated_date":"08/04/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001084-pip01-10"},{"decision_number":"P/44/2011","pip_number":"Telcagepant","active_substance":"telcagepant","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Film-coated tablet;Age appropriate dosage form, other","condition_indication":"Migraine with or without aura","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/03/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"10/06/2009","last_updated_date":"05/04/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/telcagepant"},{"decision_number":"P/46/2011","pip_number":"EMEA-001060-PIP01-10","active_substance":"(E)-4-(2-(6-(2-(2-(2-[18F]fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine","invented_name":"","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Solution for injection","condition_indication":"Diagnosis of Alzheimer's disease","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/03/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"05/04/2011","last_updated_date":"05/04/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001060-pip01-10"},{"decision_number":"P/45/2011","pip_number":"EMEA-000719-PIP02-10","active_substance":"atorvastatin (L-lysine salt);amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Prevention of atherosclerotic heart disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/03/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gedeon Richter Plc.; mrpRichter@richter.hu; Hungary; +36 14314040; +36 14315415","first_published_date":"05/04/2011","last_updated_date":"05/04/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000719-pip02-10"},{"decision_number":"P/40/2011","pip_number":"EMEA-001023-PIP01-10","active_substance":"romidepsin","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/02/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Celgene Europe B.V.; Tel. +41 327298500; E-mail: medinfo.emea@celgene.com","first_published_date":"08/03/2011","last_updated_date":"08/03/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001023-pip01-10"},{"decision_number":"P/25/2011","pip_number":"EMEA-000552-PIP01-09-M01","active_substance":"briakinumab","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution for injection","condition_indication":"Psoriasis vulgaris","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"26/01/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44 (0)1628 408248","first_published_date":"24/02/2011","last_updated_date":"24/02/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000552-pip01-09-m01"},{"decision_number":"P/36/2011","pip_number":"EMEA-001042-PIP01-10","active_substance":"recombinant human granulocyte colony stimulating factor;recombinant human albumin fusion protein","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of chemotherapy induced neutropenia","routes_of_administration":"Subcutaneous use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"28/01/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Teva Pharmaceuticals Europe B.V; info@ratiopharm.de; Germany; Phone: +49 73140202; Fax: +49 7314027832","first_published_date":"24/02/2011","last_updated_date":"24/02/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001042-pip01-10"},{"decision_number":"P/16/2011","pip_number":"EMEA-000913-PIP01-10","active_substance":"nepafenac","invented_name":"Nevanac; Nevanac","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution;Suspension","condition_indication":"Prevention of post operative pain and inflammation associated with cataract surgery","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/01/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alcon Laboratories (UK) Ltd.; Doug.MacHatton@AlconLabs.com; United States; Phone: +1 8175518974; Fax: +1 8176154607","first_published_date":"24/02/2011","last_updated_date":"24/02/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000913-pip01-10"},{"decision_number":"P/17/2011","pip_number":"EMEA-001048-PIP01-10","active_substance":"perindopril arginine;Indapamide;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of arterial hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"21/01/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierTel. +33 1 55 72 60 00E-mail: mail.pip.enquiries@fr.netgrs.com","first_published_date":"24/02/2011","last_updated_date":"24/02/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001048-pip01-10"},{"decision_number":"P/22/2011","pip_number":"EMEA-000976-PIP01-10","active_substance":"Grass pollen allergen extract from Dactylis glomerata L., Anthoxanthum odoratum L., Lolium perenne L., Poa prantensis L. and Phleum pratense L.","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"25/01/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Stallergenes S.A.; pip.germany@stallergenes.fr; France; Phone: +33 155592100; Fax: +33 155592002","first_published_date":"24/02/2011","last_updated_date":"24/02/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000976-pip01-10"},{"decision_number":"P/34/2011","pip_number":"EMEA-000977-PIP01-10)","active_substance":"house dust mites allergen extract from Dermatophagoides pteronyssinus and Dermatophagoides farinae (50/50)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"28/01/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Stallergenes S.A.; pip.germany@stallergenes.fr; France; Phone: +33 155592100; Fax: +33 155592002","first_published_date":"24/02/2011","last_updated_date":"24/02/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000977-pip01-10"},{"decision_number":"P/23/2011","pip_number":"EMEA-001029-PIP01-10","active_substance":"tesamorelin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Lyophilisate for solution for injection","condition_indication":"Treatment of HIV-associated lipodystrophy","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/01/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Theratechnologies Inc; communications@theratech.com; Canada; Phone: +1 5143367800","first_published_date":"24/02/2011","last_updated_date":"24/02/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001029-pip01-10"},{"decision_number":"P/27/2011","pip_number":"EMEA-000084-PIP02-10","active_substance":"rizatriptan","invented_name":"Maxalt and associated names","therapeutic_area":"Pain","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of migraine","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"28/01/2011","compliance_outcome":"Positive","compliance_opinion_date":"14/09/2011","compliance_procedure_number":"EMEA-C-000084-PIP02-10","contact_for_public_enquiries":"Merck, Sharp & Dohme (Europe) Inc.; Tel. +31 412770000; E-mail: regaffairseurope@organon.com","first_published_date":"23/02/2011","last_updated_date":"23/02/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000084-pip02-10"},{"decision_number":"P/13/2011","pip_number":"EMEA-000866-PIP01-10","active_substance":"Dermatophagoides farinae;Dermatophagoides pteronyssinus","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/01/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ALK-Abelló A/S; ldidk@alk-abello.com; ALKMRPdk@alk-abello.com; Denmark; Phone: +45 457478079; Fax: +45 45748600","first_published_date":"07/02/2011","last_updated_date":"07/02/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000866-pip01-10"},{"decision_number":"P/12/2011","pip_number":"EMEA-000863-PIP01-10","active_substance":"pollen from Alnus glutinosa, Betula verrucosa and Corylus avellana","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/01/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ALK-Abelló A/S; ldidk@alk-abello.com; ALKMRPdk@alk-abello.com; Denmark; Phone: +45 457478079; Fax: +45 45748600","first_published_date":"07/02/2011","last_updated_date":"07/02/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000863-pip01-10"},{"decision_number":"P/5/2011","pip_number":"Ecallantide","active_substance":"Ecallantide (recombiant inhibitor of human plasma kallikrein)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of hereditary angioedema","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/01/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dyax s.a.; ndauteuil@dyax.com; United States; Phone: +1 6172505773; Fax: +1 6172252501","first_published_date":"07/02/2011","last_updated_date":"07/02/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ecallantide"},{"decision_number":"P/14/2011","pip_number":"EMEA-000249-PIP01-10","active_substance":"Influenza Virus Type A, H3N2Influenza Virus Type A, H1N1Influenza Virus Type B","invented_name":"Fluenz; Fluenz","therapeutic_area":"Vaccines","pharmaceutical_forms":"Nasal spray suspension","condition_indication":"Prevention of influenza infection","routes_of_administration":"Intranasal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/01/2011","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"MedImmune, LLC; dekkere@medimmune.com; United States; Phone: +1 3013984040; Fax: +1 3013984015","first_published_date":"07/02/2011","last_updated_date":"07/02/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000249-pip01-10"},{"decision_number":"P/339/2010","pip_number":"EMEA-000934-PIP01-10","active_substance":"Dermatophagoides pteronyssinus;Dermatophagoides farinae","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"26/01/2011","last_updated_date":"26/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000934-pip01-10"},{"decision_number":"P/340/2010","pip_number":"EMEA-000935-PIP01-10","active_substance":"Dermatophagoides pteronyssinus","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"26/01/2011","last_updated_date":"26/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000935-pip01-10"},{"decision_number":"P/342/2010","pip_number":"EMEA-000948-PIP01-10","active_substance":"Dermatophagoides pteronyssinus;Dermatophagoides farinae","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"26/01/2011","last_updated_date":"26/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000948-pip01-10"},{"decision_number":"P/338/2010","pip_number":"EMEA-000933-PIP01-10","active_substance":"Dermatophagoides farinae","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"26/01/2011","last_updated_date":"26/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000933-pip01-10"},{"decision_number":"P/336/2010","pip_number":"EMEA-001036-PIP01-10","active_substance":"Interferon alpha 2b","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Vaginal cream","condition_indication":"Treatment of cervical intraepithelial neoplasia (CIN grade I and II)","routes_of_administration":"Vaginal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Helix BioPharma Corp; t.hinkley@helixbiopharma.com; Canada; Phone: +1 905 8412300; Fax: +1 905 8412244","first_published_date":"26/01/2011","last_updated_date":"26/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001036-pip01-10"},{"decision_number":"P/341/2010","pip_number":"EMEA-000947-PIP01-10","active_substance":"Dermatophagoides farinae","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"26/01/2011","last_updated_date":"26/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000947-pip01-10"},{"decision_number":"P/343/2010","pip_number":"EMEA-000949-PIP01-10","active_substance":"Dermatophagoides pteronyssinus","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"26/01/2011","last_updated_date":"26/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000949-pip01-10"},{"decision_number":"P/344/2010","pip_number":"EMEA-000960-PIP01-10","active_substance":"Dermatophagoides pteronyssinus","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"26/01/2011","last_updated_date":"26/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000960-pip01-10"},{"decision_number":"P/333/2010","pip_number":"EMEA-000964-PIP01-10","active_substance":"grass pollen;cereal pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000964-pip01-10"},{"decision_number":"P/318/2010","pip_number":"EMEA-000943-PIP01-10","active_substance":"rye pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000943-pip01-10"},{"decision_number":"P/325/2010","pip_number":"EMEA-000954-PIP01-10","active_substance":"grass pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000954-pip01-10"},{"decision_number":"P/327/2010","pip_number":"EMEA-000956-PIP01-10","active_substance":"modified allergen extract of pollen from Phleum pratense","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of rhino-conjuctivitis;Treatment of allergic rhinitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000956-pip01-10"},{"decision_number":"P/319/2010","pip_number":"EMEA-000944-PIP01-10","active_substance":"birch pollen;alder pollen;hazel pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000944-pip01-10"},{"decision_number":"P/313/2010","pip_number":"EMEA-000938-PIP01-10","active_substance":"grass pollen;rye pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000938-pip01-10"},{"decision_number":"P/316/2010","pip_number":"EMEA-000941-PIP01-10","active_substance":"hazel pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000941-pip01-10"},{"decision_number":"P/329/2010","pip_number":"EMEA-000958-PIP01-10","active_substance":"birch pollen;alder pollen;hazel pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000958-pip01-10"},{"decision_number":"P/315/2010","pip_number":"EMEA-000940-PIP01-10","active_substance":"grass pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000940-pip01-10"},{"decision_number":"P/323/2010","pip_number":"EMEA-000951-PIP01-10","active_substance":"grass pollen;cereal pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000951-pip01-10"},{"decision_number":"P/330/2010","pip_number":"EMEA-000959-PIP01-10","active_substance":"aqueous allergen extract of birch","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000959-pip01-10"},{"decision_number":"P/332/2010","pip_number":"EMEA-000963-PIP01-10","active_substance":"grass pollen;birch pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000963-pip01-10"},{"decision_number":"P/335/2010","pip_number":"EMEA-000966-PIP01-10","active_substance":"aqueous allergen extract of pollen from Phleum pratense","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000966-pip01-10"},{"decision_number":"P/334/2010","pip_number":"EMEA-000965-PIP01-10","active_substance":"grass pollen;rye pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000965-pip01-10"},{"decision_number":"P/317/2010","pip_number":"EMEA-000942-PIP01-10","active_substance":"modified allergen extract of pollen from Phleum pratense","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of rhino-conjuctivitis;Treatment of allergic rhinitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000942-pip01-10"},{"decision_number":"P/331/2010","pip_number":"EMEA-000962-PIP01-10","active_substance":"grass pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oral solution","condition_indication":"","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000962-pip01-10"},{"decision_number":"P/326/2010","pip_number":"EMEA-000955-PIP01-10","active_substance":"hazel pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000955-pip01-10"},{"decision_number":"P/322/2010","pip_number":"EMEA-000950-PIP01-10","active_substance":"grass pollen;birch pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000950-pip01-10"},{"decision_number":"P/328/2010","pip_number":"EMEA-000957-PIP01-10","active_substance":"rye pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000957-pip01-10"},{"decision_number":"P/320/2010","pip_number":"EMEA-000945-PIP01-10","active_substance":"birch pollen;hazel pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000945-pip01-10"},{"decision_number":"P/314/2010","pip_number":"EMEA-000939-PIP01-10","active_substance":"grass pollen;rye pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000939-pip01-10"},{"decision_number":"P/312/2010","pip_number":"EMEA-000937-PIP01-10","active_substance":"grass pollen;cereal pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000937-pip01-10"},{"decision_number":"P/324/2010","pip_number":"EMEA-000953-PIP01-10","active_substance":"grass pollen;rye pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000953-pip01-10"},{"decision_number":"P/321/2010","pip_number":"EMEA-000946-PIP01-10","active_substance":"birch pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000946-pip01-10"},{"decision_number":"P/289/2010","pip_number":"EMEA-000961-PIP01-10","active_substance":"Dermatophagoides pteronyssinus;Dermatophagoides farinae","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"25/01/2011","last_updated_date":"25/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000961-pip01-10"},{"decision_number":"P/298/2010","pip_number":"EMEA-000851-PIP01-10","active_substance":"Pollen from Dactylis glomerata, Festuca pratensis, Lolium perenne, Phleum pratense, Poa pratensis, Secale cereale and Artemisia vulgaris","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of rhino-conjuctivitis;Treatment of allergic rhinitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ALK-Abelló A/S; lcndk@alk-abello.com; ALKMRPdk@alk-abello.com; Denmark; Phone: +45 45748037; Fax: +45 45748600","first_published_date":"24/01/2011","last_updated_date":"24/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000851-pip01-10"},{"decision_number":"P/307/2010","pip_number":"EMEA-000929-PIP01-10","active_substance":"mugwort pollen;grass pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"24/01/2011","last_updated_date":"24/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000929-pip01-10"},{"decision_number":"P/302/2010","pip_number":"EMEA-000864-PIP01-10","active_substance":"Pollen from Dactylis glomerata, Festuca pratensis, Lolium perenne, Phleum pratense, Secale cereale (20% each)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oralmucosal drops","condition_indication":"Treatment of rhino-conjuctivitis;Treatment of allergic rhinitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ALK-Abelló A/S; ldidk@alk-abello.com; ALKMRPdk@alk-abello.com; Denmark; Phone: +45 457478079; Fax: +45 45748600","first_published_date":"24/01/2011","last_updated_date":"24/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000864-pip01-10"},{"decision_number":"P/299/2010","pip_number":"EMEA-000856-PIP01-10","active_substance":"Pollen from Dactylis glomarata, Lolium perenne, Phleum pratense, Poa pratensis and Anthoxhantum odoratum (20% each)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oralmucosal drops","condition_indication":"Treatment of rhino-conjuctivitis;Treatment of allergic rhinitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ALK-Abelló A/S; ldidk@alk-abello.com; ALKMRPdk@alk-abello.com; Denmark; Phone: +45 457478079; Fax: +45 45748600","first_published_date":"24/01/2011","last_updated_date":"24/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000856-pip01-10"},{"decision_number":"-","pip_number":"EMEA-000869-PIP01-10","active_substance":"Pollen from Dactylis glomarata (16%), Festuca pratensis (16%), Lolium perenne (16%), Phleum pratense (16%), Poa pratensis (16%), Secale cereale (20%)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oralmucosal drops","condition_indication":"Treatment of rhino-conjuctivitis;Treatment of allergic rhinitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ALK-Abelló A/S; ldidk@alk-abello.com; ALKMRPdk@alk-abello.com; Denmark; Phone: +45 457478079; Fax: +45 45748600","first_published_date":"24/01/2011","last_updated_date":"24/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000869-pip01-10"},{"decision_number":"P/291/2010","pip_number":"EMEA-000527-PIP02-10","active_substance":"ranibizumab","invented_name":"Lucentis","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection in pre-filled syringe","condition_indication":"Treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia","routes_of_administration":"Intravitreal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"24/01/2011","last_updated_date":"24/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000527-pip02-10"},{"decision_number":"P/308/2010","pip_number":"EMEA-000930-PIP01-10","active_substance":"birch pollen;alder pollen;hazel pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"24/01/2011","last_updated_date":"24/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000930-pip01-10"},{"decision_number":"P/311/2010","pip_number":"EMEA-000936-PIP01-10","active_substance":"grass pollen;birch pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"24/01/2011","last_updated_date":"24/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000936-pip01-10"},{"decision_number":"P/297/2010","pip_number":"EMEA-000850-PIP01-10","active_substance":"pollen from Dactylis glomerata, Festuca pratensis, Lolium perenne, Phleum pratense, Poa pratensis, Secale cereale, Betula verrucosa, Corylus avellana and Alnus glutinosa","invented_name":"EMEA-000850-PIP01-10","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of rhino-conjuctivitis;Treatment of allergic rhinitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ALK-Abelló A/S; lcndk@alk-abello.com; ALKMRPdk@alk-abello.com; Denmark; Phone: +45 45748037; Fax: +45 45748600","first_published_date":"24/01/2011","last_updated_date":"24/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000850-pip01-10"},{"decision_number":"P/309/2010","pip_number":"EMEA-000931-PIP01-10","active_substance":"birch pollen;hazel pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ROXALL Medizin GmbHE-mail: info@roxall.deTel.: +49 408972520","first_published_date":"24/01/2011","last_updated_date":"24/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000931-pip01-10"},{"decision_number":"P/304/2010","pip_number":"EMEA-000867-PIP01-10","active_substance":"Pollen from Phleum pratense","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of rhino-conjuctivitis;Treatment of allergic rhinitis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ALK-Abelló A/S; ldidk@alk-abello.com; ALKMRPdk@alk-abello.com; Denmark; Phone: +45 457478079; Fax: +45 45748600","first_published_date":"24/01/2011","last_updated_date":"24/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000867-pip01-10"},{"decision_number":"P/301/2010","pip_number":"EMEA-000859-PIP01-10","active_substance":"pollen from Dactylis glomarata (8%), Lolium perenne (8%), Phleum pratense (8%), Poa pratensis (8%), Anthoxhantum odoratum (8%), Secale cereale (10%), Betula pendula (16.7%), Corylus avellana (16.6%) and Alnus glutinosa (16.6%)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of rhino-conjuctivitis;Treatment of allergic rhinitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ALK-Abelló A/S; ldidk@alk-abello.com; ALKMRPdk@alk-abello.com; Denmark; Phone: +45 457478079; Fax: +45 45748600","first_published_date":"24/01/2011","last_updated_date":"24/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000859-pip01-10"},{"decision_number":"P/293/2010","pip_number":"EMEA-000824-PIP01-09","active_substance":"nalmefene hydrochloride dihydrate","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment for alcohol dependence","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"H. Lundbeck A/S; E-mail: information@lundbeck.com; Tel. +45 36301311;  ","first_published_date":"24/01/2011","last_updated_date":"24/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000824-pip01-09"},{"decision_number":"P/303/2010","pip_number":"EMEA-000865-PIP01-10","active_substance":"Betula verrucosa","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ALK-Abelló A/S; ldidk@alk-abello.com; ALKMRPdk@alk-abello.com; Denmark; Phone: +45 457478079; Fax: +45 45748600","first_published_date":"24/01/2011","last_updated_date":"24/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000865-pip01-10"},{"decision_number":"P/278/2010","pip_number":"EMEA-000906-PIP01-10","active_substance":"alnus glutinosa","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal drops","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"HAL Allergy BVE-mail: RA@hal-allergy.nlTel.: +31 881959092","first_published_date":"11/01/2011","last_updated_date":"11/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000906-pip01-10"},{"decision_number":"P/282/2010","pip_number":"EMEA-000910-PIP01-10","active_substance":"allergen extract of Secale cereale pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal drops","condition_indication":"Treatment of rhino-conjuctivitis;Treatment of allergic rhinitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"HAL Allergy BVE-mail: RA@hal-allergy.nlTel.: +31 881959092","first_published_date":"11/01/2011","last_updated_date":"11/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000910-pip01-10"},{"decision_number":"P/281/2010","pip_number":"EMEA-000909-PIP01-10","active_substance":"allergen extract of Phleum pratense pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal drops","condition_indication":"Treatment of rhino-conjuctivitis;Treatment of allergic rhinitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"HAL Allergy BVE-mail: RA@hal-allergy.nlTel.: +31 881959092","first_published_date":"11/01/2011","last_updated_date":"11/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000909-pip01-10"},{"decision_number":"P/276/2010","pip_number":"EMEA-000904-PIP01-10","active_substance":"Lolium perenne;Poa pratensis","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal drops","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"HAL Allergy BVE-mail: RA@hal-allergy.nlTel.: +31 881959092","first_published_date":"11/01/2011","last_updated_date":"11/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000904-pip01-10"},{"decision_number":"P/277/2010","pip_number":"EMEA-000905-PIP01-10","active_substance":"Lolium perenne;Poa pratensis;secale cereale;Phleum pratense","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal drops","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"HAL Allergy BVE-mail: RA@hal-allergy.nlTel.: +31 881959092","first_published_date":"11/01/2011","last_updated_date":"11/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000905-pip01-10"},{"decision_number":"P/283/2010","pip_number":"EMEA-000911-PIP01-10","active_substance":"Betula verrucosa;corylus avellana;alnus glutinosa","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal drops","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"HAL Allergy BVE-mail: RA@hal-allergy.nlTel.: +31 881959092","first_published_date":"11/01/2011","last_updated_date":"11/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000911-pip01-10"},{"decision_number":"P/279/2010","pip_number":"EMEA-000907-PIP01-10","active_substance":"Dermatophagoides pteronyssinus;Dermatophagoides farinae","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal drops","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"HAL Allergy BVE-mail: RA@hal-allergy.nlTel.: +31 881959092","first_published_date":"11/01/2011","last_updated_date":"11/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000907-pip01-10"},{"decision_number":"P/275/2010","pip_number":"EMEA-000903-PIP01-10","active_substance":"Betula verrucosa","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal drops","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"HAL Allergy BVE-mail: RA@hal-allergy.nlTel.: +31 881959092","first_published_date":"11/01/2011","last_updated_date":"11/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000903-pip01-10"},{"decision_number":"P/280/2010","pip_number":"EMEA-000908-PIP01-10","active_substance":"corylus avellana","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal drops","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"HAL Allergy BVE-mail: RA@hal-allergy.nlTel.: +31 881959092","first_published_date":"11/01/2011","last_updated_date":"11/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000908-pip01-10"},{"decision_number":"P/270/2010","pip_number":"EMEA-000619-PIP02-10","active_substance":"pralatrexate","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection;Solution for infusion","condition_indication":"Treatment of Hodgkin lymphoma;Treatment of lymphoblastic non-Hodgkin lymphoma;Treatment of mature B-cell non-Hodgkin lymphoma;Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)","routes_of_administration":"Intravenous use;Intrathecal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"02/12/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allos Therapeutics Limited; pedinfo@allos.com; United States; Phone: +1 3034266262; Fax: +1 3034129160","first_published_date":"10/01/2011","last_updated_date":"10/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000619-pip02-10"},{"decision_number":"P/272/2010","pip_number":"Eritoran","active_substance":"Eritoran","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder and solvent for solution for infusion","condition_indication":"Sepsis","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"29/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eisai Limited; United Kingdom; Tel. +44 (0)20 8600 1400; Fax +44 8456 761401; E-mail: lmedinfo@eisai.net","first_published_date":"10/01/2011","last_updated_date":"10/01/2011","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/eritoran"},{"decision_number":"P/257/2010","pip_number":"EMEA-000841-PIP01-10","active_substance":"aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extracts of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis pollen (Grasses-Mix) and Secale cereale (Cultivated Rye) pollen (50/50)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LETI Pharma GmbH; paediatrics@leti.de; Germany; Phone: +49 2302202860; Fax: +49 23022028620","first_published_date":"21/12/2010","last_updated_date":"21/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000841-pip01-10"},{"decision_number":"P/260/2010","pip_number":"EMEA-000920-PIP01-10","active_substance":"Dermatophagoides pteronyssinus","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal solution","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LETI Pharma GmbH; paediatrics@leti.de; Germany; Phone: +49 2302202860; Fax: +49 23022028620","first_published_date":"21/12/2010","last_updated_date":"21/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000920-pip01-10"},{"decision_number":"P/261/2010","pip_number":"EMEA-000921-PIP01-10","active_substance":"mixture of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis allergen extracts","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal solution","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LETI Pharma GmbH; paediatrics@leti.de; Germany; Phone: +49 2302202860; Fax: +49 23022028620","first_published_date":"21/12/2010","last_updated_date":"21/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000921-pip01-10"},{"decision_number":"P/264/2010","pip_number":"EMEA-000924-PIP01-10","active_substance":"Phleum pratense allergen extract","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal solution","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LETI Pharma GmbH; paediatrics@leti.de; Germany; Phone: +49 2302202860; Fax: +49 23022028620","first_published_date":"21/12/2010","last_updated_date":"21/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000924-pip01-10"},{"decision_number":"P/249/2010","pip_number":"EMEA-000793-PIP01-09","active_substance":"aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergic extract of equal amounts of Phleum pratense pollen and Secale cereale (cultivated rye) pollen (50/50)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LETI Pharma GmbH; paediatrics@leti.de; Germany; Phone: +49 2302202860; Fax: +49 23022028620","first_published_date":"21/12/2010","last_updated_date":"21/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000793-pip01-09"},{"decision_number":"P/259/2010","pip_number":"EMEA-000919-PIP01-10","active_substance":"Betula alba","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal solution","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LETI Pharma GmbH; Germany; E-mail: paediatrics@leti.de; Tel. +49 2302 202860; Fax +49 2302 2028620","first_published_date":"21/12/2010","last_updated_date":"21/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000919-pip01-10"},{"decision_number":"P/267/2010","pip_number":"EMEA-000986-PIP01-10","active_substance":"ocriplasmin","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of symptomatic focal vitreomacular adhesion","routes_of_administration":"Intravitreal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"26/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ThromboGenics; lenerose.arfelt@thrombogenics.com; Belgium; Phone: +32 16751440; Fax: +32 16751311","first_published_date":"21/12/2010","last_updated_date":"21/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000986-pip01-10"},{"decision_number":"P/256/2010","pip_number":"EMEA-000840-PIP01-10","active_substance":"aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extracts of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis pollen (Grasses-Mix)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LETI Pharma GmbH; paediatrics@leti.de; Germany; Phone: +49 2302202860; Fax: +49 23022028620","first_published_date":"21/12/2010","last_updated_date":"21/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000840-pip01-10"},{"decision_number":"P/235/2010","pip_number":"EMEA-000189-PIP01-08-M01","active_substance":"eptacog alfa pegol (activated)","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Hereditary factor VIII and factor IX deficiency","routes_of_administration":"Subcutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"26/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; E-mail: paediatrics@novonordisk.com; Tel: +45 44448888;  ","first_published_date":"21/12/2010","last_updated_date":"21/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000189-pip01-08-m01"},{"decision_number":"P/263/2010","pip_number":"EMEA-000923-PIP01-10","active_substance":"mixture of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis (Grasses-Mix) and Secale cereale (75/25) allergen extracts","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal solution","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LETI Pharma GmbH; paediatrics@leti.de; Germany; Phone: +49 2302202860; Fax: +49 23022028620","first_published_date":"21/12/2010","last_updated_date":"21/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000923-pip01-10"},{"decision_number":"P/265/2010","pip_number":"EMEA-000925-PIP01-10","active_substance":"mixture of Phleum pratense and Secale cereale allergen extracts","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal solution","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LETI Pharma GmbH; paediatrics@leti.de; Germany; Phone: +49 2302202860; Fax: +49 23022028620","first_published_date":"21/12/2010","last_updated_date":"21/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000925-pip01-10"},{"decision_number":"P/262/2010","pip_number":"EMEA-000922-PIP01-10","active_substance":"mixture of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis (Grasses-Mix) and Secale cereale (50/50) allergen extracts","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal solution","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LETI Pharma GmbH; paediatrics@leti.de; Germany; Phone: +49 2302202860; Fax: +49 23022028620","first_published_date":"21/12/2010","last_updated_date":"21/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000922-pip01-10"},{"decision_number":"P/258/2010","pip_number":"EMEA-000918-PIP01-10","active_substance":"birch, hazel and alder allergen extracts","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal solution","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LETI Pharma GmbH; paediatrics@leti.de; Germany; Phone: +49 2302202860; Fax: +49 23022028620","first_published_date":"21/12/2010","last_updated_date":"21/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000918-pip01-10"},{"decision_number":"P/247/2010","pip_number":"EMEA-000791-PIP01-09","active_substance":"aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergic extract of equal amounts of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis pollen (Grasses-Mix) and Secale cereale (Cultivated Rye) pollen (75/25)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LETI Pharma GmbH; paediatrics@leti.de; Germany; Phone: +49 2302202860; Fax: +49 23022028620","first_published_date":"21/12/2010","last_updated_date":"21/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000791-pip01-09"},{"decision_number":"P/246/2010","pip_number":"EMEA-000790-PIP01-09","active_substance":"aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergic extract of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis pollen (grasses-mix) and birch pollen (50/50)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LETI Pharma GmbH; paediatrics@leti.de; Germany; Phone: +49 2302202860; Fax: +49 23022028620","first_published_date":"21/12/2010","last_updated_date":"21/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000790-pip01-09"},{"decision_number":"P/255/2010","pip_number":"EMEA-000839-PIP01-10","active_substance":"aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extract of Phleum pratense pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LETI Pharma GmbH; paediatrics@leti.de; Germany; Phone: +49 2302202860; Fax: +49 23022028620","first_published_date":"21/12/2010","last_updated_date":"21/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000839-pip01-10"},{"decision_number":"P/230/2010","pip_number":"EMEA-000288-PIP01-08-M02","active_substance":"moxifloxacin hydrochloride","invented_name":"Avalox and associated names; Octegra and associated names; Actimax and associated names; Actira and associated names","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Solution for infusion;Granules and solvent for oral suspension","condition_indication":"Acute Exacerbation of Chronic Bronchitis;Community Acquired Pneumonia;Complicated Intra-Abdominal Infection;Complicated Skin and Skin Structure Infections;Pelvic Inflammatory Disease;Treatment of acute bacterial sinusitis","routes_of_administration":"Oral use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"24/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer Schering Pharma AG; pediatrics.medical-affairs-europe@bayerhealthcare.com; Germany; Phone: +49 3046815333; Fax: +49 3046895333","first_published_date":"21/12/2010","last_updated_date":"21/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000288-pip01-08-m02"},{"decision_number":"P/229/2010","pip_number":"Rosuvastatin (calcium)","active_substance":"rosuvastatin calcium","invented_name":"Crestor and associated names","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Homozygous Familial Hypercholesterolaemia;Prevention of cardiovascular events;Primary combined (mixed) dyslipidaemia;Primary hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"24/11/2010","compliance_outcome":"Positive","compliance_opinion_date":"11/10/2013","compliance_procedure_number":"EMEA-C-000022-PIP01-07-M04","contact_for_public_enquiries":"AstraZeneca AB (UK); Tel. +44 2073045345; E-mail: paediatrics@astrazeneca.com","first_published_date":"21/12/2010","last_updated_date":"07/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/rosuvastatin-calcium"},{"decision_number":"P/231/2010","pip_number":"EMEA-000712-PIP01-09","active_substance":"Fentanyl citrate","invented_name":"","therapeutic_area":"Neonatology-Paediatric Intensive Care","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of acute pain;Prevention of acute pain","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"23/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"EPMC Pharma SPRL; Hugo.Lagercrantz@ki.se; Sweden; Phone: + 46 8709845273; Fax: + 46 8709845273","first_published_date":"20/12/2010","last_updated_date":"20/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000712-pip01-09"},{"decision_number":"P/232/2010","pip_number":"EMEA-000764-PIP01-09","active_substance":"4-Hydroxy-n-(2-hydroxyethyl)-butyramide","invented_name":"","therapeutic_area":"Anaesthesiology","pharmaceutical_forms":"Solution for injection;Solution for infusion","condition_indication":"Sedation","routes_of_administration":"Intravenous use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"23/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dr. Franz Köhler Chemie GmbH; info@koehler-chemie.de; Germany; Phone: +49 625110830; Fax: +49 62511083246","first_published_date":"20/12/2010","last_updated_date":"20/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000764-pip01-09"},{"decision_number":"P/244/2010","pip_number":"EMEA-000742-PIP01-09","active_substance":"recombinant Bet v1 folding variant (rBet v1-FV)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of allergic rhinitis;Treatment of rhino-conjuctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergopharma J. Ganzer KG; info@allergopharma.de; Germany; Phone: +49 40727650; Fax: +49 407227713","first_published_date":"20/12/2010","last_updated_date":"20/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000742-pip01-09"},{"decision_number":"P/237/2010","pip_number":"EMEA-000380-PIP04-10","active_substance":"recombinant human monoclonal antibody to human interleukin 17A (AIN457)","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of chronic non-infectious uveitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"20/12/2010","last_updated_date":"20/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000380-pip04-10"},{"decision_number":"P/239/2010","pip_number":"Infliximab","active_substance":"infliximab","invented_name":"Remicade; Remicade","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Ankylosing spondylitis;Juvenile idiopathic arthritis;Psoriatic arthritis;Rheumatoid arthritis;Treatment of Crohn's disease;Treatment of psoriasis;Treatment of ulcerative colitis","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/11/2010","compliance_outcome":"Positive","compliance_opinion_date":"16/09/2011","compliance_procedure_number":"EMEA-C-000549-PIP01-09-M01","contact_for_public_enquiries":"Centocor B.V.; info@remicade.eu; The Netherlands; Phone: +31 202015009; Fax: +-*31 713065101","first_published_date":"20/12/2010","last_updated_date":"20/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/infliximab"},{"decision_number":"P/245/2010","pip_number":"EMEA-000789-PIP01-09","active_substance":"aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergic extract of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and poa pratensis pollen (grasses-mix) and birch, alder and hazel pollen (tree-mix) (50/50)","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of rhino-conjuctivitis;Treatment of allergic rhinitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"26/11/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LETI Pharma GmbH; paediatrics@leti.de; Germany; Phone: +49 2302202860; Fax: +49 23022028620","first_published_date":"20/12/2010","last_updated_date":"20/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000789-pip01-09"},{"decision_number":"P/233/2010","pip_number":"EMEA-000049-PIP01-07-M03","active_substance":"clopidogrel","invented_name":"Plavix; Plavix","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Oral formulation;Film-coated tablet","condition_indication":"Prevention of thromboembolic events","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"26/11/2010","compliance_outcome":"Positive","compliance_opinion_date":"10/12/2010","compliance_procedure_number":"EMEA-C-000049-PIP01-07-M03","contact_for_public_enquiries":"Sanofi Pharma Bristol-Myers Squibb SNC; sylvie.gabriel@sanofi-aventis.com; France; Phone: +33 153774152; Fax: +33 153774133","first_published_date":"20/12/2010","last_updated_date":"20/12/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000049-pip01-07-m03"},{"decision_number":"P/197/2010","pip_number":"EMEA-000991-PIP01-10","active_substance":"lidocaine hydrochloride;phenylephrine hydrochloride;tropicamide","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection","condition_indication":"Prevention of pain during cataract surgery","routes_of_administration":"Intraocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"26/10/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Laboratoires Théa; E-mail: s.momege@laboratoires-thea.fr; Tel. +33 473981436;  ","first_published_date":"25/11/2010","last_updated_date":"25/11/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000991-pip01-10"},{"decision_number":"P/220/2010","pip_number":"EMEA-000812-PIP01-09","active_substance":"grass pollen;rye pollen;birch pollen;alder pollen;hazel pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/10/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergy Therapeutics (UK) Ltd; Tel. +44(0)1903 844 700; E-mail: infoservices@allergytherapeutics.com","first_published_date":"25/11/2010","last_updated_date":"25/11/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000812-pip01-09"},{"decision_number":"P/203/2010","pip_number":"EMEA-000807-PIP01-09","active_substance":"Dermatophagoides pteronyssinus;Dermatophagoides farinae","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal solution","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/10/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergy Therapeutics (UK) Ltd; Tel. +44(0)1903 844 700; E-mail: infoservices@allergytherapeutics.com","first_published_date":"25/11/2010","last_updated_date":"25/11/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000807-pip01-09"},{"decision_number":"P/212/2010","pip_number":"EMEA-000608-PIP01-09","active_substance":"Pagibaximab","invented_name":"","therapeutic_area":"Neonatology-Paediatric Intensive Care","pharmaceutical_forms":"Solution for infusion","condition_indication":"Prevention of bacterial sepsis","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/10/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biosynexus, Incorporated; Veronika.Alt@eraconsulting.com; Germany; Phone:+49 5161989011; Fax: +49 5161989018","first_published_date":"25/11/2010","last_updated_date":"25/11/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000608-pip01-09"},{"decision_number":"P/223/2010","pip_number":"EMEA-000826-PIP01-09","active_substance":"phentermine;topiramate","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of obesity","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vivus BV; Tam@vivus.com; United States; Phone: + 1 6509345200","first_published_date":"25/11/2010","last_updated_date":"25/11/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000826-pip01-09"},{"decision_number":"P/215/2010","pip_number":"EMEA-000758-PIP01-09","active_substance":"derivative of 4,4'-(1-methylene)-bisbenzonitrile","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of endometriosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"25/11/2010","last_updated_date":"25/11/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000758-pip01-09"},{"decision_number":"P/216/2010","pip_number":"EMEA-000806-PIP01-09","active_substance":"grass pollen;rye pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Oromucosal solution","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/10/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergy Therapeutics (UK) Ltd; Tel. +44(0)1903 844 700; E-mail: infoservices@allergytherapeutics.com","first_published_date":"25/11/2010","last_updated_date":"25/11/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000806-pip01-09"},{"decision_number":"P/206/2010","pip_number":"EMEA-000894-PIP01-10","active_substance":"Ingenol mebutate","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Gel","condition_indication":"Treatment of actinic keratosis;Treatment of squamous cell carcinoma","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/10/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LEO Pharma A/S; paediatrics@leo-pharma.com; Denmark; Phone: +45 44945888; Fax: +45 72263321","first_published_date":"25/11/2010","last_updated_date":"25/11/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000894-pip01-10"},{"decision_number":"P/219/2010","pip_number":"EMEA-000811-PIP01-09","active_substance":"grass pollen;rye pollen;birch pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/10/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergy Therapeutics (UK) Ltd; Tel. +44(0)1903 844 700; E-mail: infoservices@allergytherapeutics.com","first_published_date":"25/11/2010","last_updated_date":"25/11/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000811-pip01-09"},{"decision_number":"P/218/2010","pip_number":"EMEA-000810-PIP01-09","active_substance":"grass pollen;rye pollen;birch pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/10/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergy Therapeutics (UK) Ltd; Tel. +44(0)1903 844 700; E-mail: infoservices@allergytherapeutics.com","first_published_date":"25/11/2010","last_updated_date":"25/11/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000810-pip01-09"},{"decision_number":"P/222/2010","pip_number":"EMEA-000814-PIP01-09","active_substance":"birch pollen;alder pollen;hazel pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of allergic rhinitis / rhino-conjunctivitis","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/10/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergy Therapeutics (UK) Ltd.; tom.holdich@allergytherapeutics.com; United Kingdom; Phone: +44 1903844725; Fax: +44 1903844726","first_published_date":"25/11/2010","last_updated_date":"25/11/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000814-pip01-09"},{"decision_number":"P/225/2010","pip_number":"EMEA-001006-PIP01-10","active_substance":"1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)-, monoethanesulfonate","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Capsule, soft","condition_indication":"Treatment of idiopathic pulmonary fibrosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"25/11/2010","last_updated_date":"25/11/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001006-pip01-10"},{"decision_number":"P/214/2010","pip_number":"Dronabinol","active_substance":"Dronabinol","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Oral solution","condition_indication":"Treatment of central and peripheral neuropathic pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"29/10/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bionorica AG; info@bionorica.de; Germany; Phone: +49 918132190; Fax: +49 9181231265","first_published_date":"25/11/2010","last_updated_date":"25/11/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/dronabinol"},{"decision_number":"P/213/2010","pip_number":"Fampridine","active_substance":"Fampridine","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Prolonged-release tablet","condition_indication":"Multiple sclerosis with walking disability","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/10/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Acorda Therapeutics, Inc.; CTA.submissions@biogenidec.com; United Kingdom; Phone: +44 1628501000; Fax: +44 1628501010","first_published_date":"25/11/2010","last_updated_date":"25/11/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/fampridine"},{"decision_number":"P/199/2010","pip_number":"EMEA-000352-PIP01-08-M01","active_substance":"motavizumab","invented_name":"","therapeutic_area":"Neonatology-Paediatric Intensive Care","pharmaceutical_forms":"Solution for injection","condition_indication":"Serious lower respiratory tract disease caused by respiratory syncytial virus (RSV)","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/10/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. : +44 1628644475","first_published_date":"24/11/2010","last_updated_date":"24/11/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000352-pip01-08-m01"},{"decision_number":"P/188/2010","pip_number":"EMEA-000886-PIP01-10","active_substance":"amlodipine camsylate;Losartan potassium","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/09/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Hanmi Europe Limited; minasong@hanmi.co.kr; Republic of Korea; +82 24109184; +82 24108799","first_published_date":"29/10/2010","last_updated_date":"29/10/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000886-pip01-10"},{"decision_number":"P/175/2010","pip_number":"EMEA-000901-PIP01-10","active_substance":"(R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrilephosphate","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of myelofibrosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/09/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"29/10/2010","last_updated_date":"29/10/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000901-pip01-10"},{"decision_number":"P/185/2010","pip_number":"EMEA-000737-PIP01-09","active_substance":"afamelanotide","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Implant","condition_indication":"Prevention of actinic keratosis;Prevention of drug phototoxic response;Treatment of congenital erythropoietic porphyria;Treatment of polymorphic light eruption;Treatment of solar urticaria","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/09/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Clinuvel UK Limited; mail@clinuvel.com; Australia; +61 396604900; +61 396604999","first_published_date":"29/10/2010","last_updated_date":"29/10/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000737-pip01-09"},{"decision_number":"P/169/2010","pip_number":"EMEA-000703-PIP01-09","active_substance":"vildagliptin;metformin hydrochloride","invented_name":"Eucreas","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/09/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"29/10/2010","last_updated_date":"29/10/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000703-pip01-09"},{"decision_number":"P/176/2010","pip_number":"EMEA-000901-PIP02-10","active_substance":"(R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrilephosphate","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of essential thrombocythaemia;Treatment of polycythaemia vera","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/09/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"29/10/2010","last_updated_date":"29/10/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000901-pip02-10"},{"decision_number":"P/189/2010","pip_number":"EMEA-001002-PIP01-10","active_substance":"copper (64Cu) chloride","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Radiopharmaceutical precursor;Solution","condition_indication":"Radiolabelling agent","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/09/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sparkle Srl; p.panichelli@sparklepet.it; Italy; +39 0733229739; +39 0733560352","first_published_date":"29/10/2010","last_updated_date":"29/10/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001002-pip01-10"},{"decision_number":"P/155/2010","pip_number":"EMEA-000998-PIP01-10","active_substance":"bazedoxifene;conjugated estrogens","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Postmenopausal osteoporosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/09/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Ltd; United Kingdom; E-mail: kulminder.nowacki@pfizer.com; Tel. +44 (0)1628 692253; Fax +44 (0)1628 692283","first_published_date":"29/10/2010","last_updated_date":"29/10/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000998-pip01-10"},{"decision_number":"P/184/2010","pip_number":"EMEA-000632-PIP01-09","active_substance":"Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, trivalent","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection in pre-filled syringe","condition_indication":"Prevention of influenza","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"24/09/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Abbott Biologicals B.V.Email: Filip.Goossens@abbott.comTel.: +32 477777148","first_published_date":"29/10/2010","last_updated_date":"29/10/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000632-pip01-09"},{"decision_number":"P/168/2010","pip_number":"EMEA-000915-PIP01-10","active_substance":"lixisenatide;insulin glargine","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/09/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi-aventis R&D; sylvie.gabriel@sanofi-aventis.com; France; +33 153774152; +33 153774133","first_published_date":"29/10/2010","last_updated_date":"29/10/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000915-pip01-10"},{"decision_number":"P/181/2010","pip_number":"EMEA-000464-PIP02-10","active_substance":"pasireotide","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection;Powder and solvent for suspension for injection","condition_indication":"Treatment of acromegaly and pituitary gigantism","routes_of_administration":"Subcutaneous use;Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/09/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"29/10/2010","last_updated_date":"29/10/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000464-pip02-10"},{"decision_number":"P/148/2010","pip_number":"EMEA-000687-PIP01-09-M02","active_substance":"Pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted), containing antigen equivalent to Influenza A/California/7/2009","invented_name":"Arepanrix; Arepanrix","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension and emulsion for emulsion for injection","condition_indication":"Influenza","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/08/2010","compliance_outcome":"Positive","compliance_opinion_date":"12/12/2014","compliance_procedure_number":"EMEA-C-000687-PIP01-09-M02","contact_for_public_enquiries":"GlaxoSmithKline Biologicals S.A. (UK); E-mail: eu.paediatric-plans@gsk.com; Tel.: +1 438 899 8201","first_published_date":"07/10/2010","last_updated_date":"07/10/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000687-pip01-09-m02"},{"decision_number":"P/160/2010","pip_number":"EMEA-000892-PIP01-10","active_substance":"clindamycin phosphate;tretinoin","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Gel","condition_indication":"Treatment of acne vulgaris","routes_of_administration":"Cutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/08/2010","compliance_outcome":"Positive","compliance_opinion_date":"10/12/2010","compliance_procedure_number":"EMEA-C-000892-PIP01-10","contact_for_public_enquiries":"MEDA Pharma GmbH & Co. KG; info@medapharma.de; Country: Germany; Phone: +49 617288801; Fax: +49 61728881112","first_published_date":"06/10/2010","last_updated_date":"06/10/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000892-pip01-10"},{"decision_number":"P/159/2010","pip_number":"EMEA-000885-PIP01-10","active_substance":"telmisartan;hydrochlorothiazide","invented_name":"MicardisPlus; MicardisPlus","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/08/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"06/10/2010","last_updated_date":"06/10/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000885-pip01-10"},{"decision_number":"P/163/2010","pip_number":"EMEA-001000-PIP01-10","active_substance":"valsartan;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/08/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Krka, d.d., Novo mesto; helen.staresinic@krka.biz; Country: Slovenia; Phone: +385 99110291; Fax: +385 16312153","first_published_date":"06/10/2010","last_updated_date":"06/10/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001000-pip01-10"},{"decision_number":"P/161/2010","pip_number":"EMEA-000896-PIP01-10","active_substance":"Indapamide;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/08/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierTel. +33 1 55 72 60 00E-mail: mail.pip.enquiries@fr.netgrs.com","first_published_date":"06/10/2010","last_updated_date":"06/10/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000896-pip01-10"},{"decision_number":"P/162/2010","pip_number":"EMEA-000983-PIP01-10","active_substance":"perindopril erbumine;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/08/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Krka, d.d., Novo mesto; E-mail: sendi.kersnic@krka.biz; Tel. +386 1475 1159;  ","first_published_date":"06/10/2010","last_updated_date":"06/10/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000983-pip01-10"},{"decision_number":"P/138/2010","pip_number":"Darunavir","active_substance":"darunavir","invented_name":"Prezista; Prezista","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Oral suspension","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"31/07/2010","compliance_outcome":"Positive","compliance_opinion_date":"13/12/2011","compliance_procedure_number":"EMEA-C-000038-PIP01-07-M03","contact_for_public_enquiries":"Janssen-Cilag International NV; E-mail: info@its.jnj.com; Country: Belgium; Phone: +32 15293100; Fax: +32 15286347","first_published_date":"27/08/2010","last_updated_date":"27/08/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/darunavir"},{"decision_number":"P/135/2010","pip_number":"EMEA-000829-PIP01-09","active_substance":"levonorgestrel;ethinylestradiol","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Contraception","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/07/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Teva Pharma B.V.; Sonja.Katanec-Frankovic@pliva.com; Lidija.Brnic@pliva.com; Silvana.Giljanovic@pliva.hr; Country: Croatia; Phone: +385 13723085; Fax: +385 3723157","first_published_date":"26/08/2010","last_updated_date":"26/08/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000829-pip01-09"},{"decision_number":"P/146/2010","pip_number":"EMEA-000663-PIP01-09-M03","active_substance":"A/California/7/2009 influenza-like virus strain","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Influenza","routes_of_administration":"Intramuscular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/07/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Vaccines & Diagnostics GmbH & Co. KG; E-mail: pip.seq@seqirus.com; Phone: +39 0577 243046;  ","first_published_date":"26/08/2010","last_updated_date":"26/08/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000663-pip01-09-m03"},{"decision_number":"P/134/2010","pip_number":"EMEA-000823-PIP01-10","active_substance":"amlodipine besilate;perindopril tert-butylamine","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/07/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gedeon Richter Plc.; E-mail: mrpRichter@richter.hu; Country: Hungary; Phone: +36 14314040; Fax: +36 14315415","first_published_date":"26/08/2010","last_updated_date":"26/08/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000823-pip01-10"},{"decision_number":"P/147/2010","pip_number":"EMEA-000884-PIP01-10","active_substance":"tafamidis meglumine","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Capsule, soft","condition_indication":"Neuropathic heredofamilial amyloidosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/07/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"FoldRx Pharmaceuticals; E-mail: PIP_enquiries@pfizer.com; United States; Phone: +44 1304 646607; Fax: +44 1304 653601","first_published_date":"26/08/2010","last_updated_date":"26/08/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000884-pip01-10"},{"decision_number":"P/136/2010","pip_number":"EMEA-000887-PIP01-10","active_substance":"amlodipine;ramipril","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/07/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"EGIS Pharmaceuticals PLC; E-mail: registry@egis.hu; Country: Hungary; Phone: +36 14692414; Fax: +36 14692415","first_published_date":"26/08/2010","last_updated_date":"26/08/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000887-pip01-10"},{"decision_number":"P/129/2010","pip_number":"EMEA-000641-PIP01-09","active_substance":"4-0-(ß-D-galactopiranosyl)-D-xylopyranose","invented_name":"","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Powder for oral solution","condition_indication":"Diagnosis of intestinal lactase deficiency","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/07/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Lactest SL; E-mail: jlmartin@lactest.com; Country: Spain; Phone: +34911467897; Fax: +34 915938262","first_published_date":"26/08/2010","last_updated_date":"26/08/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000641-pip01-09"},{"decision_number":"P/139/2010","pip_number":"EMEA-000198-PIP04-10","active_substance":"dexamethasone","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Intravitreal implant in applicator","condition_indication":"Treatment of diabetic macular oedema","routes_of_administration":"Intravitreal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/07/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergan Pharmaceuticals International Limited; E-mail: ml-eu_reg_affairs@allergan.com; Tel. +44 (0)1628 4944444","first_published_date":"26/08/2010","last_updated_date":"26/08/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000198-pip04-10"},{"decision_number":"P/125/2010","pip_number":"Lidocaine/tetracaine","active_substance":"lidocaine;tetracaine","invented_name":"","therapeutic_area":"Anaesthesiology","pharmaceutical_forms":"Cream","condition_indication":"Local anaesthesia","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/07/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ZARS Pharma; E-mail: PliaglisEU@zars.com; Country: United States; Phone: +1 8013500202; Fax: +1 8013500909","first_published_date":"26/08/2010","last_updated_date":"26/08/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/lidocaine-tetracaine"},{"decision_number":"P/133/2010","pip_number":"EMEA-000735-PIP01-09","active_substance":"omalizumab","invented_name":"Xolair; Xolair","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Powder and solvent for solution for injection;Solution for injection in pre-filled syringe","condition_indication":"Treatment of allergic asthma;Treatment of chronic idiopathic urticaria;Treatment of chronic spontaneous urticaria","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/07/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"26/08/2010","last_updated_date":"26/08/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000735-pip01-09"},{"decision_number":"P/116/2010","pip_number":"EMEA-000816-PIP01-09","active_substance":"sodium sulfate;potassium sulfate;magnesium sulfate heptahydrate","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Oral solution","condition_indication":"Diseases of the intestines","routes_of_administration":"Oral use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"07/07/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ipsen Pharma; E-mail: paediatrics.plans@ipsen.com; Tel. +33 58335820","first_published_date":"29/07/2010","last_updated_date":"29/07/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000816-pip01-09"},{"decision_number":"P/117/2010","pip_number":"EMEA-000820-PIP01-09","active_substance":"omeprazole;diclofenac (sodium)","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Modified release capsule","condition_indication":"Ankylosing spondylitis;Osteoarthritis;Rheumatoid arthritis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/07/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Temmler Werke GmbH; E-mail: avril.mankel@ndareg.com; Tel.: +49 8935854000","first_published_date":"29/07/2010","last_updated_date":"29/07/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000820-pip01-09"},{"decision_number":"P/118/2010","pip_number":"EMEA-000833-PIP01-10","active_substance":"chimeric antibody to mesothelin (MORAB-009)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of mesothelioma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/07/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eisai Ltd; E-mail: angela_miller@eisai.net; Country: United Kingdom; Phone: +44 8456765089","first_published_date":"29/07/2010","last_updated_date":"29/07/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000833-pip01-10"},{"decision_number":"P/111/2010","pip_number":"EMEA-000763-PIP01-09","active_substance":"tulobuterol","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Transdermal patch","condition_indication":"Asthma;Episodic wheeze","routes_of_administration":"Transdermal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/07/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CSI GmbH; E-mail: CSI.GmbH.cs@gmail.com; Tel.: +1 4083706150","first_published_date":"29/07/2010","last_updated_date":"29/07/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000763-pip01-09"},{"decision_number":"P/61/2010","pip_number":"EMEA-000250-PIP01-08-M02","active_substance":"nomegestrol acetate;17 beta-estradiol","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Contraception","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"09/03/2010","compliance_outcome":"Positive","compliance_opinion_date":"21/05/2010","compliance_procedure_number":"EMEA-C-000250-PIP01-08-M02","contact_for_public_enquiries":"N.V. Organon; Tel. +33 180 464 738; E-mail: pip.information@merck.com","first_published_date":"28/07/2010","last_updated_date":"28/07/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000250-pip01-08-m02"},{"decision_number":"P/70/2010","pip_number":"Diamorphine hydrochloride","active_substance":"diamorphine hydrochloride","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Dependence to intravenous heroin use","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/05/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Genus Pharmaceuticals Limited; E-mail: katyg@genuspharma.com; Country: United Kingdom; Phone: +44 1635568405","first_published_date":"28/07/2010","last_updated_date":"28/07/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/diamorphine-hydrochloride"},{"decision_number":"P/68/2010","pip_number":"EMEA-000781-PIP01-09","active_substance":"sorafenib tosilate","invented_name":"Nexavar; Nexavar","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Differentiated thyroid cancer","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/05/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer Schering Pharma AG; E-mail: pediatrics.medical-affairs-europe@bayerhealthcare.com; Country: Germany; Phone: +49 3046815333; Fax: +49 3046815333","first_published_date":"28/07/2010","last_updated_date":"28/07/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000781-pip01-09"},{"decision_number":"P/67/2010","pip_number":"Diamorphine","active_substance":"Diamorphine","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment-resistant heroin dependence","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/05/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Azanta A/S; E-mail: cm@azanta.com; Country: Denmark; Phone: +45 33267477","first_published_date":"28/07/2010","last_updated_date":"28/07/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/diamorphine"},{"decision_number":"P/69/2010","pip_number":"Forodesine hydrochloride","active_substance":"forodesine hydrochloride","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Treatment of Cutaneous T-Cell Lymphoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/05/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Mundipharma Research Ltd; E-mail: paediatric@mundipharma-rd.eu; Country: United Kingdom; Phone: +44 1223424900; Fax: +44 1223426054","first_published_date":"28/07/2010","last_updated_date":"28/07/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/forodesine-hydrochloride"},{"decision_number":"P/65/2010","pip_number":"Octocog alfa","active_substance":"octocog alfa","invented_name":"Advate; Advate","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Haemophilia A (congenital Factor VIII deficiency)","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/05/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Baxter AG; E-mail: juliana_brankova@baxter.com; Country: Austria; Phone: +43 1201002548; Fax: + 43 120100727","first_published_date":"28/07/2010","last_updated_date":"28/07/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/octocog-alfa"},{"decision_number":"P/66/2010","pip_number":"Avotermin","active_substance":"avotermin","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Scar conditions and fibrosis of the skin;Hypertrophic disorders of skin and keloid scars","routes_of_administration":"Intradermal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"04/05/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Renovo Ltd; E-mail: David.Fairlamb@renovo.com; Country: United Kingdom; Phone: +44 1612767132; Fax: +44 1612767200","first_published_date":"28/07/2010","last_updated_date":"28/07/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/avotermin"},{"decision_number":"P/64/2010","pip_number":"EMEA-000100-PIP01-07-M01","active_substance":"Iron, aqua carbonate hydroxy oxo starch sucrose complex","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Powder for oral suspension","condition_indication":"Hyperphosphataemia in chronic kidney disease","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/05/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"28/07/2010","last_updated_date":"28/07/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000100-pip01-07-m01"},{"decision_number":"P/86/2010","pip_number":"EMEA-000477-PIP01-08","active_substance":"cediranib maleate","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of high-grade glioma","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/06/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB (UK); Tel. +44 2037496236; E-mail: paediatrics@astrazeneca.com","first_published_date":"27/07/2010","last_updated_date":"27/07/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000477-pip01-08"},{"decision_number":"P/78/2010","pip_number":"EMEA-000351-PIP01-08","active_substance":"mometasone furoate","invented_name":"Nasonex and associated names","therapeutic_area":"Oto-rhino-laryngology","pharmaceutical_forms":"Nasal spray;Suspension","condition_indication":"Seasonal and perennial allergic rhinitis","routes_of_administration":"Nasal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/05/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Schering-Plough Research Institute, a division of Schering Corporation; E-mail: regaffairseurope@organon.com; Tel: +31 412770000","first_published_date":"27/07/2010","last_updated_date":"27/07/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000351-pip01-08"},{"decision_number":"P/82/2010","pip_number":"EMEA-000805-PIP01-09","active_substance":"vorinostat","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Malignant pleural mesothelioma;Treatment of Cutaneous T-Cell Lymphoma","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/04/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme Ltd; Belgium; E-mail: pip.information@merck.com; Tel. +31 412663179; Fax +31 412662571","first_published_date":"27/07/2010","last_updated_date":"27/07/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000805-pip01-09"},{"decision_number":"P/91/2010","pip_number":"EMEA-000801-PIP01-09","active_substance":"Fluocinolone acetonide","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Intravitreal implant in applicator","condition_indication":"Treatment of diabetic macular oedema","routes_of_administration":"Intravitreal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/06/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Campharm Ltd.; E-mail: craig.mccarthy@campharm.eu; Country: France; Phone: +33 494508996; Fax: +33 494506824","first_published_date":"26/07/2010","last_updated_date":"26/07/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000801-pip01-09"},{"decision_number":"P/90/2010","pip_number":"EMEA-000585-PIP01-09","active_substance":"bisoctrizole;titanium dioxide","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Cream","condition_indication":"Treatment of solar urticaria","routes_of_administration":"Cutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/06/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Orfagen; E-mail: info@orfagen.com; Country: France; Phone: +33 562247683; Fax: +33 562247686","first_published_date":"26/07/2010","last_updated_date":"26/07/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000585-pip01-09"},{"decision_number":"P/93/2010","pip_number":"EMEA-000165-PIP02-09","active_substance":"sitagliptin phosphate monohydrate;metformin hydrochloride","invented_name":"Janumet and associated names","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet;Modified-release tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/06/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe), Inc.; Belgium; E-mail: pip.information@merck.com; Tel. +31 412663179; Fax +31 412662571","first_published_date":"26/07/2010","last_updated_date":"26/07/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000165-pip02-09"},{"decision_number":"P/75/2010","pip_number":"Levonorgestrel","active_substance":"levonorgestrel","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Intrauterine delivery system","condition_indication":"Contraception","routes_of_administration":"Intrauterine use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"05/05/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer Schering Pharma AG; E-mail: pediatrics.medical-affairs-europe@bayerhealthcare.com; Country: Germany; Phone: +49 3046815333; Fax: +49 3046895333","first_published_date":"22/07/2010","last_updated_date":"22/07/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/levonorgestrel"},{"decision_number":"P/59/2010","pip_number":"Esomeprazole magnesium/acetylsalisylic acid","active_substance":"esomeprazole magnesium;acetylsalicylic acid","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Capsule","condition_indication":"Duodenal ulcer;Gastric ulcer","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/03/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB (Sweden); Tel. +46 8 5532791; E-mail: paediatrics@astrazeneca.com","first_published_date":"18/05/2010","last_updated_date":"18/05/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/esomeprazole-magnesium-acetylsalisylic-acid"},{"decision_number":"P/47/2010","pip_number":"Budesonide / salmeterol xinafoate","active_substance":"Budesonide;salmeterol xinafoate","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Inhalation powder;Capsule, hard","condition_indication":"Asthma","routes_of_administration":"Inhalation use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/03/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Laboratoires SMB s.a.; E-mail: regulatory@smb.be; Country: Belgium; Phone: +32 24114828","first_published_date":"18/05/2010","last_updated_date":"18/05/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/budesonide-salmeterol-xinafoate"},{"decision_number":"P/41/2010","pip_number":"Tartaric acid","active_substance":"tartaric acid","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Nebuliser solution","condition_indication":"Stress incontinence, female","routes_of_administration":"Inhalation use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/03/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pneumoflex E.U. Limited; E-mail: info@interfaceconsultancy.com; Country: United Kingdom; Phone: +44 1377288420; Fax: +44 1377288420","first_published_date":"18/05/2010","last_updated_date":"18/05/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/tartaric-acid"},{"decision_number":"P/57/2010","pip_number":"Taliglucerase alfa","active_substance":"taliglucerase alfa","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Powder for solution for infusion","condition_indication":"Gaucher Disease, acute neuronopathic;Gaucher Disease (except acute neuronopathic)","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"09/04/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Protalix B.V.; einata@protalix.com; Israel; Phone: +972 9028100 / ext.137; Fax: +972 9889489","first_published_date":"18/05/2010","last_updated_date":"18/05/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/taliglucerase-alfa"},{"decision_number":"P/23/2010","pip_number":"Strontium ranelate","active_substance":"strontium ranelate","invented_name":"Protelos; Protelos","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Granules for oral suspension","condition_indication":"Osteoporosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/03/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierE-mail: mail.pip.enquiries@servier.comTel.: +33 155726000","first_published_date":"19/04/2010","last_updated_date":"19/04/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/strontium-ranelate"},{"decision_number":"P/28/2010","pip_number":"Dalcetrapib","active_substance":"dalcetrapib","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Lipoprotein deficiency","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"05/03/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration Limited; info.paediatrics@roche.com; Switzerland; Phone: +41 616879411; Fax: +41 616879233","first_published_date":"19/04/2010","last_updated_date":"19/04/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/dalcetrapib"},{"decision_number":"P/24/2010","pip_number":"Strontium ranelate","active_substance":"strontium ranelate","invented_name":"Osseor; Osseor","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Granules for oral suspension","condition_indication":"Osteoporosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"02/03/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Les Laboratoires ServierE-mail: mail.pip.enquiries@servier.comTel.: +33 155726000","first_published_date":"19/04/2010","last_updated_date":"19/04/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/strontium-ranelate-0"},{"decision_number":"P/27/2010","pip_number":"Pramipexole dihydrochloride monohydrate","active_substance":"pramipexole dihydrochloride monohydrate","invented_name":"Sifrol; Sifrol","therapeutic_area":"Neurology","pharmaceutical_forms":"Immediate release tablet","condition_indication":"Combined vocal and multiple motor tic disorder (de la Tourette);Restless Legs Syndrome","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/03/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"19/04/2010","last_updated_date":"19/04/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/pramipexole-dihydrochloride-monohydrate-0"},{"decision_number":"P/26/2010","pip_number":"EMEA-000391-PIP01-08-M01","active_substance":"nevirapine","invented_name":"Viramune; Viramune","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Prolonged-release tablet;Tablet;Oral suspension","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/03/2010","compliance_outcome":"Positive","compliance_opinion_date":"06/08/2010","compliance_procedure_number":"EMEA-C-000391-PIP01-08-M01","contact_for_public_enquiries":"","first_published_date":"19/04/2010","last_updated_date":"19/04/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000391-pip01-08-m01"},{"decision_number":"P/6/2010","pip_number":"EMEA-000744-PIP01-09","active_substance":"valsartan;hydrochlorothiazide;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"25/01/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm Ltd.; E-mail: paediatric.enquiries@novartis.com; Country: Switzerland; Phone: +41 61 324 1111; Fax: +41 61 324 8001","first_published_date":"25/02/2010","last_updated_date":"25/02/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000744-pip01-09"},{"decision_number":"P/4/2010","pip_number":"EMEA-000714-PIP01-09","active_substance":"Larvae of Lucilia sericata","invented_name":"","therapeutic_area":"Other","pharmaceutical_forms":"Larvae enclosed in a mesh bag with foam pieces","condition_indication":"Sloughy and necrotic venous and mixed venous/arterial leg ulcers","routes_of_administration":"Epilesional use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"25/01/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ZooBiotic Limited; E-mail: enquiries@zoobiotic.co.uk; Country: United Kingdom; Phone: +44 8452301810; Fax: +44 1656668047","first_published_date":"25/02/2010","last_updated_date":"25/02/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000714-pip01-09"},{"decision_number":"P/9/2010","pip_number":"EMEA-000551-PIP01-09","active_substance":"Givinostat","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Oral suspension","condition_indication":"Juvenile idiopathic arthritis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/01/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Italfarmaco SpA; E-mail: c.durzo@italfarmaco.com; Country: Italy; Phone: +39 0264432584; Fax: +39 0264433554","first_published_date":"25/02/2010","last_updated_date":"25/02/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000551-pip01-09"},{"decision_number":"P/266/2009","pip_number":"EMEA-000552-PIP01-0","active_substance":"recombinant human monoclonal antibody to the p40 subunit of human interleukin-12 and human interleukin-23 of the IgG1-class (ABT-874)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Solution for injection","condition_indication":"Psoriasis vulgaris","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"23/12/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Abbott Laboratories Ltd; E-mail: pediatric_oncology_immunology@abbott.com; Country: United Kingdom; Phone: +44 1628644475; Fax: +44 1628644330","first_published_date":"25/02/2010","last_updated_date":"25/02/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000552-pip01-0"},{"decision_number":"P/3/2010","pip_number":"EMA-000699-PIP01-09","active_substance":"linagliptin;metformin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"25/01/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"25/02/2010","last_updated_date":"25/02/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-000699-pip01-09"},{"decision_number":"P/5/2010","pip_number":"EMEA-000719-PIP01-09","active_substance":"atorvastatin (L-lysine salt);amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Hypertension with dyslipidemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"25/01/2010","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Gedeon Richter Plc.; E-mail: mrpRichter@richter.hu; Country: Hungary; Phone: +36 14314040; Fax: +36 14315415","first_published_date":"25/02/2010","last_updated_date":"25/02/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000719-pip01-09"},{"decision_number":"P/241/2009","pip_number":"Fluorouracil / salicylic acid","active_substance":"Fluorouracil;salicylic acid","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Solution","condition_indication":"Treatment of actinic keratosis","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Almirall Hermal GmbH; E-mail: info@alimirall.de; Country: Germany; Phone: +49 40727040; Fax: +49 407229296","first_published_date":"25/01/2010","last_updated_date":"25/01/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/fluorouracil-salicylic-acid"},{"decision_number":"P/261/2009","pip_number":"Tramadol hydrochloride, Paracetamol","active_substance":"tramadol hydrochloride;paracetamol","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Prolonged-release tablet","condition_indication":"Pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/12/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Labopharm Europe Limited; E-mail: info@labopharm.com; Country: Ireland; Phone: +353 18540140; Fax: +353 18540144","first_published_date":"25/01/2010","last_updated_date":"25/01/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/tramadol-hydrochloride-paracetamol"},{"decision_number":"P/251/2009","pip_number":"Amlodipine besilate / bisoprolol fumarate","active_substance":"amlodipine besilate;Bisoprolol fumarate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Chronic stable angina pectoris;Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/12/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"EGIS Pharmaceuticals PLC; E-mail: regulatory@egis.hu; Country:  Hungary; Phone: +36 14692414; Fax: +36 14692415","first_published_date":"25/01/2010","last_updated_date":"25/01/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/amlodipine-besilate-bisoprolol-fumarate"},{"decision_number":"P/260/2009","pip_number":"Tramadol hydrochloride, Paracetamol","active_substance":"tramadol hydrochloride;paracetamol","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Prolonged-release tablet","condition_indication":"Pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/12/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Labopharm Europe Limited; E-mail: info@labopharm.com; Country: Ireland; Phone: +353 18540140; Fax: +353 18540144","first_published_date":"25/01/2010","last_updated_date":"25/01/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/tramadol-hydrochloride-paracetamol-0"},{"decision_number":"P/258/2009","pip_number":"Fentanyl citrate","active_substance":"Fentanyl citrate","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Nasal spray;Solution","condition_indication":"Acute pain","routes_of_administration":"Nasal use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"23/12/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Nycomed Danmark ApS; E-mail: corporatecommunications@nycomed.com; Country: Switzerland; Phone: +41 445551510","first_published_date":"25/01/2010","last_updated_date":"25/01/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/fentanyl-citrate"},{"decision_number":"P/240/2009","pip_number":"Saxagliptin / metformin","active_substance":"saxagliptin;Metformin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb / AstraZeneca EEIG; Email: medical.information@bms.com; Tel.: +44 1895523740","first_published_date":"25/01/2010","last_updated_date":"25/01/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/saxagliptin-metformin"},{"decision_number":"P/259/2009","pip_number":"EMEA-000564-PIP01-09","active_substance":"paracetamol;Ibuprofen","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Film-coated tablet;Suspension","condition_indication":"Acute pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/12/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Vale Pharmaceuticals Limited; E-mail: majella.ryan@ivowen.com; Country: Ireland; Phone: +353 526180664; Fax: +353 526180665","first_published_date":"25/01/2010","last_updated_date":"25/01/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000564-pip01-09"},{"decision_number":"P/255/2009","pip_number":"Allogeneic ex vivo expanded umbilical cord blood cells","active_substance":"allogeneic ex vivo expanded umbilical cord blood cells","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Treatment of acute lymphoblastic leukaemia;Treatment of acute myeloid leukaemia;Treatment of chronic myeloid leukaemia (CML);Treatment of Hodgkin lymphoma;Treatment of myelodysplastic syndromes;Treatment of non-Hodgkin lymphoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/12/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Teva Pharma GmbH; E-mail: Ekkehard.Baader@TEVA.DE; Country: Germany; Phone: +49 61059767617; Fax: +49 61059767660","first_published_date":"25/01/2010","last_updated_date":"25/01/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/allogeneic-ex-vivo-expanded-umbilical-cord-blood-cells"},{"decision_number":"P/264/2009","pip_number":"EMEA-000492-PIP01-08-M01","active_substance":"moxifloxacin hydrochloride","invented_name":"Actimax and associated names","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Solution for infusion;Granules and solvent for oral suspension","condition_indication":"Acute Exacerbation of Chronic Bronchitis;Community Acquired Pneumonia;Complicated Intra-Abdominal Infection;Complicated Skin and Skin Structure Infections;Pelvic Inflammatory Disease;Treatment of acute bacterial sinusitis","routes_of_administration":"Oral use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"23/12/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer Schering Pharma AG; E-mail: steven.kowalsky@bayer.com; Country: United States; Phone: +1 9734872107","first_published_date":"25/01/2010","last_updated_date":"25/01/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000492-pip01-08-m01"},{"decision_number":"P/256/09","pip_number":"EMEA-000612-PIP01-09","active_substance":"nitric oxide","invented_name":"INOmax; INOmax","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Inhalation gas","condition_indication":"Other pulmonary heart disease;Persistent Pulmonary Hypertension","routes_of_administration":"Endotracheopulmonary use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"22/12/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"INO Therapeutics AB; E-mail: Cecilia.dahlgren@linde-gas.com; Country: Sweden; Phone: +46 702500055; Fax: +46 87655287","first_published_date":"25/01/2010","last_updated_date":"25/01/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000612-pip01-09"},{"decision_number":"P/242/2009","pip_number":"EMEA-000281-PIP01-08-M02","active_substance":"recombinant human monoclonal antibody of the IgG1 class to insulin-like growth factor-1 receptor (RO4858696)","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Ewing sarcoma family of tumours (including Ewing sarcoma of bone, peripheral primitive neuroectodermal tumour, extraskeletal Ewing sarcoma, and Askin tumour)","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"02/12/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Roche Registration Limited; E-mail: info.paediatrics@roche.com; Tel.: +41 616879411","first_published_date":"25/01/2010","last_updated_date":"25/01/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000281-pip01-08-m02"},{"decision_number":"P/265/2009","pip_number":"EMEA-000493-PIP01-08-M01","active_substance":"moxifloxacin hydrochloride","invented_name":"Actira and associated names","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Solution for infusion;Granules and solvent for oral suspension","condition_indication":"Acute Exacerbation of Chronic Bronchitis;Community Acquired Pneumonia;Complicated Intra-Abdominal Infection;Complicated Skin and Skin Structure Infections;Pelvic Inflammatory Disease;Treatment of acute bacterial sinusitis","routes_of_administration":"Oral use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"23/12/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer Schering Pharma AG; E-mail: steven.kowalsky@bayer.com; Country: United States; Phone: +1 9734872107","first_published_date":"25/01/2010","last_updated_date":"25/01/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000493-pip01-08-m01"},{"decision_number":"P/263/2009","pip_number":"EMEA-000491-PIP01-08-M01","active_substance":"moxifloxacin hydrochloride","invented_name":"Octegra and associated names","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Film-coated tablet;Solution for infusion;Granules and solvent for oral suspension","condition_indication":"Acute Exacerbation of Chronic Bronchitis;Community Acquired Pneumonia;Complicated Intra-Abdominal Infection;Complicated Skin and Skin Structure Infections;Pelvic Inflammatory Disease;Treatment of acute bacterial sinusitis","routes_of_administration":"Oral use;Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"23/12/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer Schering Pharma AG; E-mail: steven.kowalsky@bayer.com; Country: United States; Phone: +1 9734872107","first_published_date":"25/01/2010","last_updated_date":"25/01/2010","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000491-pip01-08-m01"},{"decision_number":"P/236/2009","pip_number":"EMEA-000656-PIP01-09","active_substance":"aliskiren hemifumarate;amlodipine besilate;hydrochlorothiazide","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/11/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm Ltd.; E-mail: paediatric.enquiries@novartis.com; Country: Switzerland; Phone: +41 61 324 1111; Fax: +41 61 324 8001","first_published_date":"23/12/2009","last_updated_date":"23/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000656-pip01-09"},{"decision_number":"P/235/2009","pip_number":"EMEA-000631-PIP01-09","active_substance":"simvastatin;ramipril;acetyl salicylic acid","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, hard","condition_indication":"Prevention of Ischaemic Heart Disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/11/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ferrer Internacional, S.A; E-mail: jrandreu@ferrergrupo.com / silviamartin@ferrergrupo.com; Phone: +34 936003801 / +34 935093227","first_published_date":"23/12/2009","last_updated_date":"23/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000631-pip01-09"},{"decision_number":"P/220/2009","pip_number":"Latanoprost","active_substance":"Latanoprost","invented_name":"Xalatan","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution","condition_indication":"Treatment of glaucoma","routes_of_administration":"Ocular use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"03/11/2009","compliance_outcome":"Positive","compliance_opinion_date":"19/03/2010","compliance_procedure_number":"EMEA-C-000011-PIP01-07-M03","contact_for_public_enquiries":"Pfizer Global Research & Development; E-mail: PIP_Enquiries@pfizer.com; Country: United Kingdom; Phone: +44 13046446607; Fax: +44 1304646607 ","first_published_date":"23/12/2009","last_updated_date":"23/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/latanoprost"},{"decision_number":"P/221/2009","pip_number":"Soluble yeast beta-1,3/1,6-glucan","active_substance":"soluble yeast beta-1,3/1,6-glucan","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Cutaneous solution","condition_indication":"Treatment of diabetic foot ulcer","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/11/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biotec Pharmacon ASA; E-mail: info@biotec.no; Country: Norway; Phone: +47 77648900; Fax: +4777648901","first_published_date":"23/12/2009","last_updated_date":"23/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/soluble-yeast-beta-13-16-glucan"},{"decision_number":"P/228/2009","pip_number":"Olmesartan medoxomil / amlodipine besilate / hydrochlorothiazide","active_substance":"olmesartan medoxomil;amlodipine besilate;hydrochlorothiazide","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/11/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Daiichi Sankyo Europe GmbH; E-mail: service@daiichi-sankyo.eu; Country: Germany; Phone: +49 8978080; Fax: +49 897808267","first_published_date":"23/12/2009","last_updated_date":"23/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/olmesartan-medoxomil-amlodipine-besilate-hydrochlorothiazide"},{"decision_number":"P/226/2009","pip_number":"Olmesartan medoxomil / amlodipine besilate / hydrochlorothiazide","active_substance":"olmesartan medoxomil;amlodipine besilate;hydrochlorothiazide","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/11/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Daiichi Sankyo Europe GmbH; E-mail: service@daiichi-sankyo.eu; Country: Germany; Phone: +49 8978080; Fax: +49 897808267","first_published_date":"23/12/2009","last_updated_date":"23/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/olmesartan-medoxomil-amlodipine-besilate-hydrochlorothiazide-0"},{"decision_number":"P/230/2009","pip_number":"EMEA-000658-PIP01-08","active_substance":"nomegestrol acetate;17 beta-estradiol","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Contraception","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"13/11/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"NV Organon (part of Schering Plough); Tel.+ 33 180 464 738; E-mail: pip.information@merck.com","first_published_date":"23/12/2009","last_updated_date":"23/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000658-pip01-08"},{"decision_number":"P/227/2009","pip_number":"Olmesartan medoxomil / amlodipine besilate / hydrochlorothiazide","active_substance":"olmesartan medoxomil;amlodipine besilate;hydrochlorothiazide","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/11/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Daiichi Sankyo Europe GmbH; E-mail: service@daiichi-sankyo.eu; Country: Germany; Phone: +49 8978080; Fax: +49 897808267","first_published_date":"23/12/2009","last_updated_date":"23/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/olmesartan-medoxomil-amlodipine-besilate-hydrochlorothiazide-1"},{"decision_number":"P/201/2009","pip_number":"Ibuprofen / Famotidine","active_substance":"Ibuprofen;Famotidine","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Tablet","condition_indication":"Chronic pain due to arthropathies","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"09/10/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Horizon Therapeutics Inc.; E-mail: twalbert@horizontherapeutics.com; Tel.: +1 2243833000","first_published_date":"07/12/2009","last_updated_date":"07/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ibuprofen-famotidine"},{"decision_number":"P/183/2009","pip_number":"EMEA-000527-PIP01-08","active_substance":"ranibizumab","invented_name":"Lucentis; Lucentis","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection in a vial;Solution for injection in pre-filled syringe","condition_indication":"Visual impairment due to diabetic macular edema;Visual impairment due to macular edema associated with branch retinal vein occlusion;Visual impairment due to macular edema associated with central retinal vein occlusion","routes_of_administration":"Intravitreal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/09/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"07/12/2009","last_updated_date":"07/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000527-pip01-08"},{"decision_number":"P/190/2009","pip_number":"Clopidogrel","active_substance":"clopidogrel","invented_name":"Clopidogrel BMS; Clopidogrel BMS","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Age appropriate oral formulation;Film-coated tablet","condition_indication":"Thromboembolic events","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/09/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG; E-mail: sylvie.gabriel@sanofi-aventis.com; Country: France; Phone: +33 153774152; Fax: +33 153774133","first_published_date":"07/12/2009","last_updated_date":"07/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/clopidogrel-1"},{"decision_number":"P/215/2009","pip_number":"Ulipristal acetate","active_substance":"ulipristal acetate","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Leiomyoma of uterus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"30/10/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"PregLem SA; E-mail: info@preglem.com; Country: Switzerland; Phone: +41 228840340; Fax: +41 228840349","first_published_date":"07/12/2009","last_updated_date":"07/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ulipristal-acetate"},{"decision_number":"P/217/2009","pip_number":"Chloroprocaine hydrochloride","active_substance":"chloroprocaine hydrochloride","invented_name":"","therapeutic_area":"Anaesthesiology","pharmaceutical_forms":"Solution for injection","condition_indication":"Intrathecal anaesthesia","routes_of_administration":"Intrathecal use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"30/10/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sintetica Italia S.r.l; E-mail: italia@sintetica.com; Country: Switzerland; Phone: +41 916404250; Fax: +41 916468561","first_published_date":"07/12/2009","last_updated_date":"07/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/chloroprocaine-hydrochloride"},{"decision_number":"P/208/2009","pip_number":"Skimmed cow's milk powder","active_substance":"skimmed cow's milk powder","invented_name":"Diallertest","therapeutic_area":"Other","pharmaceutical_forms":"Cutaneous patch","condition_indication":"Cow's milk allergy","routes_of_administration":"Cutaneous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/10/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"DBV Technologies; E-mail: isabelle.pascal@dbv-technologies.com / laurent.martin@dbv-technologies.com; Country: France; Phone: +33 155427895; Fax: +33 143261083","first_published_date":"07/12/2009","last_updated_date":"07/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/skimmed-cows-milk-powder"},{"decision_number":"P/177/2009","pip_number":"EMEA-000315-PIP01-08","active_substance":"6,7-dihydro-5H-pyrrolo[1,2-c] imidazol-5-yl) - (benzo derivative)","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"07/09/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Recordati Rare Diseases; Tel. +33 1 47 73 64 58; E-mail: RRDinfo@recordati.com","first_published_date":"07/12/2009","last_updated_date":"07/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000315-pip01-08"},{"decision_number":"P/203/2009","pip_number":"EMEA-000565-PIP01-09","active_substance":"Dirucotide acetate","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Lyophilisate for solution for injection","condition_indication":"Secondary progressive multiple sclerosis","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/10/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"07/12/2009","last_updated_date":"07/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000565-pip01-09"},{"decision_number":"P/189/2009","pip_number":"Clopidogrel","active_substance":"clopidogrel","invented_name":"Clopidogrel Zentiva (previously Clopidogrel Winthrop); Clopidogrel Winthrop","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Age appropriate oral formulation;Film-coated tablet","condition_indication":"Thromboembolic events","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"22/09/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi Pharma Bristol-Myers Squibb SNC; E-mail: sylvie.gabriel@sanofi-aventis.com; Country: France; Phone: +33 153774152; Fax: +33 153774133","first_published_date":"07/12/2009","last_updated_date":"07/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/clopidogrel"},{"decision_number":"P/200/2009","pip_number":"EMEA-000012-PIP01-07-M01","active_substance":"montelukast sodium","invented_name":"Singulair","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Chewable tablet;Oral granules","condition_indication":"Asthma","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"01/10/2009","compliance_outcome":"Positive","compliance_opinion_date":"15/01/2010","compliance_procedure_number":"EMEA-C-000012-PIP01-07-M01","contact_for_public_enquiries":"Merck Sharp & Dohme Ltd.; E-mail: regaffairseurope@organon.com; Tel: +31 412770000","first_published_date":"07/12/2009","last_updated_date":"07/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000012-pip01-07-m01"},{"decision_number":"P/218/2009","pip_number":"Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerized, allergenic extract of birch, alder and hazel pollen","active_substance":"aluminium hydroxide adsorbed;depigmented glutaraldehyde polymerised;birch pollen;alder pollen;hazel pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection (multidose vial)","condition_indication":"Treatment of allergic rhinitis;Treatment of allergic rhinoconjunctivitis due to pollen","routes_of_administration":"Subcutaneous use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"30/10/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LETI Pharma GmbH; E-mail: renner@leti.de; Country: Germany; Phone: +49 2302202860; Fax: +49 23022028620","first_published_date":"07/12/2009","last_updated_date":"07/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerized-allergenic-extract-birch-alder-hazel-pollen"},{"decision_number":"P/209/2009","pip_number":"EMEA-000331-PIP01-08-M01","active_substance":"esomeprazole magnesium trihydrate;esomeprazole sodium","invented_name":"Nexium Control; Nexium and associated names","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Gastro-resistant tablet;Gastro-resistant granules for oral suspension;Powder for solution for injection or infusion","condition_indication":"Duodenal ulcer;Gastric ulcer;Gastro-oesophageal reflux disease;Peptic ulcer, site unspecified;Zollinger-Ellison syndrome","routes_of_administration":"Intravenous use;Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"30/10/2009","compliance_outcome":"Positive","compliance_opinion_date":"16/07/2010","compliance_procedure_number":"EMEA-C-000331-PIP01-08-M01","contact_for_public_enquiries":"AstraZeneca AB (Sweden); Tel. +46 8 5532791; E-mail: paediatrics@astrazeneca.com","first_published_date":"07/12/2009","last_updated_date":"07/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000331-pip01-08-m01"},{"decision_number":"P/191/2009","pip_number":"Alanine, arginine, aspartic acid, cysteine/cystine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine monohydrate, methionine, ornithine hydrochloride, phenylalanine, proline, serine, taurine, threonine, tryptophan, tyrosine, valine; sod...","active_substance":"alanine;arginine;aspartic acid;cysteine;cystine;glutamic acid;glycine;histidine;isoleucine;leucine;lysine monohydrate;methionine;ornithine hydrochloride;phenylalanine;proline;serine;taurine;threonine;tryptophan;tyrosine;valine;sodium chloride;potassium acetate;magnesium acetate tetrahydrate;calcium chloride;sodium glycerophosphate;glucose;soya bean oil;olive oil","invented_name":"","therapeutic_area":"Nutrition","pharmaceutical_forms":"Solution for infusion","condition_indication":"Parenteral nutrition","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"02/10/2009","compliance_outcome":"Positive","compliance_opinion_date":"16/10/2009","compliance_procedure_number":"EMEA-C-000112-PIP01-07-M01","contact_for_public_enquiries":"Baxter World Trade SPRL; E-mail: jacek_bedkowski@baxter.com; Country: Belgium; Phone: +32 26501850; Fax: +32 26501679","first_published_date":"07/12/2009","last_updated_date":"07/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/alanine-arginine-aspartic-acid-cysteine-cystine-glutamic-acid-glycine-histidine-isoleucine-leucine-lysine-monohydrate-methionine-ornithine-hydrochloride-phenylalanine-proline-serine-taurine-threonine"},{"decision_number":"P/214/2009","pip_number":"EMEA-000487-PIP01-08","active_substance":"bromocriptine (mesilate)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"30/10/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"VeroScience EU Ltd; E-mail: Paeds-Enquiries@veroscience.com; Country: United States; Phone: +1 5085320832; Fax: +1 4018160524","first_published_date":"07/12/2009","last_updated_date":"07/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000487-pip01-08"},{"decision_number":"P/216/2009","pip_number":"Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerized allergic extract of birch pollen","active_substance":"aluminium hydroxide adsorbed;depigmented glutaraldehyde polymerised;birch pollen","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Suspension for injection (multidose vial)","condition_indication":"Treatment of allergic rhinitis;Treatment of allergic rhinoconjunctivitis due to pollen","routes_of_administration":"Subcutaneous use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"30/10/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LETI Pharma GmbH; E-mail: renner@leti.de; Country: Germany; Phone: +49 2302202860; Fax: +49 23022028620","first_published_date":"07/12/2009","last_updated_date":"07/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerized-allergic-extract-birch-pollen"},{"decision_number":"P/195/2009","pip_number":"EMEA-000611-PIP01-09","active_substance":"pegaptanib sodium","invented_name":"Macugen; Macugen","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Solution for injection","condition_indication":"Diabetic retinopathy","routes_of_administration":"Intravitreal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/10/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Global Research & Development; E-mail: PIP_Enquiries@pfizer.com; Country: United Kingdom; Phone: +44 13046446607; Fax: +44 1304646607 ","first_published_date":"07/12/2009","last_updated_date":"07/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000611-pip01-09"},{"decision_number":"P/204/2009","pip_number":"EMEA-000436-PIP01-08","active_substance":"mannitol","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Inhalation powder;Capsule, hard","condition_indication":"Cystic fibrosis with pulmonary disease","routes_of_administration":"Inhalation use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"21/10/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pharmaxis Pharmaceuticals Limited; E-mail: med.info@pharmaxis.com.au; Tel.: +61 294547257","first_published_date":"07/12/2009","last_updated_date":"07/12/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000436-pip01-08"},{"decision_number":"P/161/2009","pip_number":"Testosterone","active_substance":"testosterone","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Transdermal patch","condition_indication":"Treatment of hypoactive sexual desire disorder","routes_of_administration":"Transdermal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/08/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Procter & Gamble Pharmaceuticals UK Ltd; E-mail: Medinfo.im@pg.com; Country: Germany; Phone: +49 1726583443; Fax: +49 6196891378","first_published_date":"22/10/2009","last_updated_date":"22/10/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/testosterone"},{"decision_number":"P/169/2009","pip_number":"Sitagliptin phosphate monohydrate / simvastatin","active_substance":"sitagliptin phosphate monohydrate;simvastatin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/08/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe), Inc.; Belgium; E-mail: pip.information@merck.com; Tel. +31 412663179; Fax +31 412662571","first_published_date":"22/10/2009","last_updated_date":"22/10/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/sitagliptin-phosphate-monohydrate-simvastatin"},{"decision_number":"P/170/2009","pip_number":"Simvastatin / sitagliptin phosphate monohydrate","active_substance":"simvastatin;sitagliptin phosphate monohydrate","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/08/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe), Inc.; Belgium; E-mail: pip.information@merck.com; Tel. +31 412663179; Fax +31 412662571","first_published_date":"22/10/2009","last_updated_date":"22/10/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/simvastatin-sitagliptin-phosphate-monohydrate"},{"decision_number":"P/171/2009","pip_number":"Sitagliptin phosphate monohydrate / simvastatin","active_substance":"sitagliptin phosphate monohydrate;simvastatin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/08/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe), Inc.; Belgium; E-mail: pip.information@merck.com; Tel. +31 412663179; Fax +31 412662571","first_published_date":"22/10/2009","last_updated_date":"22/10/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/sitagliptin-phosphate-monohydrate-simvastatin-0"},{"decision_number":"P/163/2009","pip_number":"EMEA-000557-PIP01-09","active_substance":"patupilone","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Malignant neoplasm of other and unspecified genital organs - Fallopian tube (oviduct, uterine tube);Malignant neoplasm of the retroperitoneum and peritoneum - Peritoneum, unspecified","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"12/08/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"22/10/2009","last_updated_date":"22/10/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000557-pip01-09"},{"decision_number":"W/185/2009","pip_number":"Tramadol / paracetamol","active_substance":"tramadol;paracetamol","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Moderate to severe pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/09/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"TEVA Pharma B.V.; E-mail: sandy.eisen@tevauk.com; Country: United Kingdom; Phone: +44 7921495663","first_published_date":"22/10/2009","last_updated_date":"22/10/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/tramadol-paracetamol"},{"decision_number":"P/157/2009","pip_number":"EMEA-000521-PIP01-08","active_substance":"5-aminolevulinic acid hydrochloride","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Gel","condition_indication":"Treatment of actinic keratosis","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/08/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Biofrontera Bioscience GmbHE-mail: r.gahlmann@biofrontera.comPhone: +49 214876320","first_published_date":"22/10/2009","last_updated_date":"22/10/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000521-pip01-08"},{"decision_number":"P/181/2009","pip_number":"EMEA-000513-PIP01-08","active_substance":"paracetamol;opium","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Capsule, hard","condition_indication":"Pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/09/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Solvay Pharma; E-mail: jean-pascal.yaher@solvay.com; Country: France; Phone: +33 146258513; Fax: +33 146258626","first_published_date":"22/10/2009","last_updated_date":"22/10/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000513-pip01-08"},{"decision_number":"P/158/2009","pip_number":"Desvenlafaxine succinate monohydrate","active_substance":"Desvenlafaxine succinate monohydrate","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Prolonged-release tablet","condition_indication":"Treatment of major depressive disorder","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/08/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Laboratorios Almirall S.A.; E-mail: fernando.ferrer@almirall.es; Country: Spain; Phone: +34 932913667; Fax: +34 932912813","first_published_date":"22/10/2009","last_updated_date":"22/10/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/desvenlafaxine-succinate-monohydrate"},{"decision_number":"P/166/2009","pip_number":"Live bacterium B. thetaiotaomicron","active_substance":"Live bacterium B. thetaiotaomicron","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Live Bacteria in an Enteric Coated Capsule","condition_indication":"Treatment of Crohn's disease","routes_of_administration":"Oral use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"21/08/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"4D Pharma Research LtdE-mail: katrina.lawrie@4dpharmaplc.comTel. +44 (0)1224 437369","first_published_date":"22/10/2009","last_updated_date":"22/10/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/live-bacterium-b-thetaiotaomicron"},{"decision_number":"P/160/2009","pip_number":"EMEA-000571-PIP01-09","active_substance":"testosterone","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Transdermal patch","condition_indication":"Treatment of hypoactive sexual desire disorder","routes_of_administration":"Transdermal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/08/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Procter & Gamble Pharmaceuticals UK Ltd; E-mail: Medinfo.im@pg.com; Country: Germany; Phone: +49 1726583443; Fax: +49 6196891378","first_published_date":"22/10/2009","last_updated_date":"22/10/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000571-pip01-09"},{"decision_number":"P/155/2009","pip_number":"EMEA-000395-PIP01-08","active_substance":"Midazolam Hydrochloride","invented_name":"Buccolam","therapeutic_area":"Neurology","pharmaceutical_forms":"Oromucosal solution","condition_indication":"Epileptic seizures","routes_of_administration":"Oromucosal use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/08/2009","compliance_outcome":"Positive","compliance_opinion_date":"06/08/2010","compliance_procedure_number":"EMEA-C-000395-PIP01-08","contact_for_public_enquiries":"Auralis Limited; E-mail: medinfo@auralis.co.uk; Country: United Kingdom; Phone: +44 1748828868; Fax: +44 8703837414","first_published_date":"22/10/2009","last_updated_date":"22/10/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000395-pip01-08"},{"decision_number":"P/156/2009","pip_number":"EMEA-000411-PIP01-08","active_substance":"mifepristone;misoprostol","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Medical Abortion","routes_of_administration":"Oral use;Vaginal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/08/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sun Pharmaceutical Industries Europe B.V.; E-mail: secretary.netherlands@sunpharma-europe.com; Country: Netherlands; Phone: +31 235685501; Fax: +31 235685505","first_published_date":"22/10/2009","last_updated_date":"22/10/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000411-pip01-08"},{"decision_number":"P/182/2009","pip_number":"EMEA-000514-PIP01-08","active_substance":"paracetamol;opium","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Capsule, hard","condition_indication":"Pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/09/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Solvay Pharma; E-mail: jean-pascal.yaher@solvay.com; Country: France; Phone: +33 146258513; Fax: +33 146258626","first_published_date":"22/10/2009","last_updated_date":"22/10/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000514-pip01-08"},{"decision_number":"P/125/2009","pip_number":"EMEA-000005-PIP01-07-M01","active_substance":"valsartan","invented_name":"Diovan","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral liquid dosage formulation","condition_indication":"Heart failure following recent myocardial infarction;Treatment of heart failure;Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"26/06/2009","compliance_outcome":"Positive","compliance_opinion_date":"21/08/2009","compliance_procedure_number":"EMEA-C-000005-PIP01-07-M01","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"22/10/2009","last_updated_date":"22/10/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000005-pip01-07-m01"},{"decision_number":"P/175/2009","pip_number":"EMEA-000042-PIP01-07","active_substance":"N-Acetyl-L-Cysteine (corresponds to L-Cysteine), L-Alanine, L-Alanyl-L-Glutamine (corresponds to L-Alanine and L-Glutamine), L-Arginine, Glycine, Glycyl-L-Tyrosine (corresponds to Glycine and L-Tyrosine), L-Histidine, L-Isoleucine, L-Leucine, L-Lysine acetate (corresponds to L-Lysine), LMethionine, L-Phenylalanine, L-Proline, L-Serine, Taurine, L-Threonine, L-Tryptophan, L-Valine","invented_name":"","therapeutic_area":"Nutrition","pharmaceutical_forms":"Solution for infusion","condition_indication":"Supplementation of amino-acids where parenteral nutrition is required.","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"07/09/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Fresenius Kabi Deutschland GmbH; E-mail: pr-fre@fresenius.com; Country: Germany; Phone: +49 61726080; Fax: +49 61726082294","first_published_date":"22/10/2009","last_updated_date":"22/10/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000042-pip01-07"},{"decision_number":"P/188/2009","pip_number":"Vicriviroc maleate","active_substance":"vicriviroc maleate","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of human immunodeficiency virus (HIV-1) infection","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"11/09/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Schering-Plough Europe; E-mail: paediatric@spcorp.com; Country: Netherlands; Phone: +31 412662755; Fax: +31 412662571","first_published_date":"22/10/2009","last_updated_date":"22/10/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/vicriviroc-maleate"},{"decision_number":"P/172/2009","pip_number":"Sitagliptin phosphate monohydrate / simvastatin","active_substance":"sitagliptin phosphate monohydrate;simvastatin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/09/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe), Inc.; Belgium; E-mail: pip.information@merck.com; Tel. +31 412663179; Fax +31 412662571","first_published_date":"22/10/2009","last_updated_date":"22/10/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/sitagliptin-phosphate-monohydrate-simvastatin-1"},{"decision_number":"P/140/2009","pip_number":"Estradiol valerate / Dienogest","active_substance":"Estradiol valerate;Dienogest","invented_name":"Qlaira","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Excessive, frequent and irregular menstruation;Contraception","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/07/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer Schering Pharma AG; E-mail: pediatrics.medical-affairs-europe@bayerhealthcare.com; Country: Germany; Phone: +49 3046815333; Fax: +49 3046895333","first_published_date":"16/09/2009","last_updated_date":"16/09/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/estradiol-valerate-dienogest"},{"decision_number":"P/147/2009","pip_number":"Aqueous extract of grass pollen from Dactylis glomerata, Festuca pratensis, Holcus lanatus, Lolium perenne, Phleum pratense and Poa pratensis","active_substance":"aqueous extract of grass pollen from Dactylis glomerata, Festuca pratensis, Holcus lanatus, Lolium perenne, Phleum pratense and Poa pratensis","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Solution for sublingual use","condition_indication":"Treatment of rhinitis or rhinoconjunctivitis due to grass pollen","routes_of_administration":"Sublingual use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"20/07/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergopharma J. Ganzer KG; E-mail: Anja.Menzel@Allergopharma.de; Country: Germany; Phone: +49 4072765464; Fax: +49 4072765466","first_published_date":"16/09/2009","last_updated_date":"16/09/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/aqueous-extract-grass-pollen-dactylis-glomerata-festuca-pratensis-holcus-lanatus-lolium-perenne-phleum-pratense-poa-pratensis"},{"decision_number":"P/138/2009","pip_number":"Omacetaxine mepesuccinate","active_substance":"omacetaxine mepesuccinate","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Philadelphia chromosome positive chronic myeloid leukaemia in patients who have the T315I Bcr-Abl kinase domain mutation and who are resistant to prior imatinib therapy.","routes_of_administration":"Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/07/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ChemGenex Europe S.A.S.; E-mail: abenichou@chemgenex.com; Country: France; Phone: +33 478429526; Fax: +33 478425571","first_published_date":"16/09/2009","last_updated_date":"16/09/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/omacetaxine-mepesuccinate"},{"decision_number":"P/133/2009","pip_number":"Insulin glargine","active_substance":"insulin glargine","invented_name":"Lantus; Lantus","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection;Solution for injection in a vial;Solution for injection in a cartridge","condition_indication":"Treatment of type I diabetes mellitus;Treatment of type II diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/07/2009","compliance_outcome":"Positive","compliance_opinion_date":"18/11/2011","compliance_procedure_number":"EMEA-C-000387-PIP01-08","contact_for_public_enquiries":"Sanofi-Aventis Deutschland GmbH; E-mail: sylvie.gabriel@sanofi-aventis.com; Country: France; Phone: + 33 153774152; Fax: 33 153774133","first_published_date":"16/09/2009","last_updated_date":"16/09/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/insulin-glargine"},{"decision_number":"P/139/2009","pip_number":"Clostridium collagenase","active_substance":"Clostridium collagenase","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Dupuytren's Contracture;Peyronie's Disease","routes_of_administration":"Intralesional use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/07/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Pfizer Limited; Tel. + 44 1304646607; E-mail: pip_enquiries@pfizer.com","first_published_date":"16/09/2009","last_updated_date":"16/09/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/clostridium-collagenase"},{"decision_number":"P/136/2009","pip_number":"Insulin glargine","active_substance":"insulin glargine","invented_name":"Toujeo (previously Optisulin); Optisulin","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection;Solution for injection in a vial;Solution for injection in a cartridge","condition_indication":"Treatment of type I diabetes mellitus;Treatment of type II diabetes mellitus","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/07/2009","compliance_outcome":"Positive","compliance_opinion_date":"18/11/2011","compliance_procedure_number":"EMEA-C-000396-PIP01-08","contact_for_public_enquiries":"Sanofi-Aventis Deutschland GmbH; E-mail: sylvie.gabriel@sanofi-aventis.com; Country: France; Phone: + 33 153774152; Fax: + 33 153774133","first_published_date":"16/09/2009","last_updated_date":"16/09/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/insulin-glargine-0"},{"decision_number":"P/130/2009","pip_number":"Drospirenone / ethinylestradiol, betadex clathrate / L-5-methyltetrahydrofolic acid, calcium salt","active_substance":"drospirenone;L-5-methyltetrahydrofolic acid, calcium salt;ethinylestradiol;betadex clathrate","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Contraception;Inappropriate diet and eating habits","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/07/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer Schering Pharma AG; E-mail: pediatrics.medical-affairs-europe@bayerhealthcare.com; Country: Germany; Phone: +49 3046815333; Fax: +49 3046895333","first_published_date":"16/09/2009","last_updated_date":"16/09/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/drospirenone-ethinylestradiol-betadex-clathrate-l-5-methyltetrahydrofolic-acid-calcium-salt-1"},{"decision_number":"P/116/2009","pip_number":"Human plasma proteins","active_substance":"Human plasma proteins","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for infusion","condition_indication":"Thrombotic thrombocytopenic purpura;Treatment of acquired coagulation factor deficiency;Hereditary deficiency of clotting factors","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/06/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Octapharma Pharmazeutika Produktionsges.m.b.H; E-mail: medical-affairs@octapharma.com; Country: Austria; Phone: +43 1610321245; Fax: +43 1610329249","first_published_date":"11/08/2009","last_updated_date":"11/08/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/human-plasma-proteins"},{"decision_number":"P/120/2009","pip_number":"EMEA-000517-PIP01-08","active_substance":"aliskiren hemifumarate;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/06/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"11/08/2009","last_updated_date":"11/08/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000517-pip01-08"},{"decision_number":"P/124/2009","pip_number":"Colesevelam hydrochloride","active_substance":"colesevelam hydrochloride","invented_name":"Cholestagel; Cholestagel","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Heterozygous Familial Hypercholesterolaemia;Homozygous Familial Hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"19/06/2009","compliance_outcome":"Positive","compliance_opinion_date":"24/07/2009","compliance_procedure_number":"EMEA-C-000543-PIP01-09","contact_for_public_enquiries":"Genzyme Europe B.V.; E-mail: MedInfo@genzyme.com; Tel.: +31 356991499","first_published_date":"11/08/2009","last_updated_date":"11/08/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/colesevelam-hydrochloride"},{"decision_number":"P/122/2009","pip_number":"Human autologous mesenchymal adult stem cells extracted from adipose tissue","active_substance":"human autologous mesenchymal adult stem cells extracted from adipose tissue","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Treatment of anorectal fistula;Treatment of rectal fistula;Treatment of anal fistula","routes_of_administration":"Intralesional use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/06/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CELLERIX, S.A.; E-mail: mpascual@cellerix.com; Country: Spain; Phone: +34 918049264; Fax: +34 918049263","first_published_date":"11/08/2009","last_updated_date":"11/08/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/human-autologous-mesenchymal-adult-stem-cells-extracted-adipose-tissue"},{"decision_number":"P/115/2009","pip_number":"Pravastatin sodium / Fenofibrate","active_substance":"Pravastatin sodium;fenofibrate","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Capsule, hard","condition_indication":"Disorders of lipoprotein metabolism and other hyperlipidaemias","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/06/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Laboratoires SMB s.a.; E-mail: regulatory@smb.be; Country: Belgium; Phone: +32 24114828; Fax: +32 24120991","first_published_date":"11/08/2009","last_updated_date":"11/08/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/pravastatin-sodium-fenofibrate"},{"decision_number":"P/118/2009","pip_number":"EMEA-000515-PIP01-08","active_substance":"aliskiren hemifumarate;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/06/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"11/08/2009","last_updated_date":"11/08/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000515-pip01-08"},{"decision_number":"P/121/2009","pip_number":"Dienogest / ethinylestradiol (as betadex clathrate) / L-5-methyltetrahydrofolic acid, calcium salt","active_substance":"Dienogest;ethinylestradiol bethadex clathrate;L-5-methyltetrahydrofolic acid, calcium salt","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Contraception;Inappropriate diet and eating habits;Treatment of acne vulgaris","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/06/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer Schering Pharma AG; E-mail: pediatrics.medical-affairs-europe@bayerhealthcare.com; Country: Germany; Phone: +49 3046815333; Fax: +49 3046895333","first_published_date":"11/08/2009","last_updated_date":"11/08/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/dienogest-ethinylestradiol-betadex-clathrate-l-5-methyltetrahydrofolic-acid-calcium-salt"},{"decision_number":"P/117/2009","pip_number":"EMEA-000512-PIP01-08","active_substance":"recombinant human anti-Rhesus D monoclonal antibody (LFB-R593)","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Solution for injection","condition_indication":"Rh(D) alloimmunisation","routes_of_administration":"Intravenous use;Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/06/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LFB Biotechnologies; E-mail: chwedura@lfb.fr; Country: France; Phone: + 33 320494413; Fax: + 33 320494418","first_published_date":"11/08/2009","last_updated_date":"11/08/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000512-pip01-08"},{"decision_number":"P/111/2009","pip_number":"Human Papillomavirus1 Type 6 L1 protein / Human Papillomavirus1 Type 11 L1 protein / Human Papillomavirus1 Type 16 L1 protein / Human Papillomavirus1 Type 18 L1 protein","active_substance":"human Papillomavirus1 Type 6 L1 protein;human Papillomavirus1 Type 11 L1 protein;human papillomavirus1 type 16 L1 protein;human Papillomavirus1 Type 18 L1 protein","invented_name":"Silgard; Silgard","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection;Suspension for injection in pre-filled syringe","condition_indication":"Infection by Human Papillomavirus","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"16/06/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.; The Netherlands; E-mail: pip.information@merck.com; Tel. +31 4126 63179; Fax +31 4126 62571","first_published_date":"11/08/2009","last_updated_date":"11/08/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/human-papillomavirus1-type-6-l1-protein-human-papillomavirus1-type-11-l1-protein-human-papillomavirus1-type-16-l1-protein-human-papillomavirus1-type-18-l1-protein"},{"decision_number":"P/109/2009","pip_number":"EMEA-000369-PIP01-08","active_substance":"clazosentan","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Sequelae of cerebrovascular disease induced by vasospasm","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"16/06/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"11/08/2009","last_updated_date":"11/08/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000369-pip01-08"},{"decision_number":"P/113/2009","pip_number":"EMEA-000465-PIP01-08","active_substance":"triamcinolone acetonide","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Suspension for injection","condition_indication":"Visualisation during vitrectomy","routes_of_administration":"Intravitreal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/06/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alcon Laboratories (UK) Ltd.; Doug.MacHatton@AlconLabs.com; United States; Phone: +1 8175518974; Fax: +1 8176154607","first_published_date":"11/08/2009","last_updated_date":"11/08/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000465-pip01-08"},{"decision_number":"P/119/2009","pip_number":"EMEA-000516-PIP01-08","active_substance":"aliskiren hemifumarate;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/06/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"11/08/2009","last_updated_date":"11/08/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000516-pip01-08"},{"decision_number":"P/112/2009","pip_number":"EMEA-000444-PIP01-08","active_substance":"dexamethasone;ciprofloxacin hydrochloride","invented_name":"","therapeutic_area":"Oto-rhino-laryngology","pharmaceutical_forms":"Ear drops, suspension","condition_indication":"Other infective otitis externa;Otitis media, unspecified","routes_of_administration":"Auricular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/06/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alcon Laboratories (UK) Ltd.; Doug.MacHatton@AlconLabs.com; United States; Phone: +1 8175518974; Fax: +1 8176154607","first_published_date":"11/08/2009","last_updated_date":"11/08/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000444-pip01-08"},{"decision_number":"P/92/2009","pip_number":"Simvastatin / fenofibrate","active_substance":"simvastatin;fenofibrate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Combined dyslipidemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/05/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"FOURNIER Laboratories Ireland Ltd; E-mail: hubert.thole@solvay.com; Country: Germany; Phone: +49 5118573564","first_published_date":"09/07/2009","last_updated_date":"09/07/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/simvastatin-fenofibrate"},{"decision_number":"P/101/2009","pip_number":"Cladribine","active_substance":"Cladribine","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Tablet","condition_indication":"Multiple Sclerosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/05/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"KGaA; E-mail: service@merck.de; Country: Germany; Phone: +49 6151720; Fax: +49 6151722000","first_published_date":"09/07/2009","last_updated_date":"09/07/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/cladribine"},{"decision_number":"P/84/2009","pip_number":"Bromfenac sodium sesquihydrate","active_substance":"bromfenac sodium sesquihydrate","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Eye drops, solution;Solution","condition_indication":"Postoperative ocular inflammation","routes_of_administration":"Ocular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/05/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Croma Pharma GmbH; E-mail: office@croma.at; Country: Austria; Phone: +43 2262684680; Fax: +43 226268468 165","first_published_date":"09/07/2009","last_updated_date":"09/07/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/bromfenac-sodium-sesquihydrate"},{"decision_number":"P/90/2009","pip_number":"Drospirenone / ethinylestradiol, betadex clathrate / L-5-methyltetrahydrofolic acid, calcium salt","active_substance":"drospirenone;L-5-methyltetrahydrofolic acid, calcium salt;ethinylestradiol;betadex clathrate","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Contraception;Inappropriate diet and eating habits","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/05/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer Schering Pharma AG; E-mail: pediatrics.medical-affairs-europe@bayerhealthcare.com; Country: Germany; Phone: +49 3046815333; Fax: +49 3046895333","first_published_date":"09/07/2009","last_updated_date":"09/07/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/drospirenone-ethinylestradiol-betadex-clathrate-l-5-methyltetrahydrofolic-acid-calcium-salt"},{"decision_number":"P/91/2009","pip_number":"EMEA-000488-PIP01-08","active_substance":"rubidium (82Rb)","invented_name":"","therapeutic_area":"Diagnostic","pharmaceutical_forms":"Radionuclide generator","condition_indication":"Visualisation of myocardial perfusion for diagnostic purposes","routes_of_administration":"Intravenous use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"18/05/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Advanced Accelerator Applications; Email: infomed@adacap.com    ; Tel. +33 (0)450993070","first_published_date":"09/07/2009","last_updated_date":"09/07/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000488-pip01-08"},{"decision_number":"P/89/09","pip_number":"Drospirenone / ethinylestradiol, betadex clathrate / L-5-methyltetrahydrofolic acid, calcium salt","active_substance":"drospirenone;L-5-methyltetrahydrofolic acid, calcium salt;ethinylestradiol;betadex clathrate","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Contraception;Inappropriate diet and eating habits","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"18/05/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer Schering Pharma AG; E-mail: pediatrics.medical-affairs-europe@bayerhealthcare.com; Country: Germany; Phone: +49 3046815333; Fax: +49 3046895333","first_published_date":"09/07/2009","last_updated_date":"09/07/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/drospirenone-ethinylestradiol-betadex-clathrate-l-5-methyltetrahydrofolic-acid-calcium-salt-0"},{"decision_number":"P/100/2009","pip_number":"EMEA-000118-PIP01-07-M01","active_substance":"abatacept","invented_name":"Orencia; Orencia","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Juvenile Arthritis;Rheumatoid arthritis","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"19/05/2009","compliance_outcome":"Positive","compliance_opinion_date":"29/05/2009","compliance_procedure_number":"EMEA-C-000118-PIP01-07-M01","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610","first_published_date":"09/07/2009","last_updated_date":"09/07/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000118-pip01-07-m01"},{"decision_number":"P/74/2009","pip_number":"Bismuth subcitrate potassium / Metronidazole / Tetracycline hydrochloride","active_substance":"bismuth subcitrate potassium;Metronidazole;tetracycline hydrochloride","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Capsule","condition_indication":"Helicobacter pylori infection","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/04/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Axcan Pharma SA; E-mail: cboudes@axcan.com; Country: France; Phone: +33 130461916; Fax: +33 130466547","first_published_date":"10/06/2009","last_updated_date":"10/06/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/bismuth-subcitrate-potassium-metronidazole-tetracycline-hydrochloride"},{"decision_number":"P/69/2009","pip_number":"Calcipotriol hydrate / hydrocortisone","active_substance":"calcipotriol hydrate;hydrocortisone","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Ointment","condition_indication":"Psoriasis vulgaris","routes_of_administration":"Cutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"20/04/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"LEO Pharma A/S; E-mail: paediatrics@leo-pharma.com; Tel. +45 4494 5888;  ","first_published_date":"10/06/2009","last_updated_date":"10/06/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/calcipotriol-hydrate-hydrocortisone"},{"decision_number":"P/73/2009","pip_number":"Mercaptopurine monohydrate","active_substance":"Mercaptopurine monohydrate","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Oral suspension","condition_indication":"Treatment of acute lymphoblastic leukaemia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"20/04/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Nova Laboratories Limited; E-mail: mercaptopurine.info@novalabs.co.uk; Country: United Kingdom; Phone: +44 1162230100; Fax: +44 1162230101","first_published_date":"10/06/2009","last_updated_date":"10/06/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/mercaptopurine-monohydrate"},{"decision_number":"P/75/2009","pip_number":"EMEA-000464-PIP01-08","active_substance":"pasireotide","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection;Powder and solvent for suspension for injection","condition_indication":"Overproduction of pituitary ACTH;Pituitary dependant Cushing's disease;Pituitary dependant hyperadrenocorticism","routes_of_administration":"Subcutaneous use;Intramuscular use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/04/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"10/06/2009","last_updated_date":"10/06/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000464-pip01-08"},{"decision_number":"P/49/2009","pip_number":"Melatonin (Circadin)","active_substance":"melatonin","invented_name":"Circadin; Circadin","therapeutic_area":"Neurology","pharmaceutical_forms":"Prolonged-release tablet","condition_indication":"Primary insomnia","routes_of_administration":"Oral use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"24/03/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"RAD Neurim Pharmaceuticals EEC Ltd; E-mail: talin@neurim.com; Tel.: +972 37684902","first_published_date":"18/05/2009","last_updated_date":"18/05/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/melatonin-circadin"},{"decision_number":"P/54/2009","pip_number":"Bisoprolol fumarate / acetylsalicylic acid","active_substance":"Bisoprolol fumarate;acetylsalicylic acid","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule","condition_indication":"Angina pectoris;Essential hypertension;Secondary hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/03/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ASA Pharma Plc; E-mail: anndonegan@asapharma.ie; Tel.: +353 5224853","first_published_date":"18/05/2009","last_updated_date":"18/05/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/bisoprolol-fumarate-acetylsalicylic-acid"},{"decision_number":"P/50/2009","pip_number":"Bisoprolol fumarate / acetylsalicylic acid","active_substance":"Bisoprolol fumarate;acetylsalicylic acid","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule","condition_indication":"Angina pectoris;Essential hypertension;Secondary hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/03/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ASA Pharma Plc; E-mail: anndonegan@asapharma.ie; Tel.: +353 5224853","first_published_date":"18/05/2009","last_updated_date":"18/05/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/bisoprolol-fumarate-acetylsalicylic-acid-0"},{"decision_number":"P/51/2009","pip_number":"Bisoprolol fumarate / acetylsalicylic acid","active_substance":"Bisoprolol fumarate;acetylsalicylic acid","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule","condition_indication":"Angina pectoris;Essential hypertension;Secondary hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/03/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ASA Pharma Plc; E-mail: anndonegan@asapharma.ie; Tel.: +353 5224853","first_published_date":"18/05/2009","last_updated_date":"18/05/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/bisoprolol-fumarate-acetylsalicylic-acid-1"},{"decision_number":"P/43/2009","pip_number":"EMEA-000433-PIP01-08","active_substance":"Dirucotide acetate","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Multiple Sclerosis","routes_of_administration":"Intravenous use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"23/03/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly & Company Limited; E-mail: eu_paediatric@lilly.com ; Tel. +44 (0)1276 483000","first_published_date":"18/05/2009","last_updated_date":"18/05/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000433-pip01-08"},{"decision_number":"P/42/2009","pip_number":"Maribavir","active_substance":"Maribavir","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Tablet;Age appropriate oral formulation","condition_indication":"Cytomegaloviral disease","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"23/03/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ViroPharma SPRL; E-mail: john.watson@viropharma.com; Country: United Kingdom; Phone: +44 2075721222; Fax: +44 2075721221","first_published_date":"18/05/2009","last_updated_date":"18/05/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/maribavir"},{"decision_number":"P/53/2009","pip_number":"Bisoprolol fumarate / acetylsalicylic acid","active_substance":"Bisoprolol fumarate;acetylsalicylic acid","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule","condition_indication":"Angina pectoris;Essential hypertension;Secondary hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/03/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ASA Pharma Plc; E-mail: anndonegan@asapharma.ie; Tel.: +353 5224853","first_published_date":"18/05/2009","last_updated_date":"18/05/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/bisoprolol-fumarate-acetylsalicylic-acid-2"},{"decision_number":"P/52/2009","pip_number":"Bisoprolol fumarate / acetylsalicylic acid","active_substance":"Bisoprolol fumarate;acetylsalicylic acid","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule","condition_indication":"Angina pectoris;Essential hypertension;Secondary hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/03/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"ASA Pharma Plc; E-mail: anndonegan@asapharma.ie; Tel.: +353 5224853","first_published_date":"18/05/2009","last_updated_date":"18/05/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/bisoprolol-fumarate-acetylsalicylic-acid-3"},{"decision_number":"P/44/2009","pip_number":"Dexamethasone","active_substance":"dexamethasone","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Intravitreal implant in applicator","condition_indication":"Chronic non-infectious intermediate or posterior uveitis","routes_of_administration":"Intravitreal use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"23/03/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Allergan Pharmaceuticals International Limited; E-mail: ml-eu_reg_affairs@allergan.com; Tel. +44 (0)1628 4944444","first_published_date":"18/05/2009","last_updated_date":"18/05/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/dexamethasone-0"},{"decision_number":"P/45/2009","pip_number":"Glucose monohydrate","active_substance":"glucose monohydrate","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Oral solution","condition_indication":"Pain","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"24/03/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cblaya & Mhuguet S.L.; E-mail: miguel@aguanafree.com; Country: Spain; Phone: +34 629232280; Fax: +34 933713118","first_published_date":"18/05/2009","last_updated_date":"18/05/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/glucose-monohydrate"},{"decision_number":"P/38/2009","pip_number":"EMEA-000435-PIP01-08","active_substance":"17-allylamino-17-demethoxygeldanamycin hydroquinone, hydrochloride","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder and solvent for solution for infusion","condition_indication":"Treatment of gastrointestinal stromal tumours","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"04/03/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Voisin Consulting SARL; E-mail: Monique.allaire@infi.com; Tel.: +1 6174531105","first_published_date":"18/05/2009","last_updated_date":"18/05/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000435-pip01-08"},{"decision_number":"P/64/2009","pip_number":"EMEA-000278-PIP01-08-M01","active_substance":"purified diphtheria toxoid;purified tetanus toxoid;Five component acellular pertussis [Purified Pertussis Toxoid (PT), Purified Filamentous Haemagglutinin (FHA), Purified Fimbriae Types 2 and 3 (FIM), and Purified Pertactin (PRN)];purified polyribosylribitol phosphate capsular polysaccharide of Haemophilus influenzae type b covalently bound to Tetanus protein (PRP-T);Inactivated Type 1 Poliovirus (Mahoney);Inactivated Type 2 Poliovirus (MEF-1);Inactivated Type 3 Poliovirus (Saukett)","invented_name":"PEDIACEL","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection in pre-filled syringe;Suspension for injection in a vial","condition_indication":"Active immunisation against infectious diseases caused by Haemophilus influenzae type b, Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis and poliovirus types 1, 2 and 3","routes_of_administration":"Intramuscular use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"31/03/2009","compliance_outcome":"Positive","compliance_opinion_date":"18/09/2009","compliance_procedure_number":"EMEA-C-000278-PIP01-08-M01","contact_for_public_enquiries":"Sanofi Pasteur MSD SNC; E-mail: piplan@spmsd.com; Country: France; Phone: +33 437284000; Fax: Not available","first_published_date":"18/05/2009","last_updated_date":"18/05/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000278-pip01-08-m01"},{"decision_number":"P/20/2009","pip_number":"Anastrozole","active_substance":"anastrozole","invented_name":"Arimidex and associated names","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Gynaecomastia;McCune-Albright syndrome;Short stature due to Growth Hormone deficiency;Testotoxicosis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"06/02/2009","compliance_outcome":"Positive","compliance_opinion_date":"03/04/2009","compliance_procedure_number":"EMEA-C-000283-PIP01-08","contact_for_public_enquiries":"AstraZeneca AB (UK); Tel. +44 2037496236; E-mail: paediatrics@astrazeneca.com","first_published_date":"23/04/2009","last_updated_date":"23/04/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/anastrozole"},{"decision_number":"P/28/2009","pip_number":"EMEA-000189-PIP01-08","active_substance":"pegylated recombinant factor VIIa","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Hereditary factor VIII and factor IX deficiency","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"23/02/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novo Nordisk A/S; E-mail: pbq@novonordisk.com; Tel.: +45 44439347","first_published_date":"23/04/2009","last_updated_date":"23/04/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000189-pip01-08"},{"decision_number":"P/22/2009","pip_number":"Candesartan cilexetil","active_substance":"Candesartan cilexetil","invented_name":"Blopress and associated names","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet;Suspension for oral use","condition_indication":"Diabetic retinopathy;Essential hypertension;Heart Failure","routes_of_administration":"Oral use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"20/02/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Global Research and Development Centre (Europe) Ltd; E-mail: m.mantock@tgrd.com; Tel.: +44 2077595248","first_published_date":"23/04/2009","last_updated_date":"23/04/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/candesartan-cilexetil"},{"decision_number":"P/24/2009","pip_number":"Drospirenone / ethinylestradiol bethadex clathrate","active_substance":"drospirenone;ethinylestradiol bethadex clathrate","invented_name":"Yaz and associated names","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Contraception;Treatment of acne","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/02/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer Schering Pharma AG; E-mail: joachim.marr@bayerhealthcare.com; Country: Germany; Phone: +49 3046817617; Fax: +49 3046815348","first_published_date":"23/04/2009","last_updated_date":"23/04/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/drospirenone-ethinylestradiol-bethadex-clathrate"},{"decision_number":"P/36/2009","pip_number":"Lapatinib ditosylate monohydrate","active_substance":"Lapatinib ditosilate monohydrate","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Carcinoma of the head and neck (Covered by class waiver: oropharyngeal epithelial carcinoma, excluding nasopharyngeal carcinoma)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/02/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Glaxo Group Limited; Tel. +41 613 241 111; E-mail: paediatric.enquiries@novartis.com;  ","first_published_date":"23/04/2009","last_updated_date":"23/04/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/lapatinib-ditosylate-monohydrate"},{"decision_number":"P/12/2009","pip_number":"EMEA-000313-PIP01-08","active_substance":"Ibuprofen;paracetamol","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Fever;Pain","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/01/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"PAREXEL Consulting; E-mail:gemma.slade@parexel.com; Country: UK; Phone: +44 1895614615; Fax: +44 1895614375","first_published_date":"23/04/2009","last_updated_date":"23/04/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000313-pip01-08"},{"decision_number":"P/32/2009","pip_number":"EMEA-000344-PIP01-08","active_substance":"aliskiren hemifumarate;hydrochlorothiazide","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/02/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"23/04/2009","last_updated_date":"23/04/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000344-pip01-08"},{"decision_number":"P/21/2009","pip_number":"Candesartan cilexetil","active_substance":"Candesartan cilexetil","invented_name":"Atacand and associated name","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet;Suspension for oral use","condition_indication":"Diabetic retinopathy;Essential hypertension;Heart Failure","routes_of_administration":"Oral use","decision_type":"RP: decision refers to a refusal on a proposed Paediatric Investigation Plan","decision_date":"20/02/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"23/04/2009","last_updated_date":"23/04/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/candesartan-cilexetil-0"},{"decision_number":"P/34/2009","pip_number":"EMEA-000126-PIP01-07","active_substance":"pemetrexed disodium","invented_name":"Alimta; Alimta","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for concentrate for solution for infusion","condition_indication":"Carcinoma of the head and neck (Covered by class waiver: oropharyngeal epithelial carcinoma, excluding nasopharyngeal carcinoma);Malignant pleural mesothelioma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/02/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly and Company Limited (US); Tel.: +1 31 75448941; E-mail: wagle_asvari@lilly.com","first_published_date":"23/04/2009","last_updated_date":"23/04/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000126-pip01-07"},{"decision_number":"P/31/2009","pip_number":"EMEA-000343-PIP01-08","active_substance":"aliskiren hemifumarate;hydrochlorothiazide","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Essential hypertension","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"23/02/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"23/04/2009","last_updated_date":"23/04/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000343-pip01-08"},{"decision_number":"P/13/2009","pip_number":"EMEA-000377-PIP01-08","active_substance":"telmisartan;amlodipine besilate","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Arterial hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/01/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"06/03/2009","last_updated_date":"06/03/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000377-pip01-08"},{"decision_number":"P/17/2009","pip_number":"Raltitrexed","active_substance":"raltitrexed","invented_name":"Tomudex","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution for injection or infusion","condition_indication":"Mesothelioma of the pleura","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/01/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Hospira UK Limited; E-mail: medinfouk@hospira.com; Tel.: +44 1926821010","first_published_date":"06/03/2009","last_updated_date":"06/03/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/raltitrexed"},{"decision_number":"P/16/2009","pip_number":"EMEA-000399-PIP01-08","active_substance":"valsartan;hydrochlorothiazide;amlodipine besilate","invented_name":"Imprida HCT; Imprida HCT","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/01/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm Ltd.; E-mail: paediatric.enquiries@novartis.com ; Country: Switzerland; Phone: +41 613246715; Fax: +41 613242224","first_published_date":"06/03/2009","last_updated_date":"06/03/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000399-pip01-08"},{"decision_number":"P/15/2009","pip_number":"EMEA-000398-PIP01-08","active_substance":"valsartan;hydrochlorothiazide;amlodipine besilate","invented_name":"Dafiro HCT; Dafiro HCT","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/01/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm Ltd.; E-mail: paediatric.enquiries@novartis.com; Country: Switzerland; Phone: +41 61 324 1111; Fax: +41 61 324 8001","first_published_date":"06/03/2009","last_updated_date":"06/03/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000398-pip01-08"},{"decision_number":"P/14/2009","pip_number":"EMEA-000397-PIP01-08","active_substance":"valsartan;hydrochlorothiazide;amlodipine besilate","invented_name":"Copalia HCT; Copalia HCT","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/01/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm Ltd.; E-mail: paediatric.enquiries@novartis.com; Country: Switzerland; Phone: +41 61 324 1111; Fax: +41 61 324 8001","first_published_date":"06/03/2009","last_updated_date":"06/03/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000397-pip01-08"},{"decision_number":"P/1/2009","pip_number":"EMEA-000192-PIP01-08","active_substance":"aliskiren hemifumarate;valsartan","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/01/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"06/03/2009","last_updated_date":"06/03/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000192-pip01-08"},{"decision_number":"P/6/2009","pip_number":"Casopitant","active_substance":"casopitant","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution for infusion;Film-coated tablet","condition_indication":"Nausea and vomiting","routes_of_administration":"Intravenous infusion;Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"27/01/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Glaxo Group Limited; E-mail: eu.paediatric-plans@gsk.com; Tel. +44 (0)20 8990 3650","first_published_date":"06/03/2009","last_updated_date":"06/03/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/casopitant"},{"decision_number":"P/11/2009","pip_number":"Human Papillomavirus type 16 L1 protein / Human Papillomavirus type 18 L1 protein","active_substance":"human papillomavirus type 16 L1 protein;human papillomavirus type 18 L1 protein","invented_name":"Cervarix; Cervarix","therapeutic_area":"Vaccines","pharmaceutical_forms":"Suspension for injection","condition_indication":"Infection by Human Papillomavirus in females","routes_of_administration":"Intramuscular injection","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"27/01/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline Biologicals S.A.; E-mail: eu.paediatric-plans@gsk.com; Tel.: +1 438 899 8201","first_published_date":"06/03/2009","last_updated_date":"06/03/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/human-papillomavirus-type-16-l1-protein-human-papillomavirus-type-18-l1-protein"},{"decision_number":"P/4/2009","pip_number":"EMEA-000025-PIP01-07-M01","active_substance":"mometasone furoate;formoterol fumarate dihydrate","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Pressurised metered dose inhaler (MDI) with HFA-227 as propellant;Suspension","condition_indication":"Persistent asthma","routes_of_administration":"Inhalation use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"27/01/2009","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe), Inc.Email: pip.information@merck.com Tel. +31 412663179","first_published_date":"06/03/2009","last_updated_date":"06/03/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000025-pip01-07-m01"},{"decision_number":"P/118/2008","pip_number":"Ibuprofen, diphenhydramine hydrochloride","active_substance":"Ibuprofen;diphenhydramine hydrochloride","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Capsule, soft","condition_indication":"Mild to moderate pain with sleeplessness","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Wyeth Consumer Healthcare; E-mail: whilesa@wyeth.com; Tel.: +44 2392682249","first_published_date":"29/01/2009","last_updated_date":"29/01/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ibuprofen-diphenhydramine-hydrochloride"},{"decision_number":"P/123/2008","pip_number":"Clopidogrel","active_substance":"clopidogrel","invented_name":"Iscover; Iscover","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Oral formulation;Film-coated tablet","condition_indication":"Thromboembolic events","routes_of_administration":"Oral use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"05/12/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bristol-Myers Squibb Pharma EEIG; E-mail: sylvie.gabriel@sanofi-aventis.com; Country: France; Phone: +33 153774152; Fax: +33 153774133","first_published_date":"29/01/2009","last_updated_date":"29/01/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/clopidogrel-0"},{"decision_number":"P/120/2008","pip_number":"Omega-3-acid (85% ethyl esters of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a ratio of 0.9-1.5), simvastatin","active_substance":"omega-3-acid (85% ethyl esters of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a ratio of 0.9-1.5);simvastatin","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Capsule, soft","condition_indication":"Atherosclerotic cardiovascular disease following past myocardial infarction","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sigma-Tau SpA; E-mail: Giulia.Bruno@sigma-tau.it; Phone: +39 0691393657","first_published_date":"29/01/2009","last_updated_date":"29/01/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/omega-3-acid-85-ethyl-esters-eicosapentaenoic-acid-epa-docosahexaenoic-acid-dha-ratio-09-15-simvastatin"},{"decision_number":"P/114/2008","pip_number":"Sitagliptin phosphate monohydrate, metformin hydrochloride","active_substance":"sitagliptin phosphate monohydrate;metformin hydrochloride","invented_name":"Janumet; Janumet","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp and Dohme (Europe), Inc.; Belgium; E-mail: pip.information@merck.com; Tel. +31 412663179; Fax +31 412662571","first_published_date":"29/01/2009","last_updated_date":"29/01/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/sitagliptin-phosphate-monohydrate-metformin-hydrochloride"},{"decision_number":"P/106/2008","pip_number":"Perflubutane","active_substance":"perflubutane","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Lyophilisate for suspension for injection","condition_indication":"Visualisation of myocardial perfusion for diagnostic purposes","routes_of_administration":"Intravenous use","decision_type":"RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)","decision_date":"28/11/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Nycomed Danmark ApS; E-mail: kristina.allikmets@nycomed.com; Tel.: +45 46771655","first_published_date":"29/01/2009","last_updated_date":"29/01/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/perflubutane"},{"decision_number":"P/110/2008","pip_number":"EMEA-000044-PIP01-08","active_substance":"TGp1PTH1-34 L-Asparaginyl-L-glutaminyl-L-glutamyl-L-glutaminyl-L-valy1-L-seryl-L-prolyl-L-leucyl-L-tyrosyl-L-lysil-L-asparaginyl-L-arginyl-L-seryl-L-valyl-L-seryl-L-glutamyl-L-isoleucyl-L-glutaminyl-Lleucyl-L-methionyl-L-histidyl-L-asparaginyl-L-leucyl-L-glycyl-L-lysyl-L-histidyl-L-leucyl-Lasparaginyl-L-seryl-L-methionyl-L-glutamyl-L-arginyl-L-valyl-L-glutamyl-L-tryptophanyl-L-leucyl-L-arginyl-L-lysyl-L-lysyl-L-leucyl-L-glutamyl-L-asparty-L-valyl-L-histidyl-L-asparaginyl-Lphenylalanine-, acetate salt","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Solution for injection","condition_indication":"Solitary bone cysts","routes_of_administration":"Intraosseous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/12/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Kuros Biosurgery International AG; E-mail: info@kuros.ch; Country: Switzerland; Phone: +41 442005647; Fax: +41 442005747","first_published_date":"29/01/2009","last_updated_date":"29/01/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000044-pip01-08"},{"decision_number":"P/116/2008","pip_number":"Sitagliptin phosphate monohydrate, metformin hydrochloride","active_substance":"sitagliptin phosphate monohydrate;metformin hydrochloride","invented_name":"Velmetia; Velmetia","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp and Dohme (Europe), Inc.; Belgium; E-mail: pip.information@merck.com; Tel. +31 412663179; Fax +31 412662571","first_published_date":"29/01/2009","last_updated_date":"29/01/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/sitagliptin-phosphate-monohydrate-metformin-hydrochloride-0"},{"decision_number":"P/117/2008","pip_number":"Sitagliptin phosphate monohydrate, metformin hydrochloride","active_substance":"sitagliptin phosphate monohydrate;metformin hydrochloride","invented_name":"Efficib; Efficib","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/12/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp and Dohme (Europe), Inc.; Belgium; E-mail: pip.information@merck.com; Tel. +31 412663179; Fax +31 412662571","first_published_date":"29/01/2009","last_updated_date":"29/01/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/sitagliptin-phosphate-monohydrate-metformin-hydrochloride-1"},{"decision_number":"P/112/2008","pip_number":"3-(1H-indol-3-yl)-4-(2-(4-methyl-1-piperazinyl)-4-quinazolinyl)-1H-pyrrole-2,5-dione acetate(1:1)","active_substance":"3-(1H-indol-3-yl)-4-(2-(4-methyl-1-piperazinyl)-4-quinazolinyl)-1H-pyrrole-2,5-dione acetate(1:1)","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Chronic plaque psoriasis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"01/12/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm Limited; E-mail: paediatric.enquiries@novartis.com; Tel.: +41 613246715","first_published_date":"29/01/2009","last_updated_date":"29/01/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/3-1h-indol-3-yl-4-2-4-methyl-1-piperazinyl-4-quinazolinyl-1h-pyrrole-25-dione-acetate11"},{"decision_number":"P/129/2008","pip_number":"Pirfenidone","active_substance":"Pirfenidone","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Capsule","condition_indication":"Idiopathic Pulmonary Fibrosis (in adults)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/12/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"InterMune, Inc.; E-mail: IR@intermune.com; Country: United States; Phone: +1 4154662200; Fax: +1 4154662300","first_published_date":"29/01/2009","last_updated_date":"29/01/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/pirfenidone"},{"decision_number":"P/128/2008","pip_number":"Eprotirome","active_substance":"Eprotirome","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Gastro-resistant tablet","condition_indication":"Primary hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/12/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"KaroBio AB; E-mail: jens.kristensen@karobio.com; Country: Sweden; Phone: +46 707556005; Fax: +46 87745280","first_published_date":"29/01/2009","last_updated_date":"29/01/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/eprotirome"},{"decision_number":"P/130/2008","pip_number":"EMEA-000368-PIP01-08","active_substance":"travoprost;brinzolamide","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Suspension","condition_indication":"Treatment of glaucoma;Treatment of ocular hypertension","routes_of_administration":"Eye drops","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/12/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Alcon Laboratories (UK) Ltd.; Doug.MacHatton@AlconLabs.com; United States; Phone: +1 8175518974; Fax: +1 8176154607","first_published_date":"29/01/2009","last_updated_date":"29/01/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000368-pip01-08"},{"decision_number":"P/98/2008","pip_number":"Dienogest","active_substance":"Dienogest","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of endometriosis","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/11/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bayer Schering Pharma AG; E-mail: christian.seitz@bayerhealthcare.com; Phone: +49 3046815539","first_published_date":"07/01/2009","last_updated_date":"07/01/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/dienogest"},{"decision_number":"P/96/2008","pip_number":"EMEA-000130-PIP01-07","active_substance":"paracetamol","invented_name":"","therapeutic_area":"Pain","pharmaceutical_forms":"Solution for infusion","condition_indication":"Moderate pain and fever","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"03/11/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Baxter World Trade SA/NV; E-mail: veronique_verstraeten@baxter.com; Country: Belgium; Phone: +32 26501679; Fax: +32 26501679","first_published_date":"07/01/2009","last_updated_date":"07/01/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000130-pip01-07"},{"decision_number":"P/101/2008","pip_number":"EMEA-000249-PIP01-08","active_substance":"Influenza Virus Type A, H3N2Influenza Virus Type A, H1N1Influenza Virus Type B","invented_name":"","therapeutic_area":"Vaccines","pharmaceutical_forms":"Nasal spray suspension","condition_indication":"Influenza","routes_of_administration":"Intranasal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"03/11/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"MedImmune, LLC; E-mail: dekkere@medimmune.com; Country: United States; Telephone: +1 3013984040","first_published_date":"07/01/2009","last_updated_date":"07/01/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000249-pip01-08"},{"decision_number":"P/102/2008","pip_number":"EMEA-000371-PIP01-08","active_substance":"lenalidomide","invented_name":"Revlimid","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Myelodysplastic Syndrome","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"06/11/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Celgene Europe LimitedTel.  +41 327298500E-mail: medinfo.intl@celgene.com","first_published_date":"07/01/2009","last_updated_date":"07/01/2009","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000371-pip01-08"},{"decision_number":"P/92/2008","pip_number":"EMEA-000384-PIP01-08","active_substance":"peginterferon alfa-2b","invented_name":"ViraferonPeg; ViraferonPeg","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Powder and solvent for solution for injection in vial and in pre-filled pen","condition_indication":"Treatment of chronic viral hepatitis C","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"14/10/2008","compliance_outcome":"Positive","compliance_opinion_date":"17/10/2008","compliance_procedure_number":"EMEA-C-000384-PIP01-08","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe), Inc.; The Netherlands; E-mail: pip.information@merck.com; Tel. +31 4126 63179; Fax +31 4126 62571","first_published_date":"24/11/2008","last_updated_date":"24/11/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000384-pip01-08"},{"decision_number":"P/91/2008","pip_number":"Chimeric murine-human anti Interleukin 6 monoclonal antibody","active_substance":"chimeric murine-human anti Interleukin 6 monoclonal antibody","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for infusion;Powder for solution for infusion","condition_indication":"Castleman's disease","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/10/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"EUSA Pharma (Netherlands) B.V.; E-mail: stephen.matthews@eusapharma.com ; Tel. +44 (0)7384 547313","first_published_date":"24/11/2008","last_updated_date":"24/11/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/chimeric-murine-human-anti-interleukin-6-monoclonal-antibody"},{"decision_number":"P/73/2008","pip_number":"Ezetimibe and simvastatin (fixed combination)","active_substance":"ezetimibe;simvastatin","invented_name":"INEGY and associated trade names","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Hypercholesterolaemia;Mixed (combined) hyperlipidaemia;Sitosterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/09/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"10/10/2008","last_updated_date":"10/10/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ezetimibe-simvastatin-fixed-combination"},{"decision_number":"P/75/2008","pip_number":"Pramipexole dihydrochloride monohydrate","active_substance":"pramipexole dihydrochloride monohydrate","invented_name":"Mirapexin; Mirapexin","therapeutic_area":"Neurology","pharmaceutical_forms":"Immediate release tablet","condition_indication":"Combined vocal and multiple motor tic disorder (de la Tourette);Restless Legs Syndrome","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"12/09/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"","first_published_date":"10/10/2008","last_updated_date":"10/10/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/pramipexole-dihydrochloride-monohydrate"},{"decision_number":"P/80/2008","pip_number":"EMEA-000268-PIP01-08","active_substance":"naproxen;esomeprazole magnesium trihydrate","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Tablet","condition_indication":"Ankylosing spondylitis;Primary generalised osteoarthritis;Rheumatoid arthritis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"19/09/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB (Sweden); Tel. +46 8 5532791; E-mail: paediatrics@astrazeneca.com","first_published_date":"10/10/2008","last_updated_date":"10/10/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000268-pip01-08"},{"decision_number":"P/79/2008","pip_number":"Prilocaine, Lidocaine","active_substance":"prilocaine;lidocaine","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Cutaneous spray;Solution","condition_indication":"Premature ejaculation","routes_of_administration":"Cutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/09/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Plethora Solutions Limited; E-mail: gale.kennedy@plethorasolutions.co.uk; Country: UK; Phone: +44 2030775400; Fax: +44 2030775440","first_published_date":"10/10/2008","last_updated_date":"10/10/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/prilocaine-lidocaine"},{"decision_number":"P/78/2008","pip_number":"Bortezomib","active_substance":"bortezomib","invented_name":"Velcade; Velcade","therapeutic_area":"Oncology","pharmaceutical_forms":"Powder for solution for injection","condition_indication":"Treatment of mantle cell lymphoma","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"14/09/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Janssen-Cilag International NV; E-mail: sglawe@jacde.jnj.com; Country: Germany; Phone: +49 1737467682","first_published_date":"10/10/2008","last_updated_date":"10/10/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/bortezomib"},{"decision_number":"P/65/2008","pip_number":"Balaglitazone","active_substance":"balaglitazone","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Tablet","condition_indication":"Treatment of type II diabetes mellitus","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/08/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Rheoscience A/S; Denmark; E-mail: aos@rheoscience.com; Tel. +45 440 1960","first_published_date":"18/09/2008","last_updated_date":"18/09/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/balaglitazone"},{"decision_number":"P/66/2008","pip_number":"EMEA-000110-PIP01-07","active_substance":"aciclovir;hydrocortisone","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Cream","condition_indication":"Herpes simplex labialis","routes_of_administration":"Topical use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/08/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Medivir AB; E-mail: annelie.skagerlind@medivir.info; Country: Sweden                 ; Phone: +46 854683184; Fax: +46 854683199","first_published_date":"18/09/2008","last_updated_date":"18/09/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000110-pip01-07"},{"decision_number":"P/69/2008","pip_number":"Eplivanserin hemifumarate","active_substance":"Eplivanserin hemifumarate","invented_name":"","therapeutic_area":"Psychiatry","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Insomnia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"11/08/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Sanofi-aventis recherche & développement; E-mail: sylvie.gabriel@sanofi-aventis.com; Country: France; Phone: +33 153774152; Fax: +33 153774133","first_published_date":"18/09/2008","last_updated_date":"18/09/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/eplivanserin-hemifumarate"},{"decision_number":"P/68/2008","pip_number":"Dexamethasone","active_substance":"dexamethasone","invented_name":"","therapeutic_area":"Ophthalmology","pharmaceutical_forms":"Intravitreal implant in an applicator","condition_indication":"Other retinal vascular occlusion","routes_of_administration":"Intravitreal use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"15/08/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AbbVie LtdE-mail: paediatricteam@abbvie.comTel. +44(0) 1628925033","first_published_date":"18/09/2008","last_updated_date":"18/09/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/dexamethasone"},{"decision_number":"P/70/2008","pip_number":"EMEA-000064-PIP01-07","active_substance":"nicotinic acid;simvastatin;laropiprant","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Modified-release tablet","condition_indication":"Hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/08/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp and Dohme (Europe), Inc.; Belgium; Tel. +33 180464738; E-mail: pip.information@merck.com","first_published_date":"18/09/2008","last_updated_date":"18/09/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000064-pip01-07"},{"decision_number":"P/64/2008","pip_number":"EMEA-000071-PIP01-07","active_substance":"peginterferon alfa-2b","invented_name":"PegIntron; PegIntron","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Powder and solvent for solution for injection in vial and in pre-filled pen","condition_indication":"Treatment of chronic viral hepatitis C","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/08/2008","compliance_outcome":"Positive","compliance_opinion_date":"17/10/2008","compliance_procedure_number":"EMEA-C-000071-PIP01-07","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe), Inc.; The Netherlands; E-mail: pip.information@merck.com; Tel. +31 4126 63179; Fax +31 4126 62571","first_published_date":"18/09/2008","last_updated_date":"18/09/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000071-pip01-07"},{"decision_number":"P/63/2008","pip_number":"Ribavirin","active_substance":"ribavirin","invented_name":"Rebetol; Rebetol","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Oral solution;Capsule, hard","condition_indication":"Treatment of chronic viral hepatitis C","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"15/08/2008","compliance_outcome":"Positive","compliance_opinion_date":"17/10/2008","compliance_procedure_number":"EMEA-C-000070-PIP01-07","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe), Inc.; The Netherlands; E-mail: pip.information@merck.com; Tel. +31 4126 63179; Fax +31 4126 62571","first_published_date":"18/09/2008","last_updated_date":"18/09/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ribavirin"},{"decision_number":"P/71/2008","pip_number":"EMEA-000253-PIP01-08","active_substance":"nicotinic acid;simvastatin;laropiprant","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Modified-release tablet","condition_indication":"Hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/08/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp and Dohme (Europe), Inc.; Belgium; Tel. +33 180464738; E-mail: pip.information@merck.com","first_published_date":"18/09/2008","last_updated_date":"18/09/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000253-pip01-08"},{"decision_number":"P/72/2008","pip_number":"EMEA-000254-PIP01-08","active_substance":"nicotinic acid;simvastatin;laropiprant","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Modified-release tablet","condition_indication":"Hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/08/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp and Dohme (Europe), Inc.; Belgium; Tel. +33 180464738; E-mail: pip.information@merck.com","first_published_date":"18/09/2008","last_updated_date":"18/09/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000254-pip01-08"},{"decision_number":"P/55/2008","pip_number":"Epoetin theta","active_substance":"epoetin theta","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of anaemia","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/07/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"CT Arzneimittel GmbH; E-mail: office@ct-arzneimittel.de; Country: Germany; Phone: +49 304090080; Fax: +49 3040900821","first_published_date":"08/09/2008","last_updated_date":"08/09/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/epoetin-theta"},{"decision_number":"P/57/2008","pip_number":"Epoetin theta","active_substance":"epoetin theta","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of anaemia","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/07/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ratiopharm GmbH; E-mail: info@ratiopharm.de; Country: Germany; Phone: +49 73140202; Fax: +49 7314027832","first_published_date":"08/09/2008","last_updated_date":"08/09/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/epoetin-theta-0"},{"decision_number":"P/56/2008","pip_number":"Epoetin theta","active_substance":"epoetin theta","invented_name":"","therapeutic_area":"Haematology-Hemostaseology","pharmaceutical_forms":"Solution for injection","condition_indication":"Treatment of anaemia","routes_of_administration":"Intravenous use;Subcutaneous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/07/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ratiopharm GmbH; E-mail: info@ratiopharm.de; Country: Germany; Phone: +49 73140202; Fax: +49 7314027832","first_published_date":"08/09/2008","last_updated_date":"08/09/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/epoetin-theta-1"},{"decision_number":"P/54/2008","pip_number":"EMEA-000171-PIP01-07","active_substance":"glucosamine hydrochloride;chondroitin sulfate","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Capsule, hard;Granules in sachet","condition_indication":"Primary osteoarthritis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/07/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Bioiberica S.A.E-mail: gemma.slade@parexel.comPhone: : +44 1895614615","first_published_date":"08/09/2008","last_updated_date":"08/09/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000171-pip01-07"},{"decision_number":"P/58/2008","pip_number":"EMEA-000225-PIP01-08","active_substance":"amlodipine besilate;valsartan;hydrochlorothiazide","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"20/07/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"08/09/2008","last_updated_date":"08/09/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000225-pip01-08"},{"decision_number":"P/53/2008","pip_number":"Atorvastatin calcium","active_substance":"atorvastatin calcium","invented_name":"Sortis and associated names","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral formulation","condition_indication":"Pure hypercholesterolaemia (heterozygous, homozygous, or otherwise primary hypercholesterolaemia), combined (mixed) hyperlipidaemia; prevention of cardiovascular events","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"20/07/2008","compliance_outcome":"Positive","compliance_opinion_date":"13/11/2009","compliance_procedure_number":"EMEA-C-000073-PIP01-07","contact_for_public_enquiries":"Pfizer Limited; Tel. + 44 1304646607; E-mail: pip_enquiries@pfizer.com","first_published_date":"08/09/2008","last_updated_date":"08/09/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/atorvastatin-calcium"},{"decision_number":"P/33/2008","pip_number":"EMEA-000027-PIP01-07","active_substance":"tifacogin","invented_name":"","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Solution for infusion","condition_indication":"Septicaemia","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"24/06/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"21/07/2008","last_updated_date":"21/07/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000027-pip01-07"},{"decision_number":"P/32/2008","pip_number":"EMEA-000024-PIP01-07","active_substance":"zoledronic acid","invented_name":"Zometa; Zometa","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Powder and solvent for solution for infusion;Concentrate for solution for infusion","condition_indication":"Osteogenesis imperfecta;Prevention of fracture and bone loss in postmenopausal women with early-stage breast cancer treated with aromatase inhibitors;Prevention of skeletal related events in patients with advanced malignancies involving bone;Tumour-induced hypercalcaemia","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"24/06/2008","compliance_outcome":"Positive","compliance_opinion_date":"12/12/2008","compliance_procedure_number":"EMEA-C-000024-PIP01-07","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"21/07/2008","last_updated_date":"21/07/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000024-pip01-07"},{"decision_number":"P/45/2007","pip_number":"EMEA-000251-PIP01-08","active_substance":"nicotinic acid;laropiprant","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Prolonged-release tablet","condition_indication":"Heterozygous Familial Hypercholesterolaemia;Homozygous Familial Hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"23/06/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp and Dohme (Europe), Inc.; Belgium; Tel. +33 180464738; E-mail: pip.information@merck.com","first_published_date":"21/07/2008","last_updated_date":"21/07/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000251-pip01-08"},{"decision_number":"P/40/2008","pip_number":"AP214 Acetate (Αcetyl-(Lys)6-α-MSH, acetate salt)","active_substance":"AP214 Acetate (Αcetyl-(Lys)6-α-MSH, acetate salt)","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Concentrate for solution for infusion","condition_indication":"Acute renal failure after thoracic aortic aneurysm repair surgery;Thoracic aortic aneurysm","routes_of_administration":"Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/06/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Action Pharma A/S; E-mail: tj@actionpharma.com; Country: Denmark; Phone: +45 45475000; Fax: +45 45475001","first_published_date":"21/07/2008","last_updated_date":"21/07/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ap214-acetate-acetyl-lys6-msh-acetate-salt"},{"decision_number":"P/43/2008","pip_number":"Vernakalant hydrochloride","active_substance":"vernakalant hydrochloride","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Encapsulated tablet;Concentrate for solution for infusion","condition_indication":"Atrial fibrillation","routes_of_administration":"Oral use;Intravenous use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/06/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Cardiome UK Limited; E-mail: jmallison@cardiome.com; Country: Canada; Phone: +1 6046776905; Fax: +1 6046766970","first_published_date":"21/07/2008","last_updated_date":"21/07/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/vernakalant-hydrochloride"},{"decision_number":"P/42/2008","pip_number":"EMEA-000216-PIP01-08","active_substance":"dutasteride;tamsulosin hydrochloride","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Capsule","condition_indication":"Treatment of benign prostatic hyperplasia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/06/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.; Tel.: +1 4388998201; E-mail: axel_breitstadt@merck.com","first_published_date":"21/07/2008","last_updated_date":"21/07/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000216-pip01-08"},{"decision_number":"P/46/2007","pip_number":"EMEA-000252-PIP01-08","active_substance":"nicotinic acid;laropiprant","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Prolonged-release tablet","condition_indication":"Heterozygous Familial Hypercholesterolaemia;Homozygous Familial Hypercholesterolaemia","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"23/06/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp and Dohme (Europe), Inc.; Belgium; Tel. +33 180464738; E-mail: pip.information@merck.com","first_published_date":"21/07/2008","last_updated_date":"21/07/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000252-pip01-08"},{"decision_number":"P/39/2008","pip_number":"EMEA-000062-PIP01-07","active_substance":"taranabant","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Capsule, soft","condition_indication":"Obesity","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"24/06/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"21/07/2008","last_updated_date":"21/07/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000062-pip01-07"},{"decision_number":"P/41/2008","pip_number":"Elocalcitol","active_substance":"Elocalcitol","invented_name":"","therapeutic_area":"Uro-nephrology","pharmaceutical_forms":"Capsule","condition_indication":"Treatment of benign prostatic hyperplasia","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"24/06/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"BioXell SpA; E-mail: lorenza.olivieri@bioxell.com; Country: Italy; Phone: +39 0221049545; Fax: +39 0221049529","first_published_date":"21/07/2008","last_updated_date":"21/07/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/elocalcitol"},{"decision_number":"P/28/2008","pip_number":"Adenovirus-mediated Herpes simplex virus-thymidine kinase gene","active_substance":"adenovirus-mediated Herpes simplex virus-thymidine kinase gene","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate for solution for injection","condition_indication":"Treatment of high-grade glioma","routes_of_administration":"Intracerebral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"23/05/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Ark Therapeutics Ltd; E-mail: david.eckland@arktherapeutics.com; Country: United Kingdom; Phone: +44 2073887722; Fax: +44 2073887805","first_published_date":"17/06/2008","last_updated_date":"17/06/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/adenovirus-mediated-herpes-simplex-virus-thymidine-kinase-gene"},{"decision_number":"P/30/2008","pip_number":"Caspofungin acetate","active_substance":"caspofungin acetate","invented_name":"Cancidas (previously Caspofungin MSD); Cancidas","therapeutic_area":"Infectious diseases","pharmaceutical_forms":"Powder for concentrate for solution for infusion;Powder for solution for infusion","condition_indication":"Fungal infections","routes_of_administration":"Intravenous use","decision_type":"PM: decision on the application for modification of an agreed PIP","decision_date":"23/05/2008","compliance_outcome":"Positive","compliance_opinion_date":"04/06/2008","compliance_procedure_number":"EMEA-C-000010-PIP01-07-M01","contact_for_public_enquiries":"Merck Sharp & Dohme (Europe) Inc.Tel.: +33180464738E-mail: pip.information@merck.com","first_published_date":"17/06/2008","last_updated_date":"17/06/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/caspofungin-acetate"},{"decision_number":"P/23/2008","pip_number":"EMEA-000017-PIP01-07","active_substance":"albumin interferon alfa-2b","invented_name":"","therapeutic_area":"Gastroentology-Hepatology","pharmaceutical_forms":"Powder and solvent for solution for injection","condition_indication":"Treatment of chronic hepatitis C","routes_of_administration":"Subcutaneous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"23/05/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"17/06/2008","last_updated_date":"17/06/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000017-pip01-07"},{"decision_number":"P/29/2008","pip_number":"Arzoxifene","active_substance":"arzoxifene","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Breast carcinoma;Postmenopausal osteoporosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"23/05/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Eli Lilly and Company LtdE-mail: eu_paediatric@lilly.com Phone: +44 1256315000","first_published_date":"17/06/2008","last_updated_date":"17/06/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/arzoxifene"},{"decision_number":"P/22/2008","pip_number":"Docetaxel","active_substance":"docetaxel","invented_name":"Taxotere; Taxotere","therapeutic_area":"Oncology","pharmaceutical_forms":"Concentrate and solvent for solution for infusion","condition_indication":"Nasopharyngeal carcinoma","routes_of_administration":"Intravenous use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"16/05/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Aventis Pharma SA; E-mail: sylvie.gabriel@sanofi-aventis.com; Country: France; Phone: +33 153774152; Fax: +33 153774133","first_published_date":"04/06/2008","last_updated_date":"04/06/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/docetaxel"},{"decision_number":"P/20/2008","pip_number":"EMEA-000085-PIP01-07","active_substance":"Flibanserin","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Hypoactive Sexual Desire Disorder in Women","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/04/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"16/05/2008","last_updated_date":"16/05/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000085-pip01-07"},{"decision_number":"P/21/2008","pip_number":"Roflumilast","active_substance":"roflumilast","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Tablet","condition_indication":"Chronic obstructive pulmonary disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"28/04/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Nycomed GmbH; E-mail: corporatecommunications@nycomed.com; Country: Germany; Phone: +49 7531840; Fax: +49 7531842474","first_published_date":"16/05/2008","last_updated_date":"16/05/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/roflumilast"},{"decision_number":"P/16/2008","pip_number":"EMEA-000104-PIP01-07","active_substance":"naproxcinod","invented_name":"","therapeutic_area":"Immunology-Rheumatology-Transplantation","pharmaceutical_forms":"Capsule, hard","condition_indication":"Primary osteoarthritis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/03/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"NicOx S.A.; E-mail: emea.contact@nicox.com; Country: France; Phone: +33 97245300; Fax: +33 97245379","first_published_date":"22/04/2008","last_updated_date":"22/04/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000104-pip01-07"},{"decision_number":"P/15/2008","pip_number":"Flosfluridine tidoxil","active_substance":"Flosfluridine tidoxil","invented_name":"","therapeutic_area":"Dermatology","pharmaceutical_forms":"Capsule","condition_indication":"Treatment of actinic keratosis","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"31/03/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Heidelberg Pharma AG; E-mail: e.boehm@hdpharma.com; Country: Germany; Phone: +49 6203100963; Fax: +49 6203100918","first_published_date":"04/04/2008","last_updated_date":"04/04/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/flosfluridine-tidoxil"},{"decision_number":"P/9/2008","pip_number":"EMEA-000008-PIP01-07","active_substance":"Losartan potassium","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Film-coated tablet;Age appropriate oral liquid dosage formulation","condition_indication":"Proteinuria;Treatment of heart failure;Treatment of hypertension","routes_of_administration":"Oral use","decision_type":"P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)","decision_date":"29/02/2008","compliance_outcome":"Positive","compliance_opinion_date":"06/02/2009","compliance_procedure_number":"EMEA-C-000008-PIP01-07","contact_for_public_enquiries":"Merck, Sharp & Dohme (Europe) Inc.; Tel. +31 412770000; E-mail: regaffairseurope@organon.com","first_published_date":"19/03/2008","last_updated_date":"19/03/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000008-pip01-07"},{"decision_number":"P/3/2008","pip_number":"EMEA-000045-PIP01-07","active_substance":"telmisartan;ramipril","invented_name":"","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Risk of myocardial infarction, stroke, death from cardiovascular causes, or hospitalization forcongestive heart failure in patients at high risk of developing major cardiovascular events","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/02/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Boehringer Ingelheim International GmbH; Tel. +49 6132 778271; Email: Paediatrics@boehringer-ingelheim.com","first_published_date":"15/02/2008","last_updated_date":"15/02/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000045-pip01-07"},{"decision_number":"P/4/2008","pip_number":"EMEA-000058-PIP01-07","active_substance":"glycopyrronium bromide","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Inhalation powder;Capsule, hard","condition_indication":"Chronic obstructive pulmonary disease","routes_of_administration":"Inhalation use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/02/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"15/02/2008","last_updated_date":"15/02/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000058-pip01-07"},{"decision_number":"P/5/2008","pip_number":"EMEA-000059-PIP01-07","active_substance":"indacaterol maleate;glycopyrronium bromide","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Inhalation powder;Capsule, hard","condition_indication":"Chronic obstructive pulmonary disease","routes_of_administration":"Inhalation use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/02/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"15/02/2008","last_updated_date":"15/02/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000059-pip01-07"},{"decision_number":"P/2/2008","pip_number":"EMEA-000043-PIP01-07","active_substance":"indacaterol maleate","invented_name":"","therapeutic_area":"Pneumology-allergology","pharmaceutical_forms":"Inhalation powder;Capsule, hard","condition_indication":"Chronic obstructive pulmonary disease","routes_of_administration":"Inhalation use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/02/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"15/02/2008","last_updated_date":"15/02/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000043-pip01-07"},{"decision_number":"P/6/2008","pip_number":"EMEA-000097-PIP01-07","active_substance":"panobinostat as panobinostat lactate salt","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Capsule, hard","condition_indication":"Cutaneous T-cell lymphoma (including ICD-10 codes C84.0 (mycosis fungoides) and C84.1 (Sezary's Disease)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/02/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"15/02/2008","last_updated_date":"15/02/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000097-pip01-07"},{"decision_number":"P/8/2008","pip_number":"EMEA-000074-PIP01-07","active_substance":"rosiglitazone maleate","invented_name":"","therapeutic_area":"Neurology","pharmaceutical_forms":"Prolonged-release tablet","condition_indication":"Alzheimer's Disease","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"01/02/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"GlaxoSmithKline R&D Limited; E-mail: eu.paediatric-plans@gsk.com; Country: United Kingdom; Phone: +44 208 990 3650; Fax: +44 208 990 3511","first_published_date":"15/02/2008","last_updated_date":"15/02/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000074-pip01-07"},{"decision_number":"P/1/2008","pip_number":"Lasofoxifene tartrate","active_substance":"Lasofoxifene tartrate","invented_name":"","therapeutic_area":"Endocrinology-Gynaecology-Fertility-Metabolism","pharmaceutical_forms":"Film-coated tablet","condition_indication":"Treatment of osteoporosis in postmenopausal women at increased risk of fracture","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"07/01/2008","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Dr. Friedrich Eberth Arzneimittel GmbH; E-mail: info@eberth.de; Tel. +49 96289237670; Fax +49 962892376799","first_published_date":"16/01/2008","last_updated_date":"16/01/2008","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/lasofoxifene-tartrate"},{"decision_number":"P/2/2007","pip_number":"EMEA-000019-PIP01-07","active_substance":"everolimus","invented_name":"","therapeutic_area":"Oncology","pharmaceutical_forms":"Tablet","condition_indication":"Renal cell carcinoma and pancreatic neuroendocrine tumour","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/12/2007","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111","first_published_date":"20/12/2007","last_updated_date":"20/12/2007","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000019-pip01-07"},{"decision_number":"P/4/2007","pip_number":"Candesartan/Hydrochlorothiazide","active_substance":"Candesartan;hydrochlorothiazide","invented_name":"Blopress Comp and associated names","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Essential hypertension","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/12/2007","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"Takeda Global Research & Development Centre (Europe) Ltd; E-mail: s.abel@tgrd.com; Country: United Kingdom; Phone: +44 2077595147; Fax: +44 2077595273","first_published_date":"20/12/2007","last_updated_date":"20/12/2007","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/candesartan-hydrochlorothiazide"},{"decision_number":"P/3/2007","pip_number":"Candesartan/Hydrochlorothiazide","active_substance":"Candesartan;hydrochlorothiazide","invented_name":"Atacand Plus and associated names","therapeutic_area":"Cardiovascular diseases","pharmaceutical_forms":"Tablet","condition_indication":"Cutaneous T-cell lymphoma (including ICD-10 codes C84.0 (mycosis fungoides) and C84.1 (Sezary's Disease)","routes_of_administration":"Oral use","decision_type":"W: decision granting a waiver in all age groups for all conditions or indications","decision_date":"11/12/2007","compliance_outcome":"","compliance_opinion_date":"","compliance_procedure_number":"","contact_for_public_enquiries":"AstraZeneca AB; E-mail: paediatrics@astrazeneca.com; Tel. +44 20 7304 5345","first_published_date":"20/12/2007","last_updated_date":"20/12/2007","pip_url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/candesartan-hydrochlorothiazide-0"}]